Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer 2026-10-25 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/25/3387723/0/en/genmab-announces-updated-follow-up-analyses-from-phase-2-study-of-petosemtamab-demonstrate-meaningful-objective-response-rates-in-patients-with-metastatic-colorectal-cancer.html Media Release ———————————————————————————————————————————————————————————— NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development 2026-10-25 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/25/3387722/0/en/novabridge-biosciences-reports-mature-phase-1b-data-at-esmo-2026-positioning-givastomig-for-registrational-development.html Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen the foundation for registrational development in first-line metastatic gastroesophageal adenocarcinoma Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen the foundation for registrational development in first-line metastatic gastroesophageal adenocarcinoma ———————————————————————————————————————————————————————————— Economic Community of West African States (ECOWAS), Centre for Research and Information on Substance Abuse (CRISA) Convene Regional Conference on Substance Use Research and Data Systems 2026-10-25 · APO Group · Healthcare, Biotech & pharma, Government & policy https://www.africa-newsroom.com/press/economic-community-of-west-african-states-ecowas-centre-for-research-and-information-on-substance-abuse-crisa-convene-regional-conference-on-substance-use-research-and-data-systems?lang=en The Economic Community of West African States (ECOWAS) Commission, in collaboration with the Centre for Research and Information on Substance Abuse (CRISA), has convened the 16th Biennial International Conference on Drugs, Alcohol and Society in Africa to strengthen evidence-based responses to substance use across West Africa. Held from the 21st to 22nd of October 2026 in Abuja, Nigeria, the conference is themed “Substance Use Research and Data Systems in Africa: Advances, Relevance and Challenges.” It brings together researchers, policymakers, public health professionals and development partners to examine emerging drug trends, strengthen data systems and develop practical recommendations for prevention, treatment and rehabilitation. Delivering a statement on behalf of the ECOWAS Commissioner for Human Development and Social Affairs, Prof. Nassirou Bako-Arifari, Dr. Daniel Amankwaah, Head of the ECOWAS Drug Prevention and Control Division, highlighted the growing public health and security challenges associated with substance use and illicit drug trafficking. He disclosed that, as of September 2026, 12 drug treatment and rehabilitation centres in 10 Member States had received renovation and equipment upgrades, while more than 300 health and allied professionals had been trained in evidence-based prevention and treatment. He also highlighted ECOWAS efforts to advance Alternatives to Incarceration, promoting treatment, rehabilitation and social reintegration for eligible people who use drugs and come into contact with the criminal justice system. He reaffirmed the Commission’s commitment to strengthening regional data through the West African Epidemiology Network on Drug Use (WENDU). Representing CRISA, Prof. Gboyega Abikoye expressed satisfaction with the Centre’s achievements after more than 30 years, highlighting its work in substance use research, information sharing on alcohol use and abuse, and the organisation of workshops and conferences to advance knowledge and inform responses to drug-related challenges. In remarks delivered on behalf of the UNODC Country Representative in Nigeria, Cheikh Touré, by Dr. Akanidomo Ibanga, Project Management Support Specialist at UNODC, participants were urged to bridge the gap between research and policymaking. He emphasised that evidence must inform government decisions, resource allocation, prevention programmes and access to quality treatment and care. The conference features country-level drug situation reports, panel discussions and research presentations, including a study on alternatives to incarceration for people who use drugs in Nigeria. Through its partnership with CRISA and other stakeholders, ECOWAS continues to promote regional cooperation and evidence-informed policies for more effective and humane responses to substance use across West Africa. Distributed by APO Group on behalf of Economic Community of West African States (ECOWAS). ———————————————————————————————————————————————————————————— BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy 2026-10-25 · PressReach · Biotech & pharma https://pressreach.com/biontech-and-bristol-myers-squibb-report-encouraging-global-phase-2-data-for-pumitamig-in-advanced-nsclc-after-progression-on-immunotherapy-plus-chemotherapy Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of 36.7% following progression on or after immunotherapy plus chemotherapy An early median progression-free survival of 6.9 months was observed Significant unmet need remains for patients who have progressed on an … Continue reading "BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy" ———————————————————————————————————————————————————————————— Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer 2026-10-25 · PressReach · Finance, Healthcare, Biotech & pharma https://pressreach.com/genmab-and-incyte-announce-clinical-trial-collaboration-in-metastatic-colorectal-cancer Media Release COPENHAGEN, Denmark and WILMINGTON, Del.; October 24, 2026 Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor … Continue reading "Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer" ———————————————————————————————————————————————————————————— NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma 2026-10-25 · PressReach · Biotech & pharma https://pressreach.com/nanobiotix-announces-final-data-from-phase-1-study-evaluating-jnj-1900-nbtxr3-with-immune-checkpoint-inhibitors-as-a-2l-therapy-in-anti-pd-1-resistant-primary-cutaneous-melanoma In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy including anti-PD-1 therapy, data continue to show an acceptable safety profile and early signals of efficacy 41.7% (10/24) overall response rate (ORR) per RECIST 1.1, including 4 complete responses 75% (18/24) disease control rate (DCR) … Continue reading "NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma" ———————————————————————————————————————————————————————————— Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors 2026-10-25 · PressReach · Healthcare, Biotech & pharma https://pressreach.com/parabilis-medicines-presents-updated-phase-1-2-data-for-zolucatetide-demonstrating-compelling-efficacy-and-favorable-safety-and-tolerability-profile-in-patients-with-desmoid-tumors Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week landmark Disease control rate of 100% across all response-evaluable patients receiving a starting dose of ≥450 mg, with no disease progression and no treatment discontinuations due to TRAEs Data informed FDA-aligned dose and regimen selection for upcoming PEDESTAL … Continue reading "Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors" ———————————————————————————————————————————————————————————— Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026 2026-10-25 · PressReach · Biotech & pharma https://pressreach.com/climb-bio-presents-initial-prismn-phase-2-data-from-budoprutug-in-pmn-at-an-oral-session-at-asn-kidney-week-2026 Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027 200 mg and 600 mg doses have been generally well-tolerated Separate MCD case study described three-year steroid-free remission following budoprutug treatment, supporting … Continue reading "Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026" ———————————————————————————————————————————————————————————— 2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer 2026-10-25 · PR Newswire · Finance, Industrial, Biotech & pharma https://www.prnewswire.com/news-releases/2026-esmo--innovent-announcement-phase-2-data-presentation-for-ibi354-her2-adc-in-first-line-treatment-of-breast-cancer-302918639.html SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune,... ———————————————————————————————————————————————————————————— 2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC 2026-10-25 · PR Newswire · Finance, Industrial, Biotech & pharma https://www.prnewswire.com/news-releases/2026-esmo--innovent-presented-phase-1-study-data-for-ibi3001-a-first-in-class-egfrb7h3-bispecific-adc-302918633.html SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune,... ———————————————————————————————————————————————————————————— Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting 2026-10-25 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/zhejiang-wenda-pharma-announces-positive-results-from-phase-ii-trial-of-oral-bet-inhibitor-nhwd-870-hcl-at-the-2026-esmo-annual-meeting-302918672.html SHAOXING, China, Oct. 25, 2026 -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase II clinical trial data for NHWD-870 HCl, an oral BET inhibitor, in Chinese patients with advanced NUT carcinoma (NC).... ———————————————————————————————————————————————————————————— UNCY DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCY 2026-10-24 · GlobeNewswire · Finance, Biotech & pharma, Legal https://www.globenewswire.com/news-release/2026/10/24/3387708/673/en/uncy-deadline-notice-rosen-a-highly-recognized-law-firm-encourages-unicycive-therapeutics-inc-investors-to-secure-counsel-before-important-november-2-deadline-in-securities-class-a.html NEW YORK, Oct. 24, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— Wholesale Screw Air Compressor Exporter from China VS USA Exporter: Which Brand Delivers Superior Energy Efficiency 2026-10-24 · EIN Presswire · Energy, Food & drink, Industrial, Biotech & pharma, Semiconductors, Chemicals & materials https://www.einpresswire.com/article/951924266/wholesale-screw-air-compressor-exporter-from-china-vs-usa-exporter-which-brand-delivers-superior-energy-efficiency SHANGHAI, SHANGHAI, CHINA, October 25, 2026 / EINPresswire.com / -- Global industrial manufacturing faces double pressure: persistent inflation inflating operational overhead and rising energy costs eating into bottom-line profits. Industrial facilities across general manufacturing, petrochemicals, semiconductor manufacturing, and food and pharmaceutical sectors are actively scrutinizing utility expenditures. Compres ———————————————————————————————————————————————————————————— 2-stage Screw Compressor Factory: AIRERA Secures TUV Class 0 Certification to Lead Pharma and Food-Grade Air 2026-10-24 · EIN Presswire · Healthcare, Food & drink, Industrial, Biotech & pharma https://www.einpresswire.com/article/951924085/2-stage-screw-compressor-factory-airera-secures-tuv-class-0-certification-to-lead-pharma-and-food-grade-air SHANGHAI, SHANGHAI, CHINA, October 25, 2026 / EINPresswire.com / -- Pharma and Food-Grade Air Solutions In highly sensitive industrial manufacturing, particularly within the pharmaceutical and food and beverage sectors, the procurement logic for compressed air systems differs fundamentally from standard manufacturing applications. Compressed air in these environments acts as a direct or indirect contact medium during ———————————————————————————————————————————————————————————— Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026 2026-10-24 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/pfizers-25-valent-pediatric-pneumococcal-151800354.html Investigational vaccine shows strong immune responses in infants equivalent to PREVNAR 20 ® on shared serotypes and for five new serotypes, potentially offering the broadest protection against invasive pneumococcal disease (IPD) for pediatric population in the U.S. NEW YORK, October 24, 2026--Pfizer I ———————————————————————————————————————————————————————————— IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial 2026-10-24 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/imfinzi-durvalumab-plus-tarlatamab-dlle-143500755.html Novel combination demonstrated a median overall survival of nearly two years, the longest benefit ever reported in extensive stage disease in a Phase III trial Results reinforce IMFINZI as the backbone immunotherapy across stages of small cell lung cancer WILMINGTON, Del., October 24, 2026--Landmark re ———————————————————————————————————————————————————————————— Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit 2026-10-24 · PR Newswire · Finance, Biotech & pharma, Legal https://www.prnewswire.com/news-releases/unicycive-deadline-uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-302918542.html NEW YORK, Oct. 24, 2026 -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November... ———————————————————————————————————————————————————————————— The Urbanic Law Firm Strengthens Criminal Defense Representation Across Oklahoma 2026-10-24 · ACCESS Newswire · Biotech & pharma, Legal, Government & policy https://finance.yahoo.com/small-business/articles/urbanic-law-firm-strengthens-criminal-121500588.html OKLAHOMA CITY, OK / October 24, 2026 / The Urbanic Law Firm is strengthening its criminal defense representation across Oklahoma, providing focused legal support to individuals facing criminal allegations in state, federal, and municipal cases. Based in Oklahoma City, the firm represents clients throughout the state in matters involving DUI and DWI, domestic violence, drug offenses, sex crimes, fire ———————————————————————————————————————————————————————————— Taiwan Brings Herbal Heritage and Modern Innovation to SupplySide Global 2026 2026-10-24 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/taiwan-brings-herbal-heritage-and-modern-innovation-to-supplyside-global-2026-302918648.html LAS VEGAS, Oct. 24, 2026 -- With a healthcare system that embraces both modern medicine and Traditional Chinese medicine (TCM), Taiwan brings together herbal knowledge passed down over millennia, scientific evidence and modern pharmaceutical and biotechnology capabilities.... ———————————————————————————————————————————————————————————— Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026 2026-10-24 · PR Newswire · AI, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/likang-life-sciences-showcases-personalized-cancer-immunotherapy-and-global-ambitions-at-abu-dhabi-future-health-summit-2026-302918646.html BEIJING, Oct. 24, 2026 -- Likang Life Sciences ("Likang"), a biotechnology company advancing AI-enabled personalized cancer immunotherapies, sponsored and exhibited at the Abu Dhabi Future Health Summit 2026, held from 20 to 22 October at ADNEC Centre Abu Dhabi. The summit... ———————————————————————————————————————————————————————————— Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer 2026-10-24 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/incyte-genmab-announce-clinical-trial-110000998.html Phase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) WILMINGTON, Del. & COPENHAGEN, Denmark, October 24, 2026--Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial c ———————————————————————————————————————————————————————————— Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026 2026-10-24 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/bio-thera-announces-promising-clinical-data-for-bat8008-in-combination-with-bat1308-in-first-line-non-small-cell-lung-cancer-at-esmo-2026-302918492.html GUANGZHOU, China, Oct. 24, 2026 -- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars, today announced the presentation of clinical data for BAT8008, a TROP2-targeted antibody-drug conjugate... ———————————————————————————————————————————————————————————— Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026 2026-10-24 · PressReach · Healthcare, Biotech & pharma https://pressreach.com/compass-therapeutics-announces-publication-of-phase-2-3-companion-002-results-for-tovecimig-in-the-journal-of-clinical-oncology-and-oral-presentation-at-esmo-2026 As published in the Journal of Clinical Oncology (JCO) and presented at ESMO, COMPANION-002 met its primary endpoint of ORR and key secondary endpoint of PFS, with a 56% reduction in the risk of disease progression or death. Responses were durable, with a median duration of response (DOR) of 4.9 months, and disease control rate … Continue reading "Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026" ———————————————————————————————————————————————————————————— CatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit of PD-1 Inhibition in Neoadjuvant Bladder Cancer at ESMO 2026 2026-10-24 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/catalym-presents-phase-2-data-081500844.html Visugromab combined with PD-1 inhibitor nivolumab demonstrated higher response rates versus nivolumab alone across primary and secondary endpoints: pathologic Complete Response (pCR; 33% vs. 8%), radiographic Objective Response Rate (ORR; 60% vs. 15%) and Major Pathologic Response (MPR; 60% vs. 23%) Enhanced responses wer ———————————————————————————————————————————————————————————— Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting 2026-10-24 · PressReach · Healthcare, Biotech & pharma https://pressreach.com/immatics-presents-clinical-activity-of-ima402-prame-bispecific-and-ima203cd8-prame-cell-therapy-across-advanced-solid-tumors-in-two-oral-presentations-at-2026-esmo-annual-meeting IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profile IMA402 achieved a cORR of 32%, 12.5 months median DOR and a 1-year OS rate of 91% in advanced melanoma patients with high PRAME expression Clinical profile of IMA402 reinforces development path across multiple solid tumor indications, including … Continue reading "Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting" ———————————————————————————————————————————————————————————— Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026 2026-10-24 · PressReach · Biotech & pharma, Government & policy https://pressreach.com/zymeworks-presents-new-phase-1-data-for-folate-receptor-alpha-targeting-antibody-drug-conjugate-zw191-at-esmo-congress-2026 ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor alpha (FRα) expression levels Confirmed objective response rates (cORR) of 64.5% at the 6.4 mg/kg dose in patients with high-grade serous platinum-resistant ovarian cancer Median duration of response not yet reached at either dose level at median 7 months … Continue reading "Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026" ———————————————————————————————————————————————————————————— Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence 2026-10-24 · Bayer · Finance, Healthcare, Education, Biotech & pharma, Government & policy, Internet & apps, Chemicals & materials https://www.bayer.com/media/en-us/darolutamide-plus-adt-and-radiation-therapy-reduces-risk-of-metastasis-or-death-by-58-in-prostate-cancer-patients-at-high-risk-of-recurrence/ Berlin, October 24, 2026 – New late-breaking data to be presented today at the European Society for Medical Oncology (ESMO) Congress 2026 will show that adding Bayer’s androgen receptor inhibitor (ARi), darolutamide, to standard-of-care androgen deprivation therapy (ADT) and locoregional radiation therapy (RT), significantly improves metastasis-free survival based on conventional imaging (MFS-CI) in prostate cancer patients with high risk of recurrence compared to placebo. Darolutamide is currently not approved for this treatment setting. These data will be presented at Presidential Symposium I at the ESMO Congress 2026 (LBA4, Saturday 24 October, 16:30 CET). At a median follow-up of 3.8 years, the interim analysis demonstrated a 58% reduction in the risk of metastasis or death with darolutamide plus ADT and RT compared with placebo plus ADT and RT (hazard ratio [HR] 0.42; 95% CI: 0.27–0.66; p=0.0001). The 4-year metastasis-free survival rate was 95% for patients receiving darolutamide compared with 88% for those receiving placebo. “Prostate cancer patients at a high risk of relapse face a considerable risk of recurrence and metastatic spread, making early, highly effective intervention vital,” said Dr. Tamim Niazi, Associate Professor of Oncology at McGill University, Radiation Oncologist at the Jewish General Hospital in Montreal, Canada. and Co-Lead Investigator of the study. “The clear improvement in metastasis-free survival seen in interim results from the DASL-HiCaP trial highlights the potential of adding darolutamide to standard androgen deprivation therapy and radiation therapy to help prevent or delay disease progression in patients who are at high risk of progression despite receiving primary curative therapy.” Secondary endpoints also showed consistent positive trends with darolutamide, with a 53% reduction in the risk of prostate-specific antigen progression free survival (PSA-PFS; HR 0.47; 95% CI: 0.33–0.67), and a 4-year PSA-PFS rate of 91% versus 83% with placebo. Prostate cancer-specific survival (PCSS) and overall survival (OS) hazard ratios were 0.58 (95% CI: 0.17–1.97; 99% vs 99% at 4 years) and 0.88 (95% CI: 0.49–1.59; 97% vs 95% at 4 years), respectively, with follow-up ongoing. The safety profile of darolutamide was consistent with its known tolerability, with adverse events being similar to the placebo group. Proportions of patients experiencing Grade ≥2 adverse events of special interest for darolutamide versus placebo were: fatigue/asthenia (14% vs 10%), hypertension (7% vs 9%), fractures (2% vs 3%), and cardiac events (3% vs 3%). Any Grade ≥3 adverse event occurred in 43% of patients in the darolutamide group versus 36% in the placebo group. "These new data highlight the potential of darolutamide to make a meaningful difference for patients earlier in the course of their prostate cancer,” said Christine Roth, Executive Vice President, Global Product Strategy and Commercialization at Bayer’s Pharmaceuticals Division. “By advancing darolutamide into earlier disease settings, we aim to reach more patients across the prostate cancer care continuum. We are proud to support ANZUP, the Sydney Clinical Trials Centre, CCTG and international partners in research as we work together with the potential to improve outcomes for men living with prostate cancer.” Follow-up of participants is continuing to provide further information on longer-term outcomes, including overall survival. About the DASL-HiCaP trial (ANZUP1801)  The DASL-HiCaP trial is an investigator-initiated, randomized, placebo-controlled, Phase III trial (NCT04136353) evaluating darolutamide added to standard-of-care ADT and locoregional radiation therapy in prostate cancer patients at high risk of recurrence. DASL-HiCaP was conducted in collaboration with the University of Sydney and ANZUP Clinical Trials Group and is the fourth Phase III trial for darolutamide. Following ARAMIS, ARASENS, and ARANOTE, which demonstrated darolutamide’s efficacy and safety in advanced prostate cancer, DASL-HiCaP represents the first Phase III study of darolutamide in early prostate cancer. A total of 1,106 participants across Australia, New Zealand, Canada, the United States, Ireland and the United Kingdom were randomized 1:1 to receive darolutamide (600 mg twice daily) or matching placebo for 96 weeks, combined with an LHRH analog for 96 weeks and RT to the prostate/prostate bed and pelvic lymph nodes. The primary endpoint was metastasis-free survival based on conventional imaging (MFS-CI). Secondary endpoints included prostate-specific antigen progression free survival (PSA-PFS), prostate cancer-specific survival (PCSS), and overall survival (OS). The protocol specified an interim analysis after 87 MFS-CI events; follow-up is ongoing to evaluate long-term overall survival. About the Sydney Clinical Trials Centre The Sydney Clinical Trials Centre is a flagship research centre of the Faculty of Medicine and Health at the University of Sydney that designs and manages clinical trials. This includes responsibility for study coordination, monitoring, data acquisition and management and statistical analysis. The Sydney Clinical Trials Centre has health economics, biostatistics, systematic reviews and biomarker teams that work with trial data and inform healthcare providers about best practice. For further details, please visit its website at https://www.ctc.usyd.edu.au About ANZUP Clinical Trials Group  ANZUP (https://www.anzup.org.au) is the leading cancer-cooperative trials group bringing together all of the professional disciplines and groups involved in researching and treating urogenital cancers to conduct high-quality cancer research. ANZUP’s mission is to improve the lives of people affected by bladder, kidney, testicular, penile, and prostate cancers, towards our vision of living life without fear of cancer. ANZUP identifies gaps in evidence and areas of clinical need, collaborates with the best clinicians and researchers in genitourinary cancer and communicates frequently and effectively with the broader community along the way. ANZUP receives valuable infrastructure support from the Australian Government through Cancer Australia and research funding from Prostate Cancer Foundation of Australia. About Prostate Cancer Prostate cancer is the second most common cancer and the fourth most common cause of cancer death in men worldwide. Over 1.5 million men are diagnosed with prostate cancer each year and almost 420,000 die from the disease worldwide. By 2040, prostate cancer diagnoses are projected to increase to 2.9 million. Standard therapy for prostate cancer patients at high risk of recurrence combines radiation therapy with androgen deprivation therapy (ADT). However, despite this approach, a significant proportion of patients experience treatment failure, local recurrence, or distant metastases. Intensifying therapy early with an advanced androgen receptor inhibitor aims to improve long-term disease control and delay metastatic progression. About darolutamide (Nubeqa™) Darolutamide is an oral ARi with a distinct chemical structure that binds with high affinity to the androgen receptor and exhibits a strong antagonistic effect against the androgen receptor inhibiting the receptor function and growth of prostate cancer cells. Additionally, preclinical models and neuroimaging data in healthy humans support darolutamide's low potential for blood-brain barrier penetration and low potential for clinically relevant drug-drug interactions. Darolutamide, under the brand name Nubeqa™ plus androgen deprivation therapy (ADT), is already approved in more than 85 markets around the world, including the US, EU and China. It is approved for the treatment of adult patients with mHSPC without docetaxel in 75 markets and with docetaxel in more than 85 countries, and for adult patients with nmCRPC at high risk of developing metastatic disease in more than 85 countries. Darolutamide is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company. Darolutamide demonstrated efficacy and tolerability in pivotal Phase 3 studies, supporting its indications in nmCRPC and mHSPC with and without chemotherapy, with a favorable safety profile that offers an advancement in treatment management for physicians and patients. A robust clinical development program is underway investigating darolutamide across various stages of prostate cancer. Current ongoing trials include the Phase III ARASTEP trial evaluating the efficacy of darolutamide plus ADT compared to ADT alone in hormone-sensitive prostate cancer (HSPC), in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline. About Prostate Cancer at Bayer Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The company has the passion and determination to develop new medicines that help improve and extend the lives of people living with cancer. Prostate cancer is the second most commonly diagnosed cancer in men and a key area of focus for Bayer. The company’s franchise includes two products on the market (Nubeqa™ and Xofigo™) and several compounds in development. Bayer is focused on addressing the unique needs of patients with prostate cancer, providing treatments that extend their lives throughout the different stages of the disease and allowing them to continue with their everyday activities, so that patients can live longer, better lives. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to support efforts to master major challenges presented by a growing and aging global population and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Find more information at www.bayer.com/en/portfolio/pharmaceuticals Follow us on Facebook: http://www.facebook.com/bayer Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. ———————————————————————————————————————————————————————————— Knee Cartilage Stem Cell Therapy Korea: Non-Surgical Options and Costs Explained 2026-10-24 · MarketersMEDIA · Healthcare, Biotech & pharma https://news.marketersmedia.com/knee-cartilage-stem-cell-therapy-korea-non-surgical-options-and-costs-explained/89207234 Lydian Cosmetic Surgery Clinic in Seoul details non-surgical stem cell injections for knee osteoarthritis, covering candidacy, process, costs and realistic limits on cartilage regeneration for international patients weighing treatment in Korea. -- Lydian Cosmetic Surgery Clinic in Seoul offers non-surgical stem cell injections for knee osteoarthritis, using cells collected from a patient's own fat tissue or bone marr ———————————————————————————————————————————————————————————— Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma 2026-10-24 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/24/3387653/0/en/junshi-biosciences-announces-completion-of-first-patient-dosing-in-the-phase-3-clinical-trial-of-js203-in-combination-with-chemotherapy-for-the-treatment-of-diffuse-large-b-cell-ly.html The first patient dosing has been completed in phase 3 clinical study of JS203 (CD20/CD3 bsAb), in combination with chemotherapy in patients with R/R DLBCL ———————————————————————————————————————————————————————————— Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development 2026-10-24 · PR Newswire · Finance, AI, SaaS, Biotech & pharma https://www.prnewswire.com/news-releases/lunit-and-summit-therapeutics-announce-agreement-to-apply-ai-powered-scope-io-platform-for-tumor-microenvironment-analysis-in-immuno-oncology-development-302918571.html Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology SEOUL, South Korea, Oct. 24, 2026 -- Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today... ———————————————————————————————————————————————————————————— Pathalys Pharma Presents Positive Data from Pivotal Phase 3 Studies of Upacicalcet in Featured Oral Presentation at ASN Kidney Week 2026 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/pathalys-pharma-presents-positive-data-from-pivotal-phase-3-studies-of-upacicalcet-in-featured-oral-presentation-at-asn-kidney-week-2026-302918517.html ~ In PATH-1 and PATH-2 upacicalcet met primary and key secondary endpoints of reducing parathyroid hormone (PTH) in patients with end-stage kidney disease and Secondary Hyperparathyroidism (SHPT) on hemodialysis ~ Upacicalcet also reduced FGF23 and markers of bone turnover in the trial... ———————————————————————————————————————————————————————————— GSK presents positive data for Mo-Rez in platinum-resistant ovarian cancer 2026-10-23 · GSK · Biotech & pharma https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-data-for-mo-rez-in-platinum-resistant-ovarian-cancer/ 62% confirmed objective response rate and 12.2-month median duration of response in phase Ib trial ———————————————————————————————————————————————————————————— AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4) 2026-10-23 · Business Wire · Finance, SaaS, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/an2-therapeutics-inc-reports-inducement-210000048.html MENLO PARK, Calif., October 23, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to two newly-hired employees. On October 19 ———————————————————————————————————————————————————————————— Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development 2026-10-23 · Business Wire · Finance, AI, SaaS, Biotech & pharma https://finance.yahoo.com/healthcare/articles/summit-therapeutics-lunit-announce-agreement-203700857.html Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology MIAMI & SEOUL, South Korea, October 23, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agre ———————————————————————————————————————————————————————————— Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2026-10-23 · PR Newswire · Finance, Biotech & pharma https://www.prnewswire.com/news-releases/nektar-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302918440.html SAN FRANCISCO, Oct. 23, 2026 -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on October 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 45,750 shares of its common... ———————————————————————————————————————————————————————————— Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results 2026-10-23 · PR Newswire · Finance, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-announces-assist-ssc-trial-top-line-results-302918449.html Ifetroban was well tolerated in patients with systemic sclerosis NASHVILLE, Tenn., Oct. 23, 2026 -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announces... ———————————————————————————————————————————————————————————— Mission MSA to Host Externally Led Patient-Focused Drug Development Session on Multiple System Atrophy 2026-10-23 · PRWeb · Healthcare, Biotech & pharma, Nonprofits https://www.prweb.com/releases/mission-msa-to-host-externally-led-patient-focused-drug-development-session-on-multiple-system-atrophy-302917749.html Free, virtual meeting on March 16, 2027 will gather patient and care partner testimony on life with MSA to inform future treatments. CHICAGO, Oct. 23, 2026 -- Mission MSA, a nonprofit supporting people affected by multiple system atrophy (MSA), will host a virtual... ———————————————————————————————————————————————————————————— ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026 2026-10-23 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/23/3387598/0/en/arrivent-to-present-initial-phase-1-data-for-cdh17-targeted-adc-arr-217-in-patients-with-gastrointestinal-cancers-at-the-esmo-congress-2026.html NEWTOWN SQUARE, Pa., Oct. 23, 2026 -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that initial safety and efficacy data from the Phase 1 (NCT07066657) study of CDH17-targeted ADC ARR-217 (MRG007) in patients with gastrointestinal cancers, will be presented in a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain, on October 23-27, 2026. ArriVent plans to host a virtual webinar on October 26, 2026 at 8 am ET to discuss the data and ARR-217 program. To register for the event, click here. ———————————————————————————————————————————————————————————— GondolaBio and Children’s Tumor Foundation Announce Partnership to Advance GondolaBio’s Neurofibromatosis Type 1 Program 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/gondolabio-children-tumor-foundation-announce-200000022.html Collaboration brings Children's Tumor Foundation's deep NF1 expertise and patient and family perspectives into development of GondolaBio's neurofibromatosis type 1 (NF1) program PALO ALTO, Calif. & NEW YORK, October 23, 2026--GondolaBio, a clinical-stage biopharmaceutical company developing novel medic ———————————————————————————————————————————————————————————— Texas Involuntary Drug & Alcohol Rehab For Teenagers: Guide For Parents Released 2026-10-23 · MarketersMEDIA · Healthcare, Biotech & pharma https://news.marketersmedia.com/texas-involuntary-drug-andamp-alcohol-rehab-for-teenagers-guide-for-parents-released/89207201 Clearfork Academy, a youth mental health and rehab center in Texas, has released a guide on involuntary drug and alcohol rehab for teenagers in the state. -- Clearfork Academy has released a guide on involuntary drug and alcohol addiction treatment for teens struggling with substance use disorders in Texas. The guide acknowledges that addicted teens may resist treatment and offers insight into what parents should do ———————————————————————————————————————————————————————————— U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease 2026-10-23 · AbbVie · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/us-fda-approves-subcutaneous-induction-regimen-for-abbvies-skyrizi-risankizumab-rzaa-for-adults-with-moderately-to-severely-active-crohns-disease-302918434.html Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector... ———————————————————————————————————————————————————————————— SERB Pharmaceuticals Announces Positive Results from the Post-Authorisation Efficacy Study of Idefirix® (imlifidase) Presented at ASN Kidney Week 2026 2026-10-23 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387585/0/en/serb-pharmaceuticals-announces-positive-results-from-the-post-authorisation-efficacy-study-of-idefirix-imlifidase-presented-at-asn-kidney-week-2026.html SERB Pharmaceuticals announces positive results from the Post-Authorisation Efficacy Study (PAES) of Idefirix® (imlifidase), ———————————————————————————————————————————————————————————— GLOW Oncology and Mount Sinai Medical Center’s to Host FREE GI & GU Patient Journey Symposium on November 6 2026-10-23 · EIN Presswire · AI, Healthcare, Biotech & pharma https://www.einpresswire.com/article/951804309/glow-oncology-and-mount-sinai-medical-center-s-to-host-free-gi-gu-patient-journey-symposium-on-november-6 GLOW Oncology to Host FREE LIVE and Virtual GI and GU Patient Journey Symposium MIAMI BEACH, FL, FL, UNITED STATES, October 23, 2026 / EINPresswire.com / -- Free educational event in Miami Beach will bring patients, caregivers, and healthcare professionals together to explore clinical trials, medical advances, AI in cancer care, nurse navigation, nutrition, and survivorship. Global Leadership in Oncology & Wellness ( ———————————————————————————————————————————————————————————— Citizens Commission on Human Rights International Urges the FDA to Follow UK Warnings on Antidepressant Suicide Risk and Persistent Sexual Dysfunction 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387583/0/en/citizens-commission-on-human-rights-international-urges-the-fda-to-follow-uk-warnings-on-antidepressant-suicide-risk-and-persistent-sexual-dysfunction.html The UK’s drug regulatory agency has expanded suicide-risk information to all ages and formally recognizes antidepressant-induced sexual dysfunction The UK’s drug regulatory agency has expanded suicide-risk information to all ages and formally recognizes antidepressant-induced sexual dysfunction ———————————————————————————————————————————————————————————— Novo's Awiqli® receives FDA approval as the first and only once-weekly insulin for children 10 years of age and older with type 2 diabetes 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/novos-awiqli-receives-fda-approval-as-the-first-and-only-once-weekly-insulin-for-children-10-years-of-age-and-older-with-type-2-diabetes-302918384.html Awiqli® offers children 10 years and older a once-weekly basal insulin alternative, reducing basal injection frequency from seven times per week to one1 As type 2 diabetes incidence rates among youth continue to rise,² Awiqli® may help reduce administration barriers associated with daily... ———————————————————————————————————————————————————————————— What's Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline 2026-10-23 · PR Newswire · Finance, Biotech & pharma, Legal https://www.prnewswire.com/news-releases/whats-next-for-unicycive-therapeutics-inc-shareholders-after-39-1-stock-drop-glancy-prongay-wolke--rotter-llp-explains-securities-fraud-class-action-lead-plaintiff-deadline-302917636.html Complaint alleges Unicycive Therapeutics, Inc. misled investors between December 29, 2025 and June 29, 2026; investors may seek lead plaintiff role by November 2, 2026 LOS ANGELES, Oct. 23, 2026 -- Glancy Prongay Wolke & Rotter LLP ("Glancy") announced today that the class... ———————————————————————————————————————————————————————————— Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/hansa-biopharma-announces-positive-idefirix-paes-results-presented-in-the-high-impact-clinical-trials-session-at-asn-kidney-week-302918373.html The 1-year graft failure-free survival at 12 months post-transplant was 90%, which is clinically meaningful Graft and patient survival were 92% and 98%, respectively Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience LUND,... ———————————————————————————————————————————————————————————— 10 Italian Startups Take on Drug-Resistant Cancer, Healthcare AI and Sustainable Biotech in San Diego and Boston 2026-10-23 · EIN Presswire · AI, Healthcare, Biotech & pharma https://www.einpresswire.com/article/951832809/10-italian-startups-take-on-drug-resistant-cancer-healthcare-ai-and-sustainable-biotech-in-san-diego-and-boston The Italian Startups with Consul General Raffaella Valentini The Italian Trade Agency brings a delegation of biotech and life sciences innovators to two of America's leading industry hubs for a 4-week acceleration program SAN DIEGO, CA, UNITED STATES, October 23, 2026 / EINPresswire.com / -- New approaches to overcoming drug resistance in cancer, technologies that accelerate drug discovery, and innovative uses of bio ———————————————————————————————————————————————————————————— Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/phase-3-rainier-results-supporting-174200652.html - Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept – - Data published in NEJM and presented at ASN highlight povetacicept's unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with ———————————————————————————————————————————————————————————— Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN) 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/ionis-partner-roche-announces-phase-173700964.html – Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient subgroups – – Sefaxersen inhibits complement factor B production and has the potential to reduce kidney infla ———————————————————————————————————————————————————————————— Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN) 2026-10-23 · Roche · Healthcare, Biotech & pharma, Nonprofits, Internet & apps, Medical devices https://www.roche.com/media/releases/med-cor-2026-10-23 Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient subgroups1 As the first antisense oligonucleotide (ASO) evaluated in IgAN, sefaxersen inhibits complement factor B production and has the potential to slow IgAN disease progression by reducing kidney inflammation2 Investigational sefaxersen is intended to be a once-monthly subcutaneous injection and designed to enable convenient self-administration at home3 Despite recent advances, many people with IgAN remain at risk of disease progression and kidney failure, highlighting the need for additional targeted treatment options for those who do not respond to initial therapy4,5 Basel, 23 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today late-breaking oral presentation data from the ongoing phase III IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimised standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P<0.0001), relative to placebo at 37 weeks, as measured by 24-hour urine protein-to-creatinine ratio (UPCR).1 Proteinuria is a key indicator of kidney damage and a reduction in UPCR is strongly associated with the preservation of long-term kidney function.6,7 Results presented at the American Society of Nephrology (ASN) Kidney Week 2026 also showed that, among patients with baseline haematuria (blood in urine), a greater proportion of patients achieved haematuria resolution at Week 37 with sefaxersen versus placebo.1 “These phase III results demonstrate the potential for sefaxersen to meaningfully reduce protein in the urine, a key indicator of kidney damage, in people with IgA nephropathy,” said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development. “By inhibiting complement factor B in the liver, sefaxersen may offer a novel approach to slow disease progression in IgAN, potentially helping patients delay or avoid long-term dialysis or kidney transplantation.” The treatment effect in all prespecified subgroups was consistent with the clinically meaningful reductions in proteinuria shown in the primary endpoint results.1 Sefaxersen was well tolerated with a safety profile consistent with the previously reported phase II study, exhibiting no new safety signals.1,2 Sefaxersen is an investigational once-monthly subcutaneous injection designed to enable convenient self-administration for people with IgAN.3 The IMAgINATION study will continue as a blinded study to evaluate the change in kidney function over two years, as measured by estimated glomerular filtration rate (eGFR) at week 105. Data will be shared with health authorities, with the goal of bringing this treatment to patients as soon as possible. Typically diagnosed before the age of 40, IgAN affects at least 25 adults per million worldwide each year.8,9 IgAN, also known as Berger’s disease, is a chronic and progressive autoimmune disease that leads to end-stage kidney disease in up to 50% of patients within 20 years of diagnosis.5,10 It is the most common form of primary glomerulonephritis (inflammation of the tiny filters, glomeruli, in the kidneys) and is a major cause of chronic kidney disease as well as kidney failure.8 About sefaxersen Investigational sefaxersen is the first highly specific liver-directed antisense oligonucleotide (ASO) inhibitor of factor B production being evaluated in IgA nephropathy (IgAN).2 Serum complement factor B levels are elevated in people with IgAN. When we reduce these levels, it in turn reduces the level of protein in urine, which is a key indicator of improved kidney function.11,12 Sefaxersen is designed to provide sustained control of the alternative complement pathway, an important pathway in IgAN, enabling once-monthly subcutaneous dosing and is intended for self-administration in people with IgAN.3 In phase I and II trials, sefaxersen was shown to be generally well tolerated in healthy volunteers and people with IgAN who were at high risk of progression, and reduced proteinuria and plasma complement factor B.2,13 Roche licensed sefaxersen from Ionis Pharmaceuticals for the treatment of complement mediated diseases. About the IMAgINATION study IMAgINATION [NCT05797610] is a phase III, multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous sefaxersen, an investigational antisense inhibitor of complement factor B, in patients with primary IgA nephropathy at high risk of progression.1,14 The study enrolled 459 people, who are randomised 1:1 to receive sefaxersen or placebo for 105 weeks.1,14 Participants may switch to open-label treatment after week 105 at the investigator's discretion or after the common-close timepoint, whichever occurs first.1,14 The primary endpoint of the study is the change from baseline in the urine protein-to-creatinine ratio at 37 weeks.1,14 About primary immunoglobulin A nephropathy (IgAN) IgAN, also known as Berger’s disease, is a serious, chronic and progressive autoimmune kidney disease affecting at least 25 adults per million worldwide each year and is typically diagnosed before the age of 40 years.8-10 In IgAN, immune complexes deposit in the kidneys, which activates the complement system’s alternative pathway, leading to inflammation and subsequent kidney damage.15 It is the most common form of primary glomerulonephritis (inflammation of kidney glomeruli) and remains a leading cause of kidney failure, with up to 50% of patients experiencing end-stage kidney disease within 20 years of diagnosis.5,8 Many current therapies aim to reduce protein levels in the urine and control blood pressure to slow progression of the disease.16 Updated KDIGO 2025 guidelines* highlight the need to address both the underlying immune-mediated causes of IgAN and the downstream consequences of kidney damage.4 While new therapies have expanded treatment options, important unmet needs remain, including improved long-term preservation of kidney function and more targeted approaches that address key drivers of disease progression.4,16 About Roche in Immunology For over two decades, Roche has advanced immune system research, creating groundbreaking targeted treatments that have transformed care for people with blood disorders, neurological conditions and autoimmune diseases. With a development pipeline exploring more than 20 medical approaches, we are targeting widespread, complex conditions like chronic lung disease (COPD) and inflammatory bowel disease (IBD), alongside lupus and autoimmune kidney diseases. Our ultimate goal is to lessen the burden of chronic immune disorders on patients, healthcare systems, and society. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. *KDIGO guidelines serve as the foundational framework for healthcare organisations, policymakers, and clinicians worldwide to standardise kidney disease diagnosis, staging, and treatment. References [1] Barratt J., et al. Sefaxersen, a Novel mRNA-Targeted Therapy for IgA Nephropathy: Interim Analysis of the Phase 3 IMAgINATION Trial. Presented at: ASN Kidney Week; 2026 Oct 20-26; Denver, CO, USA. Abstract #FR-OR104. [2] Barbour SJ, et al. A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy. Kidney Int. 2026;109:592-601. [3] Barratt J, et al. IMAGINATION: a global phase 3 trial of RO7434656, an antisense oligonucleotide inhibitor of complement factor B, in IgA nephropathy. Kidney Int Rep. 2024;9 Suppl. WCN24-912. [4] Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025;108(4S):S1–S71. [5] Caster DJ, et al. Clinicopathological characteristics of adult IgA nephropathy in the United States. Kidney Int Rep. 2023;8:1792-1800. [6] Longhitano E, et al. Proteinuria and Progression of Renal Damage: The Main Pathogenetic Mechanisms and Pharmacological Approach. Medicina (Kaunas). 2024 Nov 6;60(11):1821. [7] Qin X, et al. Association Between Urinary Protein-to-Creatinine Ratio and Chronic Kidney Disease Progression: A Secondary Analysis of a Prospective Cohort Study. Front. Med. 2022; 9:854300. [8] Pitcher D, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18:727-738. [9] McGrogan A, Franssen CF and de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 2011; 26: 414-430. [10] Cleveland Clinic. IgA Nephropathy [Internet; cited 2026 October 15]. Available from: https://my.clevelandclinic.org/health/diseases/5990-iga-nephropathy. [11] Chiu YL, et al. Alternative complement pathway is activated and associated with galactose-deficient IgA. Front Immunol 2021; 12: 638309. [12] Marques F, et al. Impact of early proteinuria reduction in glomerular disease and decline of kidney function: a retrospective cohort. J Clin Med. 2022;11(19):5968. [13] McCaleb ML, et al. Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen. Immunobiology. 2025 Mar;230(2):152876. [14] ClinicalTrials.gov. A Study to Evaluate RO7434656 in Participants With Immunoglobulin A Nephropathy (IgAN) (IMAGINATION) (NCT05797610) [Internet; cited 2026 Oct 15]. Available from: https://clinicaltrials.gov/study/NCT05797610. [15] Wu MY, et al. The emerging role of pathogenesis of IgA nephropathy. J Clin Med. 2018;7:225. [16] Floege J, et al. Current treatment of IgA nephropathy. Semin Immunopathol. 2021;43:717-728. Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone: +41 79 377 83 75Albert Thottiyil Phone: +41 79 775 66 12 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.comDr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com  Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com  Attachment Media Investor Release Sefaxersen IMAgINATION ASN ———————————————————————————————————————————————————————————— Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN) 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/genentech-presents-interim-phase-iii-173000615.html - Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient subgroups - - As the first antisense oligonucleotide (ASO) evaluated in IgAN, sefaxersen inhibits complement ———————————————————————————————————————————————————————————— The Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement Scheme 2026-10-23 · Business Wire · Biotech & pharma, Legal https://finance.yahoo.com/healthcare/articles/lanier-law-firm-supports-attorney-172700408.html Litigation sought reimbursements for violations of state law in prescribing practices, charges to Medicaid program HOUSTON, October 23, 2026--Building on decades of holding pharmaceutical companies responsible for dangerous products and unlawful business practices, The Lanier Law Firm played a pivotal ———————————————————————————————————————————————————————————— Tampa General Hospital and Health Care District of Palm Beach County to Open Lakeside Cancer Center in September 2027, Expanding Access to Academic-Based Cancer Care in Florida's Rural Communities 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/tampa-general-hospital-and-health-care-district-of-palm-beach-county-to-open-lakeside-cancer-center-in-september-2027-expanding-access-to-academic-based-cancer-care-in-floridas-rural-communities-302918344.html Lakeside Cancer Center will connect cancer patients in the Glades with world-class treatment, complex care coordination and access to oncology specialists. BELLE GLADE, Fla., Oct. 23, 2026 -- Tampa General Hospital (TGH) and the Health Care District of Palm Beach County... ———————————————————————————————————————————————————————————— Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ASN Kidney Week 2026 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/palleon-pharmaceuticals-presents-phase-2-170000284.html HLX79/E-602 plus rituximab produced faster responses and a higher response rate than rituximab alone, with a safety profile suited to outpatient administration WATERTOWN, Mass., October 23, 2026--Palleon Pharmaceuticals , a clinical-stage biotechnology company developing glycan editing therapeutics fo ———————————————————————————————————————————————————————————— NEC Presents Phase I/II Results for Individualized Oral Neoantigen Therapy, NECVAX-NEO1 at ESMO 2026 2026-10-23 · ScoopAsia · Healthcare, Biotech & pharma https://scoopasia.com/nec-presents-phase-i-ii-results-for-individualized-oral-neoantigen-therapy-necvax-neo1-at-esmo-2026/ NEC Bio will be presenting results from the Phase I/II TNBC clinical trial of its orally administered individualized neoantigen therapy, NECVAX-NEO1, used in combination with checkpoint inhibitors (CPIs) and chemotherapy for patients with triple-negative breast cancer (TNBC). ———————————————————————————————————————————————————————————— KFSH Advances Gene Therapy for Sickle Cell Disease Using Patients’ Own Modified Stem Cells 2026-10-23 · EIN Presswire · Healthcare, Biotech & pharma https://www.einpresswire.com/article/951516847/kfsh-advances-gene-therapy-for-sickle-cell-disease-using-patients-own-modified-stem-cells A KFSH scientist working in the research laboratory in Riyadh RIYADH, SAUDI ARABIA, October 23, 2026 / EINPresswire.com / -- King Faisal Specialist Hospital and Research Centre (KFSH) is advancing gene therapy for sickle cell disease through a 2026 clinical trial that uses the patient’s own hematopoietic stem cells, genetically modified to address the underlying defect and offer a potential path beyond repeated suppo ———————————————————————————————————————————————————————————— Congruence Therapeutics Announces Oral Presentation on CGX-195, a Novel Small Molecule AAT Corrector, at the ERS Alpha-1 Antitrypsin (AAT) Conference 2026 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-oral-presentation-on-cgx-195-a-novel-small-molecule-aat-corrector-at-the-ers-alpha-1-antitrypsin-aat-conference-2026-302918168.html – CGX-195 increased functional, secreted Z-A1AT and reduced polymerized Z-A1AT in cellular assays and in the PiZ mouse model – MONTREAL, Oct. 23, 2026 -- Congruence Therapeutics ("Congruence"), a clinical-stage, computationally driven biotechnology company building a pipeline... ———————————————————————————————————————————————————————————— TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026 2026-10-23 · Business Wire · Healthcare, Automotive, Biotech & pharma https://finance.yahoo.com/healthcare/articles/tg-therapeutics-announces-phase-1-145500267.html First reported clinical evaluation of an allogeneic CD19-directed CAR T-cell therapy in progressive MS demonstrated an encouraging preliminary safety profile with no high-grade CAR-T associated toxicities observed 89% of evaluable participants (16/19) had stable or improved disability scores at Day 90, despite documented ———————————————————————————————————————————————————————————— Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs 2026-10-23 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/23/3387456/0/en/perspective-s-212pb-bamzireotide-navoxetan-vmt-%CE%B1-net-demonstrates-encouraging-safety-durable-disease-control-and-robust-tumor-response-across-multiple-dose-cohorts-in-phase-1-2a-tr.html SEATTLE, Oct. 23, 2026 -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, today announced new interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs). These data are being presented as a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 taking place October 23-27, 2026 in Madrid, Spain. ———————————————————————————————————————————————————————————— Savills Hong Kong Hosts Grand Reception to Celebrate 40th Anniversary, Over 300 Guests Gather to Mark Glorious Milestone 2026-10-23 · ACN Newswire · Finance, SaaS, Real estate, Biotech & pharma, Banking, Investing & markets, Nonprofits https://www.acnnewswire.com/press-release/english/111044/ Hong Kong, Oct 23, 2026 - International real estate firm Savills Hong Kong hosted a grand reception today at Cloud 39, the spectacular rooftop event venue at The Henderson in Central, to celebrate its 40th anniversary. The reception brought together more than 300 business partners, industry leaders and key stakeholders to mark the company’s significant milestone of 40 years in Hong Kong, celebrate Savills Hong Kong’s remarkable achievements over the years and explore its vision for the future. Mr Simon Shaw (right), Group Chief Executive Officer of Savills, and Mr Raymond Lee (left), Chief Executive Officer, Greater China of Savills Since establishing its presence in Hong Kong in 1986, Savills has witnessed and played a part in the city's dynamic growth and transformation over the decades. The management expressed its gratitude to business partners, clients and colleagues for their steadfast support over the years, reaffirming the Company’s commitment to professionalism and to moving forward together with the Hong Kong community. Mr Simon Shaw, Group Chief Executive Officer of Savills Mr Simon Shaw, Group Chief Executive Officer of Savills, said in his opening remarks, “Thank you for joining us to celebrate our 40th anniversary in Hong Kong. Over the past four decades, Hong Kong has experienced periods of rapid growth as well as challenging economic and property market cycles. Throughout each cycle, the property market has demonstrated its ability to adapt, recover and move forward, and our business has followed the same trajectory. None of this would have been possible without the trust and support of our clients over the years. Your confidence and loyalty have enabled us to continue to grow and thrive. Looking ahead, we will further develop across the Asia-Pacific region, while strengthening and expanding our expertise and capabilities. This region is central to Savills’ future, just as it has long been an integral part of our history. Finally, I would like to thank everyone who has contributed to our success. Together, we look to the future with confidence.” Mr Raymond Lee, Chief Executive Officer, Greater China of Savills Mr Raymond Lee, Chief Executive Officer, Greater China of Savills, said, “Many of our partners have stood alongside us for decades, and over time, those business ties have grown into lasting friendships. Thank you for entrusting us with your important projects. For us, completing a transaction is always rewarding, but the greatest recognition of our team’s efforts comes when clients choose to work with us again or recommend us to others. The strength of our Hong Kong team lies in its deep understanding of the local market, combined with its global connections. By drawing on the Group’s resources and worldwide network, we are able to offer clients a broader perspective and a more comprehensive range of services. Looking ahead, markets and technologies will continue to evolve, but our commitment to professionalism, integrity and putting our clients’ interests first will remain unchanged.” Guests gather to celebrate the 40th anniversary of Savills Hong Kong. Official Launch of the “Savills Volunteer Team” to Give Back to the Community Through Action To mark the significant milestone of its 40th anniversary, Savills Hong Kong announced the establishment of the Savills Volunteer Team, reflecting the Company’s collective commitment to turn its corporate culture of “caring for the community and giving back to society” into sustained and meaningful action. The Company firmly believes that corporate success is measured not only by business achievements, but also by its commitment to and care for society. Soon after its establishment, the volunteer team launched a series of community service initiatives. Its first initiative was a collaboration with MercyHK to support people experiencing homelessness and those in drug rehabilitation. The team subsequently visited House of Joy and Mercy to care for abandoned and stray cats, and they also partnered with Love 21 Foundation to offer care and support to people with Down syndrome and autism. The 40th anniversary reception was not only an opportunity to reflect on past achievements, but also provided a chance to look ahead to future developments. The Company will continue to leverage its international network and local expertise to provide clients with exceptional real estate advisory services, while actively fulfilling its corporate social responsibility and growing alongside Hong Kong. Appendix: Key Milestones in Savills Hong Kong’s 40-Year History Year Milestone 1986 First Pacific Company Limited acquired 100% of Hongkew Davies Properties Limited and renamed the company First Pacific Davies Properties Limited, marking the beginning of a new chapter. 1990 First Pacific Davies expanded its footprint by acquiring a 100% interest in Guardian Group, strengthening its service capabilities across the region. 1997 First Pacific Davies formed an alliance with Savills PLC and was renamed FPDSavills. 2001 Savills PLC acquired FPDSavills Asia Pacific Limited, making FPDSavills (Hong Kong) Limited a wholly owned subsidiary of Savills PLC and reinforcing its global presence. 2003 - Mr Raymond Lee was appointed Managing Director of FPDSavills (Hong Kong) Limited, leading the Hong Kong agency business to new heights. 2005 - FPDSavills (Hong Kong) Limited officially rebranded as Savills (Hong Kong) Limited, aligning all global businesses with the brand identity of the parent company. - The entire Valuation and Professional Services team from Chesterton Petty was recruited to form Savills Valuation and Professional Services Limited, further expanding the Company’s professional services offerings. 2015 - Brokered the sale of Ho Tung Gardens for HK$5.1 billion, setting a record for the most expensive residential plot sold by private tender in Hong Kong. The property was also listed among “The World’s Top 10 Most Expensive Exclusive Streets” in a survey released by Billionaire.com. 2018 - Achieved record-breaking results by facilitating the sale of the majority ownership interests in Cityplaza 3 & 4 majority portion) for HK$15 billion, as well as the HK$5.93 billion transaction of 39 Shouson Hill Road, further reinforcing its market leadership. - Savills Hong Kong’s Agency and Valuation Group recorded revenue of HK$1.066 billion and profit before tax of HK$410 million, achieving record-high results. 2021 - Concluded another property transaction exceeding HK$10 billion — KITEC was sold for HK$10.5 billion, showcasing its expertise in major deals. 2026 - Savills announced the acquisition of Eastdil Secured LLC, a leading global real estate investment bank, for US$1.1125 billion, thereby becoming the world’s second-largest advisory firm specialising in prime commercial real estate transactions above US$100 million. - Savills (Hong Kong) Limited is celebrating its 40th anniversary in the Hong Kong property market and will continue to demonstrate its professional expertise, business versatility, and market leadership in the years ahead. About Savills For over 170 years, Savills has been helping people thrive through places and spaces. Listed on the London Stock Exchange, we have more than 42,000 professionals collaborating across over 70 countries, delivering unrivalled coverage and expertise to the world of commercial and prime residential real estate. By applying world research data and trends to local and global settings, we’re able to empower our clients with insights from the forefront of the industry – bringing their aspirations to life through innovative, tailor-made solutions.  Whether we are working with a global corporate looking to expand, an investor seeking to sustainably optimise their portfolio, or a family trying to find a new home, we help our clients make better property decisions. ———————————————————————————————————————————————————————————— How Peptide Conjugate Developability Is Shaped Before a Candidate Is Nominated 2026-10-23 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387429/0/en/how-peptide-conjugate-developability-is-shaped-before-a-candidate-is-nominated.html With 63% of 106 peptide and nanobody drug conjugates still preclinical, WuXi AppTec outlines five design decisions that shape manufacturability. ———————————————————————————————————————————————————————————— Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026 2026-10-23 · GlobeNewswire · Healthcare, Automotive, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387428/0/en/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026.html Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving disability scores while removing the need for chronic immunotherapies ———————————————————————————————————————————————————————————— BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer 2026-10-23 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/beone-medicines-reports-sustained-survival-141500032.html New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 months TEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy SAN CARLOS, Calif., October 23, 2026 --( BU ———————————————————————————————————————————————————————————— Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026 2026-10-23 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/23/3387398/0/en/zentalis-pharmaceuticals-announces-meaningful-median-overall-survival-data-in-cyclin-e1-positive-platinum-resistant-ovarian-cancer-from-denali-part-1b-to-be-presented-at-the-esmo-c.html SAN DIEGO, Oct. 23, 2026 -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today presented results from an interim analysis of the DENALI Part 1b study (GOG-3066) as of a May 22, 2026 data cutoff, including the first overall survival analysis for azenosertib, at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. ———————————————————————————————————————————————————————————— Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma 2026-10-23 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387397/0/en/iovance-presents-new-data-at-esmo-2026-demonstrating-deep-durable-responses-with-lifileucel-til-cell-therapy-plus-pembrolizumab-in-frontline-advanced-melanoma.html 62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis ———————————————————————————————————————————————————————————— Employers Health selects Archimedes to reduce costs 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/employers-health-selects-archimedes-reduce-140000790.html More than 500 plan sponsors can access proven specialty-drug management solutions BRENTWOOD, Tenn., October 23, 2026--Archimedes, the nationwide leader in specialty drug management solutions, announced today that it will offer proven strategies for addressing rising specialty-drug costs to the more tha ———————————————————————————————————————————————————————————— Drug-Free Tennessee Hosts “Fueling Futures” Red Ribbon Week Breakfast for Community Leaders 2026-10-23 · PR Now · Biotech & pharma https://pressreleasenews.org/pressroom/drug-free-tennessee-hosts-fueling-futures-red-ribbon-week-breakfast-for-community-leaders A breakfast meeting of the minds on expanding youth programs that give kids better things to do than drugs ———————————————————————————————————————————————————————————— Global Clinical Trials Market Size, Share, Growth Trends, and Forecast, 2026-2035 | Clinical Trials Market set to more than Double to $144.4bn as Drugmakers Lean on Outside Researchers 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma, Insurance https://www.globenewswire.com/news-release/2026/10/23/3387296/28124/en/global-clinical-trials-market-size-share-growth-trends-and-forecast-2026-2035-clinical-trials-market-set-to-more-than-double-to-144-4bn-as-drugmakers-lean-on-outside-researchers.html New Report puts the market at $66.3bn in 2025, with oncology accounting for 38.3% and North America just over half, though patchy insurer coverage and infrastructural barriers remain stubborn obstacles for IQVIA, ICON, Medpace and Charles River Laboratories New Report puts the market at $66.3bn in 2025, with oncology accounting for 38.3% and North America just over half, though patchy insurer coverage and infrastructural barriers remain stubborn obstacles for IQVIA, ICON, Medpace and Charles River Laboratories ———————————————————————————————————————————————————————————— Pharmaceutical Metal Detector Market to Grow at a CAGR of 4.71% Through 2033 2026-10-23 · PR News Releaser · Biotech & pharma https://www.prnewsreleaser.com/news/478197 The Pharmaceutical Metal Detector Market is covered by Business Market Insights with 2025 as the base year and 2026–2033 as the forecast period. The retrieved public source material for this batch did not expose all three headline values required for ... Read more ———————————————————————————————————————————————————————————— Convergent Therapeutics to Present Phase 2 Results Demonstrating Potent Anti-Tumor Activity of CONV01-α in Lu-PSMA-Naïve Prostate Cancer at ESMO Congress 2026 2026-10-23 · Business Wire · Biotech & pharma, Government & policy https://finance.yahoo.com/healthcare/articles/convergent-therapeutics-present-phase-2-131500375.html CONV01-α demonstrates substantial anti-tumor activity in patients with rapidly progressing androgen pathway modulator-resistant (APMR) prostate cancer, achieving PSA50 and PSA90 response rates of 84% and 26%, respectively, following a two-dose regimen Deep PSA responses and favorable tolerability profile reinforce the pot ———————————————————————————————————————————————————————————— Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026 2026-10-23 · GlobeNewswire · Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/23/3387293/0/en/celcuity-presents-updated-data-from-a-phase-1b-2-study-evaluating-gedatolisib-plus-darolutamide-in-men-with-metastatic-castration-resistant-prostate-cancer-at-the-esmo-congress-202.html Median radiographic progression free survival (“rPFS”) was 15.7 months and the six-month rPFS rate (“rPFS6”) was 82.2% in patients who received prior abiraterone ———————————————————————————————————————————————————————————— Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress 2026-10-23 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/23/3387290/0/en/eikon-therapeutics-presents-data-from-parp1-selective-and-wrn-helicase-programs-at-the-european-society-for-medical-oncology-congress.html MILLBRAE, Calif., Oct. 23, 2026 -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the presentation of initial and updated data for EIK1003 and initial data for EIK1004 and EIK1005 at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain. ———————————————————————————————————————————————————————————— Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/23/3387289/0/en/pasithea-therapeutics-announces-positive-pas-004-clinical-data-from-phase-1-advanced-cancer-study-presented-at-esmo-congress-2026.html Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026 ———————————————————————————————————————————————————————————— MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN 2026-10-23 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/23/3387288/0/en/macrogenics-announces-positive-interim-phase-1-results-for-mgc026-and-highlights-plans-to-initiate-front-line-combination-study-in-scchn.html ROCKVILLE, MD, Oct. 23, 2026 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate (ADC), in patients with advanced solid tumors. These Phase 1 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain. These results demonstrated durable activity across a broad range of solid tumors, which the Company believes supports expanded development of MGC026 in front-line metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with pembrolizumab. ———————————————————————————————————————————————————————————— Oral Cavity (Mouth) Cancer - Global Clinical Trials Review, 2026 | Sponsor, Pipeline, and Enrollment Trends Highlight Strategic R&D Opportunities 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387294/28124/en/oral-cavity-mouth-cancer-global-clinical-trials-review-2026-sponsor-pipeline-and-enrollment-trends-highlight-strategic-r-d-opportunities.html Identify cost-saving trial locations, guide investment strategies, uncover business opportunities, and benchmark trial success, enrollment trends and competitors. Identify cost-saving trial locations, guide investment strategies, uncover business opportunities, and benchmark trial success, enrollment trends and competitors. ———————————————————————————————————————————————————————————— Multiple Myeloma (Kahler Disease) - Global Clinical Trials Landscape and Strategic Review, 2026 | Pipeline, Enrollment, and Sponsor Trends Reveal R&D and Partnership Opportunities 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387287/28124/en/multiple-myeloma-kahler-disease-global-clinical-trials-landscape-and-strategic-review-2026-pipeline-enrollment-and-sponsor-trends-reveal-r-d-and-partnership-opportunities.html Optimize trial ROI by identifying cost efficient locations, enrollment trends, success rates and key opportunities to sharpen investment strategies and gain a competitive edge. Optimize trial ROI by identifying cost efficient locations, enrollment trends, success rates and key opportunities to sharpen investment strategies and gain a competitive edge. ———————————————————————————————————————————————————————————— Membranous Glomerulonephritis - Global Clinical Trials Landscape and Competitive Review, 2026 | Pipeline, Enrollment, and Regional Trends Guide Strategic Investment 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387285/28124/en/membranous-glomerulonephritis-global-clinical-trials-landscape-and-competitive-review-2026-pipeline-enrollment-and-regional-trends-guide-strategic-investment.html Identify efficient trial locations, investment opportunities and competitive strategies using global trial, enrollment, sponsor and success rate insights. Identify efficient trial locations, investment opportunities and competitive strategies using global trial, enrollment, sponsor and success rate insights. ———————————————————————————————————————————————————————————— Asthma - Global Clinical Trials and Therapeutics Market Review, 2026 | Novel Biologics and Oral Therapies Drive Pipeline Investment and Partnership Opportunities 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387284/28124/en/asthma-global-clinical-trials-and-therapeutics-market-review-2026-novel-biologics-and-oral-therapies-drive-pipeline-investment-and-partnership-opportunities.html Identify strategic trial locations to save time and cost, uncover business opportunities, guide investments and benchmark enrollment trends, success rates and competitors. Identify strategic trial locations to save time and cost, uncover business opportunities, guide investments and benchmark enrollment trends, success rates and competitors. ———————————————————————————————————————————————————————————— Dermatomyositis - Global Clinical Trials Landscape and Competitive Intelligence, 2026 | Pipeline Activity and Enrollment Trends Reveal Strategic R&D Opportunities 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387282/28124/en/dermatomyositis-global-clinical-trials-landscape-and-competitive-intelligence-2026-pipeline-activity-and-enrollment-trends-reveal-strategic-r-d-opportunities.html Identify cost-saving trial locations, investment opportunities, enrollment trends and success rates to sharpen strategy and gain competitive advantage. Identify cost-saving trial locations, investment opportunities, enrollment trends and success rates to sharpen strategy and gain competitive advantage. ———————————————————————————————————————————————————————————— Florida Cancer Specialists & Research Institute Drug Development Research Featured at ESMO Congress 2026 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma, Government & policy https://www.prnewswire.com/news-releases/florida-cancer-specialists--research-institute-drug-development-research-featured-at-esmo-congress-2026-302918109.html ESMO 2026 abstracts featuring FCS research: 52P, 1017P, 1076TiP, 1021P, 1134eTiP, 1146eTiP, 1594P, 1846P, 3151P, 2216O FORT MYERS, Fla., Oct. 23, 2026 -- Findings from early-phase clinical research conducted with participation from Florida Cancer Specialists & Research... ———————————————————————————————————————————————————————————— Rheumatic Disorders - Global Clinical Trials Landscape Review, 2026 | Trial Hotspots, Enrollment Trends, and Sponsor Activity Reveal Strategic Investment Opportunities 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387281/28124/en/rheumatic-disorders-global-clinical-trials-landscape-review-2026-trial-hotspots-enrollment-trends-and-sponsor-activity-reveal-strategic-investment-opportunities.html Identify high-potential trial locations, reduce time and costs, guide investment strategies, uncover business opportunities and strengthen competitive advantage. Identify high-potential trial locations, reduce time and costs, guide investment strategies, uncover business opportunities and strengthen competitive advantage. ———————————————————————————————————————————————————————————— Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications 2026-10-23 · GlobeNewswire · Finance, SaaS, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387280/0/en/bolt-biotherapeutics-announces-acquisition-of-prana-therapies-and-120-million-concurrent-private-placement-to-advance-pra-216-in-multiple-high-value-inflammatory-indications.html REDWOOD CITY, Calif., Oct. 23, 2026 -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”) today announced the acquisition of Prana Therapies, Inc. (“Prana”), a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Following the acquisition, the Company will focus on advancing Prana’s pipeline of half-life-extended multispecific antibodies generated from its proprietary INSPIRE platform, led by PRA-216, a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis, with a Phase 2 study in eosinophilic esophagitis (EoE) planned. ———————————————————————————————————————————————————————————— PRF Technologies Issues Letter to Shareholders Highlighting $11.0 Million Cash Position, Entering Phase 2 Trial of OcuRing™-K and GridFeed™ Opportunity in AI Data Center Power 2026-10-23 · GlobeNewswire · AI, Biotech & pharma, Cloud & data centers https://www.globenewswire.com/news-release/2026/10/23/3387278/0/en/prf-technologies-issues-letter-to-shareholders-highlighting-11-0-million-cash-position-entering-phase-2-trial-of-ocuring-k-and-gridfeed-opportunity-in-ai-data-center-power.html Preliminary cash, including short-term deposits, of approximately $11.0 million as of September 30, 2026, and total liabilities of approximately $2.5 million ———————————————————————————————————————————————————————————— CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL 2026-10-23 · PR Newswire · Finance, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-provides-updated-webcast-registration-link-for-ifetroban-dmd-program-call-302917759.html NASHVILLE, Tenn., Oct. 23, 2026 -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, confirmed that it will provide an update on its ifetroban product candidate... ———————————————————————————————————————————————————————————— Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine 2026-10-23 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/23/3387264/0/en/elicio-therapeutics-presents-late-breaking-phase-2-amplify-7p-results-at-esmo-congress-2026-and-announces-simultaneous-publication-in-nature-medicine.html BOSTON, Oct. 23, 2026 -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced results from the randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P), presented in a late-breaking Proffered Paper oral session at the European Society for Medical Oncology (“ESMO”) Congress 2026 in Madrid, Spain, and simultaneously published in Nature Medicine: "Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial". ———————————————————————————————————————————————————————————— Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions 2026-10-23 · Business Wire · AI, SaaS, Biotech & pharma https://finance.yahoo.com/healthcare/articles/pathos-ai-announces-strategic-collaborations-130000398.html Tempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to license the dataset under a five-year, $55 million agreement Pathos's AI expertise and agentic AI platform, Foundry, combined with Bristol Myers Squibb's (BMS) neuroscience drug development expertise to b ———————————————————————————————————————————————————————————— Tempus Expands Strategic Collaboration with Bristol Myers Squibb 2026-10-23 · Business Wire · Finance, AI, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/tempus-expands-strategic-collaboration-bristol-130000904.html CHICAGO, October 23, 2026--Tempus AI, Inc. (NASDAQ: TEM, "Tempus") today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, "BMS"), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug ta ———————————————————————————————————————————————————————————— Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline 2026-10-23 · Business Wire · Finance, AI, SaaS, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/pathos-ai-secures-237-million-130000823.html Funding follows rapid portfolio expansion and will power the initiation of a registrational study for AI-identified asset JSKN016 NEW YORK, October 23, 2026--Pathos AI, Inc., a clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs, today announced the closing of a $23 ———————————————————————————————————————————————————————————— Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/neuromodulation-publishes-full-36-month-130000394.html – CORE-VNS is the largest prospective, multinational observational study evaluating contemporary VNS Therapy devices in people with Drug-Resistant Epilepsy – Demonstrated 76% median reduction in seizure frequency and a durable clinical benefit – Data also showed improvements in rescue medication use, healthcare resource u ———————————————————————————————————————————————————————————— Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses. 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/brenus-pharmas-novel-vivo-immunotherapy-125000466.html Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics MADRID, October 23, 2026--Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nin ———————————————————————————————————————————————————————————— Gene Synthesis: Technologies and Global Markets to Reach $7.2 Billion by 2031 2026-10-23 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387222/0/en/gene-synthesis-technologies-and-global-markets-to-reach-7-2-billion-by-2031.html “Gene synthesis is advancing precision medicine and genetic research, opening new opportunities for innovative therapies and biotechnology.” ———————————————————————————————————————————————————————————— Aimwell Partners Successfully Renegotiates Fixed-Price Debt Provision, Clearing the Path to Scale Verified Healthcare Intelligence Through Biotech Acquisitions 2026-10-23 · ACCESS Newswire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/aimwell-partners-successfully-renegotiates-fixed-120000789.html At current market prices, restructured terms would require approximately 98.6% fewer shares to convert the same debt; Company advances acquisition discussions as AimwellBio expands its network of featured healthcare companies and professionals MIAMI, FL / October 23, 2026 / Aimwell Partners Inc. (OTC PIN ———————————————————————————————————————————————————————————— Hub71 Startup, Vivan Therapeutics to Begin TuMatch™ Clinical Registration Study at Burjeel Cancer Institute, Abu Dhabi 2026-10-23 · EIN Presswire · AI, Healthcare, Biotech & pharma https://www.einpresswire.com/article/951734819/hub71-startup-vivan-therapeutics-to-begin-tumatch-clinical-registration-study-at-burjeel-cancer-institute-abu-dhabi Hub71 Startup, Vivan Therapeutics set to Begin TuMatch™ Clinical Registration Study at Burjeel Cancer Institute, Abu Dhabi Prospective study of AI-enabled clinical decision support in colorectal cancer will generate the first UAE outcomes and health-economics evidence for TuMatch™ NEW YORK CITY , NY, UNITED STATES, October 23, 2026 / EINPresswire.com / -- Vivan Therapeutics , a precision oncology company developing A ———————————————————————————————————————————————————————————— Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026 2026-10-23 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-highlight-first-in-human-phase-1-study-of-atnm-400-a-her3-targeted-non-psma-radiotherapy-in-prostate-cancer-at-esmo-2026-302917535.html First‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapy HER3‑targeted alpha radiotherapy offers a differentiated approach through a target distinct from... ———————————————————————————————————————————————————————————— Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/intensity-therapeutics-inc-to-present-invincible-4-neoadjuvant-triple-negative-breast-cancer-study-data-for-the-first-seven-7-patients-after-int230-6-treatment-cohort-a-in-an-eposter-presentation-at-the-european-society-of-m-302917587.html Pathological complete response (pCR) achieved in the breast (ypT0/Tis) and affected lymph nodes (ypN0) in 5 out of 7 patients (71%; 95% CI 29-96%) in the INT230-6 plus standard-of-care cohort No invasive breast cancer cells were detected in the axillary lymph nodes in 6 of the 7 INT230-6... ———————————————————————————————————————————————————————————— Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026 2026-10-23 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387215/0/en/immutep-announces-presentation-of-quality-of-life-data-from-eftisarc-neo-phase-ii-trial-at-esmo-2026.html Quality of life remained stable during neoadjuvant treatment with efti, pembrolizumab and radiotherapy, with statistically significant improvement after surgery ———————————————————————————————————————————————————————————— ImPact Biotech Reports Encouraging Early Clinical Results From Phase 1 Study of Padeliporfin VTP in Pancreatic Cancer, with Seven Previously Unresectable Patients Undergoing Surgical Resection Following Treatment 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387201/0/en/impact-biotech-reports-encouraging-early-clinical-results-from-phase-1-study-of-padeliporfin-vtp-in-pancreatic-cancer-with-seven-previously-unresectable-patients-undergoing-surgica.html TEL AVIV, Israel, Oct. 23, 2026 -- ImPact Biotech, a clinical-stage biotechnology company developing Padeliporfin vascular targeted photodynamic (VTP) therapy for the treatment of solid tumors, today announced the successful completion of treatment in Part A of its Phase 1 clinical trial in patients with Stage III, locally advanced, unresectable pancreatic ductal adenocarcinoma (PDAC). ———————————————————————————————————————————————————————————— Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma, Medical devices https://www.globenewswire.com/news-release/2026/10/23/3387207/0/en/humacyte-at-asn-kidney-week-phase-3-trial-built-for-women-shows-atev-advantage-over-fistula-getting-patients-off-catheters-months-sooner.html - The presenter, Dr. Roy-Chaudhury said, “These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider the ATEV as a meaningful new option.” ———————————————————————————————————————————————————————————— Salubris Biotherapeutics Announces Updated Phase 1b/2 Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology Congress 2026 2026-10-23 · Business Wire · Healthcare, Biotech & pharma, Government & policy https://finance.yahoo.com/healthcare/articles/salubris-biotherapeutics-announces-updated-phase-120000997.html JK06 continued to demonstrate a highly differentiated safety profile for an MMAE ADC among 230 patients in the target dose range; predominantly low-grade, manageable treatment-related adverse events (TRAEs) were observed with low rates of dose reduction and discontinuation Among response-evaluable squamous non-small cell ———————————————————————————————————————————————————————————— CD Bioparticles Launches Custom High-Loading EGCG Nanoparticles Development Service for Enhanced Combination Antitumor Therapy 2026-10-23 · MarketersMEDIA · Biotech & pharma https://news.marketersmedia.com/cd-bioparticles-launches-custom-high-loading-egcg-nanoparticles-development-service-for-enhanced-combination-antitumor-therapy/89207091 CD Bioparticles launches High-Loading EGCG Nanoparticles Development services to support combination antitumor therapy and efficient drug delivery. -- CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of its High-Loading EGCG Nanoparticles Development services to support researchers and biotechnology professionals in advancing combination an ———————————————————————————————————————————————————————————— Creative Diagnostics Highlights Chagas Disease Model to Support Antiviral and Antiparasitic Drug Discovery 2026-10-23 · MarketersMEDIA · SaaS, Biotech & pharma, Medical devices https://news.marketersmedia.com/creative-diagnostics-highlights-chagas-disease-model-to-support-antiviral-and-antiparasitic-drug-discovery/89207089 Creative Diagnostics announces the expansion of its preclinical evaluation platform with comprehensive Chagas Disease Model development services. -- As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the expansion of its preclinical evaluation platform with comprehensive Chagas Disease Model development services. These new in vivo solutions can support ———————————————————————————————————————————————————————————— Harvest Declares Big Pharma Split Corp. October 2026 Distributions 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/markets/stocks/articles/harvest-declares-big-pharma-split-113000757.html OAKVILLE, Ontario, October 23, 2026--Harvest Portfolios Group Inc. ("Harvest") declares the monthly cash distribution payable for Big Pharma Split Corp. of $0.1031 for each class A share (PRM:TSX) for the month ending October 31, 2026. The distribution is payable November 6, 2026 to class A shareholder ———————————————————————————————————————————————————————————— Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study 2026-10-23 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/izalontamab-brengitecan-iza-bren-reduced-113000687.html Late-breaking results to be presented in an oral presentation at ESMO 2026 With two positive Phase 3 trials in breast cancer, these data reinforce the potential of iza-bren to further redefine treatment across breast cancer subtypes Iza-bren, a potentially first-in-class dual-targeting EGFRxHER3 bispecific antibody-drug c ———————————————————————————————————————————————————————————— Hong Kong International Optical Fair Opens in November 2026-10-23 · NewMediaWire · AI, SaaS, Healthcare, Education, Fashion & luxury, Sports, Industrial, Biotech & pharma, Sustainability, Consumer electronics https://www.newmediawire.com/news/hong-kong-international-optical-fair-opens-in-november-7090830 - Showcasing Innovation, Technology and Trendsetting Designs to Capture New Opportunities in the Eyewear Industry HONG KONG - October 23, 2026 - Organised by the Hong Kong Trade Development Council (HKTDC) and co-organised by the Hong Kong Optical Manufacturers Association (HKMOA), the 34th Hong Kong International Optical Fair will be held from 4 to 6 November at the Hong Kong Convention and Exhibition Centre (HKCEC). Under the theme "Bright Eyes • New Horizons", the fair will bring together more than 600 exhibitors from 14 countries and regions, featuring a wide range of products and solutions covering smart eyewear, eye care, sports and specialist eyewear, frames, lenses and more, providing buyers with a comprehensive one-stop sourcing platform. HKTDC Associate Executive Director Smilely Lam said: "The eyewear industry is entering a new era driven by technological innovation, sustainability and changing lifestyles. AI-powered smart glasses, for example, recorded global shipments of 8.7 million units last year, representing a remarkable year-on-year increase of 322%, underscoring the sector’s strong growth momentum. The Hong Kong International Optical Fair showcases the latest products and technologies, and also inspires the industry to explore emerging market opportunities from fresh perspectives and foster cross-industry collaboration. From smart eyewear and green solutions to innovative fashion-forward designs, we look forward to providing a platform for exchanges and partnerships within and beyond the industry while reinforcing Hong Kong's position as an international business hub and regional sourcing centre." Global brands unveil the next wave of eyewear innovation This year, the fair brings together exhibitors from Hong Kong, the Chinese Mainland, Taiwan, and across Asia, Europe and the United States. Industry associations and enterprises from various regions will also be featured, including the HKOMA, Danyang in Jiangsu Province, Zhejiang, Yingtan in Jiangxi Province, Taiwan, ASEAN, Korea and the Fukui Optical Association, as well as the Visionaries of Style zone dedicated to creative designer brands. Making its debut at the fair, Daegu Health College of Korea will bring a number of local eyewear companies and showcase their innovative products. The spotlighted "Brand Name Gallery" will showcase some 200 renowned brands from around the world, highlighting the latest designs and technological innovations. The 34th Hong Kong International Optical Fair has already attracted pre-registered buyers from leading retailers and distributors worldwide, including Capitol Optical (Singapore), Eyespace Eyewear (UK), Grand Optik (Indonesia), Kaundi GmbH (Austria), Optica Halperin Ltd (Israel), Optical London Drugs (Canada), Parasite Design (France), The Optical Company (Australia) and Vision Plus (US), demonstrating the event’s strong international sourcing appeal. Capturing growth in smart eyewear and the silver economy Rapid advances in artificial intelligence and wearable technology are driving strong growth in the smart eyewear sector. According to IDC, global smart glasses shipments reached 3.566 million units in the first quarter of 2026, up 130.1% year-on-year. Meanwhile, market research firm Omdia reported that global AI eyewear shipments reached 8.7 million units in 2025, representing annual growth of 322%, highlighting the transition of smart eyewear from a niche category to mainstream adoption. This year's fair will feature a wide array of smart eyewear equipped with augmented reality (AR), AI voice assistants, real-time translation, 4K recording and navigation functions. At the same time, growing demand from the silver economy is fuelling interest in vision care and eye-health products. Exhibitors will showcase progressive lenses, smart reading glasses, bone-conduction audio glasses and eye-care devices designed for older consumers, helping to enhance quality of life and visual wellbeing. Sports eyewear, performance eyewear, sustainability-focused products and green manufacturing technologies will also be among the highlights. Industry events spotlight emerging trends and future opportunities A series of forums and seminars will be held during the fair, covering topics such as smart eyewear, performance eyewear, testing and certification, enabling industry professionals to keep abreast of the latest market developments. The 24th Hong Kong International Optometric Symposium, organised by the HKTDC and co-organised by the Hong Kong Optometric Association and The Hong Kong Polytechnic University, will take place on 5 November. Under the theme "Primary Eye Care in Action: Elevating Clinical Scope and Community Impact", experts from Chinese Mainland, Hong Kong, Australia, the United Kingdom, and the United States will share the latest research findings and clinical experiences on a wide range of topics, including paediatric eye care, digital eye strain, driving vision assessment, dry eye management, inherited retinal diseases, and collaborative management between optometrists and ophthalmologists. In addition, the 26th Hong Kong Eyewear Design Competition will hold its award presentation ceremony on the opening day of the fair. This year's theme, "Mix & Match", encourages designers to showcase eyewear as an expression of fashion and personal style through innovative designs. A new Technology Concept Award has been introduced for student participants to encourage the integration of creativity and technology. The fair will continue to adopt the EXHIBITION+ hybrid model which seamlessly integrates online and offline elements to extend business opportunities. Exhibitors and buyers can connect and arrange meetings through the Click2Match online smart business-matching platform until 13 November. During the physical event, buyers can also use the Scan2Match function on the HKTDC Marketplace App to scan exhibitors’ QR codes to bookmark favourite suppliers, access product details and interactive floor plans, and make product enquiries - enabling engagement with exhibitors before and after the fair to continue their sourcing journey. Featured Products Driven by technological innovation, demographic shifts and increasing health awareness, the eyewear industry is entering a new era of growth and transformation. This year's fair spotlights five major trends: smart technology, the silver economy, fashion and design, active lifestyles, and sustainability. Showcasing innovative products and solutions that combine technology, wellness, design and environmental responsibility, the fair offers a glimpse into the future of the industry while opening up fresh business opportunities. Highlights include: Photo Download: https://bit.ly/4iuIl1Q Websites The Hong Kong International Optical Fair: https://www.hktdc.com/event/hkopticalfair/en Event details of the Hong Kong International Optical Fair: https://www.hktdc.com/event/hkopticalfair/en/programme The 24th Hong Kong International Optometric Symposium:  https://www.hktdc.com/event/hkopticalfair/en/the-24th-hong-kong-international-optometric-symposium The HKTDC's Media Room: http://mediaroom.hktdc.com/en Fair Details Date: 4 – 6 November 2026 (Wednesday to Friday) Time: (4 to 5 November) 9:30am – 6:30pm (6 November)      9:30am – 5:00pm Venue: Hong Kong Convention and Exhibition Centre Admission: For trade visitors aged 18 or above only. Onsite Registration Fee: HK$100 per person (free for e-Badge registration and pre-registered buyers) Click2Match – Smart Business Matching Platform: Date: 28 October – 13 November Media enquiries: For enquiries, please contact: HKTDC Communication and Public Affairs Department: Navin Law Tel: (852) 2584 4525 Email: navin.cm.law@hktdc.org Winnie Kan Tel: (852) 2584 4055 Email: winnie.wy.kan@hktdc.org About HKTDC The Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. ———————————————————————————————————————————————————————————— Biotech Ingredients Market Trends, Size & Growth by 2034 2026-10-23 · PR News Releaser · Healthcare, Food & drink, Fashion & luxury, Biotech & pharma, Sustainability, Consumer goods https://www.prnewsreleaser.com/news/477958 The Biotech Ingredients Market is gaining importance as biotechnology, pharmaceutical, food, cosmetics, and personal care companies increasingly adopt biologically derived ingredients to develop innovative and sustainable products. Market Overview The Biotech Ingredients Market size is expected to reach US$ 5.09 ... Read more ———————————————————————————————————————————————————————————— Biosimilars Market Outlook and Strategic Insights by 2028 2026-10-23 · PR News Releaser · Biotech & pharma https://www.prnewsreleaser.com/news/477956 The Biosimilars Market is gaining momentum as healthcare providers, pharmaceutical companies, and regulatory authorities increasingly recognize the role of biosimilar medicines in improving access to advanced biological treatments. Biosimilars are highly similar versions of approved biological medicines that demonstrate no ... Read more ———————————————————————————————————————————————————————————— Not Just Pharmacy: How Medkart is Building India’s Smartest Generic Medicine App 2026-10-23 · EIN Presswire · Biotech & pharma https://www.einpresswire.com/article/951755575/not-just-pharmacy-how-medkart-is-building-india-s-smartest-generic-medicine-app Medkart makes it easier for users to compare branded generic medicines INDIA, October 23, 2026 / EINPresswire.com / -- Ahmedabad (Gujarat) [India], August 5: India’s pharmaceutical landscape is undergoing a vital transformation. Despite being home to one of the world’s largest medicine markets, millions of Indian families continue to struggle with the high cost of treatment. Studies show that over 50% of healthcare e ———————————————————————————————————————————————————————————— Moderna Named a Top Employer by Science for Twelfth Consecutive Year 2026-10-23 · Newswire.com · Finance, Biotech & pharma, Jobs & workplace https://www.newswire.com/news/moderna-named-a-top-employer-by-science-for-twelfth-consecutive-year Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2026 Top Employers Survey for the twelfth consecutive year. Moderna was recognized for its corporate image, leadership and direction, and work culture, reflecting its reputation for innovation and quality research, commitment to continuous improvement, and collaborative, ———————————————————————————————————————————————————————————— Alebund Pharmaceuticals Announces Poster Presentation by Partner R1 Therapeutics of Global Phase IIb Multi-Regional Clinical Trial Design for AP306 at ASN Kidney Week 2026 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/alebund-pharmaceuticals-announces-poster-presentation-by-partner-r1-therapeutics-of-global-phase-iib-multi-regional-clinical-trial-design-for-ap306-at-asn-kidney-week-2026-302917966.html SHANGHAI, Oct. 23, 2026 -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that its partner, R1 Therapeutics, Inc. ("R1"), presented a trial-in-progress poster outlining the design... ———————————————————————————————————————————————————————————— Marengo Therapeutics Announces Landmark Nature Medicine Publication Establishing First-in-Human Proof of Vβ-Directed T-Cell Biology and Antitumor Activity 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/marengo-therapeutics-announces-landmark-nature-medicine-publication-establishing-first-in-human-proof-of-v-directed-t-cell-biology-and-antitumor-activity-302917323.html First-in-human results from the STARt-001 Phase 1/2 clinical trial demonstrate selective activation of Vβ6/Vβ10 T cells expands functional effector and memory populations, generating single-agent antitumor activity in heavily pretreated, checkpoint-resistant solid tumors Peer-reviewed... ———————————————————————————————————————————————————————————— Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials 2026-10-23 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387158/0/en/aardvark-therapeutics-reports-exploratory-data-from-the-terminated-hero-and-open-label-extension-trials.html SAN DIEGO, Oct. 23, 2026 -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi syndrome (PWS) and metabolic diseases, today reported exploratory efficacy data from its previously terminated Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and open-label extension (OLE) trial. As previously announced, Aardvark unblinded the data accumulated across both the HERO trial and OLE trial to assess the totality of available efficacy and safety data to inform the path forward for ARD-101. ———————————————————————————————————————————————————————————— Hexagon Bio Raises $62 Million Series C Financing to Advance HEX-360 into the Clinic and Expand Pipeline of Antibody-Drug Conjugates with Novel Payload Mechanisms 2026-10-23 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387153/0/en/hexagon-bio-raises-62-million-series-c-financing-to-advance-hex-360-into-the-clinic-and-expand-pipeline-of-antibody-drug-conjugates-with-novel-payload-mechanisms.html Hexagon Bio raises $62 million series C financing to advance HEX-360 into the clinic. ———————————————————————————————————————————————————————————— Star Therapeutics Announces $200 Million Private Financing to Advance Pipeline of Best-in-Disease Therapies 2026-10-23 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/star-therapeutics-announces-200-million-110000867.html Financing will support Star's next phase of growth, including advancement of current preclinical programs into the clinic and continued pipeline expansion Financing follows Incyte's July 2026 acquisition of Star subsidiary Vega Therapeutics for up to $2 billion and builds on the Star team's track record of creating and ad ———————————————————————————————————————————————————————————— ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET 2026-10-23 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387147/0/en/ani-pharmaceuticals-to-discuss-third-quarter-2026-financial-results-on-november-5-2026-at-8-00-a-m-et.html PRINCETON, N.J., Oct. 23, 2026 -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, at 8:00 a.m. ET. ———————————————————————————————————————————————————————————— Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy 2026-10-23 · PressReach · Biotech & pharma https://pressreach.com/tango-presents-promising-results-from-phase-1-2-study-of-vopimetostat-and-daraxonrasib-in-pancreatic-cancer-and-provides-updates-to-development-strategy 82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer treated with vopimetostat plus daraxonrasib  Vopimetostat combinations with RAS(ON) inhibitors daraxonrasib or zoldonrasib continued to be generally well-tolerated Registrational Phase 3 study of vopimetostat plus daraxonrasib in front-line patients with MTAP-deleted pancreatic cancer … Continue reading "Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy" ———————————————————————————————————————————————————————————— DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network 2026-10-23 · Newswire.com · AI, Healthcare, Retail, Education, Food & drink, Biotech & pharma, Internet & apps https://www.newswire.com/news/datameds-ai-establishes-health-lives-here-community-respiratory-program-for Being marketed to 6,500+ Corexa Health Pharmacy Network of independent pharmacies To be launched first at Corexa Pharmacy in Lakeland, FL retail location in Q4/2026 Program will aim to bring best practices for respiratory season to community pharmacies Nuvaxovid COVID vaccine (protein-based / non-mRNA) prioritized for campaign rollout Improve telehealth availability in the pharmacy through Health Lives Here mobile app Tests to include COVID neutralizing antibodies, antibodies & acute respiratory infections Long COVID-related biomarkers (cardiovascular, incl microclots; immune; metabolic; etc) Immune profiling for other circulating respiratory diseases (influence, RSV, strep, others) Improve access to FDA-approved antivirals Pharmacist education on Tollo Health medical foods and dietary supplements ———————————————————————————————————————————————————————————— Political Consultations between Burkina Faso and The Republic 0f Turkey: Wide-Ranging Consultations to Strengthen Cooperation 2026-10-23 · APO Group · Healthcare, Energy, Education, Food & drink, Logistics, Biotech & pharma, Banking, Government & policy, Entertainment, Mining & metals https://www.africa-newsroom.com/press/political-consultations-between-burkina-faso-and-the-republic-0f-turkey-wideranging-consultations-to-strengthen-cooperation?lang=en During their stay in Ankara for the first session of political consultations between Burkina Faso and the Republic, the Burkinabe delegation led by the Comrade Secretary General of the Ministry of Foreign Affairs, Ambassador Hermann Yirigouin TOE, conducted wide-ranging consultations on October 20 and 21, 2026 with numerous figures within various Turkish state structures. Thus, the delegation visited in turn the Maarif Foundation, the Cooperation and Coordination Agency (TIKA), the Higher Education Information Council, the Ministry of Health, the Council for External Economic Relations (DEIK), and the Ministry of National Education. At the MAARIF Foundation, Ambassador Hermann Yirigouin TOE and his delegation held discussions with Anet BEY, Head of Africa at the MAARIF Foundation, assisted by colleagues. He welcomed the signing of an establishment and management agreement with the foundation, which already owns schools in Ouagadougou and Bobo-Dioulasso, and the awarding of scholarships for Burkinabe students. She also requested the foundation's support for increasing the number of these scholarships and for support in the areas of education and vocational and technical training. MAARIF agreed to all of these requests. The two parties also discussed opportunities for expanding the foundation's activities in Burkina Faso. At the Cooperation and Coordination Agency (TIKA), the Turkish development agency founded in 1992, the Secretary General of the Ministry of Foreign Affairs was received by Dr. Yahya Coskun, Vice President of the institution. TIKA has numerous achievements in Burkina Faso. Among other things, she supported the development of emergency medicine with the SAMU (Emergency Medical Service). The Agency expressed its support for a review of the project for its implementation. For 2027, it committed to providing support to Burkina Faso in the area of ​​vocational and technical training, in line with the country's endogenous development objective. The Burkinabe delegation also expressed the wish that a TIKA office could be opened soon in Ouagadougou. At the Higher Education Council, discussions between Burkinabe and Turkish representatives focused primarily on the issue of renewing the 2024 memorandum of understanding, which sets out the conditions for cooperation in academic and university matters and which has now expired. From the outset, Burkina Faso expressed its commitment to preserving the existing agreements, maintaining this cooperation, and strengthening it. The Turkish Council for Higher Education also supports this renewal and promises to increase the number of scholarships for Master's and Doctoral programs for Burkinabe students. The Turkish side stated that it was open to any proposals for improving our cooperation within the framework of the new agreement. A prioritized list of Burkina Faso's needs will be sent to Turkey immediately. Researchers from Burkina Faso will also be able to access and apply to the project bank of Turkish research centers. At the Ministry of Health, the Burkinabe delegation was received by the Vice-Minister, Professor Nurullah OKUMUS. Ambassador Hermann Yirigouin TOE praised the dynamism of cooperation between our two countries in the field of health, with the success of the first kidney transplant in Burkina Faso as a concrete achievement. The Turkish Deputy Minister expressed his country's commitment to continuing its support for Burkina Faso in organ transplantation. This support will take the form of training and skills development for trainers, keeping pace with evolving knowledge in the field. He also expressed support for facilitating agreements between Turkish public hospitals and the Burkinabe Ministry of Health as part of deepening health cooperation. Professor Nurullah OKUMUS expressed interest in the Kokologho pharmaceutical technopole project, which could offer investment opportunities to Turkish companies. At the Foreign Economic Relations Board (DEIK), which represents 4,000 Turkish companies, discussions led to a proposal to hold a business and investment forum between Burkina Faso and Turkey in Burkina Faso. Turkish exports to Burkina Faso are projected to increase from US$122.24 million in 2023 to US$177.84 million in 2025. This growth testifies to the dynamism of our trade relations, and Ambassador TOE commended the important role played by DEIK in bringing Turkish and Burkinabe businesses closer together. He urged the institution to be more actively involved in resolving disputes between Turkey and Burkinabe to prevent Burkinabe companies from continually suffering losses. DEIK, through Ms. Vahit Oguz Cetin, one of its leaders for West Africa, advocated for the facilitation of banking transactions and an agreement on the elimination of double taxation. The Burkinabe delegation explained that this issue of double taxation is addressed at the confederal level within the Confederation of Sahel States (AES). It encouraged joint ventures and the establishment of sustainable partnerships, particularly in agri-food, cold chain logistics, textiles, solar energy, mining, technical training, etc., to boost national economic development. At the Turkish Ministry of National Education, discussions focused primarily on the issue of improving the quality of education desired and sought by Burkina Faso to support its project for the economic and social transformation of the country within the framework of the Popular Progressive Revolution. The Turkish Department of Education has stated its readiness to examine all options regarding the training of teachers and administrators of the education system, the sharing of experience in vocational and technical training, the sharing of school programs and training curricula, and the implementation of new programs. He also proposed twinning projects between Turkish and Burkinabe schools for a mixing of peoples, the ambition being to leave future generations a legacy of relations based on friendship and cooperation. Between two consultations, Ambassador Hermann Yirigouin TOE and his delegation visited the Atatürk Mausoleum named after Mustafa Kemal ATATÜRK, the Founder of the Republic of Türkiye. A return to the roots of modern Türkiye, rich in lessons about the determination of a man and the nationalism of a people who knew how to take charge of their destiny and establish themselves in the concert of nations. Distributed by APO Group on behalf of Ministère des Affaires étrangères, Burkina Faso. ———————————————————————————————————————————————————————————— Bioprocess Validation Market Analysis, Development, and Competitive Landscape by 2031 2026-10-23 · PR News Releaser · Healthcare, Industrial, Biotech & pharma https://www.prnewsreleaser.com/news/477952 The Bioprocess Validation Market is gaining importance as pharmaceutical, biotechnology, and biopharmaceutical companies increasingly focus on manufacturing consistency, product quality, patient safety, and regulatory compliance. Bioprocess validation involves documented procedures used to demonstrate that manufacturing processes consistently produce products meeting ... Read more ———————————————————————————————————————————————————————————— Biopharmaceutical Fermentation Market Size, Trends & Demand by 2034 2026-10-23 · PR News Releaser · Industrial, Biotech & pharma https://www.prnewsreleaser.com/news/477950 The Biopharmaceutical Fermentation Market is gaining importance as pharmaceutical and biotechnology companies increasingly adopt advanced manufacturing technologies to develop biologics, vaccines, therapeutic proteins, enzymes, and other biotechnology-derived products. Fermentation processes utilize microorganisms, including bacteria, yeast, and other engineered biological systems, ... Read more ———————————————————————————————————————————————————————————— EXTL1 Antibody Market Trends, Share & Demand by 2034 2026-10-23 · PR News Releaser · Biotech & pharma https://www.prnewsreleaser.com/news/477943 According to The Insight Partners The EXTL1 Antibody Market size is projected to grow from US$ 1.33 billion in 2025 to US$ 2.56 billion by 2034, registering a CAGR of 8.50% during 2026–2034. The global EXTL1 Antibody Market is experiencing ... Read more ———————————————————————————————————————————————————————————— Merck Foundation Chief Executive Officer (CEO), Senator Dr. Rasha Kelej and Kenya First Lady H.E. Mrs. Rachel Ruto, E.G.H. Officially Launched their Joint Programs at the Kenya State House 2026-10-23 · APO Group · Finance, Healthcare, Media, Education, Food & drink, Fashion & luxury, Biotech & pharma, Government & policy, Nonprofits, Internet & apps, Entertainment https://merckfoundation.africa-newsroom.com/press/merck-foundation-chief-executive-officer-ceo-senator-dr-rasha-kelej-and-kenya-first-lady-he-mrs-rachel-ruto-egh-officially-launched-their-joint-programs-at-the-kenya-state-house?lang=en Merck Foundation (www.Merck-Foundation.com), the philanthropic arm of Merck KGaA Germany, launched their Educating Linda Program to support girl education at Kenya State House, in partnership with H.E. Mrs. RACHEL RUTO E.G.H, The First Lady of the Republic of Kenya and Ambassador of “Merck Foundation More Than a Mother”. During the visit, the Merck Foundation Kenya Alumni Summit 2026 was also conducted to highlight the impact of their scholarships program with the aim to build healthcare capacity and transform patient care landscape across Kenya nationwide. The program was attended by The First Lady of the Republic of Kenya H.E. Mrs. RACHEL RUTO E.G.H, Chairman of Merck Foundation Board of Trustees, Prof. Dr. Frank Stangenberg-Haverkamp, and CEO of Merck Foundation and President of “More Than a Mother” Campaign, Dr. Rasha Kelej and Kenya Minister of Health, Hon. Aden Duale. Senator Dr. Rasha Kelej (Ret.), CEO of Merck Foundation and President of “More Than a Mother” Campaign emphasized, “It is a great pleasure to meet my dear sister, H.E. Mrs. RACHEL RUTO E.G.H. First Lady of the Republic of Kenya and to recognize her for her tremendous efforts as the Ambassador of “Merck Foundation More Than a Mother”. I am proud that through our long-term partnership we have provided 328 scholarships for young Kenyan healthcare providers in 44 critical and underserved specialties. I am also happy to share that nearly 50% of these scholarships have been awarded to women healthcare providers, reinforcing our commitment to women empowerment. It was also great meeting Kenya Minister of Health, Hon. Aden Duale and our Alumni, who are the future healthcare experts of Kenya.” “We are looking forward to extending our scholarship program to more healthcare providers in partnership with First Lady of Kenya and in collaboration with Medical Societies and Ministry of Health when possible.” She added. H.E. Mrs. Rachel Ruto E.G.H., The First Lady of the Republic of Kenya expressed, “Through our impactful partnership with Merck Foundation, we are not just implementing programs, we are transforming lives. Together, we are strengthening our healthcare capacity, empowering girls through education, breaking infertility stigma, and addressing other critical social and health challenges across Kenya. We are immensely proud that, through our strong partnership, we have been able to provide 328 scholarships for our healthcare providers, not only in the capital city, but across the country. It represents a powerful investment in the future of our healthcare system, a commitment to building expertise where it is needed most, and a significant step towards ensuring equitable access to quality care for all our people. At the same time, we are equally proud to support the education of 47 high-performing yet underprivileged Kenyan schoolgirls, providing them with annual scholarships till they graduate. By empowering these young girls through education, we are not only transforming individual lives, but also shaping stronger families, communities, and a brighter future for our nation.” Prof. Dr. Frank Stangenberg-Haverkamp Chairman of Merck Foundation Board of Trustees added, “Our aim is to improve the overall health and wellbeing of people by building healthcare capacity in Kenya and across developing countries. We are strongly committed to transforming patient care through our scholarships program.” Hon. Aden Duale, Cabinet Secretary, Ministry of Health, Kenya shared, “We sincerely appreciate the Merck Foundation Scholarships Program through which 328 scholarships have been provided till today for our local healthcare providers in many critical underserved specialties, helping us to build and strengthen our healthcare capacity, across the country.” One of the important specialties that Merck Foundation is focusing on in 2025 and 2026 in Kenya is the scholarship of One Year Diploma in Nutrition, to support the program of Feeding and Food Security of Kenya First Lady. More than 90 scholarships are dedicated to this specialty across the 47 provinces of Kenya. This will create a culture shift in leading a healthy lifestyle for the whole population which will contribute to healthier communities and hence social and economic development of the whole country nationwide. The program was also attended by the Kenyan winners of Merck Foundation Media Awards 2024 and 2025. “It was a pleasure meeting and celebrating our Winners, the health and social champions, who are the voice of the voiceless”, added Dr. Rasha Kelej. Out of the total 328 scholarships, Merck Foundation has provided: 121 scholarships for one-year postgraduate diplomas and two-year master’s degrees in Diabetes, Preventative Cardiovascular Medicine, Cardiology, and Endocrinology. These programs enable doctors to establish specialized diabetes clinics across the country. 10 scholarships for Oncology, which is a critical specialty to strengthen cancer care capacity. 49 scholarships for Fertility, Embryology, and Reproductive Medicine under the “More Than a Mother” campaign, bringing hope and support to couples facing infertility challenges. 148 scholarships for other important specialties such as Internal Medicine, Psychiatry, Neurology, Emergency Medicine, Dermatology, and many more, contributing significantly to strengthening Kenya’s healthcare system. Merck Foundation has overall provided more than 2,600 scholarships for healthcare providers in 44 critical and undeserved specialties from over 52 countries. During the Summit, Merck Foundation alumni shared inspiring testimonies on how these scholarships have transformed their professional journeys and improved patient care in their communities. Merck Foundation, in partnership with the First Lady of Kenya, is also launching children’s storybooks — “More Than a Mother”, “Educating Linda”, “Jackline’s Rescue”, “Not Who You Are”, “Ride into the Future”, “Sugar Free Jude” and “Mark’s Pressure” in English and Swahili to raise awareness about critical social and health issues among young children. Thousands of copies will be distributed across schools in Kenya. These storybooks have also been adapted into animated films to further enhance their impact. Moreover, Merck Foundation has conducted 4 Editions of their Online Health Media Training for Kenyan journalists to empower them to raise awareness about sensitive social and health issues such as breaking infertility stigma, supporting girl education, ending child marriage and GBV, and promoting healthy lifestyle practices. Merck Foundation, together with the First Lady of Kenya, also organizes annual awards for media, musicians, filmmakers, and fashion designers to encourage creative talents to raise awareness about important social issues. Merck Foundation in partnership with the First Lady of the Republic of Kenya has also announced the Call for Application for their important annual Awards for Media, Musicians, Fashion Designers, Filmmakers, students, and new potential talents in these fields. Details of the Awards: 1. Merck Foundation Media Recognition Awards 2026 “Diabetes & Hypertension”: Media representatives are invited to showcase their work through strong and influential messages to promote a healthy lifestyle and raise awareness about the prevention and early detection of Diabetes and Hypertension. Submission deadline: 30th October 2026. 2. Merck Foundation Film Awards 2026 “Diabetes & Hypertension”: All Filmmakers, Students of Film Making Training Institutions, or Young Talents are invited to create and share a long or short FILMS, either drama, documentary, or docudrama to deliver strong and influential messages to promote a healthy lifestyle raise awareness about prevention and early detection of Diabetes and Hypertension. Submission deadline: 30th October 2026. 3. Merck Foundation Fashion Awards 2026 “Diabetes & Hypertension”: All Students and Designers are invited to create and share designs to deliver strong and influential messages to promote a healthy lifestyle and raise awareness about the prevention and early detection of Diabetes and Hypertension. Submission deadline: 30th October 2026. 4. Merck Foundation Song Awards 2025 “Diabetes & Hypertension”: All Singers and Musical Artists are invited to create and share a SONG with the aim to promote a healthy lifestyle and raise awareness about the prevention and early detection of Diabetes and Hypertension. Submission deadline: 30th October 2026. Apply here: https://apo-opa.co/4siT2b4 Entries for all the awards are to be submitted via email to: submit@merck-foundation.com Distributed by APO Group on behalf of Merck Foundation. Contact: mehak.handa@external.merckgroup.com Join the conversation on our social media platforms below and let your voice be heard! https://apo-opa.co/4siApEp https://apo-opa.co/4sjDsw3 https://apo-opa.co/48grr0V https://apo-opa.co/4k9Cq3t https://apo-opa.co/4stVHij https://apo-opa.co/4i0xWef www.Merck-Foundation.com https://apo-opa.co/4yD9HHU About Merck Foundation: Merck Foundation works across more than 50 countries with First Ladies, their Foundations, Ministries, and other key stakeholders. Through complementary roles in advocacy, local government coordination, healthcare & media capacity building, girls’ education, and community awareness initiatives. It is this coordinated ecosystem of partnerships—with distinct responsibilities and a shared vision—that enables Merck Foundation to build local capacity, create sustainable impact, and contribute to long-term transformation in healthcare and society. Through their various programs and initiatives, Merck Foundation has provided 2,750+ scholarships for healthcare providers from 52 countries in 44 critical and underserved specialties, awarded 1,570+ scholarships to underprivileged African schoolgirls across 21 countries, trained 4,000+ media professionals, recognized 980 award winners, and reached 9+ million followers across 15 social media channels, driving lasting impact in healthcare, education, and awareness across Africa and Asia. The Merck Foundation is dedicated to improving social and health outcomes for communities in need. While it collaborates with various partners, including governments to achieve its humanitarian goals, the foundation remains strictly neutral in political matters. It does not engage in or support any political activities, elections, or regimes, focusing solely on its mission to elevate humanity and enhance well-being while maintaining a strict non-political stance in all of its endeavors. All Merck Foundation press releases are distributed by e-mail at the same time they become available on the Merck Foundation Website.  Please visit www.Merck-Foundation.com to read more. Follow the social media of Merck Foundation: Facebook (https://apo-opa.co/4siApEp), X (https://apo-opa.co/4sjDsw3),Instagram (https://apo-opa.co/4k9Cq3t), YouTube (https://apo-opa.co/48grr0V), Threads (https://apo-opa.co/4stVHij) and Flickr (https://apo-opa.co/4i0xWef). This content is not intended for US/ Canadian audiences. ———————————————————————————————————————————————————————————— Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3 2026-10-23 · PressReach · Biotech & pharma https://pressreach.com/zymeworks-enters-into-an-exclusive-global-license-and-collaboration-agreement-with-roche-for-zw209-a-trispecific-t-cell-engager-targeting-dll3 Zymeworks to receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial, with potential for up to $718 million in additional development, commercial and sales-based milestones  Zymeworks also eligible to receive tiered high-single-digit to mid-teen royalties on global net sales protected by patents extending into 2040’s Zymeworks … Continue reading "Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3" ———————————————————————————————————————————————————————————— 2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS 2026-10-23 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/2026-esmo-lba--innovent-announces-international-phase-3-study-of-arcotatug-tavatecan-cldn18-2-adc-in-gastric-cancer-met-dual-primary-endpoints-of-pfs-and-os-302917985.html Registrational Phase 3 G-HOPE-001 Study Met Both Primary Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Overall Survival and Progression-Free Survival Benefits in Previously Treated, CLDN18.2-positive Gastric Cancer Arcotatug Tavatecan Demonstrated a... ———————————————————————————————————————————————————————————— Angel Yeast Marks 40th Anniversary, Setting Its Sights on Becoming a Global Biotech Powerhouse 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/angel-yeast-marks-40th-anniversary-setting-its-sights-on-becoming-a-global-biotech-powerhouse-302917975.html YICHANG, China, Oct. 23, 2026 -- Angel Yeast (SSE: 600298), one of the world's leading yeast manufacturers, has hosted the 2026 International Synthetic Biology Symposium and the Angel Group High-Quality Development Conference in Yichang, its headquarters city, on October... ———————————————————————————————————————————————————————————— ReGen Medical's Focused Energy Wave Technology Sets New Benchmark in Shockwave Therapy Precision 2026-10-23 · EIN Presswire · Healthcare, Energy, Biotech & pharma https://www.einpresswire.com/article/950744904/regen-medical-s-focused-energy-wave-technology-sets-new-benchmark-in-shockwave-therapy-precision RCT's focused-energy approach delivers therapeutic results in 3-5 sessions, now available at the Center for New Medicine in Irvine, California IRVINE, CA, UNITED STATES, October 23, 2026 / EINPresswire.com / -- ReGen Medical Network Teams with Center for New Medicine to Bring Advanced Regenerative Technology to Leading Integrative Medicine Practice Strategic Alliance Expands Access to Cutting-Edge Cellular and Aesthe ———————————————————————————————————————————————————————————— IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas 2026-10-23 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/ide849-shr-4849-dll3-top1-adc-updated-phase-1-results-at-esmo-2026-demonstrates-promising-anti-tumor-activity-and-preliminary-overall-survival-results-in-relapsed-small-cell-lung-cancer-and-neuroendocrine-carcinomas-302917466.html 17.4-month median OS in 2L SCLC (n=51) and 14.7-month median OS in 2L + ≥3L SCLC (n=101) 72.5% (37/51) ORR and 60.8% (31/51) cORR in 2L SCLC with 6.9-month median PFS; 68.3% (69/101) ORR and 54.5% (55/101) cORR in 2L + ≥3L SCLC with 6.8-month median PFS 76.9% (20/26) ORR and 65.4% (17/26)... ———————————————————————————————————————————————————————————— In Kinshasa, Congolese National Police (PNC), MONUSCO Police (UNPOL) and U-Report raise youth awareness on security and health 2026-10-23 · APO Group · Finance, SaaS, Healthcare, Education, Biotech & pharma, Government & policy https://www.africa-newsroom.com/press/in-kinshasa-congolese-national-police-pnc-monusco-police-unpol-and-ureport-raise-youth-awareness-on-security-and-health?lang=en The MONUSCO Police (UNPOL) supported a forum held in Kinshasa on Wednesday, 21 October, organized by the Congolese National Police (PNC) in collaboration with the U-Report platform. The forum focused on youth, peace, health and community safety. Participants included young people, health-sector stakeholders, civil society representatives and residents of Mont-Ngafula, where the local U-Report section initiated the event. The initiative aims to draw public attention to drug use and violence among young people. According to the mayor of Mont-Ngafula, the municipality is particularly affected by the use of psychoactive substances among young people, a practice that often leads to violence. “Our young people face many challenges, particularly drug use,” said Séverin Lumbu. Andréa Amisi, who coordinates U-Report in the municipality, shares the mayor’s concerns. His youth and involvement in U-Report bring him into contact with many young people. He regrets that, in the absence of opportunities and proper guidance, many young people turn to hard liquor and psychoactive substances. He also points out that most of those selling these products are young people themselves. This trade provides them with a source of income while endangering the health of other young people and undermining community safety. “This reality calls on all of us to act,” said the mayor of Mont-Ngafula. “It requires collective awareness, but above all, concrete and lasting action.” This is precisely the purpose of the forum: to bring together young people, health professionals, local authorities and the police to discuss effective ways of steering young people away from drugs and preventing urban violence. “We need responsible young people who are engaged and aware of their rights, but also of their duties towards their community and their nation,” Séverin Lumbu stressed. To combat drug use, he called for substantial efforts in education and prevention. A shared commitment to fighting drug use The police share this view. The Deputy Executive Secretary of the Committee for Monitoring Police Reform in the Democratic Republic of the Congo, which co-organized the forum, also highlighted the harmful effects of hard liquor and drug use among young people. “Drug addiction is a real scourge that destroys human lives in our society,” said Deputy Divisional Commissioner Jean-Rémy Nkanga, calling for coordinated action by all stakeholders in the sector. His appeal echoed UNPOL’s advocacy. Edmond Tapsoba, who spoke on behalf of the MONUSCO Police at the forum, reminded participants that “security is a shared responsibility,” emphasizing the important role young people play in ensuring security in a vast municipality such as Mont-Ngafula. There is indeed a link between the use of psychoactive substances and security. Dr. Patrice Milambo, coordinator of the National Programme for Combating Drug Addiction and Toxic Substances, explained that, according to African Union figures, 6% of people who commit acts of violence do so under the influence of these substances. He described the connection as “clear.” For Amisi of U-Report, the same pattern is evident. The more idle young people are, the more likely they are to turn to drugs, increasing the risk of their involvement in criminal activities. He recalled a campaign he conducted in 2024 after noticing an increase in burglaries in his municipality on evenings when Africa Cup of Nations matches were being played. The campaign revealed that many young people involved in the burglaries were using psychoactive substances. Like all the other forum participants, Andréa Amisi is calling for greater awareness-raising and educational efforts among young people to address drug addiction. U-Report is a community-based youth engagement platform that enables young people to express their views on issues that affect them. In Mont-Ngafula, the platform reports having approximately 200 active young members, with just over 5,000 others following and participating in its activities across the municipality. Distributed by APO Group on behalf of Mission de l'Organisation des Nations unies en République démocratique du Congo (MONUSCO). ———————————————————————————————————————————————————————————— Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA 2026-10-23 · PressReach · Finance, Healthcare, Food & drink, Biotech & pharma, Legal https://pressreach.com/phathom-pharmaceuticals-provides-update-on-litigation-filed-by-bdr-pharmaceuticals-against-fda FLORHAM PARK, N.J., Oct. 23, 2026 — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that BDR Pharmaceuticals International Pvt. Ltd. (BDR) has filed suit against the U.S. Food and Drug Administration (FDA) and related Federal Defendants in the United … Continue reading "Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA" ———————————————————————————————————————————————————————————— Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer 2026-10-23 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387079/0/en/phase-iii-trial-shows-veracyte-s-decipher-prostate-test-can-predict-benefit-from-adding-abiraterone-to-treatment-in-very-high-risk-prostate-cancer.html STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO ———————————————————————————————————————————————————————————— ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial 2026-10-23 · PressReach · Biotech & pharma, Government & policy https://pressreach.com/oric-pharmaceuticals-presents-potential-best-in-class-data-for-enozertinib-in-1l-nsclc-patients-with-egfr-atypical-mutations-at-esmo-congress-2026-and-plans-to-advance-enozertinib-into-a-global In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with multiple intracranial complete responses 88% 6-month landmark PFS compares favorably to current standards of care and to investigational therapies; follow-up ongoing … Continue reading "ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial" ———————————————————————————————————————————————————————————— ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026 2026-10-23 · PressReach · Healthcare, Biotech & pharma, Government & policy https://pressreach.com/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED inhibitor rinzimetostat maintained effectiveness Preclinical results, supported by translational data in mCRPC patient samples, show rinzimetostat reinforces a luminal, AR-dependent state, restricts lineage plasticity and enhances sensitivity … Continue reading "ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026" ———————————————————————————————————————————————————————————— Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease 2026-10-23 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/alnylam-announces-positive-initial-phase-074500219.html - Initial Phase 1b results show mean reduction of cerebrospinal fluid mutant huntingtin of 60 to 64% at month 3 with individual reduction of up to 83% and encouraging safety and tolerability with potential for twice yearly dosing - - Unique targeting approach reduces both mutant huntingtin and shorter mutant HTT1a- - Plac ———————————————————————————————————————————————————————————— CCHR Urges the FDA to Follow UK Warnings on Antidepressant Suicide Risk and Persistent Sexual Dysfunction 2026-10-23 · 24-7 Press Release · Healthcare, Biotech & pharma https://www.24-7pressrelease.com/press-release/539872/cchr-urges-the-fda-to-follow-uk-warnings-on-antidepressant-suicide-risk-and-persistent-sexual-dysfunction The UK's drug regulatory agency has expanded suicide-risk information to all ages and formally recognizes antidepressant-induced sexual dysfunction ———————————————————————————————————————————————————————————— Democratic Republic of the (DR) Congo: Ebola responders under pressure as outbreak expands 2026-10-23 · APO Group · Healthcare, Travel, Biotech & pharma, Government & policy https://www.africa-newsroom.com/press/democratic-republic-of-the-dr-congo-ebola-responders-under-pressure-as-outbreak-expands?lang=en Authorities in Abuja confirmed their first case of infection in an individual arriving from Uganda, which borders the worst-hit provinces in DRC. “The source of exposure is still not known and the travel history of the patient is being pieced together now in terms of her movement from Uganda up to Nigeria,” said Dr Patrick Otim, from the UN World Health Organization (WHO)’s Emergency Response programme, in an online update.  “This is rapidly evolving. As we get more information, we’ll try to determine where she was exposed. And then it’s at that point where we can say whether there is any transmission happening.” Nigeria is the fifth country this year after DRC, France, Uganda and Kenya to confirm the presence of Ebola disease caused by Bundibugyo virus.  The original DRC outbreak was declared in mid-May where it has led to more than 4,600 deaths and a total of 9,552 confirmed infections. Around six in 10 of these deaths have occurred outside health centres, indicating the continuing difficulty of halting community transmission.  The latest DRC province to confirm infections is Nord Ubangi, which borders Central African Republic, where ongoing armed violence continues to uproot thousands of people, increasing the difficulty of halting transmission. Nairobi controls The Kenyan authorities have reported a total of nine cases of infection including one death earlier this month, of a Kenyan national who had been working in DRC before flying back to Nairobi via Entebbe, Uganda. Uganda previously recorded two deaths and 20 confirmed cases of infection, before officially declaring the Ebola threat over at the end of August. “Immediately after [the death of the Kenyan patient], we commenced on contact tracing,” said Dr Patrick Amoth, Director General of Kenya’s Ministry of Health, adding that 135 contacts with the deceased patient have been traced “and we have been able to account for them, 100 per cent”. According to the Nigerian authorities, the patient developed symptoms on 7 October and sought care at a clinic before being hospitalised 48 hours later.  Genetic sequencing of the infection is underway to confirm that it is the same Ebola Bundibugyo disease circulating inside DRC. More than 40 close contacts have been identified to date, WHO has said.  “All the Infection Prevention and Control measures have been put in place to try to ensure that the risk of amplification of transmission within the health facilities is limited,” said WHO’s Dr Otim.  “The message is being passed to all the private facilities within [Abuja] and also all the other health facilities within the country to step up.” Vaccine research ongoing Inside DRC, in addition to the essential work of contact tracing, vaccination research is ongoing using Ervebo vaccine, which was originally designed for and is effective against Ebola disease caused by Zaire virus, in a bid to find out if it provides protection against Ebola Bundibugyo. “We still do not have preliminary data yet as to whether there is…sufficient cross-protection between the Ervebo vaccine – which is for the Zaire species – and the Bundibugyo species. As soon as we get it, we'll be able to share that information,” Dr Otim told journalists. Remote communities hardest-hit Responding to questions about the Ebola response inside DRC, the UN health agency highlighted ongoing transmission of infection and reports last week of 15 deaths per day in the rural commune of Mangina in Beni territory, North Kivu province.  After negotiating access, an emergency response team from WHO arrived there two weeks ago and started working with impacted communities. “There was a lot of community preoccupation and community resistance in the beginning to receive help, it’s a very highly insecure area,” said Dr Anne Ancia, WHO Country Representative in DRC.  “Ebola does not wait. It follows movement, exploits gaps and tests the strength of our health systems,” said Dr Mohamed Janabi, Regional Director for WHO Africa, underscoring that the virus is “no longer confined to one place, it is a regional concern”. He added: “We must reach people earlier, bring safe care closer and strengthen trust before fear becomes a barrier to survival. We also know that success is possible where surveillance is strong, where contacts are found and followed.” Distributed by APO Group on behalf of UN News. ———————————————————————————————————————————————————————————— Democratic Republic of Congo - Ebola response: Strengthening treatment and preserving essential care 2026-10-23 · APO Group · Finance, Healthcare, Biotech & pharma, Government & policy https://who-africa.africa-newsroom.com/press/democratic-republic-of-congo-ebola-response-strengthening-treatment-and-preserving-essential-care?lang=en “We were separated only by ropes.” When Dr Prince Afandia Alafu, 33, returns to the place where he was treated for Ebola, memories of his hospitalization resurface. In Isiro, in Haut Uélé province in northeastern of the Democratic Republic of the Congo, this general practitioner discovers, just weeks after his recovery, an expanded and better equipped treatment centre. Progress has been made to improve care for Ebola patients while allowing the hospital to gradually resume its usual activities. A few days before his admission, Dr Prince experienced persistent fever and headaches, which he initially attributed to malaria or typhoid. A test confirmed his infection with the Bundibugyo virus, responsible for the current Ebola outbreak. Accustomed to treating others, he suddenly became a patient himself. After several days of care, he managed to overcome the disease. On August 24, when he was admitted to the Isiro Ebola Treatment Centre (ETC), the facilities were still rudimentary. Spaces were cramped and care conditions difficult. Today, the centre has 50 beds and appropriate equipment. “There has really been a big improvement. Now there is electricity and water. The rooms are maintained regularly, and the conditions of care have changed,” he notes. Behind these changes lie the story of a hospital deeply shaken by the epidemic. Before Ebola arrived, the Isiro General Reference Hospital (GRH) had 130 beds and provided internal medicine, surgery, pediatrics, and obstetrics gynecology care, with an occupancy rate above 90%. When the first cases appeared in July 2026, the facility had to reorganize its services. “We had to move the pediatric ward. The pediatric pavilion became the first nucleus of the ETC within the hospital. With the increase in cases, we had to mobilize a second pavilion,” explains Dr David Kamalu, director of the GRH. The presence of Ebola patients in hospital buildings and fear of contamination gradually drove other patients away. According to Dr Kamalu, bed occupancy dropped to 30% in August. For medical teams, the challenge was immense: treating Ebola patients without interrupting care for pregnant women, children, and patients with other illnesses. As of 19 October 2026, 7 of the 13 health zones in Haut Uélé were affected by the Ebola outbreak. The province had recorded 421 confirmed cases, including 180 deaths. Isiro health zone was among the hardest hit. Under the leadership of the Ministry of Health, with support from WHO and partners, the ETC — initially with 40 beds — was expanded to 50 beds in collaboration with Médecins Sans Frontières (MSF). “This extension allows us to strengthen reception capacity and improve care for Ebola patients. It helps secure care circuits and reduce transmission risks,” emphasizes Dr Catherine Smallwood, WHO incident manager. “By having an adapted treatment centre, we also help the hospital gradually resume its usual activities.” The effects are already visible. Patients who had deserted the hospital out of fear are gradually returning. Today, we have about 55 patients hospitalized. Now that the centre is secure and circuits are better organized, patients are starting to come back for their usual care,” notes Dr Kamalu. Improved treatment capacity is accompanied by other interventions to preserve health services. WHO has delivered more than a ton of medicines, supplies, and medical equipment to the GRH, including oxygen therapy materials, personal protective equipment, beds, and mattresses, to support continuity of essential care. In Haut Uélé, health authorities also launched vaccination of frontline personnel for research purposes with the ERVEBO vaccine. Nationally, more than 9,000 agents have been vaccinated as part of this study. The effectiveness of this vaccine against the Bundibugyo Ebola virus, responsible for the current outbreak, is still under investigation. For Dr Steve Ahuka, incident manager of the Presidential Task Force dedicated to the Ebola response, complementarity of interventions is essential. “When we prevent through vaccination, when we treat the disease, when we raise awareness through survivors — these packages of activities are what make the disease recede,” he explains. For Dr Prince, the improvements are deeply meaningful. Having faced the challenges of the epidemic’s early weeks, he now sees how better care and stronger prevention are giving patients hope and helping rebuild community trust. His experience shows that Ebola does not have to be fatal: timely, appropriate care can save lives. “With the progress made in the response and the improvement of care conditions, I have hope that more patients will overcome Ebola, reunite with their families, and resume their normal lives.” Distributed by APO Group on behalf of WHO Regional Office for Africa. ———————————————————————————————————————————————————————————— Enterome Phase 1/2 data show OncoMimics™ EO4010-induced CD8 T-cell expansion was associated with longer survival in patients with colorectal cancer 2026-10-23 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387067/0/en/enterome-phase-1-2-data-show-oncomimics-eo4010-induced-cd8-t-cell-expansion-was-associated-with-longer-survival-in-patients-with-colorectal-cancer.html Enterome Phase 1/2 data show OncoMimics™ EO4010-induced CD8 T-cell expansion was associated with longer survival in patients with colorectal cancer ———————————————————————————————————————————————————————————— Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 2026-10-23 · PressReach · Healthcare, Biotech & pharma, Government & policy https://pressreach.com/evaxion-announces-89-vaccine-target-precision-and-sustained-t-cell-and-clinical-responses-at-three-year-follow-up-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01 EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses  Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress supplementing very convincing two-year data from the trial The data will be … Continue reading "Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01" ———————————————————————————————————————————————————————————— Top Drying Equipment Manufacturer Nanjing Huozao Advances Integrated Processing Solutions 2026-10-23 · EIN Presswire · Industrial, Biotech & pharma, Chemicals & materials https://www.einpresswire.com/article/951705846/top-drying-equipment-manufacturer-nanjing-huozao-advances-integrated-processing-solutions Steam Heating Vacuum Drying Oven NANJING, JIANGSU, CHINA, October 23, 2026 / EINPresswire.com / -- Nanjing Huozao Machinery Technology Co., Ltd. is strengthening its position in the industrial equipment sector through its focus on drying technology and related material-processing machinery. Based in Nanjing, China, the company serves industries such as pharmaceuticals and chemicals, where dependable equipment is impo ———————————————————————————————————————————————————————————— AdvanCell Presents Updated Phase 1 Results on ADVC001 at ESMO 2026 with Encouraging Long-term Data 2026-10-23 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/advancell-presents-updated-phase-1-060000035.html With a median follow-up of over 14 months, ADVC001, a novel Lead-212 PSMA therapy, continues to show favorable tolerability with no new safety signals in metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer Encouraging activity is seen at the two selected recommended Phase 2 doses (RP2D), 160 and 200 M ———————————————————————————————————————————————————————————— From Small Clinical Trials to a Single Patient, Genialis Demonstrates the Power of Biology-First AI in Cancer Research 2026-10-23 · Business Wire · AI, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/small-clinical-trials-single-patient-060000346.html New ESMO data from three trial-sized cohorts, and a 25-month analysis of GitLab co-founder Sid Sijbrandij's osteosarcoma highlight the potential to extract meaningful insights from limited patient data MADRID, October 23, 2026--Genialis, the therapeutic intelligence company, will present data at the Eu ———————————————————————————————————————————————————————————— Full-Life Technologies Reports Encouraging Preliminary Phase 1 Safety and PSA Decline for FL-020 in mCRPC at ESMO 2026 2026-10-23 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/full-life-technologies-reports-encouraging-preliminary-phase-1-safety-and-psa-decline-for-fl-020-in-mcrpc-at-esmo-2026-302917477.html Data updates from the ongoing Phase 1 dose-escalation study demonstrated promising therapeutic index in patients with mCRPC No dose-limiting toxicities observed; xerostomia has been predominantly Grade 1, with no cases of Grade 3 100% of lutetium-177-naive patients achieved PSA50, 88.9%... ———————————————————————————————————————————————————————————— Santhera’s Licensing Partner, Nxera Pharma, Submits Marketing Authorization Application for AGAMREE® (Vamorolone) in South Korea 2026-10-23 · GlobeNewswire · Healthcare, Food & drink, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/23/3387042/0/en/santhera-s-licensing-partner-nxera-pharma-submits-marketing-authorization-application-for-agamree-vamorolone-in-south-korea.html Pratteln, Switzerland, October 23, 2026 – Santhera Pharmaceuticals (SIX: SANN) today notes that its licensing partner Nxera Pharma Co., Ltd. (“Nxera”) has submitted a Marketing Authorization Application (MAA) to South Korea’s Ministry of Food and Drug Safety (MFDS) for AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD). ———————————————————————————————————————————————————————————— Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/galderma-relfydess-relabotulinumtoxina-receives-approval-050000597.html The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local ———————————————————————————————————————————————————————————— ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026 2026-10-23 · PR Newswire · SaaS, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/immunoforge-to-showcase-proprietary-platform-technologies-and-next-generation-oncology--phase-2-clinical-pipelines-at-bio-europe-2026-302917622.html SEOUL, South Korea and COLOGNE, Germany, Oct. 22, 2026 -- ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for rare and intractable diseases, today announced that its executive management team will participate... ———————————————————————————————————————————————————————————— Zai Lab Announces $250 Million Private Placement 2026-10-23 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/zai-lab-announces-250-million-005200382.html SHANGHAI & CAMBRIDGE, Mass., October 23, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) an innovation-driven, global biopharma company, today announced that it has entered into a securities purchase agreement for the sale of 11,340,000 American Depositary Shares ("ADSs"), each representing ten ordina ———————————————————————————————————————————————————————————— ASN 2026: HighTide Therapeutics Presents New HTD1801 Data Highlighting Therapeutic Potential in Chronic Kidney Disease 2026-10-23 · ACN Newswire · Healthcare, Biotech & pharma https://www.acnnewswire.com/press-release/english/111020/ Hong Kong, Oct 23, 2026 - HighTide Therapeutics, Inc. (02511.HK), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today presented new preclinical findings for HTD1801 in autosomal dominant polycystic kidney disease (ADPKD) at Kidney Week 2026, the 59th Annual Meeting of the American Society of Nephrology (ASN), in Denver, US. The findings demonstrate potent inhibitory activity of HTD1801 against cyst expansion in ADPKD. ADPKD is the most common inherited kidney disorder, characterized by progressive cyst formation and kidney failure by age 60 in approximately 50% of patients. Although existing treatments are available to slow disease progression in certain patients, safety risks and eligibility limitations leave substantial unmet medical needs in ADPKD. HTD1801 targets the AMPK–NLRP3 axis by activating AMPK, suppressing cAMP-driven epithelial cyst proliferation while inhibiting NLRP3 to mitigate renal inflammation and fibrotic remodeling, thereby potentially targeting key pathological processes in ADPKD. In this study, the effect of HTD1801 on forskolin (FSK)-induced cyst expansion was evaluated in PKD1−/− human iPSC-derived nephron organoids, with metformin and tolvaptan as reference comparators. The results showed that HTD1801 significantly reduced the median cystic area fraction to 10.70%, compared with 20.40% in the FSK model control group. Meanwhile, organoids with a low cystic burden (<20%) increased from 46.9% in the model control group to 97.3%, while organoids with a high cystic burden (≥30%) decreased from 8.2% to 0%. By comparison, metformin reduced the median cystic area fraction to 13.12%, while tolvaptan did not alter cyst burden, as this model does not respond to tolvaptan. These findings further expand the potential multidimensional renal benefits of HTD1801. Previous studies have demonstrated the potential of HTD1801 to improve metabolic abnormality-associated renal impairment. HTD1801 effectively suppresses cyst expansion in PKD1-mutant human nephron organoids, validating its dual effects of AMPK activation and NLRP3 inhibition in ADPKD pathogenesis. These preclinical findings provide a strong rationale for further clinical investigation of HTD1801 to explore its potential as a disease-modifying therapy for ADPKD. They further highlight the therapeutic potential of HTD1801 for patients with ADPKD and other chronic kidney diseases (CKD), particularly those currently underserved by existing treatment options. Presentation Title: HTD1801 Suppresses Cyst Expansion in PKD1-Mutant Nephron Organoids: Evidence for AMPK-NLRP3 Axis Efficacy in ADPKD Presentation Number: TH-PO0204 Date and Time: October 22, 2026, 10:00 AM–12:00 PM MDT Format: Poster Presentation Session: ADPKD and Cystic Kidney Disease – 1 [PO1201-1] Presenter: Dr. Filip Surmont, Chief Medical Officer of HighTide Therapeutics “ADPKD continues to pose a substantial unmet medical need, as progressive cyst growth can lead to deterioration of kidney function and ultimately kidney failure, underscoring the need for effective therapies that can inhibit cyst growth,” said Dr. Filip Surmont, Chief Medical Officer of HighTide Therapeutics. “The significant suppression of cyst expansion observed with HTD1801 in this study provides new scientific evidence to support its further development in ADPKD and highlights its potential as a disease-modifying therapy. We will continue to advance research on HTD1801 to further validate these findings and explore its potential therapeutic value in kidney diseases.” ———————————————————————————————————————————————————————————— Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/harbour-biomed-receives-china-nmpa-approval-of-batoclimab-injection-subcutaneous-injection-for-the-treatment-of-generalized-myasthenia-gravis-302917545.html The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 22, 2026 -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to... ———————————————————————————————————————————————————————————— ImmVira Presents Clinical Data from Three Bladder Cancer Studies at ESMO 2026 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma, Government & policy https://www.prnewswire.com/news-releases/immvira-presents-clinical-data-from-three-bladder-cancer-studies-at-esmo-2026-302915052.html SUZHOU, China, Oct. 22, 2026 -- ImmVira Group ("ImmVira") today announced that updated clinical data from three bladder cancer studies of its lead oncolytic immunotherapy candidate, MVR-T3011, will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress.... ———————————————————————————————————————————————————————————— Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering 2026-10-22 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Insurance https://www.globenewswire.com/news-release/2026/10/22/3387000/0/en/lycia-therapeutics-announces-pricing-of-upsized-initial-public-offering.html SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases, today announced the pricing of its upsized initial public offering of 17,640,000 shares of its common stock at an initial public offering price of $18.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $317.5 million. All shares of common stock to be sold in the offering will be sold by Lycia. In addition, Lycia has granted the underwriters a 30-day option to purchase up to an additional 2,646,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Lycia’s common stock is expected to begin trading on the Nasdaq Global Select Market on October 23, 2026, under the symbol “LYCA.” The offering is expected to close on October 26, 2026, subject to the satisfaction of customary closing conditions. ———————————————————————————————————————————————————————————— Sarcomatrix Therapeutics Accredited Investor Round Scheduled to Close October 31 2026-10-22 · ACCESS Newswire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/sarcomatrix-therapeutics-accredited-investor-round-232500387.html RENO, NV / October 22, 2026 / Sarcomatrix Therapeutics Corp. , a Delaware corporation based in Reno, Nevada, today reminded prospective investors that its accredited investor round, conducted under Regulation D, Rule 506(c), is scheduled to close on October 31, 2026, the closing date the company announce ———————————————————————————————————————————————————————————— Hazlet NJ Medicare Diabetic Shoe Coverage & Eligibility: Guide Released 2026-10-22 · MarketersMEDIA · Healthcare, Fashion & luxury, Biotech & pharma https://news.marketersmedia.com/hazlet-nj-medicare-diabetic-shoe-coverage-andamp-eligibility-guide-released/89207072 Hazlet Medical Supplies has released a guide covering Medicare Part B benefits for diabetic shoes, including eligibility criteria, annual limits, and 2026 out-of-pocket costs for NJ patients. -- New Jersey residents with diabetes who are uncertain about their footwear coverage options now have a dedicated resource from Hazlet Medical Supplies. The newly released guide addresses how Medicare Part B handles therapeutic ———————————————————————————————————————————————————————————— Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026 2026-10-22 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386983/0/en/mineralys-therapeutics-presents-new-lorundrostat-data-in-participants-with-hypertension-and-chronic-kidney-disease-at-asn-kidney-week-2026.html In the large, pivotal Phase 3 Launch-HTN trial, lorundrostat achieved similar significant blood pressure reductions in participants with and without CKD, with consistent reductions across Stages 1-3 CKD ———————————————————————————————————————————————————————————— HUYABIO International Announces HBI-8000 and Nivolumab Combination Reduces the Risk of Disease Progression by 27% in Patients with Advanced Melanoma in Phase 3 Trial 2026-10-22 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/huyabio-international-announces-hbi-8000-and-nivolumab-combination-reduces-the-risk-of-disease-progression-by-27-in-patients-with-advanced-melanoma-in-phase-3-trial-302917490.html Oral HBI-8000 plus intravenous nivolumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with nivolumab alone, reducing the risk of disease progression or death by 27% Median progression-free survival was 11.7 months... ———————————————————————————————————————————————————————————— Neovii Advances FDA Fast Track-Designated ATLG Program in Type 1 Diabetes With Pivotal Phase 2 Study - Company Appoints Physician-scientist Salvatore Alesci as Chief Medical Officer 2026-10-22 · NewMediaWire · Healthcare, Food & drink, Industrial, Biotech & pharma, Medical devices https://www.newmediawire.com/news/neovii-advances-fda-fast-track-designated-atlg-program-in-type-1-diabetes-with-pivotal-phase-2-study-company-appoints-physician-scientist-salvatore-alesci-as-chief-medical-officer-7090826 BOSTON, MA and RAPPERSWIL-JONA, SWITZERLAND - October 22, 2026 - Neovii Pharmaceuticals AG, a Swiss-headquartered, commercial-stage biopharmaceutical company with more than four decades of experience in antibody-based immunotherapies, today announced that it is advancing its Type 1 Diabetes (T1D) clinical program through a company-sponsored pivotal Phase 2 study in the United States and European Union. The international expansion builds on the ongoing investigator-initiated European GIRO (Grafalon in early onset) T1D study and is supported by U.S. Food and Drug Administration (FDA) Fast Track designation for anti-T-lymphocyte globulin (ATLG) for the prevention of declining C-peptide production in patients with recent-onset T1D. Patients have already been treated in GIRO, and clinical data are being generated. The expected 12-month efficacy and safety interim analysis will provide an important near-term milestone and inform the pivotal study program. This next stage marks an important expansion beyond transplantation and reflects Neovii’s strategy to apply its expertise in immune modulation to autoimmune and immune-mediated diseases with strong biological rationale and significant unmet medical need. In connection with this expansion, Neovii has appointed Salvatore “Salvo” Alesci, M.D., Ph.D., as Chief Medical Officer, effective October 15, 2026. Dr. Alesci will lead the company’s medical and clinical development activities, including translational medicine and regulatory strategy. He will oversee the Type 1 Diabetes program and help shape the company’s broader clinical development strategy, including the evaluation of future development opportunities. Scientific Rationale for ATLG in Type 1 Diabetes Type 1 Diabetes is a chronic autoimmune disease characterized by T-cell-mediated destruction of insulin-producing pancreatic beta cells. Many patients retain residual beta-cell function following diagnosis, and preserving this endogenous function remains an important therapeutic objective. ATLG is a polyclonal anti-T-lymphocyte globulin with preferential activity against activated T cells and broader effects across T-cell populations and immune pathways involved in autoimmune responses. Published clinical proof of concept in recent-onset Type 1 Diabetes was reported by Saudek et al. in a placebo-controlled study of ATLG. Together with other clinical evidence that modulation of pathogenic T-cell responses can preserve residual beta-cell function, these findings provide a clinical and mechanistic rationale for evaluating ATLG in the ongoing GIRO T1D study and company-sponsored pivotal Phase 2 study. ATLG has been used in transplantation medicine for more than four decades. Building on this extensive manufacturing, preclinical, and clinical experience, Neovii is now evaluating its potential role in autoimmune disease. The investigator-initiated European GIRO T1D study and the company-sponsored pivotal Phase 2 study in the United States and the European Union are complementary components of the ATLG clinical development program. Neovii is using emerging efficacy and safety data from GIRO to inform the pivotal study and support ongoing discussions with the FDA, European regulatory authorities, and other health authorities on a potential registration pathway. Executive Commentary Frederic Prince, Ph.D., Chief Executive Officer of Neovii Pharmaceuticals AG, commented: “Despite major advances in glucose monitoring and insulin delivery, Type 1 Diabetes continues to impose a substantial burden on patients. ATLG’s well-characterized activity against activated T cells, clinical proof of concept in recent-onset disease, and extensive clinical experience provide a strong foundation for its further evaluation. Building on the investigator-initiated GIRO T1D study, we are advancing a company-sponsored pivotal Phase 2 study to assess whether ATLG can preserve endogenous beta-cell function and reduce treatment burden. "As we take this important step in expanding Neovii’s clinical development activities, I am also delighted to welcome Salvo to Neovii as our Chief Medical Officer. His expertise in endocrinology, translational medicine, and clinical development will be highly valuable as we advance our Type 1 Diabetes program and evaluate future opportunities in immune-mediated diseases.” Salvatore Alesci, M.D., Ph.D., Chief Medical Officer of Neovii Pharmaceuticals AG, said: “I am excited to join Neovii at this important stage in the company’s evolution and help drive its expansion into Type 1 Diabetes and other immune-mediated diseases. Despite significant advances in disease management, preservation of endogenous beta-cell function remains an important therapeutic objective in Type 1 Diabetes. ATLG provides an opportunity to rigorously evaluate a differentiated immunomodulatory approach in a randomized clinical setting. I look forward to working with the Neovii team, investigators, patients, advocacy groups, and regulatory authorities to execute a scientifically rigorous Type 1 Diabetes development program and shape the company’s broader clinical strategy in immune-mediated diseases.” About Salvatore Alesci, M.D., Ph.D. Dr. Alesci is a physician-scientist and biopharmaceutical executive with combined expertise in endocrinology and immunology and more than 25 years of experience spanning translational medicine, clinical development, regulatory strategy and scientific and patient affairs. Throughout his career, he has held senior leadership roles in biotechnology and pharmaceutical organizations, leading multidisciplinary global programs from early research through late-stage clinical development. About Neovii Pharmaceuticals AG Neovii Pharmaceuticals AG is a Swiss-headquartered, fully integrated biopharmaceutical company focused on developing, manufacturing, and commercializing antibody-based therapy for immune-mediated diseases. The company markets Grafalon® (ATLG, formerly named as ATG-F), an anti-human T-lymphocyte immunoglobulin approved in multiple countries for transplantation-related indications; approved uses vary by country. Grafalon is manufactured at Neovii’s dedicated biotechnology manufacturing facility in the Munich area and is commercialized in more than 50 countries. Building on decades of expertise in immune modulation, Neovii is expanding its research and development activities into selected autoimmune and immune-mediated diseases with significant unmet medical need. ATLG is investigational in Type 1 Diabetes and has not been approved for this use. Nothing in this release should be interpreted as promoting ATLG for an unapproved indication. Forward-Looking Statement This press release contains forward-looking statements regarding Neovii’s planned clinical development activities, regulatory interactions, clinical-study design and execution, business strategy, and potential future registration pathways. These statements are based on current beliefs, expectations, and assumptions and involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Clinical development outcomes, regulatory decisions, trial initiation and enrollment, safety and efficacy findings, development timelines, manufacturing readiness, and business objectives are subject to factors beyond Neovii’s control. Fast Track designation does not guarantee that ATLG will qualify for Accelerated Approval or Priority Review, that regulatory review will be completed within any particular timeframe, or that ATLG will receive marketing approval for Type 1 Diabetes. Neovii undertakes no obligation to update these forward-looking statements except as required by applicable law. Reference: Saudek, F., et al. The Review of Diabetic Studies, Vol. 1, No. 2, 2004. Media contact Neovii Pharmaceuticals AG, info@neovii.com, www.neovii.com ———————————————————————————————————————————————————————————— Aptar Taps Pharma Packaging Veteran Virginie Maes as President of its Pharma Business 2026-10-22 · Business Wire · Finance, Healthcare, Retail, Biotech & pharma https://finance.yahoo.com/healthcare/articles/aptar-taps-pharma-packaging-veteran-213000960.html CRYSTAL LAKE, Ill., October 22, 2026--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced the appointment of Virginie Maes as President of Aptar Pharma, effective January 1, 2027. Maes joins Aptar from Amco ———————————————————————————————————————————————————————————— 42 Mercy Medical Center Physicians Named Among Region's "TOP DOCTORS" in November 2026 Issue of BALTIMORE Magazine 2026-10-22 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/42-mercy-medical-center-physicians-named-among-regions-top-doctors-in-november-2026-issue-of-baltimore-magazine-302917439.html BALTIMORE, Oct. 22, 2026 -- A total of 42 Mercy Medical Center physicians were recognized in Baltimore magazine's November 2026 "Top Doctors" issue, representing 30 separate specialties, ranging from neurosurgery to gynecologic oncology, specifically: 2026 – MERCY MEDICAL... ———————————————————————————————————————————————————————————— Agenus to Provide Third Quarter 2026 Financial Report and Development Update 2026-10-22 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/agenus-third-quarter-2026-financial-203000728.html LEXINGTON, Mass., October 22, 2026--Agenus Inc. ("Agenus") (Nasdaq: AGEN ), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026 financial results before the market opens on Thursday, November 5, 2026. The earnings release will review Agenus' rec ———————————————————————————————————————————————————————————— Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results 2026-10-22 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/puma-biotechnology-host-conference-call-201100903.html LOS ANGELES, October 22, 2026--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, November 5, 2026, following the release of its third quarter 2026 financial results. The call may be accessed by dialing 1-877-709-8 ———————————————————————————————————————————————————————————— Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2026-10-22 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/faeth-therapeutics-announces-inducement-grants-200500679.html AUSTIN, Texas, October 22, 2026--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted three new employees options to purchase an aggregate of 17,000 shares of the Company's common stock in connection with their employment (collecti ———————————————————————————————————————————————————————————— What Does Unicycive Therapeutics, Inc.'s 39.1% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline 2026-10-22 · PR Newswire · Finance, Biotech & pharma, Legal https://www.prnewswire.com/news-releases/what-does-unicycive-therapeutics-incs-39-1-stock-drop-mean-for-investors-the-law-offices-of-howard-g-smith-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302916947.html Suit alleges Unicycive Therapeutics, Inc. failed to disclose key facts to investors from December 29, 2025 through June 29, 2026; lead plaintiff deadline is November 2, 2026 BENSALEM TOWNSHIP, Pa., Oct. 22, 2026 -- The Law Offices of Howard G. Smith today reported that a... ———————————————————————————————————————————————————————————— Ionis ranked #1 on Science’s Top Employers list 2026-10-22 · Business Wire · Finance, Healthcare, Biotech & pharma, Jobs & workplace https://finance.yahoo.com/healthcare/articles/ionis-ranked-1-science-top-182500186.html CARLSBAD, Calif., October 22, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the company was named the top employer to work for by Science in its annual Top Employers survey of the biotech and pharmaceutical industries. Rising from #2 last year to #1, Ionis was recognized for it ———————————————————————————————————————————————————————————— FDA grants 510(k) clearance for BoneEnhance, the first machine learning layer on RIVANNA's Accuro XV platform 2026-10-22 · PR Newswire · AI, SaaS, Healthcare, Education, Biotech & pharma, Medical devices https://www.prnewswire.com/news-releases/fda-grants-510k-clearance-for-boneenhance-the-first-machine-learning-layer-on-rivannas-accuro-xv-platform-302917179.html Anatomy segmentation and three-dimensional skeletal visualization arrive with this clearance; an injury detection module for clinical decision support is in development on the platform roadmap CHARLOTTESVILLE, Va., Oct. 22, 2026 -- RIVANNA®, developer of AI-enabled clinical... ———————————————————————————————————————————————————————————— Warp Sciences Emerges From Stealth With $215 Million to Build U.S. Chemistry Services for Drug Research 2026-10-22 · Business Wire · AI, Healthcare, Biotech & pharma, Government & policy https://finance.yahoo.com/healthcare/articles/warp-sciences-emerges-stealth-215-180000040.html Founded by leaders from OpenAI, Terremoto Biosciences, Meta, Devoted Health, and the White House, Warp is using AI and robotics to help biotech and pharma discover new medicines faster in the U.S. The company is backed by Lightspeed, IVP, Mayfield, Lux, Premji Invest, and Menlo Ventures, among others SAN FRANCISCO, Octobe ———————————————————————————————————————————————————————————— New Grid Therapeutics GT103 Data to be Presented at ESMO 2026 2026-10-22 · Business Wire · Healthcare, Energy, Biotech & pharma https://finance.yahoo.com/healthcare/articles/grid-therapeutics-gt103-data-presented-175400994.html DURHAM, N.C., October 22, 2026--Grid Therapeutics , a clinical-stage biotechnology company committed to developing better and safer human-derived therapeutic antibodies for cancer, today announced that new data on its lead clinical asset, GT103, will be presented at the 2026 European Society for Medic ———————————————————————————————————————————————————————————— CorWave Completes Enrollment in Feasibility Study and Presents First Clinical Data on Adaptive Support with its Wave Membrane LVAD 2026-10-22 · Business Wire · Healthcare, Biotech & pharma, Medical devices https://finance.yahoo.com/healthcare/articles/corwave-completes-enrollment-feasibility-study-171700231.html CLICHY, France, October 22, 2026--CorWave SA, a clinical-stage medical technology company pioneering innovative cardiac assist devices, announces the completion of enrollment in its feasibility study of the CorWave Left Ventricular Assist System (LVAS). The company also presented the first clinical da ———————————————————————————————————————————————————————————— Array Skin Therapy Celebrates 15 Years of Expert Light Therapy With "15 Years of Light" Anniversary Campaign 2026-10-22 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/array-skin-therapy-celebrates-15-years-of-expert-light-therapy-with-15-years-of-light-anniversary-campaign-302916780.html Marking 15 years of specialized phototherapy, patient-centered care, and expanding access to drug-free treatment for psoriasis, vitiligo, eczema, and other chronic skin conditions. LOS ANGELES and ORANGE COUNTY, Calif., Oct. 22, 2026 -- Array Skin Therapy, a provider of... ———————————————————————————————————————————————————————————— OPM Announces Its 2026 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position 2026-10-22 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/opm-announces-2026-half-financial-170800273.html OPM-201: secured funding from the Michael J. Fox Foundation to support the development of the LARKIN program in Parkinson's disease OPM-101: continued preparation for the REVERT Phase 1b/2a clinical trial in advanced melanoma and partnership discussions regarding chronic inflammatory bowel diseases Significant reduction i ———————————————————————————————————————————————————————————— Vicore's Phase 2b ASPIRE Trial of Buloxibutid in IPF Passes Pre-Planned Futility Analysis and Remains on Track for Mid-2027 Topline Results 2026-10-22 · ACCESS Newswire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/vicores-phase-2b-aspire-trial-170500979.html Independent Data Monitoring Committee recommends ASPIRE continue without modification; no safety concerns identified Fully enrolled 378-patient trial advances toward 52-week readout STOCKHOLM, SE AND CAMBRIDGE, MA / October 22, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Nasdaq US:VCRE), a bi ———————————————————————————————————————————————————————————— Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 2026 2026-10-22 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/mundipharma-announces-further-phase-iii-170300644.html For Trade and Medical Media Only CAMBRIDGE, England, October 22, 2026--Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO ® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic hae ———————————————————————————————————————————————————————————— Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight 2026-10-22 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386781/0/en/alzheimer-s-disease-clinical-trial-and-competitive-landscape-enters-a-new-phase-as-200-companies-advance-clinical-programs-delveinsight.html The Alzheimer's disease competitive landscape report delivers important insights into approved as well as ongoing research on 240+ pipeline Alzheimer's disease drugs, clinical strategies, upcoming therapeutics, and commercial analysis. The Alzheimer's disease competitive landscape report delivers important insights into approved as well as ongoing research on 240+ pipeline Alzheimer's disease drugs, clinical strategies, upcoming therapeutics, and commercial analysis. ———————————————————————————————————————————————————————————— The Risk-Based Monitoring System Market Is Expected to Grow at a Steady CAGR of 11.4% Through 2030 2026-10-22 · EIN Presswire · Healthcare, Biotech & pharma https://www.einpresswire.com/article/950142997/the-risk-based-monitoring-system-market-is-expected-to-grow-at-a-steady-cagr-of-11-4-through-2030 Risk-Based Monitoring System Market Report The Business Research Company The Business Research Company’s Risk-Based Monitoring System Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, October 22, 2026 / EINPresswire.com / -- The risk-based monitoring system market is seeing rapid development driven by the evolving needs of clinical trials and regulatory de ———————————————————————————————————————————————————————————— InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026 2026-10-22 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386711/0/en/inflarx-highlights-izicopan-s-therapeutic-potential-at-kidney-week-2026.html Jena, Germany, Oct. 22, 2026 -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the presentation of new pre-clinical data on izicopan in renal disease models at the American Society of Nephrology’s Kidney Week 2026, taking place in Denver, Colorado, October 21 - 25. The in vivo and in vitro data demonstrated that izicopan robustly inhibited C5aR-mediated inflammatory responses and provided renal protection, supporting its potential as a therapeutic candidate for complement-driven kidney diseases. ———————————————————————————————————————————————————————————— Feinstein Institutes Researchers Release World’s First Map of Branches of the Human Vagus Nerve 2026-10-22 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/feinstein-institutes-researchers-release-world-152700626.html Research published in the journal Brain Stimulation details first comprehensive, surgically relevant map of human vagus nerve's organ-specific branches MANHASSET, N.Y., October 22, 2026--For too long, harnessing the therapeutic potential of the vagus nerve has been like navigating uncharted waters. Now ———————————————————————————————————————————————————————————— PLEOPHARMA TO PRESENT SURVEY DATA ON CANNABIS WITHDRAWAL IN WOMEN SEEKING CANNABIS CESSATION PleoPharma, Inc. October 22 2026-10-22 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/pleopharma-to-present-survey-data-on-cannabis-withdrawal-in-women-seeking-cannabis-cessation-pleopharma-inc-october-22-302917149.html PleoPharma presents research survey findings characterizing women's experiences with frequent cannabis use, cessation efforts, and cannabis withdrawal symptoms. PHOENIXVILLE, Pa., Oct. 22, 2026 -- PleoPharma, Inc., a clinical-stage development company focused on... ———————————————————————————————————————————————————————————— Sofusa® Holdings Relaunches as Independent Company to Advance Lymphatic Drug Delivery 2026-10-22 · Business Wire · SaaS, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/sofusa-holdings-relaunches-independent-company-143700103.html Precision lymphatic targeting platform validated with clinical data in both Rheumatoid Arthritis and in Cancer; Class II Device FDA submission planned in Q2 2027. NEW YORK, October 22, 2026--Sofusa Holdings today announced its launch as an independent, clinical-stage company pioneering the development ———————————————————————————————————————————————————————————— Frontotemporal Dementia (FTD) 7MM Market Insights, Epidemiology, and Forecast - 2036 | 15% CAGR Outlook Highlights Gene Therapy and Precision Medicine Opportunities 2026-10-22 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386600/28124/en/frontotemporal-dementia-ftd-7mm-market-insights-epidemiology-and-forecast-2036-15-cagr-outlook-highlights-gene-therapy-and-precision-medicine-opportunities.html Dublin, Oct. 22, 2026 -- "Frontotemporal Dementia - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving EyePoint Pharmaceuticals (EYPT) 2026-10-22 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386597/3080/en/levi-korsinsky-notifies-investors-of-pending-investigation-into-securities-claims-involving-eyepoint-pharmaceuticals-eypt.html DURAVYU’s Phase 3 LUCIA trial missed its primary endpoint and EYPT shares lost nearly 80% of their value in a single session. Levi & Korsinsky is investigating on behalf of shareholders who may have legal rights arising from those losses DURAVYU’s Phase 3 LUCIA trial missed its primary endpoint and EYPT shares lost nearly 80% of their value in a single session. Levi & Korsinsky is investigating on behalf of shareholders who may have legal rights arising from those losses ———————————————————————————————————————————————————————————— Charcot Marie Tooth Disease - Drug Pipeline Insights and Competitive Landscape, 2026 | 15+ Drugs Signal Gene Therapy and Neuromuscular Innovation Opportunities 2026-10-22 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386596/28124/en/charcot-marie-tooth-disease-drug-pipeline-insights-and-competitive-landscape-2026-15-drugs-signal-gene-therapy-and-neuromuscular-innovation-opportunities.html Track Charcot-Marie-Tooth pipeline innovation, from first-in-class therapies to gene therapy, with clinical progress, unmet needs, collaborations, licensing and M&A insights Track Charcot-Marie-Tooth pipeline innovation, from first-in-class therapies to gene therapy, with clinical progress, unmet needs, collaborations, licensing and M&A insights ———————————————————————————————————————————————————————————— Postpartum Depression - Global Drug Pipeline Insights and Competitive Landscape, 2026 | Novel Neuroplastogens and Long-Acting Therapies Unlock R&D and Licensing Opportunities 2026-10-22 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386595/28124/en/postpartum-depression-global-drug-pipeline-insights-and-competitive-landscape-2026-novel-neuroplastogens-and-long-acting-therapies-unlock-r-d-and-licensing-opportunities.html Dublin, Oct. 22, 2026 -- "Postpartum Depression - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Polycythemia Vera - Global Drug Pipeline Insight, 2026 | 25+ Therapies Drive JAK2-Targeted Innovation and Late-Stage Partnership Opportunities 2026-10-22 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386594/28124/en/polycythemia-vera-global-drug-pipeline-insight-2026-25-therapies-drive-jak2-targeted-innovation-and-late-stage-partnership-opportunities.html Explore the Polycythemia Vera pipeline with drug profiles, therapeutic assessments, unmet needs, collaborations, licensing, and inactive candidates Explore the Polycythemia Vera pipeline with drug profiles, therapeutic assessments, unmet needs, collaborations, licensing, and inactive candidates ———————————————————————————————————————————————————————————— AI in Clinical Trials Market Size, Share, Trends, and Forecast 2026-2035 | 14% CAGR to USD 8.67 Billion as Predictive Analytics Accelerates Drug Development 2026-10-22 · GlobeNewswire · AI, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386588/28124/en/ai-in-clinical-trials-market-size-share-trends-and-forecast-2026-2035-14-cagr-to-usd-8-67-billion-as-predictive-analytics-accelerates-drug-development.html Dublin, Oct. 22, 2026 -- "AI in Clinical Trials Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine 2026-10-22 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386581/0/en/vera-therapeutics-announces-positive-origin-3-final-efficacy-analysis-of-trutakna-atacicept-vymj-in-iga-nephropathy-presented-at-asn-kidney-week-2026-and-published-in-the-new-engla.html Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA in IgAN at ASN 2026 and Published in NEJM ———————————————————————————————————————————————————————————— Trisodium Citrate Market to Reach US$ 520.46 Million by 2034, Growing at 3.42% CAGR 2026-10-22 · PR News Releaser · Food & drink, Industrial, Biotech & pharma https://www.prnewsreleaser.com/news/477036 The global trisodium citrate market is gaining steady momentum as food and beverage manufacturers, pharmaceutical companies, and industrial producers seek versatile ingredients for product formulation and processing. Trisodium citrate, also known as sodium citrate, is the sodium salt of citric ... Read more ———————————————————————————————————————————————————————————— Navitus MedicareRx (PDP) earns top federal rating for 11th consecutive year 2026-10-22 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/navitus-medicarerx-pdp-earns-top-140000312.html Part D plan remains one of the nation's highest-rated PBM-sponsored EGWP offerings MADISON, Wis., October 22, 2026--For the 11th consecutive year, Navitus MedicareRx has earned the nation's highest rating among Prescription Drug Plan (PDP) and Employer Group Waiver Plan (EGWP) offerings, receiving a 4 ———————————————————————————————————————————————————————————— NeOnc Heads to Fox Business as Brain Cancer Milestones Put Its Mission in the Spotlight 2026-10-22 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386506/0/en/neonc-heads-to-fox-business-as-brain-cancer-milestones-put-its-mission-in-the-spotlight.html NeOnc (NASDAQ: NTHI) is taking its brain cancer story to Fox Business Network when several developments put the clinical-stage biotech in the spotlight ———————————————————————————————————————————————————————————— Psoriatic Arthritis - Global Clinical Trials Review and Competitive Landscape, 2026 | Pipeline Innovation and Trial Expansion Drive Strategic Growth 2026-10-22 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386477/28124/en/psoriatic-arthritis-global-clinical-trials-review-and-competitive-landscape-2026-pipeline-innovation-and-trial-expansion-drive-strategic-growth.html Identify cost-efficient trial locations, investment priorities and business opportunities while benchmarking enrollment trends and trial success to sharpen competitive strategy. Identify cost-efficient trial locations, investment priorities and business opportunities while benchmarking enrollment trends and trial success to sharpen competitive strategy. ———————————————————————————————————————————————————————————— Diffuse Large B-Cell Lymphoma (DLBCL) - Global Clinical Trials Review, 2026 | CAR-T and Phase III Pipelines Fuel Investment and Partnership Opportunities 2026-10-22 · GlobeNewswire · Healthcare, Automotive, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386476/28124/en/diffuse-large-b-cell-lymphoma-dlbcl-global-clinical-trials-review-2026-car-t-and-phase-iii-pipelines-fuel-investment-and-partnership-opportunities.html Identify cost-efficient trial locations, investment opportunities and enrollment trends to sharpen strategy and gain a competitive advantage. Identify cost-efficient trial locations, investment opportunities and enrollment trends to sharpen strategy and gain a competitive advantage. ———————————————————————————————————————————————————————————— Frozen Shoulder Syndrome - Global Clinical Trials Landscape and Competitive Intelligence Report, 2026 | Enrollment Trends and Sponsor Activity Reveal R&D Investment Opportunities 2026-10-22 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386465/28124/en/frozen-shoulder-syndrome-global-clinical-trials-landscape-and-competitive-intelligence-report-2026-enrollment-trends-and-sponsor-activity-reveal-r-d-investment-opportunities.html Optimize trial investment by identifying cost-efficient locations, key business opportunities, enrollment trends and competitive strategies across global markets. Optimize trial investment by identifying cost-efficient locations, key business opportunities, enrollment trends and competitive strategies across global markets. ———————————————————————————————————————————————————————————— Mycosis Fungoides - Global Clinical Trials Landscape Review, 2026 | Pipeline, Enrollment, Sponsor, and Regional Trends Reveal R&D Investment Opportunities 2026-10-22 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386464/28124/en/mycosis-fungoides-global-clinical-trials-landscape-review-2026-pipeline-enrollment-sponsor-and-regional-trends-reveal-r-d-investment-opportunities.html Identify trial locations that save time and cost, uncover investment opportunities, and shape competitive strategies with global trial, enrollment and success rate insights. Identify trial locations that save time and cost, uncover investment opportunities, and shape competitive strategies with global trial, enrollment and success rate insights. ———————————————————————————————————————————————————————————— NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome 2026-10-22 · NewMediaWire · Healthcare, Education, Food & drink, Industrial, Biotech & pharma, Government & policy https://www.newmediawire.com/news/neurothera-labs-reports-positive-progress-in-fda-approved-phase-iib-clinical-trial-for-tourette-syndrome-7090795 TORONTO, ONTARIO - October 22, 2026 - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd., today announced further progress in its U.S. Food and Drug Administration (“FDA”) approved clinical trial program evaluating SCI-110 for the treatment of Tourette Syndrome (“TS”) in adults. The Company has successfully completed the manufacturing of the investigational product and obtained the required batch release certification from a European Qualified Person (“QP”), a key regulatory milestone authorizing shipment of clinical trial material to participating study sites. The release enables site activation activities and supports the initiation of patient enrollment in the FDA-approved Phase IIb clinical trial for TS. The Phase IIb clinical trial is being conducted at three clinical sites: Yale Child Study Center at Yale School of Medicine in New Haven, Connecticut, USA; Hannover Medical School in Hanover, Germany; and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. All participating sites have successfully completed their site initiation activities and are prepared to receive clinical trial drug supplies following QP batch release. Completion of site initiation activities across all participating clinical centers, together with the successful European QP release of clinical trial supplies, marks a significant operational milestone for NeuroThera. The Company is now advancing toward patient enrollment in its Phase IIb clinical trial for TS, with investigational product shipments to study sites expected in the near term. SCI-110 is NeuroThera’s proprietary, patent-protected cannabinoid-based drug candidate, combining dronabinol and palmitoylethanolamide (PEA) in a single oral dosage form. The Phase IIb study is evaluating SCI-110's efficacy, safety and tolerability in adults with TS, a condition with substantial unmet treatment needs. About NeuroThera Labs Inc. NeuroTheraLabsInc. (TSXV:NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations. For further information, please contact: Michal Efraty IR Manager NeuroThera Labs Inc. Telephone: +972-3-7617108 Email: michal@efraty.com Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Cautionary Notice on Forward-Looking Statements This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Forward-looking information in this news release includes statements regarding: the initiation of patient enrollment in the Phase IIb clinical trial for TS; the expected timing for investigational product shipments to study sites; and the potential efficacy, safety and tolerability of SCI-110. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking information necessarily involves known and unknown risks and uncertainties, which may cause the Company's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking information. Such factors include, without limitation: the ability of the Company to progress toward patient enrollment for its Phase IIb clinical trial for TS; and the other risks described in the Company's continuous disclosure documents filed on SEDAR+ (www.sedarplus.ca). The Company does not undertake any obligation to update or revise any forward-looking information, except as required by applicable securities laws. ———————————————————————————————————————————————————————————— Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing 2026-10-22 · ACCESS Newswire · Finance, Biotech & pharma https://finance.yahoo.com/markets/stocks/articles/sunshine-biopharma-announces-reverse-stock-130000467.html FORT LAUDERDALE, FL / October 22, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced a one for twenty reverse split of its common st ———————————————————————————————————————————————————————————— P&G, Nestle, Mars, AstraZeneca, ITC and Bekaert win OMP Supply Chain Awards 2026-10-22 · ACN Newswire · AI, SaaS, Retail, Food & drink, Industrial, Logistics, Biotech & pharma, Sustainability, Consumer goods, Chemicals & materials https://www.acnnewswire.com/press-release/english/110995/ ANTWERPEN, BELGIUM, Oct 22, 2026 - OMP, a leader in AI-powered supply chain solutions, recently honored six global brands at its conferences held earlier this month in Singapore and Shanghai. The recognized companies - Procter & Gamble (P&G), Nestlé, Mars, AstraZeneca, ITC, and Bekaert - were celebrated for driving decision velocity, co-innovation, and impactful business results. Supply Chain Innovation & Excellence Award: Nestlé and Bekaert Nestlé, one of the world's largest food and beverage companies, and Bekaert, a global market and technology leader in material science of steel wire transformation and coating technologies, received OMP's Supply Chain Innovation & Excellence award for their breadth of deployment and depth of co-innovation. Nestlé aligns its supply network at the strategic, tactical, and operational levels on OMP's Unison Planning™ platform, connecting forecasting, planning, and replenishment end-to-end. As more routine work becomes touchless, planners can focus on the decisions that drive the business, and Nestlé continues to roll out best practices throughout the organization. Bekaert integrated scenario planning directly into its S&OP, shifting teams from reactive firefighting to proactive, value-driven conversations. In its green hydrogen business, what-if modeling protects mid- and long-term strategic control. Furthermore, planners use Unison Companion, OMP's generative AI assistant, to generate tables, compare scenarios, and retrieve information in natural language. "This award recognizes the ongoing transformation of our end-to-end supply chain planning," says Bo Yang, Senior Manager, Global Supply Chain Process Management at Bekaert Rubber Reinforcement. "We've moved from manual Excel calculations and individual experience to standardized planning on OMP's Unison Planning™ platform. Our decisions are now backed by data, and our planning accuracy has improved significantly." Long-Term Partnership Award: P&G and AstraZeneca P&G, with operations in approximately 70 countries, joins global biopharma leader AstraZeneca in accepting the award for proving that value compounds the longer the partnership runs. P&G celebrates 27 years of partnership with OMP dating back to 1999, and operates a planning network spanning more than 100 manufacturing sites and 200 distribution centers. The company has consolidated overlapping planning processes, with the majority of planning now handled touchlessly. "Receiving OMP's Long-Term Partnership Award reflects years of trust and teamwork between our teams," says Jen Aberilla, Director, Regional Supply Network Operations Planning at P&G. "We're proud of what we've achieved together and look forward to building on it." AstraZeneca has been working with OMP since 2021, replacing siloed, spreadsheet-based planning with a single capacity-constrained network plan. Most recently, the company has been collaborating with OMP on AI‑driven planning and advanced scenario modeling, allowing planners to focus on scenarios and exceptions. This has resulted in improved supply reliability and service levels, inventory reduction, and productivity savings. Community Engagement Award: Mars and ITC ITC's Paperboards & Specialty Papers Division, part of the Indian multi-business enterprise ITC Limited, and Mars, a global giant in confectionery, food products, and pet care services, received the Community Engagement Award for their active role in OMP Community events and councils. ITC was recognized for its commitment to openly sharing its planning transformation with the wider supply chain community. By presenting its experience to industry peers, ITC has given them a candid look at how its journey unfolds in practice, with lessons other planning teams can apply. Mars is a committed participant in the OMP Community councils and in governance through the executive board. Working with OMP, Mars has lowered inventory, consolidated its warehouse network, improved factory equipment effectiveness, and increased forecast accuracy. "The world's most demanding manufacturers plan with OMP, and it is a privilege to see those relationships deepen over 10, 20, and 27 years. The results they achieve through this community are concrete: inventory goes down, forecast accuracy goes up, and decisions happen faster. Congratulations to each of them!" says Philip Vervloesem, Chief Commercial and Markets Officer at OMP. About OMP OMP helps companies facing complex planning challenges to excel, grow and thrive by offering the best digitized supply chain planning solution on the market. Hundreds of customers in a wide range of industries - spanning consumer goods, life sciences, chemicals, metals, paper and packaging - benefit from using OMP's unique Unison Planning™. Solution and product inquiries Contact OMP +32 3 650 22 11 Media inquiries Kira Perdue (Carabiner) SOURCE: OMP ———————————————————————————————————————————————————————————— IHI and Bristol Myers Squibb Launch National Collaborative to Expand Access to Cancer Clinical Trials 2026-10-22 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/ihi-bristol-myers-squibb-launch-125500423.html Three-year initiative will bring clinical research closer to patients and address barriers to trial participation BOSTON, October 22, 2026--The Institute for Healthcare Improvement (IHI), in partnership with Bristol Myers Squibb (BMS), is launching a new Cancer Collective Action Collaborative. This thr ———————————————————————————————————————————————————————————— Laser Photonics to Host Third Quarter 2026 Earnings Call on November 12, 2026 at 8:00 a.m. Eastern Time 2026-10-22 · Newswire.com · Finance, SaaS, Energy, Industrial, Biotech & pharma, Semiconductors https://www.newswire.com/news/laser-photonics-to-host-third-quarter-2026-earnings-call-on-november-12-2026-at Laser Photonics Corporation (NASDAQ:LASE), an emerging directed energy and laser technology platform developing applications for defense, semiconductor, pharmaceutical and industrial markets (the "Company"), today announced that it will release financial results for the third quarter ended September 30, 2026 before market open on Thursday, November 12, 2026. Management will host an investor conference call at 8:00 a. ———————————————————————————————————————————————————————————— Candel Therapeutics Appoints Maria Ostrovsky as General Counsel 2026-10-22 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386313/0/en/candel-therapeutics-appoints-maria-ostrovsky-as-general-counsel.html NEEDHAM, Mass., Oct. 22, 2026 -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Maria Ostrovsky as General Counsel, effective November 3, 2026. Ms. Ostrovsky has 20 years of legal experience, most of it in the life sciences industry. She will oversee Candel’s legal and compliance functions, including corporate governance, and report to Candel’s President and Chief Executive Officer. ———————————————————————————————————————————————————————————— MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study 2026-10-22 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386256/0/en/mira-pharmaceuticals-reports-mira-55-demonstrated-significant-pain-relief-comparable-to-celebrex-in-chronic-inflammatory-pain-study.html MIRA-55 demonstrated significant pain relief comparable to Celebrex in a 21-day preclinical study of chronic inflammatory pain. ———————————————————————————————————————————————————————————— Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026 2026-10-22 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386248/0/en/replimune-to-report-the-fiscal-second-quarter-2027-financial-results-and-provide-corporate-update-on-october-28-2026.html WOBURN, Mass., Oct. 22, 2026 -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Wednesday, October 28, 2026, at 8:00 a.m. ET to discuss its financial results and provide corporate update for the fiscal second quarter ended September 30, 2026. ———————————————————————————————————————————————————————————— Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026 2026-10-22 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386247/34897/en/collegium-to-report-third-quarter-2026-financial-results-on-november-5-2026.html STOUGHTON, Mass., Oct. 22, 2026 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it will report third quarter 2026 financial results before the market opens on Thursday November 5, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. ———————————————————————————————————————————————————————————— SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases 2026-10-22 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386244/0/en/scynexis-completes-phase-1-study-of-intravenous-scy-247-a-novel-triterpenoid-antifungal-in-development-for-treatment-and-prevention-of-invasive-fungal-diseases.html JERSEY CITY, N.J., Oct. 22, 2026 -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”, or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced topline results from its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of the intravenous (IV) formulation of SCY-247, its second-generation triterpenoid (fungerp) antifungal candidate. SCY-247 is under development in both oral and intravenous (IV) formulations for the treatment and prevention of invasive fungal infections with the potential to provide therapeutic advantages by having activity against drug-resistant fungi. ———————————————————————————————————————————————————————————— RiboX Therapeutics Announces Publication in The New England Journal of Medicine Highlighting First-in-Human Circular RNA Therapy for Radiation-Induced Xerostomia 2026-10-22 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/ribox-therapeutics-announces-publication-england-120000249.html Research Letter Reports First-in-Human Use of Circular RNA Therapy, with RXRG001 Demonstrating Durable Improvements in Salivary Flow and Patient-Reported Xerostomia Symptoms Single-Dose Treatment Was Well Tolerated with No Dose-Limiting Toxicities Observed in the First Six Patients Across Two Dose Cohorts RXRG001 Recently ———————————————————————————————————————————————————————————— Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 2026-10-22 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/xeris-biopharma-report-third-quarter-120000565.html Conference call and audio webcast to be held at 8:30 a.m. ET CHICAGO, October 22, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innova ———————————————————————————————————————————————————————————— Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent 2026-10-22 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/georgiamune-menarini-group-enter-exclusive-120000812.html GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to receive $45 million in upfront and near-term payments, as part of a total deal value of up to $1.1 billion, plus royalties. FLORENCE, Italy & GAITHERSBURG, Md., October 2 ———————————————————————————————————————————————————————————— Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates 2026-10-22 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/stoke-therapeutics-host-webcast-conference-120000989.html BEDFORD, Mass., October 22, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential diseas ———————————————————————————————————————————————————————————— DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial 2026-10-22 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/diamedica-therapeutics-announces-enrollment-200th-120000870.html Independent Data Safety Monitoring Board to Conduct a Pre-Specified Interim Analysis to Assess Need for Sample Size Re-Estimation Interim Analysis Results Expected in Q1 2027 MINNEAPOLIS, October 22, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on ———————————————————————————————————————————————————————————— DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies 2026-10-22 · Newswire.com · Finance, Crypto, AI, Healthcare, Sports, Aerospace & defense, Biotech & pharma, Software & IT https://www.newswire.com/news/datameds-ai-enters-into-amended-and-restated-loi-to-license-and-acquire-ip-that Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastructure targeting market expected to grow from $9.6 billion in 2025 to $93.4 billion in 2035 Customer Acquisition Plan Leverages Existing Relationship with NFL Alumni Health Final Guidance issued by FDA Provides Roadmap for Prescription Drug Proprietary Health Lives Here™ App and DelivMeds® Software Network of 6,500 Pharmacies to Provide Nationwide Physical Healthcare Outlet ———————————————————————————————————————————————————————————— Tikva Allocell Selected to Present Preclinical CD19.SB9.CAR-EBVST Data at ACR Convergence 2026 2026-10-22 · PR Newswire · Automotive, Biotech & pharma https://www.prnewswire.com/news-releases/tikva-allocell-selected-to-present-preclinical-cd19sb9car-ebvst-data-at-acr-convergence-2026-302916122.html Oral presentation will feature preclinical research evaluating Tikva's armored allogeneic CD19 CAR T-cell therapy as a potential lymphodepletion-free approach for systemic lupus erythematosus SINGAPORE, Oct. 22, 2026 -- Tikva Allocell Pte. Ltd. ("Tikva"), a biotechnology... ———————————————————————————————————————————————————————————— BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer 2026-10-22 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Medical devices https://www.globenewswire.com/news-release/2026/10/22/3386178/0/en/blossomhill-therapeutics-announces-collaboration-with-foundation-medicine-to-develop-first-companion-diagnostic-for-bh-30643-in-egfr-c797s-mutated-non-small-cell-lung-cancer.html SAN DIEGO, Oct. 22, 2026 -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced a collaboration with Foundation Medicine, Inc. to develop a companion diagnostic assay (CDx) for the EGFR C797S resistance mutation. The collaboration will leverage the ongoing Phase 1/2 SOLARA clinical trial evaluating BH-30643 in the targeted treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients to validate the assay. ———————————————————————————————————————————————————————————— Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4 2026-10-22 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386176/0/en/ocugen-to-provide-business-update-and-third-quarter-2026-financial-results-on-november-4.html MALVERN, Pa., Oct. 22, 2026 -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, will host a conference call and live webcast on Wednesday, November 4, 2026, at 8:30 a.m. ET to provide a business update and report third quarter 2026 financial results. All related materials will be made available on the Ocugen investor website prior to the start of the call. ———————————————————————————————————————————————————————————— Antogen Opens Oklahoma City Laboratory, Expands Commercial Operations 2026-10-22 · Business Wire · Biotech & pharma, Medical devices https://finance.yahoo.com/healthcare/articles/antogen-opens-oklahoma-city-laboratory-110000708.html OKLAHOMA CITY, October 22, 2026--Antogen, Inc., a biotechnology company pioneering next-generation personalized diagnostics through immunopeptidomics, today announced that its new laboratory in Oklahoma City is fully operational and processing customer samples. This marks a significant milestone in Ant ———————————————————————————————————————————————————————————— United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization 2026-10-22 · Business Wire · Finance, Biotech & pharma, Investing & markets https://finance.yahoo.com/markets/stocks/articles/united-therapeutics-corporation-announces-additional-110000717.html SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C., October 22, 2026--United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that the company's Board of Directors has authorized a new share repurchase program for up to $2 billion of the company's common stock, av ———————————————————————————————————————————————————————————— Swim Across America-Funded Cancer Research Leads to Landmark FDA Approval of Immunotherapy for Rectal Cancer 2026-10-22 · EIN Presswire · Finance, Healthcare, Biotech & pharma https://www.einpresswire.com/article/951380757/swim-across-america-funded-cancer-research-leads-to-landmark-fda-approval-of-immunotherapy-for-rectal-cancer Dr. Luis Diaz, gastrointestinal oncologist and head of the Division of Solid Tumor Oncology at MSK, speaks at a recent Swim Across America - Long Island Sound open water swim. Drs. Andrea Cercek and Luis Diaz, along with a patient who is alive 10 years after participating in the initial clinical trial for Jemperli (dostarlimab), celebrate the funding from Swim Across America that made this clinical trial possible. Gr ———————————————————————————————————————————————————————————— Asthma Drugs Market Key Players and Opportunities by 2031 2026-10-22 · PR News Releaser · Biotech & pharma https://www.prnewsreleaser.com/news/476409 The Asthma Drugs Market is expanding as the prevalence of asthma increases and healthcare providers place greater emphasis on effective respiratory disease management. Asthma drugs are used to control airway inflammation, relieve breathing difficulties, and prevent acute asthma attacks. These ... Read more ———————————————————————————————————————————————————————————— Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies 2026-10-22 · PressReach · Finance, Healthcare, Food & drink, Biotech & pharma https://pressreach.com/cognition-therapeutics-announces-alignment-with-fda-on-pivotal-phase-3-trial-of-zervimesine-ct1812-in-dementia-with-lewy-bodies PURCHASE, N.Y., Oct. 22, 2026 — Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, has aligned with the U.S. Food and Drug Administration (FDA) on key elements of a Phase 3 study in dementia with Lewy bodies (DLB) including patient selection, dose, … Continue reading "Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies" ———————————————————————————————————————————————————————————— Two-Year FDA Award of up to $2.2 Million to Develop Wearable Digital Measures for CMT1A 2026-10-22 · EIN Presswire · Healthcare, Food & drink, Biotech & pharma, Consumer electronics https://www.einpresswire.com/article/947714593/two-year-fda-award-of-up-to-2-2-million-to-develop-wearable-digital-measures-for-cmt1a CureCMT Wearable sensors will track real-world changes in foot drop, walking, and hand function across four sites, a major step toward the first approved CMT treatment NEW YORK, NY, UNITED STATES, October 22, 2026 / EINPresswire.com / -- BioSensics LLC and CureCMT (Hereditary Neuropathy Foundation) today announced a two-year cooperative agreement award of up to $2.2 million from the U.S. Food and Drug Administration, ———————————————————————————————————————————————————————————— BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5 2026-10-22 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/beone-medicines-announce-third-quarter-100100911.html SAN CARLOS, Calif., October 22, 2026--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will ———————————————————————————————————————————————————————————— Year Two Marks a Turning Point in Sierra Leone’s Cataract Outreach, and Opens the Door to a Bigger, Faster, More Connected Year Three 2026-10-22 · APO Group · Healthcare, Automotive, Media, Education, Travel, Biotech & pharma, Sustainability, Government & policy, Jobs & workplace, Agriculture https://www.africa-newsroom.com/press/year-two-marks-a-turning-point-in-sierra-leones-cataract-outreach-and-opens-the-door-to-a-bigger-faster-more-connected-year-three?lang=en October marks a global moment for eye‑health advocacy, and Sierra Leone’s most anticipated cataract outreach campaign is entering a new phase of acceleration in the fight against avoidable blindness. The influential campaign is delivered by Choithram International Foundation (https://www.Choithrams.com/) in association with Noor Dubai Foundation, led by CEO Dr. Manal Taryam as part of Mohammed bin Rashid Al Maktoum Global Initiatives (MBRGI), and the Ministry of Health, Sierra Leone alongside Choithram Memorial Hospital, reflecting a shared commitment to world‑class eye care and the elimination of preventable blindness. Download Document: https://apo-opa.co/4ihCOKT Download Infographic: https://apo-opa.co/4z72uky Conceived in 2024, the multi‑year initiative has restored sight to thousands of Sierra Leoneans through free cataract surgeries, community screenings, and long‑term capacity building. Cataracts remain the leading cause of blindness in the country, where the 2021 RAAB study found that 5.4% of adults over 50 are blind, with cataracts responsible for nearly 60% of cases. A newly published peer-reviewed study in BMJ Open provides important evidence from the programme's first implementation cycle, demonstrating improvements in patients' vision-related quality of life while highlighting the operational challenges and adaptations necessary to deliver cataract services in resource-constrained settings. A Year of Acceleration The second surgical cycle, conducted between March and August 2026, marked a turning point. More than 5,768 adults were screened or consulted, 2,460 received medical treatment, and 1,522 cataract surgeries were performed, all this while also managing additional surgical interventions and referrals. It makes Year Two one of the largest eye‑care outreach efforts in Sierra Leone’s history, with patients travelling from across the country and neighbouring Guinea and Liberia, underscoring the programme’s growing regional reach and influence. Capacity building, a core goal of the campaign, has also seen a clear uptick. Seventeen ophthalmic professionals were trained across clinical and surgical roles, including cataract surgeons, ophthalmology nurses, OT nurses, and registrars, further strengthening the country’s long‑term eye‑care workforce. WHO (World Health Organization) notes that more than 80% of global vision impairment is preventable or treatable, underscoring the importance of programmes that combine service delivery with long‑term capacity building. This aligns with WHO’s 2030 global eye‑care targets, which call for major increases in effective cataract surgical coverage and sustained investment in national eye‑health systems. Two operating theatres ran simultaneously at Choithram Memorial Hospital, supported by Sierra Leonean staff trained through monthly exchanges with Choithram Netralaya (India). Every patient received surgery, medication, transport, accommodation, and follow‑up care at no cost, establishing a model that continues to set a benchmark for accessible eye care in the region. To help ensure that the programme delivers lasting impact, researchers Dr Gabriel Osei-Anokye and Dr Ving Fai Chan from Queen’s University Belfast (QUB) and Dr M Mansur Rabiu from Noor Dubai Foundation are leading a comprehensive evaluation. The evaluation examines programme efficiency, patient satisfaction, quality of care, and changes in patients’ quality of life following cataract surgery. Aligned with WHO standards, the research assesses not only improvements in vision and clinical outcomes, but also the wider psychosocial and socioeconomic benefits of restoring sight among people who have limited access to cataract services. Drawing on expertise in global health and eye care, the team is generating evidence to identify what works, where improvements can be made, and how lessons from the programme can inform future outreach. These findings will support the continued strengthening and sustainability of cataract services in Sierra Leone and provide learning that may be relevant to similar programmes elsewhere. Human Impact at the Centre For many beneficiaries, restored sight means restored independence. One patient, Isatu Kamara, shared: “My right eye is now very bright. I am happy with the result and I look forward to coming back next year for the left eye.” Such stories reflect the programme’s broader social impact, enabling farmers to return to work, caregivers to regain mobility, and older adults to reconnect with their families. Quality of life improves immediately, restoring dignity and participation in socio‑economic life. Independent Evaluation Published in BMJ Open Strengthens the Evidence Base A peer-reviewed study published in BMJ Open on 9 October 2026 evaluated the programme's first implementation cycle (February–August 2025), examining its achievements, operational challenges and adaptations during implementation. Led by researchers from Queen's University Belfast and programme partners Noor Dubai Foundation, the study reported that 9,117 individuals were screened and 1,433 cataract surgeries performed in Year One of the cycle. Among 271 patients with complete follow-up assessments, vision-related quality of life improved significantly by an average of 17 points, particularly in mental health, near-vision and distance-vision activities. Beyond these achievements, the evaluation highlighted important challenges, including workforce limitations, transportation barriers, incomplete clinical records and low postoperative follow-up attendance, with only 19% returning at one month. The findings emphasise that successful cataract outreach requires more than delivering surgeries; it also depends on effective referral pathways, continuity of care and responsive programme management. Lessons from the first cycle have helped identify opportunities to strengthen subsequent implementation cycles and offer valuable insights for similar programmes in resource-constrained settings. Voices from the Partnership Mr. L.T. Pagarani, Chairman, Choithrams Group “Goodness inspires more goodness, and this second year of our cataract outreach shows exactly that. After restoring sight for hundreds of people in our first cycle, we returned with even greater resolve to deepen our collaborative action. We are grateful to the Government of Sierra Leone, especially the Ministry of Health, for their partnership, and to Noor Dubai Foundation for their leadership and guidance. Above all, we honour the dedication of our doctors and staff whose work makes this impact possible. The celebration of restored vision belongs as much to the beneficiaries as it does to all of us who believe in the power of service to society.” Drs. Gabriel Osei-Anokye and Ving Fai Chan, Queen’s University Belfast “The progress we see in this second year is the careful reflection, rigorous evaluation, and a shared commitment to learning from the first cycle. Our research shows that when cataract programmes use evidence to continually improve how services are delivered, the benefits extend far beyond better vision. People regain mobility, confidence, independence, and the ability to participate more fully in their families and communities. Sierra Leone’s experience shows how strong leadership, continuous learning, and cross-sector collaboration can deliver high-quality outcomes even in challenging settings. Restoring sight is therefore more than a medical intervention; it is about enabling people to regain independence, opportunity, and their place in community life.” Looking Ahead: A Bigger, Faster, More Connected Year Three The programme now moves into its third cycle, scheduled from January to April 2027, marking another step in Sierra Leone’s long‑term journey toward eliminating avoidable blindness. With approximately 80 working days earmarked for clinical interventions, partners aim to perform 2,500 to 3,000 cataract surgeries, the most ambitious target yet, reflecting rising demand and growing national capacity. Preparations are already underway. Level 1 screenings began on 1 September, with a deliberate focus on rural provinces where access to eye care remains limited. Strengthening collaboration with district health authorities is central to this next phase, ensuring increased referrals and earlier identification of at‑risk patients. Operationally, Year Three will rely on the expanded cadre of Sierra Leonean ophthalmic staff trained during the first two cycles, supported by ongoing mentorship from Choithram Netralaya (India). With an average of 40 surgeries per day, the programme is moving steadily toward domestic clinical self‑sufficiency while maintaining world‑class standards of care. Distributed by APO Group on behalf of Choithram International Foundation. Links to additional content: Testimonials of beneficiaries in links below: Link 1: https://apo-opa.co/4z9MeiU https://apo-opa.co/4sms9mL Please refer to the following study for implementation lessons from a high‑-volume cataract screening and surgical programme in Sierra Leone: Full paper available at: https://apo-opa.co/4z5wX2z Detailed Year 1 Report Link: https://apo-opa.co/4yXEnEM Detailed Year 1 Ophthalmic Training Report Link: https://apo-opa.co/47udPiv The Infographic Shows Effective Management for Sustainable Outcomes: How Sierra Leone’s Cataract Outreach Model Restores Sight Through Coordinated Planning, Collaboration, and Data‑-Driven Impact. About Noor Dubai Foundation, Dubai, UAE:  Noor Dubai was launched with the vision of a world free from avoidable causes of blindness.  therapeutic, preventative and educational programmes to treat and prevent blindness and visual impairment in developing countries on a regional and international scale. Following the success achieved of reaching out to over 5.8 million individuals worldwide in its first year, a decree was passed by His Highness Sheikh Mohammed Bin Rashid Al Maktoum, launching the Noor Dubai Foundation as a non-governmental, non-for-profit organization, aiming to eliminate all forms of preventable blindness globally. About Queen’s University Belfast, UK: About Choithram Netralaya – Indore, India:  Choithram Netralaya is a one-stop solution for all eye problems, and provides comprehensive eye care services covering Cataracts, glaucoma, Orbit & Oculoplasty, Cornea & Retina, Paediatric Ophthalmology, Community Ophthalmology, Ocular Oncology, Corneal Transplant, Squint, Ocular Trauma, Neuro-Ophthalmology, Uveitis, Low vision aids & visual rehabilitation, Ocular Prosthesis, and Ophthalmic Anaesthesia, among other services. About Choithram Memorial Hospital, Freetown, Sierra Leone: Choithram Memorial Hospital (CMH) is a leading multispecialty healthcare provider in Freetown, Sierra Leone, committed to delivering high-quality, accessible medical care. Established in 1993, CMH has grown into one of the country’s most trusted hospitals, offering a wide range of services, including cardiology, neurology, ophthalmology, and emergency care. Situated on a five-acre campus, the hospital is equipped with modern facilities and a dedicated team of medical professionals. CMH plays a vital role in Sierra Leone’s healthcare ecosystem, providing comprehensive treatment while ensuring affordability and accessibility for all patients ———————————————————————————————————————————————————————————— HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations 2026-10-22 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/hanchorbio-and-aston-sci-join-forces-to-unlock-the-potential-of-next-generation-immunotherapy-through-cancer-vaccine-combinations-302916658.html Strategic collaboration pairs HCB101 (macrophage CD47-SIRPα blockade) with Aston Sci's Phase 2 HER2-directed DNA vaccine (AST-301) to drive durable, dual innate/adaptive antitumor immunity Initial studies focus on gastric and breast cancers; expands to evaluate AST-301 and investigational... ———————————————————————————————————————————————————————————— Vitaquest International Appoints Martin Gargiule as Chief Financial Officer 2026-10-22 · GlobeNewswire · Healthcare, Retail, Industrial, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386118/0/en/vitaquest-international-appoints-martin-gargiule-as-chief-financial-officer.html Vitaquest names Martin Gargiule CFO, adding 25+ years of consumer health, pharma, and manufacturing finance expertise to its growing leadership team. ———————————————————————————————————————————————————————————— Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026 2026-10-22 · Business Wire · Finance, Healthcare, Biotech & pharma, Government & policy https://finance.yahoo.com/healthcare/articles/ivonescimab-data-sets-across-multiple-100000492.html Highlights Include Phase II Data Supporting Clinical Development Expansion for Ivonescimab MIAMI, October 22, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that ivonescimab data will be featured in numerous presentations at the European Society for Medical Oncology 2026 Congress (ESMO 2 ———————————————————————————————————————————————————————————— Five Reputable Custom Chemical Equipment Manufacturers in China 2026: Advancing Process Engineering 2026-10-22 · EIN Presswire · Industrial, Biotech & pharma, Chemicals & materials https://www.einpresswire.com/article/951467713/five-reputable-custom-chemical-equipment-manufacturers-in-china-2026-advancing-process-engineering Logo for Jiangsu Xuyang Chemical Equipment Co.,LTD Examining Custom Design, Manufacturing Processes, and Industrial Applications CALIFORNIA, CA, UNITED STATES, October 22, 2026 / EINPresswire.com / -- CHINA, October 22, 2026 — Custom chemical equipment continues to play an important role in chemical processing, pharmaceutical production, environmental protection and advanced materials manufacturing. As process requir ———————————————————————————————————————————————————————————— Rakovina Therapeutics and Variational AI Advance Brain-Penetrant ATR Program Toward Development Candidate Selection 2026-10-22 · PressReach · AI, Biotech & pharma https://pressreach.com/rakovina-therapeutics-and-variational-ai-advance-brain-penetrant-atr-program-toward-development-candidate-selection VANCOUVER, British Columbia, Oct. 22, 2026 — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced significant preclinical progress from its kt-5000AI program, a collaboration with Vancouver-based Variational AI Inc. (“Variational AI”) focused on the discovery and development of novel, … Continue reading "Rakovina Therapeutics and Variational AI Advance Brain-Penetrant ATR Program Toward Development Candidate Selection" ———————————————————————————————————————————————————————————— ARCHIBIO Wins ITMF Start-up Award 2026 for Enzymatic PET Recycling 2026-10-22 · EIN Presswire · Biotech & pharma, Sustainability, Chemicals & materials https://www.einpresswire.com/article/951447008/archibio-wins-itmf-start-up-award-2026-for-enzymatic-pet-recycling ARCHIBIO representatives at the ITMF Start-up Award 2026 presentation in Fortaleza, Brazil. The ITMF Start-up Award 2026 certificate recognizes Yuantian Biotechnology (Tianjin) for enzymatic recycling and industrialization of waste PET plastic. ARCHIBIO presents its enzymatic PET recycling technology at the 2026 ITMF/IAF conference in Fortaleza, Brazil. ARCHIBIO representatives and some other participants at the 2026 ———————————————————————————————————————————————————————————— AgeReverse RESURGE Now Available on OneLavi.com 2026-10-22 · Newsworthy.ai · AI, SaaS, Healthcare, Retail, Food & drink, Sports, Biotech & pharma, Marketing & advertising, Internet & apps, Consumer goods https://newsworthy.ai/news/202610223065/agereverse-resurge-now-available-on-onelavicom Boca Raton, Florida Thursday Oct 22, 2026 @ 5:00 AM Eastern — AgeReverse, a Canadian longevity company focused on healthy aging and cellular vitality, today announced that its flagship RESURGE formulation is now available to U.S. consumers through OneLavi.com, marking another milestone in the company's expanding U.S. retail presence. The One Lavi launch follows the recent availability of RESURGE on Amazon and reflects AgeReverse's strategy to build a broader U.S. distribution network through multiple retail and e-commerce channels. "Expanding our availability through OneLavi is another important step in introducing AgeReverse to more consumers across the United States," said Kubi Turkmen, Founder and CEO of AgeReverse. "Our goal is to make RESURGE accessible through established retail destinations while continuing to build awareness of our comprehensive approach to healthy aging." AgeReverse developed RESURGE around the scientific framework of the 12 Hallmarks of Aging, which describes interconnected biological processes associated with aging. Rather than emphasizing a single ingredient or isolated wellness benefit, the company designed its flagship formulation to bring together multiple ingredients in a simplified daily regimen. The 90-capsule RESURGE formulation includes NMN, Resveratrol, Quercetin, Fisetin, CoQ10, Astragalus Extract, Hyaluronic Acid, Aronia Extract and Noni Berry. Key features of RESURGE include: Developed around the scientific concept of the 12 Hallmarks of Aging Combines multiple ingredients associated with antioxidant support and everyday wellness Supports nutrient metabolism, cardiovascular health and immune function Helps support collagen formation, connective tissue development and joint health Simplifies what the company describes as 12 or more individual products and 15 or more capsules per day into a three-capsule daily regimen Manufactured in GMP-certified facilities in Ontario, Canada using vegan capsules Registered as a Natural Health Product with Health Canada under NPN 80130202 The expansion onto OneLavi comes as AgeReverse continues developing its presence in the U.S. longevity and healthy aging market. The company recently participated in the ECRM Vitamin, Weight Management & Sports Nutrition Session in Palm Beach Gardens, Florida, where it introduced RESURGE and its broader product strategy during scheduled meetings with retail buyers across health, specialty, food, drug and mass retail channels. Beyond RESURGE, AgeReverse is developing a range of products focused on both internal wellness and external skin aging. Its broader plans include biological age testing, daily skincare, professional aesthetic formulations and non-invasive mesotherapy technology. "Our long-term strategy is about more than a single product or sales channel," Turkmen added. "We are building a complete range of healthy aging solutions while expanding the ways consumers can access the AgeReverse brand." The OneLavi availability represents another step in that strategy, complementing the company's existing Amazon presence and its ongoing efforts to develop additional U.S. retail relationships. RESURGE is now available on OneLavi.com and Amazon. Visit the AgeReverse Website and follow the company on Instagram and LinkedIn. About AgeReverse AgeReverse is a Canada-based longevity wellness company focused on developing science-driven products designed to support healthy aging and cellular vitality. Founded by Kubi Turkmen, who has more than 30 years of experience in anti-aging innovation, the company’s approach combines longevity research, telomere science, and wellness innovation to create comprehensive healthy aging solutions. The company’s expanding AgeReverse platform includes longevity supplements and other wellness technologies designed to support multiple biological pathways associated with aging and long-term vitality. Products are manufactured in GMP-certified facilities in Ontario, Canada. Learn more at the company’s website.  FDA Disclaimer These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. ———————————————————————————————————————————————————————————— Prilenia and Ferrer Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease 2026-10-22 · Business Wire · Healthcare, Biotech & pharma, Jobs & workplace https://finance.yahoo.com/healthcare/articles/prilenia-ferrer-announce-authorization-eu-083400162.html Recruitment is expected to start this month, rolling out to upwards of 31 sites across nine EU countries, and joining the ongoing enrollment in the US and UK, with Canada set to follow Prilenia and Ferrer will share new data analyses and clinical trial updates at the European Huntington's Disease Network (EHDN) Clinical R ———————————————————————————————————————————————————————————— Latin America’s Quiet Rise: Argentina and Brazil Enter the Biosimilars Market Spotlight 2026-10-22 · Express Press Release · Healthcare, Biotech & pharma https://express-press-release.net/news/2026/10/22/1778029 Biologic drugs transformed the treatment of cancer, autoimmune disease, and diabetes, but their cost has kept many patients and health systems from benefiting fully. Biosimilars [read full press release...] ———————————————————————————————————————————————————————————— Nxera Pharma Submits Marketing Authorization Application for Vamorolone in South Korea for the Treatment of Duchenne Muscular Dystrophy 2026-10-22 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386063/0/en/nxera-pharma-submits-marketing-authorization-application-for-vamorolone-in-south-korea-for-the-treatment-of-duchenne-muscular-dystrophy.html Nxera Pharma Submits Marketing Authorization Application for Vamorolone in South Korea for the Treatment of Duchenne Muscular Dystrophy. ———————————————————————————————————————————————————————————— Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease 2026-10-22 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/ferrer-prilenia-announce-authorization-eu-070000552.html BARCELONA, Spain, October 22, 2026--Ferrer i and Prilenia Therapeutics B.V. today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Member States (EU CT number: 2026-526093-16-00, ———————————————————————————————————————————————————————————— VitroVivo Biotech LLC Highlights Tissue Analysis Capabilities for Biomedical Researchers Through Specialized Laboratory Services 2026-10-22 · ACCESS Newswire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/vitrovivo-biotech-llc-highlights-tissue-065000606.html ROCKVILLE, MD / October 22, 2026 / VitroVivo Biotech LLC, a Maryland-based provider of histology and molecular histopathology services, is highlighting its laboratory capabilities for researchers requiring detailed tissue examination, specialized cell isolation, and reliable specimen preparation. The com ———————————————————————————————————————————————————————————— Kanazawa University research: Scientists discover hidden weaknesses in microtubules stabilized by a cancer drug 2026-10-22 · PR Newswire · Education, Biotech & pharma https://www.prnewswire.com/news-releases/kanazawa-university-research-scientists-discover-hidden-weaknesses-in-microtubules-stabilized-by-a-cancer-drug-302916588.html High-speed nanoscale imaging reveals how tiny structural defects can cause microtubules to collapse, even when stabilized by the anticancer drug paclitaxel (Taxol). KANAZAWA, Japan, Oct. 22, 2026 -- Researchers at the Nano Life Science Institute (WPI-NanoLSI) at Kanazawa... ———————————————————————————————————————————————————————————— NFL Biosciences Receives Regulatory Approval to Begin Its Phase 2 TONIC Trial for Smoking and Nicotine Cessation 2026-10-22 · Business Wire · Sports, Biotech & pharma https://finance.yahoo.com/healthcare/articles/nfl-biosciences-receives-regulatory-approval-063000395.html The TONIC Phase 2 trial evaluating NFL-102 consists of Part A (the first 40 participants) and Part B (the next 270 participants) Enrollment of the first participants (Part A) is scheduled to begin in November 2026 Analysis and communication of the results from Part A expected in April 2027 MONTPELLIER, France, October 22, ———————————————————————————————————————————————————————————— Rznomics Granted Orphan Medicinal Product Designation for RZ-001 for the Treatment of Glioma by the European Commission 2026-10-22 · PR Newswire · Biotech & pharma, Government & policy https://www.prnewswire.com/news-releases/rznomics-granted-orphan-medicinal-product-designation-for-rz-001-for-the-treatment-of-glioma-by-the-european-commission-302916450.html SEONGNAM, South Korea, Oct. 22, 2026 -- Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced today that the European Commission (EC) has granted Orphan Medicinal Product Designation to 'taspitimagene advec(RZ-001)',... ———————————————————————————————————————————————————————————— Indegene Receives Frost & Sullivan's 2026 Global Enabling Technology Leadership Recognition for AI-Powered Pharma Commercialization 2026-10-22 · PR Newswire · AI, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/indegene-receives-frost--sullivans-2026-global-enabling-technology-leadership-recognition-for-ai-powered-pharma-commercialization-302910803.html Indegene is recognized for combining domain-led AI, knowledge orchestration, and integrated execution to transform pharmaceutical commercialization workflows. SAN ANTONIO, Oct. 22, 2026 -- Frost & Sullivan is pleased to announce that Indegene has received the 2026 Global... ———————————————————————————————————————————————————————————— [Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine months of 2026 2026-10-22 · Roche · Finance, AI, SaaS, Healthcare, Real estate, Automotive, Food & drink, Industrial, Biotech & pharma, Sustainability, Investing & markets, Legal, Government & policy, Jobs & workplace, Marketing & advertising, Software & IT, Medical devices https://www.roche.com/media/releases/med-cor-2026-10-22 Ad hoc announcement pursuant to Art. 53 LR Basel, 22 October 2026 Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine months of 2026 Group sales were +6% at constant exchange rates (CER)1, +1% when reported in CHF and +7% in USD2, in the first nine months of 2026, driven by high demand for our innovative medicines and diagnostics. In the third quarter, sales grew +7% (CER) and +8% in CHF (+7% in USD), as exchange rates stabilised. Pharmaceuticals Division sales were +7% at CER, +2% when reported in CHF and +8% in USD, in the first nine months, due to continued high demand for medicines to treat severe diseases; Xolair (chronic hives, food allergies), Hemlibra (haemophilia A), Ocrevus (multiple sclerosis), Phesgo (breast cancer) and Vabysmo (severe eye diseases) were the top growth drivers. Diagnostics Division sales were +4% at CER, stable when reported in CHF and +6% in USD, in the first nine months, as demand for core lab and pathology solutions more than offset the impact of healthcare pricing reforms in China. Highlights: US approval for Tecentriq for the adjuvant treatment of stage-III DNA mismatch repair colon cancer, Gazyva/Gazyvaro for reducing the risk of relapse in patients 2 years of age and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome and Enspryng in thyroid eye disease US Priority Reviews for fenebrutinib in both relapsing and primary progressive multiple sclerosis and Enspryng in MOGAD, an autoimmune disease; vamikibart filing acceptance in uveitic macular edema, a leading cause of vision loss EU approval for Susvimo in neovascular age-related macular degeneration (nAMD), a severe eye disease, and Ocrevus in paediatric relapsing multiple sclerosis; EMA validation of application for Enspryng in MOGAD in Europe Positive data for: sefaxersen in an autoimmune condition affecting kidney function (phase III), Lunsumio in blood cancer (phase III), Tam-Peli in relapsed small-cell lung cancer (phase III) as well as enicepatide and petrelintide in overweight or obesity and type 2 diabetes (both phase II) US clearance for Elecsys pTau217 test, providing clinicians across primary and specialty care with a single-biomarker blood test to aid in identifying amyloid pathology associated with Alzheimer’s disease Launch of two new, real-time PCR tests to support public health epidemic response to the US outbreak of the Cyclospora cayetanensis parasite Delivery of molecular tests to support the Democratic Republic of the Congo health ministry-led response to the Ebola outbreak Manufacturing and R&D capacity expansion: Hillsboro injectable medicines facility and Innovation Center Boston for cardiovascular, renal and metabolic diseases in the US and small molecules facility in Basel, Switzerland Outlook for 2026 confirmed Roche CEO Thomas Schinecker: “In the third quarter, we delivered strong sales growth of +7% at constant exchange rates and +8% in Swiss francs. Most importantly, we continued to make meaningful progress for patients. We advanced another five potential new medicines into the final stage of development this year and now aim to bring up to 20 new medicines to patients by 2030. The US FDA granted Priority Review for fenebrutinib in both relapsing and primary progressive multiple sclerosis, bringing us closer to delivering the first high-efficacy, brain-penetrant oral therapy to patients. Giredestrant is also under FDA Priority Review in both early-stage and advanced breast cancer, and we are fully prepared to launch later this year, pending approval. In Diagnostics, we received US FDA clearance for Elecsys pTau217, the first and only FDA-cleared single-biomarker blood test for Alzheimer’s disease that supports both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings.  We confirm our full-year outlook.” Outlook for 2026 Roche (SIX: RO, ROP; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit range (CER) for 2026. Core earnings per share are targeted to develop in the high single digit range (CER). Roche expects to further increase its dividend in Swiss francs. SalesCHF millionsAs % of sales% change January–September 2026202520262025At CERIn CHFIn USD Group 46,49345,862100.0100.0+6+1+7          Pharmaceuticals Division36,21235,55577.977.5+7+2+8 United States18,71218,79840.241.0+50  Europe6,8196,81814.714.9+20  Japan2,3522,1395.14.7+25+10  International8,3297,80017.916.9+10+7           Diagnostics Division10,28110,30722.122.5+40+6 International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others Group sales In the first nine months of 2026, Roche sales were +6% at CER, +1% when reported in CHF, to CHF 46.5 billion due to strong demand for pharmaceutical products and diagnostic solutions. The appreciation of the Swiss franc against most currencies, notably the US dollar, had a significant impact on the results reported in Swiss francs compared to constant exchange rates. This currency impact reversed in the third quarter. Sales growth in the Pharmaceuticals Division was +7% at CER, +2% when reported in CHF, to CHF 36.2 billion, with medicines for severe diseases continuing their strong growth. The top five growth drivers – Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo – achieved total sales of CHF 16.8 billion, an increase of +12% at CER, or +6% in CHF, compared to the first nine months of 2025. Sales of products with expired patents (Avastin, Herceptin, MabThera/Rituxan, Lucentis and Actemra/RoActemra) decreased by a combined CHF 0.4 billion at CER, or CHF 0.6 billion in CHF. In the United States, sales were +5% at CER, stable when reported in CHF, due to continued growth of Xolair, Hemlibra, Ocrevus, Polivy (blood cancer) and Tecentriq (cancer immunotherapy). This growth more than compensated for the lower sales of Kadcyla (breast cancer) and Perjeta (breast cancer). Sales in Europe were +2% at CER, stable when reported in CHF, as the growing demand for Ocrevus, Phesgo and Evrysdi (spinal muscular atrophy) more than offset the impact of biosimilar competition on Actemra/RoActemra and the conversion to Phesgo on Perjeta. In Japan, sales were +25% at CER, +10% when reported in CHF, mainly due to product supply to third parties and continued growth of Lunsumio (blood cancer), Hemlibra, Polivy, Elevidys (Duchenne muscular dystrophy) and Vabysmo. There was also a positive impact of timing effects related to the implementation of a new enterprise resource planning (ERP) system. Sales in the International region were +10% at CER, +7% when reported in CHF, led by higher sales of Phesgo, Vabysmo, Hemlibra, Ocrevus and Evrysdi. In China, sales were stable at CER and when reported in CHF, driven by continued growth of Phesgo, Vabysmo, Alecensa and Polivy. The increase was partially offset by lower sales of Perjeta due to the conversion to Phesgo and Xofluza due to a milder flu season in 2025. The Diagnostics Division’s sales were +4% at CER, stable when reported in CHF, to CHF 10.3 billion as growth in demand for core lab and pathology solutions more than offset the impact of healthcare pricing reforms in China. Sales in the Europe, Middle East and Africa (EMEA) region were +3% at CER, unchanged when reported in CHF, driven by higher sales of clinical chemistry and immunodiagnostic products. In North America, sales were +9% at CER, +3% when reported in CHF, with growth across the Core Lab, Pathology Lab and Molecular Lab customer areas. Sales in Asia-Pacific were -4% at CER, or -8% when reported in CHF, due to the healthcare pricing reforms in China. In Latin America, sales growth was +12% at CER, or +11% when reported in CHF. Pharmaceuticals: key developments CompoundMilestone Regulatory Enspryng Thyroid eye diseaseFDA approves Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED) FDA approval based on phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favourable safety profile, regardless of TED activity or duration. Enspryng (satralizumab) represents an important advance for people with TED, offering the first at-home subcutaneous treatment option every four weeks during maintenance phase, allowing for greater flexibility in how treatment is administered. Enspryng is an anti-IL-6R monoclonal antibody using novel recycling antibody technology designed to inhibit IL-6 signalling upstream of autoantibody-driven pathology. TED is a rare autoimmune disease affecting approximately 155 out of every 100,000 people in the US that can lead to facial disfigurement and vision-threatening complications if left untreated. More information: Media Release, 16 October 2026 Tecentriq Different types of cancerFDA approves Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer The approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. It is the first approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, positioning Tecentriq as a new post-surgery standard of care. Nearly 25% of all colon cancers are diagnosed at stage III, and almost one in three patients with stage III colon cancer experience a recurrence within five years. Approval marks the twelfth indication for Tecentriq in the US. More information: Media Release, 9 October 2026 Fenebrutinib Multiple sclerosisFenebrutinib is the first BTK inhibitor to receive US FDA filing acceptance in both relapsing and primary progressive multiple sclerosis Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in phase III RMS trials (FENhance 1 and 2) while showing a consistent, positive trend in delaying disability. Fenebrutinib became the first investigational medicine in more than a decade to slow disability progression in a phase III PPMS trial (FENtrepid), with numerical benefit vs Ocrevus. Fenebrutinib is designed to address two drivers of MS – acute inflammation causing relapses and chronic brain inflammation driving disability progression. If approved, fenebrutinib would become the first BTK inhibitor and first high-efficacy oral treatment for both RMS and PPMS, offering a new option for the nearly 1 million people living with MS in the US. More information: Media Release, 30 September 2026 Susvimo Severe eye diseasesEuropean Commission approves Susvimo for the treatment of neovascular age-related macular degeneration   By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is the first and only continuous delivery treatment that offers an alternative to standard-of-care eye injections for nAMD. Susvimo helps people with nAMD maintain their vision with as few as two treatments per year. Data from the phase III Archway study showed that Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections. nAMD is a leading cause of vision loss in adults over 60 and affects approximately 1.7 million people across the European Union. More information: Media Release, 21 September 2026 Enspryng MOGADFDA grants Priority Review for Enspryng for MOGAD, an autoimmune disease with no approved treatments If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease). The filing acceptance is based on the phase III METEOROID study showing that Enspryng reduced the risk of relapses by 68%. The European Medicines Agency (EMA) has validated the application for Enspryng for MOGAD in Europe, with a decision expected in Q3 2027. More information: Media Release, 10 September 2026 Phase III, pivotal and other key read-outs Sefaxersen IgA nephropathyPositive interim data shows sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN) In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential. Sefaxersen inhibits complement factor B production at its primary source in the liver, thus blocking a key driver of IgAN-related kidney damage. Interim data will be presented at an upcoming medical meeting and shared with health authorities. More information: Media Release, 23 September 2026 Enicepatide ObesityRoche announces positive phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycaemic control. By week 48, 90% of patients in the 24 mg enicepatide arm met the type-2-diabetes glycaemic target of ≤6.5% HbA1c, while 62% achieved normoglycaemia (HbA1c <5.7%). At the highest 24 mg dose, enicepatide achieved a mean weight loss of 15.5% at 48 weeks, without a weight loss plateau. More information: Media Release, 22 September 2026 Lunsumio Blood cancerRegimen based on Lunsumio significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular lymphoma who have received at least one prior line of treatment. Data reinforce the potential of this regimen based on Lunsumio to improve clinical outcomes, while offering a tolerable safety profile, a simple dosing schedule and outpatient administration. CELESTIMO is the confirmatory study required to convert the accelerated approval / conditional marketing authorisation of Lunsumio monotherapy for third-line or later (3L+) follicular lymphoma to full approval, as well as to secure an indication in second-line or later (2L+) follicular lymphoma. Data will be submitted to health authorities and presented at an upcoming medical meeting. More information: Media Release, 17 September 2026 Tam-Peli Lung cancerRoche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7%. The novel B7-H3-targeted antibody-drug conjugate with a dual release mechanism of the payload is based on MediLink’s proprietary TMALIN platform, designed to maximise antitumour activity while minimising off-target toxicity. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau across multiple tumour types, with plans to rapidly initiate global trials. Tam-Peli has received US FDA and China CDE Breakthrough Therapy Designations for relapsed small-cell lung cancer. More information: Media Release, 13 September 2026 Vabysmo Severe eye diseasesVabysmo demonstrates sustained two-year results in a difficult-to-treat form of nAMD The SALWEEN study showed significant improvements in vision and retinal health. More than 60% of Asian patients with polypoidal choroidal vasculopathy (PCV), an aggressive subtype of nAMD, treated with Vabysmo showed no signs of polypoidal lesions. By the end of year two, more than 60% of patients were on an extended 20-week treatment interval, reducing treatment burden. More information: Media Release, 28 August 2026 Other ESMO presentation Lung and breast cancer portfolio Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio Phase III Krascendo 1 results demonstrated divarasib’s superiority over current standard-of-care, first-generation KRAS G12C inhibitors in previously treated advanced G12C-mutated non-small cell lung cancer. Patient-reported outcomes from phase III lidERA study showed that improved efficacy of giredestrant over standard endocrine therapy is achieved without compromising tolerability and health-related quality of life in early-stage breast cancer. Phase III results in Chinese patients with metastatic nasopharyngeal carcinoma demonstrate the potential of Tam-Peli, a next-generation B7-H3-targeted ADC, to deliver robust efficacy with a favourable safety profile in high-unmet-need solid tumours.   More information: Media Release, 19 October 2026 Vamikibart Uveitic macular edemaRoche presents new phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks. UME is the leading cause of moderate and severe vision loss in patients with uveitis, posing a significant risk of blindness if left untreated. The FDA has accepted Roche’s Biologics License Application (BLA), with an approval decision expected by July 2027. More information: Media Release, 10 October 2026 Vabysmo Severe eye diseasesRoche presents new data at EURETINA, highlighting the real-world effectiveness and safety of Vabysmo across major retinal conditions New real-world results for Vabysmo in nAMD, diabetic macular edema and retinal vein occlusion reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals. Advanced AI-enabled analysis of imaging confirms rapid and meaningful anatomical drying supporting Vabysmo as a standard-of-care therapy in routine clinical care. With more than 5,000 patients enrolled, VOYAGER is the largest, prospective, non-interventional real-world dataset evaluating Vabysmo across diverse clinical practice settings worldwide.   More information: Media Release, 1 October 2026 Giredestrant Breast cancerGiredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimus. By targeting resistance to endocrine treatments, the giredestrant combination seeks to delay disease progression and improve overall patient outcomes. The FDA has set a PDUFA goal date for giredestrant in early-stage breast cancer of 30 November 2026 and in advanced disease of 18 December 2026. More information: Media Release, 1 October 2026 Board of Directors nominationRoche proposes Dr Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to its Board of Directors at the 2027 Annual General Meeting Roche’s Board of Directors has approved to propose Dr Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board at the Annual General Meeting on 9 March 2027. Roche Chairman Severin Schwan highlighted Dr Weber’s extensive healthcare industry knowledge and leadership experience as valuable assets for the Board. Roche continues its commitment to transformative medicines and diagnostics, focusing on major disease areas and global healthcare challenges. More information: Media Release, 23 September 2026 Innovation Center BostonRoche announces grand opening of its Innovation Center Boston to drive advancements in cardiovascular, renal and metabolic diseases The centre will be a hub for Roche and Genentech, bringing together expertise in cardiovascular, renal and metabolic diseases, as well as for data science and AI specialists to drive innovation in drug discovery and development. It will expand Roche’s and Genentech’s presence in Boston, reflecting a long-term commitment to one of the world’s leading life sciences hubs. This is part of Roche and Genentech’s USD 50 billion investment in US manufacturing and R&D, building on recent investments and manufacturing milestones in Holly Springs, North Carolina, and Hillsboro, Oregon. More information: Media Release, 17 September 2026 Hillsboro facilityGenentech, Roche’s US subsidiary, announces a USD 750 million manufacturing expansion in Hillsboro, Oregon The new facility in Hillsboro, Oregon for the assembly of injectable medicines and delivery devices will further advance end-to-end US drug manufacturing capabilities. Approximately USD 750 million investment will double the size of the existing facility and is expected to create an additional 250 specialised manufacturing jobs. Flexible manufacturing capacity will support advanced drug delivery devices that can provide patients with more convenient ways to receive treatment. More information: Media Release, 20 August 2026 Pharmaceuticals sales SalesCHF millionsAs % of sales% change January–September2026202520262025At CERIn CHF Pharmaceuticals Division36,21235,555100.0100.0+7+2 United States18,71218,79851.752.9+50 Europe6,8196,81818.819.2+20 Japan2,3522,1396.56.0+25+10 International8,3297,80023.021.9+10+7 International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others Top 20 best-selling pharmaceuticals (% change at CER1)TotalUnited StatesEuropeJapanInternational CHF m%CHF m%CHF m%CHF m%CHF m% Ocrevus Multiple sclerosis5,317+73,581+51,136+9--600+21 Hemlibra Haemophilia A3,750+122,006+9769+5291+20684+23 Vabysmo Eye diseases (nAMD, DME, RVO)3,196+102,060+2585+7131+41420+65 Tecentriq Cancer immunotherapy2,615+51,243+8626-2245+6501+9 Xolair3 Chronic hives, food allergies2,521+202,521+20------ Phesgo Breast cancer2,064+18486-1657+11152+24769+43 Perjeta3 Breast cancer2,040-8824-10361-1338-20817-3 Actemra/RoActemra3 RA, COVID-191,621-10795-9328-26232+14266-4 Evrysdi Spinal muscular atrophy1,470+18497+12504+1465+7404+33 Kadcyla3 Breast cancer1,339-9442-19370-565+9462-2 Polivy Blood cancer1,302+24606+29204-9176+30316+44 Alecensa Lung cancer1,213+6391-1189-3154+15479+15 MabThera/Rituxan3 Blood cancer, RA919+3605+1294-88-16212-10 Activase/TNKase3 Cardiac diseases830+6792+5----38+12 Gazyva/Gazyvaro3 Blood cancer, lupus nephritis751+7369+4176-228+28178+25 Herceptin3 Breast and gastric cancer695-12140-15205-63-35347-13 Avastin3 Various cancer types639-12195-856+556-43332-9 Columvi Blood cancer327+67146+2492+113--89+167 Enspryng Acute inflammation of brain, spinal cord and optic nerves319+2879+1834+18138+3068+42 Pulmozyme3 Cystic fibrosis303-12214-1143-111+3845-18 DME: diabetic macular edema / nAMD: neovascular or ‘wet’ age-related macular degeneration / RVO: retinal vein occlusion / RA: rheumatoid arthritis Diagnostics key developments ProductMilestone Elecsys pTau217 Alzheimer’s diseaseRoche receives FDA clearance for Elecsys pTau217, advancing Alzheimer’s disease assessment across primary and specialty care It is the first and only FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings. The test delivers consistency across clinical settings by using the same validated cut-offs in primary and specialty care. It is designed for broad implementation across Roche’s installed base of more than 4,500 cobas laboratory instruments in the US supporting access through existing laboratory infrastructure.   More information: Investor Update, 24 August 2026 Diagnostics sales SalesCHF millionsAs % of sales% change January–September2026202520262025At CERIn CHF Diagnostics Division10,28110,307100.0100.0+40 Customer areas       Core Lab5,7555,68856.055.2+5+1 Molecular Lab1,8361,86117.918.1+3-1 Near Patient Care1,3481,47713.114.3-5-9 Pathology Lab1,3421,28113.012.4+10+5 Regions       Europe, Middle East, Africa3,6983,68636.035.8+30 North America3,3893,30532.932.1+9+3 Asia-Pacific2,3432,54722.824.7-4-8 Latin America8517698.37.4+12+11 More information on Roche’s performance in the first nine months of 2026: 9M 2026 presentation Appendix with tables  About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceuticals Divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] CER (Constant Exchange Rates). The percentage changes at constant exchange rates are calculated using simulations by reconsolidating both the 2026 and 2025 results at constant exchange rates (the average rates for the year ended 31 December 2025). For the definition of CER, see page 178 of the Roche Finance Report 2025. [2] USD (US dollars). The percentage changes for selected sales figures at US dollars are calculated by translating both the 2026 and 2025 sales figures at the respective average US dollar exchange rate for the period in question. This supplementary information is provided to assist readers when assessing comparability with other companies. [3] Products launched before 2015. Cautionary statement regarding forward-looking statements This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, such as: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone: +41 79 377 83 75Albert Thottiyil Phone: +41 79 775 66 12 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 687 5 284 e-mail: bruno.eschli@roche.comDr Sabine Borngräber Phone: +41 61 688 80 27 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 688 48 14 e-mail: birgit.masjost@roche.com  Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com   Attachments Communications appendix tables_YTD Sep 2026_Sales_02102026 Media Investor Release Roche Q3 2026 English ———————————————————————————————————————————————————————————— Ipsen delivers outstanding sales growth in the first nine months of 2026 and further upgrades its full-year guidance 2026-10-22 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386012/0/en/ipsen-delivers-outstanding-sales-growth-in-the-first-nine-months-of-2026-and-further-upgrades-its-full-year-guidance.html PARIS, FRANCE, 22 October 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the year-to-date and third quarter of 2026. ———————————————————————————————————————————————————————————— Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock 2026-10-22 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/arcus-biosciences-announces-pricing-250-025300974.html HAYWARD, Calif., October 22, 2026--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14, ———————————————————————————————————————————————————————————— Top-Journal Breakthrough (IF=81.2): Cloud-Clone AGE ELISA Kit Helps Uncover Protein Glycation Modification 2026-10-22 · EIN Presswire · SaaS, Healthcare, Biotech & pharma https://www.einpresswire.com/article/951394243/top-journal-breakthrough-if-81-2-cloud-clone-age-elisa-kit-helps-uncover-protein-glycation-modification CEB353Ge kit delivers critical molecular evidence for phase 3 clinical trial evaluating recombinant human serum albumin for cirrhotic ascites HUSTON, TX, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Against the backdrop of rapid advances in biomedical science, landmark publications in high-impact academic journals define cutting-edge research directions worldwide. On 10 September 2026, a research team from ———————————————————————————————————————————————————————————— Robbins LLP Reminds UNCY Investors of the Pending Lead Plaintiff Deadline in the Unicycive Therapeutics, Inc. Securities Class Action Lawsuit 2026-10-22 · PR Newswire · Finance, Biotech & pharma, Legal https://www.prnewswire.com/news-releases/robbins-llp-reminds-uncy-investors-of-the-pending-lead-plaintiff-deadline-in-the-unicycive-therapeutics-inc-securities-class-action-lawsuit-302916105.html SAN DIEGO, Oct. 21, 2026 -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between December 29, 2025 and June... ———————————————————————————————————————————————————————————— Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA Date of March 25, 2027 2026-10-22 · ACN Newswire · Finance, Healthcare, Food & drink, Industrial, Biotech & pharma, Legal, Nonprofits, Internet & apps https://www.acnnewswire.com/press-release/english/110981/ Mountain View, CA, 21 Oct, 2026 - Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company's investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The NDA was resubmitted following a Complete Response Letter (CRL) received in June 2026. The FDA has deemed the OLC resubmission a Class II with a six-month review period from the resubmission date, and set a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027. Unicycive Therapeutics, Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/unicycive-therapeutics. "We are pleased that the FDA has accepted the resubmission of our NDA for OLC and assigned a PDUFA date," said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. "This resubmission includes CMC data from a new third-party drug product manufacturing vendor. The new vendor's facility was last inspected by the FDA in March 2024 and received 'No Action Indicated' status. We hope to continue working with the FDA toward potential approval of this important medication to patients with CKD on dialysis who need additional treatment options for managing hyperphosphatemia." The Company does not know whether the FDA will decide to conduct a pre-approval inspection of the new third-party DP vendor. Additionally, if the original third-party manufacturing vendor is inspected in the near term and finds that its facility complies with current Good Manufacturing Practice (cGMP), the Company plans to seek FDA alignment on a shorter approval timeline. The Company resubmitted the NDA following the second CRL, which cited deficiencies previously identified at the original third-party manufacturer of the drug product, which the FDA had not been able to re-inspect during the prior submission review. The timing and outcome of any FDA inspection of the original third-party vendor will be determined solely by the FDA. The NDA is supported by data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis), multiple preclinical studies, as well as CMC data. The FDA did not raise any concerns regarding OLC's preclinical or clinical data, including safety data, included in the original NDA submission. About Oxylanthanum Carbonate OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden. Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035. About Hyperphosphatemia Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.[1] Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream. [1] Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com. Forward-looking statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; Unicycive's clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; Unicycive's dependence on third parties for manufacturing; the possibility that FDA may require inspection of any vendor prior to approval, which could delay or prevent approval of its NDA; the risk that the inspection of the original or new third-party manufacturing vendor may not occur within a timeframe that benefits its regulatory timeline, or may result in adverse findings; risks related to business interruptions, which could seriously harm its financial condition and increase its costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of its products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Unicycive's Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Investor Contacts: Kevin Gardner, LifeSci Advisors, kgardner@lifesciadvisors.com Media Contact: Unicycive Therapeutics, media@unicycive.com Additional Contact: David Shapiro, B2i Digital, Inc., +1 212-579-4844, david@b2idigital.com B2i Digital Social Media: LinkedIn X Facebook Instagram YouTube TikTok Stocktwits Reddit Pinterest Threads To learn more about the B2i Digital Media Network, visit:  https://b2idigital.com/media-network SOURCE: Unicycive Therapeutics, Inc. ———————————————————————————————————————————————————————————— Oklahoma HB 3127: Medical Marijuana Doctor Advises Patients on Workplace Drug Rules 2026-10-22 · Newsworthy.ai · Finance, AI, SaaS, Healthcare, Real estate, Energy, Automotive, Industrial, Biotech & pharma https://newsworthy.ai/news/202610223081/oklahoma-hb-3127-medical-marijuana-doctor-advises-patients-on-workplace-drug-rules OKLAHOMA CITY Wednesday Oct 21, 2026 @ 7:00 PM Central — An active Oklahoma medical marijuana license has never been an absolute guarantee of job security. Starting November 1, 2026, that legal distinction becomes significantly more critical. According to a statewide patient advisory issued by Medical Marijuana Doctor Oklahoma, licensed cardholders face substantial shifts under House Bill 3127, which allows employers to take adverse employment action following a positive marijuana test if the action is carried out under a lawful written drug and alcohol testing policy. Signed by Governor Kevin Stitt on April 17, 2026, HB 3127 amends 63 O.S. § 427.8 of the Oklahoma Medical Marijuana and Patient Protection Act. While the legislation preserves the foundational rule that employers cannot penalize someone solely for being a registered Oklahoma Medical Marijuana Authority (OMMA) license holder, it substantially narrows the positive-test protections that many working patients currently rely on. Before November 1: How Existing Law Protected Positive Tests Under current OMMA patient-rights guidance, an employer generally cannot refuse to hire, discipline, or terminate a licensed patient solely because of a positive drug screen for marijuana components or metabolites. Existing law permits exceptions only when: The individual does not hold a valid, active OMMA license; The employee possesses, consumes, or is under the influence of marijuana at work or during work hours; The individual holds a position with safety-sensitive job duties; or State protection is preempted by federal law or where compliance is required to maintain federal funding or contracts. As detailed in the enrolled HB 3127 legislative history, the amendment does not eliminate all patient safeguards, but it fundamentally rewrites the positive-test exception. A Compliant Written Policy Becomes the New Dividing Line Beginning November 1, an employer may act solely on a positive marijuana test result when that action is taken pursuant to a written drug and alcohol testing policy adopted and enforced in accordance with the Oklahoma Standards for Workplace Drug and Alcohol Testing Act. This statutory change means a valid patient license may no longer defeat an adverse employment decision based on a drug screen. However, Medical Marijuana Doctor Oklahoma emphasizes that employers do not receive unchecked authority simply because they possess an internal document labeled "drug policy." As noted in recent workplace legal analysis by Crowe & Dunlevy, an employer’s policy and testing workflow must comply strictly with state testing standards, which govern: advance written notice to employees; clearly articulated testing criteria (who, when, and what substances are tested); certified collection and laboratory procedures; employee rights to explain or rebut a positive result; and strict statutory confidentiality protections. Safety-Sensitive Jobs Move to Mandatory Zero Tolerance HB 3127 creates an explicit statutory rule for safety-sensitive positions: applicants and employees in those roles "shall be subject to a zero-tolerance drug and alcohol standard," even if the employer applies an impairment-based or more flexible rule to non-safety staff. Crucially, the amendment eliminates the former statutory wording that permitted employers to designate positions as safety-sensitive based merely on what management "reasonably believes" could impact health and safety. Under 63 O.S. § 427.8, the law ties the classification directly to actual performed duties, including: Handling, storing, disposing of, or transporting hazardous, volatile, flammable, or combustible materials; Operating a motor vehicle, machinery, equipment, or power tools; Repairing or monitoring equipment or manufacturing processes whose failure could cause personal injury or property damage; Firefighting; Operating or overseeing utilities and critical public infrastructure; Dispensing pharmaceuticals; Carrying a firearm; or Providing direct patient care or direct child care. While this statutory list is not exhaustive, it restricts employers from applying arbitrary, self-created safety-sensitive labels. Because HB 3127 does not define every operational detail of "zero tolerance," patients in potentially qualifying roles should inspect their formal job descriptions, company policies, and applicable federal regulations. Core Safeguards and Legal Remedies That Survive Unchanged Despite the expansion of employer authority, two vital legal protections remain in force: Status Discrimination Ban: Unless mandated by federal statute or federal funding agreements, an employer may not penalize an applicant or employee solely because they hold an OMMA patient card. Civil Legal Remedy for Willful Violations: Patients subjected to unlawful adverse actions retain legal recourse. The statute maintains remedies under the Oklahoma workplace testing act, which authorizes civil actions within one year of an alleged willful violation (40 O.S. § 563). At the same time, state law reiterates that medical cannabis licenses do not authorize workplace consumption. Employers maintain the absolute right to prohibit possession, use, sale, transfer, and impairment on company property or while performing job functions. What Oklahoma Patients Must Do Before November 1 Medical Marijuana Doctor Oklahoma recommends that cardholders take immediate proactive steps: Request the Written Policy: Obtain and review your employer's current written drug and alcohol testing policy to verify that it complies with the Oklahoma testing act. Review Real Job Duties: Compare your daily tasks against the statutory list of safety-sensitive functions to evaluate your risk level. Never Assume Automatic Protection: Do not assume that off-duty therapeutic use, an active card, or the lack of visible impairment will shield your employment after November 1. Preserve Documentation: Retain dated copies of testing notices, chain-of-custody documentation, laboratory results, and written employer correspondence. Seek Timely Counsel: If facing an adverse employment action that appears non-compliant, consult a qualified Oklahoma employment attorney immediately to preserve statutory claims within the one-year limitations window under 40 O.S. § 563. This advisory provides general educational information, not legal advice. Oklahoma law and workplace policies can change, and federal rules may produce a different result. Verify current requirements through the Oklahoma Legislature, the Oklahoma Medical Marijuana Authority, and qualified legal counsel. ———————————————————————————————————————————————————————————— Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl) 2026-10-21 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385989/19871/en/supernus-announces-orphan-drug-exclusivity-for-onapgo-apomorphine-hcl.html Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO ———————————————————————————————————————————————————————————— Teknova to Report Third Quarter 2026 Financial Results on November 4, 2026 2026-10-21 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385977/0/en/teknova-to-report-third-quarter-2026-financial-results-on-november-4-2026.html HOLLISTER, Calif., Oct. 21, 2026 -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2026, on Wednesday, November 4, 2026, following the close of market. ———————————————————————————————————————————————————————————— Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™ 2026-10-21 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/fresenius-medical-care-brings-kidney-care-innovation-to-critical-care-patients-with-us-launch-of-multifiltratepro-302916083.html Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S. FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous kidney replacement therapy options for U.S. patients requiring treatment... ———————————————————————————————————————————————————————————— Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026 2026-10-21 · PR Newswire · Finance, Biotech & pharma https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-third-quarter-2026-financial-results-on-october-28-2026-302916061.html Conference Call and Webcast to Follow WASHINGTON, Oct. 21, 2026 -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2026 on Wednesday, October 28, 2026, after the market closes. Vanda will host a conference call... ———————————————————————————————————————————————————————————— UNCY FINAL DEADLINE: ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCY 2026-10-21 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385965/673/en/uncy-final-deadline-rosen-leading-investor-rights-counsel-encourages-unicycive-therapeutics-inc-investors-to-secure-counsel-before-important-november-2-deadline-in-securities-class.html NEW YORK, Oct. 21, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— Kane Engages Independent Trading Group as Market Maker 2026-10-21 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385955/0/en/kane-engages-independent-trading-group-as-market-maker.html Agreement intended to support an orderly market and improve liquidity in Kane Biotech’s common shares Agreement intended to support an orderly market and improve liquidity in Kane Biotech’s common shares ———————————————————————————————————————————————————————————— Protect Yourself and Your Community: Accordia Health Encourages the Public to Get Annual Flu Vaccine 2026-10-21 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/protect-yourself-and-your-community-accordia-health-encourages-the-public-to-get-annual-flu-vaccine-302915862.html MOBILE, Ala., Oct. 21, 2026 -- As flu season gets underway, Accordia Health encourages everyone eligible to get the annual flu vaccine. Influenza, commonly known as the flu, is more than just a seasonal inconvenience. It can cause serious illness, lead to hospitalization,... ———————————————————————————————————————————————————————————— Mexico Precision Medicine Market Size, Share, Trends, and Forecast 2026-2034 | Genomics and Digital Health to Drive 7.97% CAGR, Reaching USD 2.72 Billion 2026-10-21 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385911/28124/en/mexico-precision-medicine-market-size-share-trends-and-forecast-2026-2034-genomics-and-digital-health-to-drive-7-97-cagr-reaching-usd-2-72-billion.html Genomics advances, digital health adoption and personalized care drive opportunities across oncology, diagnostics and rare disease management in Mexico. Genomics advances, digital health adoption and personalized care drive opportunities across oncology, diagnostics and rare disease management in Mexico. ———————————————————————————————————————————————————————————— Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026 2026-10-21 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385903/0/en/helus-pharma-highlights-clinical-program-advancements-at-investor-presentation-held-on-october-21-2026.html Topline data readout from APPROACH Phase 3 study of HLP003 in development for the potential adjunctive treatment of major depressive disorder (“MDD”) on track for Q4 20261,2 ———————————————————————————————————————————————————————————— Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026 2026-10-21 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/acadia-pharmaceuticals-announce-third-quarter-200500242.html Company to host conference call and webcast on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Time SAN DIEGO, October 21, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, after the close of the U ———————————————————————————————————————————————————————————— Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results 2026-10-21 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/vir-biotechnology-host-conference-call-200500469.html SAN FRANCISCO, October 21, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, November 4 to provide a corporate update and discuss its financial results for the third quarter ended September 30, 2026. The confere ———————————————————————————————————————————————————————————— VERAXA Biotech (VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer Pipeline 2026-10-21 · NewMediaWire · Finance, AI, Healthcare, Media, Biotech & pharma https://www.newmediawire.com/news/veraxa-biotech-vrxa-expands-human-relevant-testing-strategy-to-advance-antibody-based-cancer-pipeline-7090778 VERAXA is implementing FDA-aligned New Approach Methodologies (“NAMs”) across its preclinical research programs, aiming to improve the relevance of experimental findings to human biology while reducing animal testing. The strategy supports development of the company’s BiTAC(R) T-cell engagers, BiTAC-based antibody-drug conjugates and bispecific antibody-drug conjugates for the treatment of cancer. New three-dimensional spheroid data reportedly reinforce the ability of VERAXA’s models to assess the dual-target specificity of its lead T-cell engager candidates. An ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer required about 10 mice, compared with an estimated 200 or more for comparable in vivo efficacy studies. The company says its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity. LOS ANGELES, CA - October 21, 2026 - VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is expanding its use of human-relevant testing methods across its oncology research programs, seeking to generate more clinically informative preclinical data while reducing the number of animals required for drug development. In an October 7, 2026, company announcement, the Switzerland-based biotechnology company, with a key financial and regulatory presence in the U.S., outlined its implementation of New Approach Methodologies (“NAMs”), a collection of non-animal research techniques that includes cell-based assays, computational modeling and… Read More Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. ———————————————————————————————————————————————————————————— What Should Unicycive Therapeutics, Inc. Investors Know After 39.1% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline 2026-10-21 · PR Newswire · Finance, Biotech & pharma https://www.prnewswire.com/news-releases/what-should-unicycive-therapeutics-inc-investors-know-after-39-1-stock-drop-the-law-offices-of-frank-r-cruz-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302915800.html Lawsuit alleges Unicycive Therapeutics, Inc. made misleading statements to investors from December 29, 2025 to June 29, 2026; lead plaintiff motions are due November 2, 2026 LOS ANGELES, Oct. 21, 2026 -- The Law Offices of Frank R. Cruz today announced a class action lawsuit... ———————————————————————————————————————————————————————————— Greenberg Traurig Advises OPKO Health on $722M+ Agreement to Sell Select BioReference Health Assets to Labcorp 2026-10-21 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/greenberg-traurig-advises-opko-health-on-722m-agreement-to-sell-select-bioreference-health-assets-to-labcorp-302915762.html MIAMI, Oct. 21, 2026 -- Global law firm Greenberg Traurig, P.A. advised OPKO Health, Inc., a multinational biopharmaceutical company, on its agreement to sell select assets of its wholly owned subsidiary, BioReference Health, LLC, to Labcorp. The purchase price for the... ———————————————————————————————————————————————————————————— Breakthrough T1D Funded Clinical Trial Testing Islet Cell Transplantation with Eledon's Tegoprubart Expands to Include People with Type 1 Diabetes and Kidney Disease 2026-10-21 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/breakthrough-t1d-funded-clinical-trial-testing-islet-cell-transplantation-with-eledons-tegoprubart-expands-to-include-people-with-type-1-diabetes-and-kidney-disease-302915841.html NEW YORK, Oct. 21, 2026 -- A new clinical trial funded by Breakthrough T1D recently launched and is testing islet cell transplantation paired with Eledon Pharmaceuticals' investigational immunosuppression therapy tegoprubart in people living with type 1 diabetes (T1D) and... ———————————————————————————————————————————————————————————— Big Pharma’s Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN) 2026-10-21 · FinanceWire · Finance, Healthcare, Biotech & pharma https://financewire.com/2026/10/21/big-pharmas-obesity-shopping-spree-is-moving-beyond-glp-1s-palatin-may-fit-the-pattern-nasdaq-ptn/ WSW, NY, 21st October 2026, FinanceWire … Read More The post Big Pharma’s Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN) appeared first on FinanceWire - Financial Press Release Distribution, Finance PR. ———————————————————————————————————————————————————————————— Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment 2026-10-21 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/savara-presented-data-showing-molgramostim-171000667.html -- Post-Hoc Analysis of the Phase 2/3 IMPALA Clinical Trial Presented in a Poster Presentation at the CHEST 2026 Annual Meeting -- YARDLEY, Pa., October 21, 2026--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a post ———————————————————————————————————————————————————————————— Scientists Reveal How Deadly Andes Hantavirus Attaches to Human Cells 2026-10-21 · PR Newswire · Travel, Biotech & pharma https://www.prnewswire.com/news-releases/scientists-reveal-how-deadly-andes-hantavirus-attaches-to-human-cells-302915794.html Discovery may help develop treatments for Andes virus and other hantaviruses BRONX, N.Y., Oct. 21, 2026 -- Earlier this year, an outbreak of Andes hantavirus on a cruise ship, which killed three passengers and sickened 13, highlighted the lack of approved vaccines or... ———————————————————————————————————————————————————————————— Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight 2026-10-21 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385792/0/en/global-oral-drugs-market-is-predicted-to-surpass-usd-1-trillion-mark-by-2034-delveinsight.html The global oral drugs market is experiencing steady growth, driven by the increasing prevalence of chronic diseases and the growing demand for convenient, patient-friendly treatment options. The expansion of oral therapies across therapeutic areas such as oncology, diabetes, cardiovascular diseases, and neurological disorders is further supporting market development. In addition, the availability of generic and branded oral drugs, expanding healthcare access, and rising pharmaceutical R&D investments are contributing to market expansion. The global oral drugs market is experiencing steady growth, driven by the increasing prevalence of chronic diseases and the growing demand for convenient, patient-friendly treatment options. The expansion of oral therapies across therapeutic areas such as oncology, diabetes, cardiovascular diseases, and neurological disorders is further supporting market development. In addition, the availability of generic and branded oral drugs, expanding healthcare access, and rising pharmaceutical R&D investments are contributing to market expansion. ———————————————————————————————————————————————————————————— William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage 2026-10-21 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/william-blair-expands-biotech-research-163000938.html CHICAGO, October 21, 2026--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm's continued expansion of its biotech offering. Young joined William Blair in May 2026 as part of a broader investment in the firm's equitie ———————————————————————————————————————————————————————————— Median Technologies to Showcase iCRO’s Central and AI-Powered Imaging Services for Oncology Clinical Trials at ESMO 2026 2026-10-21 · Business Wire · AI, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/median-technologies-showcase-icro-central-154500262.html Median Technologies is a leading provider of central imaging services and AI-powered image analysis for oncology clinical trials The Company will host an interactive session on the implementation of RANO 2.0 in central imaging review for neuro-oncology trials at booth #1098 The Company will also present an ePoster on the ———————————————————————————————————————————————————————————— Citrus Grandis Fruit Extract Market Trends Shaping Future Growth by 2034 2026-10-21 · PR News Releaser · Food & drink, Biotech & pharma https://www.prnewsreleaser.com/news/475804 The Citrus Grandis Fruit Extract Market is expected to experience significant growth through 2034, driven by increasing demand for natural ingredients across food, beverage, pharmaceutical, nutraceutical, and cosmetic applications. Derived from pomelo fruit, Citrus Grandis extract contains valuable bioactive compounds, ... Read more ———————————————————————————————————————————————————————————— Immunis Wins Grand Prize in National Academy of Medicine Healthy Longevity Global Competition 2026-10-21 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/immunis-wins-grand-prize-national-150200149.html Grand Prize recognizes IMM01-STEM and its potential to restore muscle function, metabolic health and quality of life as people age IRVINE, Calif., October 21, 2026--Immunis, Inc., a clinical-stage biotechnology company developing first-in-class multi-active biologics for muscle health and healthy agin ———————————————————————————————————————————————————————————— DOCS Shareholder Alert: November 16, 2026 Lead Plaintiff Deadline in Doximity, Inc. Securities Class Action - Contact Levi & Korsinsky 2026-10-21 · PR Newswire · Finance, Biotech & pharma https://www.prnewswire.com/news-releases/docs-shareholder-alert-november-16-2026-lead-plaintiff-deadline-in-doximity-inc-securities-class-action---contact-levi--korsinsky-302915100.html Alert: Claims focus on alleged misrepresentations about Doximity's revenue growth and market share as the lawsuit contends that decelerating sales, contracting net income, and a shift in how pharmaceutical customers deployed advertising budgets were not disclosed to investors. NEW YORK,... ———————————————————————————————————————————————————————————— World Health Organization (WHO) supports Nigeria after first Ebola case confirmed 2026-10-21 · APO Group · Healthcare, Travel, Biotech & pharma https://www.africa-newsroom.com/press/world-health-organization-who-supports-nigeria-after-first-ebola-case-confirmed?lang=en The patient is a woman who recently travelled from Uganda and began showing symptoms on 7 October, four days after her arrival.  The woman sought care at a private health facility in the capital, Abuja, on 11 October; laboratory testing confirmed the diagnosis on 20 October.  She remains in isolation and is receiving medical care as investigations continue to determine the likely source of her infection and reconstruct her full travel and exposure history.   Contact tracing underway  WHO said the Nigerian health authorities have so far identified 44 contacts who are being monitored amid intensified efforts to find other people who may have been exposed.  Infection prevention and control measures are being ramped up in the private health facility where the woman sought care.   Cases in five countries  Nigeria is the fifth country to detect Ebola Bundibugyo virus disease since an outbreak was declared in the Democratic Republic of the Congo (DRC) in mid-May – the deadliest in the country’s history.  More than 9,500 cases and more than 4,200 deaths were recorded as of 18 October, according to latest data from the Congolese health authorities. There is currently no vaccine to treat the virus.  Uganda also faced a deadly outbreak which was officially declared over in late August, while nine cases have been reported in Kenya and one in the Netherlands that are linked to the DRC.  Containing virus spread   The Nigeria Centre for Disease Control and Prevention has activated its incident management system to coordinate response efforts, WHO said.  The UN agency stressed that rapid identification of cases, timely follow-up of contacts and effective infection prevention and control are critical to contain the spread of the virus.   WHO and partners are working closely with the Nigerian health authorities to strengthen control measures, including case investigation, contact tracing, infection prevention and control. The agency is also assisting with the provision of essential supplies including personal protective equipment for health workers.   Meanwhile, WHO has advised all countries in the region to sustain a high level of readiness as the DRC outbreak continues to evolve.   Governments are also advised to maintain strong disease surveillance and ensure that laboratories can safely test suspected cases, among other measures.  WHO has not recommended any restrictions regarding travel and trade with affected countries.  Distributed by APO Group on behalf of UN News. ———————————————————————————————————————————————————————————— NeOnc Deepens Abu Dhabi Research Ties as Its Brain Cancer Story Moves Forward 2026-10-21 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385643/0/en/neonc-deepens-abu-dhabi-research-ties-as-its-brain-cancer-story-moves-forward.html NeOnc (Nasdaq: NTHI) signed a MoU with the Department of Health – Abu Dhabi to support research and clinical capability in oncology and CNS ———————————————————————————————————————————————————————————— Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder 2026-10-21 · Newswire.com · Healthcare, Biotech & pharma https://www.newswire.com/news/jaguar-health-s-crofelemer-shows-benefit-for-intestinal-failure-if-in-third Mutation of the GUCY2C gene is the third IF-related congenital enteropathy, in addition to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF), for which crofelemer has demonstrated benefit in reducing parenteral support needs in pediatric patients Company plans to file NDA for crofelemer for MVID in mid-2027 to obtain FDA approval ———————————————————————————————————————————————————————————— IMUNON Announces Strategic Sale of ThermoDox® 2026-10-21 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385502/0/en/imunon-announces-strategic-sale-of-thermodox.html Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial ———————————————————————————————————————————————————————————— Santa Ana Bio to Present Preclinical Data on SAB05, a CD40-Targeted Glucocorticoid Antibody-Drug Conjugate, at ACR Convergence 2026 2026-10-21 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385497/0/en/santa-ana-bio-to-present-preclinical-data-on-sab05-a-cd40-targeted-glucocorticoid-antibody-drug-conjugate-at-acr-convergence-2026.html ALAMEDA, Calif., Oct. 21, 2026 -- Santa Ana Bio, a clinical-stage precision immunology company, today announced that preclinical data on SAB05, its CD40-targeted glucocorticoid antibody-drug conjugate (ADC), will be presented in a poster at ACR Convergence 2026, the annual meeting of the American College of Rheumatology (ACR), taking place November 6–11, 2026, in Orlando, Florida. ———————————————————————————————————————————————————————————— VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling 2026-10-21 · GlobeNewswire · SaaS, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385494/37000/en/vivosim-labs-extends-namkind-platform-with-human-disease-models-for-efficacy-testing-and-mechanistic-biomarker-profiling.html Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials ———————————————————————————————————————————————————————————— MindWalk Screens 890,634 Antibody Sequences for Immune Risk in Under Five Hours 2026-10-21 · Business Wire · AI, Retail, Biotech & pharma, Semiconductors https://finance.yahoo.com/healthcare/articles/mindwalk-screens-890-634-antibody-120100487.html New white paper shows LensAI™ immunogenicity screening running at up to 43% lower cost per sequence on Amazon EC2 Hpc8a instances powered by AMD EPYC processors, making a critical drug-safety check practical at the scale AI-driven discovery now demands AUSTIN, Texas, October 21, 2026--MindWalk Holdings ———————————————————————————————————————————————————————————— Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026 2026-10-21 · Roche · Healthcare, Automotive, Travel, Biotech & pharma, Sustainability, Government & policy, Medical devices, Chemicals & materials https://www.roche.com/media/releases/med-cor-2026-10-21 Fenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in multiple sclerosis (MS) Fenebrutinib FENhance 1 & 2 Phase III pooled data show a 55% reduction in annualised relapse rate (ARR) vs active comparator Following European Commission paediatric approval on 15 October, new Ocrevus OPERETTA 2 Phase III data show 90% of children aged 10–17 remained relapse-free over two years Featured in "Best of MSToronto2026", Enspryng METEOROID Phase III data highlight significant attack reduction and improved functional recovery in MOGAD, an underserved autoimmune disease Basel, 21 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new Phase III data for investigational fenebrutinib in multiple sclerosis (MS), demonstrating reduced markers of chronic brain inflammation as well as more comprehensive disease control versus active comparators.1-3 These findings, alongside new Ocrevus® (ocrelizumab) and Enspryng® (satralizumab) data, will be featured across more than 40 abstracts at MSToronto2026 (10th ACTRIMS- ECTRIMS Meeting), held 21 to 23 October in Toronto. Highlights include a fenebrutinib late-breaking presentation and an Enspryng presentation in the “Best of MSToronto2026.4 “Addressing long-term disability progression to preserve people’s independence remains a critical challenge in neuroinflammatory diseases, and particularly in multiple sclerosis,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Our recent data indicate that fenebrutinib can inhibit disease activity inside and outside the central nervous system, underscoring its potential to transform care for people living with relapsing and primary progressive forms of multiple sclerosis.” Fenebrutinib targets progressive biology inside the brain New data from the pivotal trials in RMS (FENhance 1 and 2) and PPMS (FENtrepid) support the potential of fenebrutinib as the first and only high-efficacy oral medicine for both forms of MS. Reduction of chronic active lesions (Late-breaking oral #O137): In the first prospective demonstration of a therapeutic effect on chronic active lesions in MS Phase III clinical trials, data show fenebrutinib reduced the volume of slowly expanding lesions (SELs) by up to 30% (p<0.001) in RMS (over 96 weeks) and PPMS (over 120 weeks), along with a 62% (p=0.001) reduction in accumulation of paramagnetic rim lesions (PRLs) in RMS, versus active comparators. These findings demonstrate that fenebrutinib directly targets chronic neuroinflammation in the brain, a primary driver of disability progression in MS.1 Comprehensive disease control (Poster #P1434): In the pooled RMS trials, three quarters (75%) of fenebrutinib-treated patients showed no evidence of disease activity (NEDA-3) meaning zero relapses, zero MRI activity and zero worsening disability at nearly two years, a 70% reduction (p<0.001) versus the comparator. These results show fenebrutinib’s potential to suppress disease activity and delay progression.2 Preserving brain volume and function (Oral #O089): Pooled RMS data show fenebrutinib reduced the annualised relapse rate (ARR) by 55% versus the comparator (p<0.001) over 96 weeks. In addition, fenebrutinib reduced annual total brain volume loss by 23% (p<0.001) and 12-week composite confirmed disability progression by 16% (p=0.04). These findings demonstrate fenebrutinib’s potential to control relapses, to slow brain tissue loss caused by neuronal cell death and to preserve function.3 Ocrevus provides consistent benefits across all age groups New data show that Ocrevus provides significant and consistent efficacy across a broad MS patient population, from children 10 years of age to older adults. Two-year data and immune function in paediatric MS (3 posters on the Phase III OPERETTA 2 study): 90% of children with relapsing-remitting MS (RRMS) treated with Ocrevus, who were 10-17 years old at trial entry, remained free of relapses over two years (#P1439).5 Ocrevus selectively depleted target B cells with little to no effect on other immune cells (#P1407), while preserving pre-existing immunity to common childhood vaccines in 81–100% of patients (#P1415). The European Commission approved Ocrevus in this indication on 15 October, following FDA approval in May.6,7 Two-year data in patients >55 years old (Poster #P1426 on the Phase IIIb CONSONANCE study): 53% of participants over 55 years old treated with Ocrevus showed no disability progression after two years, similarly to younger participants (55%), showing Ocrevus maintains its effect on progression as people age.8 Switching from other treatments to Ocrevus: Real-world data show progression was the leading reason for patients switching from ofatumumab to Ocrevus (ePoster #EP2733).9 A separate analysis of patients treated with Ocrevus or ofatumumab for one year show Ocrevus was associated with lower MRI lesion activity (Poster #P0305).10 Enspryng reduces risk of attack and is associated with improved recovery Exploratory analyses of the pivotal METEOROID trial suggest that in addition to significantly lowering the risk of relapse (AAN 2026), Enspryng was associated with improved recovery and reduced disability progression, which is critical to prevent permanent damage to the optic nerves, spinal cord or brain in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). These findings reinforce Enspryng’s potential to become the first FDA-approved treatment for MOGAD, with a decision in the U.S. expected in January 2027.4,11 Relapse recovery (Oral #O035): Patients treated with Enspryng achieved numerically superior recovery at 12 weeks post relapse versus placebo (median change in Expanded Disability Status Scale [EDSS] of -2 vs -0.5). Overall function was stable (median 0) with Enspryng, compared to worsening (median 0.5) with placebo, as measured with the EDSS at the end of the double-blind period or first relapse.4  About fenebrutinib Fenebrutinib is an investigational oral, central nervous system (CNS)-penetrant, reversible and non-covalent Bruton’s tyrosine kinase (BTK) inhibitor with an optimised pharmacokinetics (PK) profile. Fenebrutinib can act throughout the body and also cross the blood-brain barrier into the CNS to target chronic inflammation. It is uniquely designed to target relapsing and progressive biology by inhibiting cells in the immune system known as B cells and microglia. Targeting B cells helps control the acute inflammation that causes relapses, while targeting microglia inside the brain addresses the chronic damage that is thought to drive long-term disability progression. While most current BTK inhibitors are covalent and irreversible, meaning they form a permanent chemical bond with the enzyme, fenebrutinib is non-covalent and reversible, meaning it binds and then eventually releases the enzyme. About Ocrevus® (ocrelizumab) Ocrevus is a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage. Ocrevus IV and Ocrevus subcutaneous (SC; marketed as Ocrevus Zunovo® [ocrelizumab hyaluronidase-ocsq] in the U.S.) are the only therapies approved for both RMS (including relapsing-remitting multiple sclerosis [RRMS] and active, secondary progressive multiple sclerosis [SPMS], as well as clinically isolated syndrome [CIS] in the U.S.) and primary progressive multiple sclerosis (PPMS). Both Ocrevus IV and SC are administered every six months. The initial IV dose is given as two 300 mg infusions two weeks apart with subsequent doses given as single 600 mg infusions. Ocrevus SC is given as a single 920 mg subcutaneous injection every six months. About Enspryng® (satralizumab) Enspryng, developed by Chugai, a member of the Roche Group, is a humanised monoclonal antibody that binds to both soluble and membrane-bound interleukin-6 receptors (IL-6R), thereby inhibiting IL-6 mediated signalling, a key pathway involved in inflammation. Enspryng incorporates Chugai’s proprietary antibody recycling technology, which enables pH-dependent binding to IL-6R and repeated engagement of the target, extending antibody circulation and supporting sustained inhibition of IL-6 mediated signalling. Enspryng is the first and only IL-6R inhibitor treatment currently approved in approximately 90 countries for neuromyelitis optica spectrum disorder (NMOSD), including in the U.S. and E.U., with a well-established safety profile in over 16,000 patients. Enspryng was also recently approved for the treatment of thyroid eye disease (TED) in the U.S. Roche is committed to developing Enspryng in additional neurological autoimmune and inflammatory diseases that may benefit from inhibition of IL-6 mediated signalling, including myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and autoimmune encephalitis (AIE). About Roche in Neurology Neurology is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new diagnostics and treatments that help improve the lives of people with chronic and potentially devastating diseases globally. Roche is investigating more than a dozen medicines for neurological conditions, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Roche Diagnostics has developed a broad range of approved and investigational tools, including digital and blood-based tests and cerebrospinal fluid (CSF) assays, aiming to more effectively detect, diagnose and monitor neurological conditions. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neurology today. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Oh J, et al. Fenebrutinib Shows a Therapeutic Effect on MS Progressive Biology: Outcomes on Paramagnetic Rim Lesions and Slowly Expanding Lesions in the Phase III FENhance I/II and FENtrepid Trials in Relapsing and Primary Progressive Multiple Sclerosis (#O137). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 23 October 2026; Toronto, Canada. [2] Cerqueira JJFCA, et al. No Evidence of Disease Activity With Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results From the Phase III FENhance 1 and 2 Trials (#P1434). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 22 October 2026; Toronto, Canada. [3] Sormani MP, et al. Efficacy of Fenebrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis: Pooled Analysis Results From the FENhance 1 and 2 Studies (#O089). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 21 October 2026; Toronto, Canada. [4] Marignier R, et al. Severity and Recovery of Relapses in Patients with Relapsing MOGAD Treated with Satralizumab: Results from the Phase 3 METEOROID Study (#O035). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 22 October 2026; Toronto, Canada. [5] Deiva K, et al. OPERETTA 2: Continued Follow-Up of the Efficacy and Safety Profile of Ocrelizumab in Pediatric Relapsing-Remitting MS (#P1439). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 22 October 2026; Toronto, Canada. [6] Bar-Or A, et al. Impact of Ocrelizumab vs Fingolimod on Immune Function in Pediatric Patients With MS in the OPERETTA 2 Study (#P1407). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 22 October 2026; Toronto, Canada. [7] Banwell B, et al. Vaccination and Disease-Modifying Therapies: Impact of Ocrelizumab vs Fingolimod on Preexisting Vaccine Seropositivity and Vaccine-Preventable Infections in Pediatric Patients With MS in OPERETTA 2 (#P1415). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 22 October 2026; Toronto, Canada. [8] Butzkueven H, et al. Ocrelizumab Maintains Clinical and Safety Outcomes in Older Patients (>55 Years) with Progressive Multiple Sclerosis: 2-Year Results from the CONSONANCE Study (#P1426). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 22 October 2026; Toronto, Canada. [9] Marriott J, et al. Switching Patients with Multiple Sclerosis from Ofatumumab to Ocrelizumab: A Real-World Study of Canadian Healthcare Professionals (#EP2733). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 21-23 October 2026; Toronto, Canada. [10] Ziemssen T, et al. Brain Volume Loss and T2 Lesion Activity in RRMS: Real-World Longitudinal Comparison of Ocrelizumab vs. Ofatumumab (#P0305). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 21 October 2026; Toronto, Canada. [11] Levy M, et al. Safety and Efficacy of Satralizumab in Patients with Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD): Results from the Phase 3 METEOROID Trial (PL5.006). Presented at: 78th Annual Meeting of the American Academy of Neurology (AAN) 2026; 21 April 2026; Chicago, IL, USA. Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone:  +41 79 377 83 75Albert Thottiyil Phone: +41 79 775 66 12 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.comDr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com  Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com  Attachment Media&Investor Release MSToronto2026 English ———————————————————————————————————————————————————————————— Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026 2026-10-21 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385449/0/en/rhythm-pharmaceuticals-to-report-third-quarter-2026-financial-results-on-tuesday-november-3-2026.html BOSTON, Oct. 21, 2026 -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 3, 2026 to report its third quarter 2026 financial results and provide a corporate update. ———————————————————————————————————————————————————————————— Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026 2026-10-21 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385439/35501/en/geron-plans-to-announce-third-quarter-2026-financial-results-on-november-4-2026.html FOSTER CITY, Calif., Oct. 21, 2026 -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that it will release its third quarter 2026 financial results and business highlights before the market opens on Wednesday, November 4, 2026, via press release, which will be available on the Investors section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. ———————————————————————————————————————————————————————————— Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026 2026-10-21 · Business Wire · Automotive, Biotech & pharma https://finance.yahoo.com/healthcare/articles/genentech-presents-pivotal-trial-data-120000419.html Fenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in multiple sclerosis (MS) Fenebrutinib FENhance 1 & 2 Phase III pooled data show a 55% reduction in annualized relapse rate (ARR) vs acti ———————————————————————————————————————————————————————————— CHARBONE Strengthens Its Industrial Gas Offering With a Filling Unit in Sorel-Tracy 2026-10-21 · NewMediaWire · Finance, AI, SaaS, Energy, Industrial, Aerospace & defense, Biotech & pharma, Semiconductors https://www.newmediawire.com/news/charbone-strengthens-its-industrial-gas-offering-with-a-filling-unit-in-sorel-tracy-7090774 VARENNES, QUEBEC - October 21, 2026 - CHARBONE CORPORATION (TSXV: CH; OTCQB: CHHYF; FSE: K47) (“CHARBONE” or the “Company”), a vertically integrated industrial gases company focused on production, distribution and storage of clean ultra-high purity (“UHP”) hydrogen and other strategic industrial gases, announces the addition of an industrial gas cylinder filling unit at its Sorel-Tracy site. This new activity aims to support revenue growth, broaden the commercial offering and develop the Company's customer base in Quebec and other Canadian regions. Specifically, this unit will allow CHARBONE to fill hydrogen and helium cylinders directly from the onset at its Sorel-Tracy site, with the ability to expand to other industrial gases and specialized mixtures in the future. These cylinders, also known as gas cylinders, are used to store, transport, and supply the gases required for various customer applications. CHARBONE will thus directly manage this step in preparing the products for its customers. This new activity represents a further step in the development of CHARBONE's integrated platform. It aims to expand the markets accessible to the Company and generate new revenue opportunities through an offering tailored to the needs of industrial, commercial, and institutional clients. A new lever for business development The filling unit will primarily serve the Quebec market, while also supporting CHARBONE's business development elsewhere in Canada. Target customers include private companies and distribution partners, including independent distributors. The offering will also address supply needs related to certain government contracts and the defense sector. By adding cylinder filling to the activities of its Sorel-Tracy site, CHARBONE is internalizing a step previously sources externally, which is expected to support margin improvement and enhance control over product quality and delivery timelines. This enables the Company to expand the services offered to its customers, develop new business relationships and strengthen its position in industrial gases. Dave Gagnon, President and CEO of CHARBONE, declares: “Our goal is to make Sorel-Tracy a growth engine for CHARBONE. By handling the filling of helium cylinders ourselves, and later industrial gases and specialty mixtures, we are expanding our offering and opening up new opportunities to grow our revenue with a diverse clientele. We are building a Canadian industrial gas group with the ambition of becoming a leading supplier for companies seeking to source their gases from a Canadian partner, reliably. Our priority is to develop lasting relationships with our customers and translate this business expansion into long-term value creation for our shareholders.” Expanding Market Presence Across Quebec and CanadaThis initiative further develops CHARBONE beyond hydrogen production, expanding the activities and services offered within its industrial gas platform. Helium, in particular, represents a high-demand industrial gas with constrained supply, making direct cylinder filling a strategically important capability for CHARBONE’s customers across sectors like semiconductors, aerospace and defense, and advanced manufacturing. The Company intends to leverage this new unit to increase its presence in Quebec and develop business opportunities with Canadian buyers seeking a long-term supply partner. CHARBONE to Present at the Emerging Growth Conference The Company has been invited to present at the upcoming Emerging Growth Conference, a live, interactive online event giving individual and institutional investors, advisors, and analysts the opportunity to receive a brief recap of recent achievements and path forward from CHARBONE’s CFO and Corporate Secretary, Benoit Veilleux. Date: Thursday, October 29, 2026 Time: 3:10 PM ET Register: https://goto.webcasts.com/starthere.jsp?ei=1772210&tp_key=8ae90219a3&sti=ch About CHARBONE CORPORATION CHARBONE is a vertically integrated industrial gases company focused on developing and operating a network of supply hubs for the production, storage, and distribution of Ultra-High Purity (UHP) strategic industrial gases. The Company serves customers across sectors including semiconductors, artificial intelligence and data centers, advanced pharmaceuticals, and aerospace and defense technologies, where UHP gases are critical for high-precision manufacturing processes and operational performance. CHARBONE is advancing a network of clean UHP hydrogen production plants across North America and selected international markets. The Company’s modular, decentralized, and demand-driven approach, combined with its integrated storage and distribution platform for all UHP gases, supports scalable growth, enhances operational flexibility, and enables more stable and diversified revenue generation. This model allows CHARBONE to efficiently serve mid-tier industrial gas customers with a reliable supply of UHP gases, including hydrogen, helium, oxygen, and any other high-demand gases that are often difficult to source reliably at the regional level. The Company is committed to supporting the global transition to a lower-carbon economy by providing accessible, decentralized clean hydrogen and specialty gases, while addressing supply gaps for underserved industrial customers and accelerating the shift towards localized clean energy. CHARBONE is listed on the TSX Venture Exchange (TSXV: CH), the OTC Markets (OTCQB: CHHYF), and the Frankfurt Stock Exchange (FSE: K47). For more information, please visit: www.charbone.com. Forward-Looking Statements This news release contains statements that are “forward-looking information” as defined under Canadian securities laws (“forward-looking statements”). These forward-looking statements are often identified by words such as “intends”, “anticipates”, “expects”, “believes”, “plans”, “likely”, or similar words. The forward-looking statements reflect management's expectations, estimates, or projections concerning future results or events, based on the opinions, assumptions and estimates considered reasonable by management at the date the statements are made. Although Charbone believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements involve risks and uncertainties, and undue reliance should not be placed on forward-looking statements, as unknown or unpredictable factors could cause actual results to be materially different from those reflected in the forward-looking statements. The forward-looking statements may be affected by risks and uncertainties in the business of Charbone. These risks, uncertainties and assumptions include, but are not limited to, those described under “Risk Factors” in the Corporation’s Filing Statement dated March 31, 2022, which is available on SEDAR+ at www.sedarplus.ca; they could cause actual events or results to differ materially from those projected in any forward-looking statements. Except as required under applicable securities legislation, Charbone undertakes no obligation to publicly update or revise forward-looking information. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Charbone Corporation Telephone: +1 450 678 7171   Email: ir@charbone.com   Benoit Veilleux CFO and Corporate Secretary ———————————————————————————————————————————————————————————— INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027 2026-10-21 · GlobeNewswire · Finance, Industrial, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385399/0/en/inmune-bio-advances-ebstrocel-toward-potential-uk-approval-in-mid-2027.html BOCA RATON, Fla., Oct. 21, 2026 -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its final pre-Marketing Authorisation Application (pre-MAA) package to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Ebstrocel™ (CORDStrom™), its investigational cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company has updated its regulatory submission strategy, as faster-than-expected manufacturing progress supports a full MAA submission in early February 2027, with potential UK approval in mid-2027, subject to MHRA review. ———————————————————————————————————————————————————————————— Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto 2026-10-21 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385400/0/en/kyverna-therapeutics-presents-full-one-year-registrational-data-set-demonstrating-sustained-clinical-benefit-of-miv-cel-in-stiff-person-syndrome-at-ms-toronto.html Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies ———————————————————————————————————————————————————————————— Companion Animal Vaccines Market to Reach US$ 8.71 Billion by 2034, Growing at a CAGR of 7.93% 2026-10-21 · PR News Releaser · Biotech & pharma https://www.prnewsreleaser.com/news/475525 The global Companion Animal Vaccines Market is witnessing sustained growth as vaccination remains an important part of companion animal healthcare. The global market encompasses vaccines developed for companion animals and is projected to expand significantly during the forecast period. Increasing ... Read more ———————————————————————————————————————————————————————————— Nanoscope Therapeutics Announces Publication of Preclinical Data Showing Targeted, Durable Vision Restoration with OCT-Guided, Non-Viral Gene Delivery 2026-10-21 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/nanoscope-therapeutics-announces-publication-of-preclinical-data-showing-targeted-durable-vision-restoration-with-oct-guided-non-viral-gene-delivery-302914928.html Optical coherence tomography (OCT)-guided nano-enhanced optical delivery (NOD) delivered multi-characteristic opsin (MCO) genes to precisely selected regions of the retina without a viral vector A single treatment produced retinal and cortical light responses that were sustained for up to... ———————————————————————————————————————————————————————————— Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027 2026-10-21 · GlobeNewswire · Finance, Healthcare, Food & drink, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385397/0/en/unicycive-therapeutics-announces-fda-acceptance-of-oxylanthanum-carbonate-new-drug-application-resubmission-and-pdufa-date-of-march-25-2027.html MOUNTAIN VIEW, Calif., Oct. 21, 2026 -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company’s investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The NDA was resubmitted following a Complete Response Letter (CRL) received in June 2026. The FDA has deemed the OLC resubmission a Class II with a six-month review period from the resubmission date, and set a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027. ———————————————————————————————————————————————————————————— Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026 2026-10-21 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385392/0/en/invivyd-presents-vms063-a-potential-best-in-class-monoclonal-antibody-candidate-for-the-treatment-and-prevention-of-measles-at-idweek-2026.html NEW HAVEN, Conn., Oct. 21, 2026 -- Invivyd, Inc. (Nasdaq: IVVD) today announced the presentation of preclinical data describing its novel, potential first- and best-in-class investigational monoclonal antibody candidate VMS063 at IDWeek 2026™ in Washington, D.C. Data demonstrated highly potent in vitro antiviral activity against contemporary measles fusion protein (MeV-F) variants, supporting its potential utility for both treatment and prevention (pre/post-exposure prophylaxis) of measles. ———————————————————————————————————————————————————————————— Biosafety Cabinet Market Growth Outlook With 7.6% CAGR Through 2028 2026-10-21 · PR News Releaser · Biotech & pharma https://www.prnewsreleaser.com/news/475523 The Biosafety Cabinet market continues to play a vital role in supporting laboratory safety, biomedical research, and pharmaceutical development activities. The region remains a major contributor to market growth due to the presence of advanced healthcare infrastructure, increasing investments in ... Read more ———————————————————————————————————————————————————————————— Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer 2026-10-21 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385364/0/en/entrada-therapeutics-appoints-linea-aspesi-as-chief-people-officer.html Entrada Therapeutics announces the appointment of Linea Aspesi as Chief People Officer. ———————————————————————————————————————————————————————————— Sitryx to Participate in Upcoming Investor Conferences 2026-10-21 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385362/0/en/sitryx-to-participate-in-upcoming-investor-conferences.html Oxford, UK and Boston, MA – October 21, 2026 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announced that management will be participating in the following upcoming investor conferences: ———————————————————————————————————————————————————————————— BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE 2026-10-21 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385361/29446/en/biocryst-announces-u-s-fda-approval-of-orladeyo-150-mg-oral-pellets-for-adults-and-adolescents-with-hae.html —Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients’ individual needs and preferences— ———————————————————————————————————————————————————————————— Sundance Biosciences Announces Presentation of Phase 1 Results for SUN-627, a Brain-Penetrant TYK2 Inhibitor for the Treatment of Multiple Sclerosis (MS) 2026-10-21 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385356/0/en/sundance-biosciences-announces-presentation-of-phase-1-results-for-sun-627-a-brain-penetrant-tyk2-inhibitor-for-the-treatment-of-multiple-sclerosis-ms.html SUN-627 demonstrated favorable safety, tolerability, and pharmacokinetics for oral, once-daily dosing in healthy volunteers ———————————————————————————————————————————————————————————— Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) 2026-10-21 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385358/34323/en/roivant-and-priovant-announce-positive-results-in-clarity-1-and-clarity-2-phase-3-trials-for-brepocitinib-in-non-infectious-uveitis-niu.html BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Oct. 21, 2026 -- Roivant (Nasdaq:ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis (NIU). Brepocitinib met the primary endpoint for both the CLARITY-1 and CLARITY-2 studies. Brepocitinib also achieved statistically significant and clinically meaningful benefit on all key secondary endpoints, including measurements of sustained steroid-free quiescence at Week 48, chorioretinal vascular leakage, resolution of macular edema and patient-reported visual functioning. These results were achieved despite a substantially more aggressive steroid taper than precedent NIU trials. ———————————————————————————————————————————————————————————— Satellos to Participate in Upcoming Investor Conferences 2026-10-21 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385357/0/en/satellos-to-participate-in-upcoming-investor-conferences.html TORONTO, Oct. 21, 2026 -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that management will participate in the following investor conferences in November. ———————————————————————————————————————————————————————————— European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) 2026-10-21 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/european-commission-approves-keytruda-pembrolizumab-104500304.html First and only PD-1 inhibitor plus antibody-drug conjugate regimen approved in the European Union (EU) for patients with MIBC regardless of cisplatin eligibility RAHWAY, N.J., October 21, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Commiss ———————————————————————————————————————————————————————————— Lunit Highlights AI-Powered Pathology Insights Across Cancer Types at ESMO 2026 2026-10-21 · MarketersMEDIA · AI, SaaS, Healthcare, Biotech & pharma, Government & policy, Medical devices https://news.marketersmedia.com/lunit-highlights-ai-powered-pathology-insights-across-cancer-types-at-esmo-2026/89206863 Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that five studies involving its AI-powered pathology platform, Lunit SCOPE, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid, Spain. -- Five studies to be presented, with key research examining AI-based biomarker assessment and tumor micr ———————————————————————————————————————————————————————————— FIRST PATIENT SITE OPENS: Burjeel Cancer Institute at Burjeel Medical City Launches World’s First Clinical Site for BioSapien’s MediChip™ Chemotherapy Platform 2026-10-21 · MarketersMEDIA · SaaS, Healthcare, Biotech & pharma, Medical devices https://news.marketersmedia.com/first-patient-site-opens-burjeel-cancer-institute-at-burjeel-medical-city-launches-worlds-first-clinical-site-for-biosapiens-medichiptm-chemotherapy-platform/89206845 Burjeel Cancer Institute in Abu Dhabi has opened the world’s first clinical site for BioSapien’s MediChip, a biodegradable implant delivering chemotherapy directly to tumors. Its Phase I trial will evaluate safety in localized rectal cancer, exploring potential reductions in systemic exposure and treatment-related complications. -- Announced at Abu Dhabi Health Summit Burjeel Cancer Institute at Burjeel Medical City ———————————————————————————————————————————————————————————— Healthcare and Life Sciences Leaders Build on NVIDIA to Advance Drug Discovery and Expand Patient Care 2026-10-21 · PressReach · Healthcare, Industrial, Biotech & pharma https://pressreach.com/healthcare-and-life-sciences-leaders-build-on-nvidia-to-advance-drug-discovery-and-expand-patient-care News Summary: NVIDIA and the UW Medicine Institute for Protein Design debut RFD4-Proteina, a new open model that combines programmable protein design with search capabilities, unlocking new frontiers in biology. Siemens Healthineers is advancing the next generation of adaptive radiotherapy, using NVIDIA intelligence to increase access to life-saving cancer care with agentic co-planning, patient-specific simulation … Continue reading "Healthcare and Life Sciences Leaders Build on NVIDIA to Advance Drug Discovery and Expand Patient Care" ———————————————————————————————————————————————————————————— Non-Invasive Drug Delivery Market Size to Worth US$ XX Million by 2034, at a CAGR of 9.4% 2026-10-21 · PR News Releaser · Biotech & pharma https://www.prnewsreleaser.com/news/475483 According to the latest market analysis published by The Insight Partners, the Non-Invasive Drug Delivery Market is registering a CAGR of 9.4% from 2026 to 2034. The Non-Invasive Drug Delivery Market Research study enhances the decision-making capabilities and helps to ... Read more ———————————————————————————————————————————————————————————— Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer 2026-10-21 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/summit-therapeutics-ecog-acrin-cancer-100500515.html Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 MIAMI, October 21, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab, a novel, potential first-in-clas ———————————————————————————————————————————————————————————— MC Services to Support BIO-Europe® 2026 in Cologne as Media Partner 2026-10-21 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385326/0/en/mc-services-to-support-bio-europe-2026-in-cologne-as-media-partner.html Munich, Düsseldorf, Germany, Oct. 21, 2026 -- Munich, Düsseldorf, October 21, 2026 — MC Services AG, a leading international corporate communications and investor relations firm for life sciences and healthcare, will support BIO-Europe® 2026 as media partner. Taking place in Cologne, Germany, November 9-11, 2026, MC Services invites international, national and regional media, coordinates interview opportunities with attending biotech and pharma executives and experts, and facilitates background conversations that give journalists direct access to the companies, perspectives and developments shaping the biopharma sector. ———————————————————————————————————————————————————————————— Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026 2026-10-21 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/personalis-next-personal-data-showcasing-100000410.html Late-breaking oral presentation highlights the role of ultrasensitive ctDNA in drug development; first data from prospective B-STRONGER-1 study in early-stage triple-negative breast cancer FREMONT, Calif., October 21, 2026--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision on ———————————————————————————————————————————————————————————— Lumen Bio Reports Positive Phase 2 Results from the RePreve Clinical Trial (LMN-201 for C. difficile Infection) 2026-10-21 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/lumen-bio-reports-positive-phase-2-results-from-the-repreve-clinical-trial-lmn-201-for-c-difficile-infection-302915046.html - Global cure observed in 83.3% of LMN-201 recipients versus 36.4% randomized to placebo - LMN-201 treatment plus standard-of-care antibiotics demonstrated a six-fold reduction in C. difficile infection recurrence compared to standard-of-care antibiotics and placebo (9.1% versus 55.6%) -... ———————————————————————————————————————————————————————————— TNT Coming Soon to Walmart.com as U.S. Expansion Continues 2026-10-21 · Newsworthy.ai · AI, SaaS, Healthcare, Energy, Retail, Gaming, Education, Food & drink, Sports, Biotech & pharma https://newsworthy.ai/news/202610213062/tnt-coming-soon-to-walmartcom-as-us-expansion-continues Boca Raton, Florida Wednesday Oct 21, 2026 @ 5:00 AM Eastern — True Nutrition Technology (TNT), the German sports nutrition brand serving more than 500,000 customers, is moving forward with plans to make its products available on Walmart.com, marking another step in the company's ongoing expansion into the United States. The upcoming Walmart.com availability will build on TNT's existing presence through Amazon and OneLavi, expanding the online retail options available to American consumers interested in the company's German sports nutrition portfolio. "Walmart.com represents another important opportunity for TNT as we continue building our presence in the United States," said Markus Himmelstoss, Managing Director of TNT. "We've established a strong customer base in Europe, and our goal is to make TNT more accessible to American consumers through the online retail platforms they already know and use." Expanding Access to German Sports Nutrition TNT's U.S. retail strategy is focused on introducing its established European sports nutrition portfolio to a broader American audience through recognized retail platforms. The company's product lineup includes Creatine Monohydrate Creapure®, CLEAR WHEY protein isolate, Synapsensause Pre-Workout, and Game Changer, a carbohydrate and electrolyte formulation. TNT has developed its brand around German product development, quality standards, and a focus on athletes and active consumers. As the company expands in the United States, its retail strategy emphasizes both product availability and building awareness of TNT as an established international sports nutrition brand. "We believe American consumers appreciate quality, transparency, and brands with a clear identity," Himmelstoss said. "TNT has spent years building that foundation in Germany and Europe. Our U.S. expansion is about introducing that same commitment to a new market." Building on Recent U.S. Retail Activity The planned Walmart.com availability follows TNT's participation in the September ECRM Vitamin, Weight Management & Sports Nutrition Session in Palm Beach Gardens, Florida, where the company introduced its product portfolio to U.S. retail buyers. That participation was part of TNT's broader effort to develop relationships within the American retail marketplace while continuing to expand its online distribution. With Amazon and OneLavi already providing access to TNT products in the United States, Walmart.com represents another opportunity to broaden the brand's reach. The company views its U.S. expansion as a long-term effort that combines established retail platforms, brand education, and continued introductions to American consumers. Continuing TNT's U.S. Growth TNT's expansion reflects its strategy of building on an established European customer base while adapting to the opportunities of the American sports nutrition marketplace. The company plans to continue supporting its existing U.S. retail presence while preparing for its upcoming Walmart.com availability. "Every new retail platform gives us another opportunity to introduce TNT to consumers who may not yet be familiar with our brand," Himmelstoss said. "We're excited about the progress we're making and look forward to continuing that growth in the United States." TNT products are currently available to U.S. consumers through Amazon and OneLavi, with Walmart.com availability planned. Where American Consumers Can Purchase TNT Products TNT Creatine Monohydrate Creapure®  Powder on OneLavi TNT Synapsensause Pre-Workout "Wild Berry" Pre-Workout Booster on Amazon TNT Synapsensause Pre-Workout "Wild Berry" Pre-Workout Booster on OneLavi TNT Clear Whey Protein Isolate - Peach Iced Tea on OneLavi About TNT (True Nutrition Technology) Founded in Germany by former athletes Michael Weigl and Markus Himmelstoss, TNT (True Nutrition Technology) is a leading sports nutrition brand trusted by more than 500,000 customers. Since 2012, TNT has produced premium supplements under strict German quality standards, with every product independently lab-tested for safety, purity, and transparency. TNT’s core product lineup includes Creatine Monohydrate Creapure®, CLEAR WHEY Protein, and Synapsensause Pre-Workout-three performance-focused supplements widely used by athletes to support strength, recovery, energy, and training intensity. From advanced protein blends to innovative vegan formulations, TNT develops evidence-based nutrition designed to help athletes and everyday individuals perform at their best. More than just supplements, TNT represents a passion for sport, health, and performance. Built on German precision and a culture of honesty, TNT continues to expand globally with one mission: delivering the highest quality nutrition-for us, and for you. FDA Disclaimer These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. ———————————————————————————————————————————————————————————— Chen Qiyu: Building on "Affordability & Reliability", Fosun Expands the Global Reach of Chinese Innovative Drugs 2026-10-21 · PR Newswire · Industrial, Biotech & pharma, Sustainability https://www.prnewswire.com/news-releases/chen-qiyu-building-on-affordability--reliability-fosun-expands-the-global-reach-of-chinese-innovative-drugs-302915240.html HONG KONG, Oct. 21, 2026 -- On 20 October, the Sustainability Global Leaders Conference 2026 was held in Shanghai. The Conference, themed "Building a Resilient Future Together: Global Governance, Innovation-Driven Growth, and Industrial Upgrading", brought together more than... ———————————————————————————————————————————————————————————— Vistin Pharma ASA: Invitation to Q3 2026 conference call 2026-10-21 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385194/0/en/vistin-pharma-asa-invitation-to-q3-2026-conference-call.html Oslo, Norway, 21 October 2026 ———————————————————————————————————————————————————————————— Global Bioprocessing Support Services Market Report 2026 | Capitalize on $4.13B by 2030 as Thermo Fisher, Merck, Sartorius and Samsung Biologics Scale Single-Use Solutions 2026-10-21 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385165/28124/en/global-bioprocessing-support-services-market-report-2026-capitalize-on-4-13b-by-2030-as-thermo-fisher-merck-sartorius-and-samsung-biologics-scale-single-use-solutions.html Boost ROI by outsourcing services, adopting single-use integrated platforms, and standardizing scale-up, optimization and compliance to cut costs and speed production. Boost ROI by outsourcing services, adopting single-use integrated platforms, and standardizing scale-up, optimization and compliance to cut costs and speed production. ———————————————————————————————————————————————————————————— Bioconjugation Market Report 2026: Global Size, Share, Trends and 2030 Forecast | Capitalize on Targeted Therapeutics | Thermo Fisher, Merck, Danaher, Lonza, and Agilent Lead the Industry 2026-10-21 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385159/28124/en/bioconjugation-market-report-2026-global-size-share-trends-and-2030-forecast-capitalize-on-targeted-therapeutics-thermo-fisher-merck-danaher-lonza-and-agilent-lead-the-industry.html Dublin, Oct. 21, 2026 -- "Bioconjugation Market Report 2026" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Clinical Trials Matching Software Market Trends in AI-Based Recruitment 2026-10-21 · Express Press Release · AI, Healthcare, Biotech & pharma https://express-press-release.net/news/2026/10/21/1777835 The global clinical trials matching software market was valued at USD 210.7 million in 2025 and is expected to reach USD 237.9 million in 2026. [read full press release...] ———————————————————————————————————————————————————————————— Human Plasma Like Medium Market Global Report 2026 | Capitalize on 8.6% CAGR as Thermo Fisher Scientific, Sartorius, Sigma Aldrich and HiMedia Advance IVD and Gene Therapy 2026-10-21 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385156/28124/en/human-plasma-like-medium-market-global-report-2026-capitalize-on-8-6-cagr-as-thermo-fisher-scientific-sartorius-sigma-aldrich-and-himedia-advance-ivd-and-gene-therapy.html Dublin, Oct. 21, 2026 -- "Human Plasma Like Medium Market Report 2026" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Global Longevity BioTech Market Size and Forecast Report 2026-2030 | Capitalize on 10.7% CAGR as Insilico Medicine, Calico, and Altos Labs Lead the Industry 2026-10-21 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385154/28124/en/global-longevity-biotech-market-size-and-forecast-report-2026-2030-capitalize-on-10-7-cagr-as-insilico-medicine-calico-and-altos-labs-lead-the-industry.html Dublin, Oct. 21, 2026 -- "Longevity BioTech Market Report 2026" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Germany Cell Culture Microcarrier Consumables Market Forecast, 2025-2031 | Biologics, Cell Therapies, and Synthetic Microcarriers Create Growth Opportunities 2026-10-21 · GlobeNewswire · Biotech & pharma, Sustainability https://www.globenewswire.com/news-release/2026/10/21/3385150/28124/en/germany-cell-culture-microcarrier-consumables-market-forecast-2025-2031-biologics-cell-therapies-and-synthetic-microcarriers-create-growth-opportunities.html Germany’s ROI opportunities center on synthetic microcarriers, biopharma, vaccines and cell therapies, with automation, single-use systems and sustainable materials improving scale and efficiency. Germany’s ROI opportunities center on synthetic microcarriers, biopharma, vaccines and cell therapies, with automation, single-use systems and sustainable materials improving scale and efficiency. ———————————————————————————————————————————————————————————— White Biotechnology (Industrial Biotechnology) Market - Global Forecast 2026-2032 | AI and Circular Feedstocks Drive 8.51% CAGR to USD 567.36 Billion 2026-10-21 · GlobeNewswire · AI, Industrial, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385149/28124/en/white-biotechnology-industrial-biotechnology-market-global-forecast-2026-2032-ai-and-circular-feedstocks-drive-8-51-cagr-to-usd-567-36-billion.html Dublin, Oct. 21, 2026 -- "White Biotechnology Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Regulation, Raw Materials and Risk: The Hidden Brakes on the Cell Culture Market 2026-10-21 · Express Press Release · Biotech & pharma https://express-press-release.net/news/2026/10/21/1777802 Cell culture has moved from a basic research technique to the backbone of modern biologics, vaccines, and regenerative medicine. Grand View Research projects the market [read full press release...] ———————————————————————————————————————————————————————————— Samsung Biologics Reports Third Quarter 2026 Financial Results 2026-10-21 · PR Newswire · Finance, Industrial, Biotech & pharma https://www.prnewswire.com/news-releases/samsung-biologics-reports-third-quarter-2026-financial-results-302915131.html Recorded Q3'26 revenue of KRW 1,490 billion and operating profit of KRW 640 billion Plant 5 ramp-up and U.S. manufacturing operations contribute to earnings performance Raised 2026 revenue growth guidance to 20% while advancing strategic investments in portfolio and capacity expansion... ———————————————————————————————————————————————————————————— WuXi Biologics Receives Top-Honor Jade Award at The Asset Corporate Sustainability Leadership Awards 2026 2026-10-21 · PR Newswire · Industrial, Biotech & pharma, Sustainability https://www.prnewswire.com/news-releases/wuxi-biologics-receives-top-honor-jade-award-at-the-asset-corporate-sustainability-leadership-awards-2026-302915102.html Also Named Best in Transition (Hong Kong) Recognized for ESG Leadership and Green and Digital Transformation SHANGHAI, Oct. 21, 2026 -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it... ———————————————————————————————————————————————————————————— Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research 2026-10-21 · Business Wire · SaaS, Industrial, Biotech & pharma https://finance.yahoo.com/healthcare/articles/okomera-announces-commercial-agreement-servier-060000468.html Okomera reaches a key milestone in its industrial rollout with the first commercial installation of its integrated platform, combining hardware, software and biology, in the laboratories of an international pharmaceutical group. Servier will use Okomera's technology to evaluate new therapeutic approaches in oncology and i ———————————————————————————————————————————————————————————— Parkinson’s Disease Drugs Market Trends Driving Growth to US$ 16.62 Billion by 2033 2026-10-21 · PR News Releaser · Biotech & pharma https://www.prnewsreleaser.com/news/474745 The Parkinsons Disease Drugs Market size was valued at US$ 8.37 billion in 2025 and is projected to reach US$ 16.62 billion by 2033, growing at a CAGR of 8.95% during 2026–2033. Market growth is best understood as the interaction ... Read more ———————————————————————————————————————————————————————————— First Patient Treated in the C-FLASH-01 ConformalFLASH® Clinical Trial 2026-10-21 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385095/0/en/first-patient-treated-in-the-c-flash-01-conformalflash-clinical-trial.html First Patient Treated in the C-FLASH-01 ConformalFLASH® Clinical Trial ———————————————————————————————————————————————————————————— AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership 2026-10-21 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/amwc-dubai-2026-galderma-reinforces-050000408.html Galderma will present eight posters spanning its full Injectable Aesthetics portfolio at AMWC Dubai 2026, highlighting the complementary benefits of Sculptra® and Restylane®, and pooled phase III study data for Relfydess® (relabotulinumtoxinA)1-8 With 30 years of innovation, Restylane continues to evolve through the devel ———————————————————————————————————————————————————————————— Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference 2026-10-21 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/innate-pharma-participate-stifel-healthcare-050000114.html MARSEILLE, France, October 21, 2026--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (" Innate " or the " Company "), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in the following investor conferences: Stifel Healthcare Conference Dates: November 10–12, 2026 Location: ———————————————————————————————————————————————————————————— Oracle e AstraZeneca collaborano per promuovere l'innovazione basata sull’AI in ambito sanitario 2026-10-21 · Oracle · AI, SaaS, Healthcare, Biotech & pharma, Software & IT https://www.oracle.com/news/announcement/oracle-and-astrazeneca-partner-to-advance-ai-enabled-healthcare-2026-10-20/ Austin, Texas and Abu Dhabi—Oct 20, 2026 Oracle today announced an agreement with AstraZeneca to explore how AI and real-world data can help clinicians identify eligible patients for clinical trials, accelerate evidence generation, and bring relevant research insights into everyday care. The collaboration is expected to combine AstraZeneca’s scientific and therapeutic expertise with Oracle’s health data, cloud, AI, a ———————————————————————————————————————————————————————————— 오라클·아스트라제네카, AI 기반 헬스케어 혁신 위한 협력 추진 2026-10-21 · Oracle · AI, SaaS, Healthcare, Biotech & pharma, Software & IT https://www.oracle.com/news/announcement/oracle-and-astrazeneca-partner-to-advance-ai-enabled-healthcare-2026-10-20/ Austin, Texas and Abu Dhabi—Oct 20, 2026 Oracle today announced an agreement with AstraZeneca to explore how AI and real-world data can help clinicians identify eligible patients for clinical trials, accelerate evidence generation, and bring relevant research insights into everyday care. The collaboration is expected to combine AstraZeneca’s scientific and therapeutic expertise with Oracle’s health data, cloud, AI, a ———————————————————————————————————————————————————————————— Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight 2026-10-21 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385077/0/en/metabolic-dysfunction-associated-steatohepatitis-clinical-trial-and-competitive-landscape-expands-as-180-companies-target-new-treatment-options-delveinsight.html The metabolic dysfunction-associated steatohepatitis competitive landscape report delivers important insights into approved as well as ongoing research on 200+ pipeline MASH drugs, clinical strategies, upcoming therapeutics, and commercial analysis. The metabolic dysfunction-associated steatohepatitis competitive landscape report delivers important insights into approved as well as ongoing research on 200+ pipeline MASH drugs, clinical strategies, upcoming therapeutics, and commercial analysis. ———————————————————————————————————————————————————————————— Teknova Announces Pricing of $40 Million Public Offering of Common Stock 2026-10-21 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385068/0/en/teknova-announces-pricing-of-40-million-public-offering-of-common-stock.html HOLLISTER, Calif., Oct. 20, 2026 -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $40 million. Teknova has also granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of its common stock. All of the shares of common stock in the offering are to be sold by Teknova. The offering is expected to close on or about October 22, 2026, subject to the satisfaction of customary closing conditions. ———————————————————————————————————————————————————————————— Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value 2026-10-21 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/hengrui-pharma-previews-esmo-congress-2026-64-research-findings-highlight-continued-progress-across-innovative-pipelines-to-advance-clinical-value-302914820.html 64 research findings have been accepted, including three Proffered Paper presentations and three Rapid Oral presentations, spanning more than ten areas of oncology and supportive care. More than 10 studies have been selected to highlight the latest findings on HER2- and HER3-targeted... ———————————————————————————————————————————————————————————— Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB) 2026-10-21 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/ionis-partner-gsk-announces-hibsago-012000956.html – Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care – – Six-month treatment with option of at-home administration after first dose – – CHB affects approximately 1.7 million people in the U.S. – CARLSBAD, Calif., October 21, 2026--Ionis Pharmaceutic ———————————————————————————————————————————————————————————— Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock 2026-10-21 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385059/0/en/disc-medicine-announces-pricing-of-450-million-upsized-public-offering-of-common-stock.html WATERTOWN, Mass., Oct. 20, 2026 -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an upsized underwritten public offering of shares of its common stock. Disc is selling 6,000,000 shares of common stock at a public offering price of $75.00 per share. In addition, Disc has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds to Disc from this offering are expected to be $450 million, before deducting underwriting discounts and commissions and other offering expenses, assuming no exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on October 22, 2026, subject to the satisfaction of customary closing conditions. ———————————————————————————————————————————————————————————— Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors 2026-10-21 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385058/1453/en/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors.html NEW YORK, Oct. 20, 2026 -- Wolf Popper LLP is continuing its investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE). ———————————————————————————————————————————————————————————— HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China 2026-10-21 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385054/0/en/hutchmed-announces-closing-of-kras-egfr-antibody-conjugate-therapy-license-to-gsk-outside-china.html HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 20, 2026 -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September 3, 2026  and following the completion of customary closing conditions including antitrust regulatory reviews, the exclusive development and license agreement between HUTCHMED Limited (a subsidiary of the Company) and a subsidiary of GSK plc (“GSK”) has closed. The agreement grants the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830. ———————————————————————————————————————————————————————————— Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB) 2026-10-20 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/hibsago-bepirovirsen-approved-us-treatment-235800297.html Approval based on phase III data showing unprecedented functional cure rates compared to standard of care Six-month treatment with option of self-administration after first dose CHB affects approximately 1.7 million people in the US1 PHILADELPHIA, October 20, 2026--GSK plc (LSE/NYSE: GSK) today announc ———————————————————————————————————————————————————————————— Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL 2026-10-20 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3385051/0/en/ascentage-pharma-s-lisaftoclax-granted-breakthrough-therapy-designation-in-china-for-treatment-na%C3%AFve-cll-sll.html Lisa granted breakthrough designation for Lisa in China ———————————————————————————————————————————————————————————— Unicycive Therapeutics, Inc. Investors Have Until November 2nd to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff Role 2026-10-20 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3385048/0/en/unicycive-therapeutics-inc-investors-have-until-november-2nd-to-contact-bragar-eagel-squire-p-c-seeking-lead-plaintiff-role.html Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options ———————————————————————————————————————————————————————————— Telix Reports Third Quarter 2026 Financial Performance 2026-10-20 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3385039/0/en/telix-reports-third-quarter-2026-financial-performance.html MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a financial update on its commercial and operational performance for the quarter ended September 30, 2026 (Q3 2026). ———————————————————————————————————————————————————————————— Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 2026-10-20 · PR Newswire · Finance, Biotech & pharma https://www.prnewswire.com/news-releases/atrium-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302914657.html SAN DIEGO, Oct. 20, 2026 -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on October 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to... ———————————————————————————————————————————————————————————— BioVersys Announces Publication of BV100 Lung Penetration and Drug Interaction Data in two Leading Peer-reviewed Antimicrobial Journals 2026-10-20 · NewMediaWire · Healthcare, Education, Biotech & pharma https://www.newmediawire.com/news/bioversys-announces-publication-of-bv100-lung-penetration-and-drug-interaction-data-in-two-leading-peer-reviewed-antimicrobial-journals-7090767 International Journal of Antimicrobial Agents publishes data showing that BV100 reaches concentrations in lung fluid and alveolar macrophages approximately 35-fold and over 300-fold higher, respectively, than in plasma, providing a strong pharmacological rationale for BV100 use in severe CRAB pneumonia Journal of Antimicrobial Chemotherapy publishes data showing BV100 is a mild CYP3A inducer and a mild substrate for CYP3A inhibitors, a milder drug interaction profile than rifampicin, supporting its use alongside the many medicines given to critically ill patients Both Phase 1 datasets form part of the clinical solid pharmacology foundation of RIV-TARGET, the ongoing Phase 3 registration trial of BV100 in hospital- and ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC); trial enrollment is ongoing, with topline data read-out anticipated for early 2028 BASEL, SWITZERLAND - October 20, 2026 - BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today the publication of two Phase 1 clinical pharmacology studies of BV100, its lead clinical asset, in two leading peer-reviewed journals in the field of antimicrobial therapy: the International Journal of Antimicrobial Agents, the official journal of the International Society of Antimicrobial Chemotherapy, and the Journal of Antimicrobial Chemotherapy, the official journal of the British Society for Antimicrobial Chemotherapy. Dr. Glenn Dale, Chief Development Officer of BioVersys and co-author of the publications, commented: "These two papers address the questions that matter most for an intravenous antibiotic in critically ill pneumonia patients. BV100 has very good distribution in lung fluid and alveolar macrophages, and its drug-interaction profile is mild and manageable. We are pleased to share these data with the infectious disease and critical care community as we continue to enroll patients in our Phase 3 study RIV-TARGET." Dr. Marc Gitzinger, Chief Executive Officer and founder of BioVersys, added: "Carbapenem-resistant Acinetobacter baumannii represents one of the highest medical needs in infectious disease, and patients fighting these life-threatening infections have very few options. These data continue to strengthen the growing scientific basis for BV100 therapy in CRABC pneumonia and bring us a step closer to delivering a much-needed new treatment option to patients and the physicians who care for them." International Journal of Antimicrobial Agents: lung penetration study The paper, entitled "Pulmonary Penetration of Intravenous Rifabutin in Healthy Participants: A Multiple-Dose Pharmacokinetic Study," was published in the International Journal of Antimicrobial Agents (DOI: 10.1016/j.ijantimicag.2026.108014). In 36 healthy male participants receiving BV100 (intravenous rifabutin) 300 mg every 12 hours for four days, concentrations of rifabutin in lung fluid and alveolar macrophages exceeded plasma concentrations at every time point, with median penetration ratios of approximately 35-fold and over 300-fold, respectively, and repeated dosing was well tolerated. The authors conclude that these pulmonary exposures provide a strong pharmacological rationale for further clinical evaluation of BV100 in severe CRAB pneumonia. Journal of Antimicrobial Chemotherapy: drug-drug interaction studies The paper, entitled "BV100 (rifabutin IV) drug interaction studies in healthy subjects with index CYP450 3A probes midazolam and itraconazole," was published in the Journal of Antimicrobial Chemotherapy (DOI: 10.1093/jac/dkag317). Across two Phase 1 studies, BV100 was shown to be a mild CYP3A inducer, reducing midazolam exposure by approximately 47%, and a mild substrate for CYP3A inhibitors, with rifabutin exposure increasing 1.3- to 1.7-fold with itraconazole. This is a milder interaction profile than that of rifampicin, a strong CYP3A inducer, and BV100 was safe and well tolerated in both studies. BV100 is currently studied in two clinical trials: the pivotal Phase 3 global registrational trial, RIV-TARGET and the open-label Phase 2b differentiation trial, RIV-CARE in collaboration with ADVANCE-ID. In September 2026, BV100 was granted Fast Track Designation by the US FDA, under the Qualified Infectious Disease Product (QIDP) Designation received in 2019. About BioVersys BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. Derived from the company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company’s most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 3), and tuberculosis (alpibectir, Phase 2, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). BioVersys is located in the biotech hub of Basel, Switzerland. About BV100 BV100 is a novel formulation of rifabutin suitable for intravenous administration, with a recently discovered novel mode of action showing an active uptake of rifabutin into the Gram-negative bacterial species, Acinetobacter baumannii. For the first time, BV100 allows for the targeting of the RNA-polymerase enzyme in Gram-negative bacteria with a human-suitable dose. BV100 is being developed for the treatment of infections caused by Acinetobacter baumannii calcoaceticus complex (ABC), including carbapenem-resistant ABC (CRABC) in critically important indications of ventilator associated bacterial pneumonia (VABP), hospital-acquired bacterial pneumonia (HABP) and bloodstream infections (BSI). BV100 was granted US FDA Fast Track Designation in 2026 and QIDP Designation in May 2019, making BV100 eligible for priority FDA review and a five-year extension of market exclusivity upon approval of the first QIDP indication. About Acinetobacter baumannii Acinetobacter baumannii calcoaceticus complex (ABC) are Gram-negative bacteria found in the environment (e.g., in soil and water) and an opportunistic pathogen in humans, typically infecting critically ill and immunocompromised patients, that can result in severe pneumonia and bloodstream infections in addition to affecting other parts of the body. ABC is considered a significant worldwide threat in the healthcare setting given its ability to survive for prolonged periods on surfaces, combined with its ability to develop or acquire resistance to standard of care antibiotics, e.g. carbapenems. Carbapenem-resistance as well as multi-drug resistance (MDR) rates for ABC are among the highest recorded for any bacteria in current times (The Lancet 2022; 399: 629–55). Incidence and resistance rates for ABC are trending upwards and COVID-19 has exacerbated this significantly. BioVersys forecasts the annual number of carbapenem-resistant A. baumannii infections in hospitals to have surpassed one million globally and due to the limited treatment options, such infections come with high (up to 50%) mortality rates. Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning BioVersys and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioVersys to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioVersys is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. BioVersys contact  Anca Cighi, Head of IR and Communications, Tel. +41 79 949 33 09; Mail: anca.cighi@bioversys.com For IR: IR@bioversys.com;  Website: www.bioversys.com ———————————————————————————————————————————————————————————— Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment 2026-10-20 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/zoetis-receives-fda-approval-convenia-204200936.html Convenia RTU for Dogs can provide up to 14 days of antibiotic treatment of susceptible bacterial skin infections in dogs in a single injection by a veterinary professional Pyoderma – a bacterial skin infection—is one of the top 5 reasons for vet visits for dogs.1 Administration at the veterinary clinic helps dog owners av ———————————————————————————————————————————————————————————— Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2 2026-10-20 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/alcon-acquires-neurotech-encelto-only-203500177.html Expands Alcon's retina portfolio with ENCELTO, an encapsulated cell therapy intended for surgical implantation in the eye for patients with MacTel Type 2, a rare retinal disease Alcon's established presence and expertise in surgical retina is expected to accelerate commercialization and patient access Broadens Alcon's off ———————————————————————————————————————————————————————————— TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call 2026-10-20 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/trisalus-life-sciences-host-third-203200508.html WESTMINSTER, Colo., October 20, 2026--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced tha ———————————————————————————————————————————————————————————— Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026 2026-10-20 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/stevanato-group-report-third-quarter-203000991.html PIOMBINO DESE, Italy, October 20, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third qua ———————————————————————————————————————————————————————————— INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Unicycive Therapeutics, Inc. to Contact Law Firm 2026-10-20 · PR Newswire · Finance, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/investor-action-notice-moore-law-pllc-encourages-investors-in-unicycive-therapeutics-inc-to-contact-law-firm-302914521.html Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shareholders should email fletcher@fmoorelaw.com NEW YORK, Oct. 20, 2026 -- What is the Investigation About? On June 30, 2026, before the market opened, Unicycive disclosed that the FDA had issued a second Complete Response Letter... ———————————————————————————————————————————————————————————— Systech Launches New All-in-One Pharma Packaging and Serialization Stations 2026-10-20 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/systech-launches-new-all-in-one-pharma-packaging-and-serialization-stations-302914327.html DOWNERS GROVE, Ill., Oct. 20, 2026 -- Systech, part of Markem-Imaje and Dover and a leading provider of pharmaceutical serialization and traceability solutions, today announced the launch of two new integrated packaging solutions designed to help pharmaceutical manufacturers... ———————————————————————————————————————————————————————————— AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026 2026-10-20 · PR Newswire · Finance, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/amgen-to-present-at-the-european-society-of-medical-oncology-congress-2026-302914593.html THOUSAND OAKS, Calif., Oct. 20, 2026 -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society of Medical Oncology Congress (ESMO) 2026 on Saturday, October 24, 2026 at 11:30 a.m. PT. Murdo Gordon, executive vice... ———————————————————————————————————————————————————————————— Uganda: Mbarara University pharmacy course accredited - Tayebwa 2026-10-20 · APO Group · Education, Sports, Biotech & pharma https://www.africa-newsroom.com/press/mbarara-university-pharmacy-course-accredited-tayebwa?lang=en Deputy Speaker Thomas Tayebwa has said the Bachelor of Pharmacy programme at Mbarara University of Science and Technology (MUST) remains accredited by the National Council for Higher Education (NCHE) for the next four years despite a dispute over its professional recognition by the Pharmaceutical Society of Uganda (PSU). Tayebwa made the remarks during the plenary sitting on Tuesday, 20 October 2026 following concerns over the PSU’s reported withdrawal of the professional recognition of the programme. Tayebwa revealed that he contacted the NCHE Executive Director, who confirmed that the programme remains accredited.  “The students are learning and being taught an accredited course,” Tayebwa told Parliament. He added that NCHE accredited the programme in consultation with relevant stakeholders including the Pharmaceutical Society. The Deputy Speaker said there is an overlap in the mandates of the Pharmaceutical Society and the National Council for Higher Education under the laws governing pharmacy training. He directed the Minister for Education and Sports to present a comprehensive statement to Parliament on Thursday, 22 October 2026. He also asked the minister to consult the Attorney General and directed the Attorney General to present the legal framework governing the matter. The Leader of the Opposition, Hon.  Joel Ssenyonyi said the concerns raised by PSU appear to extend beyond programme recognition to the qualifications of the person heading Mbarara University Department of Pharmacy. Ssenyonyi said a letter from the professional body questioned whether the department was headed by someone with the qualifications required for the position. He urged the government and relevant authorities to address the concerns promptly to prevent further uncertainty among students and graduates. “If it is a question of somebody heading a department who requires a particular set of qualifications, I think that should be sorted out so that students are not in disarray,” Ssenyonyi said. Distributed by APO Group on behalf of Parliament of the Republic of Uganda. ———————————————————————————————————————————————————————————— 101 Therapeutics to Present Phase 2/3 Data on Macrophage-Targeted, Steroid-Sparing Glucocorticoid 101-PGC-005 at ACR Convergence 2026 2026-10-20 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/101-therapeutics-present-phase-2-184600576.html Poster 0122 on Sunday, November 8: CD206-targeted dexamethasone prodrug was superior to systemic dexamethasone in a 309-patient randomized trial (HR 2.31; p<0.0001), with no systemic steroid added in the '005 arm; abstract positions ' 005 as a potential steroid-sparing adjunct to biologic therapy, including in PMR, sJIA, ———————————————————————————————————————————————————————————— Quantum BioPharma (QNTM) Featured in Men's Fitness Article Examining Unbuzzd Clinical Trial Results 2026-10-20 · NewMediaWire · Finance, AI, Healthcare, Media, Biotech & pharma https://www.newmediawire.com/news/quantum-biopharma-qntm-featured-in-men-s-fitness-article-examining-unbuzzd-clinical-trial-results-7090759 LOS ANGELES, CA - October 20, 2026 - Quantum BioPharma (NASDAQ: QNTM) was featured in a Men’s Fitness article by Lakshan Weeraratne examining clinical trial results for Unbuzzd, an alcohol recovery formulation developed by Quantum and licensed to Unbuzzd Wellness. The article highlights findings from a company-sponsored, placebo-controlled study involving 26 healthy adults, with 24 completing both treatment sessions. Researchers reported significantly lower estimated blood alcohol concentrations at several time points, improved self-rated alertness and reduced headache severity on certain assessments. Among 17 participants identified as rapid responders, the average percentage decline in estimated blood alcohol during the first 30 minutes was 40.7% greater with Unbuzzd than with placebo. The Men’s Fitness article also emphasized the study’s limitations, including its small sample size, company sponsorship and mixed results across broader measures of hangover severity and cognitive impairment. While the findings suggest potential benefits for certain alcohol recovery measures, the article noted that larger, independent clinical trials are needed to confirm the results. It also cautioned that increased alertness does not indicate sobriety or fitness to drive. About Quantum BioPharma Ltd. Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. ———————————————————————————————————————————————————————————— Just One in Ten Rheumatologists Satisfied with Current Systemic Sclerosis Treatments as Emerging Therapies Raise Expectations, According to Spherix Global Insights 2026-10-20 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384792/0/en/just-one-in-ten-rheumatologists-satisfied-with-current-systemic-sclerosis-treatments-as-emerging-therapies-raise-expectations-according-to-spherix-global-insights.html New research highlights growing optimism for disease-modifying therapies, even as physicians weigh the transformative potential of cell therapy against safety and practical considerations; Novartis' ianalumab emerges as a leading non-cell therapy contender. New research highlights growing optimism for disease-modifying therapies, even as physicians weigh the transformative potential of cell therapy against safety and practical considerations; Novartis' ianalumab emerges as a leading non-cell therapy contender. ———————————————————————————————————————————————————————————— Delivering for North Carolina: Safer Streets, Bigger Paychecks, and a Manufacturing Boom Under President Trump 2026-10-20 · The White House · Industrial, Aerospace & defense, Biotech & pharma https://www.whitehouse.gov/releases/2026/10/delivering-for-north-carolina-safer-streets-bigger-paychecks-and-a-manufacturing-boom-under-president-trump/ President Donald J. Trump returns to North Carolina today with a clear record of results that put Tar Heel families, workers, seniors, and communities first. Since taking office, the Trump Administration has driven down crime, returned money to workers’ and seniors’ pockets, and unleashed a surge of advanced manufacturing, pharmaceutical, aerospace, biotechnology, and SI investment […] The post Delivering for North Carolina: Safer Streets, Bigger Paychecks, and a Manufacturing Boom Under President Trump appeared first on The White House. ———————————————————————————————————————————————————————————— Florida Cancer Specialists & Research Institute Leadership Review of Step Therapy Policies Details Troubling Impacts to Cancer Patients 2026-10-20 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/florida-cancer-specialists--research-institute-leadership-review-of-step-therapy-policies-details-troubling-impacts-to-cancer-patients-302914368.html FORT MYERS, Fla., Oct. 20, 2026 -- Insurer-driven step-editing practices in oncology continue to increase the risk of serious harm to cancer patients and providers, according to an extensive review conducted by physician and executive leaders of Florida Cancer Specialists &... ———————————————————————————————————————————————————————————— Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion 2026-10-20 · Newswire.com · Finance, Healthcare, Real estate, Retail, Industrial, Biotech & pharma https://www.newswire.com/news/cosmos-health-ceo-greg-siokas-issues-letter-to-shareholders-highlighting-record Key Highlights Record revenue: preliminary nine-month 2026 revenue of approximately $54.3 million, up 19%, with every quarter of 2026 setting a record 2026 outlook reaffirmed: full-year revenue expected to surpass $90 million, up approximately 38%, the largest single-year revenue increase in the Company's history Record fourth quarter expected: revenue of approximately $35.7 million or more, up approximately 81% from the fourth quarter of 2025 Multiple engines of growth: pharmaceutical contract manufacturing and distribution, proprietary brands and U.S. e-commerce all expected to contribute U.S. e-commerce scaling rapidly: 8,940 active U.S. subscriptions as of October 19, 2026, up 42% in five days, with approximately $15 million in revenue and $10.5 million in gross profit expected in the fourth quarter Record CMO pipeline: more than 32.7 million units at Cana Laboratories, up sixfold since mid-2024 Record distribution volumes: CosmoFarm serving more than 1,500 pharmacies, with revenue up approximately 4.3 times under Cosmos Health ownership Global brand expansion: proprietary brands sold in more than 40 countries, with particular momentum in Europe and the Gulf Diversified balance sheet: approximately $20 million in non-core assets, including real estate and digital assets, and total liabilities down 13.3% in the first half of 2026 Share repurchases: more than 5.1 million shares repurchased for approximately $1.1 million R&D in weight management: advancing CCX0722, a hydrogel-based weight-management device with patent applications in four major markets Path to 2029: < ———————————————————————————————————————————————————————————— China Healthcare Cold Chain Logistics Market Size, Share, Trends, and Forecast 2025-2034 | Market to Reach USD 8.59 Billion as Biologics and Smart Storage Drive 8.90% CAGR 2026-10-20 · GlobeNewswire · Logistics, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384775/28124/en/china-healthcare-cold-chain-logistics-market-size-share-trends-and-forecast-2025-2034-market-to-reach-usd-8-59-billion-as-biologics-and-smart-storage-drive-8-90-cagr.html Biopharmaceuticals lead demand as firms invest in cold storage, IoT-enabled monitoring, predictive analytics and reusable thermal packaging to improve compliance, efficiency and shipment integrity. Biopharmaceuticals lead demand as firms invest in cold storage, IoT-enabled monitoring, predictive analytics and reusable thermal packaging to improve compliance, efficiency and shipment integrity. ———————————————————————————————————————————————————————————— SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test 2026-10-20 · Newswire.com · SaaS, Biotech & pharma https://www.newswire.com/news/sod-sciences-welcomes-vivos-therapeutics-as-strategic-investor-and-partner-in Partnership unites the ReBalU Protocol, Vivos's sleep platform, and a new test for cells primed for chronic disease, reaching nearly 500,000 chronic‑disease patients ———————————————————————————————————————————————————————————— Correction: ITM and Lumara Bio Announce Dose-Response Analysis for ¹⁷⁷Lu-edotreotide (ITM-11) and Data Supporting Early-Stage Pipeline at EANM 2026 2026-10-20 · GlobeNewswire · Healthcare, Education, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384695/0/en/correction-itm-and-lumara-bio-announce-dose-response-analysis-for-lu-edotreotide-itm-11-and-data-supporting-early-stage-pipeline-at-eanm-2026.html Vienna, October 20, 2026 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Lumara Bio, a dedicated oncology therapeutics division of ITM, today announced that data supporting its targeted precision oncology portfolio were featured in three oral presentations and one e-poster at the European Association of Nuclear Medicine (EANM) 2026 Congress, held from October 17-21 in Vienna, Austria. The presentations further support ITM’s late- and early-stage radiopharmaceutical pipeline, highlighting novel therapeutic and diagnostic candidates across Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), clear cell Renal Cell Carcinoma (ccRCC), and glioblastoma. “The data presented at EANM 2026 underscore the therapeutic potential of our deep targeted radiopharmaceutical pipeline, which leverages different targets, both established and novel radioisotopes, and addresses several difficult-to-treat oncology indications,” said Dr. Celine Wilke, chief medical officer of ITM. “Whether derived from ITM’s Phase 3 COMPETE trial or through the valuable insights of independent, investigator-initiated research, this growing evidence base supports the continued development of these novel radiopharmaceuticals across cancers with significant unmet medical need.” Higher Cumulative Tumor Absorbed Dose of 177Lu-edotreotide is Associated with Improved Clinical Response in GEP-NETs Dr. Anthime Flaus of the Hospices Civils de Lyon in Bron, France gave an oral presentation featuring a late-stage dose-response analysis from ITM’s Phase 3 COMPETE trial evaluating non-carrier-added (n.c.a.) 177Lu-edotreotide (ITM-11) in patients with Grade 1 or 2 GEP-NETs. The analysis assessed the relationship between tumor cumulative absorbed dose and treatment response in 106 evaluable patients who received 4 treatment cycles of ¹⁷⁷Lu-edotreotide therapy. Higher cumulative tumor absorbed doses were associated with a better Best Overall Response (BOR). The Objective Response Rate (ORR) increased from 12% in the lowest dose quartile (Q1) to 64% in the highest dose quartile (Q4), with three complete responses occurring in patients with a cumulative dose above 86.1 Gy (Q3 and Q4). Cumulative tumor absorbed dose and tumor type were the main predictors of response in multivariate logistic regression models. Lesion-level analysis also identified a statistically significant association between absorbed dose and response. "The dosimetry data from the COMPETE trial offer insights into how tumor absorbed dose correlates with objective response," said Dr. Anthime Flaus, study author and physician at the Hospices Civils de Lyon. "Understanding this dose-response relationship provides important evidence that could potentially support the development of more individualized radiopharmaceutical treatment approaches, with the goal of optimizing patient care and outcomes." Early-Stage Pipeline Data Presented at EANM 2026 The conference also highlighted promising clinical and translational data supporting the further development of other ITM pipeline candidates. These data, derived from independent trials and research initiated by investigators, offer valuable clinical insights to support the further development of ITM candidates currently in Phase 1 trials, including: Ga-DPI-4452 (also known as [68Ga]Ga-DPI-4452, or CAIX peptide), an investigational diagnostic imaging agent for ccRCC; [161Tb]Tb-DOTA-LM3 (Tb-DOTA-LM3) as a potential therapeutic for somatostatin receptor (SSTR)-positive tumors; and n.c.a. 177Lu-TTM for intra-cavitary immunoradiotherapy in patients with glioblastoma. Ga-DPI-4452 Demonstrates High Tumor Uptake and Superior Detection of ccRCC Compared to Conventional CT Dr. Alina Küper of the Department of Nuclear Medicine at University Hospital Essen in Germany highlighted in an oral presentation the interim results from an independent bicenter retrospective registry evaluating Ga-DPI-4452 PET/CT for imaging 98 patients with suspected or proven ccRCC. In the analysis, Ga-DPI-4452 demonstrated abnormal findings in 91.8% of patients with subsequently confirmed ccRCC. Additionally, Ga-DPI-4452 exhibited high tumor uptake and superior detection efficacy across 153 predefined anatomical regions compared to conventional CT imaging, including in renal primary tumors/recurrence, regional lymph nodes, distant lymph nodes, bone metastases, and visceral metastases. Lower Peptide Mass of [161Tb]Tb-DOTA-LM3 Increases Tumor Absorbed Dose in Metastatic GEP-NETs In an oral presentation, Dr. Julia G. Fricke and Prof. Damian Wild, Physician-Scientists and Researchers in Nuclear Medicine and Theranostics at the University Hospital Basel, Switzerland, shared safety, dosimetry, and preliminary efficacy data from the Phase 0b BETA PLUS study for the SSTR2 antagonist [161Tb]Tb-DOTA-LM3. In the study evaluating dosimetry in 6 patients with metastatic GEP-NETs, a peptide mass-dependent effect was observed, wherein a lower peptide mass (<100 µg vs. 300–400 μg) increased the tumor absorbed dose (23.3 vs. 12.5 Gy/GBq, p=<0.001). Improved tumor-to-kidney (8.24 vs. 7.23, p=0.14) and tumor-to-bone marrow (53.4 vs 45.9, p=0.074) absorbed dose ratios were also observed with a lower peptide mass. The radiopharmaceutical candidate showed preliminary evidence of antitumor activity with no dose-limiting toxicities, supporting further clinical evaluation. Immunohistological Expression Patterns of Carbonic Anhydrase XII in Glioblastoma Support Continued Development of n.c.a. 177Lu-TTM An e-poster by Julia Schuler of the Institute of Pathology at the Technical University of Munich in Germany highlighted translational research evaluating the presence of carbonic anhydrase XII (CAXII) in the infiltration zone of primary glioblastomas. Immunohistochemical analysis found high CAXII expression in the infiltration zone. These findings highlight CAXII as a promising target for intracavitary radioimmunotherapies and support the continued investigation of this targeted approach for the treatment of glioblastoma. 177Lu-edotreotide (ITM-11), Ga-DPI-4452, Tb-DOTA-LM3, and n.c.a. 177Lu-TTM are investigational products and are not approved by any regulatory authority for the safety and/or efficacy of any intended use. About the COMPETE Trial The COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic investigational agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is also being evaluated in COMPOSE, a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, somatostatin receptor (SSTR)-positive GEP-NETs. About Ga-DPI-4452 (ITM-94) Ga-DPI-4452 (also known as [68Ga]Ga-DPI-4452, CA-IX peptide, or ITM-94) is an investigational gallium-68-radiolabeled PET imaging agent targeting carbonic anhydrase IX (CAIX), a cell surface protein that plays a key role in tumor growth, invasion, and metastasis. ITM-94 is designed to non-invasively improve the characterization of indeterminate renal masses and enable more accurate diagnosis and disease staging of clear cell renal cell carcinoma (ccRCC). ITM-94 received Fast Track Designation from the FDA in October 2025. ITM-94 is an investigational product and is not approved by any regulatory authority for the safety and/or efficacy of any intended use. About Tb-DOTA-LM3 (ITM-63) Tb-DOTA-LM3 (also known as [161Tb]-DOTA-LM3 or ITM-63) is an investigational terbium-161-radiolabeled targeted therapeutic acting as a somatostatin receptor 2 (SSTR2) antagonist. It is designed to deliver highly localized therapeutic radiation directly to SSTR-positive tumors and is currently being evaluated for the treatment of metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ITM-63 is an investigational product and is not approved by any regulatory authority for the safety and/or efficacy of any intended use. About n.c.a. 177Lu-TTM (ITM-31) N.c.a. 177Lu-TTM (also known as LuCaFab or ITM-31) is an investigational targeted radiotherapeutic consisting of a carbonic anhydrase XII (CAXII)-specific antibody Fab fragment coupled with ITM’s medical radioisotope, non-carrier-added (n.c.a.) lutetium-177. It targets CAXII, a cell surface protein commonly expressed in the infiltration zone of primary glioblastomas. ITM-31 is designed as an intracavitary radioimmunotherapy to directly target and eliminate remaining tumor cells following surgical resection and standard-of-care therapies in patients with glioblastoma. ITM-31 is an investigational product and is not approved by any regulatory authority for the safety and/or efficacy of any intended use. About ITM Isotope Technologies Munich SE ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com About Lumara Bio Lumara Bio, a division of ITM, builds on more than two decades of radiopharmaceutical expertise and is advancing a focused pipeline of targeted therapies for cancers where treatment options remain limited. https://lumarabio.com ITM Contact Corporate Communications Kathleen Noonan/Julia Westermeir Phone: +49 89 329 8986 1500 Email: communications@itm-radiopharma.com Investor Relations Ben Orzelek Phone: +49 89 329 8986 1009 Email: investors@itm-radiopharma.com ———————————————————————————————————————————————————————————— UNCY DEADLINE: SueWallSt Reminds Unicycive Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline 2026-10-20 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384635/0/en/uncy-deadline-suewallst-reminds-unicycive-therapeutics-inc-investors-of-upcoming-securities-class-action-deadline.html A securities class action alleges Unicycive Therapeutics told shareholders its oxylanthanum carbonate application was on track without ever inspecting its third-party manufacturer's facility for cGMP compliance. UNCY purchasers who lost $3.01 per share have specific rights under the federal securities laws. A securities class action alleges Unicycive Therapeutics told shareholders its oxylanthanum carbonate application was on track without ever inspecting its third-party manufacturer's facility for cGMP compliance. UNCY purchasers who lost $3.01 per share have specific rights under the federal securities laws. ———————————————————————————————————————————————————————————— New PHIL Research on the Future of Pharma DTP: 3 in 4 Leaders Report Direct-to-Patient a Major Strategic Priority Today, Growing 20% in "Mission Critical" Significance in 2027 2026-10-20 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/phil-research-future-pharma-dtp-140000317.html A new research survey of 74 U.S. life sciences leaders finds direct-to-patient's mission-critical urgency is rising and uncovers the strategic and operational shifts that will establish the programs built to lead. SCOTTSDALE, Ariz., October 20, 2026--PHIL Inc. , a direct-to-patient (DTP) and digital h ———————————————————————————————————————————————————————————— Oracle and AstraZeneca Partner to Advance AI-enabled Healthcare Innovation 2026-10-20 · WebWire · AI, SaaS, Healthcare, Biotech & pharma https://www.webwire.com/ViewPressRel.asp?aId=363075 Oracle today announced an agreement with AstraZeneca to explore how AI and real-world data can help clinicians identify eligible patients for clinical trials, accelerate evidence generation, and bring relevant research insights into everyday care. The collaboration is expected to combine AstraZeneca's scientific and therapeutic expertise with Oracle's health data, cloud, AI, analytics, and clinical workflow capabilities. - - Through a non-binding agreement, the companies plan to explore sel... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=363075 ———————————————————————————————————————————————————————————— Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer 2026-10-20 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384572/0/en/oncolytics-biotech-to-present-reo-033-trial-in-progress-abstract-at-esmo-showcasing-pelareorep-s-potential-in-colorectal-cancer.html Oncolytics Biotech® Will Present REO 033 Trial in Progress Abstract at ESMO 2026 Showcasing Pelareorep’s Potential in Colorectal Cancer ———————————————————————————————————————————————————————————— Ponaman Healthcare Consulting Comments on HRSA's Rebate Pilot Approvals and the New CMS 340B Claims Repository 2026-10-20 · PR Now · Healthcare, Biotech & pharma https://pressreleasenews.org/pressroom/ponaman-healthcare-consulting-comments-on-hrsas-rebate-pilot-approvals-and-the-new-cms-340b-claims-repository PHOENIX, AZ, October 2026. Two federal agencies took separate steps on October 1 that ask 340B covered entities for claim-level data. The Health Resources and Services Administration approved rebate plans from 10 drug manufacturers for its revised 340B Rebate Model Pilot Program,… ———————————————————————————————————————————————————————————— Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026 2026-10-20 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/guardant-health-highlights-broad-liquid-130200706.html Research reinforces the significance of genomic and epigenomic profiling approaches to characterize tumor types, identify biomarkers, and support risk stratification Presentations reflect Guardant's strong biopharma and academic collaborations, along with public-private partnerships in Europe PALO ALTO, Calif., October 20 ———————————————————————————————————————————————————————————— NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials 2026-10-20 · Newswire.com · Healthcare, Biotech & pharma https://www.newswire.com/news/nanoviricides-revolutionary-broad-spectrum-drug-candidate-nv-387-has The Spreading Ebola Epidemic as well as Mpox Endemic in Africa Disproportionately Impact Children; The Measles Outbreaks Primarily Impact Children ———————————————————————————————————————————————————————————— GOA Therapeutics Launches $300 Million Stock Offerings to Advance First in Class Drug Candidate for Acute Alcohol Intoxication 2026-10-20 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384387/0/en/goa-therapeutics-launches-300-million-stock-offerings-to-advance-first-in-class-drug-candidate-for-acute-alcohol-intoxication.html Eligible investors can now participate in the development of GOA26, designed to rapidly lower blood alcohol concentration and sequester acetaldehyde Eligible investors can now participate in the development of GOA26, designed to rapidly lower blood alcohol concentration and sequester acetaldehyde ———————————————————————————————————————————————————————————— Bionyra Pharma Announces Positive Interim Phase 1 Results for BYN-002, a Long-Acting Anti-TL1A Antibody 2026-10-20 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/bionyra-pharma-announces-positive-interim-120100621.html Favorable interim safety and tolerability profile observed across single and multiple ascending dose cohorts in healthy volunteers Favorable immunogenicity, with single digit percentage Anti-drug Antibody (ADA) incidence at predicted therapeutic dose levels Extended pharmacokinetics and target suppression support potentia ———————————————————————————————————————————————————————————— PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors 2026-10-20 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384300/37149/en/pds-biotechnology-appoints-three-accomplished-pharma-industry-executives-to-board-of-directors.html John Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Phase 3 trial in Metastatic Colorectal Cancer (mCRC) and PDS0101 toward potential partnerships John Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Phase 3 trial in Metastatic Colorectal Cancer (mCRC) and PDS0101 toward potential partnerships ———————————————————————————————————————————————————————————— YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs 2026-10-20 · GlobeNewswire · Finance, AI, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384299/0/en/yd-bio-and-eg-biomed-partner-with-joiiup-to-launch-ai-driven-cancer-risk-assessment-for-corporate-wellness-programs.html TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic innovations, today announced a strategic collaboration with EG BioMed Co., Ltd., a Taiwan registered company and an affiliate of YD Bio (“EG BioMed”), and digital health provider JoiiUp. The partnership integrates an AI Cancer Risk Assessment (the “Assessment”), jointly developed by YD Bio and EG BioMed, into JoiiUp’s JoiiSports app, expanding access to personalized health insights for corporate wellness programs and healthcare institutions. ———————————————————————————————————————————————————————————— AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community 2026-10-20 · AbbVie · Healthcare, Sports, Biotech & pharma, Payments & fintech https://www.prnewswire.com/news-releases/abbvie-named-official-pharmaceutical-partner-of-the-mclaren-mastercard-formula-1-team-launches-abbvie-race-to-innovate-to-support-immunology-community-302913976.html Multi-year, purpose-driven campaign connects McLaren's on-track performance with support for global patient advocacy organizations serving people... ———————————————————————————————————————————————————————————— Kane Biotech Signs Distribution Agreement with The Stevens Company 2026-10-20 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384247/0/en/kane-biotech-signs-distribution-agreement-with-the-stevens-company.html Expands Kane Biotech’s commercial footprint and access to the revyve® product line across Canada ———————————————————————————————————————————————————————————— LASE Strengthens Financial Management and Corporate Governance Appoints Tim Peterman Chief Financial Officer 2026-10-20 · Newswire.com · Finance, SaaS, Energy, Industrial, Biotech & pharma, Semiconductors https://www.newswire.com/news/lase-strengthens-financial-management-and-corporate-governance-appoints-tim Laser Photonics Corporation (NASDAQ:LASE), an emerging directed energy and laser technology platform developing applications for defense, semiconductor, pharmaceutical and industrial markets (the "Company"), today announced the appointment of Tim Peterman as Chief Financial Officer. Mr. Peterman's appointment, together with the Company's recent engagements of Sheppard, Mullin, Richter & Hampton LLP ("Sheppard") as ou ———————————————————————————————————————————————————————————— Slate Medicines Strengthens Board of Directors with Appointment of Stephen K. Brannan, MD, and John D. Young 2026-10-20 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384223/0/en/slate-medicines-strengthens-board-of-directors-with-appointment-of-stephen-k-brannan-md-and-john-d-young.html RALEIGH, N.C., Oct. 20, 2026 -- Slate Medicines, Inc. (“Slate”), a clinical-stage biotechnology company committed to advancing innovative new therapies that may broaden the treatment paradigm and potentially improve outcomes for people with migraine and other headache disorders, today announced the appointment of Stephen K. Brannan, MD, and John D. Young to the company’s Board of Directors. Dr. Brannan brings more than 25 years of clinical development experience in CNS disorders and most recently served as the Chief Medical Officer of Karuna Therapeutics. Mr. Young brings more than 35 years of biopharmaceutical industry experience, including serving as a member of the Executive Leadership Team at Pfizer, most recently as Group President and Chief Business Officer. ———————————————————————————————————————————————————————————— Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026 2026-10-20 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384218/0/en/odyssey-therapeutics-presents-completed-phase-2a-od-001-induction-results-strengthening-clinical-proof-of-concept-at-ueg-week-2026.html Favorable tolerability profile and oral administration underscore the potential of OD-001 as a monotherapy and backbone for combination regimens in IBD ———————————————————————————————————————————————————————————— Nano24 Reports Positive Phase 2b Results for Inhaled EXO-CD24 in Acute Respiratory Distress Syndrome (ARDS) at the CHEST Annual Meeting 2026 2026-10-20 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/nano24-reports-positive-phase-2b-110000839.html Primary endpoint met, with 85% free of respiratory failure at Day 7 vs. 33.3% with placebo (p<0.0001) 72% reduction in risk of death at day-28 (HR 0.28; p=0.033), with benefit sustained at six months Hospital stay cut from 14.4 to 6.5 days (p=0.0001) Well tolerated; no treatment-related serious adverse events Nano24 plans ———————————————————————————————————————————————————————————— Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy 2026-10-20 · PressReach · Healthcare, Biotech & pharma https://pressreach.com/quoin-pharmaceuticals-announces-publication-of-peer-reviewed-paper-on-qrx003-for-netherton-syndrome-in-dermatology-and-therapy – Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published – Case Report Details 21 Months of Compassionate Use Treatment in a Pediatric Patient – Patient’s Skin Improved from Severe to Clear with Complete Elimination of Pruritus (itch) – After 21 Months of Treatment with QRX003, Patient’s Skin Remains Fully … Continue reading "Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy" ———————————————————————————————————————————————————————————— Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania 2026-10-20 · PressReach · Biotech & pharma https://pressreach.com/rapport-therapeutics-announces-positive-topline-results-from-its-phase-2-trial-of-rap-219-for-the-treatment-of-bipolar-mania The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania score (0.4 points; p=0.024) RAP-219–treated patients had a 15.4-point mean reduction in YMRS total score from baseline at Week 3 All 11 items measured by the … Continue reading "Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania" ———————————————————————————————————————————————————————————— WELL Health Strengthens Privacy and AI Governance Leadership with Appointment of Samara Starkman as Chief Privacy Officer and Vice President, Legal & Regulatory 2026-10-20 · Newsfile · AI, Healthcare, Biotech & pharma https://www.newsfilecorp.com/release/319929/WELL-Health-Strengthens-Privacy-and-AI-Governance-Leadership-with-Appointment-of-Samara-Starkman-as-Chief-Privacy-Officer-and-Vice-President-Legal-Regulatory WELL appoints recognized privacy and healthcare law expert Samara Starkman as Chief Privacy Officer and Vice President, Legal & Regulatory, to lead enterprise privacy, AI governance and healthcare regulatory strategy across the organization.Ms. Starkman previously led the privacy department at Cancer Care Ontario (now part of Ontario Health), co-founded INQ Consulting and was a Partner at INQ Law, advising major Ontario hospitals, pharmaceutical and health-tech companies. Ms. Starkman's... ———————————————————————————————————————————————————————————— Grünenthal advances proprietary Nociceptin Receptor (NOP) Agonist into Phase II trial in acute pain 2026-10-20 · Pressat · Healthcare, Biotech & pharma https://pressat.co.uk/releases/grnenthal-advances-proprietary-nociceptin-receptor-nop-agonist-into-phase-ii-trial-in-acute-pain-620afdc3f719cfbd2439f36ace101568/ Tuesday 20 October, 2026 Aachen, Germany, 20 October 2026 – The investigational compound has a unique mechanism of action that selectively engages with the NOP receptor and may represent a first-in-class therapy option for acute moderate to severe pain. Earlier this year, the investigational compound was shown to be safe and well-tolerated in a Phase I trial, supporting progression to Phase II.[1] KF7040-21 is a randomised, double-blind, placebo- and active-controlled Phase II trial comprising a Proof of Concept (PoC) phase and a dose-ranging phase. Overall, up to 400 participants are expected to be enrolled. Initially, 96 participants will be included in the PoC phase. Following completion of this phase, an interim analysis will inform the decision to proceed to the dose-ranging phase, in which up to 304 additional participants may be enrolled to compare three dose levels of the investigational compound with placebo and an active comparator. Further information can be found on clinicaltrials.gov. “The start of this Phase II trial is an important step in our efforts to provide patients living with pain with novel treatment options,” says Uli Brödl, Chief Scientific Officer at Grünenthal. “By selectively activating the nociceptin receptor, our investigational compound may offer a differentiated approach to deliver safe and effective pain relief.” About Bunionectomy Bunionectomy is accepted by regulatory authorities as a postoperative hard (bony) tissue pain model in which the analgesic effect of an investigational compound may be evaluated as a treatment for acute pain.[3] About the NOP Receptor Although the NOP receptor shares some sequence identity (~60%) with the opioid receptors μ-OP (MOP), κ-OP (KOP), and δ-OP (DOP), it possesses little or no affinity for opioid peptides or morphine-like compounds. Likewise, opioid receptors possess little affinity towards NOP's endogenous ligand nociceptin.[6] About Grünenthal Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2025, Grünenthal employed around 4,100 people and achieved revenues of €1.8 billion. For further information, please contact: Christopher Jansen, Global Communications at Grünenthal christopher.jansen@grunenthal.com [1] Grünenthal Data on File [2] my.clevelandclinic.org (accessed 23 June 2026) [3] Singla et al. Bunionectomy as an Acute Postoperative Pain Model: Overview of Common Experimental Methods, and Insights from Past Clinical Trials. Journal of Pain Research 2024; 17: 4399-4420. [4] Henderson G, McKnight AT. The orphan opioid receptor and its endogenous ligand-- nociceptin/orphanin FQ. Trends in Pharmacological Sciences 1997; 18 (8): 293–300. [5] Lin AP, Ko MC. The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability. ACS Chem Neurosci. 2013; 4(2): 214-24. [6] Butour et al. Recognition and activation of the opioid receptor-like ORL 1 receptor by nociceptin, nociceptin analogs and opioids. European Journal of Pharmacology 1997; 321(1): 97–103. ———————————————————————————————————————————————————————————— Global PARP Inhibitor Biomarkers Market Size, Share, Growth, Trends, and Forecast, 2026 to 2034 | Precision Oncology and HRD Testing Fuel 8.6% CAGR 2026-10-20 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384140/28124/en/global-parp-inhibitor-biomarkers-market-size-share-growth-trends-and-forecast-2026-to-2034-precision-oncology-and-hrd-testing-fuel-8-6-cagr.html Dublin, Oct. 20, 2026 -- "PARP Inhibitor Biomarkers Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2026 To 2034" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch 2026-10-20 · PressReach · Finance, Healthcare, Food & drink, Industrial, Biotech & pharma https://pressreach.com/alvotech-receives-fda-approval-for-new-simlandi-manufacturing-process-that-more-than-doubles-output-per-batch REYKJAVIK, Iceland and LONDON, Oct. 20, 2026 — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI® (adalimumab-ryvk), Alvotech’s biosimilar to Humira® (adalimumab). The FDA … Continue reading "Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch" ———————————————————————————————————————————————————————————— Germany Human Neuregulin Molecular Reagent Market Forecast, 2025-2031 | Biotech R&D and Personalized Medicine Fuel High-Purity Reagent Opportunities 2026-10-20 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384066/28124/en/germany-human-neuregulin-molecular-reagent-market-forecast-2025-2031-biotech-r-d-and-personalized-medicine-fuel-high-purity-reagent-opportunities.html Dublin, Oct. 20, 2026 -- "Human Neuregulin Molecular Reagent Market in Germany" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Netherlands Bioconjugation Market Report 2025-2031 | Targeted Therapies, Personalized Medicine, and Biotech Investment Create Strategic Growth Opportunities 2026-10-20 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384064/28124/en/netherlands-bioconjugation-market-report-2025-2031-targeted-therapies-personalized-medicine-and-biotech-investment-create-strategic-growth-opportunities.html Dublin, Oct. 20, 2026 -- "Bioconjugation Market in the Netherlands" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Global Single Use Assemblies Market - Forecast 2026-2032 | USD 19.18 Billion Opportunity as Biologics, Closed Processing, and AI Adoption Fuel 12.52% CAGR 2026-10-20 · GlobeNewswire · AI, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384063/28124/en/global-single-use-assemblies-market-forecast-2026-2032-usd-19-18-billion-opportunity-as-biologics-closed-processing-and-ai-adoption-fuel-12-52-cagr.html Dublin, Oct. 20, 2026 -- "Single Use Assemblies Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Single-Use Bioprocessing Market - Global Forecast, Trends, and Opportunities, 2026-2032 | Biologics and AI Adoption Drive 16.26% CAGR Toward USD 59.77 Billion 2026-10-20 · GlobeNewswire · AI, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384059/28124/en/single-use-bioprocessing-market-global-forecast-trends-and-opportunities-2026-2032-biologics-and-ai-adoption-drive-16-26-cagr-toward-usd-59-77-billion.html Dublin, Oct. 20, 2026 -- "Single-use Bioprocessing Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Flow Cytometry Market - Global Forecast 2026-2032 | AI, Spectral Cytometry, and Cell Therapy Demand Drive 9.70% CAGR Toward USD 12.57 Billion by 2032 2026-10-20 · GlobeNewswire · AI, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384058/28124/en/flow-cytometry-market-global-forecast-2026-2032-ai-spectral-cytometry-and-cell-therapy-demand-drive-9-70-cagr-toward-usd-12-57-billion-by-2032.html Dublin, Oct. 20, 2026 -- "Flow Cytometry Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Cell Culture Market - Global Size, Share, Trends, and Forecast 2026-2032 | USD 80.23 Billion Opportunity Fueled by Biologics, Cell Therapies, AI, and Single-Use Systems 2026-10-20 · GlobeNewswire · AI, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384057/28124/en/cell-culture-market-global-size-share-trends-and-forecast-2026-2032-usd-80-23-billion-opportunity-fueled-by-biologics-cell-therapies-ai-and-single-use-systems.html Dublin, Oct. 20, 2026 -- "Cell Culture Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Germany Cell Culture Carrier Consumables Market Forecast, 2025-2031 | Biologics and Cell-Based Therapies Drive 6.6% Global CAGR and Demand for Advanced Culture Plates 2026-10-20 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384056/28124/en/germany-cell-culture-carrier-consumables-market-forecast-2025-2031-biologics-and-cell-based-therapies-drive-6-6-global-cagr-and-demand-for-advanced-culture-plates.html Dublin, Oct. 20, 2026 -- "Cell Culture Carrier Consumable Market in Germany" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Food Biotechnology Market - Global Industry Size, Share, Trends, and Forecast 2026-2032 | Precision Fermentation and AI Fuel 10.72% CAGR Toward USD 66.50 Billion by 2032 2026-10-20 · GlobeNewswire · AI, Food & drink, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384055/28124/en/food-biotechnology-market-global-industry-size-share-trends-and-forecast-2026-2032-precision-fermentation-and-ai-fuel-10-72-cagr-toward-usd-66-50-billion-by-2032.html Dublin, Oct. 20, 2026 -- "Food Biotechnology Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— AltruBio Presents Phase 2a Data of ALTB-268 in Advanced Therapy-Refractory Ulcerative Colitis at UEG Week 2026 2026-10-20 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384042/0/en/altrubio-presents-phase-2a-data-of-altb-268-in-advanced-therapy-refractory-ulcerative-colitis-at-ueg-week-2026.html SAN FRANCISCO, Oct. 20, 2026 -- AltruBio Inc. ("AltruBio" or "the Company"), a clinical-stage biotech company developing novel immune modulators to address the unmet need in immunological and inflammatory diseases, today announced positive data from its open-label Phase 2a ASCEND UC2a trial evaluating ALTB-268, its first-in-class subcutaneous (SC) PSGL-1 immune modulator, in patients with moderately to severely active ulcerative colitis (UC) who had all failed prior advanced therapies. ———————————————————————————————————————————————————————————— ADAP Advocacy Launches Interactive AIDS Drug Assistance Program Grassroots Advocacy Hub 2026-10-20 · 24-7 Press Release · Biotech & pharma https://www.24-7pressrelease.com/press-release/539692/adap-advocacy-launches-interactive-aids-drug-assistance-program-grassroots-advocacy-hub Resource Features State-Focused Widgets for Finding Members of Congress, Communicating with Federal & State Lawmakers, and a Community Calendar—Initial Rollout Includes Florida, Illinois, Iowa, Pennsylvania, Texas, and Utah ———————————————————————————————————————————————————————————— Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance 2026-10-20 · PressReach · Finance, Healthcare, Biotech & pharma https://pressreach.com/anteris-advances-global-paradigm-trial-expansion-with-german-regulatory-clearance MINNEAPOLIS and BRISBANE, Australia, Oct. 19, 2026 — Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance from the German Federal Institute for Drugs and Medical Devices (BfArM) for the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial for patients with severe … Continue reading "Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance" ———————————————————————————————————————————————————————————— Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting 2026-10-20 · PressReach · Finance, Healthcare, Sports, Biotech & pharma https://pressreach.com/oculis-to-present-late-breaking-phase-2-acuity-biomarker-analyses-of-privosegtor-in-optic-neuritis-at-the-10th-joint-actrims-ectrims-meeting Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today announced that new biomarker data from … Continue reading "Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting" ———————————————————————————————————————————————————————————— Ambrose Healthcare Acquires AM-Pharma for Up to €161 Million, Expanding its Rare Disease Pipeline and Gaining a European Base 2026-10-20 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/20/3384032/0/en/ambrose-healthcare-acquires-am-pharma-for-up-to-161-million-expanding-its-rare-disease-pipeline-and-gaining-a-european-base.html Ambrose Healthcare acquires AM-Pharma for up to €161m, adding HPP drug ilofotase alfa to its rare disease pipeline and its first European base in Utrecht. ———————————————————————————————————————————————————————————— Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update 2026-10-20 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/innate-pharma-announces-conference-call-050000254.html MARSEILLE, France, October 20, 2026--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (" Innate " or the " Company ") today announces that the Company will hold a conference call on Thursday, November 5, 2026, at 2 p.m. CET / 8 a.m. ET, to provide a business and financial update fo ———————————————————————————————————————————————————————————— OpenAI acquires Orchestra Bio 2026-10-20 · OpenAI · AI, Biotech & pharma https://openai.com/index/openai-to-acquire-orchestra-bio OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, helping biopharma teams accelerate drug development and advance new treatments. ———————————————————————————————————————————————————————————— CropLife Asia Welcomes New BASF, Corteva and FMC Representatives to Board 2026-10-20 · ACN Newswire · Retail, Food & drink, Logistics, Biotech & pharma https://www.acnnewswire.com/press-release/english/110892/ SINGAPORE, Oct 20, 2026 - CropLife Asia, the regional association representing the plant science industry, today announced the appointment of three new representatives to its Board of Directors: Sergi Vizoso-Sansano of BASF Agricultural Solutions, Subroto Geed of Corteva Agriscience and Sebastià Pons of FMC. Sergi succeeds Simone Barg as BASF's representative on the Board, Subroto succeeds Brook Cunningham as Corteva's representative, while Sebastià succeeds Rahoul Sawani as FMC's representative. The appointments also coincide with a transition in CropLife Asia's leadership, with Paul Luxton, Head of Asia, Syngenta, formerly VicePresident, assuming the presidency, succeeding Simone Barg. Sergi Vizoso-Sansano leads BASF Agricultural Solutions in Asia Pacific. He brings nearly 30 years of international experience with BASF across Europe and the Americas. Prior to his current role, he served as Senior Vice President, Agricultural Solutions Latin America, based in São Paulo, and also held leadership roles within CropLife associations in Latin America.  Subroto Geed is President, Asia Pacific, at Corteva Agriscience, having previously served as the company's Head of South Asia. He brings extensive experience in business leadership, commercial strategy and operations across multiple industries and markets. Prior to joining Corteva, he held senior leadership positions across consumer healthcare, nutrition and beverages, with responsibilities spanning business growth, marketing, supply chain management and organizational development. His cross-sector experience brings a valuable perspective on business transformation, strategic partnerships and market development. Sebastià Pons is the Executive Vice President and President, FMC Eurasia, leading FMC's business across Europe, the Middle East, Africa and Asia Pacific from Geneva. He joined FMC in 2017 and most recently served as President for Europe, Middle East and Africa. Before joining FMC, he spent 20 years with DuPont Crop Protection in regional and global roles across Europe and the United States. He has also served on the Board of CropLife Europe.  Paul Luxton has served as Head of Asia at Syngenta since January 2024, overseeing the company's business across key Asian markets, including Southeast Asia, Bangladesh and Korea. He previously led Syngenta's Australia and New Zealand business, having served as Country Head since 2008. With extensive experience in agricultural business leadership and industry engagement, Paul brings a strong understanding of the opportunities and challenges facing agriculture across the region. He previously served as President of CropLife Australia and was Vice-President of CropLife Asia before assuming the presidency. “We are pleased to welcome Sergi, Subroto and Sebastià to the CropLife Asia Board. Their combined international experience and diverse perspectives will strengthen our work to advance science-based policies, responsible stewardship and agricultural innovation across Asia. We also thank our outgoing Board representatives for their contributions and look forward to working with Paul in his role as President,” said Siang Hee Tan, Executive Director of CropLife Asia.   CropLife Asia extends its sincere appreciation to Simone Barg for her leadership as President of the Board, and to Brook Cunningham and Rahoul Sawani for their contributions as Board representatives. The association thanks them for their service and commitment to its work across Asia. CropLife Asia Board of Directors The CropLife Asia Board leadership and company representatives are now as follows: Paul Luxton, Syngenta – President Malu Nachreiner, Bayer Crop Science – Treasurer Subroto Geed, Corteva Agriscience – Secretary Dai Ito, Sumitomo Chemical – Member Sergi Vizoso-Sansano, BASF Agricultural Solutions – Member Sebastià Pons, FMC – Member About CropLife Asia CropLife Asia is a non-profit society and the regional organization of CropLife International, the voice of the global plant science industry. We advocate for a safe, secure food supply, and our vision is food security enabled by innovative agriculture. CropLife Asia supports the work of 15 member associations across the continent and is led by six member companies at the forefront of crop protection, seeds and/or biotechnology research and development. For more information, visit us at www.croplifeasia.org.   For more information please contact: Cindy Lim Associate Director, Public Affairs & Strategic Partnerships CropLife Asia cindy.lim@croplifeasia.org ———————————————————————————————————————————————————————————— UNICYCIVE DEADLINE: ROSEN, LEADING TRIAL COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCY 2026-10-19 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/319876/UNICYCIVE-DEADLINE-ROSEN-LEADING-TRIAL-COUNSEL-Encourages-Unicycive-Therapeutics-Inc.-Investors-to-Secure-Counsel-Before-Important-November-2-Deadline-in-Securities-Class-Action-UNCY New York, New York--(October 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs... ———————————————————————————————————————————————————————————— Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System 2026-10-19 · PressReach · Finance, Healthcare, Food & drink, Biotech & pharma https://pressreach.com/health/haemonetics-announces-fda-approval-of-perqseal-elite-vascular-closure-system/ BOSTON, Oct. 19, 2026 — Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of the PerQseal® Elite vascular closure system for large-bore arterial procedures. The approval expands Haemonetics’ portfolio of clinically-differentiated large-bore closure devices for structural heart … Continue reading "Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System" ———————————————————————————————————————————————————————————— CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM 2026-10-19 · PressReach · Finance, Healthcare, Biotech & pharma https://pressreach.com/biotech/cumberland-pharmaceuticals-announces-national-call-to-present-an-update-on-its-ifetroban-dmd-program/ NASHVILLE, Tenn., Oct. 19, 2026 — Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announced today that it will provide an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy (“DMD”). A national … Continue reading "CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM" ———————————————————————————————————————————————————————————— Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026 2026-10-19 · PressReach · Finance, Biotech & pharma https://pressreach.com/biotech/jazz-pharmaceuticals-to-report-third-quarter-financial-results-on-november-2-2026/ DUBLIN, Oct. 19, 2026 — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 third quarter financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to discuss the results and provide a business and financial … Continue reading "Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026" ———————————————————————————————————————————————————————————— UNCY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026 2026-10-19 · Newsfile · Biotech & pharma https://www.newsfilecorp.com/release/319733/UNCY-SHAREHOLDER-NOTICE-Faruqi-Faruqi-LLP-Reminds-Unicycive-Therapeutics-UNCY-Investors-of-Securities-Class-Action-Lawsuit-Deadline-on-November-2-2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. -... ———————————————————————————————————————————————————————————— Cutting-Edge Uro-Oncology: Urology Cancer Treatments with Dr. Sanjay Gogoi 2026-10-19 · freePRnow · Healthcare, Biotech & pharma http://www.freePRnow.com/pr/cutting-edge-uro-oncology-urology-cancer-treatments-with-dr-sanjay-gogoi Dr. Sanjay Gogoi top urologist India, is deeply committed to maintaining the highest clinical standards, fostering a meaningful doctor-patient relationship and developing personalized treatment strategies tailored to the unique needs of each patient. ———————————————————————————————————————————————————————————— Innovative Trials launches global education programme as survey exposes major misconceptions about clinical trials 2026-10-19 · PRWeb · Healthcare, Education, Biotech & pharma https://www.prweb.com/releases/innovative-trials-launches-global-education-programme-as-survey-exposes-major-misconceptions-about-clinical-trials-302912283.html New research finds almost three quarters of UK adults believe they understand clinical trials, yet many misunderstand how they work. Now, Innovative Trials - a leading clinical trial patient engagement, recruitment and retention company - has launched a new global public education... ———————————————————————————————————————————————————————————— Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel 2026-10-19 · PressReach · Finance, Biotech & pharma https://pressreach.com/health/vivos-therapeutics-closes-acquisition-of-stake-in-sod-sciences-and-50-interest-in-pseudohypoxia-test-opening-a-potential-path-to-access-more-than-325000-new-patients-through-the-aha-channel/ LITTLETON, Colo., Oct. 19, 2026 — Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos” or the “Company”) today announced that it has closed its acquisition of an 11% fully diluted equity interest in SOD Sciences, Inc. (“SOD Sciences” or “SOD”) and a 50% undivided co-ownership interest in SOD's pseudohypoxia early‑warning test, the "Primed Cell for … Continue reading "Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel" ———————————————————————————————————————————————————————————— West Declares Quarterly Dividend 2026-10-19 · PressReach · Finance, Biotech & pharma https://pressreach.com/health/west-declares-quarterly-dividend/ EXTON, Pa., Oct. 19, 2026 — On October 19, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, declared a fourth-quarter dividend of $0.26 per share on the Company’s common stock, an 18% increase over the $0.22 per share paid in the prior quarter. This … Continue reading "West Declares Quarterly Dividend" ———————————————————————————————————————————————————————————— NORMA Group Provides Details on NewNORMA Strategy and Sets Financial Ambition Through 2031 2026-10-19 · NewMediaWire · Finance, SaaS, Healthcare, Real estate, Energy, Automotive, Industrial, Aerospace & defense, Logistics, Biotech & pharma, Sustainability https://www.newmediawire.com/news/norma-group-provides-details-on-newnorma-strategy-and-sets-financial-ambition-through-2031-7090736 Through 2031, NORMA Group aims to achieve average annual sales growth before currency effects of 1 to 3%, an adjusted EBIT margin of more than 10%, and cash conversion1 of over 70% Strategic business units: Mobility & New Energy to strengthen competitiveness, capacity utilization, and cash generation; Industry Applications to drive profitable growth Sales Push, Footprint optimization, and Transformation aimed at accelerating profitable growth, improving capacity utilization, and reducing structural costs Disciplined capital allocation focused on financial strength and organic growth; new dividend policy starting in fiscal year 2027 targeting a payout ratio of at least 10% of the adjusted Group Net Income; accompanied by potential share buybacks MAINTAL, GERMANY - October 19, 2026 - At its Strategy Update in Frankfurt, NORMA Group provides further details on the next steps in implementing its NewNORMA strategy and presents its financial ambition through 2031. Following the completion of major portfolio and capital measures in recent months, the focus is now shifting to operational execution. The three key initiatives to achieve profitable growth and an adjusted EBIT margin of more than 10% are Sales Push, Footprint, and Transformation. These initiatives aim to increase the utilization of NORMA Group's existing asset base through profitable business while reducing its structural cost base. In doing so, NORMA Group is laying the foundation for growth, margin improvement, and stronger cash generation. Birgit Seeger, CEO of NORMA Group: “With our NewNORMA strategy, we are laying the groundwork for a successful future for NORMA Group. We have a strong industrial foundation that we now intend to leverage even more effectively. To achieve this, we are intensifying our commercial activities, making better use of our production assets, and reducing our structural costs. This will strengthen our competitiveness, increase profitability, and improve cash generation. Our vision is a focused, high-performing NORMA Group – an Industrial Powerhouse for connecting technology.” Two strategic business units with clearly defined profiles The NewNORMA strategy is based on the realignment of the two clearly defined strategic business units, Mobility & New Energy and Industry Applications. The two business units contribute to NORMA Group's ambition with distinct value-creation priorities: Mobility & New Energy forms the Group's resilient core business. The realignment of this business unit focuses on strengthening competitiveness, improving the utilization of the existing asset base, increasing profitability, and ensuring resilient cash generation. Industry Applications is the Group's driver of profitable growth. Going forward, the business unit aims to expand selectively into structurally attractive growth markets, tap into additional sources of growth, and broaden NORMA Group's sales base. NORMA Group is leveraging its existing engineering expertise in fastening, connecting, and fluid-handling technology to develop new fields of application. These include data centers, battery energy storage systems, heat pumps, and household appliances. Additional orders will largely be served using existing production capacity, thereby improving capacity utilization and fixed-cost absorption. Starting 2027, NORMA Group will consistently align its internal management structure with the two global strategic business units. Under the new SBU-led operating model, both business units will assume end-to-end responsibility for customers, pricing, growth, capacity utilization, and financial performance. By bringing together commercial, operational, and financial responsibility under clear business ownership, NORMA Group is shortening decision-making processes and creating the conditions for faster and more effective execution of the NewNORMA strategy. More business on a more efficient operating base NORMA Group is implementing its NewNORMA strategy through three closely interconnected initiatives: As part of its Sales Push, NORMA Group is intensifying commercial execution, strengthening customer relationships, and systematically winning profitable business to improve the utilization of existing capacity. To this end, Sales and Engineering are working more closely together. The Company is leveraging proven technologies more effectively across new customers and applications and increasingly aligning pricing decisions with the market. Through target costing, required cost structures are defined even before a contract is awarded, enabling the Company to offer competitive prices while maintaining profitability. Initial successes are already visible: In the first nine months of 2026, cumulative lifetime sales won in the Mobility & New Energy business unit increased by approximately 45% compared with the prior-year period. In addition, NORMA Group is consistently aligning itself with demand, costs, manufacturing expertise, and customer requirements. In doing so, the company flexibly allocates orders across its global network. This improves plant utilization, reduces unit costs, and strengthens the company’s competitive position in new tenders. Measures already implemented or underway include the consolidation of manufacturing sites in China, the concentration of production in Mexico, and the closure of a distribution center in Australia, as well as the planned closure of the regional office in Singapore. At the same time, NORMA Group is strengthening its Shared Service Center in Novi Sad, Serbia. Another key focus is the manufacturing footprint in EMEA. The existing network, which comprises nine production sites, is currently structurally operating below capacity. NORMA Group therefore intends to consolidate production, concentrate manufacturing volumes at fewer sites, and make more targeted use of best-cost locations. By 2031, the company expects these measures to generate an additional annualized EBIT contribution of approximately EUR 20 to 30 million. In addition to generating more business and improving capacity utilization, NORMA Group is reducing its structural cost base through its transformation program. To this end, the Company is simplifying its organization, reducing complexity, standardizing and automating core processes, and strengthening performance management through clear financial KPIs. Based on the measures already initiated and the additional measures under the transformation program, as well as the EMEA footprint optimization, NORMA Group expects to achieve total additional annualized EBIT savings of approximately EUR 70 to 90 million by 2031 compared to fiscal year 2026. Financial ambition through 2031 NORMA Group aims to achieve average annual currency-adjusted net sales growth of 1 to 3% through 2031. Growth momentum is expected to increasingly come from the Industry Applications business unit, while Mobility & New Energy will contribute to the financial ambition primarily through operational improvements. The adjusted EBIT margin is targeted to exceed 10% by FY3(1). Profitable volume growth, an improved product mix, higher capacity utilization, and a lower structural cost base are expected to drive sustainable margin improvement. Improved operational profitability forms the basis for stronger cash generation. By 2031, NORMA Group aims to achieve cash conversion¹ of over 70%, supported by disciplined working capital management and capital expenditure. Okan Celiker, Group CFO: “Our financial ambition is underpinned by clear operational measures that we have already started implementing and will continue to expand systematically. We are combining profitable volume growth and an improved mix with higher capacity utilization, lower structural costs, and strict working capital and investment discipline. This is how we will improve our margins and translate operational improvements into stronger cash flows.” Disciplined capital allocation and new dividend policy NORMA Group aligns its capital allocation with strategic priorities, expected returns, and financial performance. Its highest priority is to maintain a strong and efficient balance sheet. In the medium term, NORMA Group targets a ratio of net debt to adjusted EBITDA of up to 1.5x. Within this framework, the Company prioritizes organic, profitable growth with a clear focus on increasing productivity. This includes, in particular, the continued implementation of the Sales Push and targeted investments in research and development. NORMA Group will only allocate capital where the strategic fit and expected risk-adjusted returns meet its defined value-creation criteria. The Management Board of NORMA Group has resolved to change the Company's dividend policy. Starting in fiscal year 2027, the dividend payout will target a payout ratio of at least 10% of the adjusted Group Net Income, provided that the Company's economic situation and liquidity position permit. Subject to approval by the Annual General Meeting, the dividend will be paid once a year for the preceding fiscal year. With the revised dividend policy, NORMA Group will maintain a reliable base dividend while increasing financial flexibility to invest in profitable growth and additionally carry out potential share buybacks. Share buybacks are conducted taking into account the company's financial flexibility and alternative uses of capital. The presentations from Strategy Update 2026 and further information are available on the Company's website: www.normagroup.com/global/en/investor-relations/publications-and-events/strategy-update-2026 (1) Cash conversion is defined as adjusted EBIT plus depreciation of property, plant and equipment and amortization of intangible assets, less investments from operating business, the change in trade working capital, and cash outflows from income taxes, divided by adjusted EBIT. Contact Media Christian Filipcic VP Sales Enablement IA & Group Marketing, Corporate Communications E-Mail: Christian.Filipcic@normagroup.com Tel.: +49 152 23587192 Investors Pia-Maria Görner Director Investor Relations & Corporate Responsibility E-Mail: IR@normagroup.com About NORMA Group NORMA Group is an international market leader in engineered and standardized connecting technology. With around 6,000 employees, NORMA Group supplies customers in over 100 countries with more than 40,000 product solutions. NORMA Group supports its customers and business partners in responding to global challenges such as climate change and the increasing scarcity of resources. NORMA Group’s innovative connecting solutions are used in electric and combustion vehicles, ships and aircraft, in energy and infrastructure systems, in machinery, pharma, agriculture and white goods as well as in buildings. NORMA Group generated sales of around EUR 820 million in 2025. The company has a global network of 19 production sites and numerous sales offices in Europe, North, Central and South America and the Asia-Pacific region. Its headquarters are located in Maintal near Frankfurt/Main. NORMA Group SE is listed on the Frankfurt Stock Exchange in the regulated market (Prime Standard) and is a member of the SDAX. Disclaimer This press release contains certain future-oriented statements. Future-oriented statements include all statements which do not relate to historical facts and events and contain future-oriented expressions such as “believe,” “estimate,” “assume,” “expect,” “forecast,” “intend,” “could,” or “should” or expressions of a similar kind. Such future-oriented statements are subject to risks and uncertainties since they relate to future events and are based on the company’s current assumptions, which may not in the future take place or be fulfilled as expected. The company points out that such future-oriented statements provide no guarantee for the future and that the actual events including the financial position and profitability of NORMA Group SE and developments in the economic and regulatory fundamentals may vary substantially (particularly on the down side) from those explicitly or implicitly assumed in these statements. Even if the actual results for NORMA Group SE, including its financial position and profitability and the economic and regulatory fundamentals, are in accordance with such future-oriented statements in this press release, no guarantee can be given that this will continue to be the case in the future. ———————————————————————————————————————————————————————————— Pentixapharm Highlights Growing International Evidence Supporting Phase 3 PANDA Study in Primary Aldosteronism at EANM 2026 2026-10-19 · NewMediaWire · SaaS, Healthcare, Biotech & pharma https://www.newmediawire.com/news/pentixapharm-highlights-growing-international-evidence-supporting-phase-3-panda-study-in-primary-aldosteronism-at-eanm-2026-7090735 Published research and new congress data from Europe and Asia show that Pentixafor PET can identify unilateral primary aldosteronism with high specificity, reinforcing the rationale for the Phase 3 PANDA study Multiple scientific contributions, mainly from independent academic groups in Europe and Asia, reflect strong interest in CXCR4, the biological target of Pentixapharm’s diagnostic and therapeutic programs Pentixapharm advances preparations for its pivotal U.S.-centric Phase 3 PANDA study, authorized to proceed by the FDA and designed to evaluate non-invasive subtyping to help guide the choice between surgery and medical treatment in hypertensive patients with underlying primary aldosteronism BERLIN, GERMANY - October 19, 2026 - Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), a clinical-stage biotechnology company developing radiopharmaceutical diagnostics and therapeutics, today reported that data being presented at the Annual Congress of the European Association of Nuclear Medicine (EANM 2026) in Vienna add to the growing international evidence for Pentixafor PET in primary aldosteronism, the indication of its pivotal Phase 3 PANDA study of [⁶⁸Ga]Ga-PentixaFor PET/CT. The aim is to identify, with a simple scan, the patients with one-sided disease who can benefit from surgery, and to reduce the need for adrenal vein sampling, the current standard of care and an invasive catheter procedure. “Our pivotal Phase 3 study PANDA will answer a clear question: can we use a simple imaging procedure to identify the patients who can be helped by surgery, and spare them the invasive and burdensome catheter examination required today?” said Dr. Dirk Pleimes, Chief Executive Officer of Pentixapharm. “Data from independent groups in Europe, Asia and Australia increasingly point in this direction, and our preparations for PANDA in the U.S. are in full swing. CXCR4 also remains central to our work in hemato-oncology, where we aim to combine imaging with targeted bone marrow conditioning before stem cell transplantation.” PANDA and the international evidence PANDA is designed to evaluate [⁶⁸Ga]Ga-PentixaFor PET/CT for non-invasive subtyping in adults with confirmed primary aldosteronism in a registrational setting. Primary aldosteronism is a common, underdiagnosed hormonal cause of high blood pressure. Patients with one-sided disease can benefit from surgical removal of the affected adrenal gland instead of lifelong medical therapy with mineralocorticoid receptor antagonists or aldosterone synthase inhibitors, but identifying them currently requires adrenal vein sampling. The FDA confirmed in June 2026 that the study may proceed and granted Fast Track designation for this indication in July 2026. Preparations for the study in the United States are progressing. At EANM 2026, the prospective PENTALON study from Paris (OP-048) added a French cohort to a consistent picture from independent studies on three continents. In the Monash study from Australia (Journal of Nuclear Medicine, 2026), Pentixafor PET identified one-sided disease with high specificity, was well tolerated and was preferred by almost all patients over the catheter procedure. The first stage of the CASTUS study in the Netherlands pointed in the same direction. In PENTALON, where the disease was often not visible on CT, the investigators see a clinical role for Pentixafor PET in sparing selected patients the catheter procedure and in supporting decisions on surgery. Larger datasets from China, generated independently of Pentixapharm, complete the picture. Together, these results support the approach of the Phase 3 PANDA study. Hemato-oncology: multiple myeloma and PENTHERA In multiple myeloma, investigators from CHU Nantes and collaborating French centers are scheduled to present an interim analysis of [⁶⁸Ga]Ga-PentixaFor PET/CT for initial staging and treatment-response assessment on October 21 (OP-875). The presentation contributes to the growing clinical evidence supporting CXCR4-targeted molecular imaging in hematological malignancies. These findings are particularly relevant to Pentixapharm’s broader theranostic strategy, which aims to translate CXCR4-targeted imaging into precision radiopharmaceutical treatment.Pentixapharm’s planned Phase I/II PENTHERA clinical program will investigate the combined use of PentixaFor imaging to identify CXCR4-expressing disease and [⁹⁰Y]Y-PentixaTher for targeted bone marrow conditioning prior to stem cell transplantation in patients with multiple myeloma and acute myeloid leukemia. PentixaFor and PentixaTher are investigational radiopharmaceutical candidates. Further congress information is available at https://eanm26.eanm.org/. About Pentixapharm Pentixapharm Holding AG (Frankfurt Prime Standard: PTP) is a clinical-stage biotechnology company headquartered in Berlin developing innovative nuclear medicine approaches to help physicians detect, characterize, and treat serious diseases with greater precision. The Company’s compounds are designed to deliver medical radioisotopes specifically to defined biological targets - either for high-resolution molecular imaging or for targeted radioligand therapy. Pentixapharm’s pipeline is built on CXCR4 targeting, a receptor with strong scientific validation across multiple disease areas, and encompasses diagnostic and therapeutic programs in endocrine, cardiovascular, and oncological indications. The lead program, [⁶⁸Ga]Ga-PentixaFor, is being advanced into the registrational Phase 3 PANDA study for non-invasive subtyping of primary aldosteronism. The PENTHERA program advances the CXCR4-directed theranostic platform into Phase I/II in oncology. Complementing the CXCR4 platform, Pentixapharm is also developing a next-generation antibody platform targeting CD24, an emerging immune checkpoint in difficult-to-treat cancers. Forward-looking statements This press release contains forward-looking statements based on the current beliefs, expectations and assumptions of the management of Pentixapharm Holding AG. These statements relate to future events, prospects or financial performance and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially, positively or negatively, from those expressed or implied by such forward-looking statements. Such factors include, among others, changes in general economic and business conditions, competitive pressures, the introduction of competing products, limited market acceptance of new products, services or technologies, regulatory developments and changes in business strategy. Pentixapharm Holding AG does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements are made only as of the date of this press release. All information provided in this press release is supplied without any warranty or guarantee as to its accuracy, completeness or timeliness. To the extent permitted by law, Pentixapharm Holding AG assumes no liability in connection with this press release. Pentixapharm Investor and Media Contact Robert-Rossle-StraBe 10 13125 Berlin Germany E-Mail: ir@pentixapharm.com Website: www.pentixapharm.com ———————————————————————————————————————————————————————————— CardioComm Solutions and CancerCare Manitoba Launch Remote QT/QTc Interval Monitoring Pilot for Breast Cancer Patients 2026-10-19 · Newsfile · Biotech & pharma https://www.newsfilecorp.com/release/319717/CardioComm-Solutions-and-CancerCare-Manitoba-Launch-Remote-QTQTc-Interval-Monitoring-Pilot-for-Breast-Cancer-Patients Toronto, Ontario--(October 19, 2026) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company") announces a collaboration with CancerCare Manitoba ("CCMB") on a pilot study evaluating remote electrocardiogram ("ECG") monitoring for potential QT/QTc interval prolongation after patients begin selected breast cancer drug therapies.During the approximately one-year pilot, patients will use CardioComm's HeartCheck™ CardiBeat handheld ECG monitor for scheduled home... ———————————————————————————————————————————————————————————— Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026 2026-10-19 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383889/0/en/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026.html Structure Therapeutics' poster presentations at The Obesity Society's Annual Meeting ———————————————————————————————————————————————————————————— Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors 2026-10-19 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/eloxx-pharmaceuticals-appoints-biopharmaceutical-industry-veteran-geno-germano-to-its-board-of-directors-302913021.html Mr. Germano brings more than 35 years of biopharmaceutical leadership experience, including as Group President of Pfizer's Global Innovative Pharmaceutical business Extensive public company board experience, including current service as Chairman of Entera Bio and as a director of... ———————————————————————————————————————————————————————————— Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials 2026-10-19 · GlobeNewswire · Finance, SaaS, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383875/0/en/fortrea-completes-acquisition-of-the-early-phase-services-division-from-worldwide-clinical-trials.html Expands Fortrea’s early clinical development network with dedicated bioanalytical capabilities, increased clinical research unit capacity and a more integrated platform for clients Expands Fortrea’s early clinical development network with dedicated bioanalytical capabilities, increased clinical research unit capacity and a more integrated platform for clients ———————————————————————————————————————————————————————————— Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats 2026-10-19 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383872/0/en/mineralys-therapeutics-expands-its-board-of-directors-with-the-appointments-of-kristine-peterson-and-lonnel-coats.html The addition of Ms. Peterson and Mr. Coats brings additional commercial and product launch experience to Mineralys ahead of the December 22 PDUFA target action date for lorundrostat The addition of Ms. Peterson and Mr. Coats brings additional commercial and product launch experience to Mineralys ahead of the December 22 PDUFA target action date for lorundrostat ———————————————————————————————————————————————————————————— Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026 2026-10-19 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383870/0/en/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026.html Features FORTIFY, the ongoing Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors ———————————————————————————————————————————————————————————— Artificial Intelligence in Genomics Market - Global Forecast to 2036 | Market to Reach USD 19.96 Billion at 26.5% CAGR, Fueled by Precision Medicine and AI-Driven Drug Discovery 2026-10-19 · GlobeNewswire · AI, SaaS, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383883/28124/en/artificial-intelligence-in-genomics-market-global-forecast-to-2036-market-to-reach-usd-19-96-billion-at-26-5-cagr-fueled-by-precision-medicine-and-ai-driven-drug-discovery.html Software, genome sequencing, drug discovery and cloud platforms lead adoption, while precision medicine, diagnostics and AI-enabled services create new opportunities. Software, genome sequencing, drug discovery and cloud platforms lead adoption, while precision medicine, diagnostics and AI-enabled services create new opportunities. ———————————————————————————————————————————————————————————— Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma 2026-10-19 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/delcath-systems-highlights-clinical-program-200100121.html QUEENSBURY, N.Y., October 19, 2026--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced presentations related to its clinical development programs at the European Society for Medical Oncology ( ———————————————————————————————————————————————————————————— HCA Healthcare Foundation Awards $25,000 to Waypoint to Expand the Network of Adults Supporting Youth Mental Wellness Across Virginia 2026-10-19 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383814/0/en/hca-healthcare-foundation-awards-25-000-to-waypoint-to-expand-the-network-of-adults-supporting-youth-mental-wellness-across-virginia.html Grant supports Waypoint's Therapeutic Resources team and its free Youth Mental Health First Aid and Community Resiliency Model trainings Grant supports Waypoint's Therapeutic Resources team and its free Youth Mental Health First Aid and Community Resiliency Model trainings ———————————————————————————————————————————————————————————— Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer 2026-10-19 · GlobeNewswire · Finance, Healthcare, Food & drink, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383813/0/en/jemperli-dostarlimab-approved-in-the-u-s-as-first-and-only-immunotherapy-for-adults-with-msi-h-dmmr-locally-advanced-rectal-cancer.html SAN DIEGO, Oct. 19, 2026 -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/ mismatch repair deficient (dMMR) locally advanced rectal cancer. ———————————————————————————————————————————————————————————— Robbins LLP Urges ARDX Stockholders to Contact the Firm for Information About the Securities Class Action Against Ardelyx, Inc. 2026-10-19 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383811/32719/en/robbins-llp-urges-ardx-stockholders-to-contact-the-firm-for-information-about-the-securities-class-action-against-ardelyx-inc.html Ardelyx, Inc. faces allegations that it misled investors regarding the true state of its commercial performance and growth prospects of its two core drugs. ———————————————————————————————————————————————————————————— Amedea Pharma Presents 2026 Medical Innovation Olympics Winners -- Finalists Earn San Francisco Presentations During J.P. Morgan 2027 2026-10-19 · PR Newswire · Healthcare, Sports, Biotech & pharma https://www.prnewswire.com/news-releases/amedea-pharma-presents-2026-medical-innovation-olympics-winners--finalists-earn-san-francisco-presentations-during-jp-morgan-2027-302912941.html DIAPIN Therapeutics and Adelle Diagnostics win Gold at Rockefeller Center NEW YORK, Oct. 19, 2026 -- Jessica Reed, CEO, DIAPIN Therapeutics, and Maria Grazia Ruocco, CEO/Co-Founder, Adelle Diagnostics, won PRODUCT and CONCEPT Gold at the fifth annual Medical Innovation... ———————————————————————————————————————————————————————————— Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight 2026-10-19 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383774/0/en/migraine-market-is-expected-to-expand-at-6-growth-rate-by-2036-owing-to-the-development-of-novel-mechanisms-beyond-cgrp-including-pacap-targeted-therapies-trpa1-antagonists-and-nex.html The migraine market is expected to grow steadily over the forecast period (2026–2036) driven by the rising global prevalence of migraine, improving diagnosis rates, and increasing awareness of chronic and high-frequency migraine. In addition, the introduction of novel, differentiated therapies such as Elismetrep (Kallyope), Dysport (abobotulinumtoxinA; Ipsen), Xeomin (incobotulinumtoxinA; Merz Therapeutics GmbH), Bocunebart (AG09222; Lundbeck), EVO756 (Evommune), and others that move beyond traditional acute treatments is expected to further expand the market. The migraine market is expected to grow steadily over the forecast period (2026–2036) driven by the rising global prevalence of migraine, improving diagnosis rates, and increasing awareness of chronic and high-frequency migraine. In addition, the introduction of novel, differentiated therapies such as Elismetrep (Kallyope), Dysport (abobotulinumtoxinA; Ipsen), Xeomin (incobotulinumtoxinA; Merz Therapeutics GmbH), Bocunebart (AG09222; Lundbeck), EVO756 (Evommune), and others that move beyond traditional acute treatments is expected to further expand the market. ———————————————————————————————————————————————————————————— MaaT Pharma Receives FDA Feedback Following Pre-IND Meeting Supporting Continued Development of MaaT034 in Solid Tumors 2026-10-19 · Business Wire · Healthcare, Food & drink, Industrial, Biotech & pharma https://finance.yahoo.com/healthcare/articles/maat-pharma-receives-fda-feedback-163000083.html Positive pre-Investigational New Drug (pre-IND) interaction with the Food Drug Administration (FDA) on Chemistry, Manufacturing and Controls (CMC) and nonclinical topics supports MaaT034's continued advancement FDA alignment on the IND-enabling strategy indicates that no additional non-clinical studies are anticipated to ———————————————————————————————————————————————————————————— Global Drug Delivery in Cancer Market Size, Share, and Trends Analysis - Forecast to 2036 | Market to Reach USD 141.8 Billion as ADCs, Lipid Nanoparticles, and Asia-Pacific Drive 11.6% CAGR 2026-10-19 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383732/28124/en/global-drug-delivery-in-cancer-market-size-share-and-trends-analysis-forecast-to-2036-market-to-reach-usd-141-8-billion-as-adcs-lipid-nanoparticles-and-asia-pacific-drive-11-6-cagr.html Optimize ROI by targeting antibody-drug conjugates, subcutaneous delivery and Asia-Pacific expansion, backed by segment insights and competitive benchmarking. Optimize ROI by targeting antibody-drug conjugates, subcutaneous delivery and Asia-Pacific expansion, backed by segment insights and competitive benchmarking. ———————————————————————————————————————————————————————————— Orano Med Appoints Matthew Fyfe as Chief Scientific Officer 2026-10-19 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/orano-med-appoints-matthew-fyfe-153000885.html VILLEJUIF, France, October 19, 2026--Orano Med, a subsidiary of the Orano group specializing in nuclear medicine, today announced the appointment of Matthew Fyfe as Chief Scientific Officer. Dr. Fyfe is a seasoned drug hunter with more than 25 years' experience in successful drug discovery and developm ———————————————————————————————————————————————————————————— New Global Healthy Living Foundation Report Urges States to Protect Pharmacy Vaccine Access Amid Federal Regulatory Uncertainty 2026-10-19 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/global-healthy-living-foundation-report-152200544.html State laws that make pharmacist immunization depend on federal ACIP action can reduce or restrict adults' access to vaccines at their neighborhood pharmacies. The report lays out a three-tier legal framework states can adopt now. UPPER NYACK, N.Y., October 19, 2026--As federal vaccine policy remains in ———————————————————————————————————————————————————————————— Pinion Immunotherapeutics CEO Dr. Gregory Glenn to Speak at World Vaccine Congress Europe 2026 in Amsterdam 2026-10-19 · Business Wire · AI, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/pinion-immunotherapeutics-ceo-dr-gregory-150600389.html Panel on chronic conditions and off-target effects of vaccines, and a presentation on Pinion's EBV immunotherapeutic program ROCKVILLE, Md., October 19, 2026--Pinion Immunotherapeutics, a clinical-stage biotechnology company developing AI-designed mRNA immunotherapeutics for latent viral infections and ———————————————————————————————————————————————————————————— Hippocratic AI Adds Seven Senior Executives Across Operations, Legal, Government, Pharma, Partnerships, Marketing, and Finance As Company Expands into Next Generation of Healthcare AI 2026-10-19 · Business Wire · AI, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/hippocratic-ai-adds-seven-senior-141900644.html MENLO PARK, Calif., October 19, 2026--Hippocratic AI today announced seven senior executive appointments spanning operations, legal, government solutions, pharma, global partnerships, marketing, and finance. The hires follow the company's August 13 launch of Agentic Orchestrators — teams of conversatio ———————————————————————————————————————————————————————————— Parvus Therapeutics Announces FDA Clearance of Investigational New Drug Application for PVT201 2026-10-19 · PR.com · SaaS, Healthcare, Biotech & pharma https://www.pr.com/press-release/982034 FDA Clearance of Investigational New Drug Application for PVT201, in development for the treatment of autoimmune liver disease and prevention of organ transplant rejection, is the first candidate from the Parvus nanomedicine immune tolerance platform to clear an IND. [PR.com] ———————————————————————————————————————————————————————————— Riboscience to Present First Overall Survival and Immune Activation Data from Phase 1b Study of ENPP1 Inhibitor RBS2418 as Monotherapy and in Combination in Advanced Metastatic Cancers Including MSS CRC, at ESMO 2026 2026-10-19 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/riboscience-to-present-first-overall-survival-and-immune-activation-data-from-phase-1b-study-of-enpp1-inhibitor-rbs2418-as-monotherapy-and-in-combination-in-advanced-metastatic-cancers-including-mss-crc-at-esmo-2026-302910827.html PALO ALTO, Calif., Oct. 19, 2026 -- Riboscience, a clinical-stage biotechnology company developing first-in-class immunotherapies, today announced that Phase 1b data for RBS2418, its lead oral ENPP1 inhibitor, will be presented in a poster at the European Society for Medical... ———————————————————————————————————————————————————————————— ISPE Names Sanofi S.A. the 2026 ISPE Facility of the Year Awards (FOYA) Overall Winner for its Modulus Project 2026-10-19 · PR Newswire · Industrial, Biotech & pharma https://www.prnewswire.com/news-releases/ispe-names-sanofi-sa-the-2026-ispe-facility-of-the-year-awards-foya-overall-winner-for-its-modulus-project-302912661.html Sanofi S.A. has earned ISPE's top FOYA honor for excellence and innovation in pharmaceutical facility design and manufacturing. NORTH BETHESDA, Md., Oct. 19, 2026 -- The International Society for Pharmaceutical Engineering (ISPE) has recognized Sanofi S.A. as the FOYA Overall... ———————————————————————————————————————————————————————————— Roquette Brings Broad Portfolio of Excipient Solutions and Technical Expertise to AAPS PharmSci 360 2026 2026-10-19 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/roquette-brings-broad-portfolio-excipient-140000858.html WILMINGTON, Del., October 19, 2026--Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will showcase its expansive portfolio of excipients, capsules, coatings, and biopharma solutions at AAPS PharmSci 360 2026. The conference and trade show will take place Oc ———————————————————————————————————————————————————————————— Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series 2026-10-19 · Newsfile · Finance, SaaS, Healthcare, Biotech & pharma https://www.newsfilecorp.com/release/319697/Phio-Pharmaceuticals-Announces-Participation-in-the-Renmark-Financial-Communications-Live-Virtual-NonDeal-Roadshow-Series King of Prussia, Pennsylvania--(October 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA therapeutic platform, including its lead clinical candidate PH-762 for the treatment of... ———————————————————————————————————————————————————————————— Cotecna Group Acquires Energon Labs, Strengthening Global Pharmaceutical Testing Capabilities and Expanding Its Presence in India 2026-10-19 · NewMediaWire · Finance, SaaS, Healthcare, Retail, Food & drink, Industrial, Logistics, Biotech & pharma, Sustainability https://www.newmediawire.com/news/cotecna-group-acquires-energon-labs-strengthening-global-pharmaceutical-testing-capabilities-and-expanding-its-presence-in-india-7090729 GENEVA, SWITZERLAND and HYDERABAD, INDIA - October 19, 2026 - Cotecna, a leading provider of Testing, Inspection and Certification (TIC) services, today announced the acquisition of Energon Labs, a cGMP-compliant, USFDA-inspected, ISO 9001:2015 and ISO 17025:2017 certified analytical testing laboratory based in Hyderabad, India. The acquisition strengthens Cotecna's global Life Sciences platform and expands its pharmaceutical testing capabilities across the Pharmaceutical, Biopharmaceutical, Medical Device and Packaging sectors. Serving customers across India, the United States, Asia-Pacific, and the Middle East, Energon is recognized for its scientific excellence, regulatory expertise and commitment to quality. Strategically located in Hyderabad, one of the world's leading pharmaceutical and biotechnology hubs, Energon provides Cotecna with access to highly specialized scientific talent, advanced laboratory infrastructure and a well-established pharmaceutical ecosystem. India is also one of the world's fastest-growing pharmaceutical markets and a critical manufacturing hub for global healthcare supply chains. The acquisition enhances the Cotecna's ability to support both Indian and international  customers with high-quality, regulatory-compliant testing services while delivering greater responsiveness, scalability and operational efficiency across key markets. The addition of Energon further complements Cotecna's growing pharmaceutical testing network which includes Cotecna Life Sciences, Shiva Analyticals and Neotron Pharma. Together, this capabilities strengthen the Group's ability to support customers throughout the product lifecycle and address evolving global quality, compliance and regulatory requirements. Energon offers a comprehensive portfolio of analytical testing and quality assurance services, including analytical method development and validation, stability studies, impurity profiling, extractables and leachables, glass delamination studies, peptides and oligonucleotide characterisation, raw material and finished product testing, in-vitro binding studies, packaging compatibility studies, and regulatory support services. These capabilities will further strengthen Cotecna's position as a trusted partner to pharmaceutical manufacturers serving regulated markets worldwide. Sebastien Dannaud, Chief Executive Officer of Cotecna Group, commented: “We are pleased to welcome Energon Labs to the Cotecna Group. This acquisition represents another important step to support our ambition to become one of the largest providers of Life Sciences testing services in India, and strengthens our position in one of the world's most important pharmaceutical markets.” Amit Chopra, CEO South Asia and Middle East, Cotecna Group, added: "I am delighted to welcome Manikanth Reddy and the talented team of Energon Labs to the Cotecna group. This acquisition aligns perfectly with our strategy of building a comprehensive pharmaceutical testing ecosystem across key growth markets. Energon's strong technical capabilities, experienced team and established customer relationships will enhance our ability to serve pharmaceutical, biopharmaceutical and medical device companies across India and globally. Together, we are creating a stronger platform to support the evolving needs of the pharmaceutical and healthcare sectors. " Manikanth Reddy, Founder, Energon, said: "Joining the Cotecna Group opens an exciting new chapter for Energon Labs. Over the years, we have focused on building a laboratory recognized for quality, scientific expertise and reliability. Becoming part of a global organization like Cotecna provides new opportunities to expand our capabilities, strengthen our service offerings and deliver even greater value to our customers. Our team remains committed to maintaining the highest standards of analytical excellence while supporting the continued growth of the life sciences industry.” About Energon Labs Energon Labs is a cGMP-compliant, USFDA-inspected, ISO 9001:2015 and ISO 17025:2017 certified analytical testing laboratory located in Hyderabad, India. The company provides comprehensive analytical testing, quality assurance and regulatory support services to pharmaceutical, biopharmaceutical, medical device and packaging industries, serving customers across India, the United States, Asia Pacific and the Middle East. About Cotecna Founded in Switzerland in 1974, Cotecna is a leading provider of Testing, Inspection and Certification services. With operations in more than 55 countries, Cotecna helps clients ensure quality, safety, compliance and sustainability across global supply chains. The Group serves customers across agriculture and food, pharmaceuticals, minerals and metals, consumer products, certification and ESG services through a worldwide network of experts, laboratories and technical specialists. ———————————————————————————————————————————————————————————— Phase 3 trial in China successfully confirms ACARIZAX® safety and efficacy in patients with house dust mite allergy 2026-10-19 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383521/0/en/phase-3-trial-in-china-successfully-confirms-acarizax-safety-and-efficacy-in-patients-with-house-dust-mite-allergy.html Inside Information ———————————————————————————————————————————————————————————— Afreximbank and partners advance Africa’s automotive investment agenda at Alamein Africa Forum 2026-10-19 · APO Group · SaaS, Energy, Automotive, Media, Food & drink, Industrial, Logistics, Biotech & pharma https://afreximbank.africa-newsroom.com/press/afreximbank-and-partners-advance-africas-automotive-investment-agenda-at-alamein-africa-forum?lang=en African Export-Import Bank (Afreximbank) (www.Afreximbank.com), in partnership with the African Association of Automotive Manufacturers (AAAM), the African Continental Free Trade Area (AfCFTA) Secretariat, the Ministry of Trade and Investment of Egypt, and the Department of Trade and Industry of South Africa, hosted the Africa Automotive Investment Forum on the sidelines of the Alamein Africa Forum held in El Alamein, Egypt recently. The two-day Forum brought together high-level African automotive industry policymakers, private sector original equipment manufacturers (OEMs) and Africa-based component manufacturers. The Forum sought to sensitise policymakers on the policy changes and reforms needed to develop the automotive sector, enable investors to engage directly with both policymakers and manufacturers, and facilitate potential joint ventures and supply agreements or engagements leading to future deals. Afreximbank noted that the Forum prioritised joint ventures and technology transfer agreements between global auto giants and African enterprises with the expectation of creating highly skilled engineering, manufacturing and technical jobs for Africa's growing youth demographic while significantly boosting local small and medium enterprises within the secondary supply tier. It described the automotive sector as a strategic priority because it serves as a powerful catalyst for Africa’s industrialisation, intra-African trade and economic resilience, noting that several African countries were already making important strides in the development of a manufacturing sector that had attracted increasing investment into the emerging auto industry, including new energy vehicles. Highlighting the significance of the Forum for Afreximbank, Mrs. Kanayo Awani, Executive Vice President, Intra-African Trade and Export Development, said: “The automotive sector is a critical pillar for advancing Africa’s industrialisation and achieving the structural transformation championed by Afreximbank. By driving regional value chain integration, the automotive industry directly aligns with our mandate to foster intra-African trade under the AfCFTA framework. Supporting this sector allows Afreximbank to catalyse high-impact investments, stimulate manufacturing capabilities, create skilled employment, and significantly reduce the continent's heavy reliance on vehicle imports. Investing in the African automotive ecosystem is not merely a financing opportunity, but a strategic imperative that accelerates economic diversification and establishes Africa as a competitive player in the global industrial economy.” Mrs. Awani said that significant investment opportunities existed in Africa’s automotive manufacturing sector, including component manufacturing, leveraging the continent’s growing skills base and raw materials such as lithium, cobalt, manganese, nickel, copper, iron and steel. She added that Afreximbank was championing the development of a pan-African automotive manufacturing sector comprising an interrelated component and vehicle manufacturing ecosystem, supported by intra-African supply chains and trade. Mrs. Awani noted that Afreximbank had committed US$1 billion towards financing Africa’s automotive sector as part of its strategy to promote manufacturing, trade and industrial development across Africa. The Forum witnessed the signing of a joint venture agreement between Malben Engineering from South Africa and Egypt-based industrial conglomerate El Araby Group to establish a joint platform for manufacturing components serving Egyptian, South African and broader African markets. The undertaking combines El Araby Group’s industrial, engineering, and technological capabilities with Malben Engineering’s experience spanning over 50 years in manufacturing and forming metal automotive components.  The joint venture illustrates the type of commercial partnership that will spur development of intra-African automotive supply chains and trade. Mr. Tarek Mosaad, President of the African Association of Automotive Manufacturers (AAAM) said: “with the AfCFTA Rules of Origin now agreed, the foundation for a more integrated automotive industry is in place. Our focus must shift to turning ambition into action by creating factories, strengthening supplier ecosystems, generating jobs, and increasing intra-African trade.” He noted that “AAAM remains focused on three key priorities: Growing local content through regional value chains Making it easier to move automotive products across borders Ensuring Africa plays a meaningful role in shaping the future of mobility| In his call to action, he cautioned that “investors are not looking at 54 separate African markets. They are looking at one integrated opportunity.” H.E. Wamkele Mene, Secretary-General of the AfCFTA Secretariat, echoed the sentiments expressed by Afreximbank and AAAM and outlined three priorities for advancing the Strategy for the African Automotive Sector under the AfCFTA framework, namely: “developing investment-ready projects and competitive production locations; strengthening regional supplier networks and deepening localisation; and establishing commercially viable regional production.” In a further step towards advancing these priorities, the AfCFTA Secretariat and the African Association of Automotive Manufacturers (AAAM) signed a Memorandum of Understanding (MoU) to strengthen cooperation in developing Africa's automotive industry. The MoU provides a framework for cooperation in implementing the Strategy for the African Automotive Sector under the AfCFTA, covering automotive Rules of Origin, customs procedures and trade facilitation, automotive policy and standards, capacity building, regional supplier and value-chain development, mineral beneficiation, investment mobilisation and emerging automotive technologies. The partnership will also support ongoing efforts by the AfCFTA Secretariat and Afreximbank to advance the AfCFTA Automotive Investment Plan, with a focus on mobilising investment and strengthening competitive regional automotive production networks. The Forum also witnessed the establishment of a joint Egypt-South Africa Business Council designed to develop bilateral trade and investment projects across various priority sectors that include automotive, mining and mineral resources, renewable energy, agriculture and food production, pharmaceuticals, transport and logistics infrastructure – leveraging the Suez Canal and national ports in both countries to facilitate increased trade between northern and southern Africa. For a more practical experience, delegates moved from policy discussion to industry exposure through curated site visits to OEMs Nissan Motor Corporation, General Motors Egypt, Al Mansour Automotive and components manufacturer Mobica in 6th of October City. The visits offered a first-hand view of Egypt’s automotive industrial base, showcasing the progression from vehicle assembly and localisation to supplier development, manufacturing capabilities and regional market reach, while illustrating the tangible opportunities for investment, technology transfer and cross-border value-chain integration that can help position Africa as a competitive automotive manufacturing hub. With African vehicle demand expected to reach 5 million by 2035 as well as rising interest in new energy vehicles globally, industry stakeholders and policymakers are seeing opportunities to drive domestic industrialisation through the automotive sector and renewables, leveraging African raw materials. Forum participants emphasised that the policy incentives must be right and that the provision of affordable financing will help drive demand and capital investments. Distributed by APO Group on behalf of Afreximbank. Media Contact: Vincent Musumba press@afreximbank.com Alexandre Siewe Alexandre.Siewe@au-afcfta.org    AAAM coms@aaamafrica.com  Follow Afreximbank on: https://apo-opa.co/3Wj3OCh https://apo-opa.co/4i4FpHR https://apo-opa.co/4seRkHO https://apo-opa.co/47scZmq About Afreximbank:  For more information, visit: www.Afreximbank.com About AfCFTA:  For more information, visit: AU-AfCFTA.org   About AAAM:  AAAM’s mission is to create sustainable and affordable mobility solutions, facilitate strategic linkages and partnerships, and develop regional automotive value chains that promote production and trade within and beyond the African Continental Free Trade Area (AfCFTA). AAAM is also committed to championing access to affordable financing for both the automotive industry and consumers.  Today, AAAM proudly represents a network of more than 70 members spanning the continent, working together to shape Africa’s automotive future.  For more information visit https://AAAMAfrica.com/ ———————————————————————————————————————————————————————————— BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter 2026-10-19 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383509/0/en/biocardia-announces-fda-acceptance-of-de-novo-pre-submission-package-for-helix-catheter-marketing-clearance-fda-substantive-review-and-meeting-expected-this-quarter.html SUNNYVALE, Calif., Oct. 19, 2026 -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted its pre-submission package for marketing clearance of its Helix catheter (“Helix”) intended for therapeutic and diagnostic agent delivery. ———————————————————————————————————————————————————————————— Lirio Drives 20%+ Boost in Vaccination Uptake Across Millions of Patients with Behavioral Science-Backed Patient Engagement 2026-10-19 · Business Wire · AI, SaaS, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/lirio-drives-20-boost-vaccination-130000478.html Personalized outreach across five vaccine types cut unsubscribe rates 62%, with nearly half of vaccinated patients acting after just two nudges KNOXVILLE, Tenn., October 19, 2026--Lirio , the first-ever behavioral science and AI-powered behavioral intelligence platform that empowers people to live the ———————————————————————————————————————————————————————————— Bio Decontamination Market Growth, Share & Trends by 2034 2026-10-19 · PR News Releaser · Biotech & pharma https://www.prnewsreleaser.com/news/474480 The Bio Decontamination Market is expanding as healthcare facilities, pharmaceutical manufacturers, biotechnology companies, and research laboratories increasingly prioritize contamination control and sterile operating environments. Bio decontamination involves the use of specialized technologies and chemical agents to eliminate or reduce biological ... Read more ———————————————————————————————————————————————————————————— TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026 2026-10-19 · PR Newswire · Finance, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/transcode-therapeutics-to-present-phase-1a-clinical-trial-data-for-ttx-mc138-at-esmo-congress-2026-302911592.html Poster presentation to highlight the Phase 1a clinical evaluation of TTX-MC138 in patients with advanced solid tumors BOSTON, Oct. 19, 2026 -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the... ———————————————————————————————————————————————————————————— ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer 2026-10-19 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383400/0/en/arrivent-announces-cancer-cell-publication-highlighting-firmonertinib-in-egfr-pacc-mutant-non-small-cell-lung-cancer.html NEWTOWN SQUARE, Pa., Oct. 19, 2026 -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the publication of FURTHER Phase 1b (FURMO-002; NCT05364073) results of firmonertinib in Cancer Cell, highlighting the preclinical and clinical findings supporting its potential, if approved, as the first oral, chemotherapy-free targeted therapy for treatment-naïve patients with advanced EGFR PACC-mutant non-small cell lung cancer (NSCLC). ———————————————————————————————————————————————————————————— Telescope Innovations to Participate in the Canadian Delegation to BIOPLUS-INTERPHEX Korea (BIX) 2026 2026-10-19 · Newsfile · AI, Biotech & pharma https://www.newsfilecorp.com/release/319591/Telescope-Innovations-to-Participate-in-the-Canadian-Delegation-to-BIOPLUSINTERPHEX-Korea-BIX-2026 Vancouver, British Columbia--(October 19, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a leading developer of Physical AI systems, including Self-Driving Laboratories ("SDL"), enabling technologies, and services for the global pharmaceutical and high-value chemical industries, today announced that it has been chosen to join the Canadian business delegation to BIOPLUS-INTERPHEX Korea ("BIX"), taking place October 27-30,... ———————————————————————————————————————————————————————————— Ambassador Han Jing Calls on Honourable (Hon.) Professor (Prof.) Roma Chilengi, Minister of Health of Zambia 2026-10-19 · APO Group · Healthcare, Biotech & pharma https://www.africa-newsroom.com/press/ambassador-han-jing-calls-on-honourable-hon-professor-prof-roma-chilengi-minister-of-health-of-zambia?lang=en On October 19, 2026, Ambassador Han Jing paid a courtesy call on Hon. Prof. Roma Chilengi, Minister of Health of Zambia. Ambassador Han congratulated Prof. Chilengi on his appointment and said that, under the strategic guidance of the two Heads of State, China-Zambia comprehensive strategic and cooperative partnership has continued to grow. China attaches great importance to health cooperation and stands ready to strengthen communication and coordination with the Zambian side, deepen cooperation in medical team dispatches, pharmaceutical supplies assistance, health infrastructure development, and continue to improve the health and well-being of the Zambian people. Prof. Chilengi thanked China for its long-standing support for Zambia’s health sector, noting that Zambia values its traditional friendship with China and looks forward to further deepening bilateral cooperation in health and achieving more tangible outcomes. Distributed by APO Group on behalf of Embassy of the People's Republic of China in the Republic of Zambia. ———————————————————————————————————————————————————————————— OncoC4 Announces NMPA Acceptance of Two IND Applications for Cesalatamig Combination Studies with ADCs and Pan-RAS Inhibitors 2026-10-19 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/oncoc4-announces-nmpa-acceptance-of-two-ind-applications-for-cesalatamig-combination-studies-with-adcs-and-pan-ras-inhibitors-302911871.html — New Studies Expand Cesalatamig into Biomarker-driven Precision Immuno-oncology Strategies — Cesalatamig is Also Being Evaluated in Ongoing Phase 2 Studies in the United States and in China ROCKVILLE, Md. , Oct. 19, 2026 -- OncoC4 Inc., a late clinical-stage... ———————————————————————————————————————————————————————————— ZAP Surgical Secures $36 Million Led by Catalio Capital Management to Scale Non-Invasive Brain Surgery 2026-10-19 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/zap-surgical-secures-36-million-111500164.html The Investment underscores ZAP's momentum in neuro-oncology and emerging neuropsychiatric applications SAN CARLOS, Calif., October 19, 2026--ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced it has secured $36 million in financing led by Catalio Capital ———————————————————————————————————————————————————————————— Protego Announces FDA IND Clearance for Phase 2/3 Study of PROT-001 in AL Amyloidosis 2026-10-19 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/protego-announces-fda-ind-clearance-for-phase-23-study-of-prot-001-in-al-amyloidosis-302912132.html - Clearance enables initiation of SHIELD-AL, a pivotal study in newly diagnosed patients with lambda AL amyloidosis - Investigational oral light chain stabilizer to be evaluated as an add-on to standard-of-care plasma cell-directed therapy SAN DIEGO, Oct. 19, 2026 -- Protego... ———————————————————————————————————————————————————————————— Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma 2026-10-19 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/xencor-host-webcast-discuss-results-110100971.html PASADENA, Calif., October 19, 2026--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a webcast on Monday, October 26 at 7:00 a.m. EDT (4:00 a.m. PDT) to discuss results from the Phase 1 ———————————————————————————————————————————————————————————— Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan 2026-10-19 · PR Newswire · Finance, Biotech & pharma https://www.prnewswire.com/news-releases/insmed-launches-brinsupri-tablets-25-mg-brensocatib-hydrate-for-the-treatment-of-non-cystic-fibrosis-bronchiectasis-in-japan-302911560.html —BRINSUPRI, a First-in-Disease and First-in-Class Treatment for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), Is Now Available by Prescription in Japan— BRIDGEWATER, N.J., Oct. 19, 2026 -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical... ———————————————————————————————————————————————————————————— Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP) 2026-10-19 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383263/0/en/disc-medicine-announces-success-on-all-primary-and-secondary-endpoints-in-the-pivotal-phase-3-apollo-trial-of-bitopertin-in-adults-and-adolescents-with-erythropoietic-protoporphyri.html WATERTOWN, Mass., Oct. 19, 2026 -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP). The trial met all its primary and secondary endpoints. ———————————————————————————————————————————————————————————— Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM 2026-10-19 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383261/0/en/lexeo-therapeutics-to-host-educational-event-focused-on-clinical-endpoints-and-outcome-measures-in-pkp2-acm.html Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM ———————————————————————————————————————————————————————————— Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer 2026-10-19 · GlobeNewswire · SaaS, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383260/0/en/marker-therapeutics-awarded-2-6-million-fda-orphan-products-development-grant-to-advance-mt-601-in-pancreatic-cancer.html Competitive selection reinforces independent recognition of the scientific rationale and development potential of Marker’s multi-antigen recognizing T cell platform Competitive selection reinforces independent recognition of the scientific rationale and development potential of Marker’s multi-antigen recognizing T cell platform ———————————————————————————————————————————————————————————— EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD 2026-10-19 · GlobeNewswire · Healthcare, Biotech & pharma, Semiconductors https://www.globenewswire.com/news-release/2026/10/19/3383257/0/en/eyepoint-announces-topline-results-from-lucia-the-second-pivotal-phase-3-clinical-trial-of-duravyu-in-wet-amd.html EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYUTM in Wet AMD ———————————————————————————————————————————————————————————— Frontier Medicines to Present First Clinical Data for FMC-376, an Equipotent KRAS G12C ON+OFF Inhibitor, at ESMO Congress 2026 2026-10-19 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/frontier-medicines-present-first-clinical-110000158.html BOSTON & SOUTH SAN FRANCISCO, Calif., October 19, 2026--Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced the company will pr ———————————————————————————————————————————————————————————— Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases 2026-10-19 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/zipalertinib-demonstrates-clinically-meaningful-intracranial-110000252.html Intracranial Objective Response Rate of 30.2% was observed in 43 evaluable patients Results to be shared in poster presentation at ESMO Congress 2026 PRINCETON, N.J. & CAMBRIDGE, Mass., October 19, 2026--Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Co ———————————————————————————————————————————————————————————— United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD 2026-10-19 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/united-therapeutics-announces-fda-clearance-110000554.html The development of a soft mist inhaler ( SMI ) represents a further advancement of treprostinil delivery devices to potentially address a wider range of patient tolerability profiles A soft mist formulation may be beneficial for patients with pulmonary hypertension associated with chronic obstructive pulmonary disease ( P ———————————————————————————————————————————————————————————— Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma 2026-10-19 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/summit-therapeutics-announces-opening-global-110000235.html SMT112-216 Is a Randomized Multiregional Phase II Study Evaluating Ivonescimab Alone and in Combination with Cadonilimab or Ipilimumab in Previously Untreated Advanced ccRCC Study Is Being Conducted in Collaboration with Summit's Partner Akeso, with Clinical Trial Sites in the U.S. and China MIAMI, October 19, 2026 --( BU ———————————————————————————————————————————————————————————— TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, a Potential First-in-Class Treatment for Migraine 2026-10-19 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/trigemx-bio-tcgx-acquisition-corp-110000534.html Transaction Includes Concurrent $160 million Private Investment in Public Equity (PIPE) Financing and Expected Gross Proceeds of Approximately $246 million NEW YORK & PALO ALTO, Calif., October 19, 2026--TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class t ———————————————————————————————————————————————————————————— Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss 2026-10-19 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/veradermics-oral-vdphl01-achieved-early-110000656.html VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01 VDPHL01 demonstrated increases in target area hair count (TAHC) of ———————————————————————————————————————————————————————————— AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib 2026-10-19 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/astrazeneca-present-overall-survival-data-110000626.html CLARITY-Gastric01 data will demonstrate potential of Sone-Ve to establish new treatment for broad population of CLDN18.2-positive gastric cancer patients SAFFRON results will highlight clinical benefit of adding savolitinib to backbone TAGRISSO in MET-driven 2nd-line EGFRm lung cancer VOLGA and DeLLphi-305 data will showc ———————————————————————————————————————————————————————————— Condition monitoring prevents six hours of downtime and saves 288,000 bottles 2026-10-19 · Express Press Release · Healthcare, Food & drink, Biotech & pharma https://express-press-release.net/news/2026/10/19/1774558 KOLDING, Denmark, 2026-10-19 — Unplanned downtime remains one of the biggest hidden costs in food, beverage, dairy, pharma and other hygienic industries. [read full press release...] ———————————————————————————————————————————————————————————— Antibody Drug Conjugates Market size to reach US$ 67.51 Billion by 2033 2026-10-19 · PR News Releaser · Biotech & pharma https://www.prnewsreleaser.com/news/474274 The Antibody Drug Conjugates Market is covered by Business Market Insights with 2025 as the base year and 2026–2033 as the forecast period. The Antibody Drug Conjugates Market size was valued at US$ 21.27 Billion in 2025 and is projected ... Read more ———————————————————————————————————————————————————————————— United States Smart Pills Market - Size, Share, Trends, and Forecast 2026-2034 | AI-Enabled Diagnostics and Drug Delivery Fuel 11.66% CAGR to $4.61 Billion 2026-10-19 · GlobeNewswire · AI, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383182/28124/en/united-states-smart-pills-market-size-share-trends-and-forecast-2026-2034-ai-enabled-diagnostics-and-drug-delivery-fuel-11-66-cagr-to-4-61-billion.html Dublin, Oct. 19, 2026 -- "United States Smart Pills Market - Drug Delivery Innovation & Forecast 2026-2034" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma 2026-10-19 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/ideaya-biosciences-and-servier-announce-data-from-three-clinical-trials-at-esmo-2026-supporting-the-potential-of-darovasertib-to-become-a-foundational-new-therapy-for-patients-across-the-treatment-journey-of-uveal-melanoma-302911853.html OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical benefits for patients with metastatic uveal melanoma, irrespective of HLA-A*02:01 allele status or line of therapy OptimUM-01 data demonstrates encouraging clinical... ———————————————————————————————————————————————————————————— Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma 2026-10-19 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383146/0/en/zymeworks-appoints-suzanne-monahan-as-senior-vice-president-commercial-and-general-manager-theravance-biopharma.html VANCOUVER, British Columbia , Oct. 19, 2026 -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that Suzanne Monahan has been appointed Senior Vice President, Commercial and General Manager, Theravance Biopharma, effective immediately. Reporting directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks, Ms. Monahan will lead Zymeworks’ commercial strategy and execution for YUPELRI® (revefenacin), the first and only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for the maintenance treatment of chronic obstructive pulmonary disease (COPD), following the Company’s recent acquisition of Theravance Biopharma. ———————————————————————————————————————————————————————————— TLC590 Achieves Statistically Significant Reductions in Pain and Opioid Use Versus Both Placebo and Liposomal Bupivacaine in Pivotal Phase 3 Trial 2026-10-19 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383135/0/en/tlc590-achieves-statistically-significant-reductions-in-pain-and-opioid-use-versus-both-placebo-and-liposomal-bupivacaine-in-pivotal-phase-3-trial.html TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 -- TLC BioSciences Corp. (TPEx: TLC-KY; ticker: 7924; “TLC”) today announced positive topline results from its pivotal Phase 3 trial of TLC590, an investigational extended-release formulation of ropivacaine, for the management of postsurgical pain following bunionectomy. The trial met its primary endpoint, with TLC590 significantly reducing pain intensity through 72 hours after surgery compared with placebo (p=0.0024); rescue opioid consumption was also significantly lower. In a head-to-head comparison with liposomal bupivacaine, an approved long-acting local anesthetic, TLC590 also demonstrated statistically significant superiority in both pain intensity and rescue opioid consumption. The analgesic benefit of TLC590 over both comparators was maintained through 168 hours. These results support the potential of TLC590 as a single-dose, non-opioid option for durable postsurgical pain relief with reduced opioid use. ———————————————————————————————————————————————————————————— Belite Bio Announces Uplisting to the Nasdaq Global Select Market 2026-10-19 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383134/0/en/belite-bio-announces-uplisting-to-the-nasdaq-global-select-market.html SAN DIEGO, Oct. 19, 2026 -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has received approval from Nasdaq to transfer the listing of its securities from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the Nasdaq Global Select Market will commence at the open of market on October 19, 2026, under the Company’s existing ticker symbol “BLTE.” ———————————————————————————————————————————————————————————— BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026 2026-10-19 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/beone-medicines-highlights-rapidly-accelerating-100000109.html New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne's solid tumor pipeline Multiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data ———————————————————————————————————————————————————————————— AHF Blasts PhRMA for Attacks On, and Noncompliance with 340B Program 2026-10-19 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/ahf-blasts-phrma-attacks-noncompliance-100000846.html HRSA review finds 4 out of 5 drugmakers out of compliance with mandatory discount drug pricing WASHINGTON, October 19, 2026--In response to news in the 340B Report last week that was highly critical of the drug industry's noncompliance with compulsory elements of the 340B drug pricing program, AIDS Hea ———————————————————————————————————————————————————————————— Live Vaccines Market Size, Growth & Demand by 2034 2026-10-19 · PR News Releaser · Biotech & pharma https://www.prnewsreleaser.com/news/474134 According to The Insight Partners, the Live Vaccines Market size is expected to reach US$ 41.14 billion by 2034 from US$ 18.31 billion in 2025, registering a CAGR of 9.41% during 2026–2034. The global Live Vaccines Market is experiencing significant ... Read more ———————————————————————————————————————————————————————————— Cell Line Development Market - Global Forecast 2026-2032 | AI, Automation, and Biologics Demand Drive 10.02% CAGR, Creating a USD 23.24 Billion Opportunity by 2032 2026-10-19 · GlobeNewswire · AI, SaaS, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383070/28124/en/cell-line-development-market-global-forecast-2026-2032-ai-automation-and-biologics-demand-drive-10-02-cagr-creating-a-usd-23-24-billion-opportunity-by-2032.html Boost ROI through platform standardization, AI-ready automation, early quality assessment, scalable workflows and strategic CDMO partnerships that cut rework and speed development Boost ROI through platform standardization, AI-ready automation, early quality assessment, scalable workflows and strategic CDMO partnerships that cut rework and speed development ———————————————————————————————————————————————————————————— Vaccines Market Analysis Set to Reach US$ 118.94 Billion by 2031 2026-10-19 · PR News Releaser · Biotech & pharma https://www.prnewsreleaser.com/news/474119 The Global Vaccines Market is experiencing steady growth, driven by increasing immunization initiatives, rising awareness of preventable diseases, and continued investment in vaccine research and development. Vaccines play a critical role in preventing infectious diseases, reducing healthcare burdens, and supporting ... Read more ———————————————————————————————————————————————————————————— Aquaculture Vaccines Market Size, Growth Trends, Key Drivers, and Future Outlook Through 2031 2026-10-19 · PR News Releaser · Biotech & pharma https://www.prnewsreleaser.com/news/474111 The global aquaculture vaccines market is experiencing notable growth, supported by increasing demand for effective disease prevention solutions in aquaculture. The market size is projected to reach US$ 0.82 billion by 2031, increasing from US$ 0.31 billion in 2023. This ... Read more ———————————————————————————————————————————————————————————— Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis 2026-10-19 · Eli Lilly and Company · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/lillys-omvoh-mirikizumab-mrkz-meets-primary-endpoint-of-clinical-remission-and-is-the-first-il-23p19-inhibitor-to-report-one-year-phase-3-results-in-pediatric-ulcerative-colitis-302911320.html Building on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label... ———————————————————————————————————————————————————————————— Sensorion Announces the Appointment of Peter Weber, MD, MBA, as Chief Medical Officer 2026-10-19 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/sensorion-announces-appointment-peter-weber-082800942.html Dr. Weber, an otologist and neurotologist who led the clinical development of the first FDA-approved gene therapy for genetic hearing loss, joins as SENS-601 advances into the clinic MONTPELLIER, France & CAMBRIDGE, Mass., October 19, 2026--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) ("the Compan ———————————————————————————————————————————————————————————— AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease 2026-10-19 · AbbVie · Biotech & pharma https://www.prnewswire.com/news-releases/abbvie-presents-data-for-abbv-466-a-novel-dual-targeting-therapy-demonstrating-higher-endoscopic-remission-rates-than-either-anti-il-23-or-anti-47-monotherapy-in-moderate-to-severe-crohns-disease-302911816.html In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7... ———————————————————————————————————————————————————————————— Kaplan Fox Encourages Unicycive Therapeutics, Inc. (UNCY) Investors Seeking Recovery to Contact the Firm Before November 2, 2026 2026-10-19 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/319642/Kaplan-Fox-Encourages-Unicycive-Therapeutics-Inc.-UNCY-Investors-Seeking-Recovery-to-Contact-the-Firm-Before-November-2-2026 New York, New York--(October 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) on behalf of investors that purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Unicycive and have suffered losses, you may CLICK HERE to contact us. You may... ———————————————————————————————————————————————————————————— Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform 2026-10-19 · Newsfile · SaaS, Biotech & pharma https://www.newsfilecorp.com/release/319586/Defence-Therapeutics-Wins-Best-Poster-Award-and-Takes-Center-Stage-at-World-ADC-San-Diego-2026-a-Key-Recognition-in-the-Field-Highlighting-the-Potential-of-Its-Accum-Platform Montreal, Quebec--(October 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® drug-delivery platform, is pleased to announce two significant achievements at World ADC San Diego 2026, held October 12-15: winning the conference's Best Poster Award for its Accum®-ADC research and leading a main-stage... ———————————————————————————————————————————————————————————— Pharmaceutical E-commerce Market Set to Reach US$ 644.61 Billion by 2034 2026-10-19 · PR News Releaser · Retail, Biotech & pharma https://www.prnewsreleaser.com/news/473938 The pharmaceutical e-commerce market is transforming how consumers access prescription medications, over-the-counter (OTC) drugs, and other healthcare products. Online pharmacies and digital healthcare platforms provide convenient ordering, home delivery, prescription management, and access to medication information. The growing adoption of ... Read more ———————————————————————————————————————————————————————————— Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 2026-10-19 · GlobeNewswire · Finance, AI, SaaS, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3383014/0/en/evaxion-reports-sustained-clinical-responses-for-all-patients-at-three-year-follow-up-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01.html COPENHAGEN, Denmark, October 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new three-year clinical outcome data for personalized cancer vaccine EVX-01 in patients with advanced melanoma. ———————————————————————————————————————————————————————————— WuXi Biologics at Festival of Biologics Basel 2026: Turning Scientific Complexity into Commercial Certainty 2026-10-19 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/wuxi-biologics-at-festival-of-biologics-basel-2026-turning-scientific-complexity-into-commercial-certainty-302912371.html BASEL, Switzerland, Oct. 19, 2026 -- More than 3,000 industry professionals gathered at Festival of Biologics Basel 2026 to exchange insights on the future of biologics. Extending this industry conversation, WuXi Biologics hosted its 3rd annual Basel CRDMO+ Day, convening... ———————————————————————————————————————————————————————————— Active Pharmaceutical Ingredient Market to Reach US$ 481.7 Billion by 2033 2026-10-19 · PR News Releaser · SaaS, Biotech & pharma https://www.prnewsreleaser.com/news/473792 The Active Pharmaceutical Ingredient (API) Market size was valued at US$ 255.78 billion in 2025 and is projected to reach US$ 481.7 billion by 2033, registering a CAGR of 8.23% from 2026 to 2033. Rising demand for generic medicines, expansion ... Read more ———————————————————————————————————————————————————————————— Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease 2026-10-19 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3382993/0/en/oculis-completes-randomization-in-predict-1-registrational-trial-of-licaminlimab-for-tnfr1-mediated-dry-eye-disease.html High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials ———————————————————————————————————————————————————————————— Nouscom Raises €120 Million ($135 Million) in Oversubscribed Series D Financing and will Present Long-Term Cancer Interception Clinical Data in Lynch Syndrome Carriers at ESMO 2026-10-19 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3382989/0/en/nouscom-raises-120-million-135-million-in-oversubscribed-series-d-financing-and-will-present-long-term-cancer-interception-clinical-data-in-lynch-syndrome-carriers-at-esmo.html BASEL, Switzerland – October 19, 2026 – Nouscom, a clinical-stage, cancer interception focused biotech developing next-generation immunotherapies, today announced the closing of an oversubscribed €120 million ($135 million) Series D financing. The round was co-led by M Ventures and Revelation Partners alongside new investors Angelini Industries (through Angelini Investments), the European Investment Bank (through Aurea, its co-investment facility with Angelini Ventures), and Neva SGR (Intesa Sanpaolo Group). Nouscom’s other existing international life sciences investors, 5AM Ventures, Andera Partners, Angelini Ventures, Bpifrance (through its InnoBio2 fund), CDP Venture Capital (through its Large Ventures Fund), EQT Life Sciences, Indaco Venture Partners, Panakes Partners, Versant Ventures and XGEN Ventures, all participated in the round. The strong demand for the round reflects investor conviction in Nouscom’s pipeline and recently published clinical data. ———————————————————————————————————————————————————————————— PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026 2026-10-19 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/puretech-announces-presentation-phase-1b-060000837.html Oral presentation to highlight encouraging clinical activity and favorable safety of LYT-200 in heavily pretreated patients with R/R HR-MDS and AML Results reinforce the potential of LYT-200 as a first-in-class, mutation-agnostic treatment for a broad R/R HR-MDS population, where treatment options remain extremely limited ———————————————————————————————————————————————————————————— Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S. 2026-10-19 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3382985/0/en/telix-and-ekalia-to-collaborate-on-astatine-211-production-in-the-u-s.html MELBOURNE, Australia and LOUVAIN-LA-NEUVE, Belgium and PARIS and INDIANAPOLIS, Oct. 19, 2026 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Ekalia, a joint venture between IBA (Ion Beam Applications S.A., EURONEXT) and Framatome, today announced a collaboration to advance scalable United States (U.S.) production of astatine-211 (211At), an alpha-emitting radioisotope being investigated for targeted alpha therapy. ———————————————————————————————————————————————————————————— Cosmo Announces Positive Phase 2 Study of Rifamycin 1% Topically Acting Gel, Meeting the Primary Endpoint in Distal Ulcerative Colitis and Ulcerative Proctitis 2026-10-19 · Newsfile · Healthcare, Biotech & pharma https://www.newsfilecorp.com/release/319677/Cosmo-Announces-Positive-Phase-2-Study-of-Rifamycin-1-Topically-Acting-Gel-Meeting-the-Primary-Endpoint-in-Distal-Ulcerative-Colitis-and-Ulcerative-Proctitis Ad hoc announcement pursuant to Art. 53 LR 46.2% clinical remission with rifamycin 1% topically acting gel vs 14.3% with placebo (p=0.0190). The therapy represents a new non-immune suppressive treatment modality, designed to achieve delivery to the distal colon with a novel liquid to gel delivery system, and a neutral pH. The results suggest that the anti-microbial properties of rifamycin may be positively affecting the gut... ———————————————————————————————————————————————————————————— Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio 2026-10-19 · Roche · Healthcare, Automotive, Biotech & pharma, Medical devices https://www.roche.com/media/releases/med-cor-2026-10-19 Phase III Krascendo 1 results demonstrated divarasib’s superiority over current standard of care, first-generation KRAS G12C inhibitors in previously treated advanced G12C-mutated non-small cell lung cancer Patient-reported outcomes from phase III lidERA study showed improved efficacy of giredestrant over standard endocrine therapy is achieved without compromising tolerability and health-related quality of life in early-stage breast cancer Phase III results in Chinese patients with metastatic nasopharyngeal carcinoma demonstrate the potential of Tam-Peli, a next-generation B7-H3-targeted ADC, to deliver robust efficacy with a favourable safety profile in high-unmet-need solid tumours Basel, 19 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data, including two late-breaking abstracts, across lung, breast and other cancers at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting, held from 23 to 27 October in Madrid. “Our presentations at ESMO 2026 highlight the depth and impact of Roche’s oncology pipeline, driven by emerging science capable of bringing new treatment benefits across diverse and high-unmet-need cancers,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “From establishing head-to-head superiority with divarasib in KRAS G12C-mutated lung cancer to advancing patient-centered oral SERD therapies like giredestrant and next-generation ADCs such as Tam-Peli, we are committed to delivering medicines that not only extend life, but also seek to improve treatment experience, tolerability and quality of life for people living with cancer. Divarasib demonstrated superior efficacy and best-in-class potential in KRAS G12C NSCLC Roche will share phase III Krascendo 1 results, which demonstrated divarasib’s best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer. Krascendo 1 is the only global head-to-head trial to evaluate a next-generation KRAS G12C inhibitor versus approved first-generation inhibitors.1 Results for this potential best-in-class, next-generation KRAS G12C-targeted therapy will be presented as a late-breaking abstract during a Presidential Symposium. Giredestrant data support its potential to become the new standard of care in early-stage and advanced breast cancer Roche will present new data highlighting the potential role of giredestrant, an investigational, oral, potent next-generation selective oestrogen receptor degrader (SERD) and full antagonist,2 in oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, a subtype in which more than 90% of cases are diagnosed at an early-stage (I-III).3-6 Key presentations from early-stage to advanced disease include: Patient-reported outcomes from the phase III lidERA Breast Cancer trial suggesting that the improved efficacy of giredestrant compared to endocrine therapy is achieved without compromising tolerability or Health-Related Quality of Life. Exploratory biomarker findings from the evERA Breast Cancer trial of giredestrant in combination with everolimus in ER-positive, HER2-negative advanced breast cancer in the post-cyclin-dependent kinase 4/6 inhibitor setting. Updated interim results for giredestrant plus inavolisib from the MORPHEUS Breast Cancer trial evaluating giredestrant treatment combinations in ER-positive, HER2-negative locally advanced or metastatic breast cancer. Data demonstrate the potential of a next generation B7-H3 targeted antibody-drug conjugate (ADC) Tam-Peli (tambotatug pelitecan) New data will also be presented for Tam-Peli, an investigational next generation B7-H3-targeted ADC designed to deliver high-potency anti-tumour activity while limiting off-target toxicity.7 Tam-Peli is currently being investigated across multiple solid tumour indications: ESMO data include late-breaking interim phase III results in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma, analyses of interstitial lung disease in patients with advanced solid tumours from phase I/II studies, and phase I efficacy and safety data for Tam-Peli in patients with locally advanced or metastatic NSCLC. These findings build on the TAISHAN-302 phase III data in second-line small cell lung cancer presented at the World Conference on Lung Cancer in September, where the study met all three specified endpoints of overall survival, progression free survival and objective response rate at its first interim analysis. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong, and Macau, and plans to rapidly initiate global trials across multiple tumour types. Overview of key presentations featuring Roche medicines and molecules: Medicine or moleculeAbstract titleAbstract number/ presentation details Lung cancer DivarasibKrascendo 1: Efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC.#LBA5 Proffered Paper Session Presidential Symposium II Sunday 25.10.2026 16:30 - 16:42 CET DivarasibKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer. #2551 TiP Poster NSCLC, Early-Stage Monday 26.10.2026 12:00 – 12:45 CET Tam-PeliTambotatug pelitecan (YL201): Efficacy and safety in locally advanced/ metastatic NSCLC from a phase I study. #2577 Poster NSCLC, Locally Advanced Monday 26.10.2026 12:00 – 12:45 CET Non-specificImmunogenomic signature associated with ICI-related pneumonitis in non-small-cell lung cancer (NSCLC) patients.#4247 Rapid Oral Basic Science and Translational Research Sunday 25.10.2026 09:14 - 09:19 CET Breast cancer GiredestrantPatient (pt)-reported outcomes (PROs) from the phase III lidERA Breast Cancer (BC) trial of giredestrant (GIRE) in pts with oestrogen receptor-positive, HER2-negative early BC (ER+, HER2− eBC).  #538 Rapid Oral Breast Cancer, Early-Stage Friday 23.10.2026 16:20 – 16:25 CEST GiredestrantRetrospective exploratory biomarker (BM) analyses from evERA Breast Cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients with oestrogen receptor-positive, HER2-negative advanced BC (ER+, HER2− aBC) in the post-CDK4/6 inhibitor (I) setting.#2 Rapid Oral Breast Cancer, Advanced Stage Saturday 24.10.2026 10:20 – 10:25 CEST GiredestrantUpdated interim analysis of giredestrant (GIRE) + inavolisib (INAVO) in MORPHEUS Breast Cancer (BC): A phase Ib/II study of GIRE treatment (tx) combinations in patients (pts) with oestrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2− LA/mBC).#23 Poster Advanced Breast Cancer, Other Saturday 24.10.2026 12:00 – 12:45 CEST PertuzumabReal-world eligibility for DESTINY-Breast11 (DB-11) neoadjuvant escalation criteria and outcomes of DB-11-eligible vs DB-11-ineligible patients with HER2-positive early breast cancer (HER2+ eBC).#594 Poster Breast Cancer, Early-Stage Saturday 24.10.2026 12:00 – 12:45 CEST ZN-1041BREnnA: Phase II/III randomised study of ZN-A-1041 or tucatinib (TUC), in combination with trastuzumab + capecitabine (HX), in patients with HER2-positive locally advanced or metastatic breast cancer (HER2+LA/mBC) with or without central nervous system (CNS) metastases. #1796 TiP Poster HER2+ Breast Cancer Saturday 24.10.2026 12:00 – 12:45 CEST Solid tumours Tam-Peli Tambotatug pelitecan (YL201): Analyses of interstitial lung disease in patients with advanced solid tumours from phase I/II studies. #1057 Poster Developmental Therapeutics Friday 23.10.2026 15:15 – 16:00 CEST YL211 (cMET ADC)Phase I First-in-Human (FIH) Results of YL211, a c-Met targeting Antibody-Drug Conjugate (ADC), in patients (pts) with advanced solid tumors.#1017 Poster Developmental Therapeutics Friday 23.10.2026 15:15 – 16:00 CEST Tam-Peli Tam-Peli versus chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): a multicenter, randomised, open-label, phase III study (TAISHAN-301).#LBA43 Proffered Paper Session Head and Neck Cancer Sunday 25.10.2026 08:40 - 08:50 CET Tecentriq (atezolizumab) + Avastin (bevacizumab)Outcomes by baseline tumor burden using 6-and-12 scores and the up-to-7 criteria in TALENTACE: phase III study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo/Bev) or on demand TACE alone in patients  with systemically untreated, unresectable hepatocellular carcinoma (uHCC). #1700 ePoster Hepatocellular Carcinoma Tecentriq (atezolizumab)ATOMIC (A021502/AIO-KRK-0317): Presentation and outcomes in patients (pts) with stage III d-MMR early-onset colon cancer (EOCC) and average-onset colon cancer (AOCC).#858 Poster Colon Cancer Sunday 25.10.2026 12:00 - 12:45 CET Tecentriq (atezolizumab)Adjuvant atezolizumab in patients with MSI-high/MMR-deficient stage III colorectal cancer ineligible for oxaliplatin-based chemotherapy: the phase II ANTONIO-study (AIO-KRK-0220).#802 Poster Colon Cancer Sunday 25.10.2026 12:00 - 12:45 CET About Roche in Oncology For over 60 years, Roche has delivered transformative medicines and diagnostics, redefining the treatment of some of the most challenging cancers. Driven by a vision of a future where cancer can be cured, we focus our efforts on cancers with the highest societal impact and where we bring deep expertise, including breast, lung, and blood cancers, while pursuing breakthrough innovation in other areas of unmet need. Our pipeline features a diverse array of modalities, from small molecules and antibodies to next-generation ADCs and allogeneic CAR T-cell therapies. By advancing best-in-class precision medicine, pioneering novel combinations, and leveraging key technologies and partnerships, Roche tackles oncology's toughest challenges with the goal of delivering life-changing outcomes for people with cancer. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Gadgeel S, et al. P3.12D.07 Divarasib Versus Adagrasib or Sotorasib in Pretreated KRAS G12C+ Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). J of Thorac Oncol. 2024; 19 (10, Supplement): S349. [2] Martin M, et al. Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase 2, randomised, open-label acelERA BC study. Presented at: ESMO Annual Meeting; 2022 September 9-13; Paris, France. Abstract #211MO. [3] F. Hoffmann‑La Roche Ltd. (2026) SEER Explorer All BCa by Stage. Data on file. [4] F. Hoffmann‑La Roche Ltd. (2026) Stage Distribution. Data on file. [5] F. Hoffmann‑La Roche Ltd. (2026) KREBS and TRM. Data on file. [6] F. Hoffmann‑La Roche Ltd. (2026). UK_CRUK_EDHub_IncidenceByStageRCRD_DataTable2026-01-08. Data on file. [7] Xu J, et al. Cancer Res. 2023;83:6304. Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone:  +41 79 377 83 75Albert Thottiyil Phone: +41 79 775 66 12 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.comDr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com  Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com   Attachment Media&Investor Release Roche ESMO 2026 English ———————————————————————————————————————————————————————————— NUCLIDIUM and NorthStar Enter Long-term Strategic Partnership to Advance NUCLIDIUM’s Copper-67 Radiotheranostic Oncology Pipeline 2026-10-19 · GlobeNewswire · Industrial, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3382978/0/en/nuclidium-and-northstar-enter-long-term-strategic-partnership-to-advance-nuclidium-s-copper-67-radiotheranostic-oncology-pipeline.html NUCLIDIUM formed a longterm strategic partnership through which NorthStar will produce Copper-67 and provide radiopharmaceutical manufacturing services. ———————————————————————————————————————————————————————————— JJP Biologics Doses the First Patients in Phase 1b Clinical Trial of Nebaprubart in Rheumatoid Arthritis (RA) 2026-10-19 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3382977/0/en/jjp-biologics-doses-the-first-patients-in-phase-1b-clinical-trial-of-nebaprubart-in-rheumatoid-arthritis-ra.html Warsaw, Poland – October 19, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotechnology company advancing first-in-class therapies for immune-mediated diseases and cancer, today announces that the first patients have been dosed in its Phase 1b trial of nebaprubart, an investigational potential first-in-class anti-CD89 antagonist, for the treatment of seropositive rheumatoid arthritis. ———————————————————————————————————————————————————————————— Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830 2026-10-19 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/19/3382975/0/en/zealand-pharma-announces-positive-topline-results-from-the-multiple-ascending-dose-part-of-phase-1-trial-with-kv1-3-ion-channel-blocker-zp9830.html Press release – No. 21 / 2026 ———————————————————————————————————————————————————————————— Infleqtion Convenes Business Leaders in London to Chart Quantum Commercial Value 2026-10-19 · Business Wire · Energy, Biotech & pharma https://finance.yahoo.com/technology/ai/articles/infleqtion-convenes-business-leaders-london-040000303.html Quantum Application Forum, 3 November 2026, gives executives a practical view of where quantum can create commercial value Summary : Real-world quantum use cases: One-day forum on quantum applications for business and public sector priorities in financial services, healthcare, pharmaceuticals, materials science, energy an ———————————————————————————————————————————————————————————— ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer 2026-10-19 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/esmo-2026-preview--mabwell-to-present-clinical-results-for-nectin-4-targeting-adc-9mw2821-in-adc-pretreated-triple-negative-breast-cancer-302911988.html SHANGHAI, Oct. 18, 2026 -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical data on its Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821 (Bulumtatug Fuvedotin, "BFv")... ———————————————————————————————————————————————————————————— /C O R R E C T I O N - AbbVie/ 2026-10-19 · AbbVie · Healthcare, Biotech & pharma, Government & policy https://www.prnewswire.com/news-releases/abbvie-to-present-data-at-the-2026-european-society-for-medical-oncology-esmo-congress-highlighting-progress-across-its-expanding-solid-tumor-portfolio-302911997.html In the news release, AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its... ———————————————————————————————————————————————————————————— ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology 2026-10-18 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/esmo-2026-presentations-deepen-evidence-221000279.html Natera and its collaborators will present 20 abstracts, including 4 rapid oral presentations Signatera ™ Genome with Phased and Structural Variants, which has achieved detection below 1 part per 10 million and an LOD95 of 1 part per million, will be featured in Natera's ESMO program AUSTIN, Texas, October 18, 2026 --( BUS ———————————————————————————————————————————————————————————— AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio 2026-10-18 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/abbvie-to-present-data-at-the-2026-european-society-for-medical-oncology-esmo-congress-highlighting-progress-across-its-expanding-solid-tumor-portfolio-302911997.html New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation ADCs, combination approaches and precision medicine AbbVie's largest ESMO... ———————————————————————————————————————————————————————————— Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress 2026-10-18 · Eli Lilly and Company · Finance, Healthcare, Biotech & pharma, Government & policy https://www.prnewswire.com/news-releases/lilly-to-showcase-advances-across-its-oncology-pipeline-at-the-2026-european-society-for-medical-oncology-esmo-congress-302911565.html Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio will be presented at the European Society for... ———————————————————————————————————————————————————————————— Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract 2026-10-18 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/18/3382952/0/en/zentalis-pharmaceuticals-announces-first-overall-survival-data-for-azenosertib-from-denali-part-1b-published-in-esmo-congress-2026-abstract.html SAN DIEGO, Oct. 18, 2026 -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that overall survival (OS) data from an interim analysis of the DENALI Part 1b study (GOG-3066) have been published in the abstract for the upcoming rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026. ———————————————————————————————————————————————————————————— Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress 2026-10-18 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/18/3382951/0/en/eikon-therapeutics-announces-availability-of-seven-abstracts-for-presentation-at-the-european-society-for-medical-oncology-congress.html Presentations to cover updates across Eikon’s clinical pipeline including: ———————————————————————————————————————————————————————————— Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 2026-10-18 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/incyte-highlight-key-oncology-data-220500880.html Four rapid oral presentations at ESMO will feature new data for INCB161734, a KRAS G12D inhibitor, and INCA33890 1 , a TGFβR2×PD-1 bispecific antibody Both investigational therapies are being evaluated in ongoing Phase 3 programs Incyte will host an investor event and webcast on Monday, October 26, 2026 from 7:30 – 9:00 C ———————————————————————————————————————————————————————————— Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss 2026-10-18 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/veradermics-hold-conference-call-discuss-220000578.html Conference call will take place on Monday, October 19, 2026, at 8:00 am ET NEW HAVEN, Conn., October 18, 2026--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it wi ———————————————————————————————————————————————————————————— Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP) 2026-10-18 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/18/3382949/0/en/disc-medicine-to-host-corporate-webcast-to-discuss-topline-results-from-the-apollo-phase-3-trial-of-bitopertin-in-erythropoietic-protoporphyria-epp.html WATERTOWN, Mass., Oct. 18, 2026 -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will host a corporate webcast to discuss topline results from the APOLLO Phase 3 trial of bitopertin in EPP. The webcast will be held on Monday, October 19, 2026 at 8:00 a.m. ET. ———————————————————————————————————————————————————————————— Antheia Secures $80 Million Conditional Funding Commitment from Department of War's Office of Strategic Capital 2026-10-18 · PR Newswire · Finance, Industrial, Logistics, Biotech & pharma https://www.prnewswire.com/news-releases/antheia-secures-80-million-conditional-funding-commitment-from-department-of-wars-office-of-strategic-capital-302911991.html Financing supports Antheia's domestic manufacturing strategy to onshore critical medicine supply chains MENLO PARK, Calif., Oct. 18, 2026 -- Antheia, the advanced biosynthesis company delivering 21st-century pharmaceutical manufacturing and innovation, today announced it has... ———————————————————————————————————————————————————————————— UNICYCIVE DEADLINE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY 2026-10-18 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/319603/UNICYCIVE-DEADLINE-ROSEN-NATIONAL-TRIAL-COUNSEL-Encourages-Unicycive-Therapeutics-Inc.-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-UNCY New York, New York--(October 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs... ———————————————————————————————————————————————————————————— UNICYCIVE DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY 2026-10-18 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/18/3382925/673/en/unicycive-deadline-rosen-top-ranked-investor-counsel-encourages-unicycive-therapeutics-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-uncy.html NEW YORK, Oct. 18, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026 2026-10-18 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/18/3382917/0/en/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026.html WALTHAM, Mass., Oct. 18, 2026 -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced presentations at United European Gastroenterology Week (UEGW) 2026 in Barcelona. The presentations include the first scientific congress presentation of clinical data across all three of Spyre’s IBD antibodies—SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23)—which are now being tested as monotherapies and pairwise combinations in the SKYLINE study, as well as new preclinical data demonstrating additive efficacy of these complementary mechanisms. ———————————————————————————————————————————————————————————— New Progress -- XellSmart Unveiled Phase I Results of Off-the-Shelf Parkinson's Disease Cell Therapy at MDS & Completed Blinded Phase II Enrollment 2026-10-18 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/new-progress--xellsmart-unveiled-phase-i-results-of-off-the-shelf-parkinsons-disease-cell-therapy-at-mds--completed-blinded-phase-ii-enrollment-302911915.html SEOUL, South Korea and SHANGHAI, Oct. 18, 2026 -- New clinical data for XellSmart's off-the-shelf cell therapy for Parkinson's Disease was presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS), one of the world's most prestigious... ———————————————————————————————————————————————————————————— UNCY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026 2026-10-17 · Newsfile · Biotech & pharma https://www.newsfilecorp.com/release/319380/UNCY-SHAREHOLDER-ACTION-REMINDER-Faruqi-Faruqi-LLP-Reminds-Unicycive-Therapeutics-UNCY-Investors-of-Securities-Class-Action-Lawsuit-Deadline-on-November-2-2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. -... ———————————————————————————————————————————————————————————— Masimo's smartSET™ FDA Clearance Offers Breakthrough Innovation in Pulse Oximetry to Help Improve Critical Patient Outcomes 2026-10-17 · PR Newswire · AI, SaaS, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/masimos-smartset-fda-clearance-offers-breakthrough-innovation-in-pulse-oximetry-to-help-improve-critical-patient-outcomes-302911711.html Industry-Leading Pulse Oximetry Platform Now Features First-of-Its-Kind Atrial Fibrillation (AFib) Detection with Previously Cleared AI-Enabled Opioid-Induced Respiratory Depression (OIRD) Detection Designed Together to Deliver Earlier Clinical Insights IRVINE, Calif., Oct. 17, 2026... ———————————————————————————————————————————————————————————— Prostate Cancer Foundation Expands Radiopharmaceutical Think Tank as Field Enters Pivotal Growth Phase 2026-10-17 · Business Wire · SaaS, Industrial, Biotech & pharma https://finance.yahoo.com/healthcare/articles/prostate-cancer-foundation-expands-radiopharmaceutical-123000697.html – PCF Think Tank aims to increase adoption of radiopharmaceuticals as major oncology therapeutic platform in prostate cancer treatment and to other tumor types – – New members Orano Med, Telix and Siemens Healthineers join PCF and industry leaders at kickoff meeting at 2026 EANM Annual Congress to address key challenges i ———————————————————————————————————————————————————————————— Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia 2026-10-17 · PR Newswire · SaaS, Healthcare, Automotive, Food & drink, Biotech & pharma https://www.prnewswire.com/news-releases/vivacta-bio-and-grit-bio-announce-fda-orphan-drug-designation-for-in-vivo-car-t-therapy-gt801-in-autoimmune-hemolytic-anemia-302911806.html SHANGHAI, Oct. 17, 2026 -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta Bio"), a company spun out of the in vivo CAR-T platform of Beijing Grit Biotherapeutics Co., Ltd. ("Grit Bio"), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan... ———————————————————————————————————————————————————————————— UNICYCIVE DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY 2026-10-17 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/319576/UNICYCIVE-DEADLINE-ROSEN-NATIONAL-INVESTOR-COUNSEL-Encourages-Unicycive-Therapeutics-Inc.-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-UNCY New York, New York--(October 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs... ———————————————————————————————————————————————————————————— Super Patch Reviews 2026: Looking for a Drug-Free Addition to Your Wellness Routine? What to Know Before Trying These SuperPatches 2026-10-17 · Newswire.com · Biotech & pharma https://www.newswire.com/news/super-patch-reviews-2026-looking-for-a-drug-free-addition-to-your-wellness For readers drawn to a wearable approach, this review explores Super Patch's brand-stated drug-free design, product-specific research, pricing, and practical considerations to help assess personal fit. ———————————————————————————————————————————————————————————— Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) 2026-10-16 · GlobeNewswire · Finance, SaaS, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382822/0/en/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4.html BRISBANE, Calif., Oct. 16, 2026 -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on October 7, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). ———————————————————————————————————————————————————————————— Avicanna Transitions US Listing to OTCQB 2026-10-16 · GlobeNewswire · Industrial, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382821/0/en/avicanna-transitions-us-listing-to-otcqb.html TORONTO, Oct. 16, 2026 -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQB: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products announces that in the US, the Company will transition to OTCQB effective October 16, 2026. ———————————————————————————————————————————————————————————— Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 2026-10-16 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382817/0/en/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html PHILADELPHIA, Oct. 16, 2026 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on October 15, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 111,615 shares of Iovance’s common stock to twenty-one new, non-executive employees. ———————————————————————————————————————————————————————————— Kane Biotech Announces $250,000 Insider Loan 2026-10-16 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382812/0/en/kane-biotech-announces-250-000-insider-loan.html Unsecured, non-interest-bearing loan provides additional working capital support Unsecured, non-interest-bearing loan provides additional working capital support ———————————————————————————————————————————————————————————— Actinium Pharmaceuticals Announces Inducement Grants to New Employees 2026-10-16 · PR Newswire · Finance, Biotech & pharma https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-inducement-grants-to-new-employees-302911600.html NEW YORK, Oct. 16, 2026 -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced inducement equity awards to Matt David, M.D., the Company's newly appointed Chief Financial... ———————————————————————————————————————————————————————————— Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) 2026-10-16 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/stoke-therapeutics-announces-inducement-grants-202000298.html BEDFORD, Mass., October 16, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential diseas ———————————————————————————————————————————————————————————— LASE Appoints Dmitri Nikitin Executive Chairman 2026-10-16 · Newswire.com · Finance, SaaS, Energy, Industrial, Biotech & pharma, Semiconductors https://www.newswire.com/news/lase-appoints-dmitri-nikitin-executive-chairman Laser Photonics Corporation (NASDAQ:LASE), an emerging directed energy and laser technology platform developing applications for defense, semiconductor, pharmaceutical and industrial markets (the "Company"), today announced the appointment of Dmitri Nikitin, the Company's founder, as Executive Chairman of the Board of Directors and principal executive officer responsible for leading the Company, with the authority an ———————————————————————————————————————————————————————————— Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2026-10-16 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382791/0/en/zenas-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html WALTHAM, Mass., Oct. 16, 2026 -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on October 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted an aggregate of 74,900 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”). ———————————————————————————————————————————————————————————— Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia 2026-10-16 · PR Newswire · Finance, Healthcare, Food & drink, Biotech & pharma https://www.prnewswire.com/news-releases/viatris-receives-us-fda-approval-for-ryzumvi-for-the-treatment-of-presbyopia-302911593.html PITTSBURGH, Oct. 16, 2026 -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. RYZUMVI is... ———————————————————————————————————————————————————————————— 4DMT Announces New Employment Inducement Grants 2026-10-16 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382788/0/en/4dmt-announces-new-employment-inducement-grants.html EMERYVILLE, Calif., Oct. 16, 2026 -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on October 13, 2026, the compensation committee of the Company’s board of directors granted 13 new non-executive employees options to purchase an aggregate of 260,000 shares of the Company’s common stock and 157,600 Restricted Stock Units (RSUs). Each stock option has an exercise price per share equal to $12.36, which was the closing trading price on October 13, 2026, the date of grant. The stock options and RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company. ———————————————————————————————————————————————————————————— Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2026-10-16 · GlobeNewswire · Finance, SaaS, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382786/0/en/korro-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html CAMBRIDGE, Mass., Oct. 16, 2026 -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to two newly hired employees. ———————————————————————————————————————————————————————————— Prelude Therapeutics to Participate in the Chardan Healthcare Conference 2026-10-16 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382782/0/en/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference.html WILMINGTON, Del., Oct. 16, 2026 -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Chardan Healthcare Conference taking place in New York City on October 20, 2026. ———————————————————————————————————————————————————————————— FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes 2026-10-16 · Business Wire · Healthcare, Retail, Biotech & pharma https://finance.yahoo.com/healthcare/articles/fda-approves-alcon-brytly-redness-195700822.html One drop works to significantly reduce redness, with results lasting up to 12 hours 1 Lasts up to 50% longer than Lumify 1-2,* Expands Alcon's portfolio of consumer eye care solutions and will be available in major retailers nationwide and online in the coming months GENEVA, October 16, 2026--Alcon (SI ———————————————————————————————————————————————————————————— Nephron Pharmaceuticals Announces Leadership Transition 2026-10-16 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/nephron-pharmaceuticals-announces-leadership-transition-193000591.html Lou Kennedy departs from CEO role; Haywood Miller appointed Interim CEO Company remains focused on executing its transformation strategy and growth priorities while continuing to deliver safe, effective medications to customers and the patients they serve WEST COLUMBIA, S.C., October 16, 2026--Nephron ———————————————————————————————————————————————————————————— AHN Cancer Center Launches RANDY'S Trial, Funded by Community Support and Inspired by a Firefighter's Legacy 2026-10-16 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/ahn-cancer-center-launches-randys-trial-funded-by-community-support-and-inspired-by-a-firefighters-legacy-302911433.html Clinical trial funded through The Randy & Stephanie Meyer Spread Goodness Fund seeks to expand surgical options for patients facing appendix and other peritoneal cancers PITTSBURGH, Oct. 16, 2026 -- Allegheny Health Network (AHN) Cancer Center today announced the launch of... ———————————————————————————————————————————————————————————— Did You Lose Money Investing in Anavex Life Sciences Corp.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AVXL 2026-10-16 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/319444/Did-You-Lose-Money-Investing-in-Anavex-Life-Sciences-Corp.-Robbins-LLP-Urges-Investors-with-Significant-Losses-to-Contact-the-Firm-for-Information-About-Their-Rights-Against-AVXL San Diego, California--(October 16, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Anavex Life Sciences Corp. (NASDAQ: AVXL) securities between November 26, 2025 and August 28, 2026, inclusive (the "Class Period"). Anavex describes itself as "a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of... ———————————————————————————————————————————————————————————— Eight EU Capitals Want to Ban Products That Don’t Exist Yet 2026-10-16 · Pressat · AI, Healthcare, Media, Biotech & pharma https://pressat.co.uk/releases/eight-eu-capitals-want-to-ban-products-that-dont-exist-yet-f045a17467df603ee920325ddf1869d8/ Friday 16 October, 2026 Brussels, Belgium (October 16, 2026) — We Are Innovation is urging the European Commission to reject calls for a “market freeze” on new nicotine products in the upcoming revision of the Tobacco Products Directive (TPD). The network warns that the proposal contradicts the competitiveness agenda the EU adopted after the Draghi report. On 6 October, the health ministers of the Netherlands, Belgium, Finland, France, Hungary, Latvia, Slovenia and Spain jointly asked the Commission to include a market freeze in the revised Directive. The proposal would bar any new product containing nicotine, anything with nicotine-like properties, or anything that resembles them from entering the EU market. The ministers also call for a ban on flavorings, caps on nicotine content, and standardized designs across all categories. They justify these measures as a way to prevent consumers from substituting one product for another. We Are Innovation argues that the proposal tests whether the EU has absorbed the lessons of The Future of European Competitiveness, the 2024 report by Mario Draghi. The report found that EU companies invest roughly half as much in research and innovation, as a share of GDP, as their American counterparts. It also warned that Europe is stuck in a “middle technology trap” and identified overregulation as a central cause. Between 2019 and 2024, the United States passed around 3,500 federal laws, while the EU adopted about 13,000 acts, many based on precautionary logic that hits small firms and newcomers hardest. According to We Are Innovation, the freeze would go further than any precautionary rule currently in force. Ordinary precautionary measures wait until a product exists. A market freeze would ban products before they are invented, with no evidence to evaluate, no cost-benefit analysis, and no assessment of relative risk. Novelty alone would be grounds for exclusion. By design, a rule meant to stop consumers from substituting products would stop smokers from switching away from cigarettes, the most harmful nicotine product on the market. The network points to Sweden as evidence that a different approach works. Sweden applied the same tobacco control measures as its neighbors, including high cigarette taxes, smoking bans, and health warnings. However, it also allowed adult smokers to switch to safer alternatives: first snus, then nicotine pouches from 2016. In 2022, rather than banning pouches, Sweden regulated them with age restrictions, nicotine limits, and labeling requirements. The results include: Smoking prevalence fell from 11.4% in 2012 to 3.7% in 2025, making Sweden smoke-free.Sweden records 36% fewer lung cancer deaths than the EU average.Nicotine pouches reached groups that snus never did. Among women, smoking fell from 11.2% in 2015 to 5.7% in 2024. We Are Innovation also warns that a market freeze would extend well beyond the nicotine sector. Investors in batteries, biotechnology and artificial intelligence would read it as a signal of how Europe treats new products and new entrants in general. Tetiana Rak, We Are Innovation's COO, comments, “Brussels has spent two years praising the Draghi report and promising simplification. A market freeze would ban innovations that do not yet exist, on the sole ground that they are new. If Europe wants to close its innovation gap, it cannot start by telling entrepreneurs that their products are unwelcome before they have even been invented. Swedish experience has shown that smart regulation, not prohibition, is what makes a population smoke-free.” We Are Innovation calls on the Commission to apply the method Draghi recommended and that its own Better Regulation toolbox already requires. This means quantifying a rule’s costs before adopting it, regulating nicotine products according to their relative risk, and protecting minors through age verification and enforcement rather than category bans. The network remains available to provide research and evidence to EU institutions and Member States throughout the TPD revision. ENDS ABOUT WE ARE INNOVATION We Are Innovation is a dynamic network of individuals and institutions who deeply believe in innovation's power to drive progress and solve the world's most pressing problems. With over 60 think tanks, foundations, and NGOs based worldwide, We Are Innovation represents the diverse voices of a global civil society committed to advancing human creativity, adopting new technologies, and promoting innovative solutions. Through our collaborative approach and cutting-edge expertise, we are driving global transformative change. To learn more about our work, visit us at https://www.weareinnovation.global/. ———————————————————————————————————————————————————————————— Starton Therapeutics to Participate in Spotlight Panel at BioFuture 2026 2026-10-16 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/starton-therapeutics-participate-spotlight-panel-173500009.html PARAMUS, N.J., October 16, 2026--Starton Therapeutics Inc. ("Starton"), a clinical-stage biotechnology company employing standard-of-care therapies with proprietary delivery technologies, announced today that Chief Medical Officer Dr. Jamie Oliver, Pharm.D., will participate as a panelist at BioFuture ———————————————————————————————————————————————————————————— Edmonton Airport Expands Air Cargo Ambitions as Terracap Breaks Ground on New Airside Facility 2026-10-16 · Travel PR News · Travel, Logistics, Biotech & pharma https://travelprnews.com/article/edmonton-airport-expands-air-cargo-ambitions-as-terracap-breaks-ground-on-new-airside-facility/?utm_source=rss&utm_medium=rss&utm_campaign=edmonton-airport-expands-air-cargo-ambitions-as-terracap-breaks-ground-on-new-airside-facility The 50,000-square-foot warehouse project will connect directly to Apron VIII and adds to Terracap’s existing cargo footprint at YEG. KEY TAKEAWAYS Terracap has broken ground on a new 50,000-square-foot airside cargo facility at Edmonton International Airport. The planned building fronts Apron VIII and is designed for time-sensitive goods including pharmaceuticals and perishables. Canada has committed... Read the full news article ———————————————————————————————————————————————————————————— Myosin Therapeutics Invited to Present at BioFuture 2026 in New York City 2026-10-16 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/myosin-therapeutics-invited-to-present-at-biofuture-2026-in-new-york-city-302911396.html JUPITER, Fla., Oct. 16, 2026 -- Myosin Therapeutics today announced that, following its selection as a 2026–2027 National Cancer Institute (NCI) SBIR Investor Initiatives Showcase Company, it has been invited to present at BioFuture 2026, taking place October 27–28 in New... ———————————————————————————————————————————————————————————— Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia 2026-10-16 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382714/0/en/opus-genetics-announces-fda-approval-of-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia.html Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia ———————————————————————————————————————————————————————————— GenSight Biologics Announces the Closing of its €1.0 Million Fundraising Supported by Existing Shareholders 2026-10-16 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/gensight-biologics-announces-closing-1-160000985.html NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA PARIS, October 16, 2026--Regulatory News: GenSight Biologics (the " Company ") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and ———————————————————————————————————————————————————————————— ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors 2026-10-16 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/immunitybio-reports-phase-3-data-154900100.html Peer-reviewed publication reports long-term outcomes from the QUILT-3.032 study supporting durable disease control and bladder preservation CULVER CITY, Calif., October 16, 2026--ImmunityBio, Inc. ( NASDAQ: IBRX ), a commercial-stage immunotherapy company, today announced the publication of long-term d ———————————————————————————————————————————————————————————— Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026 2026-10-16 · ScoopAsia · Healthcare, Biotech & pharma https://scoopasia.com/eisai-deepens-its-oncology-evidence-base-at-esmo-congress-2026/ TOKYO, October 16, 2026 - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the presentation of clinical research across its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2026, taking place in Madrid from October 23 to ———————————————————————————————————————————————————————————— AI in Drug Discovery Market Size to Worth USD 17.56 Billion by 2031, at a CAGR of 28.1% – MarketsandMarkets™ 2026-10-16 · GlobeNewswire · AI, SaaS, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382680/0/en/ai-in-drug-discovery-market-size-to-worth-usd-17-56-billion-by-2031-at-a-cagr-of-28-1-marketsandmarkets.html Delray Beach, FL, Oct. 16, 2026 -- MarketsandMarkets™ projects the global AI in drug discovery market to grow from USD 5.09 billion in 2026 to USD 17.56 billion by 2031, at a CAGR of 28.1% during the forecast period. Market growth is driven by the growing pharmaceutical demand to reduce drug discovery timelines and R&D costs, increasing adoption of generative AI and foundation models, expanding availability of multi-omics datasets, and investments in AI-enabled drug discovery platforms. Increasing strategic collaborations between pharmaceutical companies and AI technology providers, coupled with advances in cloud computing, high-performance computing, and computational biology, are further boosting the adoption of AI across early-stage drug discovery. ———————————————————————————————————————————————————————————— Why Virtual Asset Providers Are Financial Crime Investigation’s Most Underused Ally 2026-10-16 · Africa Publicity · Biotech & pharma https://africapublicity.com/why-virtual-asset-providers-are-financial-crime-investigations-most-underused-ally/ By Japhet Gana, Group Head, Transaction Risk & Financial Crimes, Yellow Card I recently spent five days in Nairobi watching investigators, regulators, and virtual asset providers work through the same simulated scenarios in the same room, at a training run by the United Nations Office on Drugs and Crime. I walked in expecting a […] ———————————————————————————————————————————————————————————— Global Frankincense Extract Market Size, Growth, Share and Outlook 2026–2034 2026-10-16 · PR News Releaser · Biotech & pharma https://www.prnewsreleaser.com/news/473695 The global Frankincense Extract Market is gaining momentum as consumers increasingly seek natural ingredients for personal care, wellness, aromatherapy, and pharmaceutical applications. Frankincense extract, derived from the resin of Boswellia trees, has a long history of use in traditional wellness ... Read more ———————————————————————————————————————————————————————————— Chipscreen Biosciences Announces NMPA IND Approval for NW001, a PD-L1-Targeted Epigenetic Immune-Modulating Antibody Conjugate 2026-10-16 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/chipscreen-biosciences-announces-nmpa-ind-133000474.html SHENZHEN, China, October 16, 2026--Shenzhen Chipscreen Biosciences Co., Ltd. ("Chipscreen Biosciences") (SSE: 688321) today announced that NW001, a first-in-class epigenetic immune-modulating antibody conjugate (EIMAC) co-developed with Chengdu Chipscreen Newway Biosciences Co., Ltd., has obtained IND ———————————————————————————————————————————————————————————— NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus 2026-10-16 · Newsfile · Finance, SaaS, Healthcare, Biotech & pharma https://www.newsfilecorp.com/release/319351/NeOncs-Most-Challenging-Test-Yet-CompassionateUse-Update-Puts-NEO100s-Potential-in-Focus Houston, Texas--(October 16, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is confronting one of the most consequential tests of its investigational brain-cancer platform as it pursues treatment options for patients facing some of the most difficult challenges in neuro-oncology. The company recently reported an early clinical update involving a critically ill three-year-old boy with an aggressive brain tumor who, after receiving investigational intranasal NEO100 through... ———————————————————————————————————————————————————————————— Moleculin Announces Reverse Stock Split 2026-10-16 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382623/0/en/moleculin-announces-reverse-stock-split.html HOUSTON, Oct. 16, 2026 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on October 20, 2026, and the Company’s common stock will open for trading on The Nasdaq Capital Market on October 20, 2026 on a post-split basis, under the existing ticker symbol “MBRX” but with a new CUSIP number 60855D 507. ———————————————————————————————————————————————————————————— SafeSpace Global Extends Exclusive BMRT Security Agreement to Houses of Worship and Addiction Treatment Centers 2026-10-16 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382621/0/en/safespace-global-extends-exclusive-bmrt-security-agreement-to-houses-of-worship-and-addiction-treatment-centers.html BMRT’s Base Molecular Resonance™ Technology Detects the Molecular Signature of a Concealed Firearm from More Than 500 Feet Away and Identifies Drugs Inside Vehicles and Backpacks at a Distance; Expansion Adds More Than 374,000 U.S. Congregations and Treatment Facilities to SafeSpace Global’s Addressable Market ———————————————————————————————————————————————————————————— UNCY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026 2026-10-16 · Newsfile · Biotech & pharma https://www.newsfilecorp.com/release/319259/UNCY-EQUITY-ACTION-REMINDER-Faruqi-Faruqi-LLP-Reminds-Unicycive-Therapeutics-UNCY-Investors-of-Securities-Class-Action-Lawsuit-Deadline-on-November-2-2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. -... ———————————————————————————————————————————————————————————— Animal Drug Compounding Market Outlook Highlights Rising Veterinary Demand 2026-10-16 · Express Press Release · Biotech & pharma https://express-press-release.net/news/2026/10/16/1777080 The right medication is not always available in the right strength, dosage form, or flavor for every animal. A dog may struggle with tablets, a [read full press release...] ———————————————————————————————————————————————————————————— From Taiwan to the World: PharmaEssentia Expands Global Reach With New Drug Approvals, Overseas Investments 2026-10-16 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/taiwan-world-pharmaessentia-expands-global-120100250.html From Taiwan to the world: PharmaEssentia expands global reach with new drug approvals, overseas investments TAIPEI, Taiwan, October 16, 2026--PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through new drug approvals, clinical trials a ———————————————————————————————————————————————————————————— Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement 2026-10-16 · PR Newswire · Finance, Industrial, Biotech & pharma https://www.prnewswire.com/news-releases/scinai-immunotherapeutics-announces-closing-of-4-0-million-financing-through-a-private-placement-and-warrant-inducement-302911221.html JERUSALEM, Oct. 16, 2026 -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and manufacturing organization ("CDMO") alongside an immunology-focused therapeutic development... ———————————————————————————————————————————————————————————— Azitra, Inc. Announces Reverse Stock Split 2026-10-16 · PR Newswire · Finance, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/azitra-inc-announces-reverse-stock-split-302910544.html Common Stock Will Begin Trading on a Split-Adjusted Basis on October 26, 2026 BRANFORD, Conn., Oct. 16, 2026 -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced... ———————————————————————————————————————————————————————————— Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors 2026-10-16 · PR Newswire · Finance, Biotech & pharma https://www.prnewswire.com/news-releases/curis-inc-announces-pricing-of-8-5-million-private-placement-priced-at-the-market-under-nasdaq-rules-with-existing-healthcare-focused-institutional-investors-302910890.html LEXINGTON, Mass., Oct. 16, 2026 -- Curis, Inc. (Nasdaq: CRIS) ("Curis" or the "Company"), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it has entered into... ———————————————————————————————————————————————————————————— Royalty Pharma declares fourth quarter 2026 dividend 2026-10-16 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382547/0/en/royalty-pharma-declares-fourth-quarter-2026-dividend.html NEW YORK, Oct. 16, 2026 -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2026 of $0.235 per Class A ordinary share. ———————————————————————————————————————————————————————————— Virion Therapeutics to Present Long-Term Follow-Up Data of VRON-0200 Treatment in Chronic Hepatitis B in a Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026 2026-10-16 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/virion-therapeutics-present-long-term-120000152.html PHILADELPHIA, October 16, 2026--Virion Therapeutics, LLC , a clinical-stage biotechnology company, developing T cell-based immunotherapies that contain checkpoint modifiers , today announced that an abstract reporting long-term follow-up data of VRON-0200, its novel, first-in-class, immunotherapy for ———————————————————————————————————————————————————————————— Palleon Pharmaceuticals Announces Oral Presentation of Interim Phase 2 trial data for HLX79/E-602 in Membranous Nephropathy at the 2026 American College of Rheumatology (ACR) Convergence 2026-10-16 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/palleon-pharmaceuticals-announces-oral-presentation-120000634.html – Presentation will provide interim Phase 2 clinical data on HLX79/E-602, a first-in-class human sialidase enzyme therapeutic, in patients with membranous nephropathy – WALTHAM, Mass., October 16, 2026--Palleon Pharmaceuticals, a clinical-stage biotechnology company developing novel therapeutics for au ———————————————————————————————————————————————————————————— Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer 2026-10-16 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/ironwood-pharmaceuticals-appoints-tammi-gaskins-113000437.html – Tom McCourt to Retire from CEO Post After 17 Years at Ironwood and Four Decades of Distinguished Industry Leadership Bringing Transformational Medicines to Patients – BOSTON, October 16, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life- ———————————————————————————————————————————————————————————— 20 Years Old, with a 50/50 Chance of Survival: Does High-Risk Leukemia in Young Adults Represent a Failure in Research Priorities? 2026-10-16 · Send2Press · Sports, Biotech & pharma https://www.send2press.com/wire/20-years-old-with-a-50-50-chance-of-survival-does-high-risk-leukemia-in-young-adults-represent-a-failure-in-research-priorities/ ST. PETERSBURG, Fla., Oct. 16, 2026 (SEND2PRESS NEWSWIZRE) -- While modern pediatric leukemia treatment stands as one of oncology's greatest triumph stories, a quiet and urgent crisis persists for adolescent and young adult (AYA) patients diagnosed with high-risk acute blood cancers. St. Petersburg-based Jackson Copeland Foundation targets the massive survival disparity gap in AYA acute myeloid leukemia, raising funds for pioneering research with Oct. 30 Anchors & Irons Invitational charity golf tournament in Clearwater. ———————————————————————————————————————————————————————————— Innovative Massage Therapy Expands Focus on Chronic Stress-Related Physical Tension in Albuquerque. 2026-10-16 · PR Now · Biotech & pharma https://pressreleasenews.org/pressroom/innovative-massage-therapy-expands-focus-on-chronic-stress-related-physical-tension-in-albuquerque As August workloads peak across New Mexico, Innovative Massage Therapy makes appointment-based therapeutic services available to clients throughout Albuquerque, Bernalillo County, Sandoval County, Rio Rancho, and Santa Fe. Albuquerque, NM, August 3, 2026 - The National Institute … ———————————————————————————————————————————————————————————— Global Asthma Drugs Market Size, Share, Trends, and Forecast 2026-2035 | Biologics, Pediatric Expansion, and Asia-Pacific Demand Drive Growth to USD 41.18 Billion 2026-10-16 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382360/28124/en/global-asthma-drugs-market-size-share-trends-and-forecast-2026-2035-biologics-pediatric-expansion-and-asia-pacific-demand-drive-growth-to-usd-41-18-billion.html Dublin, Oct. 16, 2026 -- "Asthma Drugs Market by Mode of Administration; Medication; Application; Organization Type; Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— ADC Cytotoxic Payloads and Warheads Market Size, Share, Trends, and Forecast to 2035 | Precision Oncology and Next-Generation ADCs Unlock USD 469.3 Million Opportunity 2026-10-16 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382350/28124/en/adc-cytotoxic-payloads-and-warheads-market-size-share-trends-and-forecast-to-2035-precision-oncology-and-next-generation-adcs-unlock-usd-469-3-million-opportunity.html Prioritize topoisomerase inhibitors, clinical ADCs, capacity expansion and strategic partnerships to capture rising precision oncology demand. Prioritize topoisomerase inhibitors, clinical ADCs, capacity expansion and strategic partnerships to capture rising precision oncology demand. ———————————————————————————————————————————————————————————— Biotech Boom Fuels Clinical Lab Evolution as Global IVD Medical Services Market Adapts to the Genomic Shift 2026-10-16 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382345/28124/en/biotech-boom-fuels-clinical-lab-evolution-as-global-ivd-medical-services-market-adapts-to-the-genomic-shift.html Extensive report evaluates the impact of advanced molecular diagnostics, changing U.S. Medicare fee schedules, and the "genetic blizzard" on hospital and laboratory testing demand. Extensive report evaluates the impact of advanced molecular diagnostics, changing U.S. Medicare fee schedules, and the "genetic blizzard" on hospital and laboratory testing demand. ———————————————————————————————————————————————————————————— Germany Precision Oncology Diagnostics Market Size, Share, Trends, and Forecast to 2035 - NGS-based Panels and Liquid Biopsies Drive 15% CAGR Toward USD 5.18 Billion 2026-10-16 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382344/28124/en/germany-precision-oncology-diagnostics-market-size-share-trends-and-forecast-to-2035-ngs-based-panels-and-liquid-biopsies-drive-15-cagr-toward-usd-5-18-billion.html Dublin, Oct. 16, 2026 -- "Germany Precision Oncology Diagnostics Market by Test Type (Companion Diagnostics, NGS-based Panels, Liquid Biopsy Tests, IHC / FISH-based Tests, PCR-based Tests), Type of Technology, Disease Indication, Sample Type, End User and Regional Hub - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— China Next-Generation Antibody-Drug Conjugate (ADC) Innovation Market Forecast to 2035 | USD 1.33 Billion Opportunity Fueled by Global Licensing and Bispecific ADC Growth 2026-10-16 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382343/28124/en/china-next-generation-antibody-drug-conjugate-adc-innovation-market-forecast-to-2035-usd-1-33-billion-opportunity-fueled-by-global-licensing-and-bispecific-adc-growth.html Benchmark China-origin ADC assets, licensing partners and innovation hubs to guide market-entry, capital allocation and portfolio stress-testing Benchmark China-origin ADC assets, licensing partners and innovation hubs to guide market-entry, capital allocation and portfolio stress-testing ———————————————————————————————————————————————————————————— AgeReverse RESURGE Now Available to U.S. Consumers on Amazon 2026-10-16 · Newsworthy.ai · AI, SaaS, Healthcare, Retail, Food & drink, Sports, Biotech & pharma https://newsworthy.ai/news/202610163064/agereverse-resurge-now-available-to-us-consumers-on-amazon Boca Raton, Florida Friday Oct 16, 2026 @ 5:00 AM Eastern — AgeReverse, a Canadian longevity company focused on healthy aging and cellular vitality, today announced that its flagship RESURGE formulation is now available to U.S. consumers on Amazon, marking another significant step in the company’s expansion into the American market. The Amazon launch follows a series of U.S. expansion initiatives for AgeReverse, including the company’s recent participation in the ECRM Vitamin, Weight Management & Sports Nutrition Session in Palm Beach Gardens, Florida. With RESURGE now available through one of the country’s largest online marketplaces, AgeReverse is expanding consumer access while continuing to introduce its broader science-first approach to healthy aging. “Making RESURGE available on Amazon is an important milestone for AgeReverse because it gives consumers across the United States convenient access to our first product in the market,” said Kubi Turkmen, Founder and CEO of AgeReverse. “We are building AgeReverse around a comprehensive view of healthy aging, and RESURGE represents the internal wellness component of that larger vision.” AgeReverse developed RESURGE around the scientific concept of the 12 Hallmarks of Aging, a framework used by researchers to describe interconnected biological processes associated with aging. Rather than focusing on a single ingredient or isolated wellness benefit, the company designed RESURGE as a multi-ingredient formulation intended to support multiple aspects of healthy aging and everyday wellness. The 90-capsule formulation combines ingredients including NMN, Resveratrol, Quercetin, Fisetin, CoQ10, Astragalus Extract, Hyaluronic Acid, Aronia Extract and Noni Berry into a simplified three-capsule daily regimen. Key features and benefits of RESURGE include: Designed to support all 12 Hallmarks of Aging through a comprehensive longevity-focused formulation Combines ingredients including NMN, Resveratrol, Quercetin, Fisetin, CoQ10, Astragalus Extract, Hyaluronic Acid, Aronia Extract, and Noni Berry Provides antioxidant support to help protect cells from oxidative stress and free radical damage Supports nutrient metabolism and overall cellular health Helps support cardiovascular health and immune system function Supports collagen formation, connective tissue development, and skin quality Helps maintain healthy joints, cartilage, bones, gums, and connective tissue Includes herbal ingredients traditionally used as capillary and blood vessel protectants Consolidates what the company describes as 15+ supplement protocols into a simplified 3-capsule daily routine Manufactured in GMP-certified facilities in Ontario, Canada using vegan capsules Registered as a Natural Health Product with Health Canada The Amazon availability also advances a broader AgeReverse strategy that extends beyond nutritional wellness. The company is developing a complete range of healthy aging products and technologies intended to address both internal wellness and external skin aging. The planned AgeReverse product range includes a Bioage Test, daily skincare products developed around the 12 Hallmarks of Aging, professional mesotherapy products for the medical aesthetics and medspa markets, and non-invasive mesotherapy technology designed to deliver skincare formulations without needles. “Our vision has always extended beyond one product,” Turkmen added. “We believe healthy aging should be approached from both inside and outside the body. RESURGE gives U.S. consumers an introduction to that philosophy, and Amazon gives us an important channel for building awareness and accessibility as the AgeReverse product range grows.” AgeReverse is positioning its expanding portfolio around a science-first philosophy aimed at men and women interested in longevity, healthy aging, cellular wellness and maintaining vitality as they age. The company plans to serve both consumers and professionals in the medical aesthetics market as additional products are introduced. RESURGE is now available to U.S. consumers on Amazon. AgeReverse plans to continue expanding its product range and U.S. presence as additional products become available. Visit the AgeReverse Website and follow the company on Instagram and LinkedIn. About AgeReverse AgeReverse is a Canada-based longevity wellness company focused on developing science-driven products designed to support healthy aging and cellular vitality. Founded by Kubi Turkmen, who has more than 30 years of experience in anti-aging innovation, the company’s approach combines longevity research, telomere science, and wellness innovation to create comprehensive healthy aging solutions. The company’s expanding AgeReverse platform includes longevity supplements and other wellness technologies designed to support multiple biological pathways associated with aging and long-term vitality. Products are manufactured in GMP-certified facilities in Ontario, Canada. FDA Disclaimer These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. ———————————————————————————————————————————————————————————— Creative BioTherapeutics Named 2026 Prix Galien USA Best Startup Nominee for Work Advancing CBT300 2026-10-16 · 24-7 Press Release · Biotech & pharma https://www.24-7pressrelease.com/press-release/539672/creative-biotherapeutics-named-2026-prix-galien-usa-best-startup-nominee-for-work-advancing-cbt300 Recognition marks a new chapter for the oncology-focused biotechnology company as it continues development of its investigational biologic candidate targeting mechanisms associated with cancer recurrence and treatment resistance. ———————————————————————————————————————————————————————————— Friendly Recovery Center Publishes New Resource on Low Libido and How Therapy Can Improve Intimacy 2026-10-16 · 24-7 Press Release · Biotech & pharma https://www.24-7pressrelease.com/press-release/539532/friendly-recovery-center-publishes-new-resource-on-low-libido-and-how-therapy-can-improve-intimacy Educational article explores the emotional, physical, and relationship factors affecting sexual desire and how therapeutic support may help improve intimacy. ———————————————————————————————————————————————————————————— Three Orelabrutinib Studies Presented in Oral Sessions at the 88th Annual Meeting of the Japanese Society of Hematology 2026-10-16 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382259/0/en/three-orelabrutinib-studies-presented-in-oral-sessions-at-the-88th-annual-meeting-of-the-japanese-society-of-hematology.html BEIJING, Oct. 16, 2026 -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that three studies of orelabrutinib, its novel BTK inhibitor, have been selected for oral presentations at the 88th Annual Meeting of the Japanese Society of Hematology (JSH 2026). ———————————————————————————————————————————————————————————— Microbiotica Raises £36 Million ($48 Million) in Series C Financing to Advance Pipeline into Phase 2 Clinical Development 2026-10-16 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382257/0/en/microbiotica-raises-36-million-48-million-in-series-c-financing-to-advance-pipeline-into-phase-2-clinical-development.html CAMBRIDGE, United Kingdom, Oct. 16, 2026 -- Microbiotica, a clinical-stage biopharma company developing a pipeline of orally-dosed, precision microbiome medicines, today announces the first close of a £36 million ($48 million) Series C financing. ———————————————————————————————————————————————————————————— FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED) 2026-10-16 · Roche · AI, Healthcare, Education, Food & drink, Biotech & pharma, Sustainability, Medical devices, Chemicals & materials https://www.roche.com/media/releases/med-cor-2026-10-16 FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favourable safety profile, regardless of TED activity or duration1,2   Enspryng (satralizumab) represents an important advance for people with TED, offering the first at-home SC treatment option every four weeks during maintenance phase, allowing for greater flexibility in how treatment is administered1 Enspryng is an anti-IL-6R mAb using novel recycling antibody technology designed to inhibit IL-6 signalling upstream of autoantibody-driven pathology2,3 TED is a rare autoimmune disease affecting approximately 155 out of every 100,000 people in the US that can lead to facial disfigurement and vision-threatening complications if left untreated3-7 Basel, 16 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Enspryng® (satralizumab) for the treatment of adults with thyroid eye disease (TED), providing patients with the first and only at-home subcutaneous treatment option. Enspryng can be administered by a person living with TED or a caregiver following training from a healthcare provider.1 “Today’s FDA approval of Enspryng provides an important new option for people with thyroid eye disease, who have long faced limited treatment choices,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “As the first subcutaneous treatment for this condition, Enspryng offers a positive safety and efficacy profile and the potential for at-home administration.” "Treating thyroid eye disease requires balancing efficacy, safety, and the practical realities of long-term treatment,” said César A. Briceño, MD, Clinical Trial Investigator and Associate Professor of Ophthalmology at the Scheie Eye Institute, University of Pennsylvania. “As a clinical trial investigator, I have seen firsthand the potential of targeted therapies such as Enspryng. The availability of an effective subcutaneous treatment option could provide greater flexibility for both patients and physicians while reducing the logistical burden associated with infusion-based therapies. Enspryng has the potential to meaningfully expand our therapeutic options for patients with thyroid eye disease." The totality of data from the pivotal Phase III SatraGO programme (SatraGO-1 and SatraGO-2) provided clinically meaningful improvements in patients with TED.1,2 While SatraGO-1 did not meet its pre-specified primary efficacy endpoint at Week 24, SatraGO-2 achieved significant and clinically meaningful difference in proptosis response (52.9% in the Enspryng group compared to 23.4% in the placebo group) and in diplopia reduction (60.7% in the Enspryng group compared to 25.8% in the placebo group) in the active TED population.1,2 Consistent results were achieved in the overall population (including both active and chronic patients) in SatraGO-2.1,2 No new safety signals were identified in the SatraGO trials, with Enspryng’s safety profile consistent with its known profile in neuromyelitis optica spectrum disorder (NMOSD).1,2 Full results were shared at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Fall Scientific Symposium in October 2025.2 “Thyroid eye disease not only affects a person’s eyes through bulging and vision problems, but it also takes a profound emotional toll on confidence, identity, relationships and daily life,” said Christine Gustafson, Chief Executive Officer of the TED Community Organization. “Until now, our community has had very limited choices. The approval of Enspryng represents a critical turning point through a convenient, targeted option.” The approval in TED, following a priority review designation, marks the second indication for Enspryng, following an approval in neuromyelitis optica spectrum disorder (NMOSD) in 2020.1,8,9 This follows a recent acceptance by the FDA for priority review in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).10 Enspryng is also being studied in additional neurological autoimmune and inflammatory diseases that may benefit from inhibition of IL-6 mediated signalling. About SatraGO-1 and -2 SatraGO-1 (NCT05987423) and -2 (NCT06106828) are identically designed, Phase III, randomised, placebo-controlled, multicentre studies to determine the efficacy, durability and tolerability of Enspryng for the treatment of adults with active, moderate‑to‑severe TED and chronic TED. The studies enrolled a total of 258 patients from 19 countries. Participants were randomised 1:1 to receive Enspryng or placebo. The primary endpoints were the proportion of participants with active, moderate-to-severe TED who achieved an at least 2 mm reduction in proptosis in the study eye from baseline at week 24.2,3 About thyroid eye disease (TED) TED, also known as Graves’ ophthalmopathy, is a complex inflammatory autoimmune disease, affecting the area around the eyes and the eyes themselves, that can be sight-threatening, debilitating and disfiguring.4,5 The most common symptoms are redness, swelling of the eyes, eyelid retraction, appearance of a stare, bulging of one or both eyes (proptosis), double vision (diplopia) and pain.4,6 TED is a progressive rare disease that affects approximately 155 people out of every 100,000.3-5,7 It most commonly occurs in people with hyperthyroidism, approximately 50% of whom experience at least mild TED, but it can also affect people with hypothyroidism or normal thyroid function.4,11 Despite existing approved treatments for TED, a medical need remains for therapies that are effective, well-tolerated, and have a convenient route of administration.3 About Enspryng® (satralizumab) Enspryng, developed by Chugai, a member of the Roche Group, is a humanised monoclonal antibody that is designed to bind to both soluble and membrane-bound interleukin-6 receptors (IL-6R), thereby inhibiting IL-6 mediated signalling, a known key pathway involved in inflammation. Enspryng incorporates Chugai’s proprietary antibody recycling technology, which enables pH-dependent binding to IL-6R and repeated engagement of the target, extending antibody circulation and supporting sustained inhibition of IL-6 mediated signalling.1-3,12 Enspryng is the first and only IL-6R inhibitor treatment currently approved in approximately 90 countries for neuromyelitis optica spectrum disorder (NMOSD), including in the European Union and United States, with a well established safety profile in over 16,000 patients.1,13 Roche is committed to developing Enspryng in additional neurological autoimmune and inflammatory diseases that may benefit from inhibition of IL-6 mediated signalling, including autoimmune encephalitis (AIE) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The FDA granted priority review of the Enspryng supplemental Biologics License Application (sBLA) for MOGAD in September 2026 with an approval decision expected in January 2027.10 Enspryng has orphan drug designation in the United States and European Union for NMOSD and MOGAD and in the United States for anti-NMDA receptor autoimmune encephalitis (anti-NMDAR AIE) and leucine-rich glioma-inactivated 1 autoimmune encephalitis (LGI1 AIE). About Roche in Ophthalmology At Roche, we are on a mission to save and restore eyesight. Over 330 million people around the world are blind, or living with vision loss, creating a profound personal and socioeconomic burden. With the broadest pipeline in Ophthalmology, we continue to invest at scale to redefine what is medically possible in eye care. Our comprehensive ophthalmology pipeline integrates diverse targets, advanced delivery systems, cell and gene therapies, and AI-augmented imaging capabilities, targeting multiple vision-threatening conditions, including retinal vascular and diabetic eye diseases, geographic atrophy, and autoimmune conditions, such as thyroid eye disease and uveitic macular edema. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Enspryng (satralizumab) Prescribing Information. [2] Briceño C, et al. Primary Results of the Phase 3 SatraGO-1 and SatraGO-2 Trials: Efficacy and Safety of Satralizumab in Thyroid Eye Disease. Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Fall Scientific Symposium, October 16–17, 2025. [3] Ezra D, Collins A, Haskova Z, et al. Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials. Ophthalmol Ther. 2025;14(12):3119-3132. doi:10.1007/s40123-025-01255-3 [4] McAlinden C. An overview of thyroid eye disease. Eye Vis (Lond). 2014;1:9. doi:10.1186/s40662-014-0009-8 [5] Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, Natural History, Risk Factors, and Prevention of Graves' Orbitopathy. Front Endocrinol (Lausanne). 2020;11:615993. doi:10.3389/fendo.2020.615993 [6] Thyroid eye disease. British Thyroid Foundation. Accessed October 12, 2026. https://www.btf-thyroid.org/thyroid-eye-disease-leaflet [7] Moledina M, Damato EM, Lee V. The changing landscape of thyroid eye disease: current clinical advances and future outlook. Eye (Lond). 2024;38(8):1425-1437. doi:10.1038/s41433-024-02967-9 [8] FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED). Accessed October 12, 2026. https://www.roche.com/media/releases/med-cor-2026-06-30 [9] FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD). Accessed October 12, 2026. https://www.roche.com/media/releases/med-cor-2020-08-17 [10] U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments. Accessed October 12, 2026. https://www.roche.com/media/releases/med-cor-2026-09-10 [11] Bahn RS. Emerging pharmacotherapy for treatment of Graves' disease. Expert Rev Clin Pharmacol. 2012;5(6):605-607. doi:10.1586/ecp.12.54 [12] Heo YA. Satralizumab: First Approval. Drugs. 2020;80(14):1477-1482. doi:10.1007/s40265-020-01380-2 [13] Enspryng (satralizumab) Summary of Product Characteristics. Accessed October 12, 2026. https://www.ema.europa.eu/en/documents/product-information/enspryng-epar-product-information_en.pdf Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone:  +41 79 377 83 75Albert Thottiyil Phone: +41 79 775 66 12 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.comDr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com  Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com   Attachment Media & investor Release Enspryng TED FDA English ———————————————————————————————————————————————————————————— FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED) 2026-10-16 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/fda-approves-genentech-enspryng-first-050000618.html FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favorable safety profile, regardless of TED activity or duration Enspryng (satralizumab-mwge) represents an important advance for peo ———————————————————————————————————————————————————————————— Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer 2026-10-16 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382247/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-enrolls-first-patient-in-phase-ib-ii-combination-trial-in-metastatic-colorectal-cancer.html Extending the Company's Immunologically Cold Tumor Strategy into Colorectal Cancer Extending the Company's Immunologically Cold Tumor Strategy into Colorectal Cancer ———————————————————————————————————————————————————————————— City Therapeutics Announces Pricing of Upsized Initial Public Offering 2026-10-16 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382239/0/en/city-therapeutics-announces-pricing-of-upsized-initial-public-offering.html City Therapeutics Announces Pricing of Upsized Initial Public Offering ———————————————————————————————————————————————————————————— CYCJET UV Laser Coding for Flexible Packaging Compliance 2026-10-16 · GlobeNewswire · SaaS, Food & drink, Industrial, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/16/3382233/0/en/cycjet-uv-laser-coding-for-flexible-packaging-compliance.html SHANGHAI, Oct. 15, 2026 -- China released GB 7718-2025 on March 16, 2025, with implementation set for March 16, 2027. As the food and pharmaceutical packaging industries face growing demands for marking clarity and traceability, CYCJET, brand of Shanghai Yuchang Industrial Co., Ltd., has launched the LU5T mini UV laser printer to deliver high-contrast coding on transparent films, aluminum foil, and colored composite films, while supporting production line integration. ———————————————————————————————————————————————————————————— UNICYCIVE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - UNCY 2026-10-16 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/319220/UNICYCIVE-DEADLINE-ROSEN-TRUSTED-INVESTOR-COUNSEL-Encourages-Unicycive-Therapeutics-Inc.-Investors-with-Losses-in-Excess-of-100K-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-UNCY New York, New York--(October 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs... ———————————————————————————————————————————————————————————— Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase 2026-10-15 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/estrella-immunopharma-treats-first-patient-224500869.html Patient received two infusions three weeks apart at the recommended Phase II dose; no treatment-related serious adverse events observed through the first month of follow-up EMERYVILLE, Calif., October 15, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage b ———————————————————————————————————————————————————————————— Symrise Expands Global Production Platform for Sustainable Musk Fragrance Ingredient 2026-10-15 · NewMediaWire · SaaS, Food & drink, Fashion & luxury, Industrial, Biotech & pharma https://www.newmediawire.com/news/symrise-expands-global-production-platform-for-sustainable-musk-fragrance-ingredient-7090659 Investment in world-scale capacity expansion in India for Globalide® to strengthen global supply Sustainable macrocyclic musk fragrance ingredient supports customers in developing future-ready fragrance formulations Globalide® strengthens portfolio of differentiated specialties and supports ONE Symrise strategy HOLZMINDEN, GERMANY - October 15, 2026 - Symrise is investing in an additional production capacity for Globalide® in India, expanding its global footprint for this strategic fragrance ingredient. The company is thus strengthening its ability to supply a sustainable macrocyclic musk fragrance ingredient and is moving closer to high-growth customer markets. At the same time, Symrise is expanding its Aroma Molecules business in an attractive product segment. The investment supports the ONE Symrise strategy through targeted capital allocation, resilient value creation and profitable growth driven by differentiated ingredients. “The investment in our Globalide® production footprint underlines our ambition to strengthen strategic product areas that create tangible value for our customers. With this step we are advancing our Scent & Care portfolio. Also, we are generating additional momentum for Symrise’s growth in line with our ONE Symrise strategy,” says Michael Friede, President Scent & Care at Symrise. Globalide® supports sustainable fragrance concepts In the fast-growing global fragrance ingredients market, ingredients that combine strong olfactory performance with versatility across applications and modern fragrance creations continue to gain importance. To deliver on this demand, Symrise is investing in additional world-scale production capacity for Globalide® in India.  The biodegradable macrocyclic musk ingredient adds long-lasting, elegant notes to fragrances and supports customers in developing more sustainable fragrance formulations. “With the additional production capacity in India, we are moving closer to the fast-growing markets in Asia while adding another pillar to our long-term global manufacturing footprint,” says Dr Keke Hiller, Global President Aroma Molecules at Symrise. “Globalide® combines high fragrance quality with a contemporary profile. Drawing on our product and technology expertise, we help customers develop attractive, future-ready products for consumers." Strengthening global supply through targeted investment By expanding its production footprint, Symrise is further strengthening its position in the market for specialty fragrance ingredients. The additional capacity increases flexibility across the global supply network and provides the foundation for meeting growing demand for Globalide® over the long term. Customers benefit from reliable access to an ingredient that combines high-quality fragrance performance with broad formulation versatility. About Symrise Symrise is a global supplier of flavors and fragrances, cosmetic base and active ingredients, and functional ingredients. Its customers include manufacturers of perfume, cosmetics, food, and beverages, as well as the pharmaceutical industry and producers of dietary supplements and pet food. With sales of around EUR 4.9 billion in the 2025 financial year, the company is one of the world’s leading providers. Headquartered in Holzminden, Germany, the Group has more than 100 sites in Europe, Africa and the Middle East, Asia, North America, and Latin America. Together with its customers, Symrise develops new ideas and market-ready concepts for products that have become an indispensable part of everyday life. Economic success and corporate responsibility are inextricably linked. Symrise - always inspiring more... www.symrise.com Media contact: Christina Witter Phone: +49 55 31 90-2182 E-mail: christina.witter@symrise.com Social media: linkedin.com/company/Symrise youtube.com/agsymrise xing.com/companies/symrise instagram.com/symriseag instagram.com/finefragrancestories_bySymrise instagram.com/symrise.ci ———————————————————————————————————————————————————————————— Kaplan Fox Advises Investors of Unicycive Therapeutics, Inc. (UNCY) of an Upcoming Securities Class Action Deadline on November 2, 2026 2026-10-15 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/318984/Kaplan-Fox-Advises-Investors-of-Unicycive-Therapeutics-Inc.-UNCY-of-an-Upcoming-Securities-Class-Action-Deadline-on-November-2-2026 New York, New York--(October 15, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) on behalf of investors that purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Unicycive and have suffered losses, you may CLICK HERE to contact us. You may... ———————————————————————————————————————————————————————————— New JAVMA Study Validates Accuplex™ by Antech™ as a Robust Option for Tick-Borne Disease Screening in Dogs 2026-10-15 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/javma-study-validates-accuplex-antech-203700724.html Peer-reviewed research finds Accuplex™ demonstrated significantly higher sensitivity for Ehrlichias spp. antibody detection compared to the SNAP® 4Dx® Plus test. LOVELAND, Colo., October 15, 2026--Antech, a global leader in veterinary diagnostics, today announced the publication of a new study in the J ———————————————————————————————————————————————————————————— Harmit Singh Joins Albertsons® Companies Board of Directors 2026-10-15 · Levi Strauss & Co. · Food & drink, Biotech & pharma https://www.levistrauss.com/2026/10/15/harmit-singh-albertsons/ Today, Albertsons® Companies, one of the largest food and drug retailers in the U.S., announced that it has named Levi Strauss & Co. Chief Financial and Growth Officer Harmit Singh to its board of directors. “I am honored to join Albertsons’ Board of Directors,” said Harmit. “Albertsons has a strong legacy, a portfolio of trusted… The post Harmit Singh Joins Albertsons® Companies Board of Directors appeared first on Levi Strauss & Co. ———————————————————————————————————————————————————————————— Global Biomarker-Driven Drug Development Market - Strategic Insights and Forecasts, 2026-2031 | Precision Medicine and Multi-Omics Drive 10.2% CAGR to USD 35.9 Billion 2026-10-15 · GlobeNewswire · AI, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/15/3381904/28124/en/global-biomarker-driven-drug-development-market-strategic-insights-and-forecasts-2026-2031-precision-medicine-and-multi-omics-drive-10-2-cagr-to-usd-35-9-billion.html Boost ROI through pharma-diagnostic collaborations, AI-driven analytics, multi-omics investment, and co-developed companion diagnostics and targeted therapies. Boost ROI through pharma-diagnostic collaborations, AI-driven analytics, multi-omics investment, and co-developed companion diagnostics and targeted therapies. ———————————————————————————————————————————————————————————— BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical Operations 2026-10-15 · Newsfile · Healthcare, Biotech & pharma https://www.newsfilecorp.com/release/319127/BetterLife-Pharma-Appoints-Sheila-Leitzinger-as-Head-of-Clinical-Operations Vancouver, British Columbia--(October 15, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, today announced that Sheila Leitzinger has joined the Company as Head of Clinical Operations.In this role, Ms. Leitzinger will lead clinical trial planning and execution for the initial healthy volunteer study of BETR-001, the Company's lead candidate, before the... ———————————————————————————————————————————————————————————— ORYZON further strengthens vafidemstat’s patent portfolio with new decisions to grant 2026-10-15 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/15/3381556/0/en/oryzon-further-strengthens-vafidemstat-s-patent-portfolio-with-new-decisions-to-grant.html MADRID and CAMBRIDGE, Mass., Oct. 15, 2026 -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that it has received new decisions to grant for patent applications in South Korea, the Philippines, New Zealand and Mexico, further strengthening its extensive patent portfolio for vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for psychiatric and neurodevelopmental disorders. ———————————————————————————————————————————————————————————— Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis 2026-10-15 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/15/3381553/0/en/eupraxia-pharmaceuticals-reaches-its-enrollment-target-for-the-resolve-trial-investigating-ep-104gi-for-the-treatment-of-eosinophilic-esophagitis.html VANCOUVER, British Columbia, Oct. 15, 2026 -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the ongoing RESOLVE study evaluating the safety and efficacy of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”) has reached its enrollment target. ———————————————————————————————————————————————————————————— Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates 2026-10-15 · GlobeNewswire · Finance, Healthcare, Industrial, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/15/3381552/0/en/jyong-biotech-announces-proposed-texas-facility-to-support-potential-commercialization-of-its-drug-candidates.html New Taipei City, Taiwan, Oct. 15, 2026 -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it plans to establish a potential new manufacturing facility and U.S. operations center in Texas. The initiative is intended to support the Company’s U.S. operations and position it for the potential future commercialization of its proprietary investigational drug candidates, if approved. ———————————————————————————————————————————————————————————— Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026 2026-10-15 · GlobeNewswire · Finance, SaaS, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/15/3381545/0/en/nautilus-biotechnology-to-announce-third-quarter-2026-financial-results-on-october-27-2026.html SEATTLE, Oct. 15, 2026 -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2026 before market open on Tuesday, October 27, 2026. ———————————————————————————————————————————————————————————— Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings 2026-10-15 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/xeris-biopharma-reinforces-leadership-endocrinology-120000138.html Clinical and scientific data presentations in support of Gvoke® (glucagon) injection, Recorlev® (levoketoconazole), and the investigational XP-8121 program underscore Xeris's leadership in endocrinology, including the treatments for Severe Hypoglycemia, Cushing's Syndrome, and Hypothyroidism CHICAGO, October 15, 2026 --( ———————————————————————————————————————————————————————————— Global Antibody Drug Conjugates (ADC) Market Forecast 2026-2030 by Cancer, Payload, Target, Product, User, and Region | Pipeline Growth and Licensing Deals Fuel Expansion 2026-10-15 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/15/3381450/28124/en/global-antibody-drug-conjugates-adc-market-forecast-2026-2030-by-cancer-payload-target-product-user-and-region-pipeline-growth-and-licensing-deals-fuel-expansion.html Map ADC opportunities across cancer type, payload, target, product, user and country, with insights on 100 companies, strategic plans, risks and growth drivers. Map ADC opportunities across cancer type, payload, target, product, user and country, with insights on 100 companies, strategic plans, risks and growth drivers. ———————————————————————————————————————————————————————————— insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies 2026-10-15 · Business Wire · AI, SaaS, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/insitro-announces-strategic-collaboration-astrazeneca-100000993.html Collaboration applies insitro's Virtual Human causal AI discovery platform to two diseases defined by patient heterogeneity and high unmet medical need insitro to receive $40 million upfront and up to approximately $1.46 billion in potential discovery, development, and commercial milestones, and tiered royalties SOUTH SAN ———————————————————————————————————————————————————————————— Roxus® ED Nasal Spray Now Available in the U.S.: Peak Blood Levels in About 10 Minutes, Not an Hour 2026-10-15 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/roxus-ed-nasal-spray-now-available-in-the-us-peak-blood-levels-in-about-10-minutes-not-an-hour-302909282.html Available by prescription through telemedicine partner Mavrox.com/Roxus . LTR Pharma Limited (ASX: LTP), the Australian pharmaceutical company, today announced that Roxus® is now available to men across the U.S. Roxus is a prescription nasal spray for erectile dysfunction (ED) that delivers vardenafil, the same type of ED medicine as Viagra®, used in tablets for more than 20 years, through LTR's pro ———————————————————————————————————————————————————————————— ORGANA Highlights In-House Manufacturing and GMP Practices 2026-10-15 · Newsworthy.ai · AI, SaaS, Healthcare, Retail, Food & drink, Industrial, Biotech & pharma https://newsworthy.ai/news/202610153058/organa-highlights-in-house-manufacturing-and-gmp-practices Springville, UT Thursday Oct 15, 2026 @ 5:00 AM Eastern — ORGANA, a Utah-based wellness company offering mineral and botanical products, is highlighting an important distinction in its business model: the company manufactures its products in-house, following Good Manufacturing Practices (GMP), rather than relying on third-party contract manufacturers. While many wellness brands outsource manufacturing to specialized production facilities, ORGANA maintains direct responsibility for its manufacturing operations. This approach gives the company greater oversight of production processes, quality-control procedures and the consistency of its product portfolio. For ORGANA, in-house manufacturing is part of a broader commitment to maintaining control over how its products are produced, from raw materials through finished goods. "There's a difference between selling a product with your name on it and actually manufacturing that product yourself," said Larry Mills, CEO of ORGANA. "We've chosen to handle our own manufacturing because we want direct oversight of the products we put into the marketplace. Quality is something we take seriously throughout the process." ORGANA follows GMP practices in its manufacturing operations, emphasizing established production procedures, quality controls and consistency. By keeping manufacturing in-house, the company can oversee its processes directly rather than depending on outside manufacturers to manage production on its behalf. The company's manufacturing approach supports a portfolio of mineral and botanical wellness products, including: Plant-Derived Trace Minerals - A liquid mineral product sourced from an ancient mineral deposit in Utah, offering naturally occurring trace minerals in a convenient format. Liquid Oxygen 125 PPM - A liquid product that is part of ORGANA's broader wellness portfolio. Essiac Tea - A botanical product based on a traditional herbal blend. Pomegranate Mineral Drink - A pomegranate-flavored liquid mineral product offering another way to incorporate minerals into everyday routines. These products reflect ORGANA's focus on mineral and botanical formulations, with in-house manufacturing providing a consistent approach to production oversight across the portfolio. Maintaining its own manufacturing operations also allows ORGANA to keep product development and production closely connected. As the company continues to grow its retail presence, this operating model remains an important part of its approach to quality and customer confidence. "Consumers don't always know who actually makes the products they're buying," Mills added. "For us, manufacturing isn't something we've handed off to another company. It's part of who we are and how we operate." ORGANA products are available through Amazon, Walmart and OneLavi.com, providing consumers with access to the company's mineral and botanical wellness portfolio. As ORGANA continues expanding its presence in the U.S. marketplace, the company plans to maintain its focus on in-house manufacturing, GMP practices and direct oversight of production. About ORGANA International Founded in 1997, ORGANA International is a wellness company committed to delivering natural, bioavailable products that help people live healthier lives. From trace minerals and liquid oxygen to magnesium creams and detoxification teas, ORGANA’s product line is designed to restore vital elements often missing in modern lifestyles. Headquartered in Springville, Utah, ORGANA is a customer-first company with a 5-star BBB rating and nearly three decades of dedication to natural wellness. FDA Disclaimer These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. ———————————————————————————————————————————————————————————— Sunnybrook Announces the Marg Gillespie Precision Oncology Centre to Advance Personalized Cancer Care 2026-10-15 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/sunnybrook-announces-marg-gillespie-precision-090000142.html $29 million in philanthropic support is the reason Sunnybrook will create a purpose-built clinical trials hub to accelerate discovery, advance personalized cancer care and increase access to emerging therapies for future patients. TORONTO, October 15, 2026--Sunnybrook Health Sciences Centre is proud t ———————————————————————————————————————————————————————————— TNT Says Don't Wait Until January to Reset Your Fitness Routine 2026-10-15 · Newsworthy.ai · AI, SaaS, Healthcare, Energy, Retail, Gaming, Education, Travel, Food & drink, Sports, Biotech & pharma https://newsworthy.ai/news/202610153060/tnt-says-dont-wait-until-january-to-reset-your-fitness-routine Boca Raton, Florida Thursday Oct 15, 2026 @ 4:00 AM Eastern —  Coming off its recent participation at ECRM, where True Nutrition Technology (TNT) featured its German sports nutrition portfolio during meetings with U.S. retail buyers, the company is turning its attention to a familiar seasonal fitness pattern: waiting until January to start again. TNT says fall offers an opportunity to do the opposite. Rather than allowing changing schedules, shorter days and the approaching holiday season to interrupt established fitness routines, athletes and active consumers can use the final months of the year to focus on consistency and enter January with momentum already established. "January gets a tremendous amount of attention in the fitness industry, but there's no reason to wait for a date on the calendar to get serious about your routine," said Markus Himmelstoss, Managing Director of TNT. "Fall can be a great time to reset, establish consistency and build habits that are already in place when the new year arrives." Fall Brings a Different Training Rhythm For many people, the transition from summer to fall changes how and when they train. Daylight hours become shorter, temperatures change, vacations end, school schedules return, and outdoor activities may begin shifting indoors. At the same time, the approaching holiday season can make regular training more difficult to maintain. TNT believes adapting to those changes is more useful than treating them as a reason to put fitness goals on hold until January. "Consistency doesn't mean every workout or every week has to look exactly the same," Himmelstoss said. "Schedules change. Seasons change. The important thing is finding a routine that works with those changes instead of continually stopping and starting." Building the Routine Before January The New Year's fitness surge has become an annual tradition, with January often associated with new gym memberships, new training programs and renewed attention to nutrition. TNT's message this fall is simple: the habits people hope to begin in January can start in October. Establishing a realistic training schedule during October, November and December can allow people to experiment with workout times, adjust routines and develop greater consistency before the calendar turns to a new year. That philosophy reflects TNT's broader approach to sports nutrition and training, which emphasizes supporting an active lifestyle over time rather than focusing on short-term trends. A Portfolio Built Around Active Lifestyles TNT's portfolio includes Creapure Creatine Monohydrate, CLEAR WHEY protein isolate, Synapsensause Pre-Workout, and Game Changer, its carbohydrate and electrolyte formulation. The German brand has built a customer base of more than 500,000 consumers and is now expanding its presence in the United States. Its recent ECRM participation was part of that effort, introducing U.S. retail buyers to TNT's broader portfolio while the company continues building awareness and distribution in the American market. "Whether someone trains year-round or is trying to get back into a routine, the fundamentals don't suddenly become important on January 1," Himmelstoss said. "Our message is to start where you are, build consistency and carry that momentum into the new year." TNT products are available to U.S. consumers through Amazon and OneLavi. Where American Consumers Can Purchase TNT Products TNT Creapure® Creatine Monohydrate Powder on OneLavi TNT Synapsensause Pre-Workout "Wild Berry" Pre-Workout Booster on Amazon TNT Synapsensause Pre-Workout "Wild Berry" Pre-Workout Booster on OneLavi TNT Clear Whey Protein Isolate - Peach Iced Tea on OneLavi About TNT (True Nutrition Technology) Founded in Germany by former athletes Michael Weigl and Markus Himmelstoss, TNT (True Nutrition Technology) is a leading sports nutrition brand trusted by more than 500,000 customers. Since 2012, TNT has produced premium supplements under strict German quality standards, with every product independently lab-tested for safety, purity, and transparency. TNT’s core product lineup includes Creatine Monohydrate with Creapure®, CLEAR WHEY Protein, and Synapsensause Pre-Workout-three performance-focused supplements widely used by athletes to support strength, recovery, energy, and training intensity. From advanced protein blends to innovative vegan formulations, TNT develops evidence-based nutrition designed to help athletes and everyday individuals perform at their best. More than just supplements, TNT represents a passion for sport, health, and performance. Built on German precision and a culture of honesty, TNT continues to expand globally with one mission: delivering the highest quality nutrition-for us, and for you. FDA Disclaimer These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. ———————————————————————————————————————————————————————————— invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal 2026-10-15 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/15/3381304/0/en/invios-publishes-positive-clinical-data-on-cbl-b-silenced-autologous-cell-therapy-apn401-in-peer-reviewed-journal.html invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal ———————————————————————————————————————————————————————————— DaltonTx awarded grant to accelerate AI-powered tuberculosis drug discovery 2026-10-15 · GlobeNewswire · AI, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/15/3381301/0/en/daltontx-awarded-grant-to-accelerate-ai-powered-tuberculosis-drug-discovery.html DaltonTx awarded grant to accelerate AI-powered tuberculosis drug discovery ———————————————————————————————————————————————————————————— Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325 2026-10-15 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/15/3381299/0/en/mission-therapeutics-doses-first-parkinson-s-patient-in-phase-1b-study-of-potential-disease-modifying-treatment-mtx325.html Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325 ———————————————————————————————————————————————————————————— Pharmaceutical Contract Manufacturing Market Expansion Driven by Outsourcing 2026-10-15 · Express Press Release · Industrial, Biotech & pharma https://express-press-release.net/news/2026/10/15/1776816 The pharmaceutical industry is changing how medicines move from development to commercial production. Instead of building every manufacturing capability internally, drug developers are increasingly relying [read full press release...] ———————————————————————————————————————————————————————————— Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board 2026-10-15 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/evotec-appoints-dr-joanna-holbrook-as-chief-scientific-officer-and-member-of-the-management-board-302909597.html Will lead Evotec's global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovation Brings more than 25 years of global experience in pharma, biotechnology and academia HAMBURG, Germany, Oct. 15, 2026... ———————————————————————————————————————————————————————————— OMass Therapeutics Announces $310 Million Series C Financing to Advance Portfolio of Small Molecule Therapeutics in Endocrinology and Immunology 2026-10-15 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/15/3381281/0/en/omass-therapeutics-announces-310-million-series-c-financing-to-advance-portfolio-of-small-molecule-therapeutics-in-endocrinology-and-immunology.html Financing co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with strong participation from additional new and existing investors ———————————————————————————————————————————————————————————— Unicycive Therapeutics, Inc. Class Action Reminder - Robbins LLP Encourages UNCY Investors to Contact the Firm About Their Rights 2026-10-14 · GlobeNewswire · Healthcare, Industrial, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/14/3381228/32719/en/unicycive-therapeutics-inc-class-action-reminder-robbins-llp-encourages-uncy-investors-to-contact-the-firm-about-their-rights.html Robbins LLP is investigating whether UNCY failed to properly inspect its third-party vendor's manufacturing facility per FDA requirements. ———————————————————————————————————————————————————————————— Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program 2026-10-14 · PR Newswire · Finance, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-provides-update-on-vqw-765-clinical-development-program-302909083.html Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpoint Consistent with prior studies, VQW-765 was safe and well tolerated WASHINGTON, Oct. 14, 2026 -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an... ———————————————————————————————————————————————————————————— Colossal Accelerates the Full Dodo De-extinction Pipeline 2026-10-14 · PR Newswire · AI, SaaS, Biotech & pharma https://www.prnewswire.com/news-releases/colossal-accelerates-the-full-dodo-de-extinction-pipeline-302908617.html New AI platform GenoMorph identifies candidate regulatory DNA linked to the dodo's distinctive craniofacial anatomy, while technologies adapted from earlier species programs advance Nicobar pigeon germ-cell development, chicken stem-cell chimeras and embryo gene editing. DALLAS, Oct. 14,... ———————————————————————————————————————————————————————————— MindMaze Therapeutics Reports New Home-Based Rehabilitation Results Ahead of MindMotion Lite Launch 2026-10-14 · NewMediaWire · AI, SaaS, Healthcare, Automotive, Biotech & pharma https://www.newmediawire.com/news/mindmaze-therapeutics-reports-new-home-based-rehabilitation-results-ahead-of-mindmotion-lite-launch-7090625 Multi-site Program Demonstrates Threefold Increase in Rehabilitation Training Dose, With 84% Delivered Independently and Significant Improvements Across Functional Measures GENEVA, SWITZERLAND - October 14, 2026 - MindMaze Therapeutics (SIX: MMTX), a global leader in scalable precision neurotherapeutics, today announced new real-world evidence from a multi-site program conducted with Vibra Healthcare, presented yesterday at the American Congress of Rehabilitation Medicine (ACRM) in Washington, DC. The program demonstrated that home-based rehabilitation using MindMotion increased total motor-training dose by a median factor of three compared with usual outpatient therapy alone. 84% of active training was completed independently, without direct therapist supervision. Participants also showed statistically significant improvements in functional independence, balance, mobility and cognition, alongside high patient satisfaction. Building on previously reported inpatient results with Vibra Healthcare, the findings further support MindMaze Therapeutics' strategy to extend high-dose, high-intensity neurorehabilitation into patients' homes. This is particularly relevant to the Company's upcoming launch of MindMotion Lite, expected by year-end 2026. Recently announced, the tablet-based solution is designed to deliver the full range of MindMotion GO neurotherapeutic activities with substantially reduced hardware requirements, simplifying home deployment and supporting broader adoption by healthcare providers. “Earlier this year, we showed that MindMaze's high-dose, high-intensity therapy, integrated into inpatient rehabilitation, delivers superior functional outcomes in a resource-efficient way,” said Zach Henderson, CEO of MindMaze Therapeutics. “Now, we are demonstrating that this value can extend into the home to address a well-recognized gap in care once patients leave the clinic, in line with the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery. These results, combined with our upcoming MindMotion Lite tablet-based solution, will help make high-quality neurotherapeutics more accessible. Together, these milestones bring us closer to our mission of making neurotherapeutics available at scale.” Study Design and Results The retrospective, multi-site quality improvement program evaluated 177 rehabilitation episodes involving 172 adults with a range of neurological conditions, primarily stroke, across four Vibra Healthcare outpatient sites, without a control group. Participants followed an eight-week home-training program using MindMotion GO, with an optional four-week extension and periodic therapist supervision. Key findings included: Training dose: Patients completed an average of 174 minutes of active training per week, with 84.4% delivered asynchronously. The additional home training increased total motor-training dose by a median factor of 3.0 compared with usual outpatient therapy alone, based on published assumptions for active practice during usual care. Feasibility and engagement: 92.7% successfully completed home setup, while 80.2% achieved the predefined minimum training exposure. Among surveyed participants, 83.8% of satisfaction ratings were positive. Functional outcomes: Statistically significant pre–post improvements were observed in independence (Barthel Index: +10.4 points), balance (Berg Balance Scale: +10.5 points), cognition (SLUMS: +3.4 points) and mobility (Timed Up and Go: −8.8 seconds) among participants with available paired assessments. The full poster, High-Dose, Home-Based Neurorehabilitation Using Gamified Technology: A Multi-Site Quality Improvement Program, is available at mindmazetherapeutics.com/mindmaze-platform/clinical-evidence. About MindMaze Therapeutics MindMaze Therapeutics (SIX: MMTX) is a global leader in scalable, precision neurotherapeutics, dedicated to redefining the recovery trajectory for patients around the world. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy. The company's FDA-listed and CE-marked products are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson's disease, and other neurological disorders. With an extensive library of rigorous clinical validation, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine. For more information, visit www.mindmazetherapeutics.com. Media & Investor Contacts Jeremy Meinen, Chief Financial Officer ir@mindmazetherapeutics.com DISCLAIMER This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise. Additional features: File: Press release_MindMaze_Home-Based Rehabilitation Results ———————————————————————————————————————————————————————————— Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2026-10-14 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/14/3381162/0/en/compass-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html BOSTON, Oct. 14, 2026 -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to a new employee under the Company’s 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). ———————————————————————————————————————————————————————————— Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026 2026-10-14 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/14/3381161/33333/en/coherus-oncology-to-host-webcast-to-disclose-interim-tagmokitug-clinical-data-on-october-28-2026.html REDWOOD CITY, Calif., Oct. 14, 2026 -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced that the Company will release interim clinical data related to its tagmokitug development program evaluating the cytolytic CCR8 antibody with toripalimab in multiple solid tumors on Wednesday, October 28, 2026. Coherus management will host a webcast from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time to discuss the data and provide additional context. The company has invited key opinion leaders to join the webcast and provide their clinical perspective. ———————————————————————————————————————————————————————————— Gerresheimer Improves Its EcoVadis Rating and is Once Again Awarded Gold 2026-10-14 · NewMediaWire · Finance, SaaS, Healthcare, Logistics, Biotech & pharma, Sustainability https://www.newmediawire.com/news/gerresheimer-improves-its-ecovadis-rating-and-is-once-again-awarded-gold-7090623 Gerresheimer among the top 5% of all rated companies Overall score increased to 82 out of 100 points Ranked in the top 1% in sustainable procurement DUSSELDORF, GERMANY - October 14, 2026 - Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries, has once again been awarded Gold by the sustainability rating provider EcoVadis. EcoVadis evaluates the management systems of companies worldwide in the categories of environment, labor and human rights, ethics, and sustainable procurement. More than 175,000 companies are evaluated by EcoVadis each year. In the latest rating, Gerresheimer increased its score from 78 (2025) to 82 out of 100 points. This places Gerresheimer among the top 5% of all companies rated by EcoVadis and within the top 2% in its industry. With this rating result, Gerresheimer underscores its progress in consistently implementing its sustainability targets. "With the improved EcoVadis rating and our first voluntary report based on the CSRD, we are making our sustainability performance measurable and transparent for our customers," explains Wolf Lehmann, CFO of Gerresheimer AG. "We remain committed to consistently pursuing our ambitious sustainability targets in the future." Gerresheimer among the top 2% in its industry Since 2011, Gerresheimer has relied on EcoVadis to have its sustainability management independently assessed across four different dimensions. In 2022, Gerresheimer achieved Gold status for the first time with a score of 68 out of 100 points and continued to improve its overall rating in the following years. In 2026, the company once again increased its score to 82 out of 100 points, placing Gerresheimer not only among the top 5% of all companies evaluated by EcoVadis but also within the top 2% in the industry. Gerresheimer performs particularly well in the area of sustainable procurement. Here, Gerresheimer ranks among the top 1% in the industry, underscoring the importance of responsible supply chains for its own sustainability performance. Internationally recognized sustainability rating EcoVadis’ comprehensive Corporate Social Responsibility (CSR) assessment framework is based on internationally recognized standards such as the UN Global Compact, the conventions of the International Labor Organization (ILO), the standards of the Global Reporting Initiative (GRI), the ISO 26000 standard, the CERES Principles, and the UN Guiding Principles on Business and Human Rights. The EcoVadis rating thus covers a wide range of information on companies performance in the areas of the environment, labor and human rights, ethics, and sustainable procurement, while taking industry-specific characteristics into account. Ambitious sustainability targets Gerresheimer has set ambitious goals to achieve measurable progress in the areas of climate protection, the circular economy, responsible supply chains, and social responsibility. With clear performance indicators, transparent reporting, and independent assessments, Gerresheimer ensures that progress is documented comprehensively and can be compared with international benchmarks. For the 2025 financial year, Gerresheimer has, for the first time, voluntarily submitted an audited, non-financial consolidated report based on the Corporate Sustainability Reporting Directive (CSRD). In doing so, the company has significantly advanced the structure of its sustainability reporting. The report is available for download here. In addition, Gerresheimer discloses relevant data annually on the EcoVadis platform and as part of the CDP rating. MSCI, Sustainalytics, and ISS also evaluate the company’s sustainability performance. An overview of Gerresheimer’s external sustainability assessments is available here. About Gerresheimer  Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of primary packaging solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes infusion, dropper and syrup bottles, tablet containers, vials, syringes, pens, auto-injectors, inhalers, ampoules, cartridges, on-body devices as well as digital solutions for therapy support. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With 39 production sites in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. The Group generated revenues of around EUR 2.3bn in 2025 and employs over 13,000 people. Gerresheimer AG is listed on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). www.gerresheimer.com Contact Gerresheimer Media   Jutta Lorberg Group Senior Director Communication & Marketing T +49 211 6181 264 jutta.lorberg@gerresheimer.com Dersim Korkmaz Manager Corporate Communication T +49 211 6181 296 dersim.korkmaz@gerresheimer.com   Investor Relations   Guido Pickert Vice President Investor Relations T +49 211 6181 220 gerresheimer.ir@gerresheimer.com ———————————————————————————————————————————————————————————— SS Innovations International (SSII) Submits FDA Response for SSi Mantra Surgical Robotic System 2026-10-14 · NewMediaWire · Finance, AI, Healthcare, Gaming, Media, Food & drink, Biotech & pharma https://www.newmediawire.com/news/ss-innovations-international-ssii-submits-fda-response-for-ssi-mantra-surgical-robotic-system-7090618 LOS ANGELES, CA - October 14, 2026 - SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced that it submitted its response to a request for additional information from the U.S. Food and Drug Administration (FDA) on Oct. 5, 2026, regarding its 510(k) submission for the SSi Mantra surgical robotic system. The response includes final data from an expanded human clinical and human factors validation study, as well as a bridging study completed in August 2026 at Hospital Internacional de Colombia, a member of the Mayo Clinic Care Network. The submission covers the initial indication of cholecystectomy, or gallbladder removal. The company anticipates that the FDA will complete its review of the response and 510(k) submission in the first quarter of 2027, advancing its efforts to introduce the SSi Mantra system to the U.S. market. To view the full press release, visit https://ibn.fm/A6dJ8 About SS Innovations SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery.  Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.  Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates. About the SSi Mantra The SSi Mantra surgical robotic system is a modular, multi-arm system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that is intended to provide equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart is designed to provide the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. ———————————————————————————————————————————————————————————— Portnoy Law Firm Announces Class Action on Behalf of Unicycive Therapeutics, Inc. Investors 2026-10-14 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/14/3381072/0/en/portnoy-law-firm-announces-class-action-on-behalf-of-unicycive-therapeutics-inc-investors.html LOS ANGELES, Oct. 14, 2026 -- The Portnoy Law Firm advises Unicycive Therapeutics, Inc., (“Unicycive” or the "Company") (NASDAQ: UNCY) investors of a class action on behalf of investors that bought securities between December 29, 2025 - June 29, 2026, inclusive (the “Class Period”). Unicycive investors have until November 2, 2026 to file a lead plaintiff motion. ———————————————————————————————————————————————————————————— CVS Caremark: Why Transparency Matters in Pharmacy Benefits 2026-10-14 · 3BL Media · SaaS, Healthcare, Media, Biotech & pharma, Sustainability https://www.3blmedia.com/news/cvs-caremark-why-transparency-matters-pharmacy-benefits CVS Caremark: Why Transparency Matters in Pharmacy Benefits Mon, 10/19/2026 - 08:15 Body Originally published on CVS Health Company Newsroom Key points 87% of employers say improving cost transparency is one of the biggest opportunities for PBMs CVS Caremark offers tools and solutions that provide greater visibility into pharmacy spending and cost drivers Understanding what drives health care costs has become increasingly important across the health care system. Employers, patients, providers and policymakers are looking for clearer insights into spending, treatment options and strategies that can help make medications and care more affordable and accessible. Key findings from the CVS Caremark-Employee Benefit News study on PBM transparency Recent research conducted by CVS Caremark and Employee Benefit News (EBN) highlights the growing importance of transparency in pharmacy benefits management. In The State of Pharmacy Management survey, 87% of employers said improving cost transparency represents one of the biggest opportunities for pharmacy benefit managers (PBMs), reflecting growing demand for clearer information and greater predictability when managing pharmacy benefits. For many employers, transparency is about making more informed decisions. While most employers report concerns about medication costs, only a minority believe they have significant influence over pharmacy spending. The survey also found that only 24% believe medication costs are fully transparent, highlighting the need for clearer information across the health care system. As health care becomes more complex, employers increasingly want partners that can help them understand not only what they are spending, but what is driving those costs. In the survey, employers identified visibility into pharmacy spending, benefit navigation support and access to affordable medications as key areas where PBMs can provide additional value. How CVS Caremark is bringing greater transparency to pharmacy benefits CVS Caremark is addressing these needs through tools designed to provide more informed benefit decisions. One example is CVS Caremark TrueCost™, which offers a pricing model focused on predictability, accountability, and greater understanding of how pharmacy benefit dollars are spent. Transparency also means giving employers better access to information. CVS Caremark's myPBM platform helps clients monitor pharmacy benefit trends, plan performance and cost drivers, helping identify opportunities for savings and optimize benefit strategies. Transparency can also make health care easier to navigate for patients and providers. When prescribers and pharmacists have access to Real-Time Benefits information and lower-cost alternatives, they can help patients better understand their options before arriving at the pharmacy counter. CVS Caremark has also expanded reporting capabilities that provide clients with greater visibility into drug pricing, rebates, and member costs. CVS CostVantage® and CVS Health's broader approach to transparency Across CVS Health, similar efforts are helping bring greater simplicity to the broader health care system. CVS CostVantage®, for example, is designed to align pharmacy reimbursement more closely with the underlying cost of medications and the services pharmacists provide. CVS Health describes the model as an important step toward greater transparency and sustainability across the pharmacy ecosystem. The CVS Caremark-EBN survey findings point to a broader trend across health care: employers are seeking more than cost management alone. They want clearer information, practical tools and greater confidence that they understand where health care dollars are going and how benefit decisions affect affordability, access and employee health. As health care continues to evolve, transparency will remain an important part of helping employers navigate change. By combining data-driven insights, enhanced reporting, point-of-care cost information and solutions such as TrueCost™, CVS Caremark is helping bring greater transparency to pharmacy benefits and support more informed health care decisions. Featured Image Type of Content Article ———————————————————————————————————————————————————————————— Late-Breaking Clinical Trial Results Announced at VIVA 2026 2026-10-14 · PR Newswire · Healthcare, Education, Biotech & pharma https://www.prnewswire.com/news-releases/late-breaking-clinical-trial-results-announced-at-viva-2026-302908752.html LAS VEGAS, Oct. 14, 2026 -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announced results from Late-Breaking Clinical Trial sessions at VIVA 2026, held at Bellagio... ———————————————————————————————————————————————————————————— Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib for Use as a First-line Treatment Option for Unresectable or Metastatic Hepatocellular Carcinoma 2026-10-14 · GlobeNewswire · Healthcare, Food & drink, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/14/3380931/0/en/elevar-therapeutics-resubmits-new-drug-application-to-fda-for-combination-of-camrelizumab-plus-rivoceranib-for-use-as-a-first-line-treatment-option-for-unresectable-or-metastatic-h.html FORT LEE, N.J., Oct. 14, 2026 -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients with cancer, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational drug rivoceranib, an oral VEGF-TKI, in combination with camrelizumab, an anti-PD-1 antibody, as a first-line systemic treatment option for unresectable or metastatic hepatocellular carcinoma (uHCC). ———————————————————————————————————————————————————————————— The Expanding Peptide Conjugate Landscape: Strategies for Complex Peptide Synthesis, Upcoming Webinar Hosted by Xtalks 2026-10-14 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/the-expanding-peptide-conjugate-landscape-strategies-for-complex-peptide-synthesis-upcoming-webinar-hosted-by-xtalks-302908584.html In this free webinar, learn how synthesis strategies can support the development of increasingly complex peptide conjugates. The featured speaker will discuss route selection, conjugation, purification and analytical methods across peptide-drug, radionuclide, oligonucleotide and... ———————————————————————————————————————————————————————————— New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups 2026-10-14 · WebWire · Healthcare, Biotech & pharma https://www.webwire.com/ViewPressRel.asp?aId=362822 � New prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposure � Findings build on first positive results where TREMFYA achieved combined fistula remission rates of up to 28% across dosing groups � Results come from the first dedicated Phase 3 randomized, placebo-controlled trial in adults managing Crohn's disease with perianal fistula in more than 20 years Johnson & Johnson today announce... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=362822 ———————————————————————————————————————————————————————————— NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development 2026-10-14 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/14/3380886/0/en/neonc-strengthens-boardroom-firepower-as-abu-dhabi-opens-a-new-path-for-brain-cancer-drug-development.html NeOnc (NASDAQ:NTHI) is strengthening its boardroom, as its clinical-development progress seeks to advance treatments for some of the most difficult cancers ———————————————————————————————————————————————————————————— Why Legacy Pathology Archives Matter for Rare-Disease Research 2026-10-14 · 3BL Media · AI, SaaS, Healthcare, Media, Education, Biotech & pharma https://www.3blmedia.com/news/why-legacy-pathology-archives-matter-rare-disease-research Why Legacy Pathology Archives Matter for Rare-Disease Research Mon, 10/19/2026 - 08:15 Body Why it matters Rare-disease research needs larger, richer historical datasets Digitized archives make decades of evidence searchable Historical tissue can reveal patterns previously missed Pathology archives often contain decades of clinically valuable information that is difficult to access in its original format. Glass slides may reveal evidence of disease patterns and support diagnostic decisions and tissue characteristics that were essential at the time of creation, but as scientific research data they are difficult to search, share and study at scale. As digital pathology matures, those archives are increasingly being viewed differently: not simply as storage, but as valuable research assets. Archives hold more than history This shift is significant because some of the most important questions in medicine cannot be answered with a small sample set. Rare diseases, unusual presentations and long-term retrospective analysis often require access to large collections of historical material. When slides are digitized, they become easier to review, compare, and organize for broader scientific use. Most importantly, not all slides need to be collocated for research as the data can be shared digitally. What was once a physical archive can begin to function as a structured digital dataset. This is where ScanVan™ excels. ScanVan is Leidos’ high-throughput whole-slide digitization platform, designed to bring scanning capability directly to the archive and help convert large volumes of glass slides into digital assets without requiring the collection to be moved off-site. In that sense, ScanVan is not the story itself; it is the operational example of how large-scale archive digitization can happen in practice. The opportunity is impactful for hospital systems and pharmaceutical organizations that are interested in retrospective research, biomarker discovery and future AI-enabled analysis. Digital pathology makes it easier to examine archived tissue in a consistent format, identify patterns across cases and connect specimen-level information to the larger research environment. The larger and more organized the archive, the more useful it becomes for research teams trying to understand rare conditions, compare historical samples or generate hypotheses for future studies. Unlocking value that’s already there A platform like ScanVan supports high-volume digitization in a way that is practical for large, complex archives. The work still has to be done carefully—with strong attention to image quality, chain of custody and operational control—but once the archive is digitized, it becomes a resource that can be used in new ways. In that sense, legacy pathology archives represent an untapped source of scientific value. They are already rich with information. Digitization simply makes that information easier to see, study and apply. For health systems, the question is no longer whether the archive has value. The question is how to unlock it. ScanVan by the numbers Developed in collaboration with the University of Pittsburgh’s Computational Pathology and AI Center of Excellence, ScanVan is designed for collections ranging from thousands to millions of slides. Based on 12-hour scanning days, Monday through Friday, the platform can digitize: More than 16,000 slides per week More than 67,000 slides per month More than 800,000 slides per year These figures demonstrate the operational scale required to turn a legacy archive into a usable research resource. Three things to remember Digitized slides can be shared and studied without physically collocating pathology collections Archive digitization requires strong image quality, chain-of-custody and operational controls ScanVan enables high-volume slide digitization while keeping pathology archives on-site   LEARN MORE ABOUT SCANVAN Canonical URL https://www.leidos.com/insights/why-legacy-pathology-archives-matter-rare-disea… Featured Image Type of Content Article ———————————————————————————————————————————————————————————— Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London 2026-10-14 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/14/3380698/0/en/century-therapeutics-to-attend-2026-jefferies-global-healthcare-conference-in-london.html PHILADELPHIA, Oct. 14, 2026 -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the company will attend the upcoming 2026 Jefferies Global Healthcare Conference in London on November 18, 2026. ———————————————————————————————————————————————————————————— CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference 2026-10-14 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/14/3380635/0/en/camp4-to-participate-in-chardan-s-10th-annual-healthcare-conference.html WATERTOWN, Mass., Oct. 14, 2026 -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the company will participate in a panel during Chardan’s 10th Annual Healthcare Conference on October 20, 2026. Details below: ———————————————————————————————————————————————————————————— Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference 2026-10-14 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/14/3380634/0/en/tvardi-therapeutics-to-participate-in-chardan-s-10th-annual-healthcare-conference.html HOUSTON, Oct. 14, 2026 -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will present at Chardan’s 10th Annual Healthcare Conference in New York City on Tuesday, October 20, 2026, at 1:30 PM ET. ———————————————————————————————————————————————————————————— Artificial Intelligence in Precision Medicine Market Demand Across Healthcare Applications 2026-10-14 · Express Press Release · AI, Biotech & pharma https://express-press-release.net/news/2026/10/14/1776728 The Artificial Intelligence in Precision Medicine Market is entering a high-growth phase as healthcare providers and pharmaceutical companies increasingly use AI to understand disease biology, [read full press release...] ———————————————————————————————————————————————————————————— Microvascular Therapeutics Selected to Present Investment Opportunity at ACQUICON 2026 2026-10-14 · PR.com · Healthcare, Biotech & pharma https://www.pr.com/press-release/981562 Microvascular Therapeutics, Inc. (“MVT”), a clinical-stage biotechnology company developing next-generation ultrasound imaging and therapeutic technologies, today announced that it has been selected to present in the ACQUICON 2026 Deal Room on Tuesday, October 20, 2026, from 12:30–1:30 p.m. Mountain Time at the Karen Gail Miller Conference Center in Salt Lake City. [PR.com] ———————————————————————————————————————————————————————————— Recent Release, "One Couple, Two Badges," from Page Publishing Author Sean Michaels, Chronicles a True Battle Against a Dangerous Criminal Enterprise 2026-10-14 · PR.com · Biotech & pharma https://www.pr.com/press-release/981207 Sean Michaels has completed a new book, "One Couple, Two Badges," a gripping account of two DEA agents whose partnership transformed from professional collaboration into an unbreakable bond forged in danger. Beginning as independent operatives working in tandem against street-level drug distribution, these agents soon recognized that dismantling the infrastructure at ground level would never achieve lasting [PR.com] ———————————————————————————————————————————————————————————— Global Digital Biomarkers Market Size, Share, Competitive Landscape, and Forecast - 2033 | AI and Remote Monitoring Drive 13.80% CAGR Toward USD 18.1 Billion 2026-10-14 · GlobeNewswire · AI, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/14/3380441/28124/en/global-digital-biomarkers-market-size-share-competitive-landscape-and-forecast-2033-ai-and-remote-monitoring-drive-13-80-cagr-toward-usd-18-1-billion.html Digital biomarkers can reduce clinical trial costs, improve compliance and outcomes, while remote monitoring lowers hospital readmissions and supports personalized care Digital biomarkers can reduce clinical trial costs, improve compliance and outcomes, while remote monitoring lowers hospital readmissions and supports personalized care ———————————————————————————————————————————————————————————— Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg 2026-10-14 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/14/3380396/0/en/alvotech-and-advanz-pharma-announce-first-known-regulatory-submission-worldwide-for-proposed-biosimilar-to-eylea-8-mg.html AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg) ———————————————————————————————————————————————————————————— Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda 2026-10-14 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/cancer-drug-spending-is-headed-past-400-billion-as-colorectal-and-pancreatic-cancers-move-up-the-research-agenda-302908253.html SAN DIEGO, Oct. 14, 2026 -- Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United States accounting for roughly 46% of the total. The... ———————————————————————————————————————————————————————————— Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-Pacific Markets 2026-10-14 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/14/3380361/0/en/nxera-pharma-enters-into-exclusive-license-supply-and-commercialization-agreement-with-synmosa-for-quviviq-daridorexant-across-eight-asia-pacific-markets.html Tokyo, Japan and Cambridge, UK, 14 October 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”; TSE: 4565) today announces that its subsidiary, Nxera Pharma Japan Co., Ltd. (“Nxera Pharma Japan”), has entered into an exclusive license, supply and commercialization agreement (the “Agreement”) with Taiwan-headquartered Synmosa Biopharma Corporation (“Synmosa”) for QUVIVIQ® (daridorexant), a treatment for insomnia, in Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia and New Zealand (the “Territory”). ———————————————————————————————————————————————————————————— Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM 2026-10-14 · PR Newswire · Finance, Biotech & pharma https://www.prnewswire.com/news-releases/telix-highlights-pivotal-trials-in-prostate-brain-and-renal-cancers-and-next-generation-theranostics-at-eanm-302907930.html MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2026 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that 20 company-related abstracts will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) to be... ———————————————————————————————————————————————————————————— Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity 2026-10-13 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/13/3380291/0/en/rhythm-pharmaceuticals-announces-commercial-launch-of-imcivree-setmelanotide-in-japan-for-patients-with-acquired-hypothalamic-obesity.html -- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan for patients living with acquired hypothalamic obesity -- ———————————————————————————————————————————————————————————— Orum Therapeutics Doses First Patient in Phase 1 Trial of ORM-1153, a CD123-GSPT1 Degrader-Antibody Conjugate 2026-10-13 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/13/3380286/0/en/orum-therapeutics-doses-first-patient-in-phase-1-trial-of-orm-1153-a-cd123-gspt1-degrader-antibody-conjugate.html Orum announced that the first patient has been dosed in a Phase 1 clinical trial evaluating ORM-1153, the Company’s investigational CD123-GSPT1 DAC. ———————————————————————————————————————————————————————————— SEC Qualifies GOA Therapeutics’ Public Offering to Sell Up to $300 Million in Stock; Set for Launch October 15 2026-10-13 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/13/3380284/0/en/sec-qualifies-goa-therapeutics-public-offering-to-sell-up-to-300-million-in-stock-set-for-launch-october-15.html Financing strategy is designed to advance GOA26, a first-in-class drug candidate for the treatment of acute alcohol intoxication and poisoning Financing strategy is designed to advance GOA26, a first-in-class drug candidate for the treatment of acute alcohol intoxication and poisoning ———————————————————————————————————————————————————————————— Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH 2026-10-13 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/13/3380250/0/en/liquidia-announces-global-settlement-resolving-all-pending-litigation-with-united-therapeutics-ensuring-continued-commercialization-of-yutrepia-in-pah.html MORRISVILLE, N.C., Oct. 13, 2026 -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it has entered into a global settlement agreement with United Therapeutics Corporation (Nasdaq: UTHR) that resolves all pending litigation between the companies. Importantly, YUTREPIA® (treprostinil) inhalation powder will remain available to patients with PAH without disruption. ———————————————————————————————————————————————————————————— INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD 2026-10-13 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/13/3380221/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-acadia-pharmaceuticals-inc-acad.html NEW YORK, Oct. 13, 2026 -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. ———————————————————————————————————————————————————————————— Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases 2026-10-13 · GlobeNewswire · AI, SaaS, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/13/3380182/0/en/generate-biomedicines-and-zealand-pharma-enter-collaboration-and-license-agreement-to-develop-protein-therapeutics-engineered-with-ai-for-metabolic-diseases.html Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions ———————————————————————————————————————————————————————————— Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases 2026-10-13 · GlobeNewswire · AI, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/13/3380177/0/en/zealand-pharma-and-generate-biomedicines-enter-collaboration-and-license-agreement-to-develop-protein-therapeutics-engineered-with-ai-for-metabolic-diseases.html Press release – No. 20 / 2026 ———————————————————————————————————————————————————————————— Suvoda makes Sofia AI assistant available for clinical trials to drive faster answers and action 2026-10-13 · PR Newswire · AI, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/suvoda-makes-sofia-ai-assistant-available-for-clinical-trials-to-drive-faster-answers-and-action-302903864.html Key Takeaways Clinical trials require guard railed AI that's purpose built for the regulated industry that has high human stakes and required audit trails. Sofia helps make complex, fast-moving trial data more accessible to study teams who manage large volumes of time-sensitive work. Study teams can get faster answers and take confident action. Sofia goes beyond information retrieval and can execute authorized system ———————————————————————————————————————————————————————————— Global In Vivo Cell Therapy Market Size, Share, Trends, and Forecast, 2026-2033 | Targeted Delivery and Cell Engineering Drive 49.6% CAGR Toward USD 5.72 Billion 2026-10-13 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/13/3379922/28124/en/global-in-vivo-cell-therapy-market-size-share-trends-and-forecast-2026-2033-targeted-delivery-and-cell-engineering-drive-49-6-cagr-toward-usd-5-72-billion.html Target North America and invest in targeted delivery and programmable cell-engineering to unlock new revenue streams in precision medicine. Target North America and invest in targeted delivery and programmable cell-engineering to unlock new revenue streams in precision medicine. ———————————————————————————————————————————————————————————— Treasure Global Signs MOU to Expand Medical Supply and Pharmaceutical Distribution Across Southeast Asia 2026-10-13 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/13/3379903/0/en/treasure-global-signs-mou-to-expand-medical-supply-and-pharmaceutical-distribution-across-southeast-asia.html Collaboration Targets Government and Institutional Procurement with Six-Month Exclusivity Collaboration Targets Government and Institutional Procurement with Six-Month Exclusivity ———————————————————————————————————————————————————————————— Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics 2026-10-13 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/13/3379885/18421/en/alaunos-therapeutics-announces-acquisition-of-velaris-therapeutics.html Acquisition of Velaris and concurrent oversubscribed $350 million private placement positions the Company to deliver multiple proof-of-concept datasets in pulmonary arterial hypertension ———————————————————————————————————————————————————————————— Nuravax and Institute for Molecular Medicine Announce Publication of Phase 1 Results for AV-1959R Amyloid-Beta Vaccine 2026-10-13 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/nuravax-and-institute-for-molecular-medicine-announce-publication-of-phase-1-results-for-av-1959r-amyloid-beta-vaccine-302905613.html Randomized, placebo-controlled study in 16 cognitively unimpaired participants met safety and immunogenicity objectives; all 12 vaccine recipients developed anti-Aβ antibodies after two priming doses Randomized, double-blind, placebo-controlled Phase 1 trial enrolled 16 cognitively... ———————————————————————————————————————————————————————————— MBX Biosciences to Participate in Upcoming November Investor Conferences 2026-10-13 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/13/3379600/0/en/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences.html CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor conferences: ———————————————————————————————————————————————————————————— Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference 2026-10-13 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/13/3379598/0/en/metagenomi-therapeutics-inc-to-participate-in-the-chardan-10th-annual-healthcare-conference.html EMERYVILLE, Calif., Oct. 13, 2026 -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a panel discussion titled “Genome Editing: Next-Wave Platforms Beyond CRISPR 1.0” at the Chardan 10th Annual Healthcare Conference on Tuesday, October 20, 2026, at 10:30 a.m. ET, being held in New York, NY. ———————————————————————————————————————————————————————————— aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry 2026-10-13 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/13/3379597/0/en/atyr-pharma-announces-publication-demonstrating-anti-fibrotic-effects-of-atyr0101-in-the-journal-of-biological-chemistry.html aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry ———————————————————————————————————————————————————————————— Envisagenics Awarded $2M+ NCI SBIR Grant to Expand AI-Driven RNA Splicing Analysis Capabilities Across Oncology Portfolio 2026-10-13 · GlobeNewswire · Finance, AI, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/13/3379587/0/en/envisagenics-awarded-2m-nci-sbir-grant-to-expand-ai-driven-rna-splicing-analysis-capabilities-across-oncology-portfolio.html Funding will advance translational readiness across Envisagenics’ cancer-specific programs for internal development and strategic partnering ———————————————————————————————————————————————————————————— TaiMed Biologics to Present Oral and Poster Presentations on TMB-365 and TMB-365/TMB-380 Combination Therapy at IDWeek 2026 2026-10-13 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/13/3379586/0/en/taimed-biologics-to-present-oral-and-poster-presentations-on-tmb-365-and-tmb-365-tmb-380-combination-therapy-at-idweek-2026.html Company will present on a single-dose escalation study of TMB-365 and on resistance in the context of the long-acting TMB-365 and TMB-380 maintenance regimen in people living with HIV Company will present on a single-dose escalation study of TMB-365 and on resistance in the context of the long-acting TMB-365 and TMB-380 maintenance regimen in people living with HIV ———————————————————————————————————————————————————————————— IFx 2.0 Market Size and Sales Forecast in the 7MM - 2034 | Phase III Momentum and Checkpoint Inhibitor Combinations Expand Commercial Potential 2026-10-13 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/13/3379448/28124/en/ifx-2-0-market-size-and-sales-forecast-in-the-7mm-2034-phase-iii-momentum-and-checkpoint-inhibitor-combinations-expand-commercial-potential.html Late-stage development, KEYTRUDA combination potential, orphan drug advantages and multiple tumor expansion position IFx-2.0 for faster adoption and portfolio returns. Late-stage development, KEYTRUDA combination potential, orphan drug advantages and multiple tumor expansion position IFx-2.0 for faster adoption and portfolio returns. ———————————————————————————————————————————————————————————— Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinic 2026-10-13 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/13/3379439/0/en/sibylla-biotech-appoints-usman-azam-ceo-gianluca-fuggetta-cfo-and-expands-executive-team-to-drive-transition-to-clinic.html Milan, Italy, October 13, 2026 – Sibylla Biotech today announced key executive appointments, including Usman Azam, MD, as Chief Executive Officer and Gianluca Fuggetta, MSc, MBA, as Chief Financial Officer. Both bring significant international corporate expertise, with Dr. Azam contributing more than 25 years of global biopharmaceutical executive, scientific and clinical development leadership. Co-founder and previous CEO Lidia Pieri, PhD, MBA, will remain with the company in the role of Chief Operating Officer. Sibylla also announced the promotion of Elena Ardini, MSc, from Vice President, Research and Development to Chief Scientific Officer. The executive leadership team expansion highlights the company’s progress in validating its differentiated folding interference protein degradation technology and its commitment to bringing its lead program into clinical evaluation. ———————————————————————————————————————————————————————————— Zelluna ASA: Invitation to Third Quarter 2026 Results Webcast Including ZIMA-101 Clinical Progress Update 2026-10-13 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/13/3379317/0/en/zelluna-asa-invitation-to-third-quarter-2026-results-webcast-including-zima-101-clinical-progress-update.html Oslo, 13 October 2026 – Zelluna (OSE: ZLNA), a clinical-stage biotechnology Company pioneering allogeneic, off-the-shelf T-cell receptor-based natural killer (TCR-NK) cell therapies for solid cancers, will publish its financial results for the third quarter of 2026 on Thursday, 5 November 2026. ———————————————————————————————————————————————————————————— Akiram Therapeutics: First clinical results from AKIR001 to be presented at EANM 2026 2026-10-13 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/akiram-therapeutics-first-clinical-results-from-akir001-to-be-presented-at-eanm-2026-302906622.html Akiram Therapeutics, a Swedish clinical-stage biotech company specializing in molecular radiotherapy, announces that the first clinical data from the ongoing Phase I trial of its lead drug candidate 177Lu-AKIR001 will be presented at the EANM 2026 Congress in Vienna, October 17-21.... ———————————————————————————————————————————————————————————— Frost & Sullivan Released the 2026 Global Gene Therapy Industry Development Blue Book 2026-10-13 · Newsfile · Healthcare, Industrial, Biotech & pharma https://www.newsfilecorp.com/release/318512/Frost-Sullivan-Released-the-2026-Global-Gene-Therapy-Industry-Development-Blue-Book Shanghai, China--(October 12, 2026) - Frost & Sullivan officially released the 2026 Global Gene Therapy Industry Development Blue Book in October 2026, in collaboration with industry partners. The report systematically examines the industry's development history, core technology classifications, policy and capital market dynamics, upstream and downstream value chains, bottlenecks in viral vector manufacturing, clinical progress across key indications, reimbursement pathways, and... ———————————————————————————————————————————————————————————— GCCL and LabConnect Sign MOU to Expand Global Clinical Trial Collaboration 2026-10-13 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/gccl-and-labconnect-sign-mou-to-expand-global-clinical-trial-collaboration-302906189.html Linking North American and Asia-Pacific Capabilities to Support Joint Sales and Project Execution SEOUL, South Korea and RALEIGH, N.C., Oct. 12, 2026 -- GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced today... ———————————————————————————————————————————————————————————— Teva to Host R&D Day on Wednesday, November 11 in New York City 2026-10-12 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/12/3379270/0/en/teva-to-host-r-d-day-on-wednesday-november-11-in-new-york-city.html TEL AVIV, Israel, Oct. 12, 2026 -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D Day, Teva’s leadership will discuss its R&D pipeline, its near-term value-creation potential over the next five years, and Teva’s ongoing transformation into an innovative biopharma company through the Pivot to Growth strategy. ———————————————————————————————————————————————————————————— M&A Healthcare Advisors Advises Innovo Detox on Sale to R&S Holdings, Inc. 2026-10-12 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/ma-healthcare-advisors-advises-innovo-detox-on-sale-to-rs-holdings-inc-302906156.html LOS ANGELES, Oct. 12, 2026 -- M&A Healthcare Advisors (MAHA), a FINRA-licensed investment bank focused on the healthcare industry, is pleased to announce the sale of Innovo Detox (Innovo), a Pennsylvania-based provider of substance use disorder (SUD) treatment and drug and... ———————————————————————————————————————————————————————————— Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist 2026-10-12 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/12/3379251/0/en/biomea-fusion-to-announce-phase-i-results-for-bmf-650-its-next-generation-oral-small-molecule-glp-1-receptor-agonist.html Company to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT) Company to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT) ———————————————————————————————————————————————————————————— BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 2026-10-12 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/12/3379226/0/en/bridgebio-oncology-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on October 10, 2026, under BBOT’s 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in September 2026. ———————————————————————————————————————————————————————————— Mental Health Screening Month: How Tech Is Fixing Therapy’s First-Month Dropout Problem 2026-10-12 · 3BL Media · SaaS, Healthcare, Retail, Media, Biotech & pharma https://www.3blmedia.com/news/mental-health-screening-month-how-tech-fixing-therapys-first-month-dropout-problem Mental Health Screening Month: How Tech Is Fixing Therapy’s First-Month Dropout Problem Mon, 10/12/2026 - 15:35 Body Every week, millions of people sit down with their mental health therapy provider, take a deep breath, and try to answer a deceptively simple question: “So, how was your week?” For many, answering that question feels like trying to reconstruct a faded memory. The intense anxiety felt while sitting in traffic on Tuesday or the sudden wave of overwhelm on Thursday evening has lost its sharp edges by Monday morning. Clients often spend the first 15 minutes of a 50-minute appointment trying to recap past events rather than diving into meaningful healing work. This disconnect between weekly visits is a major contributor to a quiet crisis in mental healthcare: one in four clients discontinue psychotherapy, most after a single session. At the same time, the market has been flooded with thousands of standalone consumer wellness apps, with research showing that roughly 89% - 92% of mental health applications are abandoned by clients. The reason is simple: self-guided algorithms can’t replace the trust, empathy and safety of a human therapist. Image Why Do Standalone Apps Fail Where Clinician-Guided Tools Succeed? Unlike standalone apps that ask users to navigate their mental health journeys alone, next-generation platforms are designed to operate directly within existing clinical practices. By keeping the mental healthcare provider at the center of the care journey, technology transforms from a passive self-help tool into an active bridge between sessions. Exemplifying this shift is ReliefAI Health, a digital health venture created through LG NOVA (the North American Innovation Center for LG Electronics), exemplifies this shift. ReliefAI is built as a digital cognitive behavioral therapy (CBT) platform, for providers and clients.   The mobile app enables clients to engage with their care plan daily and capture their mental state throughout their week.  This gives providers the ability to understand what is going on with their clients at those crucial times to be better able to assess and support their clients through the therapy process.  Rather than relying on paper notebooks or delayed memory, clients can use voice-journaling features while emotional experiences are still raw, work with interactive CBT exercises, complete clinical assessments and capture real-time mood patterns on their own schedule. How Does Between-Session Tracking Turn Passive Time Into Active Care? When technology integrates seamlessly into a clinic’s electronic health records system, the impact on care continuity is profound. "We see a crucial opportunity for technology to transform mental healthcare by strengthening the vital relationship between therapists and their clients," says the head of LG NOVA Sokwoo Rhee, Executive Vice President of Innovation at LG Electronics. "ReliefAI answers that need." Instead of starting an appointment with a blank slate, clinicians can review synthesized, objective data beforehand—observing mood trends, completed assessments and key themes from voice entries. Mental health providers begin the session already informed, bypassing routine recaps to focus immediately on deeper therapeutic progress. Rhee says this continuous model provides several distinct advantages for both clients and providers: Keeping clients connected to their therapeutic goals throughout the week can significantly reduce early dropout rates and help individuals stay committed through the critical first month. Tracking real-time insights that allow providers to tailor treatment plans dynamically and show clients tangible evidence of their growth over time. Remote therapeutic monitoring frameworks give practices structured clinical documentation and continuous engagement capabilities. What Does a Human-Centered Future for Mental Healthcare Look Like? As National Depression & Mental Health Screening Month highlights the growing demand for accessible, effective care, the narrative around digital health is evolving. The future of mental healthcare does not belong to standalone algorithms or automated substitutes for human connection, according to Rhee. Instead, the true breakthrough lies in next-generation platforms giving practitioners the data and visibility they need to do their best work, he says, adding: “By turning the days between sessions into an active, supported part of the healing process, clinician-guided technology can help assure that more people stay in care, build resilience and experience lasting well-being.” Featured Image Type of Content Article ———————————————————————————————————————————————————————————— SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease 2026-10-12 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/sparx-global-randomized-controlled-trial-by-translumina-initiated-to-advance-evidence-for-drug-coated-balloons-in-complex-coronary-disease-302905988.html LUCERNE, Switzerland and NEW DELHI, Oct. 12, 2026 -- The SPARX Global Randomized Controlled Trial (RCT) has been officially initiated, marking the launch of the multinational randomized trial evaluating a drug-coated balloon (DCB)-first strategy against contemporary... ———————————————————————————————————————————————————————————— Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit 2026-10-12 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/aardvark-therapeutics-inc-aard-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302905387.html LOS ANGELES, Oct. 12, 2026/PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Aardvark Therapeutics, Inc. IF YOU SUFFERED A LOSS ON YOUR AARDVARK THERAPEUTICS, INC. INVESTMENTS,... ———————————————————————————————————————————————————————————— UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky 2026-10-12 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/12/3379158/3080/en/uncy-shareholder-alert-november-2-2026-lead-plaintiff-deadline-in-unicycive-therapeutics-inc-securities-class-action-contact-levi-korsinsky.html A securities class action names Unicycive Therapeutics' Chief Executive Officer and Chief Financial Officer as individual defendants under Section 20(a) control person claims, alleging they controlled disclosures telling shareholders a third-party manufacturer had made "significant progress" toward FDA compliance that the Company had never verified through its own inspection A securities class action names Unicycive Therapeutics' Chief Executive Officer and Chief Financial Officer as individual defendants under Section 20(a) control person claims, alleging they controlled disclosures telling shareholders a third-party manufacturer had made "significant progress" toward FDA compliance that the Company had never verified through its own inspection ———————————————————————————————————————————————————————————— LEAD TECH Turns Booth LU-8931 into a Working Production Line at Pack Expo 2026, Demonstrating CIJ and UV Laser Coding on a Live Conveyor System 2026-10-12 · PR Newswire · Food & drink, Biotech & pharma https://www.prnewswire.com/news-releases/lead-tech-turns-booth-lu-8931-into-a-working-production-line-at-pack-expo-2026-demonstrating-cij-and-uv-laser-coding-on-a-live-conveyor-system-302905597.html The Continuous Inkjet Printer and UV Laser Marking Machine Manufacturer Behind 70,000+ Global Installations Invites Food, Beverage, and Pharmaceutical Manufacturers to See Both Systems Run at Production Speed at Booth LU-8931, Chicago, October 18–21 CHICAGO, Oct. 12, 2026 --... ———————————————————————————————————————————————————————————— Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis 2026-10-12 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/12/3378850/0/en/nexentis-mitocarex-bio-expands-computational-biology-capabilities-to-advance-disease-pathway-analysis.html MitoCareX expands its internal bioinformatics expertise to broaden the analysis of disease biology within its computational drug-discovery activities ———————————————————————————————————————————————————————————— Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- and Short-Acting G-CSF Options 2026-10-12 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/accord-biopharma-launches-filkri-filgrastim-laha-now-offers-both-long--and-short-acting-g-csf-options-302903915.html FILKRI is available with a permanent Q-code, standardizing the billing and reimbursement process across all sites of care. RALEIGH, N.C., Oct. 12, 2026 -- Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology,... ———————————————————————————————————————————————————————————— Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026 2026-10-12 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/12/3378849/0/en/palisade-bio-presents-new-clinical-pharmacokinetic-pharmacodynamic-and-mechanistic-data-strengthening-the-phase-2-rationale-for-pali-2108-in-ulcerative-colitis-and-crohn-s-disease-.html Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 development ———————————————————————————————————————————————————————————— Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C 2026-10-12 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/12/3378847/0/en/ardelyx-presents-real-world-data-at-acg-2026-showing-reduced-healthcare-resource-utilization-following-ibsrela-initiation-in-adults-with-ibs-c.html Additional presentations highlight the design of an ongoing Phase 3 study evaluating tenapanor in chronic idiopathic constipation and the impact of IBS-C symptom burden on quality of life Additional presentations highlight the design of an ongoing Phase 3 study evaluating tenapanor in chronic idiopathic constipation and the impact of IBS-C symptom burden on quality of life ———————————————————————————————————————————————————————————— Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway 2026-10-12 · PR Newswire · Finance, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/six-month-pilot-study-demonstrates-improved-guideline-adherence-following-implementation-of-standardized-cirrhosis-clinical-pathway-302905573.html LAVAL, QC, Oct. 12, 2026 -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management... ———————————————————————————————————————————————————————————— Global RNA Drugs Market Strategic Outlook, 2021-2031: Delivery, Value Chain, and Competition | 13%-15% CAGR Unlocks Pipeline and Manufacturing Opportunities 2026-10-12 · GlobeNewswire · Industrial, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/12/3378710/28124/en/global-rna-drugs-market-strategic-outlook-2021-2031-delivery-value-chain-and-competition-13-15-cagr-unlocks-pipeline-and-manufacturing-opportunities.html "RNA Drugs Market Strategic Analysis: Delivery Innovations, Value Chain, and Competitive Dynamics" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Global Oligonucleotide Synthesis Market Forecast to 2031 | Market to Reach US$32.72 Billion at 17.4% CAGR as RNA Therapeutics and Molecular Diagnostics Scale 2026-10-12 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/12/3378706/28124/en/global-oligonucleotide-synthesis-market-forecast-to-2031-market-to-reach-us-32-72-billion-at-17-4-cagr-as-rna-therapeutics-and-molecular-diagnostics-scale.html "Oligonucleotide Synthesis Market: Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Artificial Intelligence (AI) in Drug Discovery Market - Global Strategic Insights and Forecast, 2026-2031 | 31.7% CAGR Drives a USD 3.97 Billion Opportunity by 2031 2026-10-12 · GlobeNewswire · AI, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/12/3378704/28124/en/artificial-intelligence-ai-in-drug-discovery-market-global-strategic-insights-and-forecast-2026-2031-31-7-cagr-drives-a-usd-3-97-billion-opportunity-by-2031.html "Artificial Intelligence in Drug Discovery Market - Strategic Insights and Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— DuLac Farmaceutici Takes Next Step in U.S. Retail Growth Following ECRM Meetings 2026-10-12 · Newsworthy.ai · AI, SaaS, Healthcare, Retail, Food & drink, Sports, Industrial, Biotech & pharma, Sustainability https://newsworthy.ai/news/202610123049/dulac-farmaceutici-takes-next-step-in-us-retail-growth-following-ecrm-meetings Boca Raton, Florida Monday Oct 12, 2026 @ 5:00 AM Eastern — DuLac Farmaceutici is following up with prospective retail and distribution partners after participating in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session, held September 14-17 in Palm Beach Gardens, Florida. This event is marking another step in the Italian pharmaceutical company's effort to build a broader U.S. retail presence beyond its established Amazon business. The event provided an opportunity to discuss DuLac’s Italian-developed portfolio with buyers across health, specialty, food, drug and mass retail channels. The company is now continuing those conversations to explore product assortment and distribution opportunities in the United States. DuLac’s portfolio includes its high-concentration Arnica Gel 98% range, topical leg-care products, and the Dinaven and Diosmin lines. The portfolio reflects the company’s Italian manufacturing expertise, botanical formulation capabilities, and more than 30 years of pharmaceutical industry experience. Building on an Existing E-Commerce Presence DuLac enters these discussions with products already available to U.S. consumers through its Amazon storefront and OneLavi. Customer feedback provides an additional point of reference for prospective partners: The company’s Arnica Gel 98% listing on Amazon.com has an average customer rating of 4.5 out of 5 stars, offering prospective partners a reference point for consumer feedback as they evaluate the portfolio. "Our priority following ECRM is to work with prospective partners to identify the DuLac products that best fit their customers and channels,” said Gabriele Bollani, Founder and CEO of DuLac Farmaceutici. “We want to build lasting relationships by combining our Italian formulation and manufacturing expertise with a clear understanding of each partner’s commercial needs.” Italian Expertise Behind the Portfolio During the meetings, DuLac introduced buyers to the research and manufacturing approach behind its products, including its proprietary Arnica Montana Arricchita™ project and its work with botanical ingredients and advanced extraction technologies. The company’s European pharmacy heritage and Italian production provide the foundation for its portfolio. Follow-up discussions will focus on the products relevant to each prospective partner, their positioning and the requirements for a potential launch. U.S. Retail and Distribution Opportunities Following ECRM, DuLac is continuing discussions with prospective partners to assess product assortment, channel fit and distribution opportunities, while building on its existing U.S. e-commerce presence. The company's long-term objective is to establish DuLac as a nationally recognized U.S. brand across multiple channels, combining its European pharmacy heritage and Italian manufacturing with the consumer traction it has already established in the American market. About DuLac Farmaceutici DuLac Farmaceutici is an Italian pharmaceutical company specializing in dermo-cosmetic products developed through pharmaceutical-grade manufacturing standards. Built on more than 30 years of pharmaceutical industry expertise, the company combines botanical innovation, advanced extraction technologies, and modern manufacturing to create Italian-developed products for international markets. DuLac products are developed and manufactured in Italy using rigorous quality and sustainability standards. Learn more at DuLac Farmaceutici USA, through the company's Amazon Storefront, and on OneLavi. ———————————————————————————————————————————————————————————— On the 12th Edition of Global Patient Week Bristol Myers Squibb and Saudi Schizophrenia Association 'Ehtiwaa' Collaborate to Support People Living with Schizophrenia Through the 'Small Wins' Initiative 2026-10-12 · Bristol Myers Squibb · Healthcare, Biotech & pharma https://www.prnewswire.com/ae/news-releases/on-the-12th-edition-of-global-patient-week-bristol-myers-squibb-and-saudi-schizophrenia-association-ehtiwaa-collaborate-to-support-people-living-with-schizophrenia-through-the-small-wins-initiative-302905514.html Reinforcing its commitment to putting patients at the centre of everything it does, Bristol Myers Squibb (BMS), a leading global biopharmaceutical... ———————————————————————————————————————————————————————————— Micot Pharma Debuts MT200605 Huntington's Disease Research in a Poster Presentation at MDS 2026 and Expands Development into Neurodegenerative Diseases 2026-10-12 · ACN Newswire · SaaS, Healthcare, Biotech & pharma https://www.acnnewswire.com/press-release/english/110752/ Hong Kong, Oct 12, 2026 - The International Congress of Parkinson's Disease and Movement Disorders (MDS 2026) was held in Seoul, South Korea, from October 4 to 8, 2026. Micot Pharma (2335.HK) presented, for the first time in an electronic poster, nonclinical findings in Huntington's disease (HD) and Phase I clinical results in healthy volunteers for its independently developed drug candidate MT200605. Together with previously announced positive Phase II data in acute ischemic stroke (AIS), these findings are beginning to establish a development path for this small-molecule tropomyosin receptor kinase B (TrkB) agonist from acute brain injury to neurodegenerative diseases. On-site photo from the MDS 2026 Congress Organized by the International Parkinson and Movement Disorder Society, the MDS Congress is one of the largest and most influential international scientific meetings in the field. The selection of MT200605's Huntington's disease research for presentation signals recognition by the international scientific community of its clinical value in neurodegenerative diseases. For Micot Pharma, the significance of this appearance extends beyond the poster presentation itself. It brings MT200605's progress in clinical development for stroke into an international forum for scientific exchange on movement disorders and neurodegenerative diseases. It also gives the market a more complete view of the development program: animal-model findings and Phase I data in healthy volunteers are available for the HD program, Phase II topline results are available for AIS, and the TrkB mechanism provides the central link between research in acute brain injury and chronic neurodegenerative diseases. On-site photo from the MDS 2026 Congress MT200605 Explores Disease-Modifying Potential in Huntington's Disease through Motor Improvement and Preservation of Brain Structure Huntington's disease is an inherited, progressive neurodegenerative disorder. Patients gradually develop chorea, cognitive decline, and psychiatric and behavioral disturbances, eventually becoming fully dependent on care. Current treatments primarily manage symptoms; no treatment can yet halt or reverse disease progression. Protecting neurons and preserving neurological function are therefore important areas of research. The publicly available MDS 2026 abstract reports that MT200605 improved motor coordination and attenuated whole-brain, cortical, and striatal atrophy in transgenic HD mice. The study also found that levels of the striatal neuronal marker DARPP-32 were maintained and that aggregation of mutant huntingtin protein (mHTT) in the cortex was reduced. In vitro experiments showed activation of TrkB and downstream AKT signaling, as well as enhanced mitochondrial adenosine triphosphate (ATP) production in HD cells. The value of these findings lies in the converging evidence from behavioral, imaging, and cellular pathology measures. Beyond improved motor performance, changes in brain atrophy and aggregation of the disease-causing protein provide a more concrete basis for investigating a potential disease-modifying effect. The poster also presented results from a Phase I clinical study of MT200605 in healthy adults. The study used a single-center, randomized, double-blind, placebo-controlled design and comprised single ascending dose (SAD) and multiple ascending dose (MAD) stages. No serious adverse events, deaths, or withdrawals due to adverse events were reported. Drug-related adverse events were all mild and self-limiting. Pharmacokinetic results showed that drug exposure increased with dose, with no appreciable accumulation after multiple doses and an overall predictable pharmacokinetic profile. These results provide a safety and pharmacokinetic foundation for subsequent clinical studies in patient populations. TrkB Signaling Provides a Basis for Extending Development from Acute Brain Injury to Neurodegenerative Diseases A defining feature of MT200605's mechanism is its pharmacological modulation of the brain-derived neurotrophic factor (BDNF)/TrkB neurotrophic signaling pathway. This pathway contributes to neuronal survival, synaptic maintenance, and mitochondrial stability, providing an important biological basis for neuroprotection and the preservation of function. MT200605's pharmacological design reportedly combines agonism of the BDNF/TrkB pathway with attenuation of oxidative stress and relief of microcirculatory impairment caused by calcium ion-induced contraction of vascular smooth muscle. The development rationale is to explore more comprehensive neuroprotection by intervening in multiple components of the injury process. From a mechanistic perspective, targeting TrkB provides a rationale for extending MT200605's development into chronic neurodegenerative diseases. Although the pathogenic processes of stroke and Huntington's disease differ substantially, neuronal injury, loss of function, and insufficient neurotrophic support offer points of entry for research across diseases. The findings across multiple measures in the HD model provide new experimental support for this direction. Positive Phase II Stroke Results Show a Significant Reduction in Disability and Potential for Renal Protection MT200605 has completed a Phase II clinical trial in acute ischemic stroke. The multicenter, randomized, double-blind, placebo-controlled study enrolled 360 participants. The primary efficacy endpoint was the proportion of patients achieving a modified Rankin Scale (mRS) score of 0-1 at 90 days after stroke onset. Results disclosed by the company show that the proportions of patients achieving favorable functional outcomes in both the medium- and high-dose groups were higher than in the placebo group, demonstrating a treatment advantage rarely seen among drugs in this class. For the high-dose group, achieving an mRS score of 0-1 corresponded to an increase of more than 100% in the odds of functional recovery versus placebo, as reflected by the odds ratio (OR). In terms of clinical benefit, approximately one additional patient moved from "requiring assistance" to "being able to live largely independently" for every six patients treated. Over decades of neuroprotective drug development, agents demonstrating such a marked difference in functional outcomes versus placebo in a randomized controlled trial have been exceptionally rare. The difference between the high-dose group and placebo was statistically significant, and the study showed a clear dose-response relationship. The study also observed a trend toward early neurological recovery in the high-dose group, with no serious adverse events related to the investigational drug. For stroke-associated acute kidney injury (AKI), the study also observed a trend toward a dose-dependent reduction in incidence, providing exploratory clinical evidence for further research into the mechanism of "dual brain and kidney protection." The design rationale for this dual protection was validated in the Phase II trial: MT200605 significantly reduced disability and showed the potential to lower AKI incidence in patients with AIS in a dose-dependent manner. AKI incidence in the high-dose group was more than 80% lower than in the placebo group. This result addresses the existing therapeutic gap in preventing AKI in patients with AIS. Neurological Recovery and Combined Brain and Kidney Protection Offer the Potential to Fill a Therapeutic Gap Currently, no neuroprotective drug for AIS has a Class I recommendation supported by Level A evidence in Chinese clinical guidelines. Most marketed agents have Class II recommendations supported by Level B evidence. Mainstream neuroprotective drugs in China include butylphthalide, edaravone, and edaravone dexborneol. Their mechanisms are generally limited to blocking injury through one or two targets, without a mechanistic design that simultaneously promotes neural repair, and none has demonstrated a statistically significant difference in long-term functional outcomes such as those measured by the mRS. Butylphthalide has a research foundation in neuroprotection involving multiple targets. The randomized BAST trial enrolled 1,216 patients with acute ischemic stroke who received intravenous thrombolysis and/or endovascular treatment. Favorable functional outcomes at 90 days were achieved by 56.7% of patients in the butylphthalide group and 44.0% in the placebo group. The endpoint used different mRS thresholds according to baseline stroke severity, providing evidence for combining neuroprotection with reperfusion treatment. Edaravone's principal pharmacological action is free radical scavenging, while edaravone dexborneol extends antioxidant and anti-inflammatory intervention through a combination formulation. In the Phase III TASTE study involving 1,165 patients, the proportions achieving an mRS score of ≤1 at 90 days were 67.18% in the edaravone dexborneol group and 58.97% in the edaravone group. Edaravone dexborneol was superior to edaravone, with a statistically significant difference. The research indicates that MT200605's differentiation should not be reduced to a simple numerical comparison of efficacy with existing agents. The more relevant question to follow is whether the TrkB neurotrophic pathway can translate the functional outcome signals observed in patients with AIS into clinical benefits in chronic neurodegenerative diseases. As a first-in-class (FIC) investigational drug, MT200605 has completed clinical proof of concept. Its effect size far exceeds that of other neuroprotective agents, and it has the potential to become the first treatment in this field to receive high-level recommendations as a first-line option in both Chinese and international clinical guidelines. Another "silent killer" can emerge following stroke: acute kidney injury (AKI). Approximately 19% of patients with AIS develop AKI, and the risk of in-hospital death among patients with AKI is around two to three times that of patients without AKI. Product labeling for approved mainstream neuroprotective drugs advises caution or contraindicates use in patients with impaired renal function or severe renal failure. As a result, precisely those stroke patients facing a higher risk of death are excluded from treatment. A further reason to follow MT200605 is that, alongside the positive signals for 90-day functional outcomes in the AIS Phase II trial, the company has disclosed a new area of investigation: renal protection after stroke. According to Micot Pharma's announcement, AKI incidence in the high-dose group was approximately 80% lower than with placebo in the Phase II data. This means that MT200605 is currently the world's only investigational neuroprotective drug with the potential to specifically prevent and treat post-stroke AKI, and the only agent in this class that could potentially be approved and used with a "renal protection" claim in its labeling. MT200605's ability to protect both the brain and kidneys is closely linked to its distinctive mechanism of action. TrkB receptors are expressed not only in brain tissue but also in renal podocytes, renal tubular epithelial cells, and the juxtaglomerular apparatus. Their activation can stabilize the podocyte cytoskeleton, inhibit renal tubular epithelial cell apoptosis by counteracting endoplasmic reticulum stress through PI3K/AKT signaling, and activate antioxidant defenses through the nuclear translocation of nuclear factor erythroid 2-related factor 2 (NRF2), an important target of neuroprotective drugs. A single molecule protects two organs affected by stroke. The protective pathways in the brain and kidneys share the core PI3K/AKT signaling cascade, disrupting at its origin the vicious cycle of brain injury leading to AKI, worsening renal function, and further aggravation of brain injury. The MDS presentation and AIS Phase II topline results are therefore complementary. The former expands MT200605's international scientific visibility and the scope of its HD research, while the latter provides a translational foundation in patient functional outcomes. For a biopharmaceutical company focused on innovative medicines, a development program built around one mechanism, multiple disease settings, and progressively accumulating evidence at different levels often has greater scope for expansion than an early-stage narrative centered on a single indication. Conclusion In the near term, MDS 2026 has given Micot Pharma an international platform to present its research in movement disorders. Over the medium to long term, the program's value as a platform will depend on whether the company can continue to use verifiable clinical data to translate the potential of the TrkB mechanism across different disease settings into benefits for patients. For the capital markets, this is the central rationale for continuing to follow MT200605's development. ———————————————————————————————————————————————————————————— Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer 2026-10-12 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/12/3378545/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-granted-fda-fast-track-designation-for-first-line-advanced-or-metastatic-biliary-tract-cancer.html Second FDA Fast Track Designation for Opamtistomig Underscores Its Potential in Immunologically Cold Tumors Second FDA Fast Track Designation for Opamtistomig Underscores Its Potential in Immunologically Cold Tumors ———————————————————————————————————————————————————————————— InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China 2026-10-12 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/12/3378539/0/en/innocare-announces-approval-of-clinical-trial-of-bispecific-antibody-icp-b161-targeting-tl1a-and-il-23p19-in-china.html ICP-B161 delivers an extended half‑life, which allows for less frequent dosing and supports subcutaneous administration. ———————————————————————————————————————————————————————————— ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY 2026-10-11 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/11/3378536/673/en/rosen-a-ranked-and-leading-law-firm-encourages-unicycive-therapeutics-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-uncy.html WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— AARD DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD 2026-10-11 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/11/3378535/673/en/aard-deadline-notice-rosen-a-highly-recognized-law-firm-encourages-aardvark-therapeutics-inc-investors-to-secure-counsel-before-important-october-13-deadline-in-securities-class-ac.html WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Aardvark’s February 13, 2025 initial public offering (“IPO”); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the “Class Period”), of the important October 13, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026 2026-10-11 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/11/3378529/0/en/first-tracks-biotherapeutics-to-announce-top-line-data-from-cohort-1-of-phase-1b-trial-of-anb033-a-cd122-antagonist-in-celiac-disease-on-oct-12-2026.html First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT. ———————————————————————————————————————————————————————————— ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY 2026-10-11 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/318474/ROSEN-TRUSTED-INVESTOR-COUNSEL-Encourages-Unicycive-Therapeutics-Inc.-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-UNCY New York, New York--(October 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs... ———————————————————————————————————————————————————————————— Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026 2026-10-11 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/celltrion-to-present-new-analyses-of-zymfentra-infliximab-dyyb-in-crohns-disease-and-ulcerative-colitis-at-acg-2026-302903609.html New data show favorable outcomes with subcutaneous infliximab following intravenous infliximab interruption, regardless of prior antibody status, in adult patients with moderate to severely active Crohn's disease and ulcerative colitis Late-breaking analysis shows significantly higher... ———————————————————————————————————————————————————————————— Sebela Pharmaceuticals to Present Positive Phase 3 Tegoprazan Data in Non-Erosive Reflux Disease (NERD) at the American College of Gastroenterology (ACG) 2026 Meeting 2026-10-11 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/sebela-pharmaceuticals-to-present-positive-phase-3-tegoprazan-data-in-non-erosive-reflux-disease-nerd-at-the-american-college-of-gastroenterology-acg-2026-meeting-302903109.html Key Highlights: Tegoprazan is the first and only P-CAB reported to demonstrate clinical improvement in both hallmark symptoms of NERD, heartburn and regurgitation, in a prospective U.S. phase 3 clinical trial. Detailed analysis from the randomized, double-blind, placebo-controlled Phase 3... ———————————————————————————————————————————————————————————— Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss 2026-10-10 · Roche · AI, Healthcare, Food & drink, Biotech & pharma, Medical devices https://www.roche.com/media/releases/med-cor-2026-10-10 In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks1,2 UME is the leading cause of moderate and severe vision loss in patients with uveitis, posing a significant risk of blindness if left untreated3,4 The FDA has accepted Roche's Biologics License Application (BLA), with an approval decision expected by July 2027 Basel, 10 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart compared with a sham procedure that mimics intravitreal (IVT) injections in adults with uveitic macular edema (UME). Across both studies, data continue to support the potential for rapid and sustained improvements in vision and reductions in macular thickness (swelling in the back of the eye due to retinal fluid) with vamikibart treatment. The data were presented at the American Academy of Ophthalmology 2026 Annual Meeting (AAO 2026) in New Orleans, LA.1 Additionally, the U.S. Food and Drug Administration (FDA) has accepted Roche’s Biologics License Application (BLA) for vamikibart for the treatment of UME. The filing acceptance is based on the results from the MEERKAT and SANDCAT studies. The FDA is expected to make a decision on approval by July 2027. If approved, vamikibart would be the first non-steroid targeted treatment for UME, with potential to establish a new standard of care. Regulatory submissions have also been filed and accepted in the European Union, China and Japan. “These one-year results strengthen vamikibart’s clinical profile, confirming that initial visual and anatomical improvements are maintained over 52 weeks,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The acceptance of our application by the FDA and other regulatory bodies around the world brings us closer to offering a transformative, non-steroid therapy for people living with this sight-threatening condition.” “Currently, UME is commonly treated with off-label therapies or ocular steroids, the latter carrying significant long-term side effects like glaucoma and cataract formation,” said Nisha Acharya, M.D., M.S., Distinguished Professor of Ophthalmology at UCSF and Director of the Uveitis and Ocular Inflammatory Disease Service. “Vamikibart is the first non-steroid targeted therapy to demonstrate meaningful and sustained visual and anatomical improvements in people with UME, offering a potential new treatment option that directly targets the inflammation driving this sight-threatening condition.” The 16-week primary analysis results were presented at the AAO meeting in October 2025.2 In both MEERKAT and SANDCAT at 52 weeks, a numerically higher proportion of vamikibart-treated patients achieved vision gains compared to sham treatment on the primary endpoint. Key secondary endpoints showed this benefit was maintained, with sustained improvements in average change from baseline in best corrected visual acuity (BCVA) and average change from baseline in central subfield thickness (CST), a key measure of macular edema. Vamikibart demonstrated durable clinical benefit with a low treatment burden: approximately two-thirds of eligible patients required no retreatment after 16 weeks, while the majority of those who did required only one additional injection. Vamikibart was well tolerated, maintaining a favourable safety profile, with a low incidence of treatment-related ocular adverse events (AEs) and intraocular inflammation (IOI) events.1 UME is the leading cause of moderate-to-severe vision loss in individuals with uveitis, predominantly affecting working-age adults.3,4 Approximately 20% of UME patients progress to sustained blindness within three years of diagnosis.5 Standard-of-care treatments, primarily high-dose or local corticosteroids, carry substantial long-term risks, including secondary cataracts and elevated intraocular pressure leading to glaucoma.6-11 As a targeted anti-IL-6 monoclonal antibody, vamikibart is being developed to address these clinical unmet needs and deliver sustained visual preservation.1,12 About the MEERKAT and SANDCAT studies MEERKAT (NCT05642312) and SANDCAT (NCT05642325) are identical Phase III, global, parallel, multicentre, randomised, double-masked, sham comparator-controlled, 52-week trials of intravitreal (IVT) vamikibart in uveitic macular edema (UME). In both trials, patients were randomised and received treatment every four weeks with either 0.25 mg vamikibart, 1 mg vamikibart or sham IVT injection, for up to 16 weeks, followed by PRN treatment through week 52. The primary endpoint of both Phase III trials was the proportion of participants with a 15 letter or more improvement from baseline in best corrected visual acuity (BCVA) at week 16. Key secondary endpoints included the average change from baseline in BCVA and CST at week 16.  The safety of vamikibart was assessed through adverse events (AEs) such as treatment related ocular AEs, intraocular inflammation (IOI) and retinal occlusive vasculitis. The studies included participants with and without prior IVT treatment history and included patients with history of raised IOP and glaucoma.2,13,14 About uveitic macular edema (UME) UME is characterised by the buildup of fluid in the macula due to uveitis, an inflammatory eye condition.3 Although rare compared to other eye diseases, UME has a disproportionate impact on vision loss and blindness globally.3,15-20 It is the leading cause of moderate and severe vision loss in people with uveitis, and the most frequent sight threatening complication in uveitis.17-22 Uveitis accounts for 10% to 20% of blindness in the United States and Europe, and up to 25% of blindness in the developing world.23 UME has a significant negative impact on people's quality of life, including physical and mental health, social functioning, and visual function for day-to-day activities such as driving and reading.22,24,25 Steroids, the current standard of care for UME, are associated with significant serious side effects such as increased pressure in the eye, glaucoma and cataracts, and have recognised efficacy limitations.6-11 About vamikibart Vamikibart is an investigational monoclonal antibody that has been specifically engineered for IVT administration.1,2,12 It targets interleukin-6 (IL-6), a key cytokine in the inflammatory pathway in UME.1,2,12 In the Phase I DOVETAIL study, vamikibart provided rapid vision improvements and resolution of macular edema in people with UME.12 Vamikibart was also well tolerated, with no treatment-related serious adverse events reported.12 Based on the promising Phase I DOVETAIL data, Roche initiated the two identical Phase III vamikibart studies MEERKAT and SANDCAT.1,2,12 Vamikibart is being investigated in retinal diseases with recognised inflammatory pathways. Vamikibart has orphan drug designation in the United States and European Union. About Roche in Ophthalmology At Roche, we are on a mission to save and restore eyesight. Over 330 million people around the world are blind, or living with vision loss, creating a profound personal and socioeconomic burden. With the broadest pipeline in Ophthalmology, we continue to invest at scale to redefine what is medically possible in eye care. Our comprehensive ophthalmology pipeline integrates diverse targets, advanced delivery systems, cell and gene therapies, and AI-augmented imaging capabilities, targeting multiple vision-threatening conditions, including retinal vascular and diabetic eye diseases, geographic atrophy, and autoimmune conditions, such as thyroid eye disease and uveitic macular edema. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Acharya N, et al. Vamikibart for Uveitic Macular Edema: Week 52 Efficacy and Safety Results From the Phase 3 MEERKAT and SANDCAT Trials. Presented at: the American Academy of Ophthalmology Annual Meeting (AAO 2026); 2026 October 10; New Orleans, Louisiana, United States. [2] Khurana RN, et al. Efficacy and Safety of Vamikibart in Patients With Uveitic Macular Edema: First Report of Phase 3 MEERKAT/SANDCAT Trials. Presented at: the American Academy of Ophthalmology Annual Meeting (AAO 2025); 2025 October 17; Orlando, Florida, United States. [3] Massa H, Pipis SY, Adewoyin T, Vergados A, Patra S, Panos GD. Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. Clin Ophthalmol. 2019;13:1761-1777. doi:10.2147/OPTH.S180580 [4] Jones NP, Pradeep A, John B. Certification of vision impairment in patients with uveitis attending a specialist clinic. Ocul Immunol Inflamm. 2019;27(4):540-544. doi:10.1080/09273948.2018.1441874 [5] Do BK, et al. Visual Outcomes by Age and Sex in Uveitic Macular Edema: Real-World Retina Registry Analysis. Presented at: the 44th Annual Meeting of the American Society of Retinal Specialists; 2026 July 15–18; Montréal, Canada. [6] Rosenbaum JT, Bodaghi B, Couto C, et al. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review. Semin Arthritis Rheum. 2019;49(3):438-445. doi:10.1016/j.semarthrit.2019.06.004 [7] Leandro L, Beare N, Bhan K, et al. Systemic corticosteroid use in UK Uveitis practice: results from the ocular inflammation steroid toxicity risk (OSTRICH) study. Eye. 2021;35(12):3342-3349. doi:10.1038/s41433-020-01336-6 [8] Nguyen QD, Hatef E, Kayen B, et al. A Cross-sectional Study of the Current Treatment Patterns in Noninfectious Uveitis among Specialists in the United States. Ophthalmology. 2011;118(1):184-190. doi:10.1016/j.ophtha.2010.03.029 [9] Fini ME, Schwartz SG, Gao X, et al. Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine. Prog Retin Eye Res. 2017;56:58-83. doi:10.1016/j.preteyeres.2016.09.003 [10] Sen HN, Vitale S, Gangaputra SS, et al. Periocular Corticosteroid Injections in Uveitis: Effects and Complications. Ophthalmology. 2014;121(11):2275-2286. doi:10.1016/j.ophtha.2014.05.021 [11] Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. Clinical Therapeutics. 2017;39(11):2216-2229. doi:10.1016/j.clinthera.2017.09.011 [12] Sharma S, Lin P, Hu A, et al. Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized Clinical Trial. JAMA Ophthalmol. 2026;144(5):442-451. doi:10.1001/jamaophthalmol.2026.0610 [13] Hoffmann-La Roche. A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Vamikibart Administered Intravitreally in Patients With Uveitic Macular Edema. clinicaltrials.gov; 2025. Accessed September 17, 2026. https://clinicaltrials.gov/study/NCT05642312 [14] Hoffmann-La Roche. A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Vamikibart Administered Intravitreally in Patients With Uveitic Macular Edema. clinicaltrials.gov; 2026. Accessed September 17, 2026. https://clinicaltrials.gov/study/NCT05642325 [15] Teper SJ. Update on the Management of Uveitic Macular Edema. J Clin Med. 2021;10(18):4133. doi:10.3390/jcm10184133 [16] Fardeau C, Champion E, Massamba N, LeHoang P. Uveitic macular edema. Eye. 2016;30(10):1277-1292. doi:10.1038/eye.2016.115 [17] Smith JR, Thorne JE, Flaxel CJ, et al. Treatment of Noninfectious Uveitic Macular Edema with Periocular and Intraocular Corticosteroid Therapies: A Report by the American Academy of Ophthalmology. Ophthalmology. 2024;131(9):1107-1120. doi:10.1016/j.ophtha.2024.02.019 [18] Sood G, Patel BC. Uveitic Macular Edema. In: StatPearls. StatPearls Publishing; 2023. Accessed September 17, 2026. http://www.ncbi.nlm.nih.gov/books/NBK562158/ [19] Tomkins-Netzer O, Lightman SL, Burke AE, et al. Seven-Year Outcomes of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial and Follow-up Study Results. Ophthalmology. 2021;128(5):719-728. doi:10.1016/j.ophtha.2020.08.035 [20] Matas J, Llorenç V, Fonollosa A, et al. Systemic Regulatory T Cells and IL-6 as Prognostic Factors for Anatomical Improvement of Uveitic Macular Edema. Front Immunol. 2020;11:579005. doi:10.3389/fimmu.2020.579005 [21] Tomkins-Netzer O, Talat L, Bar A, et al. Long-Term Clinical Outcome and Causes of Vision Loss in Patients with Uveitis. Ophthalmology. 2014;121(12):2387-2392. doi:10.1016/j.ophtha.2014.07.007 [22] Tallouzi MO, Moore DJ, Bucknall N, et al. Outcomes important to patients with non-infectious posterior segment-involving uveitis: a qualitative study. BMJ Open Ophth. 2020;5(1):e000481. doi:10.1136/bmjophth-2020-000481 [23] Cunningham ET, Zierhut M. Vision Loss in Uveitis. Ocular Immunology and Inflammation. 2021;29(6):1037-1039. doi:10.1080/09273948.2021.2017152 [24] Tomkins-Netzer O, Lightman S, Drye L, et al. Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results. Ophthalmology. 2015;122(11):2351-2359. doi:10.1016/j.ophtha.2015.07.036 [25] Frick KD, Drye LT, Kempen JH, et al. Associations among Visual Acuity and Vision- and Health-Related Quality of Life among Patients in the Multicenter Uveitis Steroid Treatment Trial. Invest Ophthalmol Vis Sci. 2012;53(3):1169. doi:10.1167/iovs.11-8259 Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone:  +41 79 377 83 75Albert Thottiyil Phone: +41 79 775 66 12 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.comDr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com  Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com   Attachment Media Investor Release Vamikibart in UME English ———————————————————————————————————————————————————————————— Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Duolingo, Inc. (NASDAQ: DUOL); and Ensign Group, Inc. (NASDAQ: ENSG): Grabar Law Office is Investigating Claims on Your Behalf 2026-10-10 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/10/3378450/0/en/attention-long-term-shareholders-of-aardvark-therapeutics-inc-nasdaq-aard-coastal-financial-corporation-nasdaq-ccb-duolingo-inc-nasdaq-duol-and-ensign-group-inc-nasdaq-ensg-grabar-.html Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corp. (NASDAQ: CCB); Duolingo, Inc. (NASDAQ: DUOL); and Ensign Group, Inc. (NASDAQ: ENSG) ———————————————————————————————————————————————————————————— URGENT AARDVARK DEADLINE: Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th 2026-10-10 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/10/3378445/0/en/urgent-aardvark-deadline-bragar-eagel-squire-p-c-urges-aardvark-therapeutics-inc-investors-to-contact-the-firm-seeking-lead-plaintiff-role-before-october-13th.html Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aardvark (AARD) To Contact Him Directly To Discuss Their Options ———————————————————————————————————————————————————————————— LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress 2026-10-10 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/10/3378442/0/en/lb-pharmaceuticals-presents-new-preclinical-data-supporting-lb-102-s-bimodal-mechanism-of-action-and-highlights-ongoing-late-stage-clinical-development-programs-at-the-39th-ecnp-co.html LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the presentation of four posters at the 39th European College of Neuropsychopharmacology (ECNP) Congress, taking place in Munich, Germany from October 10-13, 2026. The posters highlight new preclinical data describing LB-102’s differentiated mechanism of action, the pivotal program of LB-102 in schizophrenia (NOVA-2 and NOVA-3), the ongoing late-stage development of LB-102 in bipolar depression (ILLUMINATE-1), and a previously reported analysis of LB-102’s impact on cognitive performance from the Phase 2 NOVA-1 trial in schizophrenia. ———————————————————————————————————————————————————————————— vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026 2026-10-10 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/10/3378439/0/en/vtv-therapeutics-announces-oral-presentation-at-breakthrough-t1d-clinical-and-research-congress-2026.html New research spotlights hypoglycemia-related burdens in adults with type 1 diabetes using automated insulin delivery systems New research spotlights hypoglycemia-related burdens in adults with type 1 diabetes using automated insulin delivery systems ———————————————————————————————————————————————————————————— New Opportunities for Global Cooperation: Kexing Biopharm Shines at CPHI Milan 2026 2026-10-10 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/new-opportunities-for-global-cooperation-kexing-biopharm-shines-at-cphi-milan-2026-302905014.html MILAN, Oct. 10, 2026 -- From October 06 to 08, 2026, Kexing Biopharm (688136.SH) exhibited at CPHI Milan 2026, showcasing its global innovative drug pipeline, co-developed biosimilars, and a broad portfolio of products commercialized in overseas markets. During the event, the... ———————————————————————————————————————————————————————————— RingConn Receives FDA 510(k) Clearance for Non-Invasive Blood Oxygen (SpO2) Measurement 2026-10-10 · PR Newswire · Healthcare, Food & drink, Biotech & pharma https://www.prnewswire.com/news-releases/ringconn-receives-fda-510k-clearance-for-non-invasive-blood-oxygen-spo2-measurement-302905012.html Shenzhen, China, Oct. 10, 2026 -- Shenzhen Ninenovo Technology Limited, the parent company of RingConn, announced that its Smart Ring has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for non-invasive blood oxygen (SpO2) measurement (Clearance No.... ———————————————————————————————————————————————————————————— First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer 2026-10-10 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/first-patient-dosed-in-phase-iii-perioperative-study-of-cadonilimab-pd-1ctla-4-in-colon-cancer-302904988.html HONG KONG, Oct. 10, 2026 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in... ———————————————————————————————————————————————————————————— AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline - HBSS 2026-10-09 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/09/3378412/32716/en/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-de.html Investors who lost money in AARD after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman. ———————————————————————————————————————————————————————————— MindWave Innovations Signs 3 Client Network Agreements in 10 Days, Extending MindChain into Climate Finance, Sports Media and Insurance; Apimeds Pharmaceuticals US Provides Required NYSE American Disclosure 2026-10-09 · GlobeNewswire · Finance, Sports, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/09/3378406/0/en/mindwave-innovations-signs-3-client-network-agreements-in-10-days-extending-mindchain-into-climate-finance-sports-media-and-insurance-apimeds-pharmaceuticals-us-provides-required-n.html Agreements with AQUAE, Flash Sports & Media and BlockAssure share one model: MindWave builds and operates each network and receives an allocation of 20% of its credits or tokens Agreements with AQUAE, Flash Sports & Media and BlockAssure share one model: MindWave builds and operates each network and receives an allocation of 20% of its credits or tokens ———————————————————————————————————————————————————————————— LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) 2026-10-09 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/09/3378379/0/en/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635-c-4.html LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it has granted to Dr. Susan G. Kozauer, the new Chief Medical Officer and Joseph Miller, the new Chief Financial Officer of LB Pharmaceuticals, equity awards outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity awards were granted on October 9, 2026, pursuant to the “inducement grant” exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Dr. Kozauer and Mr. Miller entering into employment with LB Pharmaceuticals. ———————————————————————————————————————————————————————————— CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency 2026-10-09 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/09/3378375/0/en/cytomed-therapeutics-limited-announces-receipt-of-nasdaq-notification-regarding-minimum-bid-price-deficiency.html CytoMed Therapeutics Limited (the “Company”) (NASDAQ: GDTC), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies, today announced that on October 6, 2026, the Company received a notice from the staff of the Nasdaq Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that for the last 30 consecutive business days, the closing bid price of the Company’s ordinary shares (the “Ordinary Shares”) was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Nasdaq notification letter has no current effect on the listing or trading of the Company’s Ordinary Shares on Nasdaq. ———————————————————————————————————————————————————————————— AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 2026-10-09 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/09/3378367/0/en/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711.html AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today reported the grant of restricted stock units (“RSUs”) covering 150,000 shares of the Company’s common stock to one newly hired non-executive employee of the Company. The award was approved by the Company’s Compensation Committee of the Board of Directors on October 5, 2026 under the Company’s 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of the Company. The RSUs vest in four equal installments, 25% on each annual anniversary of March 9, 2026. The award is subject to the terms and conditions of the Inducement Plan and the terms and conditions of the RSU agreement covering the grant. The RSUs were granted as a material inducement to the employee’s entering into employment with the Company in accordance with Section 711 of NYSE American LLC Company Guide. ———————————————————————————————————————————————————————————— Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience 2026-10-09 · 3BL Media · Finance, Healthcare, Retail, Media, Biotech & pharma https://www.3blmedia.com/news/aetna-2027-star-ratings-reflect-strong-clinical-quality-and-member-experience Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience Tue, 10/13/2026 - 08:15 Body Originally published on CVS Health Company Newsroom HARTFORD, Conn., October 13, 2026 - Aetna®, a CVS Health® company (NYSE: CVS), announced today that more than 69 percent of its Medicare Advantage (MA) members are in 2027 plans rated 4 stars or higher (out of 5 stars) by the Centers for Medicare & Medicaid Services (CMS). These results position Aetna as one of the highest-performing large, publicly traded Medicare Advantage organizations in the Star Ratings program for the third consecutive year and highlight strong performance across various clinical quality, preventive care and member experience measures. "For years, Aetna has been a leader in Star Ratings, and this year's results highlight our distinction in the market," said Steve Nelson, President of Aetna. "We continue to strengthen our business through an unwavering focus on the fundamentals and disciplined execution, and we are encouraged by our performance in areas like clinical quality and operational excellence. This focus gives us confidence in our ability to achieve our goal of returning to appropriate margins while at the same time driving continuous improvement and delivering even better experiences and outcomes for the members who count on us. Outstanding clinical quality performance Our 2027 Star Ratings results demonstrate excellence across several key clinical quality measures. Aetna achieved an outstanding score on Plan All-Cause Readmissions (4.77* out of 5 stars), showcasing the strength of our care coordination programs, provider partnerships and focus on helping members successfully transition between care settings. Keeping members out of the hospital is one of the most important indicators of health care quality. Our high-performing scores on Care for Older Adults Medication Review (5.00*) and Care for Older Adults Functional Status Assessment (4.03*) demonstrate the support we provide members in managing their health and maintaining their independence. Reinforcing our commitment to early detection and preventive care, we earned strong scores on preventive screening measures, including Colorectal Cancer Screening (4.19*) and Breast Cancer Screening (4.07*). Delivering a high-quality member experience Aetna also delivered exceptional results on measures related to member experience and the quality of our customer support. Low rates of Complaints about the Drug Plan (4.29*) demonstrate members' confidence in our service and commitment to resolving issues quickly and effectively. Strong performance on Customer Service (4.04*), Getting Needed Care (3.89*) and Getting Needed Prescription Drugs (4.07*) further highlight our focus on making health care easier to access and navigate. Aetna earned a high score on Rating of Health Care Quality (4.22*), indicating the positive experiences members had with their health care providers and the broader care experience supported by Aetna. In addition, we demonstrated operational excellence through outstanding performance in service and administrative measures, including Call Center Foreign Language Interpreter and Teletypewriter Availability (4.99*), Reviewing Appeals Decisions (4.08*), Plan Makes Timely Decisions About Appeals (4.01*) and Drug Price Accuracy (4.01*). These results underscore our commitment to providing accurate information, fair processes, timely decisions and accessible support for every member. Every year, Medicare evaluates plans based on a 5-star rating system. The Star Ratings are posted at Medicare.gov. Visit AetnaMedicare.com to learn more about the 2027 Aetna Medicare plans. Or call 1-844-588-0041 (TTY: 711), 7 days a week, 8 AM to 8 PM. The Medicare Annual Enrollment Period runs from October 15 through December 7, 2026. A licensed agent may answer your call. NOTE: Information in this release is based on 2027 Star Ratings data published by CMS on October 8, 2026, and MA and MAPD enrollment as of September 2026. Individual plan ratings may vary. *FOR STAR RATING MEASURE SCORES: All scores are based on a rating scale of five stars. About CVS Health CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of June 30, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated 37 million people through a broad range of health insurance products and related services. The Company’s integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs. About Aetna Aetna, a CVS Health business, serves an estimated 37 million people with information and resources to help them make better informed decisions about their health care. Aetna offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, and medical management capabilities, Medicaid health care management services, workers' compensation administrative services and health information technology products and services. Aetna's customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups and expatriates. For more information, visit Aetna.com. Aetna Medicare is a HMO, PPO plan with a Medicare contract. Our SNPs also have contracts with State Medicaid programs. Enrollment in our plans depends on contract renewal. See Evidence of Coverage for a complete description of plan benefits, exclusions, limitations and conditions of coverage. Plan features and availability may vary by service area. To send a complaint to Aetna, call the Plan or the number on your member ID card. To send a complaint to Medicare, call 1-800-MEDICARE (TTY users should call 1-877-486-2048), 24 hours a day/7 days a week. If your complaint involves a broker or agent, be sure to include the name of the person when filing your grievance. ©2026 Aetna Inc. Media contact Phil Blando Phillip.blando@cvshealth.com Investor contact Larry McGrath 800-201-0938 InvestorInfo@CVSHealth.com Y0001_9425651a_2027_M Featured Image Type of Content Press Release ———————————————————————————————————————————————————————————— LGF Lab Gas Flow Launches Laboratory Ultra-High Purity Gas Delivery System and Gas Scrubber Systems for Scientific Research 2026-10-09 · GlobeNewswire · Energy, Biotech & pharma, Semiconductors https://www.globenewswire.com/news-release/2026/10/09/3378318/0/en/lgf-lab-gas-flow-launches-laboratory-ultra-high-purity-gas-delivery-system-and-gas-scrubber-systems-for-scientific-research.html LGF Lab Gas Flow, a manufacturer of laboratory infrastructure, has released its integrated Ultra-High Purity Gas Delivery Systems and Laboratory Gas Scrubber Systems. Designed for scientific research, biotechnology, and semiconductor fabrication, this equipment provides contamination control, operational safety, and environmental compliance. ———————————————————————————————————————————————————————————— Sling Therapeutics Presents Data from Phase 2b/3 LIDS Clinical Trial Demonstrating Durability of Linsitinib in Thyroid Eye Disease at ASOPRS 57th Annual Fall Scientific Symposium 2026-10-09 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/sling-therapeutics-presents-data-phase-172000437.html ANN ARBOR, Mich., October 09, 2026--Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the presentation of efficacy, safety and new durability results from its Phase 2b/3 LIDS trial of linsitinib in adults with moderate to severe active TED. The data were highlighted in an oral presentation and in a poster session at the American Society of Ophthalmic Plastic and ———————————————————————————————————————————————————————————— Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference 2026-10-09 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/vertex-present-data-alyftrek-north-171500108.html BOSTON, October 09, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversib ———————————————————————————————————————————————————————————— PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress 2026-10-09 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/puretech-founded-entity-seaport-therapeutics-170000247.html BOSTON, October 09, 2026--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress ———————————————————————————————————————————————————————————— Advancing Access to Lung Cancer Care Through Artificial Intelligence Innovation 2026-10-09 · 3BL Media · AI, Healthcare, Media, Food & drink, Biotech & pharma https://www.3blmedia.com/news/advancing-access-lung-cancer-care-through-artificial-intelligence-innovation Advancing Access to Lung Cancer Care Through Artificial Intelligence Innovation Tue, 10/13/2026 - 08:00 Body Originally published on preventcancer.org This post has been sponsored by Bristol Myers Squibb as part of its sponsorship of the 2026 Prevent Cancer Gala.  Can AI help close care gaps in lung cancer? Lung cancer remains the leading cause of cancer death in the United States, with the American Cancer Society projecting about 229,000 new diagnoses and 125,000 deaths in 2026 alone. Behind those numbers lies another part of the story: Medically underserved communities, including many rural areas, experience higher mortality rates for lung cancer and are also less likely to undergo routine screening or biomarker testing. At Bristol Myers Squibb (BMS), we believe artificial intelligence (AI) can help identify and quantify these health care gaps, accelerate individual diagnosis, detect disparities in treatment pathways, predict risk of outcomes and proactively target interventions. Two ongoing collaborations help demonstrate this approach. Catching cancer earlier BMS shares the Prevent Cancer Foundation’s goal to increase awareness about the importance of lung cancer screening to enable earlier detection and better outcomes. However, lung cancer nodules can be small and easily overlooked, and they are sometimes found by chance on imaging done for unrelated reasons. Even when a nodule is spotted, more than half of these patients don’t receive proper follow-up care and may never actually see a specialist. These challenges present an opportunity for improvement that BMS is tackling through our collaboration with Microsoft. Using AI algorithms that are cleared by the U.S. Food and Drug Administration (FDA), and deployed through Microsoft’s extensive Precision Imaging Network, will help radiologists analyze X-ray and CT images to flag hard-to-detect nodules. Then, workflow tracking tools will help ensure patients flagged with nodules are connected to care rather than fall through the cracks. This multi-year collaboration is currently in its first phase, recruiting pilot sites such as rural hospitals and community clinics. Supporting better treatment decisions after diagnosis A second opportunity begins after diagnosis. For patients with advanced non-small cell lung cancer (the most common form of lung cancer), selecting the most effective therapy  depends on biomarker testing. These lab analyses identify specific genetic mutations driving a patient’s cancer. But biomarker testing doesn’t always happen as guidelines recommend, in part because lab and electronic health record systems are often disconnected. Through our collaboration with Tempus AI, BMS implemented the AI-enabled Tempus Next Pathways program across 13 community-based health systems to build a near real-time view of the patient journey, finding out where and why patients were not receiving the right care according to guidelines. The results were compelling. By providing these insights to clinical teams, guideline-directed biomarker testing rates rose from 73% to 84% across participating sites. The program also helped explain the reasons behind that gap, such as clinical factors like disease progression or transitions to hospice care, or logistical issues like patients relocating out of their previous health system. This information provided better tools to design targeted interventions. Two projects, one purpose Together, these two projects present a picture of what AI-enabled, data-driven and access-focused cancer care can look like: identifying cancer earlier through smarter imaging workflows and enabling evidence-based treatment. For BMS, that combination reflects a broader commitment, one shared with organizations like the Prevent Cancer Foundation, to help innovation in cancer care reach every community. Learn more about Advancing population health – Bristol Myers Squibb   Canonical URL https://preventcancer.org/article/advancing-access-to-lung-cancer-care-through-… Featured Image Type of Content Article ———————————————————————————————————————————————————————————— Affinia Therapeutics’ AFTX-201 and UPBEAT™ Clinical Trial in BAG3 DCM Featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 2026-10-09 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/affinia-therapeutics-aftx-201-upbeat-123000294.html WALTHAM, Mass., October 09, 2026--Affinia Therapeutics ("Affinia"), an innovative clinical-stage gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating cardiovascular diseases, today announced that AFTX-201 preclinical and translational data and the Phase 1/2 UPBEAT™ clinical trial investigating AFTX-201 in patients with BAG3-associated dilated cardiomyopathy (DCM), will be featured at the Heart Failure So ———————————————————————————————————————————————————————————— Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine) 2026-10-09 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/medincell-achieves-major-milestone-u-121400488.html MONTPELLIER, France, October 09, 2026--Medincell (Paris:MEDCL) Medincell will host Investor webcast today to discuss the implications of the approval for the Company and answer questions from analysts. ———————————————————————————————————————————————————————————— Antibody Designed by Spanish Biopharma Oncomatryx Shows That Attacking the Tumor Environment Also Kills Cancer Cells 2026-10-09 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/antibody-designed-spanish-biopharma-oncomatryx-120700199.html ZAMUDIO, Spain, October 09, 2026--Oncomatryx, the Basque biopharmaceutical company pioneering the treatment of solid tumors through their microenvironment, has taken part, together with German research institutions, in a study showing in patient tumor tissue that destroying the cells that protect the tumor also kills cancer cells. ———————————————————————————————————————————————————————————— Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial 2026-10-09 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/09/3378055/0/en/milestone-pharmaceuticals-announces-first-european-study-participant-enrolled-in-revera-301-phase-3-clinical-trial.html Dutch Cardiovascular Investigator Network (WCN) Leads European Enrollment in Phase 3 Study Evaluating Etripamil Nasal Spray for AFib-RVR Dutch Cardiovascular Investigator Network (WCN) Leads European Enrollment in Phase 3 Study Evaluating Etripamil Nasal Spray for AFib-RVR ———————————————————————————————————————————————————————————— Nuvectis Pharma to Participate in the Maxim Growth Summit 2026 2026-10-09 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/09/3378052/0/en/nuvectis-pharma-to-participate-in-the-maxim-growth-summit-2026.html Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the Maxim Growth Summit 2026 on Wednesday, October 14, 2026 in New York. ———————————————————————————————————————————————————————————— Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences 2026-10-09 · GlobeNewswire · Finance, Healthcare, Education, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/09/3378041/0/en/eupraxia-pharmaceuticals-to-present-at-upcoming-american-college-of-gastroenterology-acg-and-united-european-gastroenterology-ueg-medical-conferences.html VANCOUVER, British Columbia, Oct. 09, 2026 -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today is pleased to announce that three abstracts related to Company’s ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis ("EoE") have been accepted and will be presented at: (i) the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting & Postgraduate Course, being held October 9-14, 2026 in Nashville, Tennessee, and (ii) the United European Gastroenterology (UEG) Week 2026, being held October 17-20, 2026 in Barcelona, Spain. ———————————————————————————————————————————————————————————— Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease 2026-10-09 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/09/3378039/0/en/quince-therapeutics-relaunches-as-irulya-therapeutics-with-a-focus-on-the-clinical-development-of-lam-001-targeting-a-key-pathway-in-pulmonary-disease.html Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 ———————————————————————————————————————————————————————————— Filana Therapeutics to Participate in the 2026 Maxim Growth Summit 2026-10-09 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/09/3378038/8339/en/filana-therapeutics-to-participate-in-the-2026-maxim-growth-summit.html Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the Company’s management team will participate in the 2026 Maxim Growth Summit being held October 12-14, 2026 in New York. ———————————————————————————————————————————————————————————— New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity 2026-10-09 · Eli Lilly and Company · Finance, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/new-phase-3b-data-on-lillys-taltz-ixekizumab-and-zepbound-tirzepatide-advance-understanding-of-the-interconnected-immune-and-metabolic-biology-in-adults-with-psoriasis-and-obesity-302903148.html Eli Lilly and Company (NYSE: LLY) today announced new exploratory data from the TOGETHER-PsO Phase 3b clinical trial evaluating the concomitant use... ———————————————————————————————————————————————————————————— Advanced Technology Meets Best Urology Oncologists in India 2026-10-09 · freePRnow · Biotech & pharma http://www.freePRnow.com/pr/advanced-technology-meets-best-urology-oncologists-in-india Uro-oncology treatments encompass a range of therapeutic approaches aimed at addressing cancers of the urinary system, including the bladder, kidneys, and prostate. ———————————————————————————————————————————————————————————— Cadila Pharmaceuticals Earns Asia Book of Records Recognition for Nationwide Doctor Engagement Initiative 2026-10-09 · Webnewswire · Healthcare, Biotech & pharma https://www.webnewswire.com/2026/10/09/cadila-pharmaceuticals-earns-asia-book-of-records-recognition-for-nationwide-doctor-engagement-initiative/ ·       Achieved Global Milestone with Mass Graphology Campaign for Indian Medical Fraternity ·       An initiative celebrating clinicians’ selfless service and personal traits India’s leading global pharmaceutical manufacturer, Cadila Pharmaceuticals, has been officially recognized by the Asia Book of Records. This prestigious recognition follows a nationwide doctor engagement initiative that facilitated a handwriting analysis study involving […] ———————————————————————————————————————————————————————————— Low Grade Serous Ovarian Carcinoma Market - Global Forecast by Therapy, Administration Route, and Country, 2025-2035 | Precision Oncology Unlocks Growth 2026-10-09 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/09/3377919/28124/en/low-grade-serous-ovarian-carcinoma-market-global-forecast-by-therapy-administration-route-and-country-2025-2035-precision-oncology-unlocks-growth.html Maximize ROI through biomarker-led therapies, priority-market expansion, optimized resource allocation, and strategic co-development or acquisitions Maximize ROI through biomarker-led therapies, priority-market expansion, optimized resource allocation, and strategic co-development or acquisitions ———————————————————————————————————————————————————————————— Global Human Gene Sequencing Market Forecast 2026-2030 by Application, Technology, Workflow, Product, and Country | AI and Precision Medicine Propel Market to $21.4 Billion by 2030 2026-10-09 · GlobeNewswire · AI, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/09/3377911/28124/en/global-human-gene-sequencing-market-forecast-2026-2030-by-application-technology-workflow-product-and-country-ai-and-precision-medicine-propel-market-to-21-4-billion-by-2030.html NGS Leads as Precision Medicine, Oncology and NIPT Adoption Accelerates, While Long-Read Sequencing, AI Bioinformatics and Pharma Partnerships Unlock Opportunities NGS Leads as Precision Medicine, Oncology and NIPT Adoption Accelerates, While Long-Read Sequencing, AI Bioinformatics and Pharma Partnerships Unlock Opportunities ———————————————————————————————————————————————————————————— Prifemilast Demonstrates Superior Efficacy vs. Apremilast in Newsoara's Head-to-Head Phase 3 Psoriasis Trial; cAMPfield Advancing the Potential Best-in-Class Oral PDE4 Inhibitor in IBD 2026-10-09 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/prifemilast-demonstrates-superior-efficacy-vs-apremilast-in-newsoaras-head-to-head-phase-3-psoriasis-trial-campfield-advancing-the-potential-best-in-class-oral-pde4-inhibitor-in-ibd-302903290.html In a head-to-head Phase 3 trial, prifemilast nearly doubled the rate of PASI 75 response compared with apremilast and achieved superiority on both co-primary endpoints Results support the potential of prifemilast to deliver greater efficacy than apremilast, with low rates of serious... ———————————————————————————————————————————————————————————— Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures 2026-10-09 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/09/3377840/0/en/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib-rapidly-and-durably-improved-psoriasis-burden-across-scalp-itch-and-quality-of-life-measures.html New Phase 3 Data Demonstrates Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures ———————————————————————————————————————————————————————————— WuXi Biologics at CPHI Milan 2026: Empowering Biomanufacturing in Europe 2026-10-09 · PR Newswire · Industrial, Biotech & pharma https://www.prnewswire.com/news-releases/wuxi-biologics-at-cphi-milan-2026-empowering-biomanufacturing-in-europe-302903372.html How quality, supply resilience, manufacturing excellence and innovation are supporting the next generation of biologics. MILAN, Oct. 9, 2026 -- Europe's biologics sector is expanding as ageing populations and the rising burden of chronic, autoimmune and rare diseases increase... ———————————————————————————————————————————————————————————— aphranel® Brings Regenerative Aesthetics to MXGP Shanghai 2026 2026-10-09 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/aphranel-brings-regenerative-aesthetics-to-mxgp-shanghai-2026-302903288.html SHANGHAI, Oct. 9, 2026 -- aphranel®, a regenerative aesthetics brand developed in China by MOYOM Biotech, was an official partner of the 2026 FIM Motocross World Championship (MXGP) Shanghai, held September 11–13. At the event, the brand introduced its approach to facial... ———————————————————————————————————————————————————————————— Two Former Moderna Cancer Vaccine Scientists Join Everest Medicines, Accelerating Global Development of Its mRNA Platform 2026-10-09 · ACN Newswire · AI, SaaS, Healthcare, Automotive, Food & drink, Biotech & pharma https://www.acnnewswire.com/press-release/english/110713/ Hong Kong, Oct 9, 2026 - Everest Medicines (1952.HK) announced the appointments of Lakshmi Srinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and Brandon Coder, PhD, as Vice President, Translational Sciences & Discovery. Both executives are seasoned scientists in mRNA cancer vaccines, with deep experience spanning early discovery through clinical development and leadership roles in oncology vaccine research at Moderna and other leading biopharmaceutical companies. The appointments further strengthen the Company’s global R&D capabilities in mRNA therapeutics, and support the continued advancement of its proprietary mRNA platform and pipeline. At Everest, they will drive clinical development of the Company’s mRNA programs and expand Everest’s presence in the United States, in line with the Company’s global mRNA R&D strategy, while working closely with the China R&D team. The two scientists previously held leadership roles at Moderna, where they contributed to its mRNA cancer vaccine programs, including mRNA-4157/V940. Their experience spanning early-stage research through clinical development will support the advancement of Everest's proprietary mRNA platform and global clinical development programs. In August 2026, Moderna and Merck announced that mRNA-4157/V940 in combination with Keytruda met the primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in the Phase 3 INTerpath-001 study. The results represent the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and for an mRNA-based cancer therapy. “We are very pleased to welcome Dr. Srinivasan and Dr. Coder to Everest Medicines as we continue to strengthen our global mRNA R&D capabilities,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “Their deep experience in cancer vaccine research, translational medicine, and clinical development will be highly valuable as we advance our proprietary mRNA platform and broader pipeline. Their appointments reflect our continued commitment to investing in world-class talent and advancing our global mRNA strategy.” Dr. Srinivasan is a seasoned immunologist with 20 years of experience advancing innovative immuno-oncology therapeutics from discovery through clinical development. Her expertise spans cancer vaccines, mRNA-LNP technologies, T-cell therapies, and translational development from preclinical research through clinical proof of concept. Prior to joining Everest Medicines, Dr. Srinivasan served as Executive Director and Head of Oncology Translational Medicine at Moderna Therapeutics from 2023 to 2025. She previously held leadership roles at Repertoire Immune Medicines, Neon Therapeutics, which was later acquired by BioNTech, and Sanofi Oncology. Dr. Srinivasan has played a key role in the clinical translation of personalized neoantigen vaccines and has authored multiple high-profile publications in the field. She served as corresponding author on Phase 1b studies of NEO-PV-01 published in Cell (2020) and Cancer Cell (2022), and co-authored publications on Moderna’s intismeran autogene (mRNA-4157/V940), including the Phase 1 KEYNOTE-603 study published in Cancer Discovery (2024) and the three-year follow-up of the randomized Phase 2b KEYNOTE-942 study published in JCO Oncology Advances (2026). Dr. Coder brings more than 11 years of industry experience advancing T cell immunotherapies from discovery through investigational new drug (IND) submissions and early clinical proof of concept, with expertise in cancer vaccines, mRNA/LNP platform technology, and in vivo CAR therapies. Prior to joining Everest Medicines, Dr. Coder held scientific roles at Moderna from 2019 to 2025, most recently as Associate Scientific Director of Cancer Vaccine Research. He served as research and global pharmacology lead for intismeran autogene (mRNA-4157/V940), which reported positive results from the Phase 3 INTerpath-001 study in August 2026, becoming the first personalized neoantigen therapy and mRNA cancer therapy to achieve success in a Phase 3 clinical study. Dr. Coder also co-invented and led development of the shared-antigen discovery and vaccine design framework for mRNA-4359 and mRNA-4106. He contributed to nine IND submissions as a co-inventor, research lead, or core contributor, and co-authored the Phase 1 KEYNOTE-603 study of mRNA-4157/V940 published in Cancer Discovery (2024). Prior to joining Moderna, Dr. Coder served as Associate Director of Immuno-Oncology Research at Advaxis Immunotherapies, where he developed personalized and off-the-shelf cancer vaccines. Leveraging its proprietary AI+mRNA platform, Everest Medicines is advancing multiple mRNA oncology therapeutic vaccine and in vivo CAR-T programs for oncology and autoimmune diseases. EVM16, a personalized mRNA therapeutic cancer vaccine, has completed its first-in-human clinical data readout, demonstrating a favorable safety and tolerability profile, robust immunogenicity and promising preliminary efficacy. Selected data were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Following the Phase 1a study, EVM16 plans to initiate an investigator-initiated trial (IIT) Phase 1b study in Q4 2026 and launch new indication expansion cohorts for efficacy exploration. The company plans to submit an IND application to the U.S. Food and Drug Administration (FDA) in the first half of 2027. EVM14, an off-the-shelf tumor-associated antigen (TAA) mRNA cancer vaccine, received IND clearance from the U.S. FDA and IND approval from China’s National Medical Products Administration (NMPA) in 2025. The Phase 1 monotherapy dose-escalation study is expected to be completed in Q1 2027.EVM18, an in vivo CAR-T therapy, has initiated an IIT study in autoimmune diseases, with global IND filing underway. EVM15, an off-the-shelf immunomodulatory (IM) cancer vaccine, achieved clinical proof of concept in preclinical studies in 2025, with a clinical candidate subsequently selected. The Company plans to advance preparations for the Investigational New Drug (IND) application for EVM15 in 2026. ———————————————————————————————————————————————————————————— FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer 2026-10-09 · Roche · Healthcare, Automotive, Food & drink, Biotech & pharma, Jobs & workplace, Internet & apps, Medical devices https://www.roche.com/media/releases/med-cor-2026-10-09 FDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone1 First approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, positioning Tecentriq as a new post-surgery standard of care Nearly 25% of all colon cancers are diagnosed at stage III, and almost one in three patients with stage III colon cancer experience a recurrence within five years2,3 Approval marks the twelfth indication for Tecentriq in the US Basel, 9 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a type of tumour characterised by high mutation rates. This approval marks the twelfth indication for Tecentriq in the US. “This approval provides a new adjuvant treatment option for people with stage III dMMR colon cancer who face a high risk of disease recurrence,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Tecentriq combined with chemotherapy has the potential to become the new standard of care as the first approved immunotherapy-based regimen for this setting.” “Until now, the adjuvant standard of care for stage III colon cancer has not differed based on mismatch repair status,” said Frank A. Sinicrope, MD, Professor of Oncology at the Mayo Clinic and US Principal Investigator for the Alliance ATOMIC trial. “This milestone represents an important therapeutic advance that leverages immunotherapy to target the specific biology of dMMR stage III colon cancer after surgical resection. By reducing the risk of disease recurrence or death by 50%, atezolizumab plus chemotherapy is a practice-changing regimen that can improve clinical outcomes of this group of patients living with colon cancer, one of the most common cancers and a leading cause of cancer-related death.” The FDA approval is based on the landmark phase III ATOMIC study, recently published in The New England Journal of Medicine. ATOMIC demonstrated that adding Tecentriq to modified (m)FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50%, compared to chemotherapy alone for people with stage III dMMR colon cancer, as determined by an immunohistochemistry test, such as the VENTANA® MMR RxDx Panel.1 The 36-month disease-free survival was 86% for Tecentriq combined with mFOLFOX6 compared with 76% in the mFOLFOX6 alone group. The safety profile was consistent with previous studies of Tecentriq and mFOLFOX6.1 Colon cancer remains one of the world's most common and deadliest tumours.4 Over one million people are diagnosed globally each year, and nearly 25% of all colon cancers are diagnosed at stage III.2-4 Despite surgery and chemotherapy, nearly 30% of stage III patients experience disease recurrence within five years.2,3 Approximately 15% of colon cancer patients present with dMMR or microsatellite instability-high (MSI-H) tumours, which indicate a higher mutation rate and thus have the potential to respond to immunotherapy.5 Roche is pursuing further regulatory filings for Tecentriq, including with the European Medicines Agency, to bring this immunotherapy-based adjuvant option to patients with dMMR colon cancer worldwide as soon as possible. About the ATOMIC study ATOMIC (A021502, NCT02912559) is a phase III, randomised, open-label, multicentre study investigating the addition of Tecentriq® (atezolizumab) to modified (m)FOLFOX6 chemotherapy (a combination of folinic acid, fluorouracil, and oxaliplatin) in patients with stage III colon cancer who have a deficiency in DNA mismatch repair (dMMR). The trial enrolled 712 patients. Participants were randomised 1:1 to receive either mFOLFOX6 plus Tecentriq for 12 cycles (six months) followed by Tecentriq monotherapy for 13 cycles (an additional six months), or mFOLFOX6 alone for 12 cycles. The primary endpoint is disease-free survival (DFS). The global study in the US was sponsored by the US National Cancer Institute (NCI), part of the National Institutes of Health, and led by the Alliance for Clinical Trials in Oncology (Alliance) with participation from other NCI-funded National Clinical Trials Network (NCTN) groups. Genentech, a member of the Roche Group, provided support for the study through a Cooperative Research and Development Agreement between NCI and Genentech. The trial was led globally by Frank A. Sinicrope, MD, Professor of Oncology at the Mayo Clinic and US Principal Investigator within the Alliance. German participation in this major international academic collaboration was enabled through close cooperation between the Alliance and the AIO-Studien-gGmbH, in partnership with the AIO (Arbeitsgemeinschaft Internistische Onkologie) of the German Cancer Society (Deutsche Krebsgesellschaft, DKG), under the national leadership of Prof. Dr. Anke Reinacher-Schick (Ruhr-Universität Bochum). AIO-affiliated study sites enrolled patients during the later recruitment phase, ensuring access for eligible patients in Germany. About Tecentriq® (atezolizumab) Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1, which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells. Tecentriq has been approved for some of the most aggressive and difficult-to-treat forms of cancer, and is the first PD-(L)1 cancer immunotherapy available in both subcutaneous and intravenous formulations. About Roche in oncology For over 60 years, Roche has delivered transformative medicines and diagnostics, redefining the treatment of some of the most challenging cancers. Driven by a vision of a future where cancer can be cured, we focus our efforts on cancers with the highest societal impact and where we bring deep expertise, including breast, lung, and blood cancers, while pursuing breakthrough innovation in other areas of unmet need. Our pipeline features a diverse array of modalities, from small molecules and antibodies to next-generation ADCs and allogeneic CAR T-cell therapies. By advancing best-in-class precision medicine, pioneering novel combinations, and leveraging key technologies and partnerships, Roche tackles oncology's toughest challenges with the goal of delivering life-changing outcomes for people with cancer. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Sinicrope F, et al. Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer. N Engl J Med. 2026;394:1155-1166. [2] Gonzalez B, et al. Analyzing recurrence in colorectal cancer: Is a five years follow-up enough? Annals of Oncology. 2024;35(1);11. [3] Nors J et al. Incidence of Recurrence and Time to Recurrence in Stage I to III Colorectal Cancer: A Nationwide Danish Cohort Study. JAMA Oncology. 2024;10(1):54–62. [4] World Health Organization. Cancer [Internet; cited 2026 October]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer. [5] Boland CR, et al. Microsatellite Instability in Colorectal Cancer. Gastroenterology. 2010;138:2073–2087. Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone:  +41 79 377 83 75Albert Thottiyil Phone: +41 79 775 66 12 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.comDr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com  Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com  Attachment Media&Investor Release FDA approval for Tecentriq Tecentriq Hybreza English ———————————————————————————————————————————————————————————— From Phase III Trials to Commercialization Partnerships, MindRank's AI Drug Development Value Comes into Focus 2026-10-09 · ACN Newswire · Finance, AI, SaaS, Healthcare, Real estate, Education, Industrial, Biotech & pharma https://www.acnnewswire.com/press-release/english/110703/ Hong Kong, Oct 9, 2026 - As AI Drug Development Approaches Commercialization, MindRank Marks a Key Business Milestone How much value can AI create in the discovery and development of new medicines' For investors following the sector, the answer lies in tangible progress in drug development and business execution. A platform’s ability to consistently generate drug candidates, advance lead assets through clinical development and secure recognition from industry partners provides an important basis for assessing an AI drug developer’s growth potential. The recently announced commercialization partnership by MindRank AI Ltd. (MindRank, hereinafter “MindRank”) offers a new window into this question. On September 28, 2026, MindRank announced an exclusive commercialization partnership with 3SBio (01530.HK) subsidiaries Sunshine Mandi and Wansheng Pharmaceutical for MDR-001, its internally developed, AI-designed oral small-molecule GLP-1 receptor agonist. Covering mainland China, Hong Kong and Macau, the agreement carries a potential total transaction value of up to RMB1.75 billion, alongside a substantial share of sales revenue. MDR-001 is currently undergoing a pivotal Phase III clinical trial in China in adults with obesity or overweight. For MindRank, a clinical-stage AI-native drug discovery and development technology company, the partnership further connects drug development with commercialization planning. It lays the groundwork for marketing its lead asset following potential approval and establishes a clearer pathway for translating AI-driven research into commercial value. As its lead asset advances through pivotal clinical development, MindRank has begun preparing for post-approval marketing and channel coverage, extending the product’s development pathway into commercialization. Under the agreement, Sunshine Mandi and Wansheng Pharmaceutical will provide exclusive, comprehensive services and distribution across all channels following MDR-001’s launch. MindRank will retain all rights, title and interests in the product’s intellectual property and remain responsible for clinical development, regulatory submissions, manufacturing and supply. The transaction includes up to RMB150 million in payments for collaboration rights, up to RMB1.6 billion in royalty payments upon the fulfillment of agreed conditions, and a substantial share of sales revenue. From a business-model perspective, the agreement establishes a clear division of responsibilities. MindRank will continue investing in research and product development, while its partners will provide exclusive, comprehensive services and distribution across all channels within the agreed territories following regulatory approval and launch. In an industry that requires sustained investment, this collaboration could help MindRank retain its core asset rights while drawing on its partners’ commercial capabilities to support launch preparations and focus its own resources on strengthening its core capabilities. The partners’ willingness to make commercialization arrangements for an investigational drug also provides a new reference point for assessing its potential industry value. Clinical data address whether a product merits further development, while commercial partnerships indicate whether industry participants are willing to take part in its subsequent development. Together, these elements make MindRank’s growth story more tangible. A Lead Asset in Phase III Provides a Clearer Basis for Assessing AI-Driven R&D Capabilities The core asset underpinning the partnership is MDR-001, which continues to advance through development. In February 2026, MindRank announced that the first participant had been dosed in MOBILE, its Phase III clinical trial of MDR-001. According to the company, the multicenter, randomized, double-blind, placebo-controlled study plans to enroll approximately 750 participants across around 50 clinical centers in China to further evaluate the product’s long-term efficacy and safety. This means the evidence available to assess MindRank’s AI-driven R&D capabilities now extends to larger-scale, late-stage clinical research. For investors, the lead asset’s entry into Phase III sharpens the focus on several key questions: whether long-term efficacy can be further validated, whether safety and tolerability findings can be sustained, and whether the product can establish clinically meaningful competitive advantages. Previously disclosed Phase IIb findings supported further development. In the study, which enrolled 317 adults with obesity or overweight, participants in the MDR-001 dose groups achieved mean reductions in body weight from baseline of 8.2% to 10.3% after 24 weeks, compared with 2.5% in the placebo group. The rate of treatment discontinuation due to treatment-emergent adverse events was 0.8%. Common adverse events were primarily gastrointestinal and mostly mild to moderate. These findings remain subject to further validation in subsequent studies. For weight-management medicines, product value depends on a combination of weight-loss efficacy, long-term safety, tolerability and ease of use. Compared with the injectable peptide-based GLP-1 medicines that currently dominate the market, MDR-001’s oral small-molecule formulation can significantly improve medication adherence, while its large-scale manufacturing costs are substantially lower than those of peptide-based medicines, offering considerable market potential and commercial value. These attributes provide a promising direction for its future product positioning, although translating them into a competitive advantage will require continued accumulation of clinical evidence. Beyond progress in product development, R&D efficiency is another important lens through which to assess MindRank. According to the company, MDR-001 progressed from project initiation to preclinical candidate (PCC) nomination in just eight months, during which approximately 80 small molecules were synthesized. Its investigational new drug (IND) application was cleared in the United States within 19 months of project initiation and MDR-001 advanced to Phase III in China in approximately 4.5 years. In its July 2026 financing announcement, the company further disclosed that cumulative direct R&D investment in the program, from initiation through the start of Phase III in China, totaled approximately US$23 million. These timelines and investment figures provide a more concrete basis for understanding how MindRank organizes drug discovery and development. For drug developers, development timelines and funding requirements directly affect how many programs they can advance, how long they can sustain development and how they allocate resources to subsequent work. AI’s commercial significance must also be assessed within these real-world R&D constraints. As a flagship application of MindRank’s AI-driven drug discovery and development system, MDR-001 offers a traceable development pathway: from molecular design to clinical research and, subsequently, commercialization partnerships. The platform’s capabilities are beginning to be tested through tangible business outcomes. This provides capital markets with a more useful basis for understanding the company’s technology value than descriptions of algorithms or model parameters alone. Beyond the Lead Asset, Long-Term Growth Depends on Sustained Platform Output MDR-001 is the central focus of MindRank’s business progress at this stage, while the company’s long-term growth potential also depends on its ability to continue developing new drug assets. According to the MindRank, its  end-to-end AI drug development engine, MAP (Molecule Arts Platform), integrates biology, chemistry, computation, experimental validation and clinical learning into a unified drug discovery and development system. In July 2026, the company announced that it had completed a cumulative US$52 million Series B financing in stages, with proceeds earmarked for further platform development and the advancement of its clinical and preclinical pipeline. In September 2026, the company formally launched Intera (Intelligence Era), its life-sciences foundation model system, and released a technical report on InteraFold-Chem, the first model in the InteraFold series. From an operating perspective, platform development and pipeline advancement have the potential to reinforce each other. R&D programs bring real-world problems and experimental feedback to the platform, while platform iterations support the discovery and optimization of subsequent programs. Ultimately, the platform’s value must be reflected in sustained output: its ability to advance more molecules with development potential across different targets and disease areas, gradually building a business supported by multiple assets. MindRank has already expanded beyond metabolic diseases. In March 2025, the company disclosed that MRANK-106, an oral dual inhibitor of WEE1 and YES1, had received IND approval in the U.S. in oncology. This development provides another case through which to assess the applicability of its AI platform across different R&D areas, although the product’s potential remains subject to subsequent clinical validation. In earlier-stage research, the company disclosed in April 2026 that a collaborative study on drug discovery for Alzheimer’s disease, conducted by MindRank, the University of Macau and Imperial College London, had been published in Nature Biomedical Engineering. The work combined AI screening with experimental validation to identify small molecules meriting further investigation, demonstrating the company’s research capabilities and exploration at the forefront of drug discovery for complex diseases. These programs are at different stages, and their contributions to the company’s value need to be assessed separately. MDR-001 remains the main focus of current clinical development and commercialization preparations, while other pipeline programs and research support the platform’s broader applicability and long-term project portfolio. As more programs deliver verifiable progress, outside observers will be better positioned to assess whether the company can consistently replicate its R&D capabilities. Viewed through this lens, the recent commercialization partnership offers an opportunity to reassess MindRank. Its lead asset has entered pivotal clinical development, partners are participating in commercialization preparations at an early stage, financing supports continued R&D, and its presence across multiple areas preserves opportunities for future growth. These interconnected developments make the company’s development trajectory easier for capital markets to understand. MDR-001 remains in clinical development and has not yet received marketing approval. Its future value realization depends on clinical results, regulatory approval and commercial execution. Nevertheless, the business progress achieved to date provides a more concrete basis for assessing MindRank. For investors following opportunities at the intersection of AI and innovative medicines, the central question worth tracking is whether the company can progressively translate its established R&D capabilities into more verifiable drug assets and commercial outcomes. ———————————————————————————————————————————————————————————— World-Class Oncology on a Budget: Why Global Patients Choose India for Gastric Cancer 2026-10-09 · freePRnow · Biotech & pharma http://www.freePRnow.com/pr/world-class-oncology-on-a-budget-why-global-patients-choose-india-for-gastric-cancer India provides affordable gastric cancer treatment with advanced technology and expert oncologists. ———————————————————————————————————————————————————————————— Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026 2026-10-09 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/antengene-to-present-latest-preclinical-results-of-atg-207-cd3-tgf--bifunctional-fusion-protein-at-acr-2026-302903209.html SHANGHAI and HONG KONG, Oct. 8, 2026 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for... ———————————————————————————————————————————————————————————— Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development 2026-10-09 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/everest-medicines-appoints-two-veteran-mrna-cancer-vaccine-scientists-to-advance-global-clinical-development-302903187.html Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead, Cancer Vaccines at Moderna, join Everest Medicines Appointments support continued advancement of Everest's mRNA... ———————————————————————————————————————————————————————————— Retension Pharmaceuticals Announces Pricing of Initial Public Offering 2026-10-09 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/09/3377794/0/en/retension-pharmaceuticals-announces-pricing-of-initial-public-offering.html FALLS CHURCH, Va., Oct. 08, 2026 -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, announced today the pricing of its upsized initial public offering of 3,750,000 shares of its common stock at an initial public offering price of $12.00 per share. The gross proceeds to Retension from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Retension, are expected to be $45.0 million. All shares of common stock are being offered by Retension. Retension has granted the underwriters a 30-day option to purchase up to an additional 562,500 shares of its common stock at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on or about October 13, 2026, subject to the satisfaction of customary closing conditions. The shares are expected to begin trading on October 9, 2026 on the Nasdaq Capital Market under the ticker symbol “RTSN.” ———————————————————————————————————————————————————————————— AARD DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD 2026-10-09 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/09/3377785/673/en/aard-deadline-alert-rosen-trusted-investor-counsel-encourages-aardvark-therapeutics-inc-investors-to-secure-counsel-before-important-october-13-deadline-in-securities-class-action-.html NEW YORK, Oct. 08, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Aardvark’s February 13, 2025 initial public offering (“IPO”); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the “Class Period”), of the important October 13, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease 2026-10-09 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/innovent-announces-phase-3-restore-3-study-of-sycume-teprotumumab-n01-injection-met-primary-endpoint-in-inactive-thyroid-eye-disease-302902606.html SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED) SAN FRANCISCO and SUZHOU, China, Oct. 8, 2026 -- Innovent Biologics, Inc. ("Innovent")... ———————————————————————————————————————————————————————————— UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit 2026-10-08 · PR Newswire · Finance, Biotech & pharma https://www.prnewswire.com/news-releases/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-302902953.html NEW YORK, Oct. 8, 2026 -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November... ———————————————————————————————————————————————————————————— Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet 2026-10-08 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/08/3377767/0/en/phase-3-study-results-highlighting-deucrictibant-s-rapid-and-sustained-efficacy-in-treating-hae-attacks-published-in-the-lancet.html ZUG, Switzerland, Oct. 08, 2026 -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results of RAPIDe-3, a phase 3, global, randomized, double-blind, placebo-controlled crossover study evaluating oral deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment of HAE attacks in adolescents and adults have been published in The Lancet (Journal Impact Factor: 109.0). ———————————————————————————————————————————————————————————— Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production 2026-10-08 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/northwest-biotherapeutics-and-the-uk-national-health-service-blood-and-transplant-announce-collaboration-to-support-dcvax-l-production-302903008.html BETHESDA, Md., Oct. 8, 2026 -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, and the UK National Health Service Blood and Transplant ("NHSBT") announce that... ———————————————————————————————————————————————————————————— Kaplan Fox is Investigating Claims Against Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors 2026-10-08 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/317788/Kaplan-Fox-is-Investigating-Claims-Against-Fulcrum-Therapeutics-Inc.-FULC-on-Behalf-of-Investors New York, New York--(October 8, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us. You may also contact... ———————————————————————————————————————————————————————————— Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference 2026-10-08 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/08/3377701/0/en/sionna-therapeutics-to-present-data-at-the-2026-north-american-cystic-fibrosis-conference.html Previously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial ———————————————————————————————————————————————————————————— Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer 2026-10-08 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/guardant-health-announces-approval-europe-201200229.html PALO ALTO, Calif., October 08, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360® CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from treatment with ETCAMAH™ (camizestrant), AstraZeneca’s next-generation oral selective estrogen ———————————————————————————————————————————————————————————— Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026 2026-10-08 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/guardant-health-report-third-quarter-200500810.html PALO ALTO, Calif., October 08, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. ———————————————————————————————————————————————————————————— ORGANA Highlights Simple Wellness Habits as Fall Routines Return 2026-10-08 · Newsworthy.ai · AI, SaaS, Healthcare, Energy, Retail, Education, Travel, Food & drink, Biotech & pharma https://newsworthy.ai/news/202610083041/organa-highlights-simple-wellness-habits-as-fall-routines-return Springville, UT Thursday Oct 8, 2026 @ 3:00 PM Eastern — As summer gives way to fall and daily schedules become more structured, ORGANA is encouraging consumers to use the change of seasons as an opportunity to return to simple, consistent wellness habits. Fall often brings a shift in routines. Vacations wind down, school and work schedules settle in, temperatures cool and the busy holiday season begins to approach. For ORGANA, the transition is a reminder that wellness routines don't need to be complicated to become part of everyday life. One area that can receive less attention as temperatures fall is hydration. While people often think about water, electrolytes and minerals during hot summer months and outdoor activities, ORGANA believes attention to hydration and minerals can be part of a year-round wellness routine. "Fall is a great time to look at the little things you do every day and get back into a routine," said Larry Mills, CEO of ORGANA. "Our philosophy has always been to make wellness simple. You don't need to completely change your life when the seasons change. Consistency with a few everyday habits can go a long way." That philosophy is reflected across ORGANA's product portfolio, including its  Pomegranate Mineral Drink. ORGANA Plant-Derived Trace Minerals are sourced from an ancient mineral deposit in Utah and provide a concentrated blend of naturally occurring trace minerals. The liquid format is designed to make the product easy to incorporate into an existing daily routine. ORGANA's Pomegranate Mineral Drink combines its plant-derived mineral complex with pomegranate flavor in a ready-to-use liquid format, providing another option for consumers looking to make minerals part of their everyday routine. The company's broader wellness portfolio also includes Liquid Oxygen 125 PPM and Essiac Tea, reflecting ORGANA's focus on straightforward products that can fit into different lifestyles and routines. As consumers transition into fall, ORGANA recommends focusing on habits that are realistic enough to maintain throughout the season. Drinking water regularly, paying attention to hydration even when temperatures are cooler, maintaining a consistent sleep schedule, staying active and establishing simple daily routines can provide a more practical approach than trying to overhaul everything at once. For ORGANA, the seasonal message is also a reminder that wellness isn't limited to a particular time of year. The habits that receive attention during summer can remain part of everyday routines throughout fall and into winter. "Summer makes people naturally think about hydration," Mills said. "When the weather cools down, it's easy to stop thinking about it. We want to remind people that hydration and minerals don't have an offseason." Consumers can explore and purchase ORGANA products through the company's Amazon storefront and on OneLavi.com.  To learn more about the company's wellness philosophy visit organa.net. About ORGANA International Founded in 1997, ORGANA International is a wellness company committed to delivering natural, bioavailable products that help people live healthier lives. From trace minerals and liquid oxygen to magnesium creams and detoxification teas, ORGANA’s product line is designed to restore vital elements often missing in modern lifestyles. Headquartered in Springville, Utah, ORGANA is a customer-first company with a 5-star BBB rating and nearly three decades of dedication to natural wellness. FDA Disclaimer These statements have not been evaluated by the Food and Drug ———————————————————————————————————————————————————————————— ALCMI and Sophos IRB Form Strategic Partnership to Advance Lung Cancer Clinical Research 2026-10-08 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/alcmi-and-sophos-irb-form-strategic-partnership-to-advance-lung-cancer-clinical-research-302902845.html Partnership pairs ALCMI's international lung cancer research network with Sophos IRB's specialized oncology IRB expertise. SAN CARLOS, Calif., Oct. 8, 2026 -- The Addario Lung Cancer Medical Institute (ALCMI), an international nonprofit specializing in investigator-initiated... ———————————————————————————————————————————————————————————— Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC 2026-10-08 · GlobeNewswire · Finance, AI, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/08/3377628/0/en/tevogen-signs-letter-of-intent-to-evaluate-potential-acquisition-of-hrk-healthcare-llc.html WARREN, N.J., Oct. 08, 2026 -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with HRK Healthcare LLC (“HRK”). ———————————————————————————————————————————————————————————— From Gene Therapy to Whole-Body Health: Major ENT Research Coming to Los Angeles 2026-10-08 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/from-gene-therapy-to-whole-body-health-major-ent-research-coming-to-los-angeles-302901779.html LOS ANGELES, Oct. 8, 2026 -- More than 5,000 ear, nose and throat specialists from around the world will gather in Los Angeles next week for the American Academy of Otolaryngology–Head and Neck Surgery's 2026 Annual Meeting & OTO EXPO. The event will feature new research on... ———————————————————————————————————————————————————————————— Enoumena Therapeutics and AOP Health Announce Exclusive Canadian Commercialization Agreement for SIBBORAN(R) (landiolol) 2026-10-08 · Newsfile · Healthcare, Biotech & pharma https://www.newsfilecorp.com/release/318089/Enoumena-Therapeutics-and-AOP-Health-Announce-Exclusive-Canadian-Commercialization-Agreement-for-SIBBORANR-landiolol Montreal, Quebec and Vienna, Austria--(October 8, 2026) - Enoumena Therapeutics Inc. and AOP Health today announced an exclusive commercialization agreement to expand Canadian institutional access to PrSIBBORAN® (landiolol hydrochloride), an ultra-short-acting, selective beta-1 adrenergic receptor blocker.Authorized by Health Canada in 2023, SIBBORAN is indicated for the short-term reduction of ventricular rate in patients with supraventricular tachycardia including atrial... ———————————————————————————————————————————————————————————— Psilera Greenlit to Initiate Phase 2 of NIH Grant for Alcohol Use Disorder 2026-10-08 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/psilera-greenlit-to-initiate-phase-2-of-nih-grant-for-alcohol-use-disorder-302901477.html Government-backed research into next-generation psychedelics and neuroplastogens for addictive disorders underscores the continued momentum behind this promising drug class. TAMPA, Fla., Oct. 8, 2026 -- Psilera Inc. ("Psilera"), a leading biopharmaceutical company pioneering... ———————————————————————————————————————————————————————————— GOA Therapeutics Unveils New Data for GOA26, a First-in-Class Drug Candidate for Acute Alcohol Intoxication and Poisoning 2026-10-08 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/08/3377246/0/en/goa-therapeutics-unveils-new-data-for-goa26-a-first-in-class-drug-candidate-for-acute-alcohol-intoxication-and-poisoning.html In a porcine model of severe acute alcohol intoxication, GOA26 demonstrated a rapid reduction in blood alcohol concentration and multi-system biochemical recovery across metabolic, muscle, hematological and liver biomarkers. ———————————————————————————————————————————————————————————— Vinci Pharmaceuticals Inc. Closes More Than $8 Million Series A Financing to Advance EPIPLANT™ Drug Delivery Platform 2026-10-08 · PR Newswire · SaaS, Industrial, Biotech & pharma https://www.prnewswire.com/news-releases/vinci-pharmaceuticals-inc-closes-more-than-8-million-series-a-financing-to-advance-epiplant-drug-delivery-platform-302902416.html Key Takeaways Combined with its Seed round of $8.5M, the company has raised more than $16.5M in support of its activities. Vinci Pharmaceuticals closed an $8+ million Series A financing round to support manufacturing, testing/release activities and first-in-human studies of its EPIPLANT™... ———————————————————————————————————————————————————————————— Cyrano Therapeutics' Phase 2 FLAVOR Trial Selected to Open 72nd Annual Meeting of the American Rhinologic Society (ARS) 2026-10-08 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/cyrano-therapeutics-phase-2-flavor-trial-selected-to-open-72nd-annual-meeting-of-the-american-rhinologic-society-ars-302901896.html DELRAY BEACH, Fla., Oct. 8, 2026 -- Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company developing novel treatments for smell and taste disorders, today announced that results from the Phase 2 FLAVOR trial of CYR-064 will open the General Session at the... ———————————————————————————————————————————————————————————— argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease 2026-10-08 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/08/3376936/0/en/argenx-announces-positive-topline-results-from-phase-2-study-of-fb102-in-celiac-disease.html October 8, 2026, 7:00 AM CET ———————————————————————————————————————————————————————————— Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia 2026-10-08 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/08/3376933/0/en/addex-spin-out-neurosterix-completes-phase-1-clinical-studies-of-ntx-253-for-schizophrenia.html Ad Hoc Announcement Pursuant to Art. 53 LR ———————————————————————————————————————————————————————————— ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY 2026-10-08 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/317897/ROSEN-LEADING-INVESTOR-COUNSEL-Encourages-Unicycive-Therapeutics-Inc.-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-UNCY New York, New York--(October 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs... ———————————————————————————————————————————————————————————— Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of INHBE-Targeting siRNA RBD3133 2026-10-08 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/ribo-submits-european-clinical-trial-application-for-phase--study-of-inhbe-targeting-sirna-rbd3133-302901905.html SUZHOU, China and MÖLNDAL, Sweden, Oct. 8, 2026 -- Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the successful submission of a Phase Ⅰ Clinical Trial Application (CTA) in EU for RBD3133, a... ———————————————————————————————————————————————————————————— AusperBio to Present Long-Term Follow-Up Data of AHB-137 Treatment in Chronic Hepatitis B in Two Late-Breaking Oral Presentations at AASLD The Liver Meeting® 2026 2026-10-08 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/ausperbio-to-present-long-term-follow-up-data-of-ahb-137-treatment-in-chronic-hepatitis-b-in-two-late-breaking-oral-presentations-at-aasld-the-liver-meeting-2026-302901774.html Two abstracts on long-term follow-up data of AHB-137 treatment for chronic hepatitis B have been selected for late-breaking oral presentations at The Liver Meeting® 2026. SAN FRANCISCO, Oct. 7, 2026 -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together,... ———————————————————————————————————————————————————————————— WuXi AppTec Earns EcoVadis Gold Medal for Third Consecutive Year, Ranking Among Global Top 5% for Sustainability 2026-10-08 · PR Newswire · Industrial, Biotech & pharma, Sustainability https://www.prnewswire.com/news-releases/wuxi-apptec-earns-ecovadis-gold-medal-for-third-consecutive-year-ranking-among-global-top-5-for-sustainability-302901244.html SHANGHAI, Oct. 7, 2026 -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has received a Gold medal from EcoVadis for the third consecutive year, reflecting the Company's consistent commitment to... ———————————————————————————————————————————————————————————— Neo Dental Beverly Hills Introduces Neo-Essentialism: A Modern Approach to Clinical Decision-Making and a New Way to Think About Dentistry’s Future 2026-10-07 · GlobeNewswire · AI, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/07/3376911/0/en/neo-dental-beverly-hills-introduces-neo-essentialism-a-modern-approach-to-clinical-decision-making-and-a-new-way-to-think-about-dentistry-s-future.html As dentistry moves toward regeneration, artificial intelligence, and biologic preservation, the Beverly Hills dentist behind the concept is asking whether progress may increasingly be defined by what clinicians can preserve, not only by what they can repair or replace. As dentistry moves toward regeneration, artificial intelligence, and biologic preservation, the Beverly Hills dentist behind the concept is asking whether progress may increasingly be defined by what clinicians can preserve, not only by what they can repair or replace. ———————————————————————————————————————————————————————————— Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus 2026-10-07 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/glaukos-announces-positive-three-epioxa-200500282.html ALISO VIEJO, Calif., October 07, 2026--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the durability, visual outcomes, and safety of Epioxa®, the company's groundbreaking epi-on corneal cross-linking therapy for the treatment of keratoconus, a sigh ———————————————————————————————————————————————————————————— Tennessee Oncology Physician Contributes to Landmark Longevity Research 2026-10-07 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/tennessee-oncology-physician-contributes-to-landmark-longevity-research-302901459.html Dr. Yanjun Ma helps uncover genetic and epigenetic clues to extraordinary longevity and cancer resistance in 194-year-old giant tortoise NASHVILLE, Tenn., Oct. 7, 2026 -- Tennessee Oncology is contributing to groundbreaking research into one of biology's most enduring... ———————————————————————————————————————————————————————————— UNCY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026 2026-10-07 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/07/3376778/683/en/uncy-shareholder-action-reminder-faruqi-faruqi-llp-reminds-unicycive-therapeutics-nasdaq-uncy-investors-of-securities-class-action-lawsuit-deadline-on-november-2-2026.html Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options ———————————————————————————————————————————————————————————— Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes 2026-10-07 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/07/3376750/0/en/zealand-pharma-announces-positive-phase-2-zupreme-2-topline-results-for-amylin-analog-petrelintide-in-people-with-overweight-or-obesity-and-type-2-diabetes.html Company announcement – No. 54 / 2026 ———————————————————————————————————————————————————————————— AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC 2026-10-07 · AbbVie · Finance, Healthcare, Food & drink, Biotech & pharma https://www.prnewswire.com/news-releases/abbvies-telisotuzumab-adizutecan-temab-a-receives-two-breakthrough-therapy-designations-from-the-us-fda-for-crc-and-nsclc-302900512.html AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTDs) for... ———————————————————————————————————————————————————————————— Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy 2026-10-07 · PR Newswire · Finance, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/lipocine-announces-health-canada-approval-of-tlando-for-testosterone-replacement-therapy-302900562.html Lipocine Inc. (NASDAQ: LPCN ), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine's licensing partner Verity Pharmaceuticals Inc (Verity Pharma), Health Canada has approved TLANDO® (testosterone undecanoate) capsules for testosterone replacement therapy in adult males for the conditions associated with a deficiency or abse ———————————————————————————————————————————————————————————— AARD 6-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline 2026-10-07 · PR Newswire · Finance, Biotech & pharma https://www.prnewswire.com/news-releases/aard-6-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-302900525.html SAN FRANCISCO, Oct. 7, 2026 -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: $AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock... ———————————————————————————————————————————————————————————— FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition 2026-10-07 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/07/3376442/0/en/fda-grants-seastar-medical-breakthrough-device-designation-for-its-scd-therapy-for-the-treatment-of-hyperinflammation-in-adult-patients-with-sepsis-or-a-septic-condition.html Potentially accelerates development, assessment, and review for approval by FDA ———————————————————————————————————————————————————————————— Halia Therapeuticsto Participate in the 6th Annual Needham Private Biotech & MedTech Company Virtual 1x1 Forum 2026-10-07 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/halia-therapeuticsto-participate-in-the-6th-annual-needham-private-biotech--medtech-company-virtual-1x1-forum-302900689.html LEHI, Utah, Oct. 7, 2026 -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class therapies targeting inflammasome-driven disease biology, today announced that the Company plans to participate in the 6th Annual Needham Private Biotech... ———————————————————————————————————————————————————————————— MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer 2026-10-07 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/07/3376441/0/en/maia-biotechnology-achieves-patient-enrollment-milestones-in-ongoing-phase-2-and-pivotal-phase-3-clinical-trials-in-non-small-cell-lung-cancer.html Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study ———————————————————————————————————————————————————————————— Byondis to Profile Potential of Platform Technologies at World ADC San Diego, Advancing Strategy to Lead the Antibody-Drug Conjugate Field 2026-10-07 · GlobeNewswire · SaaS, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/07/3376438/0/en/byondis-to-profile-potential-of-platform-technologies-at-world-adc-san-diego-advancing-strategy-to-lead-the-antibody-drug-conjugate-field.html NIJMEGEN, The Netherlands – 7 October 2026 – Byondis B.V., a private biopharmaceutical company engineering antibody-drug conjugates (ADCs) to tackle the cancers that current therapies cannot reach, will share progress from its platform technology portfolio at World ADC San Diego, the world's largest ADC conference, being held from 12-15 October in San Diego, USA. ———————————————————————————————————————————————————————————— VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods 2026-10-07 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/07/3376437/37000/en/vivosim-labs-celebrates-updated-fda-regulations-allowing-greater-use-of-non-animal-testing-methods.html As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs ———————————————————————————————————————————————————————————— Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026 2026-10-07 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/07/3376430/0/en/kyverna-therapeutics-to-present-positive-data-in-stiff-person-syndrome-and-progressive-multiple-sclerosis-at-mstoronto2026.html Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no cases of IEC-HS ———————————————————————————————————————————————————————————— Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040 2026-10-07 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/07/3376420/0/en/esperion-reaches-settlement-agreement-with-sixth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-2040.html ANN ARBOR, Mich., Oct. 07, 2026 -- Esperion, a company wholly-owned by ARCHIMED, today announced that it has entered into a settlement agreement with Renata Limited (along with an affiliate). This agreement resolves the patent litigation brought by Esperion against Renata in response to Renata’s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Renata has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur. ———————————————————————————————————————————————————————————— AltruBio to Present Data from ALTB-268 Phase 2a Trial on Ulcerative Colitis at United European Gastroenterology (UEG) Week 2026 2026-10-07 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/07/3376410/0/en/altrubio-to-present-data-from-altb-268-phase-2a-trial-on-ulcerative-colitis-at-united-european-gastroenterology-ueg-week-2026.html SAN FRANCISCO, Oct. 07, 2026 -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical-stage biotech company developing novel immune modulators to address the unmet need in immunological and inflammatory diseases, today announced an oral presentation at the United European Gastroenterology (UEG) Week 2026 meeting, taking place October 17–20, 2026, in Barcelona, Spain. The presentation will feature new data from AltruBio’s Phase 2a ASCEND UC2a trial (NCT06109441) evaluating its lead asset, ALTB-268, in patients with moderately to severely active ulcerative colitis with an inadequate response to prior advanced therapy. ———————————————————————————————————————————————————————————— Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum 2026-10-07 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/07/3376419/37519/en/akebia-therapeutics-to-conduct-investor-meetings-at-the-virtual-u-s-bancorp-i-btig-kidney-health-forum.html WALTHAM, Mass., Oct. 07, 2026 -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Dr. Steven Burke, Chief R&D and Medical Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-on-one meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026. ———————————————————————————————————————————————————————————— Bexorg Awarded Up to $28.3 Million from ARPA-H to Advance Human Brain Translational Pharmacology for CNS Drug Development 2026-10-07 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/07/3376407/0/en/bexorg-awarded-up-to-28-3-million-from-arpa-h-to-advance-human-brain-translational-pharmacology-for-cns-drug-development.html - Three-phase, 36-month award aims to extend BrainEx perfusion from 24 hours to up to two weeks, enabling longitudinal studies of human brain biology and therapeutic responses - ———————————————————————————————————————————————————————————— Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants 2026-10-07 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/07/3376414/0/en/jasper-therapeutics-announces-commencement-of-an-offer-to-purchase-outstanding-warrants.html REDWOOD CITY, Calif., Oct. 07, 2026 -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported that it has commenced an offer to purchase (the "Offer") any and all of its outstanding warrants to purchase shares of its common stock, par value $0.0001 per share (the "Common Stock"), that were issued in its underwritten public offering on September 18, 2025 (the "Warrants"). The purchase price is $0.324 in cash per Warrant, without interest (the "Offer Purchase Price"). The purpose of the Offer is to reduce the number of shares of Common Stock that would become outstanding upon the exercise of the Warrants, thereby reducing the potential dilutive impact of the Warrants, and providing shareholders and prospective investors greater certainty as to the Company’s capital structure. Warrants tendered in the Offer will be retired and cancelled. ———————————————————————————————————————————————————————————— C60 Power Celebrates National C60 Day on October 9 2026-10-07 · Newsworthy.ai · AI, SaaS, Healthcare, Energy, Retail, Media, Education, Food & drink, Sports, Industrial, Aerospace & defense, Biotech & pharma https://newsworthy.ai/news/202610073034/c60-power-celebrates-national-c60-day-on-october-9 Boulder, CO Wednesday Oct 7, 2026 @ 7:00 AM Eastern — C60 Power, a woman owned wellness company specializing in Carbon 60 products for people and animals, celebrates National C60 Day every October 9.  Created by C60 Power, the observance falls on the anniversary of October 9, 1996, the day the Royal Swedish Academy of Sciences announced the Nobel Prize in Chemistry for the discovery of fullerenes. This year, consumers can enjoy educational events, community stories, and a 20% storewide sale at ShopC60.com. National C60 Day, also known as National Carbon 60 Day, C60 Day or Carbon 60 Day, recognizes the discovery of C60, also called buckminsterfullerene or a "buckyball." C60 is a hollow, spherical molecule made of exactly 60 carbon atoms arranged in 12 pentagons and 20 hexagons, the same pattern found on a classic soccer ball. A Discovery Written in the Stars In 1985, British chemist Harold Kroto joined Rice University scientists Robert Curl and Richard Smalley to recreate the chemistry of carbon rich stars in the laboratory, and their experiments revealed C60. Kroto, a longtime admirer of architect R. Buckminster Fuller's geodesic domes helped give the molecule its name in honor of Buckminster. In 1990, Wolfgang Krätschmer and Donald Huffman developed a method to produce C60 in quantities large enough to study, and the journal Science named buckminsterfullerene its Molecule of the Year for 1991. Curl, Kroto, and Smalley were awarded the 1996 Nobel Prize in Chemistry for their discovery. In 2010, astronomers using NASA's Spitzer Space Telescope detected C60 in Tc 1, a cloud of gas and dust shed by a dying star, the first confirmed sighting of buckyballs in space. "National C60 Day gives us an opportunity to honor the science that introduced this extraordinary molecule to the world. This holiday may help consumers understand the importance of purity, and 3rd-party testing, along with the opportunity to learn more about the potential of the molecule," said Jessica MacNaughton, CEO and cofounder of C60 Power. "Our goal is to make reliable C60 education more accessible and give people the information they need to make informed choices for themselves and their animals." What Researchers Are Studying Since its discovery, C60 research has expanded into chemistry, materials science, nanotechnology, energy, skincare and wellness. Its ability to interact with free radicals is one reason C60 continues to attract attention in antioxidant research. Interest in C60 and healthy aging grew after a 2012 study reported that rats given C60 dissolved in olive oil lived longer than untreated rats. Consumers can review published studies at WhatIsC60.org and ShopC60.com/research. How to Celebrate National C60 Day Share the story. Post a buckyball sketch, a molecule model or the most surprising fact you learned, tag @C60Power and use #NationalC60Day, #Carbon60 and #C60. Explore the research. Start by with reviewing the research at WhatIsC60.org, or ShopC60.com/research and share one study or question on social media with #NationalC60Day. Take the C60 Challenge. Purchase C60 at ShopC60.com on October 9th and then download the C60 30-Day Challenge Journal to track your C60 routine and how you feel. https://shopc60.com/wp-content/uploads/2025/07/c60-journal.pdf  Deals and Offers National C60 Day Sale: Save 20% storewide on C60 Power products, from C60 oils and gummies to skincare and C60 for pets. This code is valid until October 9, 2026 only at ShopC60.com.Use code CELEBRATE20 at checkout on ShopC60.com. Ready to try C60 after National C60 Day? Visit ShopC60.com and use code NATIONAL10 for 10 percent off your first order. About C60 Power C60 Power is an American woman owned wellness company,originally founded in 2016 as C60 Purple Power.  The company specializes in the manufacturing of health and wellness products containing Carbon 60 including  C60 oils, gummies, skincare, and specialty formulations for pets; , all made with 99.99 percent pure, sublimated C60, and certified organic carrier oils. All C60 Power products are third-party tested for safety, quality, purity, and bioavailability.  Where to Buy C60 Power products are available at ShopC60.com, TrulyFree.com and Amazon.com, through many healthcare providers, and at select health and wellness retailers across the United States. Media Contact Lindsay O'Neill-O'Keefe Wellness Eternal Email Contact 914-846-9444 Disclaimer: These statements have not been evaluated by the Food and Drug Administration. C60 Power products are not intended to diagnose, treat, cure, mitigate or prevent any disease. Individual results may vary. ———————————————————————————————————————————————————————————— MUVON Therapeutics Reports Positive 12-Month Phase 2 Follow-up Data Confirming Durable Efficacy of its First-in-Class Muscle Regeneration Therapy in Stress Urinary Incontinence 2026-10-07 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/07/3376254/0/en/muvon-therapeutics-reports-positive-12-month-phase-2-follow-up-data-confirming-durable-efficacy-of-its-first-in-class-muscle-regeneration-therapy-in-stress-urinary-incontinence.html Zurich, Switzerland, October 7, 2026 – MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive 12-month interim results from the Long-Term Follow-Up Study of the Phase 2 clinical trial SUISSE-MPC2 (NCT05534269), demonstrating durable, sustained and clinically relevant bladder health benefits in patients treated with its novel proprietary muscle precursor cell (MPC)-based tissue-engineered therapy for female stress urinary incontinence (SUI). SUI represents a high unmet medical need, affecting more than 150 million women worldwide, for which no approved therapy presently addresses the underlying cause. The study results were presented in an oral session at the Annual Meeting of the International Continence Society (ICS) in Maastricht, the Netherlands, on October 7, 2026 [1]. ———————————————————————————————————————————————————————————— ITM and Lumara Bio to Announce New Data for ¹⁷⁷Lu-edotreotide (ITM-11) and Ga-DPI-4452 at EANM 2026 2026-10-07 · GlobeNewswire · Healthcare, Energy, Education, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/07/3376253/0/en/itm-and-lumara-bio-to-announce-new-data-for-lu-edotreotide-itm-11-and-ga-dpi-4452-at-eanm-2026.html Garching / Munich, October 7, 2026 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Lumara Bio, a dedicated oncology therapeutics division of ITM, today announced that new data for 177Lu-edotreotide (ITM-11) and Ga-DPI-4452 (CA-IX peptide) will be unveiled in two top-rated oral presentations at the European Association of Nuclear Medicine (EANM) Congress, held from October 17 – 21, 2026 in Vienna, Austria. Anthime Flaus, MD, PhD, of the Hospital Louis Pradel in Bron, France will present dose-response findings from the Phase 3 COMPETE trial, in which patients with gastroenteropancreatic neuroendocrine tumors were treated with 177Lu-edotreotide. Alina Küper, MD, of the University Hospital Essen in Germany will present interim results from an independent, retrospective analysis of the PET/CT imaging agent Ga-DPI-4452 (CA-IX peptide) used for the imaging of clear cell renal cell carcinoma in a bicenter registry. In addition to the scientific presentations, ITM will host a booth reception and separate Meet the Expert session. At this session, Dr. Neil Quigley will share insights into the production of Actinium-225 (225Ac) using medium-energy cyclotrons and present Actineer’s approach to increase production capacity. Actineer is the joint venture between ITM and Canadian Nuclear Laboratories. Oral Presentation Details Title: Ga-DPI-4452 (CA-IX peptide) PET/CT for Imaging Clear Cell Renal Cell Carcinoma: Interim Results from a Bicentre Registry Session Title: Renal Cell Cancer and Novel Targets  Session Number: 506 Track: Clinical Oncology Date and Time: Sunday, October 18, 2026, 15:00 – 16:30 CEST Location: Hall C Presenter: Dr. Alina Küper, University Hospital Essen, Essen, Germany Title: Dose-response Analysis in Patients with Gastroenteropancreatic Neuroendocrine Tumors Receiving [¹⁷⁷Lu]Lu-edotreotide Session Title: From Clinical Dosimetry to Treatment Adaptation in [¹⁷⁷Lu] Therapy Session Number: 1505 Track: Cutting Edge Science Date and Time: Tuesday, October 20, 2026, 15:00 – 16:30 CEST Location: Hall B Presenter: Dr. Anthime Flaus, Hospital Louis Pradel, Bron, France Meet the Expert Session Title: 225Ac Production via Medium-Energy Cyclotrons: Actineer’s Path Towards Increasing Production Capacities Date and Time: Monday, October 19, 2026, 10:30 – 10:50 CEST Location: ITM Booth #415, Hall X4 Presenter: Dr. Neil Quigley, Radioisotope Scientific Expert at ITM Conference attendees will have the opportunity to learn more about ITM and Lumara Bio, a division of ITM, by visiting the company booth, #415 in Hall X4. Attendees are also invited to join the ITM team for an informal booth reception and networking opportunity on Monday, October 19, from 16:00 to 17:00 CEST. 177Lu-edotreotide (ITM-11) and Ga-DPI-4452 (CA-IX peptide) are investigational products and are not approved by any regulatory authority for the safety and/or efficacy of any intended use. About the COMPETE Trial The COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic investigational agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is an investigational product and is not approved by any regulatory authority for the safety and/or efficacy of any intended use. 177Lu-edotreotide is also being evaluated in COMPOSE, a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, somatostatin receptor (SSTR)-positive GEP-NETs. About Ga-DPI-4452 (ITM-94) Ga-DPI-4452 (also known as [68Ga]Ga-DPI-4452, CA-IX peptide, or ITM-94) is an investigational gallium-68-radiolabeled PET imaging agent targeting carbonic anhydrase IX (CAIX), a cell surface protein that plays a key role in tumor growth, invasion, and metastasis. ITM-94 is designed to non-invasively improve the characterization of indeterminate renal masses and enable more accurate diagnosis and disease staging of clear cell renal cell carcinoma (ccRCC). ITM-94 received Fast Track Designation from the FDA in October 2025. [68Ga]Ga-DPI-4452 is an investigational product and is not approved by any regulatory authority for the safety and/or efficacy of any intended use. About ITM Isotope Technologies Munich SE ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com About Lumara Bio Lumara Bio, a division of ITM, builds on more than two decades of radiopharmaceutical expertise and is advancing a focused pipeline of targeted therapies for cancers where treatment options remain limited. https://lumarabio.com ITM Contact Corporate Communications Kathleen Noonan/Julia Westermeir Phone: +49 89 329 8986 1500 Email: communications@itm-radiopharma.com Investor Relations Ben Orzelek Phone: +49 89 329 8986 1009 Email: investors@itm-radiopharma.com ———————————————————————————————————————————————————————————— LG CNS Showcases Pharma-Specific Manufacturing AX at World's Largest Pharma-Biotech Show 2026-10-07 · PR Newswire · Healthcare, Industrial, Biotech & pharma https://www.prnewswire.com/news-releases/lg-cns-showcases-pharma-specific-manufacturing-ax-at-worlds-largest-pharma-biotech-show-302900801.html Participates in CPHI Milan 2026, Expanding Manufacturing AX Reach in Pharma Showcasing key solutions for factory design, production operations, and quality management using the theme "Autonomous Factory in Pharma" SEOUL, South Korea and MILAN, Oct. 7, 2026 -- LG CNS, a... ———————————————————————————————————————————————————————————— OncoBayes progressing OB-001 to tackle ADC resistance and TKI brain penetration 2026-10-07 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/oncobayes-progressing-ob-001-to-tackle-adc-resistance-and-tki-brain-penetration-302900098.html LONDON, Oct. 7, 2026 -- OncoBayes, a privately held clinical-stage pharmaceutical company, today announced the successful completion of preclinical work with OB-001, demonstrating the product's potential to tackle two major unmet needs in oncology: ADC resistance and the... ———————————————————————————————————————————————————————————— Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia 2026-10-07 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/07/3376179/0/en/nurix-therapeutics-announces-first-patient-enrolled-in-phase-1b-2-combination-study-of-bexobrutideg-in-chronic-lymphocytic-leukemia.html First patient enrolled in cohort combining bexobrutideg with venetoclax ———————————————————————————————————————————————————————————— Palindrome Pharma Launches in Canada to Unlock Access to High-Quality Biosimilar Medicines 2026-10-07 · Newsfile · Healthcare, Biotech & pharma https://www.newsfilecorp.com/release/317821/Palindrome-Pharma-Launches-in-Canada-to-Unlock-Access-to-HighQuality-Biosimilar-Medicines Toronto, Ontario--(October 7, 2026) - Palindrome Pharma, a new pharmaceutical company focused on biosimilar medicines, today announced its launch in Canada, with a mission to broaden access to high-quality biologic therapies and contribute to a more sustainable Canadian healthcare system.As demand for biologic medicines continues to grow, biosimilars have an important role to play in creating greater choices for Canadians. Palindrome Pharma will work with global and Canadian... ———————————————————————————————————————————————————————————— ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY 2026-10-07 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/317688/ROSEN-A-GLOBALLY-RESPECTED-LAW-FIRM-Encourages-Unicycive-Therapeutics-Inc.-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-UNCY New York, New York--(October 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs... ———————————————————————————————————————————————————————————— Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes 2026-10-07 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/07/3376168/0/en/vaxcyte-announces-pricing-of-concurrent-public-offerings-of-common-stock-pre-funded-warrants-and-convertible-senior-notes.html SAN CARLOS, Calif., Oct. 06, 2026 -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants to purchase 400,000 shares of common stock and $500 million aggregate principal amount of 1.50% convertible senior notes due 2032 (the “notes”). The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The shares of common stock, pre-funded warrants and notes to be sold in the offerings are being offered by Vaxcyte. Vaxcyte has granted the underwriters of the common stock and pre-funded warrant offering a 30-day option to purchase up to an additional 1,171,875 shares of its common stock at the public offering price per share, and has granted the underwriters of the note offering a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes at the public offering price, solely to cover over-allotments, in each case less underwriting discounts and commissions. ———————————————————————————————————————————————————————————— Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026 2026-10-06 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/astellas-highlights-data-advancing-cancer-care-and-innovation-for-patients-with-hard-to-treat-cancers-at-esmo-2026-302900206.html – PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer – – VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in shaping gastric cancer treatment decisions – TOKYO, Oct. 6, 2026 -- Astellas Pharma Inc.... ———————————————————————————————————————————————————————————— Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply 2026-10-06 · GlobeNewswire · Industrial, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/06/3376052/0/en/alvotech-and-lotte-biologics-announce-us-based-manufacturing-agreement-to-increase-global-supply.html Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New York ———————————————————————————————————————————————————————————— CNBC's Becky Quick to Moderate CEO Leadership Dialogue on the Next Decade of Rare Disease at the NORD Breakthrough Summit 2026-10-06 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/cnbcs-becky-quick-to-moderate-ceo-leadership-dialogue-on-the-next-decade-of-rare-disease-at-the-nord-breakthrough-summit-302900325.html BioMarin, Jazz Pharmaceuticals, and Otsuka CEOs to Join NORD CEO to Examine What it Takes to Turn Scientific Advancements into Patient Progress WASHINGTON, Oct. 6, 2026 -- The National Organization for Rare Disorders (NORD®) today announced that CNBC "Squawk Box" co-anchor... ———————————————————————————————————————————————————————————— Cancer Prevention and Screening Takes Center Stage During D.C. Summit Convened by NCCN 2026-10-06 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/cancer-prevention-and-screening-takes-center-stage-during-dc-summit-convened-by-nccn-302900103.html National Comprehensive Cancer Network Oncology Policy Summit featured leading voices from NCI, CDC, and more. WASHINGTON, Oct. 6, 2026 -- The National Comprehensive Cancer Network® (NCCN®) hosted a two-day summit focused on expanding access to life-saving cancer prevention... ———————————————————————————————————————————————————————————— UNCY DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026 2026-10-06 · Newsfile · Biotech & pharma https://www.newsfilecorp.com/release/317666/UNCY-DEADLINE-ALERT-Faruqi-Faruqi-LLP-Reminds-Unicycive-Therapeutics-UNCY-Investors-of-Securities-Class-Action-Lawsuit-Deadline-on-November-2-2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. -... ———————————————————————————————————————————————————————————— ComplianceQuest and Zolon PCS Selected to Modernize U.S. Food and Drug Administration (FDA) Enterprise Quality Management System 2026-10-06 · ACN Newswire · AI, SaaS, Healthcare, Automotive, Food & drink, Industrial, Biotech & pharma, Cybersecurity https://www.acnnewswire.com/press-release/english/110631/ TAMPA, FLA., Oct 7, 2026 - ComplianceQuest, a leading provider of AI-powered connected Quality, Risk and Compliance (QRC) systems, and Zolon PCS, a provider of secure, mission-focused IT services to federal agencies, today announced that the U.S. Food and Drug Administration (FDA) will modernize its enterprise quality management operations on the ComplianceQuest platform. The initiative will be delivered under the FDA Cloud Quality Management System Blanket Purchase Agreement (BPA), a five-year agreement awarded to Zolon PCS as prime contractor, with ComplianceQuest as its platform partner. Together, ComplianceQuest and Zolon PCS will help FDA implement a modern, secure, AI-enabled quality management solution built on the Salesforce FedRAMP Government Cloud platform. The solution is designed to strengthen compliance, improve consistency, streamline quality processes, and deliver greater insight across FDA's centers and offices. The initiative will focus on four priorities: Connected Quality Operations: Bringing document control, training, change, CAPA, audits, other key processes coupled with reporting to support consistent execution across the sites, functions, and organizational units. Trusted Data and Enterprise Visibility: Creating a centralized foundation for quality, risk and compliance data with end-to-end traceability and real-time insight across the agency. Intelligence and Automation: Applying AI and intelligent automation to accelerate investigations, surface relevant insights, identify emerging risks, and support better decisions. Secure, Scalable Federal Delivery: Combining a platform built to support large user populations, growing data volumes, and evolving regulatory requirements with Zolon PCS's federal expertise in cloud, cybersecurity, systems integration, and agile delivery. The FDA initiative reflects a broader shift across regulated environments. As operational complexity, regulatory expectations, and quality data volumes grow, organizations are moving beyond individual quality processes toward connected, enterprise-wide approaches. ComplianceQuest's QRC platform is built for this model, unifying Quality, Risk and Compliance across Product, Quality, Manufacturing, People, Suppliers, and Customers on a single, connected system. "Quality management is evolving from individual systems and processes toward connected enterprise platforms," said Prashanth Rajendran, CEO of ComplianceQuest. "We are proud to partner with Zolon PCS to support FDA's quality system modernization. This work highlights the growing need for technology that can meet the complexity, rigor, security, and evolving requirements of highly regulated environments." "We are honored by FDA's confidence in our team and proud to support its vital public health mission," said Goutham Amarneni, President of Zolon PCS. "Modernizing quality management at this scale takes both the right platform and the right delivery partner. Together with ComplianceQuest, we are bringing FDA a secure, AI-enabled solution built for the rigor of federal operations." About ComplianceQuest ComplianceQuest is the leading AI-powered Quality, Risk and Compliance (QRC) system that connects product, manufacturing, people, and partner quality in a single system. Built on Salesforce, the platform delivers end-to-end visibility, AI-driven intelligence, and enterprise-scale execution, enabling organizations to prevent risk, ensure compliance by design, and turn quality into a driver of growth. About Zolon PCS Zolon PCS, LLC is a joint venture between Pioneer Corporate Services and Zolon Tech, Inc., delivering advanced, secure, and mission-focused IT services and consulting to federal agencies. For more information, visit zolonpcs.zolontech.com. Media Contact ComplianceQuest: marketing@compliancequest.com | 408-458-8343 | www.compliancequest.com SOURCE: ComplianceQuest ———————————————————————————————————————————————————————————— Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value 2026-10-06 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/06/3375753/0/en/jupiter-neurosciences-announces-first-patient-dosed-in-phase-2a-reset-trial-in-parkinson-s-disease-and-exploration-of-strategic-options-to-maximize-shareholder-value.html First Patient Dosed with JOTROL™ Marks Major Clinical Milestone for Jupiter Neurosciences’ Phase 2a Study Evaluating Safety, Pharmacokinetics and Biomarkers of JOTROL™ in Patients with Parkinson’s Disease ———————————————————————————————————————————————————————————— Cell Therapy Packaging Market Size, Share, Trends, and Forecast, 2026-2033 | CAR-T Commercialization and Cold-Chain Investment Propel 12.0% CAGR to $1.21 Billion 2026-10-06 · GlobeNewswire · Automotive, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/06/3375751/28124/en/cell-therapy-packaging-market-size-share-trends-and-forecast-2026-2033-car-t-commercialization-and-cold-chain-investment-propel-12-0-cagr-to-1-21-billion.html CAR-T commercialization, cryopreservation, strict tracking rules, and IoT-enabled cold chains drive demand for high-barrier cell therapy packaging. CAR-T commercialization, cryopreservation, strict tracking rules, and IoT-enabled cold chains drive demand for high-barrier cell therapy packaging. ———————————————————————————————————————————————————————————— Cell Therapy Monitoring Kits Market Size, Share, Trends, and Forecast, 2026-2033 | Market to Reach $2.5 Billion as CAR-T Adoption and Regulatory Demands Drive 7.6% CAGR 2026-10-06 · GlobeNewswire · Automotive, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/06/3375749/28124/en/cell-therapy-monitoring-kits-market-size-share-trends-and-forecast-2026-2033-market-to-reach-2-5-billion-as-car-t-adoption-and-regulatory-demands-drive-7-6-cagr.html Rising cell and gene therapy adoption, stringent quality rules, and real-time batch testing needs are driving demand for specialized monitoring kits. Rising cell and gene therapy adoption, stringent quality rules, and real-time batch testing needs are driving demand for specialized monitoring kits. ———————————————————————————————————————————————————————————— Compound Management Market Size and Share Analysis, Industry Trends, and Growth Forecasts, 2026-2031; AI-Enabled Automation and Biologics Drive 14.87% CAGR Through 2031 2026-10-06 · GlobeNewswire · AI, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/06/3375748/28124/en/compound-management-market-size-and-share-analysis-industry-trends-and-growth-forecasts-2026-2031-ai-enabled-automation-and-biologics-drive-14-87-cagr-through-2031.html Boost ROI by outsourcing sample archives to convert fixed costs into variable fees, while AI-enabled automation cuts discovery timelines, manual errors and reagent use. Boost ROI by outsourcing sample archives to convert fixed costs into variable fees, while AI-enabled automation cuts discovery timelines, manual errors and reagent use. ———————————————————————————————————————————————————————————— Orphan Drugs - Global Market Size, Share, Industry Trends, and Growth Forecasts, 2025-2031 | Biologics and Asia-Pacific Drive 6.36% CAGR to USD 334.28 Billion 2026-10-06 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/06/3375747/28124/en/orphan-drugs-global-market-size-share-industry-trends-and-growth-forecasts-2025-2031-biologics-and-asia-pacific-drive-6-36-cagr-to-usd-334-28-billion.html Boost ROI through tax credits, fee waivers, exclusivity, fast-track filings and launch sequencing; prioritize biologics, neurology and Asia-Pacific access. Boost ROI through tax credits, fee waivers, exclusivity, fast-track filings and launch sequencing; prioritize biologics, neurology and Asia-Pacific access. ———————————————————————————————————————————————————————————— Global Exosome-Based Therapeutics Market Size, Share, Trends, and Forecast, 2026-2033 | Engineered Platforms and Scalable Manufacturing Fuel 18.66% CAGR to USD 220.20 Million 2026-10-06 · GlobeNewswire · Industrial, Logistics, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/06/3375746/28124/en/global-exosome-based-therapeutics-market-size-share-trends-and-forecast-2026-2033-engineered-platforms-and-scalable-manufacturing-fuel-18-66-cagr-to-usd-220-20-million.html Investment, strategic collaborations, scalable production and advanced cargo loading are accelerating exosome therapies across oncology, neurology and regenerative medicine. Investment, strategic collaborations, scalable production and advanced cargo loading are accelerating exosome therapies across oncology, neurology and regenerative medicine. ———————————————————————————————————————————————————————————— Luminous Mind, Inc. Announces U.S. Patent for Non-Hallucinogenic Psychedelic Mushrooms 2026-10-06 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/luminous-mind-inc-announces-us-patent-for-non-hallucinogenic-psychedelic-mushrooms-302890972.html Luminous Mind, Inc. seeks strategic partnerships with leading nutraceutical, supplement, pharmaceutical, and venture groups to bring breakthrough products to market, potentially opening a billion-dollar-plus opportunity. BOSTON, Oct. 6, 2026 -- Luminous Mind, Inc. (LMI), a... ———————————————————————————————————————————————————————————— 60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA 2026-10-06 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/06/3375462/0/en/60-degrees-pharmaceuticals-plans-january-2027-hospitalized-babesiosis-data-readout-will-seek-pre-snda-meeting-with-fda.html 60 Degrees plans January 2027 results from its hospitalized babesiosis trial and will seek a pre-sNDA meeting with FDA. ———————————————————————————————————————————————————————————— Once-daily RELEXXII® (methylphenidate hydrochloride extended-release tablet) supports Attention Deficit Hyperactivity Disorder (ADHD) Awareness Month 2026-10-06 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/once-daily-relexxii-methylphenidate-hydrochloride-extended-release-tablet-supports-attention-deficit-hyperactivity-disorder-adhd-awareness-month-302899733.html ALPHARETTA, Ga., Oct. 6, 2026 -- October marks ADHD Awareness Month, shining a light on the need for timely diagnosis and personalized treatment. Vertical Pharmaceuticals is dedicated to supporting the ADHD community and the importance of precision dosing. Approximately 11.7%... ———————————————————————————————————————————————————————————— API Innovation Center Launches the U.S.’ First Benchmark for Pharmaceutical Supply Chain Fragility 2026-10-06 · GlobeNewswire · SaaS, Logistics, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/06/3375458/0/en/api-innovation-center-launches-the-u-s-first-benchmark-for-pharmaceutical-supply-chain-fragility.html More than 550 million prescriptions were filled for medicines with High or Severe supply-chain fragility, according to APIIC’s new national benchmark More than 550 million prescriptions were filled for medicines with High or Severe supply-chain fragility, according to APIIC’s new national benchmark ———————————————————————————————————————————————————————————— BullFrog AI Announces Positive Progress in Drug Discovery Program for Top 5 Global Pharmaceutical in Major Depressive Disorder 2026-10-06 · GlobeNewswire · AI, SaaS, Education, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/06/3375404/0/en/bullfrog-ai-announces-positive-progress-in-drug-discovery-program-for-top-5-global-pharmaceutical-in-major-depressive-disorder.html Achieves key commercial project milestones utilizing its proprietary artificial intelligence (“AI”) and machine learning platform to identify and prioritize therapeutic targets Achieves key commercial project milestones utilizing its proprietary artificial intelligence (“AI”) and machine learning platform to identify and prioritize therapeutic targets ———————————————————————————————————————————————————————————— Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026 2026-10-06 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/06/3375397/27423/en/galectin-therapeutics-to-present-at-the-american-association-for-the-study-of-liver-diseases-aasld-liver-meeting-2026.html NORCROSS, Ga., Oct. 06, 2026 -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the upcoming AASLD Liver Meeting 2026. The Company will deliver three presentations, including an oral presentation, a Poster of Distinction presentation, and one poster presentation, highlighting new risk analyses on noninvasive prediction of variceal development from the NAVIGATE and GT-026 Phase 2b trials of belapectin for the treatment of MASH cirrhosis and portal hypertension. The meeting will be held November 5-9, 2026, in Denver, Colorado. ———————————————————————————————————————————————————————————— Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins 2026-10-06 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/lundbeck-presents-phase-ib-data-for-lu-af28996-in-advanced-parkinsons-disease-as-phase-ii-trial-begins-302899415.html Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2026 The trial provided initial safety and tolerability data for Lu AF28996, with most treatment-emergent adverse events reported as mild... ———————————————————————————————————————————————————————————— Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market 2026-10-06 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/06/3375127/0/en/orion-pharma-announces-agreement-with-qilu-pharma-europe-for-pembrolizumab-biosimilar-for-european-market.html ORION CORPORATION PRESS RELEASE 6 OCTOBER 2026 at 9.00 EEST ———————————————————————————————————————————————————————————— ROSEN, A LONGSTANDING LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY 2026-10-06 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/317539/ROSEN-A-LONGSTANDING-LAW-FIRM-Encourages-Unicycive-Therapeutics-Inc.-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-UNCY New York, New York--(October 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs... ———————————————————————————————————————————————————————————— Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock 2026-10-06 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/06/3375081/0/en/spyre-therapeutics-announces-pricing-of-350-0-million-public-offering-of-common-stock.html WALTHAM, Mass., Oct. 05, 2026 -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the pricing of its previously announced underwritten public offering of 4,117,648 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to the Company from this offering are expected to be approximately $350.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional approximately $52.5 million of shares of the Company's common stock offered in the public offering under the same terms and conditions. The offering is expected to close on or about October 7, 2026, subject to satisfaction of customary closing conditions. ———————————————————————————————————————————————————————————— Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 2026-10-05 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/05/3375052/0/en/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html BOSTON, Oct. 05, 2026 -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 59,250 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 12,550 shares of Vor Bio’s common stock to 9 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”). ———————————————————————————————————————————————————————————— Mozart Therapeutics Presents Clinical and Preclinical Data Supporting MTX-101 at the 62nd EASD Annual Meeting 2026-10-05 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/mozart-therapeutics-presents-clinical-and-preclinical-data-supporting-mtx-101-at-the-62nd-easd-annual-meeting-302898926.html Presentations highlight Phase 1 clinical findings, proof-of-mechanism data, and translational evidence supporting the therapeutic potential of MTX-101 in adults and adolescents with Stage 3 type 1 diabetes SEATTLE, Oct. 5, 2026 -- Mozart Therapeutics, Inc. ("Mozart"), the... ———————————————————————————————————————————————————————————— Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes 2026-10-05 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/05/3375014/0/en/vaxcyte-announces-commencement-of-proposed-public-offerings-of-common-stock-pre-funded-warrants-and-convertible-senior-notes.html SAN CARLOS, Calif., Oct. 05, 2026 -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of $500 million of its common stock and pre-funded warrants and $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in separate public offerings registered under the Securities Act of 1933, as amended. All shares of common stock, pre-funded warrants and notes to be sold in the offerings will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional $75 million of shares of its common stock, and expects to grant the underwriters a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes solely to cover over-allotments. The completion of the common stock and pre-funded warrant offering will not be contingent on the completion of the note offering, and the completion of the note offering will not be contingent on the completion of the common stock and pre-funded warrant offering. The offerings are subject to market and other conditions, and there can be no assurance as to whether or when either offering may be completed, or as to the actual size or terms of either offering. ———————————————————————————————————————————————————————————— Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026 2026-10-05 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/vir-biotechnology-present-expanded-phase-200500748.html SAN FRANCISCO, October 05, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026 in Denver, CO, November 5-9, 2026. ———————————————————————————————————————————————————————————— Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2026-10-05 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/verastem-oncology-announces-inducement-grants-200200705.html BOSTON, October 05, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 380,500 restricted stock units (RSUs) to 24 new employees and stock options to purchase 50,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Vera ———————————————————————————————————————————————————————————— Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2026-10-05 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/neurogene-announces-inducement-grants-under-200100201.html NEW YORK, October 05, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 8,340 shares of the Company’s common stock to five new employees (the "Inducement Grants") on October 5, 2026 (the "Grant Date"). The Induce ———————————————————————————————————————————————————————————— Italfarmaco and VeriSIM Life Partner to Develop Novel HDAC-Targeting Therapeutics for Neuromuscular, Fibrotic, and Rare Diseases 2026-10-05 · Business Wire · AI, Biotech & pharma https://finance.yahoo.com/healthcare/articles/italfarmaco-verisim-life-partner-develop-130000517.html SAN FRANCISCO & MILAN, October 05, 2026--Italfarmaco S.p.A., a global pharmaceutical company with established expertise in histone deacetylase (HDAC) biology and therapeutic development, and VeriSIM Life, an AI-enabled drug discovery and development company, today announced a strategic collaboration to discover and develop novel HDAC-targeted therapeutic assets for neuromuscular, fibrotic, and rare diseases. ———————————————————————————————————————————————————————————— Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma 2026-10-05 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/genmab-abbvie-announce-epcoritamab-combination-185000671.html COPENHAGEN, Denmark & NORTH CHICAGO, Ill., October 05, 2026--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diff ———————————————————————————————————————————————————————————— Zag Bio Advances ZAG-101 into Clinical Development for Type 1 Diabetes 2026-10-05 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/zag-bio-advances-zag-101-171000176.html CAMBRIDGE, Mass., October 05, 2026--Zag Bio™, Inc., a biotechnology company working to set a new standard for treating autoimmune disease, today announced it has advanced its lead program for Type 1 diabetes (T1D), ZAG-101, into clinical development. The company’s first-in-human Phase 1b/2a clinical trial (LANTERN) will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ZAG-101 and explore its potential to preserve insulin-producing beta-cell function. ———————————————————————————————————————————————————————————— Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026) 2026-10-05 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/05/3374884/0/en/zealand-pharma-completion-of-share-buy-back-program-and-related-transactions-week-40-and-41-2026.html Company announcement No. 53 / 2026 ———————————————————————————————————————————————————————————— Trinity's Next Gen Launch Report Shows Pharmaceutical Launches Deliver Strong Performance in the Face of Uncertainty 2026-10-05 · PR Newswire · Finance, AI, Biotech & pharma https://www.prnewswire.com/news-releases/trinitys-next-gen-launch-report-shows-pharmaceutical-launches-deliver-strong-performance-in-the-face-of-uncertainty-302898541.html New research finds 51% of U.S. drug launches exceeded Wall Street revenue expectations in 2025, with oncology products leading the way WALTHAM, Mass., Oct. 5, 2026 -- Trinity, the leader in integrating human and artificial intelligence in life sciences commercialization,... ———————————————————————————————————————————————————————————— Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026 2026-10-05 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/05/3374774/0/en/sironax-named-to-fierce-biotech-s-fierce-15-list-of-the-most-innovative-and-promising-private-biotechs-of-2026.html Recognized for bold approach to addressing therapeutic targets Recognized for bold approach to addressing therapeutic targets ———————————————————————————————————————————————————————————— Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm 2026-10-05 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/05/3374768/34548/en/securities-fraud-investigation-into-alnylam-pharmaceuticals-inc-alny-continues-shareholders-who-lost-money-urged-to-contact-glancy-prongay-wolke-rotter-llp-a-leading-securities-fra.html LOS ANGELES, Oct. 05, 2026 -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company’s possible violations of the federal securities laws. ———————————————————————————————————————————————————————————— Science Corp. Announces Long-Term (36 Months) Results of PRIMA BCI Clinical Trial Showing Durable Vision Restoration in Blind Patients Suffering from Geographic Atrophy 2026-10-05 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/science-corp-announces-long-term-140000084.html ALAMEDA, Calif., October 05, 2026--Science Corporation, the neural engineering and brain-computer interface (BCI) company, today announced long-term (36 months) followup data from its pivotal PRIMAvera clinical trial (NCT04676854). The results were presented in a late-breaking session at the 26th EURETINA Congress of European retina specialists in Vienna by Mahi Muqit, MD, PhD, Consultant Vitreoretinal Surgeon at Moorfields Eye Hospital NHS Foundation Trust and Associate Professor at the Institu ———————————————————————————————————————————————————————————— Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial 2026-10-05 · PR Newswire · Healthcare, Automotive, Biotech & pharma https://www.prnewswire.com/news-releases/anixa-biosciences-announces-first-case-of-stable-disease-for-three-months-in-ovarian-cancer-car-t-clinical-trial-302897598.html First patient in current dose cohort exhibited no progression of her cancer three months after treatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities observed to date SAN JOSE, Calif., Oct. 5, 2026 -- Anixa... ———————————————————————————————————————————————————————————— Consano Bio Raises More Than $15 Million in Oversubscribed Financing to Advance C-1101 in Chronic Painful Lumbosacral Radiculopathy (Chronic Sciatica) 2026-10-05 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/consano-bio-raises-more-than-15-million-in-oversubscribed-financing-to-advance-c-1101-in-chronic-painful-lumbosacral-radiculopathy-chronic-sciatica-302897596.html Proceeds will fund completion of the Phase 1 trial and continued development of C-1101, a potential first-in-class disease-modifying therapeutic Clinical data expected in 1H 2027 BURLINGTON, Mass., Oct. 5, 2026 -- Consano Bio, Inc., a clinical-stage biotechnology company... ———————————————————————————————————————————————————————————— The Pharmacy Budget Trap: SHARx Warns Discounts Alone Cannot Control Total Spending 2026-10-05 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/the-pharmacy-budget-trap-sharx-warns-discounts-alone-cannot-control-total-spending-302898366.html As GLP-1 and specialty-drug utilization expands, SHARx warns employers that spending control needs forecasting, access strategies and total-spend discipline, not rebate guarantees alone. ST. LOUIS, Oct. 5, 2026 -- A larger rebate does not guarantee lower pharmacy spending,... ———————————————————————————————————————————————————————————— PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES 2026-10-05 · Newsfile · SaaS, Healthcare, Biotech & pharma https://www.newsfilecorp.com/release/317325/PharmaTher-Outlines-Corporate-Strategy-and-Upcoming-Milestones-Launches-New-Corporate-Website-and-Rebrands-PERSONALIZ3D-as-M3DICINES HighlightsM3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply.Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform's entry point, are planned for Q4 2026.Near-term products. First proprietary 503A peptide products are planned for Q4 2026, followed by a ketamine... ———————————————————————————————————————————————————————————— Forward Therapeutics Announces Positive Phase 1 Data for Potential Best-in-Class Oral TNFR1 Signaling Inhibitor FT2109, Supporting Advancement into Phase 2 Development 2026-10-05 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/05/3374463/0/en/forward-therapeutics-announces-positive-phase-1-data-for-potential-best-in-class-oral-tnfr1-signaling-inhibitor-ft2109-supporting-advancement-into-phase-2-development.html BOSTON, Oct. 05, 2026 -- Forward Therapeutics, Inc. (“Forward” or the “Company”), a clinical-stage biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today announced positive Phase 1 clinical and preclinical data for FT2109, its novel, potential best-in-class oral selective TNFR1 signaling inhibitor. The data are included in two abstracts accepted for presentation at the American College of Rheumatology (ACR) Convergence 2026, taking place November 6–11 in Orlando, Florida. ———————————————————————————————————————————————————————————— Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026 2026-10-05 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/05/3374475/0/en/celcuity-announces-multiple-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026.html Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort ———————————————————————————————————————————————————————————— OnCusp Therapeutics Announces Positive Phase 1b Data Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Resistant Ovarian Cancer (PROC) Presented at Plenary Oral Session of the IGCS 2026 Annual Global Meeting 2026-10-05 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/05/3374462/0/en/oncusp-therapeutics-announces-positive-phase-1b-data-evaluating-its-cdh6-directed-antibody-drug-conjugate-cusp06-in-platinum-resistant-ovarian-cancer-proc-presented-at-plenary-oral.html Initial Phase 1b data highlight promising clinical activity in patients with PROC and support continued clinical development of CUSP06 ———————————————————————————————————————————————————————————— Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly 2026-10-05 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/05/3374474/18623/en/marea-therapeutics-a-subsidiary-of-lisata-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-trial-of-mar002-a-potential-best-in-disease-investigational-therapy-for-the.html Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care ———————————————————————————————————————————————————————————— Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP) 2026-10-05 · GlobeNewswire · SaaS, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/05/3374470/0/en/rani-therapeutics-announces-acceptance-into-u-s-fda-s-emerging-technology-program-etp.html ~ Acceptance into ETP enables early FDA engagement to support development of the RaniPill® platform technology ~ ~ Acceptance into ETP enables early FDA engagement to support development of the RaniPill® platform technology ~ ———————————————————————————————————————————————————————————— vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D) 2026-10-05 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/05/3374468/0/en/vtv-therapeutics-announces-completion-of-enrollment-in-phase-3-catt1-study-of-cadisegliatin-in-type-1-diabetes-t1d.html Milestone advances Phase 3 program toward topline results expected in mid 2027 Milestone advances Phase 3 program toward topline results expected in mid 2027 ———————————————————————————————————————————————————————————— Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease 2026-10-05 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/05/3374466/0/en/prime-medicine-announces-first-patient-dosed-in-global-phase-1-2-clinical-trial-of-pm577a-for-h1069q-mutated-wilson-disease.html -- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation in ATP7B, the most prevalent Wilson disease-causing mutation in North America and Europe‌ -- ———————————————————————————————————————————————————————————— TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement 2026-10-05 · GlobeNewswire · Healthcare, Food & drink, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/05/3374465/0/en/tela-bio-announces-510-k-clearance-for-liora-monofilament-scaffold-for-soft-tissue-reinforcement.html MALVERN, Pa., Oct. 05, 2026 -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Company's Liora Monofilament Scaffold (“Liora”) product. ———————————————————————————————————————————————————————————— Micot's XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal Disease 2026-10-05 · ACN Newswire · SaaS, Healthcare, Energy, Automotive, Education, Food & drink, Biotech & pharma https://www.acnnewswire.com/press-release/english/110573/ Hong Kong, Oct 5, 2026 - At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), one of the world’s most influential scientific meetings in diabetes and metabolic disease, Micot Pharmaceuticals (02335.HK) presented research on XTL6001, its internally developed long-acting protein candidate and triple receptor agonist targeting GLP-1R, GCGR and MasR. The studies, covering high-quality weight management and chronic kidney disease (CKD)/diabetic kidney disease (DKD), were selected for oral presentation, bringing the Chinese-origin innovative programme onto a leading international scientific platform.   From a development perspective, XTL6001 is not designed simply to maximise headline weight loss. By combining the GLP-1R, GCGR and MasR pathways, the programme aims to address weight management, glucose and lipid metabolism, body-composition optimisation and potential renal protection within a single development framework. As the GLP-1 field continues to evolve rapidly, this integrated metabolic–renal approach gives XTL6001 a differentiated profile versus conventional incretin-based therapies and provides a clearer positioning for subsequent global clinical development and potential business development opportunities. From Posters to Oral Presentations: Building International Scientific Visibility EASD and the American Diabetes Association (ADA) Scientific Sessions are among the most prominent international scientific platforms in diabetes and metabolic disease. Research on XTL6001 was first presented in two posters at ADA 2026 in June, followed by two oral presentations at EASD. The progression from posters to oral presentation provided a higher-profile forum for the same development thesis to be presented and discussed with the international scientific community. Conference selection, of course, does not substitute for clinical validation. For an early-stage innovative programme, however, repeated exposure at major international meetings can help increase visibility among clinicians, research institutions and potential industry partners. Notably, XTL6001 presented both weight-management and CKD/DKD research at the same EASD meeting. Obesity care is increasingly moving beyond “weight loss alone” toward broader management of body composition and cardiometabolic, hepatic and renal comorbidities. The ability to deliver benefits beyond weight reduction is therefore becoming an important dimension of next-generation competition. By adding MasR to the GLP-1R/GCGR combination, XTL6001 is designed to incorporate a renal-protection component into its differentiated product profile.   Weight Loss, Muscle Preservation and Renal Protection: Differentiation Through a Triple-Target Mechanism According to company disclosures and publicly available scientific data, XTL6001 is a long-acting protein drug candidate and a triple receptor agonist targeting GLP-1R, GCGR and MasR. The programme has completed its Phase I study in China and has received clinical trial authorisation in both China and the United States. In the disclosed Phase I single ascending dose (SAD) study, 25 healthy participants received XTL6001 across a dose range of 37.5–300 mg, with additional participants receiving placebo. The study showed a favourable overall safety and tolerability profile.   Dr. Xiangling Wang, Micot Pharma’s Chief Medical Officer (CMO), presented a systematic study comparing XTL6001 The available data also indicate that XTL6001 is designed to deliver benefits beyond the headline weight loss shown on the scale. In preclinical diet-induced obesity (DIO) mouse studies, XTL6001 demonstrated greater weight reduction than semaglutide at equivalent doses and a slower rate of weight regain after treatment discontinuation. At the same dose, and despite overall food intake being comparable to or even higher than that observed with semaglutide, weight reduction was approximately 33% greater, suggesting that the effect may be driven more by increased energy expenditure and fat utilisation than by appetite suppression alone. The studies also showed selective fat loss, restoration of the proportion of muscle mass toward normal levels, a 1.61-fold greater reduction in abdominal fat versus semaglutide, and concurrent improvements in lipid and hepatic parameters, including a reduction in LDL-C of more than 80% (87.2%) and a 90.8% reduction in hepatic triglycerides, with near-complete reversal of hepatic steatosis and normalisation of ALT. These findings point to potential utility in MASH. Importantly, the comparisons with semaglutide were generated primarily in animal studies and should not be interpreted as evidence of superior efficacy in humans. In the renal programme, publicly disclosed studies used multiple animal models of kidney disease. The rationale for the triple-target mechanism can be summarised as follows: GLP-1R primarily supports improvements in metabolism and haemodynamics; GCGR may help protect renal tubules from lipotoxic injury; and MasR is intended to address glomerular structural protection and antifibrotic activity. Together, the three pathways are designed to intervene across metabolic drivers, haemodynamic abnormalities, structural injury and fibrosis in the CKD/DKD disease cascade, rather than acting as a simple combination of independent effects. XTL6001 dose-dependently reduced 24-hour urinary albumin excretion and the urine albumin-to-creatinine ratio (UACR), while improving the glomerular filtration rate (GFR). Across different models, XTL6001 showed dose-dependent reductions in albuminuria: in STZ-induced, uninephrectomised rats, 0.5 mg/kg reduced UACR by 62.9% versus vehicle control and reduced 24-hour urinary albumin by approximately 54.7%; in the alloxan model, the reduction in UACR was approximately three times that seen with finerenone monotherapy; and in a mouse CKD model, 12 mg/kg reduced urinary albumin by 80.2%, with reductions in albuminuria reaching approximately 88% across the three models. The studies also observed reductions in serum creatinine, blood urea nitrogen and serum uric acid. These findings provide further support for the programme’s “weight management–metabolic regulation–albuminuria reduction” rationale. However, the renal benefits remain predominantly preclinical and will need to be validated in randomised controlled studies in patients with CKD/DKD. The Obesity Market Is Moving Into a Multi-Target Era — MasR Gives XTL6001 a Distinct Route The next generation of obesity therapies is already progressing from single-target GLP-1 agents toward GLP-1/GIP dual agonists, GLP-1/GCGR dual agonists and GLP-1/GIP/GCGR triple agonists. Eli Lilly’s retatrutide has advanced into Phase III development, while United Laboratories’ UBT251 is in Phase II, underscoring that “multi-target” activity alone is no longer sufficient to create a durable moat. XTL6001 is differentiated by the fact that its third target is MasR rather than GIPR. According to company disclosures, activation of the MasR pathway is associated with anti-inflammatory and antifibrotic effects, promotion of muscle-protein synthesis, improvement in mitochondrial function and induction of mitochondria-mediated thermogenesis. This gives XTL6001 a development rationale that is more naturally centred on renal protection, proteinuria and broader multi-organ metabolic benefits, rather than on cross-trial comparisons of headline weight-loss efficacy where no head-to-head evidence exists. From a capital-markets and business-development perspective, XTL6001’s successive appearances at ADA and EASD, together with its upcoming presentation of hyperuricaemic nephropathy research at ASN Kidney Week 2026, are helping the programme build continuous visibility across the diabetes, obesity and nephrology communities. Presenting at international scientific meetings is not a transaction in itself, nor can it replace human efficacy data, but it can create additional touchpoints with potential licensing, co-development and regional partners. Ultimately, the asset’s value will depend on whether clinical studies in humans can validate the hypotheses around quality of weight loss, body-composition improvement and renal protection; whether its safety and tolerability profile remains competitive; and whether indications such as CKD/DKD can demonstrate reproducible and clinically translatable benefits. If these elements are progressively validated, XTL6001 could establish a more distinctive global development path in the increasingly crowded GLP-1 landscape through a combined positioning around high-quality weight management, metabolic improvement and potential renal protection. ———————————————————————————————————————————————————————————— Global Drug Discovery AI Tools Market - Strategic Forecast 2026-2032 | Generative AI, Cloud Platforms, and Integrated R&D Workflows Create New Growth Opportunities 2026-10-05 · GlobeNewswire · AI, SaaS, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/05/3374241/28124/en/global-drug-discovery-ai-tools-market-strategic-forecast-2026-2032-generative-ai-cloud-platforms-and-integrated-r-d-workflows-create-new-growth-opportunities.html Dublin, Oct. 05, 2026 -- "Drug Discovery AI Tools Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Global Methyl Grignard Reagent Market - Strategic Forecast, 2026-2032 | Pharmaceutical Demand, AI Process Control, and Resilient Supply Chains Unlock Growth Opportunities 2026-10-05 · GlobeNewswire · AI, Logistics, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/05/3374238/28124/en/global-methyl-grignard-reagent-market-strategic-forecast-2026-2032-pharmaceutical-demand-ai-process-control-and-resilient-supply-chains-unlock-growth-opportunities.html Dublin, Oct. 05, 2026 -- "Methyl Grignard Reagent Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— ToyTrends at Spielwarenmesse 2027: Therapeutic play and diverse licensed hits 2026-10-05 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/toytrends-at-spielwarenmesse-2027-therapeutic-play-and-diverse-licensed-hits-302896591.html Beyond Limits: Toys with therapeutic added value License to Play: For fans of the classics and viral newcomers NUREMBERG, Germany, Oct. 5, 2026 -- What will be played in children's rooms in the future is showcased annually at Spielwarenmesse in Nuremberg. From 2 to 6 February... ———————————————————————————————————————————————————————————— Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026 2026-10-05 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/05/3374174/0/en/transgene-will-present-a-poster-on-preclinical-data-from-a-novel-oncolytic-virus-at-sitc-2026.html Strasbourg, France, October 5, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster highlighting preclinical data with PoxSTG-EEV, a novel enveloped oncolytic virus designed for systemic delivery, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. SITC 2026 will take place November 4 - 8, 2026, in Phoenix, Arizona (USA). ———————————————————————————————————————————————————————————— AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law 2026-10-05 · PR Newswire · Finance, Biotech & pharma https://www.prnewswire.com/news-releases/aard-investors-have-opportunity-to-lead-aardvark-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law-302897891.html LOS ANGELES, Oct. 5, 2026 -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aardvark Therapeutics, Inc. ("Aardvark" or "the Company") (NASDAQ: AARD) for violations of §§10(b) and 20(a)... ———————————————————————————————————————————————————————————— ROSEN, TRUSTED TRIAL COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY 2026-10-05 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/317349/ROSEN-TRUSTED-TRIAL-COUNSEL-Encourages-Unicycive-Therapeutics-Inc.-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-UNCY New York, New York--(October 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs... ———————————————————————————————————————————————————————————— Celaid Therapeutics Completes Second Close of Series B Financing Round 2026-10-05 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/celaid-therapeutics-completes-second-close-of-series-b-financing-round-302893509.html Shionogi & Co., Ltd. and Teikoku Ventures, Inc. Join the Round to Accelerate U.S. Clinical Trial Preparations for CLD-001 TOKYO, Oct. 4, 2026 -- Celaid Therapeutics Inc. (Head Office: Bunkyo-ku, Tokyo, Japan; President and CEO: Nobuyuki Arakawa; "Celaid") today announced the... ———————————————————————————————————————————————————————————— AAVantgarde Presents Encouraging Clinical Data from AAVB-081 and Preclinical Data Supporting AAVB-039 at EURetina 2026 2026-10-04 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/04/3374151/0/en/aavantgarde-presents-encouraging-clinical-data-from-aavb-081-and-preclinical-data-supporting-aavb-039-at-euretina-2026.html The company has presented updated data from the LUCE-1 Phase 1/2 study in Usher syndrome type 1B and preclinical data supporting the clinical translation of AAVB-039 in Stargardt disease The company has presented updated data from the LUCE-1 Phase 1/2 study in Usher syndrome type 1B and preclinical data supporting the clinical translation of AAVB-039 in Stargardt disease ———————————————————————————————————————————————————————————— CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases 2026-10-04 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/csl-and-alentis-announce-global-partnership-to-develop-and-commercialise-lixudebart-for-rare-kidney-and-liver-diseases-302897821.html Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 4, 2026 -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global... ———————————————————————————————————————————————————————————— Late-Breaking Clinical Trial Results Announced at The VEINS 2026 2026-10-04 · PR Newswire · Healthcare, Education, Biotech & pharma https://www.prnewswire.com/news-releases/late-breaking-clinical-trial-results-announced-at-the-veins-2026-302897814.html LAS VEGAS, Oct. 4, 2026 -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine through education and research, today announced results from the Late-Breaking Clinical Trials presented at The VEINS 2026 conference, held at... ———————————————————————————————————————————————————————————— Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate 2026-10-04 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/04/3374145/0/en/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-data-from-opus-1-the-pivotal-adult-phase-3-trial-of-vax-31-the-company-s-31-valent-pneumococcal-conjugate-vaccine-can.html SAN CARLOS, Calif., Oct. 04, 2026 -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced it will host a webcast and conference call tomorrow, October 5, 2026 at 8:00 a.m. ET / 5:00 a.m. PT to present topline data from the OPUS-1 adult pivotal Phase 3 trial evaluating the safety, tolerability and immunogenicity of VAX-31, the Company’s 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD) and pneumococcal pneumonia. ———————————————————————————————————————————————————————————— ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY 2026-10-04 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/317170/ARS-PHARMACEUTICALS-DEADLINE-ROSEN-LEADING-INVESTOR-COUNSEL-Encourages-ARS-Pharmaceuticals-Inc.-Investors-to-Secure-Counsel-Before-Important-October-5-Deadline-in-Securities-Class-Action-SPRY New York, New York--(October 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a... ———————————————————————————————————————————————————————————— Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China 2026-10-04 · Newsfile · Healthcare, Biotech & pharma https://www.newsfilecorp.com/release/317301/Kexing-Biopharms-Investigational-AntiTL1A-Monoclonal-Antibody-GB20-Cleared-for-Clinical-Trials-in-China San Diego, California--(October 4, 2026) - Recently, Kexing Biopharma (688136.SH) announced that its wholly owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), has received a Notice of Approval for Drug Clinical Trials from China's National Medical Products Administration (NMPA), authorizing the initiation of clinical trials of GB20, a proprietary investigational anti-TL1A monoclonal antibody for inflammatory bowel disease (IBD).Inflammatory bowel... ———————————————————————————————————————————————————————————— AARDVARK DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD 2026-10-04 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/317136/AARDVARK-DEADLINE-ROSEN-TRUSTED-INVESTOR-COUNSEL-Encourages-Aardvark-Therapeutics-Inc.-Investors-to-Secure-Counsel-Before-Important-October-13-Deadline-in-Securities-Class-Action-AARD New York, New York--(October 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class... ———————————————————————————————————————————————————————————— SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026 2026-10-04 · Newsfile · Biotech & pharma https://www.newsfilecorp.com/release/317224/SPRY-INVESTOR-DEADLINE-APPROACHING-Faruqi-Faruqi-LLP-Reminds-ARS-Pharmaceuticals-Investors-of-Securities-Class-Action-Lawsuit-Deadline-on-October-5-2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ARS Pharmaceuticals between March 9, 2026 and June 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]New York, New... ———————————————————————————————————————————————————————————— Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy 2026-10-03 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/ractigen-therapeutics-presents-positive-first-in-human-data-for-rag-18-at-wms-2026-establishing-clinical-proof-of-mechanism-for-rna-activation-in-duchenne-muscular-dystrophy-302897620.html First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in human skeletal muscle in a monogenic disease. Paired muscle biopsies reveal 3.5- to 5.3-fold increases in sarcolemmal utrophin expression,... ———————————————————————————————————————————————————————————— Aetna 2027 Medicare plans offer reliable, affordable access to care & member support 2026-10-03 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/aetna-2027-medicare-plans-offer-reliable-affordable-access-to-care--member-support-302897328.html Plans designed to provide member value and access to care: $0 copays on Tier 1 drugs and covered vaccines at in-network pharmacies* $0 copays for annual physicals, colonoscopies and mammograms at in-network providers $0 copays for annual Healthy Home Visit from a licensed Signify Health... ———————————————————————————————————————————————————————————— Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026 2026-10-03 · PR Newswire · SaaS, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/antengene-to-present-latest-preclinical-results-of-novel-cos-tce-platform-in-rapid-oral-abstract-presentation-at-sitc-2026-302891249.html SHANGHAI and HONG KONG, Oct. 2, 2026 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for... ———————————————————————————————————————————————————————————— ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY 2026-10-02 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3374076/673/en/rosen-national-investor-counsel-encourages-unicycive-therapeutics-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-uncy.html NEW YORK, Oct. 02, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— Grammy-Winning Bassist Stanley Clarke Reflects on Losing Friends to Drugs and the Mentor Who Changed His Life 2026-10-02 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3374070/0/en/grammy-winning-bassist-stanley-clarke-reflects-on-losing-friends-to-drugs-and-the-mentor-who-changed-his-life.html Stanley Clarke recalls how jazz legend Chick Corea helped him step away from drugs and introduced him to Dianetics: The Modern Science of Mental Health. ———————————————————————————————————————————————————————————— XtalPi Advances Hair Loss Drug Program into IND-Enabling Studies 2026-10-02 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/xtalpi-advances-hair-loss-drug-program-into-ind-enabling-studies-302897546.html The proprietary program targets a lactate–autophagy pathway to reactivate quiescent hair follicle stem cells. In a mouse model, a candidate achieved a hair-growth score comparable to that of 5% topical minoxidil at just 1/100 of the comparator's concentration. The milestone builds on the... ———————————————————————————————————————————————————————————— NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS 2026-10-02 · GlobeNewswire · Finance, Energy, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3374067/0/en/nomad-power-solutions-announces-adjournment-of-special-meeting-of-stockholders.html BOCA RATON, Fla., Oct. 02, 2026 -- NOMAD Power Solutions, Inc. ("NOMAD" or the "Company") (Nasdaq: NMAD) (formerly LIXTE Biotechnology Holdings), a provider of transportable, utility-grade battery energy storage systems through its wholly owned subsidiary NOMAD Transportable Power Systems, today announced that its Special Meeting of Stockholders (the “Special Meeting”), reconvened on October 2, 2026, was adjourned without conducting any business. The Special Meeting will reconvene on October 30, 2026, at 1:00 PM Eastern Time. ———————————————————————————————————————————————————————————— ROSEN, SKILLED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY 2026-10-02 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/317137/ROSEN-SKILLED-INVESTOR-COUNSEL-Encourages-Unicycive-Therapeutics-Inc.-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-UNCY New York, New York--(October 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs... ———————————————————————————————————————————————————————————— ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit 2026-10-02 · PR Newswire · Finance, Biotech & pharma https://www.prnewswire.com/news-releases/ars-pharmaceuticals-deadline-spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit-302897436.html NEW YORK, Oct. 2, 2026 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff... ———————————————————————————————————————————————————————————— Novo provides update on the denecimig Biologics License Application (BLA) in the US 2026-10-02 · GlobeNewswire · Healthcare, Food & drink, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3374048/0/en/novo-provides-update-on-the-denecimig-biologics-license-application-bla-in-the-us.html Bagsværd, Denmark, 02 October 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A, with or without inhibitors in adults and children, is still ongoing. The FDA has not communicated a new timeline for expected regulatory action on the BLA. ———————————————————————————————————————————————————————————— AARD Deadline: AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit 2026-10-02 · PR Newswire · Finance, Biotech & pharma https://www.prnewswire.com/news-releases/aard-deadline-aard-investors-have-opportunity-to-lead-aardvark-therapeutics-inc-securities-fraud-lawsuit-302897375.html NEW YORK, Oct. 2, 2026 -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration... ———————————————————————————————————————————————————————————— Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2026-10-02 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3374040/0/en/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html SAN FRANCISCO, Oct. 02, 2026 -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 235,950 shares of the Company's common stock, effective as of October 1, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4). ———————————————————————————————————————————————————————————— ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 2026-10-02 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3374038/0/en/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 02, 2026 -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2026 (the “Grant Date”), ORIC granted a total of 161,550 non-qualified stock options and 26,850 restricted stock units to six new non-executive employees who began their employment with ORIC in September 2026. ———————————————————————————————————————————————————————————— Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026 2026-10-02 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3374037/0/en/mineralys-therapeutics-announces-presentation-of-new-lorundrostat-data-at-the-american-society-of-nephrology-asn-kidney-week-2026.html RADNOR, Pa., Oct. 02, 2026 -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that new data from the Launch-HTN trial of lorundrostat will be presented at the American Society of Nephrology Kidney Week 2026, taking place October 21-25 in Denver, Colorado. ———————————————————————————————————————————————————————————— Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2026-10-02 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3374035/0/en/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html WALTHAM, Mass., Oct. 02, 2026 -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 100,895 shares of its common stock to two new employees under Xilio Therapeutics’ Third Amended and Restated 2022 Inducement Stock Incentive Plan (the 2022 Inducement Stock Incentive Plan). Additionally, the company granted a non-qualified stock option to purchase 105,000 shares of its common stock under the 2022 Inducement Stock Incentive Plan to the company’s newly appointed Chief Medical Officer, Yariv Houvras, M.D., Ph.D. ———————————————————————————————————————————————————————————— NeuroSense Provides Update on Nasdaq Listing Compliance 2026-10-02 · PR Newswire · Finance, Biotech & pharma https://www.prnewswire.com/news-releases/neurosense-provides-update-on-nasdaq-listing-compliance-302897458.html Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum market value requirement CAMBRIDGE, Mass., Oct. 2, 2026 -- NeuroSense Therapeutics Ltd.... ———————————————————————————————————————————————————————————— Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2026-10-02 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3374017/0/en/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ———————————————————————————————————————————————————————————— Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 2026-10-02 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3374015/0/en/apnimed-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html CAMBRIDGE, Mass., Oct. 02, 2026 -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that on October 1, 2026, the compensation committee of Apnimed’s board of directors granted 19 new non-executive employees non-qualified stock options to purchase an aggregate of 481,300 shares of the Company’s common stock under Apnimed’s 2026 Inducement Plan (the “Plan”). Each stock option granted has an exercise price per share of $22.54, which is equal to Apnimed’s closing trading price on the grant date. One-fourth of the shares underlying each of the employee’s stock options will vest on the first anniversary of each employee’s start date and in equal monthly installments thereafter for the next three years, subject to such employee’s continued employment with the Company on such vesting dates. ———————————————————————————————————————————————————————————— Bayer to invest 2.2 billion U.S. dollars in a new manufacturing site in the United States 2026-10-02 · Bayer · Healthcare, Industrial, Biotech & pharma, Jobs & workplace, Construction & engineering https://www.bayer.com/media/en-us/bayer-to-invest-2-billion-us-dollars-in-a-new-manufacturing-site-in-the-united-states/ New Albany, Ohio, U.S., October 2, 2026 – Bayer announced on Friday plans to invest 2.2 billion U.S. dollars in a new pharmaceutical manufacturing site in New Albany, Ohio, U.S. Building on more than seven billion dollars in U.S. pharma R&D and manufacturing spend over the past five years, the project is a central element of Bayer’s long-term growth strategy and commitment to innovation and patient access in its largest pharmaceuticals market. “Bayer has long seen the United States as a key manufacturing base and innovation hub. This landmark investment underscores our commitment,” said Bayer CEO Bill Anderson. “The new site will be home to manufacturing expertise and a skilled workforce that will strengthen our ability to deliver innovative, high-quality medicines to patients both in the United States and abroad.” “The United States is a key market for Bayer’s Pharmaceuticals division. This expansion is another important step to grow our pharmaceuticals business and to meet the demand of our customers and patients in the U.S., our fastest-growing pharmaceuticals market, and beyond,” said Sebastian Guth, Global Chief Operating Officer, Bayer Pharmaceuticals and President, Bayer U.S. Planned site to create highly-skilled jobs and support Ohio’s economic development Bayer is expected to create around 600 high-value jobs in the New Albany International Business Park and roughly 1,500 construction jobs during the facility’s construction. The flexible, modular campus is designed to combine drug substance and drug product manufacturing, leverage advanced digital and automation technologies, and support our growing portfolio initially in oncology, cardiovascular and renal care. The first module, dedicated to drug substance manufacturing, is expected to become operational in 2031. A second module for drug product manufacturing is planned to follow in 2034. The new site will complement Bayer’s U.S. pharmaceuticals headquarters in Whippany, New Jersey and its other sites in Pittsburgh, Pennsylvania; Berkeley, California; Cambridge, Massachusetts; Research Triangle Park, North Carolina; and San Diego, California. “The facility will be a strong strategic addition to our global Product Supply network. As we continue to invest in our existing manufacturing sites around the globe, our planned presence in Ohio will further enhance our ability to serve our markets with greater resilience and reliability,” said Holger Weintritt, Head of Product Supply at Bayer’s Pharmaceuticals division. The site will also form part of a new U.S. based collaboration ecosystem. The ambition is to connect cutting-edge academic innovation with advanced manufacturing expertise to create a strong ecosystem that supports future-ready pharmaceutical production. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to support efforts to master major challenges presented by a growing and aging global population and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. Contact for media inquiries: Sue Ann Pentecost, phone +1 910 221 6446 Email: sueann.pentecost@bayer.com Tino Andresen, +49 214 30-66048 Email: tino.andresen@bayer.com Heidi Sylvester, phone +49 173 106-9282 Email: heidi.sylvester@bayer.com Contact for investor inquiries: Bayer Investor Relations Team, phone +49 214 30-72704 Email: ir@bayer.com www.bayer.com/en/investors/ir-team ———————————————————————————————————————————————————————————— Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL 2026-10-02 · Eli Lilly and Company · Finance, Healthcare, Food & drink, Biotech & pharma https://www.prnewswire.com/news-releases/lillys-jaypirca-pirtobrutinib-the-first-and-only-approved-non-covalent-btk-inhibitor-receives-expanded-indication-from-us-fda-for-certain-patients-with-previously-untreated-cllsll-302897416.html Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca ... ———————————————————————————————————————————————————————————— Exobiosphere to Become the First Commercial Customer of Outpost's New Space Factories, Bringing Microgravity Drug Discovery to Orbit and Back 2026-10-02 · PR Newswire · SaaS, Healthcare, Industrial, Biotech & pharma https://www.prnewswire.com/news-releases/exobiosphere-to-become-the-first-commercial-customer-of-outposts-new-space-factories-bringing-microgravity-drug-discovery-to-orbit-and-back-302897385.html Space biotech leader Exobiosphere will fly its Orbital High-Throughput System as the first customer module on Outpost's Space Factories platform — pairing repeatable microgravity access with reliable Earth return. LOS ANGELES, Oct. 2, 2026 -- Outpost Technologies Corporation... ———————————————————————————————————————————————————————————— Rice Biotech Launch Pad invents 'living pharmacy' designed to produce therapeutics inside the body 2026-10-02 · PR Newswire · Healthcare, Food & drink, Biotech & pharma https://www.prnewswire.com/news-releases/rice-biotech-launch-pad-invents-living-pharmacy-designed-to-produce-therapeutics-inside-the-body-302896947.html Durable implant to enter clinic in 2027 has multiple applications and represents new therapeutic approach that lasts full year HOUSTON, Oct. 2, 2026 -- Biologic medicines can be powerful treatments for many diseases, but their cost can limit access. According to the U.S. Food... ———————————————————————————————————————————————————————————— ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital 2026-10-02 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/abionyx-pharma-monthly-statement-total-172400266.html TOULOUSE, France, October 02, 2026--Regulatory News: ABIONYX Pharma (Paris:ABNX): ———————————————————————————————————————————————————————————— Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026 2026-10-02 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3373912/0/en/perspective-therapeutics-announces-acceptance-of-212pb-vmt01-data-for-presentation-at-sitc-2026.html SEATTLE, Oct. 02, 2026 -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that data from the Company’s lapemelanotide zapixetar (also known as [²¹²Pb]VMT01) program have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting & Pre-Conference Programs taking place November 4 to 8, 2026, in Phoenix, Arizona. SITC plans to release further details for regular abstracts on November 3, 2026. ———————————————————————————————————————————————————————————— Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo 2026-10-02 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/pfizer-litfulo-significantly-improved-facial-151500029.html NEW YORK, October 02, 2026--Pfizer Inc. (NYSE: PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a wide range of disease extent. ———————————————————————————————————————————————————————————— Dyno Therapeutics Presents New Multi-Mechanism Muscle Capsid Data at the 31st International Congress of the World Muscle Society 2026-10-02 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/dyno-therapeutics-presents-multi-mechanism-150000000.html WATERTOWN, Mass., October 02, 2026--Dyno Therapeutics presents new multi-mechanism muscle capsid data at the 31st international Congress of the World Muscle Society ———————————————————————————————————————————————————————————— BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress 2026-10-02 · PR Newswire · Finance, Biotech & pharma https://www.prnewswire.com/news-releases/biomarin-announces-five-year-phase-3-data-for-pombiliti-cipaglucosidase-alfa-atga--opfolda-miglustat-at-world-muscle-society-annual-congress-302896737.html Long-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease SAN RAFAEL, Calif., Oct. 2, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data evaluating the efficacy and safety of POMBILITI® (cipaglucosidase... ———————————————————————————————————————————————————————————— Clinical Trial Supplies Market worth $8.95 billion by 2031 - Exclusive Report by MarketsandMarkets™ 2026-10-02 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/clinical-trial-supplies-market-worth-8-95-billion-by-2031---exclusive-report-by-marketsandmarkets-302895758.html DELRAY BEACH, Fla., Oct. 2, 2026 -- According to MarketsandMarkets™, the Clinical Trial Supplies Market is projected to reach USD 8.95 billion by 2031 from USD 5.60 billion in 2026, at a CAGR of 8.9% during the forecast period. Browse 420 market data Tables and 50 Figures... ———————————————————————————————————————————————————————————— CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026 2026-10-02 · GlobeNewswire · Finance, Healthcare, Automotive, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3373871/0/en/crispr-therapeutics-to-present-clinical-data-on-zugocabtagene-geleucel-zugo-cel-in-autoimmune-disease-at-the-american-college-of-rheumatology-acr-convergence-2026.html ZUG, Switzerland and BOSTON, Oct. 02, 2026 -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company’s Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026. ———————————————————————————————————————————————————————————— Aulos Bioscience Announces Presentations of Promising Phase 1/2 Data for Imneskibart With Checkpoint Inhibitors in Non-Small Cell Lung Cancer and Melanoma at SITC 2026 Annual Meeting 2026-10-02 · Business Wire · Biotech & pharma https://finance.yahoo.com/healthcare/articles/aulos-bioscience-announces-presentations-promising-130500162.html LARKSPUR, Calif., October 02, 2026--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today announced that two presentations of new data from its ongoing Phase 1/2 study of imneskibart will be featured at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. ———————————————————————————————————————————————————————————— Pheast Therapeutics to Present Preclinical Data on PHST001, a First-in-class Antibody Targeting CD24, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting 2026-10-02 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/pheast-therapeutics-present-preclinical-data-130000969.html REDWOOD CITY, Calif., October 02, 2026--Pheast Therapeutics, a clinical-stage biotechnology company advancing next-generation targeted therapies for cancer, today announced an upcoming poster presentation of preclinical data on PHST001 at the 41st Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place from November 4-8 in Phoenix, AZ. PHST001 is a first-in-class anti-CD24 macrophage checkpoint inhibitor designed to restore immune recognition in the tumor microenvironment and is ———————————————————————————————————————————————————————————— Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026 2026-10-02 · Business Wire · Finance, Biotech & pharma https://finance.yahoo.com/healthcare/articles/agenus-present-bot-bal-long-130000536.html LEXINGTON, Mass., October 02, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona. ———————————————————————————————————————————————————————————— Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 2026-10-02 · PR Newswire · Finance, Biotech & pharma https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302896740.html SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and... ———————————————————————————————————————————————————————————— Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026 2026-10-02 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3373783/0/en/century-therapeutics-cnty-813-demonstrates-continued-advancement-toward-the-clinic-via-nonclinical-data-presented-at-easd-2026.html Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1 diabetes ———————————————————————————————————————————————————————————— R. Jude Samulski Receives Inaugural Founders Award from Chinese Society of Gene & Cell Therapy 2026-10-02 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/r-jude-samulski-receives-inaugural-founders-award-from-chinese-society-of-gene--cell-therapy-302896902.html Historic first-ever honor makes the M34 co-founder the only scientist to receive Founders Awards from leading gene and cell therapy societies across three continents CHAPEL HILL, N.C., Oct. 2, 2026 -- M34 Inc. today announced that its co-founder and chief scientific officer,... ———————————————————————————————————————————————————————————— Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 2026-10-02 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3373768/0/en/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html DALLAS, Oct. 02, 2026 -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees restricted stock units (RSUs) representing 384,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4). ———————————————————————————————————————————————————————————— Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome 2026-10-02 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3373765/0/en/teva-presents-new-efficacy-and-safety-data-with-ecopipam-an-investigational-treatment-for-pediatric-patients-with-tourette-syndrome.html PARSIPPANY, N.J., Oct. 02, 2026 -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for ecopipam, a first-in-class investigational selective D1 (dopamine) receptor antagonist for the treatment of pediatric patients with Tourette syndrome. Presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Seoul, South Korea (October 4–8, 2026), the data include a post hoc analysis of safety and efficacy during the initial 8 weeks of treatment with ecopipam, long-term efficacy and safety from an interim analysis of an ongoing open-label extension (OLE) study, post hoc subgroup analyses and preclinical receptor selectivity findings. ———————————————————————————————————————————————————————————— Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients 2026-10-02 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3373764/0/en/journal-of-child-neurology-publishes-review-highlighting-dopamine-s-role-in-tourette-syndrome-and-ecopipam-s-selective-d1-receptor-mechanism-for-tourette-syndrome-in-pediatric-pati.html PARSIPPANY, N.J., Oct. 02, 2026 -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the Journal of Child Neurology published a comprehensive review examining dopamine pathways in Tourette syndrome and the therapeutic potential of ecopipam, a first-in-class investigational selective D1 (dopamine) receptor antagonist for the treatment of pediatric patients with Tourette syndrome.1,2 The review evaluates current treatment limitations and details how selectively targeting D1 receptors in the brain’s direct motor pathway may offer a differentiated, non-antipsychotic approach for managing tics in pediatric patients.1 ———————————————————————————————————————————————————————————— Adaptogenics Appoints Accomplished Peptide Scientist Dr. J. David Warren as Chief Executive Officer 2026-10-02 · Newsfile · Healthcare, Biotech & pharma https://www.newsfilecorp.com/release/317007/Adaptogenics-Appoints-Accomplished-Peptide-Scientist-Dr.-J.-David-Warren-as-Chief-Executive-Officer Vancouver, British Columbia--(October 2, 2026) - Adaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics" or the "Company") is pleased to announce the appointment of J. David Warren, Ph.D., as Chief Executive Officer and as a director of the Company, effective October 1st, 2026.Dr. Warren brings more than two decades of experience in bioorganic chemistry, medicinal chemistry, peptide science and translational drug discovery. He is an Adjunct Associate Professor of Research in... ———————————————————————————————————————————————————————————— Datavault AI CEO to Present "Operating System for Tokenized Assets" at XRP Seoul 2026 2026-10-02 · ACN Newswire · Finance, Crypto, AI, SaaS, Healthcare, Real estate, Energy, Education, Travel, Sports, Biotech & pharma https://www.acnnewswire.com/press-release/english/110547/ PHILADELPHIA, PA, Oct 2, 2026 - Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced that Nathaniel T. Bradley, CEO of Datavault AI, will present "Operating System for Tokenized Assets" at XRP Seoul 2026 on Oct. 3, 2026, at 3:05 p.m. KST at the Grand Hyatt Seoul in Seoul, South Korea. In the session, Bradley will explain why valuation, credentialing and verified metadata belong in a single operating layer beneath every real-world asset and how the Company's DataValue®, DataScore® and Information Data Exchange® technologies perform those functions in a single sequence beneath the point of issuance. "Tokenization gets treated as an issuance problem when it is really a data problem, and the Information Data Exchange exists to solve the data problem first," said Nathaniel T. Bradley, CEO of Datavault AI. "In Seoul, we will show the XRP Ledger community why valuation, credentialing and verified metadata have to live in one operating layer beneath the asset, and how our platform runs that sequence today." Bradley will also join the panel "How Traditional Finance Is Embracing Tokenization" at 5:40 p.m. KST. Datavault AI will exhibit at the conference and deploy its ADIO acoustic data transmission technology at its booth and from the keynote stage, where ADIO audio tones will direct attendees' mobile devices to registration and giveaway experiences. The Company's participation follows its appearances at XRP Tokyo 2026 and XRP Seoul 2025 and reflects its continued focus on expanding its presence and customer development across the Asia-Pacific region. Separately, Datavault AI will distribute the first XRP Seoul 2026 Limited Edition Collectible Token, a commemorative digital token minted on the XRP Ledger, to XRP Seoul 2026 attendees. The token is intended solely as a commemorative digital collectible for conference attendees and features a custom 3D design created for the event. Following Bradley's keynote, attendees can claim the token through the ADIO web app, which directs them to register or sign in to the Datavault AI platform, where the token is delivered to their account. "This is a historic first for XRP Seoul. We're thrilled to partner with Datavault AI to bring XRP Seoul's very first commemorative collectible to our attendees: a one-of-a-kind digital keepsake that marks a moment our global community will remember for years to come," said Ben Ko, Co-founder of XRPL Korea. About XRP Seoul 2026 XRP Seoul 2026 is a global conference focused on the XRP Ledger ecosystem, institutional blockchain adoption and real-world on-chain use cases. Hosted by XRPL Korea with Ripple as title sponsor, the event takes place on Oct. 3, 2026, at the Grand Hyatt Seoul. About Datavault AI Datavault AI™ (NASDAQ:DVLT) is leading the way in AI-driven data experiences, valuation, and monetization of assets in the Web 3.0 environment. The Company's cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions. Datavault AI's Acoustic Sciences division features WiSA®, ADIO®, and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization, and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation, and secure monetization. Datavault AI's platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy, and more. The Information Data Exchange® enables Digital Twins and the licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The Company's technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation, and advertising monitoring. The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai. Forward-Looking Statements This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws) about Datavault AI Inc. ("Datavault AI," the "Company," "us," "our," or "we") and our industry that involve risks and uncertainties. In some cases, you can identify forward-looking statements because they contain words, such as "may," "might," "will," "shall," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "goal," "objective," "seeks," "likely," or "continue" or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. The absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements, including, but not limited to, statements regarding future events, the planned creation of a commemorative digital token minted on the XRP Ledger and its distribution to XRP Seoul 2026 attendees through the ADIO web app and the Datavault AI platform, the anticipated presentation by the Company's CEO at XRP Seoul 2026 and the positions to be advanced in it, the described capabilities of the Company's DataValue, DataScore, and Information Data Exchange technologies and their application to real-world asset tokenization, the Company's planned exhibit presence, the planned deployment of ADIO acoustic data transmission technology at its booth and from the keynote stage, and the expected commercial relationships and customer development opportunities arising from the Company's Asia-Pacific expansion, are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. Readers are cautioned not to place undue reliance on these and other forward-looking statements contained herein. Actual results may differ materially from those indicated by these forward-looking statements as a result of various risks and uncertainties including, but not limited to, the following: the Company's ability to create and distribute a commemorative digital token minted on the XRP Ledger to conference attendees through the ADIO web app and the Datavault AI platform as planned; the risk that the commemorative token is characterized by regulators as a security, virtual asset, or other regulated instrument in South Korea, the United States, or other jurisdictions; the Company's ability to present at and exhibit at XRP Seoul 2026 as planned; the Company's ability to deliver the described valuation, credentialing, and data exchange capabilities as a single operating layer for tokenized real-world assets; the Company's ability to deploy ADIO acoustic data transmission technology at the event venue; the Company's ability to convert event participation into commercial relationships or revenue in the Asia-Pacific region; changes in market demand for Datavault AI's services and products; changes in economic, market, or regulatory conditions; risks relating to evolving regulatory frameworks applicable to digital assets and tokenized assets in South Korea and other jurisdictions; risks associated with technological development and integration; and other risks and uncertainties as more fully described in Datavault AI's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025 and other filings that Datavault AI makes from time to time with the SEC, which are available on the SEC's website at www.sec.gov, and could cause actual results to vary from expectations. The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. Datavault AI undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. Datavault AI may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Datavault AI's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments it may make. Industry and Market Data Within this press release, we reference information and statistics regarding the market for our products. We have obtained some of this information and statistics from various independent third-party sources, including independent industry publications, reports by market research firms, and other independent sources. Some data and other information contained in this press release are also based on management's estimates and calculations, which are derived from our review and interpretation of internal surveys and independent sources. Data regarding the industries in which we compete and our market position and market share within these industries are inherently imprecise and are subject to significant business, economic and competitive uncertainties beyond our control, but we believe they generally indicate size, position and market share within this industry. While we believe such information is reliable, we have not independently verified any third-party information. While we believe our internal company research and estimates are reliable, such research and estimates have not been verified by any independent source. In addition, assumptions and estimates of our and our industry's future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause our future performance to differ materially from our assumptions and estimates. As a result, you should be aware that market, ranking and other similar industry data included in this press release, and estimates and beliefs based on that data, may not be reliable. Trademarks, Trade Names, Service Marks and Copyrights We own or have rights to use various trademarks, tradenames, service marks and copyrights, which are protected under applicable intellectual property laws. This press release also contains trademarks, tradenames, service marks and copyrights of other companies, which are, to our knowledge, the property of their respective owners. Solely for convenience, certain trademarks, tradenames, service marks and copyrights referred to in this press release may appear without the ©, ®, and ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, tradenames, service marks and copyrights. We do not intend our use or display of other parties' trademarks, tradenames, service marks or copyrights to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of us by, these other parties. Media Contact marketing@dvlt.ai Investor Contact Edward Barger VP, Investor Relations ir@dvlt.ai © 2026 Datavault AI Inc. All Rights Reserved. SOURCE: Datavault AI Inc. ———————————————————————————————————————————————————————————— Targeted Cancer Therapy Market Size and Forecast by Therapy Type, Disease Indication, End-User, and Region, 2026-2035 | Precision Oncology Drives 6.8% CAGR Toward $175.48 Billion 2026-10-02 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3373611/28124/en/targeted-cancer-therapy-market-size-and-forecast-by-therapy-type-disease-indication-end-user-and-region-2026-2035-precision-oncology-drives-6-8-cagr-toward-175-48-billion.html Precision oncology, ADC innovation and radiopharmaceutical acquisitions drive growth, while strong U.S. approvals and hospital demand reinforce expansion Precision oncology, ADC innovation and radiopharmaceutical acquisitions drive growth, while strong U.S. approvals and hospital demand reinforce expansion ———————————————————————————————————————————————————————————— Europe Alpha-Emitting Radioligand Therapy Market Trends and Forecast to 2035 | 26% CAGR Drives Market Toward USD 0.40 Billion as Isotope Capacity and Oncology Pipelines Expand 2026-10-02 · GlobeNewswire · Industrial, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3373607/28124/en/europe-alpha-emitting-radioligand-therapy-market-trends-and-forecast-to-2035-26-cagr-drives-market-toward-usd-0-40-billion-as-isotope-capacity-and-oncology-pipelines-expand.html Boost ROI by securing isotope supply, scaling GMP manufacturing, forming CDMO partnerships and targeting PSMA-led prostate cancer opportunities. Boost ROI by securing isotope supply, scaling GMP manufacturing, forming CDMO partnerships and targeting PSMA-led prostate cancer opportunities. ———————————————————————————————————————————————————————————— Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026 2026-10-02 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/ascletis-asc3635fdc-demonstrated-potential-for-once-monthly-to-once-quarterly-dosing-and-robust-weight-loss-in-preclinical-studies-presented-at-easd-2026-302894756.html HONG KONG, Oct. 2, 2026 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced the presentation of key preclinical data for its ASC36_35FDC (ASC36_35 co-formulation) at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, being held... ———————————————————————————————————————————————————————————— Vietnam Veterinary Vaccine Import Market and Top 10 Importers Guide 2023-2026 | Import Reliance and Aquaculture Growth Create Market Entry Opportunities 2026-10-02 · GlobeNewswire · Finance, Logistics, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3373594/28124/en/vietnam-veterinary-vaccine-import-market-and-top-10-importers-guide-2023-2026-import-reliance-and-aquaculture-growth-create-market-entry-opportunities.html Target Vietnam’s top veterinary vaccine importers with verified contacts and Excel data to accelerate customer acquisition, optimize supply chains and mitigate risk Target Vietnam’s top veterinary vaccine importers with verified contacts and Excel data to accelerate customer acquisition, optimize supply chains and mitigate risk ———————————————————————————————————————————————————————————— PhytoHealth CEO Angel Lee Recognized for Driving the Advancement of World's First Prescription Drug for Cancer-Related Fatigue 2026-10-02 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/phytohealth-ceo-angel-lee-recognized-for-driving-the-advancement-of-worlds-first-prescription-drug-for-cancer-related-fatigue-302897043.html Recognition highlights PhytoHealth's work in advancing PG2®, Taiwan's first approved botanical new drug, and raising clinical awareness of cancer-related fatigue TAIPEI, Oct. 2, 2026 -- PhytoHealth Corporation CEO Angel Lee has been named one of Taiwan's 27th Ten Outstanding... ———————————————————————————————————————————————————————————— Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026 2026-10-02 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/lundbeck-to-showcase-progress-across-its-movement-disorders-pipeline-with-data-in-multiple-system-atrophy-and-parkinsons-disease-at-mds-2026-302897001.html Late-breaking Phase III MASCOT oral presentation will characterize the clinical profile and diversity of participants in Lundbeck's ongoing global Phase III trial investigating amlenetug in multiple system atrophy (MSA) New research across clinical trial endpoints, biomarkers, diagnostic... ———————————————————————————————————————————————————————————— Everest Medicines Announces the Acceptance and Priority Review of VELSIPITY(R) Manufacturing Localization Application by the Center for Drug Evaluation of China's NMPA, Driving Continued Commercial Momentum 2026-10-02 · ACN Newswire · Healthcare, Industrial, Biotech & pharma https://www.acnnewswire.com/press-release/english/110556/ Hong Kong, Oct 2, 2026 - Everest Medicines recently announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the application for localized manufacturing for VELSIPITY(R) (etrasimod arginine tablets) and granted Priority Review. Localized manufacturing of VELSIPITY(R) is expected to begin in 2027, further enhancing supply capacity and supply security in China and across the Asia-Pacific region. The acceptance marks progress in the Company’s planned commercialization of VELSIPITY(R). The VELSIPITY(R) localized production project has been progressing steadily since its launch at the Company’s global manufacturing facility in Jiashan in March 2025, with ongoing efforts focused on technology transfer, process optimization and preparations for localized manufacturing. Upon commencement of production, the facility is expected to have an annual production capacity of up to 50 million tablets, helping to strengthen supply stability, reduce manufacturing costs and improve operational efficiency, while supporting the commercialization of VELSIPITY(R). VELSIPITY(R) was approved by NMPA in February, 2026, for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. As a next-generation highly selective S1P receptor modulator, VELSIPITY(R) offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily regimen for adult patients with moderately to severely active UC. The first prescription of VELSIPITY(R) in China was issued in March 2026, making its entry into clinical use. Alongside its rapid commercialization, the Company is actively participating in negotiations for the inclusion of VELSIPITY(R) in the National Reimbursement Drug List (NRDL). VELSIPITY(R) has been approved in several territories licensed to Everest Medicines, including mainland China, Hong Kong SAR, Macao SAR, Singapore, and South Korea, and is expected to receive NDA approval in Taiwan, China in the second half of 2026. On the clinical front, Ulcerative colitis (UC) is a chronic, relapsing, non-specific inflammatory bowel disease. In China, the incidence and prevalence of UC continue to increase, with a clear trend toward younger patients. The patient population is projected to increase from approximately 0.98 million in 2025 to 1.50 million by 20311,2. Multiple studies of VELSIPITY(R) presented at the 21st Congress of the European Crohn’s and Colitis Organization (ECCO 2026) and the 14th Annual Meeting of the Asian Organization for Crohn’s and Colitis (AOCC 2026) further supported its clinical profile. The data demonstrated sustained efficacy with continuous treatment for up to 3 years3. Durable benefit was observed in patients who had received only 5-ASA/thiopurine treatment, and in biologic-experienced patients4,5. Benefit was also demonstrated in patients with mildly to moderately active UC6, with favorable long-term safety and tolerability maintained for up to 5 years of treatment7. These findings further strengthen the clinical evidence base of VELSIPITY(R). The clinical value of VELSIPITY(R) has been recognized in leading international clinical guidelines. Following its inclusion in the American Gastroenterological Association (AGA) Clinical Practice Guideline in December 2024 as a first-line treatment for ulcerative colitis, VELSIPITY(R) was also included in the 2025 American College of Gastroenterology (ACG) Clinical Guideline, the 2026 Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines and the 2026 European Crohn's and Colitis Organization (ECCO) Guidelines. Everest Medicines has a commercial-scale global manufacturing site in Jiashan, Zhejiang Province. It has established a complete GMP production quality management system complying with Chinese, EU and WHO standards and holds the manufacturing license.  Localized manufacturing is expected to further enhance the commercial potential of VELSIPITY(R) by improving supply reliability and operational efficiency in China. Supported by Everest Medicines’ A2MS commercial operating system and lean management capabilities, the localized production of VELSIPITY(R) will strengthen the foundation for its continued expansion in China and further build the Company’s commercial capabilities in autoimmune diseases, supporting its long-term growth. Reference 1. Shao B, et al. Front Public Health. 2022 Oct 25;10:1032679. 2. Kaplan GG. Nat Rev Gastroenterol Hepatol. 2015;12(12):720-727. 3. D T Rubin, et al. Journal of Crohn's and Colitis, 2026, jjaf231.774. 4. B E Sands, et al. Journal of Crohn's and Colitis, 2026, jjaf231.1105. 5. C Zheng, et al. Journal of Crohn's and Colitis, 2026, jjaf231.1046. 6. D T Rubin, et al. Journal of Crohn's and Colitis, 2026, jjaf231.100. 7. D T Rubin, et al. Journal of Crohn's and Colitis, 2026, jjaf231.1256. ———————————————————————————————————————————————————————————— Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A) 2026-10-02 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3373510/20739/en/ultragenyx-announces-marketing-authorisation-application-maa-submission-to-the-european-medicines-agency-ema-for-the-first-investigational-gene-therapy-for-mps-iiia-sanfilippo-synd.html BASEL, Switzerland, Oct. 02, 2026 -- Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its investigational gene therapy, rebisufligene etisparvovec, for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type A. ———————————————————————————————————————————————————————————— Addex Therapeutics Announces Executive Management Changes 2026-10-02 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/02/3373503/0/en/addex-therapeutics-announces-executive-management-changes.html Ad Hoc Announcement Pursuant to Art. 53 LR ———————————————————————————————————————————————————————————— New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program 2026-10-01 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/01/3373489/0/en/new-drug-application-submission-initiated-for-zipalertinib-plus-chemotherapy-in-first-line-egfr-exon-20-insertion-mutation-nsclc-for-review-under-fda-real-time-oncology-review-prog.html In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC ———————————————————————————————————————————————————————————— Curaleaf International Secures Australian First with TGA Registered Liquid Medical Cannabis Inhalation Device and Extends Availability to New Zealand 2026-10-01 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/curaleaf-international-secures-australian-first-with-tga-registered-liquid-medical-cannabis-inhalation-device-and-extends-availability-to-new-zealand-302895785.html LONDON, Oct. 2, 2026 -- Curaleaf International, part of Curaleaf Holdings, Inc. (TSX: CURA) in partnership with Jupiter Research LLC, today announced that its Que Medical Inhalation Device (QMID) is available in Australia, following the registration by Australia's Therapeutic... ———————————————————————————————————————————————————————————— Medicenna Announces Results of Annual General and Special Meeting of Shareholders 2026-10-01 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/01/3373483/0/en/medicenna-announces-results-of-annual-general-and-special-meeting-of-shareholders.html TORONTO and HOUSTON, Oct. 01, 2026 -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune diseases, today announced the voting results from the Company’s annual general and special meeting of shareholders held today, October 1, 2026 (the “Meeting”). ———————————————————————————————————————————————————————————— Sarcomatrix Therapeutics Extends Accredited Investor Round to October 31 2026-10-01 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/01/3373475/0/en/sarcomatrix-therapeutics-extends-accredited-investor-round-to-october-31.html Sarcomatrix Therapeutics Extends Accredited Investor Round to October 31 ———————————————————————————————————————————————————————————— GMP Labeling Celebrates 40 Years of US Manufacturing for Regulated Industries 2026-10-01 · PR Newswire · Industrial, Logistics, Biotech & pharma https://www.prnewswire.com/news-releases/gmp-labeling-celebrates-40-years-of-us-manufacturing-for-regulated-industries-302896698.html GRANITE BAY, Calif., Oct. 1, 2026 -- As pharmaceutical and biotechnology sectors navigate evolving global supply chain risks, GMP Labeling Inc. is utilizing Manufacturing Day 2026 to highlight its nearly 40-year history as a domestic manufacturer of critical compliance... ———————————————————————————————————————————————————————————— Kaplan Fox Reminds Unicycive Therapeutics, Inc. (UNCY) Investors to Seek a Leadership Role Before Deadline on November 2, 2026 2026-10-01 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/316938/Kaplan-Fox-Reminds-Unicycive-Therapeutics-Inc.-UNCY-Investors-to-Seek-a-Leadership-Role-Before-Deadline-on-November-2-2026 New York, New York--(October 1, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) on behalf of investors that purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Unicycive and have suffered losses, you may CLICK HERE to contact us. You may... ———————————————————————————————————————————————————————————— Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair 2026-10-01 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/01/3373449/0/en/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair.html ALACHUA, Fla. and TAMPA, Fla., Oct. 01, 2026 -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it has completed its previously announced acquisition of BioCircuit Technologies, Inc. (“BioCircuit”), a privately held medical device company and developer of NerveTape™. ———————————————————————————————————————————————————————————— Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2026-10-01 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/01/3373446/0/en/zentalis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html SAN DIEGO, Oct. 01, 2026 -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on October 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 62,000 shares of the Company’s common stock to three (3) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). ———————————————————————————————————————————————————————————— CaseBioscience® Joins Team Awarded Up to $7.3 Million by ARPA-H to Advance Ambient Preservation of Cell Therapies 2026-10-01 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/casebioscience-joins-team-awarded-up-to-7-3-million-by-arpa-h-to-advance-ambient-preservation-of-cell-therapies-302896629.html FORT COLLINS, Colo., Oct. 1, 2026 -- CaseBioscience® today announced its participation in a multidisciplinary team led by Likarda that has been awarded up to $7.3 million by the Advanced Research Projects Agency for Health (ARPA-H) through its BioStabilization Systems (BoSS)... ———————————————————————————————————————————————————————————— Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2026-10-01 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/01/3373432/0/en/dianthus-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html NEW YORK and WALTHAM, Mass., Oct. 01, 2026 -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on October 1, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4). ———————————————————————————————————————————————————————————— Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants 2026-10-01 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/01/3373424/0/en/sagimet-biosciences-announces-closing-of-underwritten-offering-of-series-a-common-stock-and-pre-funded-warrants.html FOSTER CITY, Calif., Oct. 01, 2026 -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the closing of its previously announced underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so chose, in lieu of shares of Series A common stock, pre-funded warrants to purchase 2,750,010 shares of its Series A common stock (the “Pre-Funded Warrants”) at a price of $9.9999 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.0001 per share and are exercisable immediately. The gross proceeds from the offering were approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities in the offering were sold by Sagimet. ———————————————————————————————————————————————————————————— Clear Scientific Reports Positive Phase 2 Results for CS-1103, the First Investigational Therapeutic That Removes Fentanyl from the Body 2026-10-01 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/clear-scientific-reports-positive-phase-2-results-for-cs-1103-the-first-investigational-therapeutic-that-removes-fentanyl-from-the-body-302896178.html Fentanyl Phase 2 Trial met all endpoints; Phase 3 planned for H1 2027 CAMBRIDGE, Mass., Oct. 1, 2026 -- Clear Scientific, Inc. today announced positive top-line results from its Phase 2 trial of CS-1103, a small-molecule sequestrant that immediately binds and inactivates... ———————————————————————————————————————————————————————————— Cell and Gene Therapy Bio-Manufacturing Market Global Report 2026: Market to Surge to $21.46 Billion by 2030 as Thermo Fisher Scientific, Merck KGaA, Lonza and Samsung Biologics Accelerate Automation 2026-10-01 · GlobeNewswire · Industrial, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/01/3373138/28124/en/cell-and-gene-therapy-bio-manufacturing-market-global-report-2026-market-to-surge-to-21-46-billion-by-2030-as-thermo-fisher-scientific-merck-kgaa-lonza-and-samsung-biologics-accele.html Boost ROI with scalable viral-vector platforms, automated single-use processing, digital quality control, and expanded CDMO capacity through partnerships and acquisitions. Boost ROI with scalable viral-vector platforms, automated single-use processing, digital quality control, and expanded CDMO capacity through partnerships and acquisitions. ———————————————————————————————————————————————————————————— Continuous Bioprocessing Technologies Market - Global Forecast 2026-2031 | Market to Reach USD 8.5 Billion as Automation and Biologics Demand Fuel 12.1% CAGR 2026-10-01 · GlobeNewswire · AI, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/01/3373130/28124/en/continuous-bioprocessing-technologies-market-global-forecast-2026-2031-market-to-reach-usd-8-5-billion-as-automation-and-biologics-demand-fuel-12-1-cagr.html Boost ROI through automation, AI, digital twins, modular single-use systems and partnerships that cut costs, improve quality, scale production and speed time to market. Boost ROI through automation, AI, digital twins, modular single-use systems and partnerships that cut costs, improve quality, scale production and speed time to market. ———————————————————————————————————————————————————————————— Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI 2026-10-01 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/01/3372862/0/en/candel-therapeutics-announces-publication-of-phase-2a-trial-data-that-demonstrated-prolonged-survival-after-systemic-immune-reactivation-by-aglatimagene-besadenovec-plus-valacyclov.html NEEDHAM, Mass., Oct. 01, 2026 -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the publication of final phase 2a clinical trial results (NCT04495153) of aglatimagene besadenovec (aglatimagene) plus valacyclovir in patients with stage III/IV NSCLC who had shown inadequate response to ICI. The trial demonstrated a median overall survival (mOS) of 24.5 months in the evaluable population, substantially exceeding historical benchmarks for standard-of-care docetaxel chemotherapy in this patient population. ———————————————————————————————————————————————————————————— Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days 2026-10-01 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/01/3372860/0/en/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days.html PLYMOUTH MEETING, Pa., Oct. 01, 2026 -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia. This poster will be presented at the 17th European Narcolepsy Days, taking place October 2–3, 2026, in Bern, Switzerland. ———————————————————————————————————————————————————————————— 60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar 2026-10-01 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/10/01/3372857/0/en/60-degrees-pharmaceuticals-announces-date-for-hospitalized-babesiosis-study-interim-data-release-and-key-opinion-leader-webinar.html 60 Degrees Pharmaceuticals will release interim severe babesiosis study data and host a KOL investor webinar on October 6, 2026. ———————————————————————————————————————————————————————————— PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform 2026-10-01 · Newsfile · SaaS, Healthcare, Biotech & pharma https://www.newsfilecorp.com/release/316740/PharmaTher-Enters-into-Exclusive-North-American-Distribution-Agreement-with-Craft-Health-for-CraftMakeTM-Pharmaceutical-3D-Printing-Platform HighlightsPharmaTher is now the exclusive distributor in North America of Craft Health's CraftMake™ 3D printers, CraftControl™ software, CraftBlends™ printable formulations, consumables, and service.Exclusivity covers every key customer segment: compounding pharmacies (503A and 503B), telehealth and digital health companies, CDMOs, hospitals, academic, research, and government institutions, and pharmaceutical, biotechnology, and healthcare companies.PharmaTher estimates more than 10,000... ———————————————————————————————————————————————————————————— SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability 2026-10-01 · GlobeNewswire · Finance, Healthcare, Industrial, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/01/3372806/0/en/spyglass-pharma-acquires-advanced-vision-science-inc-avs-securing-scalable-commercial-iol-supply-and-accelerating-lens-portfolio-expansion-capability.html IRVINE, Calif., Oct. 01, 2026 -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”) announced today the acquisition of all the outstanding shares of common stock of Advanced Vision Science, Inc. (AVS), an ophthalmic medical device company and manufacturer of intraocular lenses (IOLs) and lens materials, for approximately $13 million in cash. This acquisition secures scalable commercial IOL manufacturing capacity for SpyGlass Pharma. AVS was a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd (Santen) and is the current supplier of SpyGlass Pharma’s IOL in its two Phase 3 registrational trials evaluating the BIM-IOL System. ———————————————————————————————————————————————————————————— Global Seamless Metal Pipes Market Size, Share, Trends, and Forecast 2021-2031 | Hydrogen, Aerospace, and Infrastructure Investment Unlock 4%-6% CAGR Opportunities 2026-10-01 · GlobeNewswire · Healthcare, Aerospace & defense, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/01/3372640/28124/en/global-seamless-metal-pipes-market-size-share-trends-and-forecast-2021-2031-hydrogen-aerospace-and-infrastructure-investment-unlock-4-6-cagr-opportunities.html Target high-margin alloy and stainless pipes for hydrogen, aerospace, pharma and water upgrades; localize supply to capture reshoring demand and reduce raw-material risk. Target high-margin alloy and stainless pipes for hydrogen, aerospace, pharma and water upgrades; localize supply to capture reshoring demand and reduce raw-material risk. ———————————————————————————————————————————————————————————— Ensera launches alliance network with SHL Medical, Stevanato Group, Ypsomed, Argonaut and American Injectables 2026-10-01 · PR Newswire · SaaS, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/ensera-launches-alliance-network-with-shl-medical-stevanato-group-ypsomed-argonaut-and-american-injectables-302894437.html DUBLIN, Oct. 1, 2026 -- Ensera, a global CDMO specializing in commercialization support for injectable drug programs, has launched the Ensera Alliance Network, bringing together leading device platform and fill-finish specialists to address the complexity of commercializing... ———————————————————————————————————————————————————————————— Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes 2026-10-01 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/01/3372565/0/en/zealand-pharma-announces-boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-.html Company announcement – No. 52 / 2026 ———————————————————————————————————————————————————————————— Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates 2026-10-01 · Newsfile · SaaS, Biotech & pharma https://www.newsfilecorp.com/release/316757/Defence-Therapeutics-to-Take-the-Stage-at-World-ADC-San-Diego-to-Discuss-the-Next-Frontier-in-AntibodyDrug-Conjugates Montreal, Quebec--(October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® platform, is pleased to announce its participation in the 17th World ADC San Diego, taking place October 12-15, 2026, in San Diego, California.World ADC San Diego is a leading global forum dedicated to antibody-drug... ———————————————————————————————————————————————————————————— Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions 2026-10-01 · Roche · AI, Healthcare, Education, Food & drink, Biotech & pharma, Government & policy, Internet & apps, Medical devices https://www.roche.com/media/releases/med-cor-2026-10-01b New real-world results for Vabysmo in nAMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals1-3 Advanced AI-enabled analysis of imaging confirms rapid and meaningful anatomical drying supporting Vabysmo as a standard-of-care therapy in routine clinical care4,5 With more than 5,000 patients enrolled, VOYAGER is the largest, prospective, non-interventional real-world dataset evaluating Vabysmo across diverse clinical practice settings worldwide1-3 Basel, 1 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the VOYAGER study evaluating the effectiveness, durability and safety of Vabysmo® (faricimab) in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO).1-3 Across all study cohorts, results confirm the real-world effectiveness of Vabysmo in line with Phase III trial results, with vision gains and robust anatomical improvements in untreated eyes and stable or improved vision with improved anatomical outcomes in previously treated eyes.1-3 In the nAMD and DME cohorts of the study, vision and central subfield thickness (CST) improved in previously untreated eyes, while vision remained stable and CST improved in previously treated eyes, after 12 months of Vabysmo treatment.1,2 In RVO, both subtypes of the disease showed improvements in efficacy in people treated with Vabysmo.3 In the central/hemi-RVO cohort, vision and CST improved in both previously untreated and treated eyes after six months of Vabysmo therapy.3 In the branch RVO cohort, vision and CST improved in previously untreated eyes, while vision remained stable and CST improved in previously treated eyes, after six months of Vabysmo treatment.3 The data are being presented at the EURETINA 2026 Annual Meeting in Vienna, Austria. “These real-world results underscore how the efficacy and safety observed in our pivotal Vabysmo studies translate directly into routine clinical practice globally,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “The sustained visual improvements and meaningful anatomical drying seen in the VOYAGER study reinforce the role of Vabysmo in helping to address important unmet needs for patients with retinal conditions.” “In daily clinical practice, we manage diverse patient populations with complex treatment histories who don’t always mirror the strict entry criteria of controlled Phase III trials.” said Professor Robyn Guymer, Chair of the VOYAGER Steering Committee and Deputy Director of the Centre for Eye Research Australia. “The latest VOYAGER data give physicians from across the world the confidence that Vabysmo delivers sustained visual gains, meaningful anatomical drying, and an established safety profile in everyday practice – whether a patient is starting treatment for the first time or transitioning from another therapy.” The new VOYAGER real-world data in nAMD, DME and RVO are consistent with previous Phase III study results and demonstrate the effectiveness, durability and safety of Vabysmo across diverse global practices.1-3 Across all cohorts of the study, the presence of subretinal fluid (SRF) or intraretinal fluid (IRF) was consistently reduced in previously untreated and treated eyes.1-3 In the nAMD and DME groups, fewer Vabysmo injections were received during months 7-12 compared with months 1-6, suggesting extension of treatment intervals.1,2  Mean change in visual acuity (VA) Early Treatment Diabetic Retinopathy Study (ETDRS) lettersMean change in central subfield thickness (CST) µmPresence of subretinal fluid (SRF) % of eyesPresence of intraretinal fluid (IRF) % of eyes nAMD (after 12 months of Vabysmo treatment)1 No prior treatment+4.6–110.572.1→25.348.5→20.6 Previously treated-0.1-26.161.6→37.935.4→25.0 DME (after 12 months of Vabysmo treatment)2 No prior treatment+8.2-127.826.5→6.887.3→58.1 Previously treated+2.7-71.322.1→9.380.5→68.1 Branch RVO (after 6 months of Vabysmo treatment)3 No prior treatment+10.0-171.336.3→11.883.8→50.0 Previously treated+2.0-59.015.9→6.682.6→80.3 Central/hemi-RVO (after 6 months of Vabysmo treatment)3 No prior treatment+16.6-287.450.7→9.885.7→29.4 Previously treated+3.9-63.414.9→10.389.4→74.4 In VOYAGER, the Vabysmo safety profile was generally consistent with that established in the Phase III studies in nAMD, DME and RVO.1-3 About VOYAGER VOYAGER is the largest global, prospective, non-interventional real-world study of Vabysmo (faricimab).1-3 It captures real-world data from 28 countries/regions across six continents representing more than 5,000 patients treated for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) or retinal vein occlusion (RVO).1-3 The study leverages state-of-the-art AI and deep learning algorithms to evaluate SD-OCT images captured during routine clinical practice.4-6 About Vabysmo® (faricimab) Vabysmo is the first bispecific antibody approved for the eye.7-9 It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilising blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking pathways involving Ang-2 and VEGF-A, Vabysmo is designed to stabilise blood vessels.9,10 Vabysmo is approved in more than 100 countries around the world, including the United States (US), Japan, the United Kingdom and the European Union (EU) for people with neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema, and in more than 60 countries, including the US, EU and Japan, for people with macular edema following retinal vein occlusion (RVO).7,8,11-14 Review by other health authorities is ongoing. About Roche in Ophthalmology At Roche, we are on a mission to save and restore eyesight. Over 330 million people around the world are blind, or living with vision loss, creating a profound personal and socioeconomic burden. With the broadest pipeline in Ophthalmology, we continue to invest at scale to redefine what is medically possible in eye care. Our comprehensive ophthalmology pipeline integrates diverse targets, advanced delivery systems, cell and gene therapies, and AI-augmented imaging capabilities, targeting multiple vision-threatening conditions, including retinal vascular and diabetic eye diseases, geographic atrophy, and autoimmune conditions, such as thyroid eye disease and uveitic macular edema. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Guymer R, et al. One-year Clinical and Anatomical Outcomes of Faricimab Treatment in Eyes With nAMD From the Global, Prospective Observational VOYAGER Study. Presented at: 26th EURETINA Congress; 1–4 October 2026; Vienna, Austria. [2] Sheth V, et al. One–Year Clinical and Anatomical Outcomes of Faricimab Treatment in Eyes With DME From the Global, Prospective Observational VOYAGER Study. Presented at: 26th EURETINA Congress; 1–4 October 2026; Vienna, Austria. [3] Hattenbach L-O, et al. Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Retinal Vein Occlusion From a Global, Prospective Observational Study: The VOYAGER Study. Presented at: 26th EURETINA Congress; 1–4 October 2026; Vienna, Austria. [4] Bailey C, et al. Anatomical Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration: 12-Month Real-World Imaging from the VOYAGER Study. Presented at:26th EURETINA Congress; 1–4 October 2026; Vienna, Austria. [5] Koh A, et al. Anatomical Outcomes of Faricimab in Patients with Diabetic Macular Edema: 12-Month Real-World Imaging from the VOYAGER Study. Presented at: 26th EURETINA Congress; 1–4 October 2026; Vienna, Austria. [6] Guymer R, Bailey C, Chaikitmongkol V, et al. Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice. Ophthalmol Sci. 2024;4(3):100442. doi:10.1016/j.xops.2023.100442. [7] United States (US) Food and Drug Administration (FDA). Highlights of Prescribing Information, Vabysmo. April 2026. [Internet; cited September 2026]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761235s008lbl.pdf [8] Medicines and Healthcare products Regulatory Agency approves faricimab through international work-sharing initiative. May 17, 2022. [Internet; cited September 2026]. Available from: https://www.gov.uk/government/news/mhra-approves-faricimab-through-international-work-sharing-initiative [9] Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729-740. doi:10.1016/S0140-6736(22)00010-1. [10] Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741-755. doi:10.1016/S0140-6736(22)00018-6. [11] European Medicines Agency. Summary of Product Characteristics, Vabysmo. August 2026. [Internet; cited September 2026]. Available from: https://www.ema.europa.eu/en/documents/product-information/vabysmo-epar-product-information_en.pdf. [12] Chugai obtains regulatory approval for Vabysmo, the only bispecific antibody in the ophthalmology field, for additional indication of macular edema associated with RVO. [Internet; cited September 2026]. Available from: https://www.chugai-pharm.co.jp/english/news/detail/20240326160000_1054.html. [13] Chugai obtains regulatory approval for Vabysmo, the first bispecific antibody in ophthalmology, for nAMD and DME. [Internet; cited September 2026]. Available from: https://www.chugai-pharm.co.jp/english/news/detail/20220328160002_909.html. [14] Roche data on file. Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone:  +41 79 377 83 75Albert Thottiyil Phone: +41 79 775 66 12 Attachment Media Release Vabysmo EURETINA 2026 English ———————————————————————————————————————————————————————————— Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD 2026-10-01 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/01/3372525/0/en/mironid-successfully-doses-initial-cohorts-in-phase-1-clinical-trial-investigating-the-company-s-first-in-class-loac-small-molecule-for-patients-with-adpkd.html Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD ———————————————————————————————————————————————————————————— Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine 2026-10-01 · Roche · Healthcare, Food & drink, Biotech & pharma, Internet & apps, Medical devices https://www.roche.com/media/releases/med-cor-2026-10-01 Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimus1 By targeting resistance to endocrine treatments, the giredestrant combination seeks to delay disease progression and improve overall patient outcomes1 The FDA has set a PDUFA goal date for giredestrant in early-stage breast cancer of 30 November 2026 and in advanced disease of 18 December 2026 Basel, 1 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that detailed results from the evERA Breast Cancer study, showing investigational giredestrant in combination with everolimus significantly improved progression-free survival (PFS) versus standard endocrine therapy plus everolimus, were published in The New England Journal of Medicine (NEJM). The evERA trial is evaluating giredestrant, an investigational oral selective oestrogen receptor degrader (SERD), in combination with everolimus in people with oestrogen receptor (ER)-positive locally advanced or metastatic breast cancer who had disease progression or recurrence following treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor and endocrine therapy.1 “Despite advancements with CDK4/6 inhibitor treatment in the first-line setting, many people with advanced breast cancer will eventually experience disease progression as their tumours become resistant to endocrine therapy,” said Dr Erica L. Mayer, Medical Oncologist at Dana-Farber Cancer Institute. “The evERA trial demonstrated that the giredestrant combination significantly delayed disease progression, potentially offering a promising all-oral treatment option in a setting where there remains a need for additional treatments to improve patient outcomes.” In the ESR1-mutated population, the median PFS was 10.0 months with giredestrant plus everolimus compared with 5.5 months in the comparator arm (stratified hazard ratio [HR]=0.38, 95% CI: 0.27-0.54, p<0.001).1 In the intent-to-treat (ITT) population, the median PFS was 8.8 months compared with 5.5 months in the giredestrant and comparator arms, respectively (HR=0.56, 95% CI: 0.44-0.71, p<0.001).1 Overall survival (OS) data were immature at the time of analysis, but a clear positive trend has been observed in the ITT (HR=0.69, 95% CI: 0.47-1.00) and ESR1-mutated populations (HR=0.62, 95% CI: 0.38-1.02).1 Follow-up for OS will continue to the next analysis. Adverse events for the giredestrant combination were manageable and consistent with the known safety profiles of the individual medicines.1 No unexpected safety findings were observed, including no photopsia and low rates of bradycardia.1 “The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the positive phase III lidERA results in early breast cancer, these findings reinforce the potential of giredestrant to redefine care in both metastatic and early disease settings.” Additional evERA analyses were presented at the 2026 American Society of Clinical Oncology Annual Meeting, showing that giredestrant plus everolimus prolongs PFS2 (time from randomisation to disease progression following second-line therapy) and chemotherapy-free survival compared with standard endocrine therapy, suggesting that the clinical benefit may be sustained beyond initial progression.2 Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer accounts for approximately 70% of breast cancer cases.3 Resistance to endocrine therapies, particularly in the post-CDK inhibitor setting, increases the risk of disease progression and is associated with poor outcomes.3,4 evERA was the first positive phase III readout for giredestrant, followed by the lidERA Breast Cancer study in the early-stage setting.1,5 Based on these evERA data, the US Food and Drug Administration (FDA) accepted Roche’s New Drug Application (NDA) for giredestrant in combination with everolimus for the treatment of people with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease has recurred during or after completing endocrine-based adjuvant therapy, or who have progressed on at least one endocrine-based regimen in the metastatic setting. The FDA is expected to decide on the application by 18 December 2026. The FDA also accepted an NDA under Priority Review for giredestrant as an adjuvant treatment for adults with ER-positive, HER2-negative, stage I, II, and III breast cancer based on the lidERA results. The FDA has set a Prescription Drug User Fee Act goal date of 30 November 2026. Roche’s expanding giredestrant clinical development programme spans distinct treatment settings and lines of therapy, reflecting our commitment to deliver innovative medicines to as many people with HR-positive breast cancer as possible. About the evERA Breast Cancer study evERA Breast Cancer [NCT05306340] is a phase III, randomised, open-label, multicentre study evaluating the efficacy and safety of giredestrant in combination with everolimus versus standard endocrine therapy in combination with everolimus in people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase (CDK)4/6 inhibitor and endocrine therapy, either in the adjuvant or locally advanced/metastatic setting.6 The co-primary endpoints are investigator-assessed progression-free survival in the intention-to-treat and ESR1-mutated populations, defined as the time from randomisation to the time when the disease progresses or a patient dies from any cause.6 In the post-CDK inhibitor setting, up to 40% of people with ER-positive disease have ESR1 mutations.7,8 Key secondary endpoints include overall survival, objective response rate, duration of response, clinical benefit rate and safety.6 About giredestrant Giredestrant is an investigational, oral, potent next-generation selective oestrogen receptor degrader and full antagonist.9 Giredestrant is designed to block oestrogen from binding to the oestrogen receptor (ER), triggering its breakdown (known as degradation) and stopping or slowing down the growth of cancer cells.10 Giredestrant has an extensive clinical development programme including five company-sponsored phase III clinical trials to address the needs of patients acrossmultiple treatment settings and lines of therapy: Giredestrant versus standard endocrine therapy as adjuvant treatment in ER-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer (lidERA Breast Cancer; NCT04961996)11 Giredestrant plus everolimus versus standard endocrine therapy plus everolimus in ER-positive, HER2-negative, locally advanced or metastatic breast cancer (evERA Breast Cancer; NCT05306340)6 Giredestrant plus palbociclib versus letrozole plus palbociclib in ER-positive, HER2-negative, endocrine-sensitive, recurrent locally advanced or metastatic breast cancer (persevERA Breast Cancer; NCT04546009)12 Giredestrant plus investigator’s choice of a cyclin-dependent kinase (CDK)4/6 inhibitor versus fulvestrant plus a CDK4/6 inhibitor in ER-positive, HER2-negative advanced breast cancer resistant to adjuvant endocrine therapy (pionERA Breast Cancer; NCT06065748)13 Giredestrant plus Phesgo® (pertuzumab, trastuzumab, and hyaluronidase subcutaneous) versus Phesgo in ER-positive, HER2-positive locally advanced or metastatic breast cancer (heredERA Breast Cancer; NCT05296798)14 About hormone receptor (HR)-positive breast cancer Globally, the burden of breast cancer continues to grow, with 2.3 million women diagnosed and 670,000 dying from the disease every year.15 Breast cancer remains the number one cause of cancer-related deaths amongst women, and the second most common cancer type.16 HR-positive, human epidermal growth factor receptor 2-negative breast cancer accounts for approximately 70% of breast cancer cases and the majority are diagnosed in the early-stage.3 A defining feature of HR-positive breast cancer is that its tumour cells have receptors that attach to hormones like oestrogen, which can contribute to tumour growth.17 Despite treatment advances, HR-positive breast cancer remains particularly challenging to treat due to its biological complexity.18 Patients often face the risk of disease progression, treatment side effects and resistance to endocrine therapy.18,19 There is an urgent need for more effective treatments that can delay clinical progression and reduce the burden of treatment on people’s lives.18,19 About Roche in breast cancer Roche has been advancing breast cancer research for more than 30 years, and it continues to be a major focus of research and development. Our legacy began with the development of the first targeted therapy for human epidermal growth factor receptor 2-positive breast cancer, and we continue to push the boundaries of science to address the complexities of all breast cancer subtypes. By leveraging our dual expertise in pharmaceuticals and diagnostics, we are dedicated to providing tailored treatment approaches and improving outcomes for every patient, from early to advanced stages of the disease. Together with our partners, we are relentlessly pursuing a cure, as we strive for a future where no one dies from breast cancer. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical Divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Mayer E, et al. Giredestrant plus Everolimus in Advanced Breast Cancer. NEJM; 2026 October. DOI:10.1056/NEJMoa2602457. [2] Jhaveri K, et al. Post-progression treatment (tx) analyses of evERA Breast Cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with estrogen receptor–positive, HER2-negative advanced BC (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i). Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; 2026 May 29 – June 02; Chicago, Illinois, US. #1016. [3] Lim E, et al. The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park). 2012;26(8):688-94,696. [4] Sahin T, et al. Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer. Cancer Treatment Reviews. 2025 April;135:102924. [5] Bardia A, et al. Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial. Presented at: San Antonio Breast Cancer Symposium (SABCS); 2025 December 9-12; San Antonio, Texas, United States. #GS1-10. [6] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) [Internet; cited 2026 September]. Available from: https://clinicaltrials.gov/study/NCT05306340. [7] Meisel J L, et al. Real-world estrogen receptor 1 (ESR1) testing patterns and results in U.S. patients with metastatic breast cancer, 2018-2024. JCO Oncol Pract. 2025;21:579. [8] Chaudhary N, et al. CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape. npj Breast Cancer. 2024;10,15. [9] Martin M, et al. Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase 2, randomised, open-label acelERA BC study. Presented at: The ESMO Annual Meeting; 2022 September 9-13; Paris, France. Abstract #211MO. [10] Metcalfe C, et al. GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes. Presented at: SABCS; 2018 December 4-8; San Antonio, Texas, USA. Abstract #P5-04-07. [11] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) [Internet; cited 2026 September]. Available from: https://clinicaltrials.gov/study/NCT04961996. [12] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) [Internet; cited 2026 September]. Available from: https://clinicaltrials.gov/study/NCT04546009. [13] ClinicalTrials.gov. A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) [Internet; cited 2026 September]. Available from: https://clinicaltrials.gov/study/NCT06065748. [14] ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) [Internet; cited 2026 September]. Available from: https://clinicaltrials.gov/study/NCT05296798. [15] World Health Organization. Breast Cancer [Internet; cited 2026 September]. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer. [16] World Health Organization. Cancer Today [Internet; cited 2026 September]. Available from: https://gco.iarc.fr/today/en/dataviz/bars?mode=cancer&types=1&group_populations=1&sexes=2&key=asr&age_end=14. [17] National Cancer Institute. Hormone Therapy for Breast Cancer [Internet; cited 2026 September]. Available from: https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet. [18] Hanker A, et al. Overcoming Endocrine Resistance in Breast Cancer. Canc Cell. 2020 Apr 13;37(4):496–513. [19] Başaran G, et al. Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treat Rev. 2018 Feb;63:144-55. Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan  Phone: +41 79 377 83 75 Albert Thottiyil  Phone: +41 79 775 66 12 Attachment 20261001 evERA phase III NEJM ———————————————————————————————————————————————————————————— Fresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansion 2026-10-01 · PR Newswire · Finance, SaaS, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/fresenius-completes-acquisition-of-mabxience-creating-a-stronger-platform-for-future-portfolio-expansion-302895070.html The transaction builds on the successful partnership between Fresenius and mAbxience established in 2022. Full ownership creates a stronger platform to enhance quality and supply resilience, while supporting future innovation and broader patient access to high-quality biosimilars.... ———————————————————————————————————————————————————————————— Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth 2026-10-01 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/emerald-clinical-trials-appoints-michael-stibilj-as-chief-executive-officer-to-lead-next-phase-of-global-growth-302894772.html SINGAPORE, Oct. 1, 2026 -- Emerald Clinical Trials, a leading global clinical research organization anchored in Asia-Pacific, today announced the appointment of Michael Stibilj as Chief Executive Officer, effective 1 October 2026. The appointment marks the beginning of the... ———————————————————————————————————————————————————————————— Jenny McCarthy Begins Therapeutic Plasma Exchange Journey to Address Mold Toxicity and Environmental Toxins 2026-09-30 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3372475/0/en/jenny-mccarthy-begins-therapeutic-plasma-exchange-journey-to-address-mold-toxicity-and-environmental-toxins.html Health advocate partners with MDLifespan to document her physician-led Advanced Therapeutic Plasma Exchange (TPE) journey and educate others living with ch ———————————————————————————————————————————————————————————— Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) 2026-09-30 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3372449/0/en/adial-pharmaceuticals-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html GLEN ALLEN, Va., Sept. 30, 2026 -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option to purchase 155,446 shares of common stock as an inducement to such person becoming an employee of the Company. ———————————————————————————————————————————————————————————— Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference 2026-09-30 · GlobeNewswire · Finance, Healthcare, Travel, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3372437/0/en/bright-minds-biosciences-to-participate-in-the-2026-fpwr-research-symposium-and-pws-family-conference.html NEW YORK, Sept. 30, 2026 -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that it will participate in the Foundation for Prader-Willi Research (FPWR) 2026 Research Symposium, October 7-8, and the PWS Family Conference, October 9-10, at the Marriott Philadelphia Downtown. ———————————————————————————————————————————————————————————— Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock 2026-09-30 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3372434/0/en/immix-biopharma-announces-closing-of-125-million-underwritten-offering-of-common-stock.html – Financing includes leading U.S. biotechnology institutional investors and mutual funds – – Financing includes leading U.S. biotechnology institutional investors and mutual funds – ———————————————————————————————————————————————————————————— Robbins LLP is Investigating Allegations that Ardelyx, Inc. Misled Investors Regarding the True State of the Company's Commercial Performance and Growth Prospects for its Two Core Drug Products 2026-09-30 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/316840/Robbins-LLP-is-Investigating-Allegations-that-Ardelyx-Inc.-Misled-Investors-Regarding-the-True-State-of-the-Companys-Commercial-Performance-and-Growth-Prospects-for-its-Two-Core-Drug-Products San Diego, California--(September 30, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Ardelyx, Inc. (NASDAQ: ARDX) common stock between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"). Ardelyx, Inc. develops and commercializes medicines, including ISBRELA for the treatment of irritable bowel syndrome with constipation and XPHOZAH for reducing... ———————————————————————————————————————————————————————————— AARDVARK DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD 2026-09-30 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/316798/AARDVARK-DEADLINE-ROSEN-GLOBAL-INVESTOR-COUNSEL-Encourages-Aardvark-Therapeutics-Inc.-Investors-with-Losses-in-Excess-of-100K-to-Secure-Counsel-Before-Important-October-13-Deadline-in-Securities-Class-Action-AARD New York, New York--(September 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the... ———————————————————————————————————————————————————————————— Oculis Announces Resignation of Lionel Carnot from Board of Directors 2026-09-30 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3372419/0/en/oculis-announces-resignation-of-lionel-carnot-from-board-of-directors.html ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announces that director Lionel Carnot will be resigning from the Board of Directors, effective today, after nearly a decade of dedicated service since 2017. ———————————————————————————————————————————————————————————— How AI could help scientists find viruses to fight drug-resistant infections 2026-09-30 · Microsoft · AI, Biotech & pharma https://techcommunity.microsoft.com/blog/microsoft-discovery-blog/developing-bioinformatics-workflows-for-phage-therapy-with-inspectable-agents/4560876 The post How AI could help scientists find viruses to fight drug-resistant infections appeared first on Source. ———————————————————————————————————————————————————————————— DEA SCHEDULE I PROPOSAL WOULD CRIMINALIZE COMPOUND WITH BREAKTHROUGH THERAPY STATUS FOR POSTPARTUM DEPRESSION 2026-09-30 · Presswire · Food & drink, Biotech & pharma https://presswire.com/release/dea-schedule-i-proposal-would-criminalize-compound-with-breakthrough-therapy-status-for-postpartum-depression/ Now SSDP is mobilizing researchers, patients, students, and the public to fight the proposed scheduling of five tryptamines. Submit a public comment to the DEA by October 23 using SSDP’s easy-to-use public comment tool. WASHINGTON, D.C. – September 30, 2026 — A psychedelic drug granted Breakthrough Therapy designation by the U.S. Food and Drug […] ———————————————————————————————————————————————————————————— Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent 2026-09-30 · GlobeNewswire · Finance, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3372294/0/en/liquidia-provides-update-on-hatch-waxman-litigation-tied-to-327-patent.html MORRISVILLE, N.C., Sept. 30, 2026 -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today issued an update regarding the litigation filed by United Therapeutics Corporation (UTHR) in the U.S. District Court for the District of Delaware (the Court) under the Hatch-Waxman Act concerning U.S. Patent No. 11,826,327 (‘327 patent) and the Company’s lead product, YUTREPIA® (treprostinil) inhalation powder. ———————————————————————————————————————————————————————————— Sugar Amplifies Damage Done to Gut Health by Antibiotics 2026-09-30 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/sugar-amplifies-damage-done-to-gut-health-by-antibiotics-302889892.html NEW YORK, Sept. 30, 2026 -- Eating sweets while taking antibiotics may worsen the harm done by the drugs to the normal community of bacteria in the gut, a new study found. The work centers on the intestinal microbiome, which harbors bacterial species that co-evolved with... ———————————————————————————————————————————————————————————— Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026 2026-09-30 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3371847/0/en/candel-therapeutics-announces-new-data-showing-sustained-immune-remodeling-more-than-two-years-after-aglatimagene-besadenovec-treatment-in-localized-prostate-cancer-at-astro-2026.html NEEDHAM, Mass., Sept. 30, 2026 -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the presentation of new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec (aglatimagene) in patients with localized intermediate- to high-risk prostate cancer at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2026. ———————————————————————————————————————————————————————————— New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis 2026-09-30 · Eli Lilly and Company · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/new-phase-3b-data-show-lillys-ebglyss-lebrikizumab-lbkz-delivered-significant-and-rapid-improvements-in-skin-clearance-itch-pain-and-patient-satisfaction-in-people-with-moderate-to-severe-hand-and-foot-atopic-dermatitis-302893734.html EBGLYSS monotherapy met its primary endpoint with more than half of patients achieving clear or almost clear skin on their hands and feet (HF-IGA... ———————————————————————————————————————————————————————————— Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences 2026-09-30 · GlobeNewswire · Automotive, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3371812/0/en/verrica-pharmaceuticals-to-present-new-ycanth-data-analysis-at-two-upcoming-dermatology-conferences.html – Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration – ———————————————————————————————————————————————————————————— Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis 2026-09-30 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3371804/0/en/eupraxia-pharmaceuticals-reports-52-week-data-from-the-highest-dose-cohort-of-ep-104gi-in-its-ongoing-phase-1b-2a-resolve-trial-for-the-treatment-of-eosinophilic-esophagitis.html VANCOUVER, British Columbia, Sept. 30, 2026 -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced updated clinical data from the Phase 1b/2a RESOLVE study highlighting the long duration of response, high remission rates and tolerability of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”). ———————————————————————————————————————————————————————————— Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer 2026-09-30 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3371798/0/en/silexion-therapeutics-announces-first-patient-successfully-dosed-in-phase-2-3-clinical-trial-of-sil204-in-locally-advanced-pancreatic-cancer.html Global Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic cancer ———————————————————————————————————————————————————————————— AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026 2026-09-30 · AbbVie · Biotech & pharma https://www.prnewswire.com/news-releases/abbvie-presents-detailed-phase-1-data-for-abbv-295-a-long-acting-amylin-analog-demonstrating-favorable-tolerability-and-pharmacokinetic-profile-at-easd-2026-302893611.html Detailed findings, to be presented in a short oral presentation, demonstrated an approximately 11- to 12-day half-life and dose-proportional... ———————————————————————————————————————————————————————————— Dental Equipment Market Forecasts Growth from $8.31B (2026) to $11.48B by 2031, Profiling Envista, Carestream Dental, Nakanishi & Dentsply Sirona 2026-09-30 · GlobeNewswire · Healthcare, Travel, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3371650/28124/en/dental-equipment-market-forecasts-growth-from-8-31b-2026-to-11-48b-by-2031-profiling-envista-carestream-dental-nakanishi-dentsply-sirona.html The global dental equipment market is projected to grow from USD 8.31 billion in 2026 to USD 11.48 billion by 2031, registering a 5.5% CAGR. Growth is driven by rising oral health disorders, demand for cosmetic and preventive dentistry, dental tourism, and adoption of digital imaging, CAD/CAM, intraoral scanners, laser dentistry, and 3D printing. Therapeutic dental equipment will hold the largest market share, while hospitals and clinics remain the leading end users. The US is expected to record North America’s fastest growth. Key players include Dentsply Sirona, Planmeca, Align Technology, Envista, Carestream Dental, Nakanishi, and A-dec. The global dental equipment market is projected to grow from USD 8.31 billion in 2026 to USD 11.48 billion by 2031, registering a 5.5% CAGR. Growth is driven by rising oral health disorders, demand for cosmetic and preventive dentistry, dental tourism, and adoption of digital imaging, CAD/CAM, intraoral scanners, laser dentistry, and 3D printing. Therapeutic dental equipment will hold the largest market share, while hospitals and clinics remain the leading end users. The US is expected to record North America’s fastest growth. Key players include Dentsply Sirona, Planmeca, Align Technology, Envista, Carestream Dental, Nakanishi, and A-dec. ———————————————————————————————————————————————————————————— Esophageal Cancer - 7MM Market Insights, Epidemiology, Competitive Landscape, and Forecast - 2036 | 6.0% CAGR Fueled by Immunotherapy and Precision Oncology 2026-09-30 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3371648/28124/en/esophageal-cancer-7mm-market-insights-epidemiology-competitive-landscape-and-forecast-2036-6-0-cagr-fueled-by-immunotherapy-and-precision-oncology.html Immunotherapy uptake, biomarker-led precision care and next-generation targeted agents are reshaping treatment, while late diagnosis and drug resistance sustain unmet need. Immunotherapy uptake, biomarker-led precision care and next-generation targeted agents are reshaping treatment, while late diagnosis and drug resistance sustain unmet need. ———————————————————————————————————————————————————————————— Toward a new era of pharmaceutical education: TUPLS and transcosmos launch a co-development project to build an AI-powered, dialogue-based learning platform 2026-09-30 · PR Newswire · AI, SaaS, Healthcare, Education, Biotech & pharma https://www.prnewswire.com/news-releases/toward-a-new-era-of-pharmaceutical-education-tupls-and-transcosmos-launch-a-co-development-project-to-build-an-ai-powered-dialogue-based-learning-platform-302893889.html Advancing support for foundational learning, patient communication, and continuous learning in clinical pharmaceutical education TOKYO, Sept. 30, 2026/PRNewswire/ -- The Tokyo University of Pharmacy and Life Science (Location: Tokyo, Japan; President: Yoshihiro Mimaki; TUPLS) and... ———————————————————————————————————————————————————————————— Bone Neoplasms - Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and ADC Pipelines Unlock Strategic Growth Opportunities Through 2036 2026-09-30 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3371647/28124/en/bone-neoplasms-market-insights-epidemiology-and-7mm-forecast-2036-precision-oncology-and-adc-pipelines-unlock-strategic-growth-opportunities-through-2036.html Target unmet needs in durable, low-toxicity therapies and use 7MM uptake, access, pipeline and competitive insights to refine development, launch and market-entry strategies. Target unmet needs in durable, low-toxicity therapies and use 7MM uptake, access, pipeline and competitive insights to refine development, launch and market-entry strategies. ———————————————————————————————————————————————————————————— Hummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell Cancers 2026-09-30 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3371639/0/en/hummingbird-bioscience-announces-first-patient-dosed-in-phase-ii-trial-of-hmbd-001-and-cetuximab-in-advanced-squamous-cell-cancers.html Hummingbird Bioscience announced that the first patient has been dosed in Phase II trial of HMBD-001 and cetuximab in advanced squamous cell cancers. ———————————————————————————————————————————————————————————— Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities 2026-09-30 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3371636/28124/en/bone-metastasis-in-solid-tumors-market-insights-epidemiology-and-7mm-forecast-2036-precision-oncology-and-radiopharmaceuticals-unlock-new-growth-opportunities.html Rising cancer survival fuels demand for targeted, radiopharmaceutical and combination therapies addressing tumor growth and the bone microenvironment. Rising cancer survival fuels demand for targeted, radiopharmaceutical and combination therapies addressing tumor growth and the bone microenvironment. ———————————————————————————————————————————————————————————— North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity 2026-09-30 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3371634/28124/en/north-america-non-viral-transfection-reagents-market-forecast-to-2035-cell-and-gene-therapy-demand-drives-8-5-cagr-and-a-usd-0-70-billion-opportunity.html Target clinical and biopharma segments, forge strategic partnerships, and differentiate with scalable, low-toxicity delivery solutions. Target clinical and biopharma segments, forge strategic partnerships, and differentiate with scalable, low-toxicity delivery solutions. ———————————————————————————————————————————————————————————— Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care 2026-09-30 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3371632/28124/en/head-and-neck-squamous-cell-carcinoma-hnscc-market-insights-epidemiology-and-market-forecast-2036-set-to-reach-2-56-billion-as-hpv-targeted-vaccines-reshape-care.html Prioritize HPV16-targeted vaccines, checkpoint inhibitor combinations and biomarker-led patient selection to overcome resistance and capture underserved HNSCC segments. Prioritize HPV16-targeted vaccines, checkpoint inhibitor combinations and biomarker-led patient selection to overcome resistance and capture underserved HNSCC segments. ———————————————————————————————————————————————————————————— Artificial Intelligence (AI) in Life Sciences Market: Trends and Forecast to 2040 | Market to Reach USD 73.05 Billion at 20% CAGR as Drug Discovery and Precision Medicine Scale 2026-09-30 · GlobeNewswire · AI, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3371631/28124/en/artificial-intelligence-ai-in-life-sciences-market-trends-and-forecast-to-2040-market-to-reach-usd-73-05-billion-at-20-cagr-as-drug-discovery-and-precision-medicine-scale.html AI boosts life sciences ROI by accelerating drug discovery, reducing R&D costs, optimizing clinical trials and enabling precision medicine through strategic tech partnerships. AI boosts life sciences ROI by accelerating drug discovery, reducing R&D costs, optimizing clinical trials and enabling precision medicine through strategic tech partnerships. ———————————————————————————————————————————————————————————— Edison Issues Report on Starpharma (SPL) 2026-09-30 · Newsfile · SaaS, Biotech & pharma https://www.newsfilecorp.com/release/316728/Edison-Issues-Report-on-Starpharma-SPL London, United Kingdom--(September 30, 2026) - Edison issues report on Starpharma (ASX: SPL)Starpharma is a biotechnology company specialised in targeted oncology, underpinned by its proprietary, clinically established dendrimer enhanced product (DEP) platform. The investment case combines two approaches to value creation: retaining more favourable economics through internally developed targeted oncology assets, while partnered programmes broaden DEP's reach, validate the... ———————————————————————————————————————————————————————————— AnaCardio raises €62.5 million Series B financing to advance transformational novel therapy in heart failure towards Phase 3 readiness 2026-09-30 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/30/3371523/0/en/anacardio-raises-62-5-million-series-b-financing-to-advance-transformational-novel-therapy-in-heart-failure-towards-phase-3-readiness.html STOCKHOLM, Sweden, 30 September 2026 – AnaCardio, a clinical-stage biopharmaceutical company developing novel therapies for heart failure, today announced the successful completion of a €62.5 million Series B financing. The round was co-led by Novo Holdings and the Ljungström family office, with participation from the originator Helsinn, existing investors Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie and LLD Nybohov Invest AB, alongside new investor Innovestor Life Science. ———————————————————————————————————————————————————————————— Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist 2026-09-30 · PR Newswire · Biotech & pharma https://www.prnewswire.com/news-releases/breaking-the-safety-barrier-insilico-medicine-nominates-ism1354-the-next-generation-small-molecule-gipr-antagonist-302893899.html CAMBRIDGE, Mass., Sept. 30, 2026 -- As population aging accelerates with demand for weight management continuing to expand, the market for GLP-1 receptor agonist (GLP-1RA) drugs is experiencing explosive growth. Tirzepatide, with annual sales of $36.507 billion in 2025, has... ———————————————————————————————————————————————————————————— AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 2026-09-30 · AbbVie · Biotech & pharma https://www.prnewswire.com/news-releases/abbvie-highlights-positive-results-from-the-phase-2-apex-part-b-study-of-zumilokibart-in-moderate-to-severe-atopic-dermatitis-as-a-late-breaker-at-eadv-2026-302893602.html Phase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater... ———————————————————————————————————————————————————————————— Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis 2026-09-30 · Roche · Healthcare, Food & drink, Biotech & pharma, Internet & apps, Medical devices, Chemicals & materials https://www.roche.com/media/releases/med-cor-2026-09-30 Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in delaying disability1 Fenebrutinib became the first investigational medicine in more than a decade to slow disability progression in a Phase III PPMS trial (FENtrepid), with numerical benefit vs Ocrevus2 Fenebrutinib is designed to address two drivers of MS – acute inflammation causing relapses and chronic brain inflammation driving disability progression1,2 If approved, fenebrutinib would become the first BTK inhibitor and first high-efficacy oral treatment for both RMS and PPMS, offering a new option for the nearly 1 million Americans living with MS3 Basel, 30 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) under priority review for fenebrutinib, an investigational non-covalent Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The filing acceptance is based on data from the comprehensive clinical programme, including the Phase III FENhance 1 and 2 RMS studies and the Phase III FENtrepid PPMS study.1,2 "People living with multiple sclerosis need treatments that go beyond controlling relapses to help preserve function and independence as the disease progresses," said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. "Three Phase III studies have demonstrated the potential for fenebrutinib to address both relapsing and progressive disease, thereby bringing us closer to an oral treatment that could make a meaningful difference across the MS spectrum." “Ocrevus transformed how we treat MS, helping more than 525,000 people live a life less defined by their disease. Yet, over a third of all people with MS still receive lower-efficacy treatment,” said Teresa Graham, Roche’s Chief Executive Officer, Pharma. “If approved, fenebrutinib could open a new chapter as the first high-efficacy oral therapy for both relapsing and primary progressive MS, helping to control disease activity while giving people more flexibility and choice.” Concurrently addressing the life-disrupting relapses and long-term disease progression – the slow, steady loss of physical and mental abilities over time – remains one of the greatest challenges in MS.4 Fenebrutinib is designed to act throughout the body and to cross the blood-brain barrier into the central nervous system to target both the acute inflammation that causes relapses and the chronic inflammation that is thought to drive disability progression.1,2 The NDA for fenebrutinib is supported by three positive Phase III studies: The FENhance 1 and 2 RMS studies showed that fenebrutinib significantly reduced relapses and both active and chronic brain lesions compared with standard of care, teriflunomide. Fenebrutinib reduced the annualised relapse rate (ARR) by 51.1% (p<0.001) in FENhance 1 and 58.5% (p<0.00001) in FENhance 2 compared with teriflunomide over 96 weeks. This equates to patients having approximately one relapse every 17 years, which is the lowest relapse rate seen in Phase III MS studies. In addition, measures of disability progression, including 12-week composite confirmed disability progression (cCDP12), showed consistent positive trends favouring fenebrutinib over teriflunomide.1 The FENtrepid PPMS study showed fenebrutinib met its primary endpoint of non-inferiority compared with Ocrevus® (ocrelizumab), the current standard of care and only approved medicine for PPMS, in reducing disability progression. Fenebrutinib numerically reduced the risk of progression by 12% compared to Ocrevus, as measured by the time to onset of cCDP12 (hazard ratio [HR] 0.88; 95% confidence interval [CI]: 0.75, 1.03), with curves separating as early as 24 weeks. A consistent treatment effect on disability progression was observed across patient subgroups, including those without active inflammation, and for the entire treatment duration after 24 weeks.2 The overall rate of serious adverse events for fenebrutinib and teriflunomide, respectively, was 9% and 9% in FENhance 1 and 11% and 6% in FENhance 2. The overall rate of serious adverse events in FENtrepid was 19% for fenebrutinib and 19% for Ocrevus. Liver enzyme elevations were comparable between the fenebrutinib and teriflunomide arms in the RMS studies and observed more often with fenebrutinib compared to Ocrevus in the PPMS study. While an imbalance in reported fatalities was observed across the three pivotal studies, the deaths occurred at different timepoints and had various causes.1,2 Overall, fenebrutinib has shown a manageable safety profile across the three Phase III trials and earlier studies, with a large safety database including more than 2,700 study participants.1,2,5 About fenebrutinib Fenebrutinib is an investigational oral, central nervous system (CNS)-penetrant, reversible and non-covalent Bruton’s tyrosine kinase (BTK) inhibitor with an optimised pharmacokinetics (PK) profile. Fenebrutinib can act throughout the body and also cross the blood-brain barrier into the CNS to target chronic inflammation. It is uniquely designed to target relapsing and progressive biology by inhibiting cells in the immune system known as B cells and microglia. Targeting B cells helps control the acute inflammation that causes relapses, while targeting microglia inside the brain addresses the chronic damage that is thought to drive long-term disability progression. While most current BTK inhibitors are covalent and irreversible, meaning they form a permanent chemical bond with the enzyme, fenebrutinib is non-covalent and reversible, meaning it binds and then eventually releases the enzyme. About multiple sclerosis Multiple sclerosis is a chronic disease that affects more than 3 million people worldwide. People with all forms of multiple sclerosis experience disease progression from the beginning of their disease. Therefore, an important goal of treating multiple sclerosis is to slow, stop and ideally prevent progression as early as possible. Approximately 85% of people with multiple sclerosis are initially diagnosed with relapsing-remitting multiple sclerosis (RRMS). Relapsing forms of the disease (RMS) include RRMS and active secondary progressive MS, and people with RMS experience relapses and worsening disability over time. Primary progressive multiple sclerosis (PPMS) is a debilitating form of the disease marked by steadily worsening symptoms but typically without distinct relapses or periods of remission. Approximately 15% of people with multiple sclerosis are diagnosed with the primary progressive form of the disease. Until the FDA approval of Ocrevus®, there had been no FDA-approved treatments for PPMS, and Ocrevus is still the only approved treatment for PPMS. About Roche in Neurology Neurology is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new diagnostics and treatments that help improve the lives of people with chronic and potentially devastating diseases globally. Roche is investigating more than a dozen medicines for neurological conditions, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Roche Diagnostics has developed a broad range of approved and investigational tools, including digital and blood-based tests and cerebrospinal fluid (CSF) assays, aiming to more effectively detect, diagnose and monitor neurological conditions. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neurology today. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Oh J, et al. Efficacy and Safety of Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results of the FENhance 1 and 2 Studies. Presented at: 2026 American Academy of Neurology (AAN) Annual Meeting; April 21, 2026; Chicago, IL, USA, and virtual. [2] Bar-Or A, et al. Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study. Presented at: Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2026; February 7, 2026; San Diego, CA, USA, and virtual. [3] MS International Federation. Atlas of MS. [Internet; cited September 2026]. Available from: https://atlasofms.org/map/global/epidemiology/number-of-people-with-ms  [4] Bittner S, Zipp F. Progression in multiple sclerosis - a long-term problem. Curr Opin Neurol. 2022;35(3):293-298. doi:10.1097/WCO.0000000000001044 [5] Bar-Or A, Dufek M, Budincevic H, et al. Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study. Lancet Neurol. 2025;24(8):656-666. doi:10.1016/S1474-4422(25)00174-7 Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone:  +41 79 377 83 75Albert Thottiyil Phone: +41 79 775 66 12 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.comDr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com  Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com  Attachment Media & Investor Release Fenebrutinib FDA Filing English ———————————————————————————————————————————————————————————— DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years 2026-09-29 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/29/3371452/0/en/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years.html Châtillon, France, September 29, 2026 ———————————————————————————————————————————————————————————— Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology 2026-09-29 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/29/3371443/0/en/zealand-pharma-to-present-additional-data-from-phase-2-zupreme-1-trial-for-petrelintide-at-easd-2026-and-announces-publication-of-trial-results-in-the-lancet-diabetes-endocrinology.html Press release – No. 18 / 2026 ———————————————————————————————————————————————————————————— Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders 2026-09-29 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/29/3371441/0/en/gain-therapeutics-announces-poster-presentation-at-international-congress-of-parkinson-s-disease-and-movement-disorders.html BETHESDA, Md., Sept. 29, 2026 -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at the International Congress of Parkinson’s Disease and Movement Disorders, being held October 4-8, 2026, in Seoul, Korea. ———————————————————————————————————————————————————————————— Pyxis Oncology Announces Proposed Public Offering 2026-09-29 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/29/3371341/0/en/pyxis-oncology-announces-proposed-public-offering.html BOSTON, Sept. 29, 2026 -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it has commenced a registered public offering (the "Offering") of (i) shares of its common stock, or in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock, and (ii) accompanying common warrants to purchase shares of common stock. Each share of common stock and each pre-funded warrant will be sold together with a common warrant to purchase one share of common stock. ———————————————————————————————————————————————————————————— New Zealand's Missing Piece in the Smoke-Free Strategy 2026-09-29 · ACN Newswire · Healthcare, Education, Food & drink, Biotech & pharma https://www.acnnewswire.com/press-release/english/110471/ WELLINGTON, New Zealand, Sept 29, 2026 - New Zealand is close to achieving something few countries have managed: making smoking genuinely uncommon. The adult smoking rate has fallen to 6.8%, a number that is significantly close to 5%, which allows a country to claim smoke-free status. According to research published this year in The Lancet Regional Health - Western Pacific, that progress did not happen by accident. It accelerated as vaping became a mainstream alternative to cigarettes, after the introduction of an adequate regulatory framework. Despite the progress, around 300,000 New Zealand adults still smoke, and the smoking rates remain particularly high amongst the Māori populations, older age groups and people from more disadvantaged socioeconomic contexts. Many have not switched to vaping, and there is little reason to assume they all will. The question now is not whether New Zealand's approach has worked. It clearly has to a broad extent. The question is how to reach the people left behind. And for that, New Zealand should look closely at Sweden. Sweden has already crossed the smoke-free threshold, with the latest figures from the Swedish Council for Information on Alcohol and Other Drugs putting daily smoking at 3.7%. The experience from this Scandinavian country offers a simple but important lesson - tobacco control works best when smokers are not only pushed away from cigarettes, but also given alternatives they are actually willing to use. Sweden did not achieve low smoking rates by going soft on cigarettes. Like other European countries, it taxes them, restricts their marketing and requires health warnings. What made Sweden different was the range of lower-risk nicotine alternatives available to adults. Smoking has fallen by around two-thirds since 2008, while smoking across the European Union remains far higher. One of the most striking comparisons comes from EU migrants living in Sweden. Their smoking rate is around 7.8%, compared with roughly 24% in their countries of origin. Whatever role culture plays, that difference strongly suggests that the policy environment matters too. There is another lesson that is particularly relevant for New Zealand: one alternative is not enough. We Are Innovation commissioned an Ipsos survey of 1,000 Swedish ex-smokers, and the results show why choice matters. Men were more likely to have moved away from cigarettes using snus, while women followed a different path. Among female ex-smokers surveyed, 56% used nicotine pouches, making pouches the most popular alternative in that group. Nicotine pouches were also the leading choice among former smokers aged 18 to 34. Across respondents, 89% said the right flavour mattered, while 61% said it was important that alternatives cost less than cigarettes. Those findings point to a basic reality of smoking cessation that policymakers sometimes overlook: smokers are not a single, uniform group. Some prefer vaping. Some do not want to inhale anything. Some dislike devices. Some respond to particular flavours, formats or price points. If the goal is to move people away from combustible tobacco, the more suitable alternatives adults have, the greater the chance that one of them will work. This is where nicotine pouches could matter for New Zealand. They involve no smoke, no vapour and no device. For smokers who have not taken to vaping, they offer a fundamentally different option. That does not mean they should be unregulated. Quite the opposite. Sweden's approach is instructive here too. Its 2022 law on tobacco-free nicotine products introduced an 18-plus age limit, labelling requirements and rules governing who can sell them. It did not respond by banning the category outright. Instead, it created a legal framework that preserved adult access while putting safeguards around youth use. New Zealand has already pursued a similar principle with vaping: allow adult access, while tightening protections for young people where needed. The Lancet's study found that youth vaping declined following stronger youth-focused rules. That is a more sensible model than pretending prohibition eliminates demand. The United States has also begun moving in this direction. In 2025, the Food and Drug Administration authorised certain nicotine pouch products for sale after reviewing their public-health implications. Public health policy should distinguish between products according to the risks they create, rather than treating all nicotine use as equivalent to smoking. The stakes are substantial. Compared with the EU average, Sweden records lower lung cancer mortality and lower cancer mortality overall. Among Swedish men, lung cancer mortality is dramatically below the EU level. Those outcomes cannot be attributed to a single product or policy, but Sweden's exceptionally low smoking rate is an important part of the picture. New Zealand has already shown that pragmatic, evidence-based harm reduction can produce results. Vaping helped accelerate the decline in smoking because it gave smokers another way out. The country should now apply that same logic to the final stretch. If hundreds of thousands of adults are still smoking, policymakers should be asking what additional alternatives could realistically help them stop. Nicotine pouches deserve to be part of that conversation. A legal, adults-only framework with clear product standards, age restrictions and youth protections would not undermine New Zealand's smokefree strategy, but extend it. Sweden's experience suggests that the final mile is not achieved by narrowing adult choice, but by expanding the number of credible alternatives to cigarettes. New Zealand is already close. The next step should be to make sure the remaining smokers have more than one route out. * Beatriz Santos is the Chief Communications Officer (CCO) at We Are Innovation. She is based in Lisbon, Portugal. Beatriz started publishing articles through her University newspaper and eventually moved to national and international reach outlets, including the well known Portuguese outlets NOVO and Observador. Her professional career includes international communications experience with the ATREVIA agency and the European Parliament. She also has two published books and is an essential part of the Students For Liberty organization in Portugal. With a focus on positive change and global cooperation, Beatriz actively seeks partnerships across the globe to promote innovative initiatives. Contact: somosinnovacionlatam@gmail.com SOURCE: We Are Innovation ———————————————————————————————————————————————————————————— Four major tech fairs open in October attracting some 6,200 exhibitors from around the world 2026-09-29 · ACN Newswire · Finance, AI, SaaS, Healthcare, Energy, Retail, Gaming, Media, Education, Food & drink, Fashion & luxury, Sports, Industrial, Aerospace & defense, Logistics, Biotech & pharma, Semiconductors, Sustainability https://www.acnnewswire.com/press-release/english/110467/ HONG KONG, Sept 29, 2026 - The Hong Kong Trade Development Council (HKTDC) will stage flagship fairs for electronics and lighting in October, including the 46th Hong Kong Electronics Fair (Autumn Edition) and the 29th electronicAsia, which will be held concurrently at the Hong Kong Convention and Exhibition Centre (HKCEC) from 13 to 16 October; the 11th Hong Kong International Outdoor and Tech Light Expo, taking place at AsiaWorld-Expo from 26 to 29 October; and the 28th Hong Kong International Lighting Fair (Autumn Edition), to be held at the HKCEC from 27 to 30 October. The four fairs are expected to attract some 6,200 exhibitors from 28 countries and regions, showcasing cutting-edge technologies and solutions spanning consumer electronics, artificial intelligence (AI), robotics, future industries, smart lighting and smart city applications. The fairs will highlight the latest achievements in innovation and technology, reflecting global trends in industrial upgrading and digital transformation. At a press conference held today to introduce the four fairs, HKTDC Associate Executive Director Silas Chu said: “The Hong Kong SAR Government's latest Policy Address and first Five-Year Plan underscore the importance of consolidating and enhancing Hong Kong's status as an international trade centre, expediting the city's development into an international innovation and technology (I&T) centre and advancing the adoption and development of AI. In support of these strategic directions, the HKTDC is introducing several new elements at this year’s October fairs, including a new Future Industries Zone at the Autumn Electronics Fair, expanded showcases and business-matching opportunities for AI and robotics technologies to help companies connect with funding, talent, technology and international markets. A dedicated GoGlobal Connect Zone will also be set up at the venue to provide advisory services for businesses, encouraging more Chinese Mainland enterprises to leverage Hong Kong as a platform for expanding into international markets. The two lighting fairs, meanwhile, will focus on key industry trends related to smart connectivity, healthy living, immersive spatial experiences and sustainability.” Presenting highlights of the Autumn Electronics Fair, electronicAsia, the Autumn Lighting Fair and the International Outdoor and Tech Light Expo at today's press conference are: DDD (centre), Associate Executive Director of the HKTDC; Steve Chuang (left), Chairman of the HKTDC Electronics/Electrical Appliances Industries Advisory Committee; and Alvin Lee (right), Chairman of the Hong Kong Electronics & Technologies Association New Future Industries Zone demonstrates synergies in the innovation and tech ecosystem The Autumn Electronics Fair and electronicAsia kick off in mid-October, bringing together over 3,200 exhibitors from 15 countries and regions. In support of the national strategy to foster future industries, this year's Electronics Fair will introduce the new Future Industries Zone. Supported by the Innovation, Technology and Industry Bureau of the HKSAR Government, the zone is jointly organised by the HKTDC and the Hong Kong Electronic Industries Association (HKEIA), with participation from some of Hong Kong's leading innovation and technology institutions. The zone will focus on five key themes: Future Computing, Future Manufacturing, Future Marine & Quantum Technologies, Future Microelectronics and Future Wellness. In addition to industry leaders such as Lenovo, AV Concept and GP Energy Tech, more than 100 exhibitors will be showcasing a wide range of cutting-edge technologies and innovative solutions. In addition, a series of thematic events and forums centred on the five key themes will be held during the fair. The distinguished speaker lineup includes Jeffrey Lam, Member of the Executive Council and Chairperson of the Board of Directors of the Hung Shui Kiu Industry Park Company Limited; Vincent Ma, Chief Executive Officer of the Hong Kong-Shenzhen Innovation and Technology Park Limited; Clara Chan, Chief Executive Officer of the Hong Kong Investment Corporation Limited; and Allen Yeung, President (Hong Kong) of the Greater Bay Area International Information Technology Industry Association. Another highlight in the Future Industries Zone will be the announcement of the Top 100 Future Industries Pioneer List, which aims to identify innovative products and solutions with strong commercial value. The fair will also feature a start-up pitching competition, as well as thematic forums dedicated to technology talent development and industry application matching, fostering closer collaboration between innovation, talent and business opportunities. GoGlobal Connect Zone helps enterprises expand into global markets As a core member of the Task Force on Supporting Mainland Enterprises in Going Global, spearheaded by the HKSAR Government, the HKTDC is setting up a dedicated GoGlobal Connect Zone at the Electronics Fair to help Chinese Mainland companies connect with international markets through Hong Kong’s professional services providers. A series of "GoGlobal" themed forums will also be held, including “Scaling Smart Consumer Innovations Worldwide”, featuring representatives from the Hong Kong Export Credit Insurance Corporation (HKECIC), TechNode and Hang Seng Bank. The forum will explore key strategies for overseas expansion, covering topics such as market entry, financing and risk management, smart manufacturing, sustainability, compliance and certification, and brand building. In addition, representatives from OCBC Bank (Hong Kong) will share insights on the ASEAN manufacturing ecosystem in the “Navigate the Opportunities and Challenges of Overseas Expansion and Next Frontier of Growth” session, helping companies interested in expanding into ASEAN markets gain a deeper understanding of the region’s economic environment, tax policies, business expansion practices and the latest market trends. Spotlight on highlighted themes: AI and Robotics, Smart Wellness and NEXTEntertainment The Autumn Electronics Fair will showcase the latest consumer electronics products and innovative technologies, with three highlighted themes: AI & Robotics, Smart Wellness and NEXTEntertainment. Related products will be featured at various thematic zones across the fair. As the convergence of AI and robotics continues to accelerate, this year’s fair will showcase more than 120 robots, primarily in RoboPark, demonstrating applications across four key scenarios: Commercial & Services, Industrial & Logistics, Entertainment & Social, and Healthcare & Rehabilitation. The impressive lineup includes AgiBot, the world’s leading humanoid robot manufacturer by shipment volume in the first half of 2026[1]; the Shenzhen Honor Smart Technology Development Co., Ltd.’s humanoid robot, winner of the 2026 Beijing E-Town Half Marathon; Booster Robotics, champion of the 2026 RoboCup; UBTECH, one of the “Shenzhen Eight Great Guardians of Embodied Intelligence”, which will present the world’s first next-generation full-sized humanoid robot designed for “urban coexistence”; and several prominent technology companies from the “Shenzhen Eight Great Guardians” and “Hangzhou Six Little Dragons”, including AI² Robotics, Digit Robotics, EngineAI, DexForce and Deep Robotics. In addition, VIGX Technology Co., Ltd. will showcase the world’s first “pocket-sized” AI exoskeleton robot, designed to overcome the bulkiness of traditional industrial exoskeletons while being portable and easy to wear. UBTECH's Walker C1 robot performs a waltz at the press conference, demonstrating its agility, fluid motion and remarkable balance capabilitiesVIGX Technologies Limited presents its latest innovation – the world's first "pocket-sized" AI exoskeleton robot, designed to overcome the bulkiness of traditional industrial exoskeletons while being portable and easy to wearManna Pacific (HK) Limited showcases an AI-powered indoor fitness screen that combines real-time motion tracking and visual guidance to help users improve posture accuracy, body coordination and workout safety. RoboPark will also feature multiple interactive experiences and showcase zones, including the RoboDog Garden for robot dog demonstrations, a robot football exhibition, the Robot Dance Battle performance, the Coffee & Popcorn Station where robots serve coffee and popcorn, as well as interactive photo spots, allowing visitors to experience firsthand the applications of robotics technology in diverse scenarios. Another highlighted theme, Smart Wellness, will cover digital health devices, smart wearables, personal care technologies, gerontech and healthy living electronics, reflecting the growing demand for solutions related to technology-enabled health management and improved quality of life. NEXTEntertainment, meanwhile, will feature extended reality (XR) technologies, smart gaming devices, digital content creation tools, AI-powered entertainment solutions and innovative consumer electronics, enhancing entertainment experiences and digital content creation capabilities. Showcasing renowned brands and start-ups with the Immersive Experience Zone The Autumn Electronics Fair will feature more than 20 themed zones, including the Hall of Fame, showcasing products from more than 560 renowned electronics brands. First-time exhibitors include companies such as HiFuture, Aoni and ZENS. The RISE Avenue zone will bring together emerging brands, featuring products ranging from gaming equipment to home entertainment systems. Another spotlight area, Adventure Hub, will include the Immersive Experience Zone, where creative technology companies will present the latest interactive gaming experiences and demonstrate virtual reality (VR) and augmented reality (AR) technologies. Visitors can try experiences such as brainwave-controlled sensors that enable users to operate games using concentration alone, without any physical controls. Over 120 emerging enterprises and start-ups will participate in the fair, primarily in the "Startup Zone”, with both the Internet of Things Hong Kong Association (IOTHK) and JimHang Academy leading groups of start-ups to showcase technologies and solutions that address real business challenges. And the Tech Hall will spotlight professional AI-driven data and Internet of Things (IoT) solutions across various industries, including intelligent monitoring systems for transportation applications. Concurrent electronicAsia to drive industry upgrading Jointly organised by the HKTDC and MMI Asia Pte Ltd and held concurrently with the Electronics Fair, electronicAsia (eAsia) will bring together exhibitors engaged in semiconductors, sensors, electronic components and manufacturing technologies. The exhibition will demonstrate how the electronics supply chain is adapting to the growing demands of AI development and digital transformation, helping enterprises seize opportunities arising from the next wave of industrial upgrading. Exhibitors including Easttop Display and Microtech Technology will unveil their latest products at the fair. Symposium on Innovation and Technology to spotlight AI and smart infrastructure A series of forums, seminars and networking events will be held during the Autumn Electronics Fair. Among the highlights is the annual Symposium on Innovation and Technology, jointly organised by the HKTDC and the Hong Kong Electronics and Technologies Association (HKETA) under the theme "AI-Driven Security & The Next-Gen Infrastructure". Distinguished speakers include Alexander Gerfer, Chief Technology Officer of Würth Elektronik Group, who will discuss how electronics technologies are powering the future of AI and intelligent systems; Dr Charles Cheung, Adjunct Associate Professor of the Department of Mathematics at Hong Kong Baptist University, who will explore how businesses can translate AI capabilities into operational excellence, innovation and business growth; and Silvia Lam Ihensekhien, Chief Security Advisor Microsoft, who will share insights into building resilient infrastructure to support AI-driven enterprises and enhance operational efficiency and competitiveness. The Hong Kong Electronics Forum, jointly organised by the HKTDC, MMI Asia Pte Ltd and the HKEIA and co-organised by Hong Kong Institute of Engineers, will explore how AI, sustainability and technological innovation are shaping the future of the electronics industry. The exhibition will also feature a series of start-up-focused activities, including enterprise-investor matching sessions, the Hong Kong Value Creation for Technology: Pitching Competition, and mentorship programmes, providing start-ups with valuable opportunities to showcase innovative ideas, expand investor networks and secure funding support to strengthen their competitiveness. Top-tier lighting technologies and global industry leaders converge at twin lighting fairs As premier annual events for the global lighting and lighting products industry, the Hong Kong International Lighting Fair (Autumn Edition) and Hong Kong International Outdoor and Tech Light Expo are expected to bring together some 3,000 exhibitors from more than 20 countries and regions. Under the theme “Beyond Illumination”, the twin lighting fairs will showcase the integration of smart technologies, sustainability, design aesthetics and lighting applications through a diverse range of thematic zones and activities. The fairs will highlight emerging industry trends and further reinforce their position as flagship platforms for the lighting industry in Asia and around the world. Leading global smart lighting and IoT industry alliances will participate in the Autumn Lighting Fair, including the Connectivity Standards Alliance, the DALI Alliance, the SILA-EMN Alliance, the Zhaga Consortium and, making its debut at the fair, KNX, the global standard for smart building and home automation. KNX, together with GVS Smart, will showcase the award-winning KNX Smart Touch S7 control panel, recipient of leading industry honours including the Red Dot Award, A’ Design Award and BDA Product Design Award. This product enables centralised control of lighting, curtains, air-conditioning systems and multiple smart home scenarios, allowing users to create personalised lighting environments and enjoy a seamless smart living experience. Hong Kong exhibitor Dimon Technology will showcase its advanced theatre lighting technologies deployed at the WestK Performing Arts Centre. The company has also provided intelligent lighting solutions for the International Gateway Centre (IGC), designed by internationally renowned architectural firm Zaha Hadid Architects, demonstrating the capability of Hong Kong lighting enterprises in delivering premium lighting technologies for landmark development projects. Hall of Connected Lighting returns with immersive lighting experiences A highlight of the Autumn Lighting Fair, the Hall of Connected Lighting will feature more than 60 leading brands, including local brand Dimon and Viliya; TUYA and Inventronics from the Chinese Mainland; Viso Systems from Denmark; Casambi from Finland; and Signify from the Netherlands. The zone will feature immersive lighting installations and application-based displays, enabling visitors to explore the latest smart lighting products and solutions through interactive light-and-shadow experiences. Among the highlights, Signify will collaborate with the Mercedes-AMG PETRONAS F1 Team to present a racing simulator experience that extends the excitement of motorsport beyond the screen into a physical environment through innovative lighting technologies. Two professional racing simulators will allow visitors to experience the thrill of high-speed driving and sharp cornering in a highly immersive setting. Premium decorative lighting brand Viliya will create Mirrorverse, an immersive mirrored art installation featuring its popular Starburst crystal chandeliers and sophisticated table lamps. The installation will demonstrate how decorative lighting can shape ambience, elevate interior design and create distinctive spatial experiences. Sunpu-Opto (HK) Limited displays its 360° Round Tube RGB Table Lamp with a high-performance RGB LED module, creating an immersive atmosphere with dynamic colour-changing light Meanwhile, Casambi, the world's leading wireless smart lighting control platform, will once again host its Artisan Café concept space at the fair. Together with renowned international lighting brand Formalighting and 12 partners from Europe, the United States and the Asia-Pacific region, Casambi will showcase its open and interconnected smart lighting ecosystem through technical presentations and application sharing. New LED Display Solution Zone creates a commercial display ecosystem Expanding the event’s product scope, the Autumn Lighting Fair will launch the new LED Display Solution Zone to foster the development of a commercial LED display ecosystem. The zone will feature LED video walls, commercial displays, transparent and flexible LED panels, immersive audio-visual systems and integrated display solutions, covering applications ranging from retail environments and corporate presentations to exhibitions, virtual production and major commercial projects. First-time exhibitor Ledman Hong Kong will present the QS Series IceScreen LED Display, which was deployed at the Milano Cortina 2026 Winter Olympic Games. Featuring large-scale 8K display technology, the solution delivers highly realistic and impactful visual experiences. The company will also introduce the LEDHUB Smart Conference Solution, which integrates large-format display, video conferencing and collaboration functions into a single platform. Winner of the 2025 TITAN Innovation Awards Gold Award, the solution has been adopted by leading institutions including The University of Hong Kong, the University of Warwick and Fudan University. Another signature zone, the Hall of Aurora, will feature some 500 renowned brands offering high-quality lighting products. Exhibitors include Hong Kong industry pioneers Prosperity Lamps & Components and Profiled Group, mainland brands Eaglerise, FSL and Leedarson, and international brands such as Finland's Lival, Germany's Cupower and Italy's Beghelli. Other featured zones include Commercial Lighting, Residential Lighting and LED Essentials. Prosperity Lamps & Components' SYMPL FUSION seamlessly integrates intelligent control and dynamic lighting, supporting multiple protocols including DALI, KNX and DMX to combine smart management with creative lighting applicationsFirst-time exhibitor Ledman Hong Kong showcases its LEDHUB Smart Conference Solution, an all-in-one platform that integrates large-format display, video conferencing and collaboration functions Outdoor and Tech Light Expo focuses on emerging smart city lighting trends The Hong Kong International Outdoor and Tech Light Expo will showcase a wide range of outdoor, commercial and industrial lighting products and solutions across three major zones: Smart Pole and Solution; Outdoor, Industrial and Technical Lighting; and Landscape and Architectural Lighting. The expo will present newly introduced photovoltaic (PV) and energy storage solutions to help cities enhance energy efficiency, alongside lighting applications for smart city development, industrial environments, professional settings, landscape projects and architectural illumination. Expo exhibitor Fonda Technology will showcase intelligent lighting solutions based on its FondaCity AIoT Cloud Platform within the Smart Pole and Solution zone, incorporating solar energy, motion sensing and various communication technologies. Approximately 70,000 smart streetlight control devices have already been deployed under Hong Kong's New Territories West smart lighting project. In addition to enabling precision lighting control, the system allows city managers to monitor operational conditions in real time via an AIoT platform, significantly enhancing urban management efficiency. Zhejiang Fonda Technology Co., Ltd. presents its multifunctional smart pole solution, which has been deployed in a project in Hong Kong’s New Territories West. Supported by approximately 70,000 smart streetlight controllers and an AIoT cloud platform, the solution enhances lighting management efficiency At the Outdoor, Industrial and Technical Lighting zone, exhibitor Zhejiang Ouruijie Lighting Technology Co., Ltd. will showcase its L10A Starship Flood Luminaire, winner of the Aladdin Lighting Award 2026 – National Best Lighting Product Award. Inspired by aircraft carrier design, the product combines a distinctive appearance with innovative lighting technology. The Landscape and Architectural Lighting zone will showcase how lighting can create unique urban atmospheres while enhancing the safety, functionality and aesthetics of public spaces. Throughout the fair period, the two lighting fairs will join hands with leading international lighting organisations to present a series of seminars, product launches and networking events. The Innovative Lighting Design Forum will be held at the Hong Kong Convention and Exhibition Centre on 27 October under the theme “Treasures of Light: Artistic Brilliance Beyond Exhibitions”. Three renowned lighting designers behind internationally acclaimed landmark projects will share the latest trends and insights, including Dr Yan Liu, Design Director, China of AT Design & Consulting Co Ltd, whose portfolio includes landmark projects such as the Louvre Museum in Paris and the Palace Museum in Beijing; Adam Meredith, Lighting Designer at MEGS Lighting from Australia, who has led lighting design projects for the Metropolitan Museum of Art in New York and M+ in Hong Kong; and Omar Elkerm, Lighting Design Manager (Africa) at Signify, who led the lighting design for several major pyramid illumination projects in Egypt. On the same day, the fair will collaborate with the Illuminating Engineering Society (IES) to launch a brand-new event, “Award-winning Illumination: Highlights from the IES Illumination Awards”. Winners of the prestigious IES Illumination Awards will share insights into the artistic and technical evolution of lighting design across different sectors. Featured speakers include Hiroyasu Shoji, Representative and Lighting Designer of Lightdesign Inc., who led the lighting design for the Grand Ring at Expo 2025 Osaka, and Kelly Jones, Co-Chief Executive Officer and President of Lighting Design Alliance, whose portfolio includes numerous projects for Disney and Universal Studios. The fair will also partner with Women in Lighting (WIL) for the first time to present “Circularity in Lighting Design” on 28 October. Leading female designers from around the world will discuss sustainable lighting design and the application of circular economy principles in the industry. Speakers include Yah Li Toh, Founder and Principal of Light Collab, who designed the lighting for the Singapore Pavilion at Expo 2020 Dubai, and Pavlina Akritas, Founder of Akritas Lighting Design, known for her work on lighting projects for some of the world's most prestigious luxury brands. Another key event, the Connected Lighting Forum, will once again be co-organised with the Shanghai Pudong Intelligent Lighting Association (SILA). Under the theme “Healing Light for the Future: Illuminating Emotional Well-being”, the forum will explore developments in intelligent and human-centric lighting technologies and their role in supporting emotional wellness, featuring case studies on the therapeutic applications of light. At AsiaWorld-Expo, a series of exhibitor and buyer activities will be held. Among the highlights, a seminar titled “Smart Tech Integration in Outdoor Lighting” on 27 October will bring together experts from the Alliance of Smart Pole Industry and another industry organisation to examine how AI is driving the next generation of smart pole applications. To facilitate sourcing and business networking across the fairs, a complimentary shuttle bus service will be provided for exhibitors and buyers between the HKCEC and AsiaWorld-Expo throughout the exhibition period. The four exhibitions will continue to adopt the HKTDC's EXHIBITION+ hybrid exhibition model, combining physical and online participation. In addition to attending the fairs in person, exhibitors and buyers can utilise the Click2Match smart business matching platform to connect, source and conduct business discussions online. The online exhibition period for the Hong Kong Electronics Fair (Autumn Edition) and electronicAsia will run from 6 to 23 October, while the online exhibitions for the Hong Kong International Lighting Fair (Autumn Edition) and Hong Kong International Outdoor and Tech Light Expo will be available from 19 October to 6 November, enabling businesses to extend their sourcing and networking activities beyond the physical fair dates. [1] Source: Counterpoint Research: Global Humanoid Robot Shipment Report for H1 2026, published on 20 August 2026. Photo download: https://bit.ly/3VBQ6dm Websites - Hong Kong Electronics Fair (Autumn Edition): https://www.hktdc.com/event/hkelectronicsfairae/en - electronicAsia: https://www.hktdc.com/event/electronicasia/en - Hong Kong International Lighting Fair (Autumn Edition): https://www.hktdc.com/event/hklightingfairae/en - Hong Kong International Outdoor and Tech Light Expo: https://www.hktdc.com/event/hkotlexpo/en Media enquiries Please contact the HKTDC’s Communications & Public Affairs Department: Hong Kong Electronics Fair (Autumn Edition) & electronicAsia Katy Wong Tel: (852) 2584 4524 Email: katy.ky.wong@hktdc.org Clayton Lauw Tel: (852) 2584 4472 Email: clayton.y.lauw@hktdc.org Hong Kong International Lighting Fair (Autumn Edition) & Hong Kong International Outdoor and Tech Light Expo Christy Lee Tel: (852) 2584 4369 Email: christy.wn.lee@hktdc.org Jane Cheung Tel: (852) 2584 4137 Email: jane.mh.cheung@hktdc.org HKTDC Media Room: https://mediaroom.hktdc.com/en About HKTDC The Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via trade publications, research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. ———————————————————————————————————————————————————————————— ILC Dover Introduces DoverDoQ™ to Advance Contained Potent Powder Transfer in Pharmaceutical Manufacturing 2026-09-29 · PR Newswire · Industrial, Biotech & pharma https://www.prnewswire.com/news-releases/ilc-dover-introduces-doverdoq-to-advance-contained-potent-powder-transfer-in-pharmaceutical-manufacturing-302888444.html ROSSENS, Switzerland, Sept. 29, 2026 -- ILC Dover, an Ingersoll Rand business and global leader in containment and material handling solutions, today announced the launch of DoverDoQ™, a semi-automatic connection system designed to enable safe, reliable, and highly contained... ———————————————————————————————————————————————————————————— AARDVARK DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AARD 2026-09-29 · Newsfile · Finance, Biotech & pharma https://www.newsfilecorp.com/release/316380/AARDVARK-DEADLINE-ROSEN-RECOGNIZED-INVESTOR-COUNSEL-Encourages-Aardvark-Therapeutics-Inc.-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-AARD New York, New York--(September 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the... ———————————————————————————————————————————————————————————— Silexion Therapeutics Announces Exercise of Warrants 2026-09-29 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/29/3370802/0/en/silexion-therapeutics-announces-exercise-of-warrants.html Cayman Islands, Sept. 29, 2026 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series E warrants to purchase up to an aggregate of 3,216,928 of the Company’s ordinary shares originally issued in August 2026 having a reduced exercise price of $0.2603 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-298137). The gross proceeds to the Company from the exercise of the warrants are expected to be $837,366.36, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about September 29, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes. ———————————————————————————————————————————————————————————— BIO-Europe 2026 to Convene Global Biopharma Decision-Makers in Cologne 2026-09-29 · GlobeNewswire · Biotech & pharma https://www.globenewswire.com/news-release/2026/09/29/3370730/0/en/bio-europe-2026-to-convene-global-biopharma-decision-makers-in-cologne.html BIO-Europe 2026 to Convene Global Biopharma Decision-Makers in Cologne ———————————————————————————————————————————————————————————— Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron 2026-09-29 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/29/3370749/0/en/nasus-pharma-announces-enrollment-and-dosing-of-first-patient-in-phase-1-study-of-ns003-intranasal-formulation-of-ondansetron.html Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026 Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026 ———————————————————————————————————————————————————————————— Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting 2026-09-29 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/09/29/3370748/0/en/dianthus-therapeutics-highlights-claseprubart-data-presentations-planned-for-2026-aanem-annual-meeting.html NEW YORK and WALTHAM, Mass., Sept. 29, 2026 -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced one oral presentation and four poster presentations for claseprubart at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place September 29 to October 2, 2026 in Orlando, Florida.